1301937	O
Molecular	O
basis	O
of	O
hexosaminidase	B-SpecificDisease
A	I-SpecificDisease
deficiency	I-SpecificDisease
and	O
pseudodeficiency	O
in	O
the	O
Berks	O
County	O
Pennsylvania	O
Dutch.	O
Following	O
the	O
birth	O
of	O
two	O
infants	O
with	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
(	O
TSD	B-SpecificDisease
)	O
,	O
a	O
non-Jewish	O
,	O
Pennsylvania	O
Dutch	O
kindred	O
was	O
screened	O
for	O
TSD	B-Modifier
carriers	O
using	O
the	O
biochemical	O
assay	O
.	O
A	O
high	O
frequency	O
of	O
individuals	O
who	O
appeared	O
to	O
be	O
TSD	B-Modifier
heterozygotes	O
was	O
detected	O
(	O
Kelly	O
et	O
al	O
.	O
,	O
1975	O
)	O
.	O
Clinical	O
and	O
biochemical	O
evidence	O
suggested	O
that	O
the	O
increased	O
carrier	O
frequency	O
was	O
due	O
to	O
at	O
least	O
two	O
altered	O
alleles	O
for	O
the	O
hexosaminidase	O
A	O
alpha-subunit	O
.	O
We	O
now	O
report	O
two	O
mutant	O
alleles	O
in	O
this	O
Pennsylvania	O
Dutch	O
kindred	O
,	O
and	O
one	O
polymorphism	O
.	O
One	O
allele	O
,	O
reported	O
originally	O
in	O
a	O
French	O
TSD	B-Modifier
patient	O
(	O
Akli	O
et	O
al	O
.	O
,	O
1991	O
)	O
,	O
is	O
a	O
GT--	O
>	O
AT	O
transition	O
at	O
the	O
donor	O
splice-site	O
of	O
intron	O
9	O
.	O
The	O
second	O
,	O
a	O
C--	O
>	O
T	O
transition	O
at	O
nucleotide	O
739	O
(	O
Arg247Trp	O
)	O
,	O
has	O
been	O
shown	O
by	O
Triggs-Raine	O
et	O
al	O
.	O
(	O
1992	O
)	O
to	O
be	O
a	O
clinically	O
benign	O
"	O
pseudodeficient	O
"	O
allele	O
associated	O
with	O
reduced	O
enzyme	O
activity	O
against	O
artificial	O
substrate	O
.	O
Finally	O
,	O
a	O
polymorphism	O
[	O
G--	O
>	O
A	O
(	O
759	O
)	O
]	O
,	O
which	O
leaves	O
valine	O
at	O
codon	O
253	O
unchanged	O
,	O
is	O
described	O
.	O

10205262	O
Analysis	O
of	O
alkaptonuria	B-Modifier
(AKU)	O
mutations	O
and	O
polymorphisms	O
reveals	O
that	O
the	O
CCC	O
sequence	O
motif	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
the	O
homogentisate	O
1,2	O
dioxygenase	O
gene	O
(HGO).	O
We	O
recently	O
showed	O
that	O
alkaptonuria	B-SpecificDisease
(	O
AKU	B-SpecificDisease
)	O
is	O
caused	O
by	O
loss-of-function	O
mutations	O
in	O
the	O
homogentisate	O
1	O
,	O
2	O
dioxygenase	O
gene	O
(	O
HGO	O
)	O
.	O
Herein	O
we	O
describe	O
haplotype	O
and	O
mutational	O
analyses	O
of	O
HGO	O
in	O
seven	O
new	O
AKU	B-Modifier
pedigrees	O
.	O
These	O
analyses	O
identified	O
two	O
novel	O
single-nucleotide	O
polymorphisms	O
(	O
INV4	O
+	O
31A--	O
>	O
G	O
and	O
INV11	O
+	O
18A--	O
>	O
G	O
)	O
and	O
six	O
novel	O
AKU	B-Modifier
mutations	O
(	O
INV1-1G--	O
>	O
A	O
,	O
W60G	O
,	O
Y62C	O
,	O
A122D	O
,	O
P230T	O
,	O
and	O
D291E	O
)	O
,	O
which	O
further	O
illustrates	O
the	O
remarkable	O
allelic	O
heterogeneity	O
found	O
in	O
AKU	B-SpecificDisease
.	O
Reexamination	O
of	O
all	O
29	O
mutations	O
and	O
polymorphisms	O
thus	O
far	O
described	O
in	O
HGO	O
shows	O
that	O
these	O
nucleotide	O
changes	O
are	O
not	O
randomly	O
distributed	O
;	O
the	O
CCC	O
sequence	O
motif	O
and	O
its	O
inverted	O
complement	O
,	O
GGG	O
,	O
are	O
preferentially	O
mutated	O
.	O
These	O
analyses	O
also	O
demonstrated	O
that	O
the	O
nucleotide	O
substitutions	O
in	O
HGO	O
do	O
not	O
involve	O
CpG	O
dinucleotides	O
,	O
which	O
illustrates	O
important	O
differences	O
between	O
HGO	O
and	O
other	O
genes	O
for	O
the	O
occurrence	O
of	O
mutation	O
at	O
specific	O
short-sequence	O
motifs	O
.	O
Because	O
the	O
CCC	O
sequence	O
motifs	O
comprise	O
a	O
significant	O
proportion	O
(	O
34	O
.	O
5	O
%	O
)	O
of	O
all	O
mutated	O
bases	O
that	O
have	O
been	O
observed	O
in	O
HGO	O
,	O
we	O
conclude	O
that	O
the	O
CCC	O
triplet	O
is	O
a	O
mutational	O
hot	O
spot	O
in	O
HGO	O
.	O

8240110	O
Phenotypic	O
variation	O
including	O
retinitis	B-SpecificDisease
pigmentosa,	I-SpecificDisease
pattern	B-SpecificDisease
dystrophy,	I-SpecificDisease
and	O
fundus	B-SpecificDisease
flavimaculatus	I-SpecificDisease
in	O
a	O
single	O
family	O
with	O
a	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin/RDS	O
gene.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
Mutations	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
have	O
been	O
reported	O
in	O
autosomal	B-SpecificDisease
dominant	I-SpecificDisease
retinitis	I-SpecificDisease
pigmentosa	I-SpecificDisease
,	O
pattern	O
macular	B-SpecificDisease
dystrophy	I-SpecificDisease
,	O
and	O
retinitis	B-SpecificDisease
punctata	I-SpecificDisease
albescens	I-SpecificDisease
.	O
We	O
report	O
herein	O
the	O
occurrence	O
of	O
three	O
separate	O
phenotypes	O
within	O
a	O
single	O
family	O
with	O
a	O
novel	O
3-base	O
pair	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
.	O
DESIGN	O
Case	O
reports	O
with	O
clinical	O
features	O
,	O
fluorescein	O
angiography	O
,	O
kinetic	O
perimetry	O
,	O
electrophysiological	O
studies	O
,	O
and	O
molecular	O
genetics	O
.	O
SETTING	O
University	O
medical	O
centers	O
.	O
PATIENTS	O
A	O
75-year-old	O
woman	O
,	O
her	O
two	O
daughters	O
(	O
aged	O
44	O
and	O
50	O
years	O
)	O
,	O
and	O
her	O
49-year-old	O
son	O
were	O
screened	O
for	O
peripherin	O
/	O
RDS	O
mutations	O
because	O
of	O
the	O
presence	O
of	O
multiple	O
phenotypes	O
within	O
the	O
same	O
family	O
.	O
RESULTS	O
The	O
mother	O
presented	O
at	O
age	O
63	O
years	O
with	O
a	O
profoundly	O
abnormal	O
electroretinogram	O
(	O
ERG	O
)	O
and	O
adult-onset	O
retinitis	B-SpecificDisease
pigmentosa	I-SpecificDisease
that	O
progressed	O
dramatically	O
over	O
12	O
years	O
,	O
with	O
marked	O
loss	O
of	O
peripheral	O
visual	O
field	O
.	O
One	O
daughter	O
developed	O
pattern	B-SpecificDisease
macular	I-SpecificDisease
dystrophy	I-SpecificDisease
at	O
age	O
31	O
years	O
.	O
At	O
age	O
44	O
years	O
,	O
her	O
ERG	O
was	O
moderately	O
abnormal	O
but	O
her	O
clinical	O
disease	O
was	O
limited	O
to	O
the	O
macula	O
.	O
Another	O
daughter	O
presented	O
at	O
age	O
42	O
years	O
with	O
macular	B-SpecificDisease
degeneration	I-SpecificDisease
and	O
over	O
10	O
years	O
developed	O
the	O
clinical	O
picture	O
of	O
fundus	B-SpecificDisease
flavimaculatus	I-SpecificDisease
.	O
Her	O
peripheral	O
visual	O
field	O
was	O
preserved	O
but	O
her	O
ERG	O
was	O
moderately	O
abnormal	O
.	O
The	O
son	O
had	O
onset	O
of	O
macular	B-SpecificDisease
degeneration	I-SpecificDisease
at	O
age	O
44	O
years	O
.	O
Pericentral	B-SpecificDisease
scotomas	I-SpecificDisease
were	O
present	O
and	O
the	O
ERG	O
was	O
markedly	O
abnormal	O
.	O
Fluorescein	O
angiography	O
revealed	O
punctate	O
pigment	O
epithelial	O
transmission	O
defects	O
.	O
CONCLUSIONS	O
A	O
3-base	O
pair	O
deletion	O
of	O
codon	O
153	O
or	O
154	O
of	O
the	O
peripherin	O
/	O
RDS	O
gene	O
can	O
produce	O
clinically	O
disparate	O
phenotypes	O
even	O
within	O
the	O
same	O
family	O
.	O
.	O

10330348	O
Splicing	O
defects	O
in	O
the	O
ataxia-telangiectasia	B-Modifier
gene,	O
ATM:	O
underlying	O
mutations	O
and	O
consequences.	O
Mutations	O
resulting	O
in	O
defective	O
splicing	O
constitute	O
a	O
significant	O
proportion	O
(	O
30	O
/	O
62	O
[	O
48	O
%	O
]	O
)	O
of	O
a	O
new	O
series	O
of	O
mutations	O
in	O
the	O
ATM	O
gene	O
in	O
patients	O
with	O
ataxia-telangiectasia	B-SpecificDisease
(	O
AT	B-SpecificDisease
)	O
that	O
were	O
detected	O
by	O
the	O
protein-truncation	O
assay	O
followed	O
by	O
sequence	O
analysis	O
of	O
genomic	O
DNA	O
.	O
Fewer	O
than	O
half	O
of	O
the	O
splicing	O
mutations	O
involved	O
the	O
canonical	O
AG	O
splice-acceptor	O
site	O
or	O
GT	O
splice-donor	O
site	O
.	O
A	O
higher	O
percentage	O
of	O
mutations	O
occurred	O
at	O
less	O
stringently	O
conserved	O
sites	O
,	O
including	O
silent	O
mutations	O
of	O
the	O
last	O
nucleotide	O
of	O
exons	O
,	O
mutations	O
in	O
nucleotides	O
other	O
than	O
the	O
conserved	O
AG	O
and	O
GT	O
in	O
the	O
consensus	O
splice	O
sites	O
,	O
and	O
creation	O
of	O
splice-acceptor	O
or	O
splice-donor	O
sites	O
in	O
either	O
introns	O
or	O
exons	O
.	O
These	O
splicing	O
mutations	O
led	O
to	O
a	O
variety	O
of	O
consequences	O
,	O
including	O
exon	O
skipping	O
and	O
,	O
to	O
a	O
lesser	O
degree	O
,	O
intron	O
retention	O
,	O
activation	O
of	O
cryptic	O
splice	O
sites	O
,	O
or	O
creation	O
of	O
new	O
splice	O
sites	O
.	O
In	O
addition	O
,	O
5	O
of	O
12	O
nonsense	O
mutations	O
and	O
1	O
missense	O
mutation	O
were	O
associated	O
with	O
deletion	O
in	O
the	O
cDNA	O
of	O
the	O
exons	O
in	O
which	O
the	O
mutations	O
occurred	O
.	O
No	O
ATM	O
protein	O
was	O
detected	O
by	O
western	O
blotting	O
in	O
any	O
AT	B-Modifier
cell	O
line	O
in	O
which	O
splicing	O
mutations	O
were	O
identified	O
.	O
Several	O
cases	O
of	O
exon	O
skipping	O
in	O
both	O
normal	O
controls	O
and	O
patients	O
for	O
whom	O
no	O
underlying	O
defect	O
could	O
be	O
found	O
in	O
genomic	O
DNA	O
were	O
also	O
observed	O
,	O
suggesting	O
caution	O
in	O
the	O
interpretation	O
of	O
exon	O
deletions	O
observed	O
in	O
ATM	O
cDNA	O
when	O
there	O
is	O
no	O
accompanying	O
identification	O
of	O
genomic	O
mutations	O
.	O
.	O

10398436	O
Beta-catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
in	O
hepatoblastoma.	B-SpecificDisease
Hepatoblastoma	B-SpecificDisease
is	O
a	O
rare	O
malignant	B-DiseaseClass
tumor	I-DiseaseClass
of	I-DiseaseClass
the	I-DiseaseClass
liver	I-DiseaseClass
that	O
occurs	O
in	O
children	O
at	O
an	O
average	O
age	O
of	O
2	O
to	O
3	O
years	O
.	O
Epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	B-Modifier
type	O
in	O
families	O
affected	O
by	O
adenomatous	B-SpecificDisease
polyposis	I-SpecificDisease
coli	I-SpecificDisease
.	O
In	O
addition	O
to	O
the	O
epidemiologic	O
data	O
,	O
molecular	O
genetic	O
studies	O
suggest	O
that	O
inactivation	O
of	O
the	O
APC	B-Modifier
tumor	I-Modifier
suppressor	O
may	O
be	O
involved	O
in	O
hepatoblastoma	B-Modifier
tumorigenesis	O
.	O
A	O
major	O
function	O
of	O
APC	O
is	O
the	O
downregulation	O
of	O
beta-catenin	O
,	O
a	O
transcription-activating	O
protein	O
with	O
oncogenic	O
potential	O
.	O
In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta-catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	B-Modifier
types	O
that	O
are	O
associated	O
with	O
adenomatous	B-SpecificDisease
polyposis	I-SpecificDisease
coli	I-SpecificDisease
,	O
we	O
observed	O
increased	O
beta-catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	B-SpecificDisease
.	O
Sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
revealed	O
an	O
activating	O
mutation	O
in	O
one	O
of	O
the	O
tumor	B-Modifier
samples	O
.	O
Our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta-catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	B-SpecificDisease
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
may	O
substitute	O
biallelic	O
APC	O
inactivation	O
in	O
this	O
tumor	B-Modifier
type	O
.	O
Genes	O
Chromosomes	O
Cancer	O
25	O
399-402	O
,	O
1999	O
.	O
.	O

8162051	O
Regionally	O
clustered	O
APC	B-Modifier
mutations	O
are	O
associated	O
with	O
a	O
severe	O
phenotype	O
and	O
occur	O
at	O
a	O
high	O
frequency	O
in	O
new	O
mutation	O
cases	O
of	O
adenomatous	B-SpecificDisease
polyposis	I-SpecificDisease
coli.	I-SpecificDisease
Germline	O
mutation	O
in	O
APC	O
at	O
5q21-22	O
results	O
in	O
the	O
dominantly	O
inherited	O
syndrome	O
adenomatous	B-SpecificDisease
polyposis	I-SpecificDisease
coli	I-SpecificDisease
(	O
APC	B-SpecificDisease
)	O
.	O
Somatic	O
mutation	O
in	O
this	O
gene	O
is	O
an	O
early	O
event	O
in	O
colorectal	O
tumourigenesis	O
.	O
Both	O
types	O
of	O
mutation	O
are	O
concentrated	O
in	O
the	O
5	O
half	O
of	O
exon	O
15	O
.	O
We	O
have	O
used	O
single	O
strand	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
and	O
heteroduplex	O
analysis	O
to	O
screen	O
for	O
variants	O
in	O
this	O
region	O
of	O
the	O
gene	O
in	O
a	O
total	O
of	O
45	O
affected	O
but	O
unrelated	O
individuals	O
.	O
Eighteen	O
patients	O
had	O
no	O
family	O
history	O
of	O
the	O
disease	O
;	O
of	O
these	O
11	O
were	O
classified	O
as	O
having	O
a	O
severe	O
phenotype	O
,	O
based	O
on	O
an	O
early	O
age	O
at	O
presentation	O
or	O
cancer	B-Modifier
development	O
.	O
This	O
compared	O
with	O
6	O
of	O
27	O
familial	O
cases	O
.	O
A	O
5	O
bp	O
deletion	O
at	O
codon	O
1309	O
reported	O
to	O
occur	O
in	O
10-15	O
%	O
of	O
unselected	O
APC	B-Modifier
patients	O
worldwide	O
,	O
was	O
found	O
in	O
5	O
of	O
the	O
18	O
new	O
mutation	O
cases	O
and	O
4	O
of	O
the	O
27	O
familial	O
cases	O
all	O
nine	O
were	O
classed	O
as	O
severe	O
.	O
A	O
further	O
3	O
new	O
mutations	O
and	O
1	O
familial	O
mutation	O
were	O
located	O
downstream	O
from	O
codon	O
1309	O
,	O
these	O
individuals	O
similarly	O
being	O
classed	O
as	O
phenotypically	O
severe	O
.	O
In	O
contrast	O
all	O
of	O
the	O
APC	B-Modifier
mutations	O
detected	O
in	O
affected	O
individuals	O
with	O
an	O
average	O
phenotype	O
were	O
located	O
prior	O
to	O
codon	O
1309	O
.	O
The	O
frequent	O
association	O
of	O
a	O
severe	O
phenotype	O
with	O
fresh	O
mutation	O
may	O
explain	O
the	O
apparent	O
conflict	O
of	O
a	O
high	O
mutation	O
rate	O
(	O
20-30	O
%	O
)	O
in	O
a	O
condition	O
,	O
which	O
on	O
average	O
,	O
is	O
lethal	O
at	O
a	O
post-reproductive	O
age	O
.	O
.	O

7825586	O
An	O
evaluation	O
of	O
genetic	O
heterogeneity	O
in	O
145	O
breast-ovarian	B-Modifier
cancer	I-Modifier
families.	O
Breast	B-Modifier
Cancer	I-Modifier
Linkage	O
Consortium.	O
The	O
breast-ovary	B-SpecificDisease
cancer-family	I-SpecificDisease
syndrome	I-SpecificDisease
is	O
a	O
dominant	O
predisposition	O
to	O
cancer	B-CompositeMention
of	I-CompositeMention
the	I-CompositeMention
breast	I-CompositeMention
and	I-CompositeMention
ovaries	I-CompositeMention
which	O
has	O
been	O
mapped	O
to	O
chromosome	O
region	O
17q12-q21	O
.	O
The	O
majority	O
,	O
but	O
not	O
all	O
,	O
of	O
breast-ovary	B-Modifier
cancer	I-Modifier
families	O
show	O
linkage	O
to	O
this	O
susceptibility	O
locus	O
,	O
designated	O
BRCA1	O
.	O
We	O
report	O
here	O
the	O
results	O
of	O
a	O
linkage	O
analysis	O
of	O
145	O
families	O
with	O
both	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
.	O
These	O
families	O
contain	O
either	O
a	O
total	O
of	O
three	O
or	O
more	O
cases	O
of	O
early-onset	O
(	O
before	O
age	O
60	O
years	O
)	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
or	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
.	O
All	O
families	O
contained	O
at	O
least	O
one	O
case	O
of	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
.	O
Overall	O
,	O
an	O
estimated	O
76	O
%	O
of	O
the	O
145	O
families	O
are	O
linked	O
to	O
the	O
BRCA1	O
locus	O
.	O
None	O
of	O
the	O
13	O
families	O
with	O
cases	O
of	O
male	B-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
appear	O
to	O
be	O
linked	O
,	O
but	O
it	O
is	O
estimated	O
that	O
92	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
76	O
%	O
-100	O
%	O
)	O
of	O
families	O
with	O
no	O
male	B-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
and	O
with	O
two	O
or	O
more	O
ovarian	B-SpecificDisease
cancers	I-SpecificDisease
are	O
linked	O
to	O
BRCA1	O
.	O
These	O
data	O
suggest	O
that	O
the	O
breast-ovarian	B-SpecificDisease
cancer-family	I-SpecificDisease
syndrome	I-SpecificDisease
is	O
genetically	O
heterogeneous	O
.	O
However	O
,	O
the	O
large	O
majority	O
of	O
families	O
with	O
early-onset	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
and	O
with	O
two	O
or	O
more	O
cases	O
of	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
are	O
likely	O
to	O
be	O
due	O
to	O
BRCA1	O
mutations	O
.	O
.	O

1317264	O
The	O
APC	B-Modifier
gene,	O
responsible	O
for	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis,	I-SpecificDisease
is	O
mutated	O
in	O
human	O
gastric	B-SpecificDisease
cancer.	I-SpecificDisease
Although	O
gastric	B-SpecificDisease
cancer	I-SpecificDisease
is	O
the	O
most	O
common	O
cancer	B-DiseaseClass
in	O
the	O
world	O
,	O
genetic	O
changes	O
during	O
its	O
carcinogenesis	O
are	O
not	O
well	O
understood	O
.	O
Since	O
some	O
gastric	B-SpecificDisease
cancers	I-SpecificDisease
are	O
considered	O
to	O
originate	O
from	O
the	O
intestinal	O
metaplasia	O
,	O
it	O
is	O
likely	O
that	O
the	O
adenomatous	B-Modifier
polyposis	I-Modifier
coli	I-Modifier
(	O
APC	B-Modifier
)	O
gene	O
,	O
the	O
mutation	O
of	O
which	O
causes	O
adenomatous	B-SpecificDisease
polyps	I-SpecificDisease
in	I-SpecificDisease
the	I-SpecificDisease
colon	I-SpecificDisease
,	O
is	O
associated	O
with	O
carcinogenesis	O
of	O
gastric	B-SpecificDisease
cancer	I-SpecificDisease
.	O
Based	O
on	O
this	O
idea	O
,	O
DNAs	O
isolated	O
from	O
gastric	B-SpecificDisease
cancers	I-SpecificDisease
were	O
examined	O
by	O
means	O
of	O
a	O
RNase	O
protection	O
analysis	O
coupled	O
with	O
polymerase	O
chain	O
reaction	O
followed	O
by	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
products	O
.	O
By	O
screening	O
nearly	O
one-half	O
of	O
the	O
coding	O
region	O
of	O
the	O
APC	B-Modifier
gene	O
in	O
44	O
tumors	B-DiseaseClass
,	O
somatic	O
mutations	O
were	O
detected	O
in	O
three	O
tumors	B-DiseaseClass
a	O
missense	O
mutation	O
,	O
a	O
nonsense	O
mutation	O
,	O
and	O
a	O
5-base	O
pair	O
deletion	O
resulting	O
in	O
a	O
frame	O
shift	O
which	O
causes	O
truncation	O
of	O
the	O
gene	O
product	O
.	O
These	O
results	O
suggest	O
that	O
the	O
mutation	O
of	O
the	O
APC	B-Modifier
gene	O
also	O
plays	O
an	O
important	O
role	O
during	O
the	O
carcinogenesis	O
of	O
at	O
least	O
some	O
gastric	B-SpecificDisease
cancers	I-SpecificDisease
.	O
.	O

1707231	O
A	O
new	O
mutation	O
in	O
the	O
proteolipid	O
protein	O
(PLP)	O
gene	O
in	O
a	O
German	O
family	O
with	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease.	I-SpecificDisease
A	O
C-to-T	O
transition	O
in	O
exon	O
4	O
of	O
the	O
PLP	O
gene	O
was	O
found	O
in	O
2	O
affected	O
males	O
and	O
two	O
obligate	O
carriers	O
in	O
a	O
German	O
family	O
with	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease	I-SpecificDisease
.	O
The	O
mutation	O
,	O
which	O
causes	O
loss	O
of	O
an	O
HphI	O
site	O
and	O
changes	O
amino	O
acid	O
155	O
from	O
threonine	O
to	O
isoleucine	O
,	O
was	O
absent	O
from	O
108	O
normal	O
chromosomes	O
.	O
There	O
are	O
5	O
concordances	O
and	O
1	O
discrepancy	O
between	O
these	O
results	O
and	O
those	O
obtained	O
by	O
magnetic	O
resonance	O
imaging	O
in	O
this	O
family	O
.	O
.	O

8499920	O
Structure	O
and	O
genomic	O
sequence	O
of	O
the	O
myotonic	B-Modifier
dystrophy	I-Modifier
(	O
DM	B-Modifier
kinase	O
)	O
gene.	O
The	O
mutation	O
causing	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
has	O
recently	O
been	O
identified	O
as	O
an	O
unstable	O
CTG	O
trinucleotide	O
repeat	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
a	O
gene	O
encoding	O
for	O
a	O
protein	O
with	O
putative	O
serine-threonine	O
protein	O
kinase	O
activity	O
.	O
In	O
this	O
report	O
we	O
present	O
the	O
genomic	O
sequences	O
of	O
the	O
human	O
and	O
murine	O
DM	B-Modifier
kinase	O
gene	O
.	O
A	O
comparison	O
of	O
these	O
sequences	O
with	O
each	O
other	O
and	O
with	O
known	O
cDNA	O
sequences	O
from	O
both	O
species	O
,	O
led	O
us	O
to	O
predict	O
a	O
translation	O
initiation	O
codon	O
,	O
as	O
well	O
as	O
determine	O
the	O
organization	O
of	O
the	O
DM	B-Modifier
kinase	O
gene	O
.	O
Several	O
polymorphisms	O
within	O
the	O
human	O
DM	B-Modifier
kinase	O
gene	O
have	O
been	O
identified	O
,	O
and	O
PCR	O
assays	O
to	O
detect	O
two	O
of	O
these	O
are	O
described	O
.	O
The	O
complete	O
sequence	O
and	O
characterization	O
of	O
the	O
structure	O
of	O
the	O
DM	B-Modifier
kinase	O
gene	O
,	O
as	O
well	O
as	O
the	O
identification	O
of	O
novel	O
polymorphisms	O
within	O
the	O
gene	O
,	O
represent	O
an	O
important	O
step	O
in	O
a	O
further	O
understanding	O
of	O
the	O
genetics	O
of	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
and	O
the	O
molecular	O
biology	O
of	O
the	O
gene	O
.	O
.	O

492335	O
Genetic	O
defect	B-SpecificDisease
in	I-SpecificDisease
secretion	I-SpecificDisease
of	I-SpecificDisease
complement	I-SpecificDisease
C5	I-SpecificDisease
in	O
mice.	O
A	O
genetic	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
fifth	I-SpecificDisease
(	I-SpecificDisease
C5	I-SpecificDisease
)	I-SpecificDisease
component	I-SpecificDisease
of	I-SpecificDisease
complement1-3	I-SpecificDisease
,	O
a	O
serum	O
glycoprotein	O
of	O
molecular	O
weight	O
(	O
MW	O
)	O
220	O
,	O
000	O
(	O
ref	O
.	O
4	O
)	O
,	O
has	O
been	O
found	O
in	O
39	O
%	O
of	O
inbred	O
strains	O
of	O
mice3	O
.	O
Sera	O
of	O
deficient	O
mice	O
lack	O
detectable	O
C5	O
activity	O
and	O
protein2	O
,	O
3	O
.	O
In	O
addition	O
deficient	O
mice	O
produce	O
antibody	O
to	O
mouse	O
C5	O
when	O
injected	O
with	O
sera	O
from	O
C5	O
sufficient	O
(	O
normal	O
)	O
strains	O
.	O
Levy	O
et	O
al	O
.	O
5	O
showed	O
that	O
somatic	O
cell	O
hybrids	O
between	O
C5	O
deficient	O
(	O
B10	O
.	O
D2	O
/	O
old	O
line	O
)	O
macrophages	O
and	O
either	O
C5	O
sufficient	O
(	O
B10	O
.	O
D2	O
/	O
new	O
line	O
)	O
mouse	O
kidney	O
or	O
chicken	O
erythroblasts	O
secreted	O
haemolytically	O
active	O
mouse	O
C5	O
in	O
vitro	O
.	O
Several	O
possible	O
molecular	O
mechanisms	O
to	O
account	O
for	O
the	O
findings	O
were	O
considered	O
,	O
but	O
insufficient	O
direct	O
data	O
were	O
available	O
to	O
choose	O
among	O
them	O
.	O
We	O
recently	O
reported	O
that	O
mouse	O
(	O
CD	O
.	O
1	O
strain	O
)	O
peritoneal	O
cells	O
in	O
culture	O
synthesise	O
and	O
secrete	O
a	O
single	O
chain	O
precursor	O
,	O
pro-C5	O
(	O
MW	O
approximately	O
210	O
,	O
000	O
)	O
,	O
of	O
the	O
two-chain	O
(	O
alpha	O
chain	O
,	O
125	O
,	O
000	O
and	O
beta	O
chain	O
83	O
,	O
000	O
MW	O
)	O
C5	O
protein6	O
.	O
Radiolabelled	O
precursor	O
C5	O
was	O
contained	O
within	O
the	O
cells	O
and	O
was	O
secreted	O
into	O
the	O
tissue	O
culture	O
media	O
.	O
Using	O
similar	O
methods	O
,	O
we	O
now	O
find	O
that	O
C5	B-SpecificDisease
deficiency	I-SpecificDisease
in	O
each	O
of	O
five	O
different	O
mouse	O
strains	O
(	O
AKR	O
,	O
SWR	O
,	O
DBA	O
/	O
2J8	O
A	O
/	O
HeJ	O
and	O
B10	O
.	O
D2	O
/	O
old	O
line	O
)	O
is	O
due	O
to	O
a	O
failure	O
in	O
secretion	O
of	O
C5	O
protein	O
and	O
not	O
to	O
a	O
failure	O
in	O
biosynthesis	O
of	O
pro-C5	O

10737981	O
beta-galactosidase	O
gene	O
mutations	O
affecting	O
the	O
lysosomal	O
enzyme	O
and	O
the	O
elastin-binding	O
protein	O
in	O
GM1-gangliosidosis	B-Modifier
patients	O
with	O
cardiac	B-SpecificDisease
involvement.	I-SpecificDisease
GM1-gangliosidosis	B-SpecificDisease
is	O
a	O
lysosomal	B-DiseaseClass
storage	I-DiseaseClass
disorder	I-DiseaseClass
caused	O
by	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
acid	I-SpecificDisease
beta-galactosidase	I-SpecificDisease
(	O
GLB1	O
)	O
.	O
We	O
report	O
five	O
new	O
beta-galactosidase	O
gene	O
mutations	O
in	O
nine	O
Italian	O
patients	O
and	O
one	O
fetus	O
,	O
segregating	O
in	O
seven	O
unrelated	O
families	O
.	O
Six	O
of	O
the	O
eight	O
patients	O
with	O
the	O
infantile	O
,	O
severe	O
form	O
of	O
the	O
disease	O
presented	O
cardiac	B-DiseaseClass
involvement	I-DiseaseClass
,	O
a	O
feature	O
rarely	O
associated	O
with	O
GM1-gangliosidosis	B-SpecificDisease
.	O
Molecular	O
analysis	O
of	O
the	O
patients	O
RNA	O
and	O
DNA	O
identified	O
two	O
new	O
RNA	O
splicing	O
defects	O
,	O
three	O
new	O
and	O
three	O
previously	O
described	O
amino	O
acid	O
substitutions	O
.	O
Interestingly	O
,	O
all	O
patients	O
with	O
cardiac	B-DiseaseClass
involvement	I-DiseaseClass
were	O
homozygous	O
for	O
one	O
of	O
these	O
mutations	O
R59H	O
,	O
Y591C	O
,	O
Y591N	O
,	O
or	O
IVS14-2A	O
>	O
G	O
.	O
In	O
contrast	O
,	O
all	O
other	O
patients	O
were	O
compound	O
heterozygous	O
for	O
one	O
of	O
the	O
following	O
mutations	O
R201H	O
,	O
R482H	O
,	O
G579D	O
,	O
IVS8	O
+	O
2T	O
>	O
C	O
.	O
Although	O
we	O
could	O
not	O
directly	O
correlate	O
the	O
presence	O
of	O
cardiac	B-DiseaseClass
abnormalities	I-DiseaseClass
with	O
specific	O
genetic	B-DiseaseClass
lesions	I-DiseaseClass
,	O
the	O
mutations	O
identified	O
in	O
patients	O
with	O
cardiomyopathy	B-DiseaseClass
fell	O
in	O
the	O
GLB1	O
cDNA	O
region	O
common	O
to	O
the	O
lysosomal	O
enzyme	O
and	O
the	O
Hbeta-Gal-related	O
protein	O
,	O
also	O
known	O
as	O
the	O
elastin	O
binding	O
protein	O
(	O
EBP	O
)	O
.	O
Consequently	O
,	O
both	O
molecules	O
are	O
affected	O
by	O
the	O
mutations	O
,	O
and	O
they	O
may	O
contribute	O
differently	O
to	O
the	O
occurrence	O
of	O
specific	O
clinical	O
manifestations	O
.	O
.	O

1384324	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease:	I-SpecificDisease
detection	O
of	O
mutations	O
Thr181----Pro	O
and	O
Leu223----Pro	O
in	O
the	O
proteolipid	O
protein	O
gene,	O
and	O
prenatal	O
diagnosis.	O
A	O
family	O
with	O
an	O
apparent	O
history	O
of	O
X-linked	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease	I-SpecificDisease
presented	O
for	O
genetic	O
counseling	O
,	O
requesting	O
carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
.	O
RFLP	O
analysis	O
using	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
probe	O
was	O
uninformative	O
in	O
this	O
family	O
.	O
A	O
prenatal	O
diagnosis	O
on	O
a	O
chorionic	O
villus	O
sample	O
(	O
CVS	O
)	O
was	O
carried	O
out	O
using	O
single-strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
of	O
a	O
variant	O
in	O
exon	O
4	O
of	O
the	O
PLP	O
gene	O
.	O
The	O
fetus	O
was	O
predicted	O
to	O
be	O
unaffected	O
.	O
Sequencing	O
of	O
the	O
exon	O
from	O
the	O
CVS	O
,	O
the	O
predicted-carrier	O
mother	O
,	O
and	O
the	O
obligate-carrier	O
grandmother	O
revealed	O
an	O
A-to-C	O
change	O
at	O
nucleotide	O
541	O
in	O
the	O
two	O
women	O
but	O
not	O
in	O
the	O
fetus	O
.	O
As	O
this	O
change	O
results	O
in	O
a	O
Thr-to-Pro	O
change	O
at	O
amino	O
acid	O
181	O
in	O
a	O
region	O
of	O
the	O
gene	O
predicted	O
to	O
be	O
part	O
of	O
a	O
transmembrane	O
segment	O
,	O
it	O
was	O
concluded	O
that	O
this	O
was	O
the	O
mutation	O
causing	O
the	O
disease	O
in	O
this	O
family	O
.	O
In	O
addition	O
,	O
in	O
a	O
second	O
family	O
,	O
an	O
exon	O
5	O
variant	O
band	O
pattern	O
on	O
SSCP	O
analysis	O
was	O
shown	O
by	O
sequencing	O
to	O
be	O
due	O
to	O
a	O
T-to-C	O
change	O
at	O
nucleotide	O
668	O
.	O
This	O
results	O
in	O
a	O
Leu-to-Pro	O
change	O
in	O
a	O
carrier	O
mother	O
and	O
in	O
her	O
two	O
affected	O
sons	O
.	O
These	O
results	O
provide	O
further	O
examples	O
of	O
mutations	O
in	O
PLP	O
that	O
cause	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease	I-SpecificDisease
and	O
illustrate	O
the	O
value	O
of	O
SSCP	O
in	O
genetic	O
analysis	O
.	O
.	O

10767343	O
Transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
expanded	O
CTG	O
repeat	O
mimic	O
closely	O
the	O
DM	B-Modifier
CTG	O
repeat	O
intergenerational	O
and	O
somatic	O
instability.	O
Myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
is	O
caused	O
by	O
a	O
CTG	O
repeat	O
expansion	O
in	O
the	O
3UTR	O
of	O
the	O
DM	B-Modifier
protein	O
kinase	O
(	O
DMPK	O
)	O
gene	O
.	O
A	O
very	O
high	O
level	O
of	O
instability	O
is	O
observed	O
through	O
successive	O
generations	O
and	O
the	O
size	O
of	O
the	O
repeat	O
is	O
generally	O
correlated	O
with	O
the	O
severity	O
of	O
the	O
disease	O
and	O
with	O
age	O
at	O
onset	O
.	O
Furthermore	O
,	O
tissues	O
from	O
DM	B-Modifier
patients	O
exhibit	O
somatic	O
mosaicism	O
that	O
increases	O
with	O
age	O
.	O
We	O
generated	O
transgenic	O
mice	O
carrying	O
large	O
human	O
genomic	O
sequences	O
with	O
20	O
,	O
55	O
or	O
>	O
300	O
CTG	O
,	O
cloned	O
from	O
patients	O
from	O
the	O
same	O
affected	O
DM	B-Modifier
family	O
.	O
Using	O
large	O
human	O
flanking	O
sequences	O
and	O
a	O
large	O
amplification	O
,	O
we	O
demonstrate	O
that	O
the	O
intergenerational	O
CTG	O
repeat	O
instability	O
is	O
reproduced	O
in	O
mice	O
,	O
with	O
a	O
strong	O
bias	O
towards	O
expansions	O
and	O
with	O
the	O
same	O
sex-	O
and	O
size-dependent	O
characteristics	O
as	O
in	O
humans	O
.	O
Moreover	O
,	O
a	O
high	O
level	O
of	O
instability	O
,	O
increasing	O
with	O
age	O
,	O
can	O
be	O
observed	O
in	O
tissues	O
and	O
in	O
sperm	O
.	O
Although	O
we	O
did	O
not	O
observe	O
dramatic	O
expansions	O
(	O
or	O
big	O
jumps	O
over	O
several	O
hundred	O
CTG	O
repeats	O
)	O
as	O
in	O
congenital	O
forms	O
of	O
DM	B-SpecificDisease
,	O
our	O
model	O
carrying	O
>	O
300	O
CTG	O
is	O
the	O
first	O
to	O
show	O
instability	O
so	O
close	O
to	O
the	O
human	O
DM	B-Modifier
situation	O
.	O
Our	O
three	O
models	O
carrying	O
different	O
sizes	O
of	O
CTG	O
repeat	O
provide	O
insight	O
on	O
the	O
different	O
factors	O
modulating	O
the	O
CTG	O
repeat	O
instability	O
.	O
.	O

10213492	O
Dominant	O
negative	O
effect	O
of	O
the	O
APC1309	O
mutation:	O
a	O
possible	O
explanation	O
for	O
genotype-phenotype	O
correlations	O
in	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis.	I-SpecificDisease
Inactivation	O
of	O
the	O
adenomatous	B-Modifier
polyposis	I-Modifier
coli	I-Modifier
(	O
APC	B-Modifier
)	O
gene	O
product	O
initiates	O
colorectal	O
tumorigenesis	O
.	O
Patients	O
with	O
familial	B-SpecificDisease
APC	I-SpecificDisease
(	O
FAP	B-SpecificDisease
)	O
carry	O
germ-line	O
mutations	O
in	O
the	O
APC	B-Modifier
gene	O
and	O
develop	O
multiple	O
colorectal	B-SpecificDisease
adenomas	I-SpecificDisease
and	O
subsequent	O
carcinomas	B-DiseaseClass
early	O
in	O
life	O
.	O
The	O
severity	O
of	O
the	O
disease	O
correlates	O
with	O
the	O
position	O
of	O
the	O
inherited	O
APC	B-Modifier
mutation	O
(	O
genotype-phenotype	O
correlation	O
)	O
.	O
Together	O
with	O
the	O
fact	O
that	O
both	O
germ-line	O
and	O
sporadic	O
APC	B-Modifier
mutations	O
cluster	O
in	O
the	O
central	O
region	O
of	O
the	O
APC	B-Modifier
gene	O
,	O
this	O
points	O
to	O
a	O
dominant	O
negative	O
effect	O
of	O
certain	O
APC	B-Modifier
mutants	O
.	O
Loss	O
of	O
APC	B-Modifier
function	O
was	O
recently	O
shown	O
to	O
result	O
in	O
enhanced	O
beta-catenin-	O
/	O
Tcf-mediated	O
transcription	O
in	O
colon	O
epithelial	O
cells	O
.	O
Here	O
,	O
we	O
provide	O
experimental	O
evidence	O
for	O
a	O
dominant	O
negative	O
effect	O
of	O
APC	B-Modifier
gene	O
products	O
associated	O
with	O
severe	O
polyposis	B-SpecificDisease
.	O
Wild-type	O
APC	B-Modifier
activity	O
in	O
beta-catenin-	O
/	O
Tcf-mediated	O
transcription	O
was	O
strongly	O
inhibited	O
by	O
a	O
mutant	O
APC	B-Modifier
that	O
is	O
truncated	O
at	O
codon	O
1309	O
.	O
In	O
contrast	O
,	O
mutant	O
APC	B-Modifier
gene	O
products	O
that	O
are	O
associated	O
with	O
attenuated	B-SpecificDisease
polyposis	I-SpecificDisease
(	O
codon	O
386	O
or	O
1465	O
)	O
interfered	O
only	O
weakly	O
with	O
wild-type	O
APC	B-Modifier
activity	O
.	O
These	O
results	O
suggest	O
a	O
molecular	O
explanation	O
for	O
the	O
genotype-phenotype	O
correlation	O
in	O
FAP	B-Modifier
patients	O
and	O
support	O
the	O
idea	O
that	O
colorectal	B-Modifier
tumor	I-Modifier
growth	O
might	O
be	O
,	O
in	O
part	O
,	O
driven	O
by	O
selection	O
for	O
a	O
mutation	O
in	O
the	O
mutation	O
cluster	O
region	O
.	O
.	O

7607677	O
Mucopolysaccharidosis	B-SpecificDisease
type	I-SpecificDisease
IVA:	I-SpecificDisease
common	O
double	O
deletion	O
in	O
the	O
N-acetylgalactosamine-6-sulfatase	O
gene	O
(GALNS).	O
Mucopolysaccharidosis	B-SpecificDisease
IVA	I-SpecificDisease
(	O
MPS	B-SpecificDisease
IVA	I-SpecificDisease
)	O
is	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
caused	O
by	O
a	O
deficiency	B-SpecificDisease
in	I-SpecificDisease
N-acetylgalactosamine-6-sulfatase	I-SpecificDisease
(	O
GALNS	O
)	O
.	O
We	O
found	O
two	O
separate	O
deletions	O
of	O
nearly	O
8	O
.	O
0	O
and	O
6	O
.	O
0	O
kb	O
in	O
the	O
GALNS	O
gene	O
,	O
including	O
some	O
exons	O
.	O
There	O
are	O
Alu	O
repetitive	O
elements	O
near	O
the	O
breakpoints	O
of	O
the	O
8	O
.	O
0-kb	O
deletion	O
,	O
and	O
this	O
deletion	O
resulted	O
from	O
an	O
Alu-Alu	O
recombination	O
.	O
The	O
other	O
6	O
.	O
0-kb	O
deletion	O
involved	O
illegitimate	O
recombinational	O
events	O
between	O
incomplete	O
short	O
direct	O
repeats	O
of	O
8	O
bp	O
at	O
deletion	O
breakpoints	O
.	O
The	O
same	O
rearrangement	O
has	O
been	O
observed	O
in	O
a	O
heteroallelic	O
state	O
in	O
four	O
unrelated	O
patients	O
.	O
This	O
is	O
the	O
first	O
documentation	O
of	O
a	O
common	O
double	O
deletion	O
a	O
gene	O
that	O
is	O
not	O
a	O
member	O
of	O
a	O
gene	O
cluster	O
.	O

1409710	O
von	B-SpecificDisease
Willebrand	I-SpecificDisease
disease	I-SpecificDisease
type	I-SpecificDisease
B:	I-SpecificDisease
a	O
missense	O
mutation	O
selectively	O
abolishes	O
ristocetin-induced	O
von	B-Modifier
Willebrand	I-Modifier
factor	O
binding	O
to	O
platelet	O
glycoprotein	O
Ib.	O
von	B-Modifier
Willebrand	I-Modifier
factor	O
(	O
vWF	O
)	O
is	O
a	O
multimeric	O
glycoprotein	O
that	O
mediates	O
the	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
by	O
binding	O
to	O
platelet	O
glycoprotein	O
Ib	O
.	O
For	O
human	O
vWF	O
,	O
this	O
interaction	O
can	O
be	O
induced	O
in	O
vitro	O
by	O
the	O
antibiotic	O
ristocetin	O
or	O
the	O
snake	O
venom	O
protein	O
botrocetin	O
.	O
A	O
missense	O
mutation	O
,	O
Gly-561--	O
>	O
Ser	O
,	O
was	O
identified	O
within	O
the	O
proposed	O
glycoprotein	O
Ib	O
binding	O
domain	O
of	O
vWF	O
in	O
the	O
proband	O
with	O
von	B-SpecificDisease
Willebrand	I-SpecificDisease
disease	I-SpecificDisease
type	I-SpecificDisease
B	I-SpecificDisease
,	O
a	O
unique	O
variant	O
characterized	O
by	O
no	O
ristocetin-induced	O
,	O
but	O
normal	O
botrocetin-induced	O
,	O
binding	O
to	O
glycoprotein	O
Ib	O
.	O
The	O
corresponding	O
mutant	O
recombinant	O
protein	O
,	O
rvWF	O
(	O
G561S	O
)	O
,	O
formed	O
normal	O
multimers	O
and	O
exhibited	O
the	O
same	O
functional	O
defect	O
as	O
the	O
patients	O
plasma	O
vWF	O
,	O
confirming	O
that	O
this	O
mutation	O
causes	O
von	B-SpecificDisease
Willebrand	I-SpecificDisease
disease	I-SpecificDisease
type	I-SpecificDisease
B	I-SpecificDisease
.	O
These	O
data	O
show	O
that	O
botrocetin	O
and	O
ristocetin	O
cofactor	O
activities	O
of	O
vWF	O
can	O
be	O
dissociated	O
by	O
a	O
point	O
mutation	O
and	O
confirm	O
that	O
these	O
mediators	O
promote	O
vWF	O
binding	O
to	O
platelets	O
by	O
different	O
mechanisms	O
.	O
The	O
normal	O
botrocetin-induced	O
binding	O
and	O
the	O
defective	O
ristocetin-induced	O
binding	O
of	O
rvWF	O
(	O
G561S	O
)	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
von	B-SpecificDisease
Willebrand	I-SpecificDisease
disease	I-SpecificDisease
type	I-SpecificDisease
B	I-SpecificDisease
may	O
be	O
a	O
failure	O
of	O
normal	O
allosteric	O
regulation	O
of	O
the	O
glycoprotein	O
Ib	O
binding	O
function	O
of	O
vWF	O
.	O
.	O

2852474	O
Complex	B-SpecificDisease
glycerol	I-SpecificDisease
kinase	I-SpecificDisease
deficiency:	I-SpecificDisease
molecular-genetic,	O
cytogenetic,	O
and	O
clinical	O
studies	O
of	O
five	O
Japanese	O
patients.	O
Five	O
male	O
Japanese	O
patients	O
with	O
complex	B-SpecificDisease
glycerol	I-SpecificDisease
kinase	I-SpecificDisease
deficiency	I-SpecificDisease
(	O
CGKD	B-SpecificDisease
)	O
and	O
their	O
relatives	O
were	O
studied	O
clinically	O
,	O
cytogenetically	O
,	O
and	O
molecular-genetically	O
.	O
All	O
patients	O
had	O
muscular	B-DiseaseClass
dystrophy	I-DiseaseClass
or	O
muscle	B-DiseaseClass
weakness	I-DiseaseClass
,	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
,	O
congenital	B-SpecificDisease
adrenal	I-SpecificDisease
hypoplasia	I-SpecificDisease
,	O
and	O
glycerol	B-DiseaseClass
kinase	I-DiseaseClass
deficiency	I-DiseaseClass
.	O
High-resolution	O
GTG-banded	O
chromosomes	O
showed	O
a	O
microdeletion	O
in	O
the	O
Xp21	O
region	O
in	O
all	O
four	O
patients	O
examined	O
and	O
in	O
all	O
five	O
mothers	O
.	O
Southern	O
hybridizations	O
,	O
after	O
digestions	O
by	O
restriction	O
endonucleases	O
,	O
with	O
various	O
cloned	O
DNAs	O
(	O
D2	O
,	O
99-6	O
,	O
B24	O
,	O
C7	O
,	O
L1-4	O
,	O
cDMD13-14	O
,	O
J66-HI	O
,	O
P20	O
,	O
J-Bir	O
,	O
ERT87-30	O
,	O
ERT87-15	O
,	O
ERT87-8	O
,	O
ERT87-1	O
,	O
XJ-1	O
.	O
1	O
,	O
754	O
,	O
cx5	O
.	O
7	O
,	O
and	O
OTC-1	O
)	O
that	O
are	O
located	O
around	O
Xp21	O
also	O
showed	O
a	O
deletion	O
in	O
the	O
genome	O
of	O
all	O
patients	O
and	O
mothers	O
.	O
Although	O
the	O
deletion	O
differed	O
in	O
size	O
among	O
patients	O
,	O
a	O
segment	O
commonly	O
absent	O
was	O
located	O
between	O
the	O
genomic	O
sequences	O
corresponding	O
to	O
L1-4	O
and	O
cDMD13-14	O
.	O
This	O
finding	O
indicated	O
that	O
the	O
gene	O
coding	O
for	O
glycerol	O
kinase	O
(	O
GK	O
)	O
is	O
located	O
within	O
this	O
segment	O
.	O
A	O
comparison	O
of	O
the	O
clinical	O
manifestations	O
of	O
the	O
present	O
five	O
patients	O
and	O
reported	O
CGKD	B-Modifier
or	O
Duchenne	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
(	O
DMD	B-Modifier
)	O
patients	O
with	O
DNA	O
deletion	O
suggests	O
the	O
existence	O
of	O
a	O
certain	O
gene	O
responsible	O
for	O
gonadotropin	B-SpecificDisease
deficiency	I-SpecificDisease
(	O
GTD	B-SpecificDisease
)	O
.	O
The	O
result	O
of	O
the	O
present	O
study	O
and	O
results	O
of	O
previous	O
studies	O
suggest	O
that	O
genes	O
for	O
ornithine	O
transcarbamylase	O
(	O
OTC	O
)	O
,	O
DMD	B-SpecificDisease
,	O
and	O
GK	O
and	O
putative	O
genes	O
responsible	O
for	O
congenital	B-SpecificDisease
adrenal	I-SpecificDisease
hypoplasia	I-SpecificDisease
(	O
AHC	B-SpecificDisease
)	O
and	O
GTD	B-SpecificDisease
are	O
arranged	O
from	O
telomere	O
to	O
centromere	O
as	O
pter--GTD--AHC--GK--DMD--OTC--cen	O

8281142	O
Genetic	O
analysis	O
of	O
the	O
BRCA1	O
region	O
in	O
a	O
large	O
breast/ovarian	O
family:	O
refinement	O
of	O
the	O
minimal	O
region	O
containing	O
BRCA1.	O
We	O
have	O
analyzed	O
a	O
single	O
multi-affected	O
breast	B-Modifier
/	I-Modifier
ovarian	I-Modifier
cancer	I-Modifier
pedigree	O
(	O
BOV3	O
)	O
and	O
have	O
shown	O
consistent	O
inheritance	O
of	O
markers	O
on	O
chromosome	O
17q	O
with	O
the	O
disease	O
confirming	O
that	O
this	O
family	O
is	O
due	O
to	O
the	O
BRCA1	O
gene	O
.	O
Analysis	O
of	O
17q	O
haplotypes	O
shows	O
a	O
recombination	O
event	O
in	O
a	O
bilateral	O
breast	B-Modifier
cancer	I-Modifier
case	O
which	O
suggests	O
that	O
the	O
BRCA1	O
gene	O
lies	O
distal	O
to	O
D17S857	O
;	O
D17S857	O
is	O
thus	O
the	O
new	O
proximal	O
boundary	O
for	O
the	O
region	O
containing	O
BRCA1	O
.	O
Combining	O
this	O
information	O
with	O
previously	O
published	O
mapping	O
information	O
suggests	O
that	O
BRCA1	O
is	O
contained	O
in	O
a	O
region	O
estimated	O
at	O
1-1	O
.	O
5	O
Mb	O
in	O
length	O
.	O
All	O
seven	O
breast	B-Modifier
tumour	I-Modifier
/	O
blood	O
pairs	O
examined	O
from	O
this	O
family	O
show	O
loss	O
of	O
heterozygosity	O
in	O
the	O
tumours	B-DiseaseClass
.	O
The	O
allel	O
retained	O
in	O
each	O
tumour	B-DiseaseClass
was	O
from	O
the	O
disease-bearing	O
chromosome	O
implicating	O
BRCA1	O
as	O
a	O
tumour	B-Modifier
suppressor	O
gene	O
.	O
We	O
have	O
sequenced	O
the	O
17	O
beta-oestradiol	O
dehydrogenase	O
genes	O
(	O
EDH17B1	O
and	O
EDH17B2	O
)	O
which	O
have	O
been	O
suggested	O
as	O
candidate	O
genes	O
for	O
BRCA1	O
in	O
four	O
members	O
of	O
this	O
family	O
.	O
No	O
germline	O
mutations	O
were	O
detected	O
.	O

7814011	O
Novel	O
mutation	O
at	O
the	O
initiation	O
codon	O
in	O
the	O
Norrie	B-Modifier
disease	I-Modifier
gene	O
in	O
two	O
Japanese	O
families.	O
We	O
have	O
identified	O
a	O
new	O
mutation	O
of	O
Norrie	B-Modifier
disease	I-Modifier
(	O
ND	B-Modifier
)	O
gene	O
in	O
two	O
Japanese	O
males	O
from	O
unrelated	O
families	O
;	O
they	O
showed	O
typical	O
ocular	O
features	O
of	O
ND	B-SpecificDisease
but	O
no	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
or	O
hearing	B-DiseaseClass
impairment	I-DiseaseClass
.	O
A	O
mutation	O
was	O
found	O
in	O
both	O
patients	O
at	O
the	O
initiation	O
codon	O
of	O
exon	O
2	O
of	O
the	O
ND	B-Modifier
gene	O
(	O
ATG	O
to	O
GTG	O
)	O
,	O
with	O
otherwise	O
normal	O
nucleotide	O
sequences	O
.	O
Their	O
mothers	O
had	O
the	O
normal	O
and	O
mutant	O
types	O
of	O
the	O
gene	O
,	O
which	O
was	O
expected	O
for	O
heterozygotes	O
of	O
the	O
disease	O
.	O
The	O
mutation	O
of	O
the	O
initiation	O
codon	O
would	O
cause	O
the	O
failure	O
of	O
ND	B-Modifier
gene	O
expression	O
or	O
a	O
defect	O
in	O
translation	O
thereby	O
truncating	O
the	O
amino	O
terminus	O
of	O
ND	B-Modifier
protein	O
.	O
In	O
view	O
of	O
the	O
rarity	O
and	O
marked	O
heterogeneity	O
of	O
mutations	O
in	O
the	O
ND	B-Modifier
gene	O
,	O
the	O
present	O
apparently	O
unrelated	O
Japanese	O
families	O
who	O
have	O
lived	O
in	O
the	O
same	O
area	O
for	O
over	O
two	O
centuries	O
presumably	O
share	O
the	O
origin	O
of	O
the	O
mutation	O
.	O
.	O

10987655	O
Detection	O
of	O
a	O
novel	O
missense	O
mutation	O
and	O
second	O
recurrent	O
mutation	O
in	O
the	O
CACNA1A	O
gene	O
in	O
individuals	O
with	O
EA-2	B-SpecificDisease
and	O
FHM.	B-SpecificDisease
Mutations	O
in	O
the	O
brain	O
specific	O
P	O
/	O
Q	O
type	O
Ca2	O
+	O
channel	O
alpha1	O
subunit	O
gene	O
,	O
CACNA1A	O
,	O
have	O
been	O
identified	O
in	O
three	O
clinically	O
distinct	O
disorders	O
,	O
viz	O
.	O
episodic	B-SpecificDisease
ataxia	I-SpecificDisease
type	I-SpecificDisease
2	I-SpecificDisease
(	O
EA-2	B-SpecificDisease
)	O
,	O
familial	B-SpecificDisease
hemiplegic	I-SpecificDisease
migraine	I-SpecificDisease
(	O
FHM	B-SpecificDisease
)	O
and	O
spinocerebellar	B-SpecificDisease
ataxia	I-SpecificDisease
6	I-SpecificDisease
(	O
SCA6	B-SpecificDisease
)	O
.	O
For	O
individuals	O
with	O
EA-2	B-SpecificDisease
,	O
the	O
mutations	O
described	O
thus	O
far	O
are	O
presumed	O
to	O
result	O
in	O
a	O
truncated	O
protein	O
product	O
.	O
Several	O
different	O
missense	O
mutations	O
have	O
been	O
identified	O
in	O
patients	O
with	O
FHM	B-SpecificDisease
.	O
At	O
least	O
two	O
of	O
these	O
mutations	O
have	O
been	O
identified	O
on	O
two	O
different	O
chromosome	O
19p13	O
haplotypes	O
and	O
thus	O
represent	O
recurrent	O
mutations	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
screened	O
several	O
individuals	O
for	O
mutations	O
in	O
all	O
47	O
exons	O
in	O
the	O
CACNA1A	O
gene	O
by	O
single-strand	O
conformation	O
analysis	O
.	O
We	O
have	O
characterised	O
a	O
novel	O
missense	O
mutation	O
,	O
G5260A	O
,	O
in	O
exon	O
32	O
in	O
a	O
family	O
segregating	O
for	O
EA-2	B-SpecificDisease
.	O
The	O
consequence	O
of	O
this	O
mutation	O
is	O
an	O
amino	O
acid	O
substitution	O
at	O
a	O
highly	O
conserved	O
position	O
within	O
the	O
CACNA1A	O
gene	O
.	O
This	O
represents	O
the	O
first	O
point	O
mutation	O
not	O
resulting	O
in	O
a	O
proposed	O
truncated	O
protein	O
.	O
Furthermore	O
,	O
this	O
mutation	O
has	O
been	O
detected	O
in	O
a	O
family	O
member	O
with	O
mild	O
clinical	O
signs	O
including	O
only	O
migraine	B-SpecificDisease
.	O
Additionally	O
,	O
a	O
second	O
previously	O
identified	O
recurrent	O
muta	O
tion	O
,	O
C2272T	O
,	O
in	O
exon	O
16	O
has	O
been	O
discovered	O
in	O
a	O
patient	O
with	O
FHM	B-SpecificDisease
.	O
.	O

10698963	O
Human	O
mutations	O
in	O
glucose	O
6-phosphate	O
dehydrogenase	O
reflect	O
evolutionary	O
history.	O
Glucose	O
6-phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
is	O
a	O
cytosolic	O
enzyme	O
encoded	O
by	O
a	O
housekeeping	O
X-linked	O
gene	O
whose	O
main	O
function	O
is	O
to	O
produce	O
NADPH	O
,	O
a	O
key	O
electron	O
donor	O
in	O
the	O
defense	O
against	O
oxidizing	O
agents	O
and	O
in	O
reductive	O
biosynthetic	O
reactions	O
.	O
Inherited	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
is	O
associated	O
with	O
either	O
episodic	B-SpecificDisease
hemolytic	I-SpecificDisease
anemia	I-SpecificDisease
(	O
triggered	O
by	O
fava	O
beans	O
or	O
other	O
agents	O
)	O
or	O
life-long	B-SpecificDisease
hemolytic	I-SpecificDisease
anemia	I-SpecificDisease
.	O
We	O
show	O
here	O
that	O
an	O
evolutionary	O
analysis	O
is	O
a	O
key	O
to	O
understanding	O
the	O
biology	O
of	O
a	O
housekeeping	O
gene	O
.	O
From	O
the	O
alignment	O
of	O
the	O
amino	O
acid	O
(	O
aa	O
)	O
sequence	O
of	O
52	O
glucose	O
6-phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
species	O
from	O
42	O
different	O
organisms	O
,	O
we	O
found	O
a	O
striking	O
correlation	O
between	O
the	O
aa	O
replacements	O
that	O
cause	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
in	O
humans	O
and	O
the	O
sequence	O
conservation	O
of	O
G6PD	O
two-thirds	O
of	O
such	O
replacements	O
are	O
in	O
highly	O
and	O
moderately	O
conserved	O
(	O
50-99	O
%	O
)	O
aa	O
;	O
relatively	O
few	O
are	O
in	O
fully	O
conserved	O
aa	O
(	O
where	O
they	O
might	O
be	O
lethal	O
)	O
or	O
in	O
poorly	O
conserved	O
aa	O
,	O
where	O
presumably	O
they	O
simply	O
would	O
not	O
cause	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
This	O
is	O
consistent	O
with	O
the	O
notion	O
that	O
all	O
human	O
mutants	O
have	O
residual	O
enzyme	O
activity	O
and	O
that	O
null	O
mutations	O
are	O
lethal	O
at	O
some	O
stage	O
of	O
development	O
.	O
Comparing	O
the	O
distribution	O
of	O
mutations	O
in	O
a	O
human	O
housekeeping	O
gene	O
with	O
evolutionary	O
conservation	O
is	O
a	O
useful	O
tool	O
for	O
pinpointing	O
amino	O
acid	O
residues	O
important	O
for	O
the	O
stability	O
or	O
the	O
function	O
of	O
the	O
corresponding	O
protein	O
.	O
In	O
view	O
of	O
the	O
current	O
explosive	O
increase	O
in	O
full	O
genome	O
sequencing	O
projects	O
,	O
this	O
tool	O
will	O
become	O
rapidly	O
available	O
for	O
numerous	O
other	O
genes	O
.	O
.	O

8364574	O
PAX6	O
mutations	O
in	O
aniridia.	B-SpecificDisease
Aniridia	B-SpecificDisease
is	O
a	O
congenital	B-DiseaseClass
malformation	I-DiseaseClass
of	I-DiseaseClass
the	I-DiseaseClass
eye	I-DiseaseClass
,	O
chiefly	O
characterised	O
by	O
iris	B-SpecificDisease
hypoplasia	I-SpecificDisease
,	O
which	O
can	O
cause	O
blindness	B-SpecificDisease
.	O
The	O
PAX6	O
gene	O
was	O
isolated	O
as	O
a	O
candidate	O
aniridia	B-Modifier
gene	O
by	O
positional	O
cloning	O
from	O
the	O
smallest	O
region	O
of	O
overlap	O
of	O
aniridia-associated	B-Modifier
deletions	O
.	O
Subsequently	O
PAX6	O
intragenic	O
mutations	O
were	O
demonstrated	O
in	O
Smalleye	O
,	O
a	O
mouse	O
mutant	O
which	O
is	O
an	O
animal	O
model	O
for	O
aniridia	B-SpecificDisease
,	O
and	O
six	O
human	O
aniridia	B-Modifier
patients	O
.	O
In	O
this	O
paper	O
we	O
describe	O
four	O
additional	O
PAX6	O
point	O
mutations	O
in	O
aniridia	B-Modifier
patients	O
,	O
both	O
sporadic	O
and	O
familial	O
.	O
These	O
mutations	O
highlight	O
regions	O
of	O
the	O
gene	O
which	O
are	O
essential	O
for	O
normal	O
PAX6	O
function	O
.	O
In	O
addition	O
,	O
the	O
frequency	O
at	O
which	O
we	O
have	O
found	O
PAX6	O
mutations	O
suggests	O
that	O
lesions	O
in	O
PAX6	O
will	O
account	O
for	O
most	O
cases	O
of	O
aniridia	B-SpecificDisease
.	O
.	O

3563511	O
Identification	O
and	O
localization	O
of	O
mutations	O
at	O
the	O
Lesch-Nyhan	B-Modifier
locus	O
by	O
ribonuclease	O
A	O
cleavage.	O
Many	O
mutations	O
leading	O
to	O
human	O
disease	O
are	O
the	O
result	O
of	O
single	O
DNA	O
base	O
pair	O
changes	O
that	O
cannot	O
be	O
identified	O
by	O
Southern	O
analysis	O
.	O
This	O
has	O
prompted	O
the	O
development	O
of	O
alternative	O
assays	O
for	O
point	O
mutation	O
detection	O
.	O
The	O
recently	O
described	O
ribonuclease	O
A	O
cleavage	O
procedure	O
,	O
with	O
a	O
polyuridylic	O
acid-paper	O
affinity	O
chromatography	O
step	O
,	O
has	O
been	O
used	O
to	O
identify	O
the	O
mutational	B-DiseaseClass
lesions	I-DiseaseClass
in	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
messenger	O
RNAs	O
of	O
patients	O
with	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
Distinctive	O
ribonuclease	O
A	O
cleavage	O
patterns	O
were	O
identified	O
in	O
messenger	O
RNA	O
from	O
5	O
of	O
14	O
Lesch-Nyhan	B-Modifier
patients	O
who	O
were	O
chosen	O
because	O
no	O
HPRT	O
Southern	O
or	O
Northern	O
blotting	O
pattern	O
changes	O
had	O
been	O
found	O
.	O
This	O
approach	O
now	O
allows	O
HPRT	O
mutation	O
detection	O
in	O
50	O
percent	O
of	O
the	O
cases	O
of	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
The	O
polyuridylic	O
acid-paper	O
affinity	O
procedure	O
provides	O
a	O
general	O
method	O
for	O
analysis	O
of	O
low	O
abundance	O
messenger	O
RNAs	O
.	O
.	O

318684	O
Hereditary	B-SpecificDisease
deficiency	I-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
third	I-SpecificDisease
component	I-SpecificDisease
of	I-SpecificDisease
complement	I-SpecificDisease
in	O
a	O
child	O
with	O
fever,	B-DiseaseClass
skin	B-DiseaseClass
rash,	I-DiseaseClass
and	O
arthralgias:	B-DiseaseClass
response	O
to	O
transfusion	O
of	O
whole	O
blood.	O
A	O
previously	O
well	O
34-month-old	O
male	O
presenting	O
with	O
fever	B-DiseaseClass
,	O
skin	B-DiseaseClass
rash	I-DiseaseClass
,	O
and	O
arthralgias	B-DiseaseClass
was	O
found	O
to	O
lack	O
C3	O
by	O
immunochemical	O
(	O
undetectable	O
)	O
and	O
hemolytic	O
(	O
1	O
%	O
normal	O
)	O
assays	O
.	O
No	O
infectious	O
agent	O
could	O
be	O
demonstrated	O
.	O
Protein	O
levels	O
of	O
Clq	O
.	O
C4	O
,	O
C5	O
,	O
properdin	O
,	O
and	O
C3b-INA	O
and	O
hemolytic	O
activities	O
of	O
complement	O
components	O
C1	O
to	O
C9	O
except	O
C3	O
were	O
normal	O
or	O
elevated	O
;	O
total	O
hemolytic	O
complement	O
activity	O
was	O
13	O
%	O
of	O
normal	O
and	O
was	O
reconstituted	O
by	O
purified	O
C3	O
.	O
Properdin	O
factor	O
B	O
was	O
702	O
(	O
normal	O
175	O
to	O
275	O
)	O
mug	O
/	O
ml	O
,	O
and	O
was	O
not	O
cleaver	O
upon	O
addition	O
of	O
zymosan	O
or	O
cobra	O
venom	O
factor	O
.	O
The	O
serum	O
had	O
normal	O
immune	O
adherence	O
activity	O
,	O
but	O
was	O
deficient	O
in	O
ability	O
to	O
opsonize	O
Candida	O
albicans	O
for	O
uptake	O
and	O
Escherichia	O
coli	O
for	O
killing	O
by	O
neurophils	O
,	O
generate	O
neutrophil	O
chemotactic	O
factors	O
and	O
inhibit	O
the	O
growth	O
of	O
E	O
.	O
coli	O
;	O
these	O
activities	O
were	O
restored	O
by	O
purified	O
C3	O
.	O
A	O
transfusion	O
of	O
320	O
ml	O
1-hour-old	O
normal	O
whole	O
blood	O
on	O
the	O
fifty-second	O
day	O
resulted	O
in	O
transitory	O
elevation	O
of	O
the	O
C3	O
level	O
to	O
25	O
mg	O
/	O
dl	O
with	O
a	O
fall-off	O
(	O
approximately	O
2	O
1	O
/	O
2	O
%	O
per	O
hour	O
)	O
to	O
undetectable	O
levels	O
by	O
69	O
hours	O
;	O
it	O
was	O
followed	O
by	O
disappearance	O
of	O
the	O
skin	B-DiseaseClass
rash	I-DiseaseClass
and	O
arthralgias	B-DiseaseClass
and	O
return	O
to	O
normal	O
of	O
the	O
previously	O
elevated	O
temperature	O
and	O
CRP	O
levels	O
.	O
C3	O
levels	O
in	O
family	O
members	O
(	O
seven	O
of	O
24	O
half-normal	O
)	O
,	O
lack	O
of	O
anti-C3	O
activity	O
,	O
normal	O
C3b-INA	O
levels	O
and	O
a	O
normal	O
rate	O
of	O
catabolism	O
of	O
transfused	O
C3	O
indicated	O
that	O
the	O
deficiency	O
was	O
inherited	O
with	O
autosomal	O
codominance	O
and	O
involved	O
decreased	B-DiseaseClass
synthesis	I-DiseaseClass
of	I-DiseaseClass
C3	I-DiseaseClass
.	O
Thus	O
,	O
this	O
child	O
is	O
a	O
unique	O
individual	O
with	O
inherited	B-SpecificDisease
C3	I-SpecificDisease
deficiency	I-SpecificDisease
presenting	O
with	O
absence	O
of	O
repeated	O
infections	O
,	O
whose	O
symptoms	O
of	O
fever	B-DiseaseClass
,	O
skin	B-DiseaseClass
rash	I-DiseaseClass
,	O
and	O
arthralgia	B-DiseaseClass
were	O
abated	O
by	O
whole	O
blood	O
transfusion	O
.	O
.	O

3615198	O
GT	O
to	O
AT	O
transition	O
at	O
a	O
splice	O
donor	O
site	O
causes	O
skipping	O
of	O
the	O
preceding	O
exon	O
in	O
phenylketonuria.	B-SpecificDisease
Classical	B-SpecificDisease
Phenylketonuria	I-SpecificDisease
(	O
PKU	B-SpecificDisease
)	O
is	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
human	I-DiseaseClass
genetic	I-DiseaseClass
disorder	I-DiseaseClass
caused	O
by	O
a	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
hepatic	I-SpecificDisease
phenylalanine	I-SpecificDisease
hydroxylase	I-SpecificDisease
(	O
PAH	O
)	O
.	O
We	O
isolated	O
several	O
mutant	O
PAH	O
cDNA	O
clones	O
from	O
a	O
PKU	B-Modifier
carrier	O
individual	O
and	O
showed	O
that	O
they	O
contained	O
an	O
internal	O
116	O
base	O
pair	O
deletion	O
,	O
corresponding	O
precisely	O
to	O
exon	O
12	O
of	O
the	O
human	O
chromosomal	O
PAH	O
gene	O
.	O
The	O
deletion	O
causes	O
the	O
synthesis	O
of	O
a	O
truncated	O
protein	O
lacking	O
the	O
C-terminal	O
52	O
amino	O
acids	O
.	O
Gene	O
transfer	O
and	O
expression	O
studies	O
using	O
the	O
mutant	O
PAH	O
cDNA	O
indicated	O
that	O
the	O
deletion	O
abolishes	O
PAH	O
activity	O
in	O
the	O
cell	O
as	O
a	O
result	O
of	O
protein	O
instability	O
.	O
To	O
determine	O
the	O
molecular	O
basis	O
of	O
the	O
deletion	O
,	O
the	O
mutant	O
chromosomal	O
PAH	O
gene	O
was	O
isolated	O
from	O
this	O
individual	O
and	O
shown	O
to	O
contain	O
a	O
GT--	O
greater	O
than	O
AT	O
substitution	O
at	O
the	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
12	O
.	O
Thus	O
,	O
the	O
consequence	O
of	O
the	O
splice	O
donor	O
site	O
mutation	O
in	O
the	O
human	O
liver	O
is	O
the	O
skipping	O
of	O
the	O
preceding	O
exon	O
during	O
RNA	O
splicing	O
.	O
.	O

2309698	O
The	O
red-green	O
visual	O
pigment	O
gene	O
region	O
in	O
adrenoleukodystrophy.	B-SpecificDisease
Although	O
recent	O
data	O
established	O
that	O
a	O
specific	O
very-long-chain	O
fatty	O
acyl-CoA	O
synthetase	O
is	O
defective	O
in	O
X-linked	B-SpecificDisease
adrenoleukodystrophy	I-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
,	O
the	O
ALD	B-Modifier
gene	O
is	O
still	O
unidentified	O
.	O
The	O
ALD	B-Modifier
locus	O
has	O
been	O
mapped	O
to	O
Xq28	O
,	O
like	O
the	O
red	O
and	O
green	O
color	O
pigment	O
genes	O
.	O
Abnormal	B-DiseaseClass
color	I-DiseaseClass
vision	I-DiseaseClass
has	O
been	O
observed	O
in	O
12	O
of	O
27	O
patients	O
with	O
adrenomyeloneuropathy	B-SpecificDisease
(	O
AMN	B-SpecificDisease
)	O
,	O
a	O
milder	O
form	O
of	O
ALD	B-SpecificDisease
.	O
Furthermore	O
,	O
rearrangements	O
of	O
the	O
color	O
vision	O
gene	O
cluster	O
were	O
found	O
in	O
four	O
of	O
eight	O
ALD	B-Modifier
kindreds	O
.	O
This	O
led	O
us	O
to	O
propose	O
that	O
a	O
single	O
DNA	O
rearrangement	O
could	O
underlie	O
both	O
ALD	B-SpecificDisease
and	O
abnormal	B-SpecificDisease
color	I-SpecificDisease
vision	I-SpecificDisease
in	O
these	O
patients	O
.	O
Study	O
of	O
34	O
French	O
ALD	B-Modifier
patients	O
failed	O
to	O
reveal	O
a	O
higher	O
than	O
expected	O
frequency	O
of	O
green	O
/	O
red	O
visual	O
pigment	O
rearrangements	O
3	O
to	O
the	O
red	O
/	O
green	O
color	O
vision	O
gene	O
complex	O
.	O
The	O
previous	O
report	O
of	O
such	O
rearrangements	O
was	O
based	O
on	O
small	O
numbers	O
and	O
lack	O
of	O
knowledge	O
that	O
the	O
frequency	O
of	O
"	O
abnormal	O
"	O
color	O
vision	O
arrays	O
on	O
molecular	O
analysis	O
was	O
twice	O
as	O
high	O
as	O
expected	O
on	O
the	O
basis	O
of	O
the	O
frequency	O
of	O
phenotypic	B-SpecificDisease
color	I-SpecificDisease
vision	I-SpecificDisease
defects	I-SpecificDisease
.	O
The	O
red	O
/	O
green	O
color	O
pigment	O
(	O
R	O
/	O
GCP	O
)	O
region	O
was	O
studied	O
by	O
pulsed-field	O
gel	O
electrophoresis	O
in	O
14	O
of	O
these	O
patients	O
,	O
and	O
we	O
did	O
not	O
find	O
any	O
fragment	O
size	O
difference	O
between	O
the	O
patients	O
and	O
normal	O
individuals	O
who	O
have	O
the	O
same	O
number	O
of	O
pigment	O
genes	O
.	O
The	O
R	O
/	O
GCP	O
region	O
was	O
also	O
analyzed	O
in	O
29	O
French	O
and	O
seven	O
North	O
American	O
ALD	B-Modifier
patients	O
by	O
using	O
six	O
genomic	O
DNA	O
probes	O
,	O
isolated	O
from	O
a	O
cosmid	O
walk	O
,	O
that	O
flank	O
the	O
color	O
vision	O
genes	O
.	O
No	O
deletions	O
were	O
found	O
with	O
probes	O
that	O
lie	O
3	O
of	O
the	O
green	O
pigment	O
genes	O
.	O
One	O
of	O
the	O
eight	O
previously	O
reported	O
ALD	B-Modifier
individuals	O
has	O
a	O
long	O
deletion	O
5	O
of	O
the	O
red	O
pigment	O
gene	O
,	O
a	O
deletion	O
causing	O
blue	O
cone	O
monochromacy	O
.	O
This	O
finding	O
and	O
the	O
previous	O
findings	O
of	O
a	O
45	O
%	O
frequency	O
of	O
phenotypic	O
color	O
vision	O
defects	O
in	O
patients	O
with	O
AMN	B-SpecificDisease
may	O
suggest	O
that	O
the	O
ALD	B-Modifier
/	O
AMN	B-Modifier
gene	O
lies	O
5	O
to	O
the	O
red	O
pigment	O
gene	O
and	O
that	O
the	O
frequent	O
phenotypic	O
color	B-DiseaseClass
vision	I-DiseaseClass
anomalies	I-DiseaseClass
owe	O
their	O
origin	O
to	O
deleted	O
DNA	O
that	O
includes	O
regulatory	O
genes	O
for	O
color	O
vision	O
.	O
It	O
is	O
possible	O
,	O
however	O
,	O
that	O
phenotypic	O
color	B-DiseaseClass
vision	I-DiseaseClass
anomalies	I-DiseaseClass
in	O
AMN	B-SpecificDisease
may	O
be	O
phenocopies	O
secondary	O
to	O
retinal	O
or	O
neural	O
involvement	O
by	O
the	O
disease	O
.	O
The	O
single	O
case	O
of	O
blue	O
cone	O
monochromacy	O
may	O
therefore	O
be	O
a	O
fortuitous	O
coincidence	O
of	O
two	O
diseases	O
.	O
.	O

10377440	O
X	O
inactivation	O
and	O
somatic	O
cell	O
selection	O
rescue	O
female	O
mice	O
carrying	O
a	O
Piga-null	O
mutation.	O
A	O
somatic	O
mutation	O
in	O
the	O
X	O
linked	O
PIGA	O
gene	O
is	O
responsible	O
for	O
the	O
deficiency	B-DiseaseClass
of	I-DiseaseClass
glycosyl	I-DiseaseClass
phosphatidylinositol	I-DiseaseClass
(	I-DiseaseClass
GPI	I-DiseaseClass
)	I-DiseaseClass
-anchored	I-DiseaseClass
proteins	I-DiseaseClass
on	O
blood	O
cells	O
from	O
patients	O
with	O
paroxysmal	B-SpecificDisease
nocturnal	I-SpecificDisease
hemoglobinuria	I-SpecificDisease
.	O
No	O
inherited	O
form	O
of	O
GPI-anchor	B-SpecificDisease
deficiency	I-SpecificDisease
has	O
been	O
described	O
.	O
Because	O
conventional	O
Piga	O
gene	O
knockout	O
is	O
associated	O
with	O
high	O
embryonic	B-SpecificDisease
lethality	I-SpecificDisease
in	O
chimeric	O
mice	O
,	O
we	O
used	O
the	O
Cre	O
/	O
loxP	O
system	O
.	O
We	O
generated	O
mice	O
in	O
which	O
two	O
loxP	O
sites	O
flank	O
part	O
of	O
Piga	O
exon	O
2	O
.	O
After	O
crossbreeding	O
with	O
female	O
mice	O
of	O
the	O
EIIa-cre	O
strain	O
,	O
the	O
floxed	O
allele	O
undergoes	O
Cre-mediated	O
recombination	O
with	O
high	O
efficiency	O
during	O
early	O
embryonic	O
development	O
.	O
Because	O
of	O
X	O
chromosome	O
inactivation	O
,	O
female	O
offspring	O
are	O
mosaic	O
for	O
cells	O
that	O
express	O
or	O
lack	O
GPI-linked	O
proteins	O
.	O
Analysis	O
of	O
mosaic	O
mice	O
showed	O
that	O
in	O
heart	O
,	O
lung	O
,	O
kidney	O
,	O
brain	O
,	O
and	O
liver	O
,	O
mainly	O
wild-type	O
Piga	O
is	O
active	O
,	O
suggesting	O
that	O
these	O
tissues	O
require	O
GPI-linked	O
proteins	O
.	O
The	O
salient	O
exceptions	O
were	O
spleen	O
,	O
thymus	O
,	O
and	O
red	O
blood	O
cells	O
,	O
which	O
had	O
almost	O
equal	O
numbers	O
of	O
cells	O
expressing	O
the	O
wild-type	O
or	O
the	O
recombined	O
allele	O
,	O
implying	O
that	O
GPI-linked	O
proteins	O
are	O
not	O
essential	O
for	O
the	O
derivation	O
of	O
these	O
tissues	O
.	O
PIGA	O
(	O
-	O
)	O
cells	O
had	O
no	O
growth	O
advantage	O
,	O
suggesting	O
that	O
other	O
factors	O
are	O
needed	O
for	O
their	O
clonal	O
dominance	O
in	O
patients	O
with	O
paroxysmal	B-SpecificDisease
nocturnal	I-SpecificDisease
hemoglobinuria	I-SpecificDisease
.	O
.	O

10636421	O
X-linked	B-SpecificDisease
retinoschisis	I-SpecificDisease
with	O
point	O
mutations	O
in	O
the	O
XLRS1	O
gene.	O
BACKGROUND	O
X-linked	B-SpecificDisease
retinoschisis	I-SpecificDisease
(	O
XLRS	B-SpecificDisease
)	O
is	O
a	O
relatively	O
rare	O
vitreoretinal	B-DiseaseClass
dystrophy	I-DiseaseClass
that	O
causes	O
visual	B-SpecificDisease
loss	I-SpecificDisease
in	O
young	O
men	O
.	O
Recently	O
,	O
a	O
gene	O
responsible	O
for	O
this	O
disease	O
,	O
designated	O
XLRS1	O
,	O
was	O
identified	O
,	O
and	O
several	O
deleterious	O
gene	O
mutations	O
were	O
reported	O
.	O
OBJECTIVE	O
To	O
analyze	O
Japanese	O
patients	O
clinically	O
diagnosed	O
as	O
having	O
XLRS	B-Modifier
formutational	O
changes	O
in	O
the	O
XLRS1	O
gene	O
.	O
METHODS	O
Ten	O
patients	O
with	O
XLRS	B-SpecificDisease
underwent	O
full	O
ophthalmologic	O
examination	O
,	O
including	O
slitlamp	O
biomicroscopy	O
and	O
dilated	O
funduscopy	O
.	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
leukocytes	O
,	O
and	O
all	O
exons	O
of	O
the	O
XLRS1	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
using	O
a	O
direct	O
sequencing	O
method	O
.	O
RESULTS	O
Point	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
were	O
identified	O
in	O
all	O
10	O
patients	O
.	O
The	O
mutations	O
were	O
identical	O
in	O
each	O
of	O
2	O
pairs	O
of	O
brothers	O
.	O
Six	O
of	O
the	O
point	O
mutations	O
represented	O
missense	O
mutations	O
,	O
1	O
was	O
a	O
nonsense	O
mutation	O
,	O
and	O
1	O
was	O
a	O
frameshift	O
mutation	O
.	O
Five	O
of	O
the	O
mutations	O
are	O
newly	O
reported	O
herein	O
.	O
CONCLUSIONS	O
The	O
discovery	O
of	O
new	O
point	O
mutations	O
in	O
this	O
study	O
increases	O
the	O
available	O
information	O
regarding	O
the	O
spectrum	O
of	O
genetic	B-DiseaseClass
abnormalities	I-DiseaseClass
and	O
clinical	O
manifestations	O
of	O
XLRS	B-SpecificDisease
.	O
However	O
,	O
the	O
limited	O
data	O
failed	O
to	O
reveal	O
a	O
correlation	O
between	O
mutation	O
and	O
disease	O
phenotype	O
.	O
CLINICAL	O
RELEVANCE	O
Identification	O
of	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
and	O
expanded	O
information	O
on	O
clinical	O
manifestations	O
will	O
facilitate	O
early	O
diagnosis	O
,	O
appropriate	O
early	O
therapy	O
,	O
and	O
genetic	O
counseling	O
regarding	O
the	O
prognosis	O
of	O
XLRS	B-SpecificDisease
.	O
.	O

7106752	O
Heterogeneity	O
of	O
"Mediterranean	O
type"	O
glucose-6-phosphate	B-SpecificDisease
dehydrogenase	I-SpecificDisease
(G6PD)	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
Spain	O
and	O
description	O
of	O
two	O
new	O
variants	O
associated	O
with	O
favism.	B-SpecificDisease
Glucose-6-phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
;	O
EC	O
1	O
.	O
1	O
.	O
1	O
.	O
49	O
from	O
thirty-six	O
unrelated	O
Spanish	O
males	O
was	O
partially	O
purified	O
from	O
blood	O
,	O
and	O
the	O
variants	O
were	O
characterized	O
biochemically	O
and	O
electrophoretically	O
according	O
to	O
the	O
methods	O
recommended	O
by	O
the	O
world	O
Health	O
Organization	O
.	O
Subjects	O
were	O
from	O
multiple	O
geographic	O
regions	O
within	O
Spain	O
,	O
and	O
all	O
suffered	O
from	O
hemolytic	B-SpecificDisease
anemia	I-SpecificDisease
,	O
either	O
acute	O
(	O
34	O
cases	O
)	O
or	O
chronic	O
nonspherocytic	O
(	O
2	O
cases	O
)	O
.	O
Almost	O
all	O
the	O
variants	O
studied	O
presented	O
residual	O
erythrocyte	O
G6PD	O
activity	O
ranging	O
from	O
0	O
to	O
10	O
%	O
of	O
normal	O
,	O
and	O
five	O
different	O
mutants	O
were	O
responsible	O
for	O
the	O
deficient	O
phenotype	O
.	O
Three	O
variants	O
were	O
similar	O
to	O
others	O
previously	O
described	O
G6PD	O
Mediterranean	O
(	O
11	O
cases	O
)	O
,	O
G6PD	O
Athens-like	O
(	O
3	O
cases	O
)	O
,	O
and	O
G6PD	O
Union	O
(	O
2	O
cases	O
)	O
.	O
The	O
remaining	O
variants	O
were	O
different	O
from	O
the	O
numerous	O
variants	O
already	O
reported	O
and	O
have	O
been	O
considered	O
as	O
new	O
mutants	O
.	O
Provisionally	O
they	O
are	O
called	O
G6PD	O
Betica	O
(	O
19	O
cases	O
)	O
and	O
G6PD	O
Menorca	O
(	O
1	O
case	O
)	O
.	O
The	O
present	O
study	O
constitutes	O
the	O
first	O
attempt	O
to	O
characterize	O
the	O
deficient	B-Modifier
G6PD	I-Modifier
variants	O
found	O
in	O
Spain	O
and	O
supplies	O
new	O
data	O
on	O
the	O
relationship	O
between	O
molecular	O
characteristics	O
of	O
deficient	O
variants	O
and	O
their	O
clinical	O
manifestations	O
.	O
The	O
most	O
important	O
findings	O
can	O
be	O
summarized	O
as	O
follows	O
(	O
1	O
)	O
The	O
Spanish	O
population	O
is	O
characterized	O
by	O
an	O
important	O
heterogeneity	O
in	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
(	O
2	O
)	O
Although	O
G6PD	O
Mediterranean	O
is	O
very	O
frequent	O
,	O
it	O
presents	O
a	O
relatively	O
high	O
degree	O
of	O
polymorphism	O
.	O
(	O
3	O
)	O
Favism	B-SpecificDisease
has	O
been	O
observed	O
associated	O
with	O
all	O
kinds	O
of	O
variants	O
described	O
here	O
.	O
(	O
4	O
)	O
G6PD	O
Betica	O
,	O
which	O
is	O
the	O
most	O
frequent	O
variant	O
found	O
in	O
subjects	O
of	O
Southern	O
Spanish	O
origin	O
,	O
has	O
been	O
observed	O
associated	O
with	O
favism	B-SpecificDisease
in	O
all	O
cases	O
except	O
one	O
.	O

10577908	O
The	O
molecular	O
basis	O
of	O
Sjogren-Larsson	B-SpecificDisease
syndrome:	I-SpecificDisease
mutation	O
analysis	O
of	O
the	O
fatty	O
aldehyde	O
dehydrogenase	O
gene.	O
Sjogren-Larsson	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
SLS	B-SpecificDisease
)	O
is	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
characterized	O
by	O
ichthyosis	B-DiseaseClass
,	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
,	O
spasticity	B-DiseaseClass
,	O
and	O
deficient	B-SpecificDisease
activity	I-SpecificDisease
of	I-SpecificDisease
fatty	I-SpecificDisease
aldehyde	I-SpecificDisease
dehydrogenase	I-SpecificDisease
(	O
FALDH	O
)	O
.	O
To	O
define	O
the	O
molecular	O
defects	O
causing	O
SLS	B-SpecificDisease
,	O
we	O
performed	O
mutation	O
analysis	O
of	O
the	O
FALDH	O
gene	O
in	O
probands	O
from	O
63	O
kindreds	O
with	O
SLS	B-SpecificDisease
.	O
Among	O
these	O
patients	O
,	O
49	O
different	O
mutations-including	O
10	O
deletions	O
,	O
2	O
insertions	O
,	O
22	O
amino	O
acid	O
substitutions	O
,	O
3	O
nonsense	O
mutations	O
,	O
9	O
splice-site	O
defects	O
,	O
and	O
3	O
complex	O
mutations-were	O
found	O
.	O
All	O
of	O
the	O
patients	O
with	O
SLS	B-SpecificDisease
were	O
found	O
to	O
carry	O
mutations	O
.	O
Nineteen	O
of	O
the	O
missense	O
mutations	O
resulted	O
in	O
a	O
severe	O
reduction	O
of	O
FALDH	O
enzyme	O
catalytic	O
activity	O
when	O
expressed	O
in	O
mammalian	O
cells	O
,	O
but	O
one	O
mutation	O
(	O
798G--	O
>	O
C	O
[	O
K266N	O
]	O
)	O
seemed	O
to	O
have	O
a	O
greater	O
effect	O
on	O
mRNA	O
stability	O
.	O
The	O
splice-site	O
mutations	O
led	O
to	O
exon	O
skipping	O
or	O
utilization	O
of	O
cryptic	O
acceptor-splice	O
sites	O
.	O
Thirty-seven	O
mutations	O
were	O
private	O
,	O
and	O
12	O
mutations	O
were	O
seen	O
in	O
two	O
or	O
more	O
probands	O
of	O
European	O
or	O
Middle	O
Eastern	O
descent	O
.	O
Four	O
single-nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
found	O
in	O
the	O
FALDH	O
gene	O
.	O
At	O
least	O
four	O
of	O
the	O
common	O
mutations	O
(	O
551C--	O
>	O
T	O
,	O
682C--	O
>	O
T	O
,	O
733G--	O
>	O
A	O
,	O
and	O
798	O
+	O
1delG	O
)	O
were	O
associated	O
with	O
multiple	O
SNP	O
haplotypes	O
,	O
suggesting	O
that	O
these	O
mutations	O
originated	O
independently	O
on	O
more	O
than	O
one	O
occasion	O
or	O
were	O
ancient	O
SLS	B-Modifier
genes	O
that	O
had	O
undergone	O
intragenic	O
recombination	O
.	O
Our	O
results	O
demonstrate	O
that	O
SLS	B-SpecificDisease
is	O
caused	O
by	O
a	O
strikingly	O
heterogeneous	O
group	O
of	O
mutations	O
in	O
the	O
FALDH	O
gene	O
and	O
provide	O
a	O
framework	O
for	O
understanding	O
the	O
genetic	O
basis	O
of	O
SLS	B-SpecificDisease
and	O
the	O
development	O
of	O
DNA-based	O
diagnostic	O
tests	O
.	O
.	O

1127526	O
Analbuminemia	B-SpecificDisease
in	O
a	O
neonate.	O
A	O
small-for-gestational-age	O
infant	O
,	O
found	O
to	O
have	O
analbuminemia	B-SpecificDisease
in	O
the	O
neonatal	O
period	O
,	O
is	O
reported	O
and	O
the	O
twelve	O
cases	O
recorded	O
in	O
the	O
world	O
literature	O
are	O
reviewed	O
.	O
Patients	O
lacking	O
this	O
serum	O
protein	O
are	O
essentially	O
asymptomatic	O
,	O
apart	O
from	O
minimal	O
ankle	B-DiseaseClass
edema	I-DiseaseClass
and	O
ease	B-DiseaseClass
of	I-DiseaseClass
fatigue	I-DiseaseClass
.	O
Apparent	O
compensatory	O
mechanisms	O
which	O
come	O
into	O
play	O
when	O
serum	O
albumin	O
is	O
low	O
include	O
prolonged	O
half-life	O
of	O
albumin	O
and	O
transferrin	O
,	O
an	O
increase	O
in	O
serum	O
globulins	O
,	O
beta	O
lipoprotein	O
,	O
and	O
glycoproteins	O
,	O
arterial	B-DiseaseClass
hypotension	I-DiseaseClass
with	O
reduced	O
capillary	O
hydrostatic	O
pressure	O
,	O
and	O
the	O
ability	O
to	O
respond	O
with	O
rapid	O
sodium	O
and	O
chloride	O
diuresis	O
in	O
response	O
to	O
small	O
volume	O
changes	O
.	O
Examination	O
of	O
plasma	O
amino	O
acids	O
,	O
an	O
investigation	O
not	O
previously	O
reported	O
,	O
revealed	O
an	O
extremely	O
low	O
plasma	O
tryptophan	O
level	O
,	O
a	O
finding	O
which	O
may	O
be	O
important	O
in	O
view	O
of	O
the	O
role	O
of	O
tryptophan	O
in	O
albumin	O
synthesis	O
.	O
.	O

10426999	O
Association	O
of	O
BRCA1	O
with	O
the	O
hRad50-hMre11-p95	O
complex	O
and	O
the	O
DNA	O
damage	O
response.	O
BRCA1	O
encodes	O
a	O
tumor	B-Modifier
suppressor	O
that	O
is	O
mutated	O
in	O
familial	B-CompositeMention
breast	I-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancers	I-CompositeMention
.	O
Here	O
,	O
it	O
is	O
shown	O
that	O
BRCA1	O
interacts	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
hRad50	O
,	O
which	O
forms	O
a	O
complex	O
with	O
hMre11	O
and	O
p95	O
/	O
nibrin	O
.	O
Upon	O
irradiation	O
,	O
BRCA1	O
was	O
detected	O
in	O
discrete	O
foci	O
in	O
the	O
nucleus	O
,	O
which	O
colocalize	O
with	O
hRad50	O
.	O
Formation	O
of	O
irradiation-induced	O
foci	O
positive	O
for	O
BRCA1	O
,	O
hRad50	O
,	O
hMre11	O
,	O
or	O
p95	O
was	O
dramatically	O
reduced	O
in	O
HCC	O
/	O
1937	O
breast	B-Modifier
cancer	I-Modifier
cells	O
carrying	O
a	O
homozygous	O
mutation	O
in	O
BRCA1	O
but	O
was	O
restored	O
by	O
transfection	O
of	O
wild-type	O
BRCA1	O
.	O
Ectopic	O
expression	O
of	O
wild-type	O
,	O
but	O
not	O
mutated	O
,	O
BRCA1	O
in	O
these	O
cells	O
rendered	O
them	O
less	O
sensitive	O
to	O
the	O
DNA	O
damage	O
agent	O
,	O
methyl	O
methanesulfonate	O
.	O
These	O
data	O
suggest	O
that	O
BRCA1	O
is	O
important	O
for	O
the	O
cellular	O
responses	O
to	O
DNA	O
damage	O
that	O
are	O
mediated	O
by	O
the	O
hRad50-hMre11-p95	O
complex	O
.	O
.	O

1302032	O
Fragile	B-SpecificDisease
X	I-SpecificDisease
syndrome	I-SpecificDisease
without	O
CCG	O
amplification	O
has	O
an	O
FMR1	O
deletion.	O
We	O
describe	O
a	O
patient	O
with	O
typical	O
clinical	O
features	O
of	O
the	O
fragile	B-SpecificDisease
X	I-SpecificDisease
syndrome	I-SpecificDisease
,	O
but	O
without	O
cytogenetic	O
expression	O
of	O
the	O
fragile	B-SpecificDisease
X	I-SpecificDisease
or	O
an	O
amplified	O
CCG	O
trinucleotide	O
repeat	O
fragment	O
.	O
The	O
patient	O
has	O
a	O
previously	O
uncharacterized	O
submicroscopic	O
deletion	O
encompassing	O
the	O
CCG	O
repeat	O
,	O
the	O
entire	O
FMR1	O
gene	O
and	O
about	O
2	O
.	O
5	O
megabases	O
of	O
flanking	O
sequences	O
.	O
This	O
finding	O
confirms	O
that	O
the	O
fragile	B-Modifier
X	I-Modifier
phenotype	O
can	O
exist	O
,	O
without	O
amplification	O
of	O
the	O
CCG	O
repeat	O
or	O
cytogenetic	O
expression	O
of	O
the	O
fragile	B-SpecificDisease
X	I-SpecificDisease
,	O
and	O
that	O
fragile	B-SpecificDisease
X	I-SpecificDisease
syndrome	I-SpecificDisease
is	O
a	O
genetically	O
homogeneous	O
disorder	O
involving	O
FMR1	O
.	O
We	O
also	O
found	O
random	O
X-inactivation	O
in	O
the	O
mother	O
of	O
the	O
patient	O
who	O
was	O
shown	O
to	O
be	O
a	O
carrier	O
of	O
this	O
deletion	O
.	O

2828430	O
Homozygous	B-SpecificDisease
hypobetalipoproteinemia:	I-SpecificDisease
a	O
disease	O
distinct	O
from	O
abetalipoproproteinemia	B-SpecificDisease
at	O
the	O
molecular	O
level.	O
apoB	O
DNA	O
,	O
RNA	O
,	O
and	O
protein	O
from	O
two	O
patients	O
with	O
homozygous	B-SpecificDisease
hypobetalipoproteinemia	I-SpecificDisease
(	O
HBL	B-SpecificDisease
)	O
were	O
evaluated	O
and	O
compared	O
with	O
normal	O
individuals	O
.	O
Southern	O
blot	O
analysis	O
with	O
10	O
different	O
cDNA	O
probes	O
revealed	O
a	O
normal	O
gene	O
without	O
major	O
insertions	O
,	O
deletions	O
,	O
or	O
rearrangements	O
.	O
Northern	O
and	O
slot	O
blot	O
analyses	O
of	O
total	O
liver	O
mRNA	O
from	O
HBL	B-Modifier
patients	O
documented	O
a	O
normal	O
size	O
apoB	O
mRNA	O
that	O
was	O
present	O
in	O
greatly	O
reduced	O
quantities	O
.	O
ApoB	O
protein	O
was	O
detected	O
within	O
HBL	B-Modifier
hepatocytes	O
utilizing	O
immunohistochemical	O
techniques	O
;	O
however	O
,	O
it	O
was	O
markedly	O
reduced	O
in	O
quantity	O
when	O
compared	O
with	O
control	O
samples	O
.	O
No	O
apoB	O
was	O
detectable	O
in	O
the	O
plasma	O
of	O
HBL	B-Modifier
individuals	O
with	O
an	O
ELISA	O
assay	O
.	O
These	O
data	O
are	O
most	O
consistent	O
with	O
a	O
mutation	O
in	O
the	O
coding	O
portion	O
of	O
the	O
apoB	O
gene	O
in	O
HBL	B-Modifier
patients	O
,	O
leading	O
to	O
an	O
abnormal	O
apoB	O
protein	O
and	O
apoB	O
mRNA	O
instability	O
.	O
These	O
results	O
are	O
distinct	O
from	O
those	O
previously	O
noted	O
in	O
abetalipoproteinemia	B-SpecificDisease
,	O
which	O
was	O
characterized	O
by	O
an	O
elevated	O
level	O
of	O
hepatic	O
apoB	O
mRNA	O
and	O
accumulation	O
of	O
intracellular	O
hepatic	O
apoB	O
protein	O
.	O
.	O

10449429	O
Aminoglycoside	O
antibiotics	O
restore	O
dystrophin	O
function	O
to	O
skeletal	O
muscles	O
of	O
mdx	O
mice.	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
dystrophin	O
gene	O
,	O
leading	O
to	O
the	O
absence	O
of	O
the	O
dystrophin	O
protein	O
in	O
striated	O
muscle	O
.	O
A	O
significant	O
number	O
of	O
these	O
mutations	O
are	O
premature	O
stop	O
codons	O
.	O
On	O
the	O
basis	O
of	O
the	O
observation	O
that	O
aminoglycoside	O
treatment	O
can	O
suppress	O
stop	O
codons	O
in	O
cultured	O
cells	O
,	O
we	O
tested	O
the	O
effect	O
of	O
gentamicin	O
on	O
cultured	O
muscle	O
cells	O
from	O
the	O
mdx	O
mouse	O
-	O
an	O
animal	O
model	O
for	O
DMD	B-SpecificDisease
that	O
possesses	O
a	O
premature	O
stop	O
codon	O
in	O
the	O
dystrophin	O
gene	O
.	O
Exposure	O
of	O
mdx	O
myotubes	O
to	O
gentamicin	O
led	O
to	O
the	O
expression	O
and	O
localization	O
of	O
dystrophin	O
to	O
the	O
cell	O
membrane	O
.	O
We	O
then	O
evaluated	O
the	O
effects	O
of	O
differing	O
dosages	O
of	O
gentamicin	O
on	O
expression	O
and	O
functional	O
protection	O
of	O
the	O
muscles	O
of	O
mdx	O
mice	O
.	O
We	O
identified	O
a	O
treatment	O
regimen	O
that	O
resulted	O
in	O
the	O
presence	O
of	O
dystrophin	O
in	O
the	O
cell	O
membrane	O
in	O
all	O
striated	O
muscles	O
examined	O
and	O
that	O
provided	O
functional	O
protection	O
against	O
muscular	B-DiseaseClass
injury	I-DiseaseClass
.	O
To	O
our	O
knowledge	O
,	O
our	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
aminoglycosides	O
can	O
suppress	O
stop	O
codons	O
not	O
only	O
in	O
vitro	O
but	O
also	O
in	O
vivo	O
.	O
Furthermore	O
,	O
these	O
results	O
raise	O
the	O
possibility	O
of	O
a	O
novel	O
treatment	O
regimen	O
for	O
muscular	B-SpecificDisease
dystrophy	I-SpecificDisease
and	O
other	O
diseases	O
caused	O
by	O
premature	O
stop	O
codon	O
mutations	O
.	O
This	O
treatment	O
could	O
prove	O
effective	O
in	O
up	O
to	O
15	O
%	O
of	O
patients	O
with	O
DMD	B-SpecificDisease
.	O
.	O

161677	O
Linkage	O
relationship	O
of	O
C2	B-SpecificDisease
deficiency,	I-SpecificDisease
HLA	O
and	O
glyoxalase	O
I	O
loci.	O
Immunogenetic	O
analysis	O
of	O
a	O
homozygous	O
C2-deficient	B-Modifier
individual	O
and	O
family	O
members	O
demonstrated	O
linkage	O
of	O
HLA-A25	O
,	O
B18	O
and	O
C2o	O
.	O
HLA-D	O
typing	O
showed	O
that	O
5	O
members	O
typed	O
with	O
homozygous	O
Dw2	O
typing	O
cells	O
from	O
an	O
individual	O
with	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
but	O
not	O
with	O
Dw2	O
typing	O
cells	O
from	O
2	O
individuals	O
with	O
normal	O
C2	O
.	O
The	O
homozygous	O
C2-deficient	B-Modifier
propositus	O
and	O
brother	O
were	O
HLA-A	O
and	O
B	O
homozygous	O
but	O
heterozygous	O
at	O
the	O
HLA-D	O
and	O
glyoxalase	O
I	O
loci	O
.	O
Therefore	O
,	O
in	O
this	O
family	O
,	O
the	O
C2o	O
gene	O
is	O
linked	O
with	O
two	O
distinct	O
haplotypes	O
HLA-A25	O
,	O
B18	O
,	O
Dw2	O
,	O
GLO1	O
and	O
HLA-A25	O
,	O
B18	O
,	O
D	O
unknown	O
,	O
GL02	O
.	O
These	O
results	O
could	O
be	O
explained	O
by	O
an	O
ancestral	O
recombinant	O
event	O
,	O
which	O
occurred	O
between	O
the	O
C2o	O
locus	O
and	O
HLA-D	O
locus	O
in	O
which	O
C2o	O
segregated	O
with	O
HLA-B	O
.	O
This	O
would	O
suggest	O
that	O
the	O
locus	O
for	O
the	O
C2o	O
gene	O
maps	O
between	O
HLA-B	O
and	O
HLA-D	O
on	O
the	O
sixth	O
chromosome	O
.	O
.	O

10875918	O
Fas	O
preassociation	O
required	O
for	O
apoptosis	O
signaling	O
and	O
dominant	O
inhibition	O
by	O
pathogenic	O
mutations.	O
Heterozygous	O
mutations	O
encoding	O
abnormal	O
forms	O
of	O
the	O
death	O
receptor	O
Fas	O
dominantly	O
interfere	O
with	O
Fas-induced	O
lymphocyte	O
apoptosis	O
in	O
human	O
autoimmune	B-SpecificDisease
lymphoproliferative	I-SpecificDisease
syndrome	I-SpecificDisease
.	O
This	O
effect	O
,	O
rather	O
than	O
depending	O
on	O
ligand-induced	O
receptor	O
oligomerization	O
,	O
was	O
found	O
to	O
stem	O
from	O
ligand-	O
independent	O
interaction	O
of	O
wild-type	O
and	O
mutant	O
Fas	O
receptors	O
through	O
a	O
specific	O
region	O
in	O
the	O
extracellular	O
domain	O
.	O
Preassociated	O
Fas	O
complexes	O
were	O
found	O
in	O
living	O
cells	O
by	O
means	O
of	O
fluorescence	O
resonance	O
energy	O
transfer	O
between	O
variants	O
of	O
green	O
fluorescent	O
protein	O
.	O
These	O
results	O
show	O
that	O
formation	O
of	O
preassociated	O
receptor	O
complexes	O
is	O
necessary	O
for	O
Fas	O
signaling	O
and	O
dominant	O
interference	O
in	O
human	O
disease	O
.	O
.	O

10807385	O
Clinicopathologic	O
features	O
of	O
BRCA-linked	B-CompositeMention
and	I-CompositeMention
sporadic	I-CompositeMention
ovarian	I-CompositeMention
cancer.	I-CompositeMention
CONTEXT	O
Most	O
hereditary	B-SpecificDisease
ovarian	I-SpecificDisease
cancers	I-SpecificDisease
are	O
associated	O
with	O
germline	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
.	O
Attempts	O
to	O
define	O
the	O
clinical	O
significance	O
of	O
BRCA	O
mutation	O
status	O
in	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
have	O
produced	O
conflicting	O
results	O
,	O
especially	O
regarding	O
survival	O
.	O
OBJECTIVE	O
To	O
determine	O
whether	O
hereditary	B-SpecificDisease
ovarian	I-SpecificDisease
cancers	I-SpecificDisease
have	O
distinct	O
clinical	O
and	O
pathological	O
features	O
compared	O
with	O
sporadic	B-SpecificDisease
(	I-SpecificDisease
nonhereditary	I-SpecificDisease
)	I-SpecificDisease
ovarian	I-SpecificDisease
cancers	I-SpecificDisease
.	O
DESIGN	O
AND	O
SETTING	O
Retrospective	O
cohort	O
study	O
of	O
a	O
consecutive	O
series	O
of	O
933	O
ovarian	B-SpecificDisease
cancers	I-SpecificDisease
diagnosed	O
and	O
treated	O
at	O
our	O
institution	O
,	O
which	O
is	O
a	O
comprehensive	O
cancer	B-Modifier
center	O
as	O
designated	O
by	O
the	O
National	O
Cancer	B-Modifier
Institute	O
,	O
over	O
a	O
12-year	O
period	O
(	O
December	O
1986	O
to	O
August	O
1998	O
)	O
.	O
PATIENTS	O
The	O
study	O
was	O
restricted	O
to	O
patients	O
of	O
Jewish	O
origin	O
because	O
of	O
the	O
ease	O
of	O
BRCA1	O
and	O
BRCA2	O
genotyping	O
in	O
this	O
ethnic	O
group	O
.	O
From	O
the	O
189	O
patients	O
who	O
identified	O
themselves	O
as	O
Jewish	O
,	O
88	O
hereditary	O
cases	O
were	O
identified	O
with	O
the	O
presence	O
of	O
a	O
germline	O
founder	O
mutation	O
in	O
BRCA1	O
or	O
BRCA2	O
.	O
The	O
remaining	O
101	O
cases	O
from	O
the	O
same	O
series	O
not	O
associated	O
with	O
a	O
BRCA	O
mutation	O
and	O
2	O
additional	O
groups	O
(	O
Gynecologic	O
Oncology	O
Group	O
protocols	O
52	O
and	O
111	O
)	O
with	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
from	O
clinical	O
trials	O
(	O
for	O
the	O
survival	O
analysis	O
)	O
were	O
included	O
for	O
comparison	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
Age	O
at	O
diagnosis	O
,	O
surgical	O
stage	O
,	O
histologic	O
cell	O
type	O
and	O
grade	O
,	O
and	O
surgical	O
outcome	O
;	O
and	O
response	O
to	O
chemotherapy	O
and	O
survival	O
for	O
advanced-stage	O
(	O
II	O
and	O
IV	O
)	O
cases	O
.	O
RESULTS	O
Hereditary	B-DiseaseClass
cancers	I-DiseaseClass
were	O
rarely	O
diagnosed	O
before	O
age	O
40	O
years	O
and	O
were	O
common	O
after	O
age	O
60	O
years	O
,	O
with	O
mean	O
age	O
at	O
diagnosis	O
being	O
significantly	O
younger	O
for	O
BRCA1-	O
vs	O
BRCA2-linked	O
patients	O
(	O
54	O
vs	O
62	O
years	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O
Histology	O
,	O
grade	O
,	O
stage	O
,	O
and	O
success	O
of	O
cytoreductive	O
surgery	O
were	O
similar	O
for	O
hereditary	O
and	O
sporadic	O
cases	O
.	O
The	O
hereditary	O
group	O
had	O
a	O
longer	O
disease-free	O
interval	O
following	O
primary	O
chemotherapy	O
in	O
comparison	O
with	O
the	O
nonhereditary	O
group	O
,	O
with	O
a	O
median	O
time	O
to	O
recurrence	O
of	O
14	O
months	O
and	O
7	O
months	O
,	O
respectively	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O
Those	O
with	O
hereditary	B-DiseaseClass
cancers	I-DiseaseClass
had	O
improved	O
survival	O
compared	O
with	O
the	O
nonhereditary	O
group	O
(	O
P	O
=	O
.	O
004	O
)	O
.	O
For	O
stage	B-DiseaseClass
III	I-DiseaseClass
cancers	I-DiseaseClass
,	O
BRCA	O
mutation	O
status	O
was	O
an	O
independent	O
prognostic	O
variable	O
(	O
P	O
=	O
.	O
03	O
)	O
.	O
CONCLUSIONS	O
Although	O
BRCA-associated	B-SpecificDisease
hereditary	I-SpecificDisease
ovarian	I-SpecificDisease
cancers	I-SpecificDisease
in	O
this	O
population	O
have	O
surgical	O
and	O
pathological	O
characteristics	O
similar	O
to	O
those	O
of	O
sporadic	B-DiseaseClass
cancers	I-DiseaseClass
,	O
advanced-stage	B-Modifier
hereditary	I-Modifier
cancer	I-Modifier
patients	O
survive	O
longer	O
than	O
nonhereditary	B-Modifier
cancer	I-Modifier
patients	O
.	O
Age	O
penetrance	O
is	O
greater	O
for	O
BRCA1-linked	B-CompositeMention
than	I-CompositeMention
for	I-CompositeMention
BRCA2-linked	I-CompositeMention
cancers	I-CompositeMention
in	O
this	O
population	O
.	O

8528199	O
WASP	O
gene	O
mutations	O
in	O
Wiskott-Aldrich	B-SpecificDisease
syndrome	I-SpecificDisease
and	O
X-linked	B-SpecificDisease
thrombocytopenia.	I-SpecificDisease
The	O
WASP	O
gene	O
has	O
been	O
recently	O
cloned	O
from	O
Xp11	O
.	O
23	O
and	O
shown	O
to	O
be	O
mutated	O
in	O
three	O
patients	O
with	O
the	O
Wiskott-Aldrich	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
WAS	B-SpecificDisease
)	O
.	O
We	O
have	O
developed	O
a	O
screening	O
protocol	O
for	O
identifying	O
WASP	O
gene	O
alterations	O
in	O
genomic	O
DNA	O
and	O
have	O
identified	O
a	O
spectrum	O
of	O
novel	O
mutations	O
in	O
12	O
additional	O
unrelated	O
families	O
.	O
These	O
missense	O
,	O
nonsense	O
and	O
frameshift	O
mutations	O
involve	O
eight	O
of	O
the	O
12	O
exons	O
of	O
the	O
gene	O
.	O
Two	O
mutations	O
creating	O
premature	O
termination	O
codons	O
were	O
associated	O
with	O
lack	O
of	O
detectable	O
mRNA	O
on	O
Northern	O
blots	O
.	O
Four	O
amino	O
acid	O
substitutions	O
,	O
Leu27Phe	O
,	O
Thr48Ile	O
,	O
Val75Met	O
and	O
Arg477Lys	O
,	O
were	O
found	O
in	O
patients	O
with	O
congenital	B-SpecificDisease
thrombocytopenia	I-SpecificDisease
and	O
no	O
clinically	O
evident	O
immune	O
defect	O
indicating	O
that	O
the	O
WASP	O
gene	O
is	O
the	O
site	O
for	O
mutations	O
in	O
X-linked	B-SpecificDisease
thrombocytopenia	I-SpecificDisease
as	O
well	O
as	O
in	O
WAS	B-SpecificDisease
.	O
A	O
T-cell	O
line	O
from	O
a	O
WAS	B-Modifier
patient	O
contained	O
two	O
independent	O
DNA	O
alterations	O
,	O
a	O
constitutional	O
frameshift	O
mutation	O
,	O
also	O
present	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
the	O
patient	O
,	O
and	O
compensatory	O
splice	O
site	O
mutation	O
unique	O
to	O
the	O
cell	O
line	O
.	O
The	O
distribution	O
of	O
eight	O
missense	O
mutations	O
provides	O
valuable	O
information	O
on	O
amino	O
acids	O
which	O
are	O
essential	O
for	O
normal	O
protein	O
function	O
,	O
and	O
suggests	O
that	O
sites	O
in	O
the	O
first	O
two	O
exons	O
are	O
hot-spots	O
for	O
mutation	O
.	O

10472529	O
Large	O
heterozygous	O
deletion	O
masquerading	O
as	O
homozygous	O
missense	O
mutation:	O
a	O
pitfall	O
in	O
diagnostic	O
mutation	O
analysis.	O
The	O
clinical	O
use	O
of	O
molecular	O
analyses	O
in	O
recessive	B-DiseaseClass
disorders	I-DiseaseClass
relies	O
on	O
the	O
exact	O
characterization	O
of	O
both	O
mutant	O
alleles	O
in	O
the	O
affected	O
patient	O
.	O
This	O
can	O
be	O
problematic	O
when	O
only	O
part	O
of	O
the	O
gene	O
is	O
examined	O
or	O
when	O
relevant	O
DNA	O
alterations	O
are	O
not	O
recognized	O
by	O
standard	O
methods	O
.	O
We	O
present	O
a	O
child	O
in	O
whom	O
phenylketonuria	B-SpecificDisease
was	O
apparently	O
caused	O
by	O
homozygosity	O
for	O
the	O
mutation	O
E390G	O
in	O
exon	O
11	O
of	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
.	O
However	O
,	O
the	O
clinical	O
severity	O
of	O
the	O
disease	O
was	O
not	O
quite	O
as	O
mild	O
as	O
expected	O
,	O
the	O
mutation	O
was	O
not	O
identified	O
in	O
the	O
father	O
despite	O
confirmed	O
paternity	O
,	O
and	O
the	O
paternal	O
allele	O
showed	O
a	O
highly	O
unusual	O
pattern	O
of	O
polymorphic	O
markers	O
in	O
the	O
PAH	O
gene	O
.	O
Presence	O
of	O
a	O
large	O
deletion	O
involving	O
exons	O
9	O
,	O
10	O
and	O
11	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
was	O
confirmed	O
by	O
long-range	O
PCR	O
.	O
Diagnostic	O
DNA	O
analyses	O
should	O
include	O
a	O
comprehensive	O
examination	O
of	O
the	O
whole	O
relevant	O
gene	O
in	O
the	O
patient	O
and	O
confirmation	O
of	O
carrier	O
status	O
in	O
both	O
parents	O
.	O
.	O

10602116	O
Pendred	B-SpecificDisease
syndrome:	I-SpecificDisease
phenotypic	O
variability	O
in	O
two	O
families	O
carrying	O
the	O
same	O
PDS	B-Modifier
missense	O
mutation.	O
Pendred	B-SpecificDisease
syndrome	I-SpecificDisease
comprises	O
congenital	B-SpecificDisease
sensorineural	I-SpecificDisease
hearing	I-SpecificDisease
loss	I-SpecificDisease
,	O
thyroid	B-SpecificDisease
goiter	I-SpecificDisease
,	O
and	O
positive	O
perchlorate	O
discharge	O
test	O
.	O
Recently	O
,	O
this	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
was	O
shown	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
PDS	B-Modifier
gene	O
,	O
which	O
encodes	O
an	O
anion	O
transporter	O
called	O
pendrin	O
.	O
Molecular	O
analysis	O
of	O
the	O
PDS	B-Modifier
gene	O
was	O
performed	O
in	O
two	O
consanguineous	O
large	O
families	O
from	O
Southern	O
Tunisia	O
comprising	O
a	O
total	O
of	O
23	O
individuals	O
affected	O
with	O
profound	O
congenital	B-SpecificDisease
deafness	I-SpecificDisease
;	O
the	O
same	O
missense	O
mutation	O
,	O
L445W	O
,	O
was	O
identified	O
in	O
all	O
affected	O
individuals	O
.	O
A	O
widened	O
vestibular	B-SpecificDisease
aqueduct	I-SpecificDisease
was	O
found	O
in	O
all	O
patients	O
who	O
underwent	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
exploration	O
of	O
the	O
inner	O
ear	O
.	O
In	O
contrast	O
,	O
goiter	B-SpecificDisease
was	O
present	O
in	O
only	O
11	O
affected	O
individuals	O
,	O
who	O
interestingly	O
had	O
a	O
normal	O
result	O
of	O
the	O
perchlorate	O
discharge	O
test	O
whenever	O
performed	O
.	O
The	O
present	O
results	O
question	O
the	O
sensitivity	O
of	O
the	O
perchlorate	O
test	O
for	O
the	O
diagnosis	O
of	O
Pendred	B-SpecificDisease
syndrome	I-SpecificDisease
and	O
support	O
the	O
use	O
of	O
a	O
molecular	O
analysis	O
of	O
the	O
PDS	B-Modifier
gene	O
in	O
the	O
assessment	O
of	O
individuals	O
with	O
severe	O
to	O
profound	O
congenital	B-SpecificDisease
hearing	I-SpecificDisease
loss	I-SpecificDisease
associated	O
with	O
inner	B-SpecificDisease
ear	I-SpecificDisease
morphological	I-SpecificDisease
anomaly	I-SpecificDisease
even	O
in	O
the	O
absence	O
of	O
a	O
thyroid	B-SpecificDisease
goiter	I-SpecificDisease
.	O
.	O

8302543	O
Macular	B-SpecificDisease
dystrophy	I-SpecificDisease
associated	O
with	O
mutations	O
at	O
codon	O
172	O
in	O
the	O
human	O
retinal	B-Modifier
degeneration	I-Modifier
slow	O
gene.	O
BACKGROUND	O
Recently	O
,	O
mutations	O
in	O
the	O
retinal	B-Modifier
degeneration	I-Modifier
slow	O
(	O
rds	O
)	O
gene	O
which	O
codes	O
for	O
peripherin-rds	O
have	O
been	O
implicated	O
as	O
a	O
cause	O
of	O
autosomal	B-SpecificDisease
dominant	I-SpecificDisease
retinitis	I-SpecificDisease
pigmentosa	I-SpecificDisease
.	O
Because	O
this	O
gene	O
is	O
expressed	O
in	O
both	O
rods	O
and	O
cones	O
,	O
mutations	O
in	O
the	O
rds	O
gene	O
might	O
be	O
expected	O
to	O
cause	O
degeneration	O
affecting	O
either	O
the	O
scotopic	O
or	O
photopic	O
systems	O
.	O
Mutations	O
at	O
codon	O
172	O
of	O
the	O
rds	O
gene	O
have	O
been	O
identified	O
in	O
three	O
families	O
with	O
autosomal	O
dominantly	O
inherited	O
,	O
progressive	O
macular	B-SpecificDisease
dystrophy	I-SpecificDisease
.	O
METHODS	O
Affected	O
individuals	O
underwent	O
ophthalmic	O
examination	O
,	O
scotopic	O
perimetry	O
,	O
dark	O
adaptometry	O
,	O
measurement	O
of	O
color-contrast	O
sensitivity	O
,	O
and	O
electroretinography	O
to	O
characterize	O
the	O
photoreceptor	O
dysfunction	O
.	O
RESULTS	O
In	O
all	O
but	O
one	O
affected	O
member	O
,	O
symptoms	O
of	O
progressive	O
central	O
visual	B-SpecificDisease
loss	I-SpecificDisease
developed	O
in	O
the	O
third	O
or	O
fourth	O
decade	O
of	O
life	O
accompanied	O
by	O
central	B-SpecificDisease
scotoma	I-SpecificDisease
and	O
well-demarcated	O
atrophy	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
retinal	I-SpecificDisease
pigment	I-SpecificDisease
epithelium	I-SpecificDisease
and	O
choriocapillaris	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
macula	I-SpecificDisease
.	O
In	O
general	O
,	O
cone	O
and	O
rod	O
thresholds	O
were	O
elevated	O
,	O
and	O
color-contrast	O
sensitivity	O
was	O
absent	O
in	O
the	O
central	O
visual	O
field	O
.	O
Peripherally	O
,	O
the	O
scotopic	O
sensitivities	O
were	O
normal	O
,	O
as	O
was	O
the	O
recovery	O
from	O
bleach	O
.	O
Cone	O
electroretinograms	O
were	O
diminished	O
in	O
amplitude	O
,	O
and	O
delayed	O
in	O
all	O
affected	O
adults	O
except	O
one	O
.	O
Rod	O
electroretinograms	O
were	O
normal	O
or	O
near	O
normal	O
in	O
amplitude	O
,	O
and	O
had	O
normal	O
implicit	O
times	O
.	O
Affected	O
asymptomatic	O
children	O
had	O
macular	O
changes	O
,	O
abnormal	O
color-contrast	O
sensitivity	O
,	O
and	O
reduced	O
pattern	O
and	O
cone	O
electroretinograms	O
.	O
CONCLUSION	O
These	O
results	O
indicate	O
that	O
mutations	O
in	O
the	O
rds	O
gene	O
can	O
be	O
expressed	O
as	O
a	O
macular	B-SpecificDisease
dystrophy	I-SpecificDisease
,	O
with	O
evidence	O
of	O
primary	O
cone	B-DiseaseClass
dysfunction	I-DiseaseClass
and	O
preservation	O
of	O
peripheral	O
rod	O
function	O
.	O
.	O

10742101	O
In	O
vivo	O
modulation	O
of	O
Hmgic	O
reduces	O
obesity.	B-SpecificDisease
The	O
HMGI	O
family	O
of	O
proteins	O
consists	O
of	O
three	O
members	O
,	O
HMGIC	O
,	O
HMGI	O
and	O
HMGI	O
(	O
Y	O
)	O
,	O
that	O
function	O
as	O
architectural	O
factors	O
and	O
are	O
essential	O
components	O
of	O
the	O
enhancesome	O
.	O
HMGIC	O
is	O
predominantly	O
expressed	O
in	O
proliferating	O
,	O
undifferentiated	O
mesenchymal	O
cells	O
and	O
is	O
not	O
detected	O
in	O
adult	O
tissues	O
.	O
It	O
is	O
disrupted	O
and	O
misexpressed	O
in	O
a	O
number	O
of	O
mesenchymal	B-Modifier
tumour	I-Modifier
cell	O
types	O
,	O
including	O
fat-cell	B-DiseaseClass
tumours	I-DiseaseClass
(	O
lipomas	B-DiseaseClass
)	O
.	O
In	O
addition	O
Hmgic-	O
/	O
-	O
mice	O
have	O
a	O
deficiency	O
in	O
fat	O
tissue	O
.	O
To	O
study	O
its	O
role	O
in	O
adipogenesis	O
and	O
obesity	B-SpecificDisease
,	O
we	O
examined	O
Hmgic	O
expression	O
in	O
the	O
adipose	O
tissue	O
of	O
adult	O
,	O
obese	B-Modifier
mice	O
.	O
Mice	O
with	O
a	O
partial	B-CompositeMention
or	I-CompositeMention
complete	I-CompositeMention
deficiency	I-CompositeMention
of	I-CompositeMention
Hmgic	I-CompositeMention
resisted	O
diet-induced	O
obesity	B-SpecificDisease
.	O
Disruption	O
of	O
Hmgic	O
caused	O
a	O
reduction	O
in	O
the	O
obesity	B-SpecificDisease
induced	O
by	O
leptin	B-SpecificDisease
deficiency	I-SpecificDisease
(	O
Lepob	O
/	O
Lepob	O
)	O
in	O
a	O
gene-dose-dependent	O
manner	O
.	O
Our	O
studies	O
implicate	O
a	O
role	O
for	O
HMGIC	O
in	O
fat-cell	O
proliferation	O
,	O
indicating	O
that	O
it	O
may	O
be	O
an	O
adipose-specific	O
target	O
for	O
the	O
treatment	O
of	O
obesity	B-SpecificDisease
.	O
.	O

7444053	O
A	O
new	O
CT	O
pattern	O
in	O
adrenoleukodystrophy.	B-SpecificDisease
A	O
new	O
CT	O
pattern	O
was	O
observed	O
in	O
2	O
patients	O
with	O
adrenoleukodystrophy	B-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
.	O
This	O
pattern	O
,	O
which	O
the	O
authors	O
call	O
Type	O
II	O
,	O
is	O
characterized	O
by	O
the	O
absence	O
of	O
posterior	O
periventricular	O
areas	O
of	O
decreased	O
attenuation	O
around	O
the	O
trigone	O
on	O
non-contrast	O
scans	O
after	O
contrast	O
infusion	O
,	O
however	O
,	O
there	O
is	O
striking	O
enhancement	O
of	O
various	O
white-matter	O
structures	O
(	O
tracts	O
or	O
fiber	O
systems	O
)	O
such	O
as	O
the	O
internal	O
capsules	O
,	O
corpus	O
callosum	O
,	O
corona	O
radiata	O
,	O
forceps	O
major	O
,	O
and	O
cerebral	O
peduncles	O
.	O
This	O
is	O
different	O
from	O
numerous	O
previous	O
descriptions	O
of	O
the	O
CT	O
pattern	O
in	O
ALD	B-SpecificDisease
.	O
Type	B-SpecificDisease
II	I-SpecificDisease
ALD	I-SpecificDisease
does	O
not	O
appear	O
to	O
have	O
been	O
seen	O
in	O
any	O
other	O
leukoencephalopathy	B-DiseaseClass
and	O
is	O
probably	O
specific	O
for	O
a	O
phenotypic	O
variant	O
or	O
an	O
evolving	O
stage	O
of	O
ALD	B-SpecificDisease
.	O
.	O

7550229	O
Molecular	O
characterization	O
of	O
galactosemia	B-Modifier
(type	O
1)	O
mutations	O
in	O
Japanese.	O
We	O
characterized	O
two	O
novel	O
mutations	O
of	O
the	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
in	O
two	O
Japanese	O
patients	O
with	O
GALT	B-SpecificDisease
deficiency	I-SpecificDisease
and	O
identified	O
N314D	O
and	O
R333W	O
mutations	O
,	O
previously	O
found	O
in	O
Caucasians	O
.	O
One	O
novel	O
missense	O
mutation	O
was	O
an	O
G-to-A	O
transition	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
the	O
substitution	O
of	O
arginine	O
by	O
histidine	O
at	O
the	O
codon	O
231	O
(	O
R231H	O
)	O
.	O
GALT	O
activity	O
of	O
the	O
R231H	O
mutant	O
construct	O
was	O
reduced	O
to	O
15	O
%	O
of	O
normal	O
controls	O
in	O
a	O
COS	O
cell	O
expression	O
system	O
.	O
The	O
other	O
was	O
a	O
splicing	O
mutation	O
,	O
an	O
A-to-G	O
transition	O
at	O
the	O
38th	O
nucleotide	O
in	O
exon	O
3	O
(	O
318A--	O
>	O
G	O
)	O
,	O
resulting	O
in	O
a	O
38-bp	O
deletion	O
in	O
the	O
GALT	O
cDNA	O
by	O
activating	O
a	O
cryptic	O
splice	O
acceptor	O
site	O
.	O
In	O
seven	O
Japanese	O
families	O
(	O
14	O
alleles	O
for	O
classic	O
form	O
and	O
one	O
allele	O
for	O
Duarte	O
variant	O
)	O
with	O
GALT	B-SpecificDisease
deficiency	I-SpecificDisease
,	O
the	O
R231H	O
and	O
318A--	O
>	O
G	O
mutations	O
were	O
found	O
only	O
on	O
both	O
alleles	O
of	O
the	O
proband	O
.	O
The	O
N314D	O
and	O
R333W	O
mutations	O
were	O
found	O
on	O
one	O
allele	O
each	O
.	O
The	O
Q188R	O
was	O
prevalent	O
in	O
the	O
United	O
States	O
but	O
not	O
in	O
Japanese	O
patients	O
.	O
The	O
N314D	O
mutation	O
was	O
associated	O
with	O
the	O
Duarte	O
variant	O
in	O
Japanese	O
persons	O
,	O
as	O
well	O
as	O
in	O
the	O
United	O
States	O
.	O
We	O
speculate	O
that	O
classic	B-Modifier
galactosemia	I-Modifier
mutations	O
appear	O
to	O
differ	O
between	O
Japanese	O
and	O
Caucasian	O
patients	O
.	O
Our	O
limited	O
data	O
set	O
on	O
galactosemia	B-Modifier
mutations	O
in	O
Japanese	O
suggests	O
that	O
the	O
N314D	O
GALT	O
mutation	O
encoding	O
the	O
Duarte	O
variant	O
arose	O
before	O
Asian	O
and	O
Caucasian	O
people	O
diverged	O
and	O
that	O
classic	B-Modifier
galactosemia	I-Modifier
mutations	O
arose	O
and	O
/	O
or	O
accumulated	O
after	O
the	O
divergence	O
of	O
Asian	O
and	O
Caucasian	O
populations	O
.	O
.	O

10888879	O
Restoration	O
of	O
photoreceptor	O
ultrastructure	O
and	O
function	O
in	O
retinal	B-Modifier
degeneration	I-Modifier
slow	O
mice	O
by	O
gene	O
therapy.	O
The	O
gene	O
Prph2	O
encodes	O
a	O
photoreceptor-specific	O
membrane	O
glycoprotein	O
,	O
peripherin-2	O
(	O
also	O
known	O
as	O
peripherin	O
/	O
rds	O
)	O
,	O
which	O
is	O
inserted	O
into	O
the	O
rims	O
of	O
photoreceptor	O
outer	O
segment	O
discs	O
in	O
a	O
complex	O
with	O
rom-1	O
(	O
ref	O
.	O
2	O
)	O
.	O
The	O
complex	O
is	O
necessary	O
for	O
the	O
stabilization	O
of	O
the	O
discs	O
,	O
which	O
are	O
renewed	O
constantly	O
throughout	O
life	O
,	O
and	O
which	O
contain	O
the	O
visual	O
pigments	O
necessary	O
for	O
photon	O
capture	O
.	O
Mutations	O
in	O
Prph2	O
have	O
been	O
shown	O
to	O
result	O
in	O
a	O
variety	O
of	O
photoreceptor	B-DiseaseClass
dystrophies	I-DiseaseClass
,	O
including	O
autosomal	B-SpecificDisease
dominant	I-SpecificDisease
retinitis	I-SpecificDisease
pigmentosa	I-SpecificDisease
and	O
macular	B-SpecificDisease
dystrophy	I-SpecificDisease
.	O
A	O
common	O
feature	O
of	O
these	O
diseases	O
is	O
the	O
loss	O
of	O
photoreceptor	O
function	O
,	O
also	O
seen	O
in	O
the	O
retinal	B-Modifier
degeneration	I-Modifier
slow	O
(	O
rds	O
or	O
Prph2	O
Rd2	O
/	O
Rd2	O
)	O
mouse	O
,	O
which	O
is	O
homozygous	O
for	O
a	O
null	O
mutation	O
in	O
Prph2	O
.	O
It	O
is	O
characterized	O
by	O
a	O
complete	O
failure	O
to	O
develop	O
photoreceptor	O
discs	O
and	O
outer	O
segments	O
,	O
downregulation	O
of	O
rhodopsin	O
and	O
apoptotic	O
loss	O
of	O
photoreceptor	O
cells	O
.	O
The	O
electroretinograms	O
(	O
ERGs	O
)	O
of	O
Prph2Rd2	O
/	O
Rd2	O
mice	O
have	O
greatly	O
diminished	O
a-wave	O
and	O
b-wave	O
amplitudes	O
,	O
which	O
decline	O
to	O
virtually	O
undetectable	O
concentrations	O
by	O
two	O
months	O
.	O
Subretinal	O
injection	O
of	O
recombinant	O
adeno-associated	O
virus	O
(	O
AAV	O
)	O
encoding	O
a	O
Prph2	O
transgene	O
results	O
in	O
stable	O
generation	O
of	O
outer	O
segment	O
structures	O
and	O
formation	O
of	O
new	O
stacks	O
of	O
discs	O
containing	O
both	O
perpherin-2	O
and	O
rhodopsin	O
,	O
which	O
in	O
many	O
cases	O
are	O
morphologically	O
similar	O
to	O
normal	O
outer	O
segments	O
.	O
Moreover	O
,	O
the	O
re-establishment	O
of	O
the	O
structural	O
integrity	O
of	O
the	O
photoreceptor	O
layer	O
also	O
results	O
in	O
electrophysiological	O
correction	O
.	O
These	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
complex	O
ultrastructural	O
cell	O
defect	O
can	O
be	O
corrected	O
both	O
morphologically	O
and	O
functionally	O
by	O
in	O
vivo	O
gene	O
transfer	O
.	O
.	O

2927388	O
Molecular	O
detection	O
of	O
chromosomal	O
translocations	O
that	O
disrupt	O
the	O
putative	O
retinoblastoma	B-Modifier
susceptibility	O
locus.	O
A	O
candidate	O
DNA	O
sequence	O
with	O
many	O
of	O
the	O
properties	O
predicted	O
for	O
the	O
retinoblastoma	B-Modifier
susceptibility	O
(	O
RB1	O
)	O
locus	O
has	O
been	O
cloned	O
(	O
S	O
.	O
H	O
.	O
Friend	O
,	O
R	O
.	O
Bernards	O
,	O
S	O
.	O
Rogelj	O
,	O
R	O
.	O
A	O
.	O
Weinberg	O
,	O
J	O
.	O
M	O
.	O
Rapaport	O
,	O
D	O
.	O
M	O
.	O
Albert	O
,	O
and	O
T	O
.	O
P	O
.	O
Dryja	O
,	O
Nature	O
[	O
London	O
]	O
323	O
643-645	O
,	O
1986	O
)	O
.	O
The	O
large	O
size	O
of	O
this	O
gene	O
(	O
ca	O
.	O
200	O
kilobases	O
[	O
kb	O
]	O
)	O
and	O
its	O
multiple	O
dispersed	O
exons	O
(	O
Wiggs	O
et	O
al	O
.	O
,	O
N	O
.	O
Engl	O
.	O
J	O
.	O
Med	O
.	O
318	O
151-157	O
,	O
1988	O
)	O
complicate	O
molecular	O
screening	O
strategies	O
important	O
in	O
prenatal	O
and	O
presymptomatic	O
diagnosis	O
and	O
in	O
carrier	O
detection	O
.	O
Here	O
we	O
used	O
field	O
inversion	O
gel	O
electrophoresis	O
(	O
FIGE	O
)	O
to	O
construct	O
a	O
restriction	O
map	O
of	O
approximately	O
1	O
,	O
000	O
kb	O
of	O
DNA	O
surrounding	O
the	O
RB1	O
locus	O
and	O
to	O
detect	O
the	O
translocation	O
breakpoints	O
in	O
three	O
retinoblastoma	B-Modifier
patients	O
.	O
DNA	O
probes	O
from	O
either	O
the	O
5	O
or	O
3	O
end	O
of	O
the	O
gene	O
were	O
used	O
to	O
detect	O
a	O
250-kb	O
EagI	O
restriction	O
fragment	O
in	O
DNA	O
from	O
unaffected	O
individuals	O
.	O
Both	O
probes	O
identified	O
an	O
additional	O
hybridizing	O
fragment	O
in	O
the	O
DNA	O
from	O
each	O
patient	O
,	O
permitting	O
the	O
breakpoints	O
in	O
all	O
three	O
to	O
be	O
mapped	O
within	O
the	O
cloned	O
RB1	O
gene	O
.	O
Analysis	O
of	O
the	O
breakpoint	O
in	O
one	O
translocation	O
cell	O
line	O
allowed	O
the	O
RB1	O
gene	O
to	O
be	O
oriented	O
with	O
its	O
5	O
end	O
toward	O
the	O
centromere	O
.	O
The	O
5	O
end	O
of	O
the	O
gene	O
also	O
appeared	O
to	O
be	O
associated	O
with	O
a	O
clustering	O
of	O
sites	O
for	O
several	O
infrequently	O
cleaving	O
restriction	O
enzymes	O
,	O
indicating	O
the	O
presence	O
of	O
an	O
HpaII	O
tiny	O
fragment	O
island	O
.	O
The	O
detection	O
and	O
mapping	O
of	O
the	O
translocation	O
breakpoints	O
of	O
all	O
three	O
retinoblastoma	B-Modifier
patients	O
to	O
within	O
the	O
putative	O
RB1	O
gene	O
substantiated	O
the	O
authenticity	O
of	O
this	O
candidate	O
sequence	O
and	O
demonstrated	O
the	O
utility	O
of	O
FIGE	O
in	O
detecting	O
chromosomal	O
rearrangements	O
affecting	O
this	O
locus	O
.	O

10369876	O
Autosomal	B-SpecificDisease
recessive	I-SpecificDisease
familial	I-SpecificDisease
neurohypophyseal	I-SpecificDisease
diabetes	I-SpecificDisease
insipidus	I-SpecificDisease
with	O
continued	O
secretion	O
of	O
mutant	O
weakly	O
active	O
vasopressin.	O
Familial	B-SpecificDisease
neurohypophyseal	I-SpecificDisease
diabetes	I-SpecificDisease
insipidus	I-SpecificDisease
is	O
an	O
autosomal	B-DiseaseClass
dominant	I-DiseaseClass
disorder	I-DiseaseClass
characterized	O
by	O
post-natal	O
development	O
of	O
arginine	B-SpecificDisease
vasopressin	I-SpecificDisease
(	I-SpecificDisease
AVP	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
due	O
to	O
mutations	O
in	O
the	O
AVP	O
gene	O
.	O
All	O
published	O
mutations	O
affect	O
the	O
signal	O
peptide	O
or	O
the	O
neurophysin-II	O
carrier	O
protein	O
and	O
are	O
presumed	O
to	O
interfere	O
with	O
processing	O
of	O
the	O
preprohormone	O
,	O
leading	O
to	O
neuronal	B-DiseaseClass
damage	I-DiseaseClass
.	O
We	O
studied	O
an	O
unusual	O
Palestinian	O
family	O
consisting	O
of	O
asymptomatic	O
first	O
cousin	O
parents	O
and	O
three	O
children	O
affected	O
with	O
neurohypophyseal	B-SpecificDisease
diabetes	I-SpecificDisease
insipidus	I-SpecificDisease
,	O
suggesting	O
autosomal	O
recessive	O
inheritance	O
.	O
All	O
three	O
affected	O
children	O
were	O
homozygous	O
and	O
the	O
parents	O
heterozygous	O
for	O
a	O
single	O
novel	O
mutation	O
(	O
C301-	O
>	O
T	O
)	O
in	O
exon	O
1	O
,	O
replacing	O
Pro7	O
of	O
mature	O
AVP	O
with	O
Leu	O
(	O
Leu-AVP	O
)	O
.	O
Leu-AVP	O
was	O
a	O
weak	O
agonist	O
with	O
approximately	O
30-fold	O
reduced	O
binding	O
to	O
the	O
human	O
V2	O
receptor	O
.	O
Measured	O
by	O
radioimmunoassay	O
with	O
a	O
synthetic	O
Leu-AVP	O
standard	O
,	O
serum	O
Leu-AVP	O
levels	O
were	O
elevated	O
in	O
all	O
three	O
children	O
and	O
further	O
increased	O
during	O
water	O
deprivation	O
to	O
as	O
high	O
as	O
30	O
times	O
normal	O
.	O
The	O
youngest	O
child	O
(	O
2	O
years	O
old	O
)	O
was	O
only	O
mildly	O
affected	O
but	O
had	O
Leu-AVP	O
levels	O
similar	O
to	O
her	O
severely	O
affected	O
8-year-old	O
brother	O
,	O
suggesting	O
that	O
unknown	O
mechanisms	O
may	O
partially	O
compensate	O
for	O
a	O
deficiency	B-DiseaseClass
of	I-DiseaseClass
active	I-DiseaseClass
AVP	I-DiseaseClass
in	O
very	O
young	O
children	O
.	O
.	O

10480348	O
Duchenne/Becker	B-CompositeMention
muscular	I-CompositeMention
dystrophy:	I-CompositeMention
correlation	O
of	O
phenotype	O
by	O
electroretinography	O
with	O
sites	O
of	O
dystrophin	O
mutations.	O
The	O
dark-adapted	O
electroretinogram	O
(	O
ERG	O
)	O
of	O
patients	O
with	O
Duchenne	B-CompositeMention
and	I-CompositeMention
Becker	I-CompositeMention
muscular	I-CompositeMention
dystrophy	I-CompositeMention
(	O
DMD	B-SpecificDisease
/	O
BMD	B-SpecificDisease
)	O
shows	O
a	O
marked	O
reduction	O
in	O
b-wave	O
amplitude	O
.	O
Genotype-phenotype	O
studies	O
of	O
mouse	O
models	O
for	O
DMD	B-SpecificDisease
show	O
position-specific	O
effects	O
of	O
the	O
mutations	O
upon	O
the	O
phenotype	O
mice	O
with	O
5	O
defects	O
of	O
dystrophin	O
have	O
normal	O
ERGs	O
,	O
those	O
with	O
defects	O
in	O
the	O
central	O
region	O
have	O
a	O
normal	O
b-wave	O
amplitude	O
associated	O
with	O
prolonged	O
implicit	O
times	O
for	O
both	O
the	O
b-wave	O
and	O
oscillatory	O
potentials	O
,	O
and	O
mice	O
with	O
3	O
defects	O
have	O
a	O
phenotype	O
similar	O
to	O
that	O
seen	O
in	O
DMD	B-Modifier
/	O
BMD	B-Modifier
patients	O
.	O
The	O
mouse	O
studies	O
suggest	O
a	O
key	O
role	O
for	O
the	O
carboxyl	O
terminal	O
dystrophin	O
isoform	O
,	O
Dp260	O
,	O
in	O
retinal	O
electrophysiology	O
.	O
We	O
have	O
undertaken	O
a	O
systematic	O
evaluation	O
of	O
DMD	B-Modifier
/	O
BMD	B-Modifier
patients	O
through	O
clinical	O
examination	O
and	O
review	O
of	O
the	O
literature	O
in	O
order	O
to	O
determine	O
whether	O
the	O
position-specific	O
effects	O
of	O
mutations	O
noted	O
in	O
the	O
mouse	O
are	O
present	O
in	O
man	O
.	O
We	O
have	O
found	O
that	O
,	O
in	O
man	O
,	O
a	O
wider	O
variation	O
of	O
DMD	B-DiseaseClass
defects	I-DiseaseClass
correlate	O
with	O
reductions	O
in	O
the	O
b-wave	O
amplitude	O
.	O
Individuals	O
with	O
normal	O
ERGs	O
have	O
mutations	O
predominantly	O
located	O
5	O
of	O
the	O
transcript	O
initiation	O
site	O
of	O
Dp260	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
most	O
important	O
determinant	O
in	O
the	O
ERG	O
b-wave	O
phenotype	O
is	O
the	O
mutation	O
position	O
,	O
rather	O
than	O
muscle	B-Modifier
disease	I-Modifier
severity	O
.	O
Forty-six	O
per	O
cent	O
of	O
patients	O
with	O
mutations	O
5	O
of	O
the	O
Dp260	O
transcript	O
start	O
site	O
have	O
abnormal	O
ERGs	O
,	O
as	O
opposed	O
to	O
94	O
%	O
with	O
more	O
distal	O
mutations	O
.	O
The	O
human	O
genotype-phenotype	O
correlations	O
are	O
consistent	O
with	O
a	O
role	O
for	O
Dp260	O
in	O
normal	O
retinal	O
electrophysiology	O
and	O
may	O
also	O
reflect	O
the	O
expression	O
of	O
other	O
C-terminal	O
dystrophin	O
isoforms	O
and	O
their	O
contributions	O
to	O
retinal	O
signal	O
transmission	O
.	O
.	O

8533762	O
A	O
new	O
glucose-6-phosphate	O
dehydrogenase	O
variant,	O
G6PD	O
Orissa	O
(44	O
Ala-->Gly),	O
is	O
the	O
major	O
polymorphic	O
variant	O
in	O
tribal	O
populations	O
in	O
India.	O
Deficiency	B-SpecificDisease
of	I-SpecificDisease
glucose-6-phosphate	I-SpecificDisease
dehydrogenase	I-SpecificDisease
(	O
G6PD	O
)	O
is	O
usually	O
found	O
at	O
high	O
frequencies	O
in	O
areas	O
of	O
the	O
world	O
where	O
malaria	B-SpecificDisease
has	O
been	O
endemic	O
.	O
The	O
frequency	O
and	O
genetic	O
basis	O
of	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
have	O
been	O
studied	O
in	O
Africa	O
,	O
around	O
the	O
Mediterranean	O
,	O
and	O
in	O
the	O
Far	O
East	O
,	O
but	O
little	O
such	O
information	O
is	O
available	O
about	O
the	O
situation	O
in	O
India	O
.	O
To	O
determine	O
the	O
extent	O
of	O
heterogeneity	O
of	O
G6PD	O
,	O
we	O
have	O
studied	O
several	O
different	O
Indian	O
populations	O
by	O
screening	O
for	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
,	O
followed	O
by	O
molecular	O
analysis	O
of	O
deficient	O
alleles	O
.	O
The	O
frequency	O
of	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
varies	O
between	O
3	O
%	O
and	O
15	O
%	O
in	O
different	O
tribal	O
and	O
urban	O
groups	O
.	O
Remarkably	O
,	O
a	O
previously	O
unreported	O
deficient	O
variant	O
,	O
G6PD	O
Orissa	O
(	O
44	O
Ala--	O
>	O
Gly	O
)	O
,	O
is	O
responsible	O
for	O
most	O
of	O
the	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
in	O
tribal	O
Indian	O
populations	O
but	O
is	O
not	O
found	O
in	O
urban	O
populations	O
,	O
where	O
most	O
of	O
the	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
is	O
due	O
to	O
the	O
G6PD	O
Mediterranean	O
(	O
188	O
Ser--	O
>	O
Phe	O
)	O
variant	O
.	O
The	O
KmNADP	O
of	O
G6PD	O
Orissa	O
is	O
fivefold	O
higher	O
than	O
that	O
of	O
the	O
normal	O
enzyme	O
.	O
This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
the	O
alanine	O
residue	O
that	O
is	O
replaced	O
by	O
glycine	O
is	O
part	O
of	O
a	O
putative	O
coenzyme-binding	O
site	O
.	O
.	O

10633128	O
Friedreich	B-SpecificDisease
ataxia:	I-SpecificDisease
an	O
overview.	O
Friedreich	B-SpecificDisease
ataxia	I-SpecificDisease
,	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
neurodegenerative	I-DiseaseClass
disease	I-DiseaseClass
,	O
is	O
the	O
most	O
common	O
of	O
the	O
inherited	B-SpecificDisease
ataxias	I-SpecificDisease
.	O
The	O
recent	O
discovery	O
of	O
the	O
gene	O
that	O
is	O
mutated	O
in	O
this	O
condition	O
,	O
FRDA	O
,	O
has	O
led	O
to	O
rapid	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
Friedreich	B-SpecificDisease
ataxia	I-SpecificDisease
.	O
About	O
98	O
%	O
of	O
mutant	O
alleles	O
have	O
an	O
expansion	O
of	O
a	O
GAA	O
trinucleotide	O
repeat	O
in	O
intron	O
1	O
of	O
the	O
gene	O
.	O
This	O
leads	O
to	O
reduced	O
levels	O
of	O
the	O
protein	O
,	O
frataxin	O
.	O
There	O
is	O
mounting	O
evidence	O
to	O
suggest	O
that	O
Friedreich	B-SpecificDisease
ataxia	I-SpecificDisease
is	O
the	O
result	O
of	O
accumulation	O
of	O
iron	O
in	O
mitochondria	O
leading	O
to	O
excess	O
production	O
of	O
free	O
radicals	O
,	O
which	O
then	O
results	O
in	O
cellular	O
damage	O
and	O
death	O
.	O
Currently	O
there	O
is	O
no	O
known	O
treatment	O
that	O
alters	O
the	O
natural	O
course	O
of	O
the	O
disease	O
.	O
The	O
discovery	O
of	O
the	O
FRDA	B-Modifier
gene	O
and	O
its	O
possible	O
function	O
has	O
raised	O
hope	O
that	O
rational	O
therapeutic	O
strategies	O
will	O
be	O
developed	O
.	O
.	O

8198124	O
Four	O
novel	O
PEPD	O
alleles	O
causing	O
prolidase	B-SpecificDisease
deficiency.	I-SpecificDisease
Mutations	O
at	O
the	O
PEPD	O
locus	O
cause	O
prolidase	B-SpecificDisease
deficiency	I-SpecificDisease
(	O
McKusick	O
170100	O
)	O
,	O
a	O
rare	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
characterized	O
by	O
iminodipeptiduria	B-SpecificDisease
,	O
skin	B-SpecificDisease
ulcers	I-SpecificDisease
,	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
,	O
and	O
recurrent	B-DiseaseClass
infections	I-DiseaseClass
.	O
Four	O
PEPD	O
mutations	O
from	O
five	O
severely	O
affected	O
individuals	O
were	O
characterized	O
by	O
analysis	O
of	O
reverse-transcribed	O
,	O
PCR-amplified	O
(	O
RT-PCR	O
)	O
cDNA	O
.	O
We	O
used	O
SSCP	O
analysis	O
on	O
four	O
overlapping	O
cDNA	O
fragments	O
covering	O
the	O
entire	O
coding	O
region	O
of	O
the	O
PEPD	O
gene	O
and	O
detected	O
abnormal	O
SSCP	O
bands	O
for	O
the	O
fragment	O
spanning	O
all	O
or	O
part	O
of	O
exons	O
13-15	O
in	O
three	O
of	O
the	O
probands	O
.	O
Direct	O
sequencing	O
of	O
the	O
mutant	O
cDNAs	O
showed	O
a	O
G--	O
>	O
A	O
,	O
1342	O
substitution	O
(	O
G448R	O
)	O
in	O
two	O
patients	O
and	O
a	O
3-bp	O
deletion	O
(	O
delta	O
E452	O
or	O
delta	O
E453	O
)	O
in	O
another	O
.	O
In	O
the	O
other	O
two	O
probands	O
the	O
amplified	O
products	O
were	O
of	O
reduced	O
size	O
.	O
Direct	O
sequencing	O
of	O
these	O
mutant	O
cDNAs	O
revealed	O
a	O
deletion	O
of	O
exon	O
5	O
in	O
one	O
patient	O
and	O
of	O
exon	O
7	O
in	O
the	O
other	O
.	O
Intronic	O
sequences	O
flanking	O
exons	O
5	O
and	O
7	O
were	O
identified	O
using	O
inverse	O
PCR	O
followed	O
by	O
direct	O
sequencing	O
.	O
Conventional	O
PCR	O
and	O
direct	O
sequencing	O
then	O
established	O
the	O
intron-exon	O
borders	O
of	O
the	O
mutant	O
genomic	O
DNA	O
revealing	O
two	O
splice	O
acceptor	O
mutations	O
a	O
G--	O
>	O
C	O
substitution	O
at	O
position	O
-1	O
of	O
intron	O
4	O
and	O
an	O
A--	O
>	O
G	O
substitution	O
at	O
position	O
-2	O
of	O
intron	O
6	O
.	O
Our	O
results	O
indicate	O
that	O
the	O
severe	O
form	O
of	O
prolidase	B-SpecificDisease
deficiency	I-SpecificDisease
is	O
caused	O
by	O
multiple	O
PEPD	O
alleles	O
.	O
In	O
this	O
report	O
we	O
attempt	O
to	O
begin	O
the	O
process	O
of	O
describing	O
these	O
alleles	O
and	O
cataloging	O
their	O
phenotypic	O
expression	O
.	O
.	O

10554035	O
Constitutional	O
von	B-Modifier
Hippel-Lindau	I-Modifier
(VHL)	O
gene	O
deletions	O
detected	O
in	O
VHL	B-Modifier
families	O
by	O
fluorescence	O
in	O
situ	O
hybridization.	O
von	B-SpecificDisease
Hippel-Lindau	I-SpecificDisease
(	I-SpecificDisease
VHL	I-SpecificDisease
)	I-SpecificDisease
disease	I-SpecificDisease
is	O
an	O
autosomal	B-DiseaseClass
dominantly	I-DiseaseClass
inherited	I-DiseaseClass
cancer	I-DiseaseClass
syndrome	I-DiseaseClass
predisposing	O
to	O
a	O
variety	O
of	O
tumor	B-Modifier
types	O
that	O
include	O
retinal	O
hemangioblastomas	B-DiseaseClass
,	O
hemangioblastomas	B-DiseaseClass
of	O
the	O
central	O
nervous	O
system	O
,	O
renal	B-SpecificDisease
cell	I-SpecificDisease
carcinomas	I-SpecificDisease
,	O
pancreatic	B-CompositeMention
cysts	I-CompositeMention
and	I-CompositeMention
tumors	I-CompositeMention
,	O
pheochromocytomas	B-DiseaseClass
,	O
endolymphatic	B-DiseaseClass
sac	I-DiseaseClass
tumors	I-DiseaseClass
,	O
and	O
epididymal	B-DiseaseClass
cystadenomas	I-DiseaseClass
[	O
W	O
.	O
M	O
.	O
Linehan	O
et	O
al	O
.	O
,	O
J	O
.	O
Am	O
.	O
Med	O
.	O
Assoc	O
.	O
,	O
273	O
564-570	O
,	O
1995	O
;	O
E	O
.	O
A	O
.	O
Maher	O
and	O
W	O
.	O
G	O
.	O
Kaelin	O
,	O
Jr	O
.	O
,	O
Medicine	O
(	O
Baltimore	O
)	O
,	O
76	O
381-391	O
,	O
1997	O
;	O
W	O
.	O
M	O
.	O
Linehan	O
and	O
R	O
.	O
D	O
.	O
Klausner	O
,	O
In	O
B	O
.	O
Vogelstein	O
and	O
K	O
.	O
Kinzler	O
(	O
eds	O
.	O
)	O
,	O
The	O
Genetic	O
Basis	O
of	O
Human	O
Cancer	O
,	O
pp	O
.	O
455-473	O
,	O
McGraw-Hill	O
,	O
1998	O
]	O
.	O
The	O
VHL	B-Modifier
gene	O
was	O
localized	O
to	O
chromosome	O
3p25-26	O
and	O
cloned	O
[	O
F	O
.	O
Latif	O
et	O
al	O
.	O
,	O
Science	O
(	O
Washington	O
DC	O
)	O
,	O
260	O
1317-1320	O
,	O
1993	O
]	O
.	O
Germline	O
mutations	O
in	O
the	O
VHL	B-Modifier
gene	O
have	O
been	O
detected	O
in	O
the	O
majority	O
of	O
VHL	B-Modifier
kindreds	O
.	O
The	O
reported	O
frequency	O
of	O
detection	O
of	O
VHL	B-Modifier
germline	O
mutations	O
has	O
varied	O
from	O
39	O
to	O
80	O
%	O
(	O
J	O
.	O
M	O
.	O
Whaley	O
et	O
al	O
.	O
,	O
Am	O
.	O
J	O
.	O
Hum	O
.	O
Genet	O
.	O
,	O
55	O
1092-1102	O
,	O
1994	O
;	O
Clinical	O
Research	O
Group	O
for	O
Japan	O
,	O
Hum	O
.	O
Mol	O
.	O
Genet	O
.	O
,	O
4	O
2233-2237	O
,	O
1995	O
;	O
F	O
.	O
Chen	O
et	O
al	O
.	O
,	O
Hum	O
.	O
Mutat	O
.	O
,	O
5	O
66-75	O
,	O
1995	O
;	O
E	O
.	O
R	O
.	O
Maher	O
et	O
al	O
.	O
,	O
J	O
.	O
Med	O
.	O
Genet	O
.	O
,	O
33	O
328-332	O
,	O
1996	O
;	O
B	O
.	O
Zbar	O
,	O
Cancer	O
Surv	O
.	O
,	O
25	O
219-232	O
,	O
1995	O
)	O
.	O
Recently	O
a	O
quantitative	O
Southern	O
blotting	O
procedure	O
was	O
found	O
to	O
improve	O
this	O
frequency	O
(	O
C	O
.	O
Stolle	O
et	O
al	O
.	O
,	O
Hum	O
.	O
Mutat	O
.	O
,	O
12	O
417-423	O
,	O
1998	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
use	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
as	O
a	O
method	O
to	O
detect	O
and	O
characterize	O
VHL	B-Modifier
germline	O
deletions	O
.	O
We	O
reexamined	O
a	O
group	O
of	O
VHL	B-Modifier
patients	O
shown	O
previously	O
by	O
single-strand	O
conformation	O
and	O
sequencing	O
analysis	O
not	O
to	O
harbor	O
point	O
mutations	O
in	O
the	O
VHL	B-Modifier
locus	O
.	O
We	O
found	O
constitutional	O
deletions	O
in	O
29	O
of	O
30	O
VHL	B-Modifier
patients	O
in	O
this	O
group	O
using	O
cosmid	O
and	O
P1	O
probes	O
that	O
cover	O
the	O
VHL	B-Modifier
locus	O
.	O
We	O
then	O
tested	O
six	O
phenotypically	O
normal	O
offspring	O
from	O
four	O
of	O
these	O
VHL	B-Modifier
families	O
two	O
were	O
found	O
to	O
carry	O
the	O
deletion	O
and	O
the	O
other	O
four	O
were	O
deletion-free	O
.	O
In	O
addition	O
,	O
germline	O
mosaicism	O
of	O
the	O
VHL	B-Modifier
gene	O
was	O
identified	O
in	O
one	O
family	O
.	O
In	O
sum	O
,	O
FISH	O
was	O
found	O
to	O
be	O
a	O
simple	O
and	O
reliable	O
method	O
to	O
detect	O
VHL	B-Modifier
germline	O
deletions	O
and	O
practically	O
useful	O
in	O
cases	O
where	O
other	O
methods	O
of	O
screening	O
have	O
failed	O
to	O
detect	O
a	O
VHL	B-SpecificDisease
gene	I-SpecificDisease
abnormality	I-SpecificDisease

8101038	O
High	O
residual	O
arylsulfatase	O
A	O
(ARSA)	O
activity	O
in	O
a	O
patient	O
with	O
late-infantile	B-SpecificDisease
metachromatic	I-SpecificDisease
leukodystrophy.	I-SpecificDisease
We	O
identified	O
a	O
patient	O
suffering	O
from	O
late-infantile	B-SpecificDisease
metachromatic	I-SpecificDisease
leukodystrophy	I-SpecificDisease
(	O
MLD	B-SpecificDisease
)	O
who	O
has	O
a	O
residual	O
arylsulfatase	O
A	O
(	O
ARSA	O
)	O
activity	O
of	O
about	O
10	O
%	O
.	O
Fibroblasts	O
of	O
the	O
patient	O
show	O
significant	O
sulfatide	O
degradation	O
activity	O
exceeding	O
that	O
of	O
adult	B-Modifier
MLD	I-Modifier
patients	O
.	O
Analysis	O
of	O
the	O
ARSA	O
gene	O
in	O
this	O
patient	O
revealed	O
heterozygosity	O
for	O
two	O
new	O
mutant	O
alleles	O
in	O
one	O
allele	O
,	O
deletion	O
of	O
C	O
447	O
in	O
exon	O
2	O
leads	O
to	O
a	O
frameshift	O
and	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
amino	O
acid	O
position	O
105	O
;	O
in	O
the	O
second	O
allele	O
,	O
a	O
G--	O
>	O
A	O
transition	O
in	O
exon	O
5	O
causes	O
a	O
Gly309--	O
>	O
Ser	O
substitution	O
.	O
Transient	O
expression	O
of	O
the	O
mutant	O
Ser309-ARSA	O
resulted	O
in	O
only	O
13	O
%	O
enzyme	O
activity	O
of	O
that	O
observed	O
in	O
cells	O
expressing	O
normal	O
ARSA	O
.	O
The	O
mutant	O
ARSA	O
is	O
correctly	O
targeted	O
to	O
the	O
lysosomes	O
but	O
is	O
unstable	O
.	O
These	O
findings	O
are	O
in	O
contrast	O
to	O
previous	O
results	O
showing	O
that	O
the	O
late-infantile	B-SpecificDisease
type	I-SpecificDisease
of	I-SpecificDisease
MLD	I-SpecificDisease
is	O
always	O
associated	O
with	O
the	O
complete	O
absence	O
of	O
ARSA	O
activity	O
.	O
The	O
expression	O
of	O
the	O
mutant	O
ARSA	O
protein	O
may	O
be	O
influenced	O
by	O
particular	O
features	O
of	O
oligodendrocytes	O
,	O
such	O
that	O
the	O
level	O
of	O
mutant	O
enzyme	O
is	O
lower	O
in	O
these	O
cells	O
than	O
in	O
others	O
.	O
.	O

3524231	O
Treatment	O
of	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
with	O
growth	O
hormone	O
inhibitors.	O
A	O
controlled	O
,	O
double-blind	O
therapeutic	O
trial	O
with	O
the	O
drug	O
mazindol	O
,	O
a	O
growth	O
hormone	O
inhibitor	O
,	O
was	O
performed	O
in	O
a	O
pair	O
of	O
7	O
1	O
/	O
2	O
year-old	O
monozygotic	O
twins	O
,	O
with	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)	O
.	O
The	O
rationale	O
for	O
this	O
trial	O
was	O
based	O
on	O
a	O
patient	O
(	O
reported	O
previously	O
)	O
affected	O
simultaneously	O
with	O
DMD	B-SpecificDisease
and	O
growth	B-SpecificDisease
hormone	I-SpecificDisease
(	I-SpecificDisease
GH	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
,	O
who	O
is	O
showing	O
a	O
benign	O
course	O
of	O
the	O
dystrophic	B-DiseaseClass
process	I-DiseaseClass
and	O
is	O
still	O
walking	O
at	O
18	O
years	O
.	O
One	O
of	O
the	O
twins	O
received	O
2	O
mg	O
of	O
mazindol	O
daily	O
,	O
while	O
the	O
other	O
received	O
a	O
placebo	O
.	O
The	O
assessment	O
,	O
repeated	O
every	O
2	O
months	O
,	O
included	O
weight	O
and	O
height	O
measurements	O
,	O
functional	O
and	O
motor	O
ability	O
tests	O
,	O
ergometry	O
and	O
determinations	O
of	O
serum	O
enzymes	O
and	O
GH	O
levels	O
.	O
After	O
one	O
year	O
of	O
trial	O
the	O
code	O
was	O
broken	O
and	O
it	O
was	O
seen	O
that	O
the	O
twin	O
under	O
placebo	O
treatment	O
was	O
strikingly	O
worse	O
than	O
his	O
brother	O
,	O
the	O
progression	O
of	O
whose	O
condition	O
was	O
practically	O
arrested	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
treatment	O
with	O
a	O
GH	O
inhibitor	O
is	O
beneficial	O
for	O
DMD	B-Modifier
patients	O
.	O
.	O

7795653	O
Decreased	O
expression	O
of	O
BRCA1	O
accelerates	O
growth	O
and	O
is	O
often	O
present	O
during	O
sporadic	B-Modifier
breast	I-Modifier
cancer	I-Modifier
progression.	O
We	O
have	O
characterized	O
expression	O
of	O
the	O
familial	B-Modifier
breast	I-Modifier
and	I-Modifier
ovarian	I-Modifier
cancer	I-Modifier
gene	O
,	O
BRCA1	O
,	O
in	O
cases	O
of	O
non-hereditary	B-SpecificDisease
(	I-SpecificDisease
sporadic	I-SpecificDisease
)	I-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
and	O
analyzed	O
the	O
effect	O
of	O
antisense	O
inhibition	O
of	O
BRCA1	O
on	O
the	O
proliferative	O
rate	O
of	O
mammary	O
epithelial	O
cells	O
.	O
BRCA1	O
mRNA	O
levels	O
are	O
markedly	O
decreased	O
during	O
the	O
transition	O
from	O
carcinoma	B-DiseaseClass
in	I-DiseaseClass
situ	I-DiseaseClass
to	O
invasive	B-DiseaseClass
cancer	I-DiseaseClass
.	O
Experimental	O
inhibition	O
of	O
BRCA1	O
expression	O
with	O
antisense	O
oligonucleotides	O
produced	O
accelerated	O
growth	O
of	O
normal	O
and	O
malignant	O
mammary	O
cells	O
,	O
but	O
had	O
no	O
effect	O
on	O
non-mammary	O
epithelial	O
cells	O
.	O
These	O
studies	O
suggest	O
that	O
BRCA1	O
may	O
normally	O
serve	O
as	O
a	O
negative	O
regulator	O
of	O
mammary	O
epithelial	O
cell	O
growth	O
whose	O
function	O
is	O
compromised	O
in	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
either	O
by	O
direct	O
mutation	O
or	O
alterations	O
in	O
gene	O
expression	O
.	O
.	O

7458742	O
Increased	O
incidence	O
of	O
cataracts	B-SpecificDisease
in	O
male	O
subjects	O
deficient	B-SpecificDisease
in	I-SpecificDisease
glucose-6-phosphate	I-SpecificDisease
dehydrogenase.	I-SpecificDisease
Glucose-6-phosphate	B-SpecificDisease
dehydrogenase	I-SpecificDisease
(	I-SpecificDisease
G6PD	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
RBCs	O
was	O
found	O
significantly	O
more	O
frequently	O
in	O
210	O
male	O
cataractous	B-Modifier
patients	O
than	O
in	O
672	O
control	O
subjects	O
of	O
Sardinian	O
origin	O
.	O
The	O
frequency	O
of	O
the	O
deficiency	O
was	O
increasingly	O
higher	O
in	O
presenile	O
cataracts	B-SpecificDisease
.	O
In	O
the	O
G6PD-deficient	B-Modifier
group	O
,	O
the	O
incidence	O
of	O
cortical	B-CompositeMention
and	I-CompositeMention
total	I-CompositeMention
cataracts	I-CompositeMention
was	O
also	O
increased	O
.	O
It	O
is	O
suggested	O
that	O
decrease	O
of	O
the	O
G6PD	O
activity	O
in	O
the	O
lens	O
,	O
which	O
accompanies	O
its	O
deficiency	O
in	O
the	O
erythrocyte	O
,	O
might	O
play	O
a	O
role	O
in	O
the	O
cataracto-genesis	O
of	O
these	O
patients	O
.	O
Moreover	O
,	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
should	O
be	O
added	O
to	O
other	O
conditions	O
,	O
such	O
as	O
the	O
galactosemic	B-Modifier
states	O
and	O
riboflavin	B-SpecificDisease
deficiency	I-SpecificDisease
,	O
where	O
cataracts	B-SpecificDisease
represent	O
a	O
sensitive	O
indicator	O
of	O
metabolic	B-DiseaseClass
abnormalities	I-DiseaseClass
of	O
the	O
RBC	O
.	O
.	O

8563759	O
Brca1	B-SpecificDisease
deficiency	I-SpecificDisease
results	O
in	O
early	O
embryonic	B-DiseaseClass
lethality	I-DiseaseClass
characterized	O
by	O
neuroepithelial	B-DiseaseClass
abnormalities.	I-DiseaseClass
The	O
breast	B-Modifier
and	I-Modifier
ovarian	I-Modifier
cancer	I-Modifier
susceptibility	O
gene	O
,	O
BRCA1	O
,	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
zinc-finger	O
protein	O
of	O
unknown	O
function	O
.	O
Mutations	O
in	O
BRCA1	O
account	O
for	O
at	O
least	O
80	O
%	O
of	O
families	O
with	O
both	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
,	O
as	O
well	O
as	O
some	O
non-familial	O
sporadic	O
ovarian	B-SpecificDisease
cancers	I-SpecificDisease
.	O
The	O
loss	O
of	O
wild-type	O
BRCA1	O
in	O
tumours	B-DiseaseClass
of	O
individuals	O
carrying	O
one	O
nonfunctional	O
BRCA1	O
allele	O
suggests	O
that	O
BRCA1	O
encodes	O
a	O
tumour	B-Modifier
suppressor	O
that	O
may	O
inhibit	O
the	O
proliferation	O
of	O
mammary	O
epithelial	O
cells	O
.	O
To	O
examine	O
the	O
role	O
of	O
BRCA1	O
in	O
normal	O
tissue	O
growth	O
and	O
differentiation	O
,	O
and	O
to	O
generate	O
a	O
potential	O
model	O
for	O
the	O
cancer	B-Modifier
susceptibility	O
associated	O
with	O
loss	O
of	O
BRCA1	O
function	O
,	O
we	O
have	O
created	O
a	O
mouse	O
line	O
carrying	O
a	O
mutation	O
in	O
one	O
Brca1	O
allele	O
.	O
Analysis	O
of	O
mice	O
homozygous	O
for	O
the	O
mutant	O
allele	O
indicate	O
that	O
Brca1	O
is	O
critical	O
for	O
normal	O
development	O
,	O
as	O
these	O
mice	O
died	O
in	O
utero	O
between	O
10	O
and	O
13	O
days	O
of	O
gestation	O
(	O
E10-E13	O
)	O
.	O
Abnormalities	O
in	O
Brca1-deficient	B-Modifier
embryos	O
were	O
most	O
evident	O
in	O
the	O
neural	O
tube	O
,	O
with	O
40	O
%	O
of	O
the	O
embryos	O
presenting	O
with	O
varying	O
degrees	O
of	O
spina	B-SpecificDisease
bifida	I-SpecificDisease
and	O
anencephaly	B-SpecificDisease
.	O
In	O
addition	O
,	O
the	O
neuroepithelium	O
in	O
Brca1-deficient	B-Modifier
embryos	O
appeared	O
disorganized	O
,	O
with	O
signs	O
of	O
both	O
rapid	O
proliferation	O
and	O
excessive	O
cell	O
death	O
.	O
.	O

8279472	O
Haplotype	O
studies	O
in	O
Wilson	B-SpecificDisease
disease.	I-SpecificDisease
In	O
51	O
families	O
with	O
Wilson	B-SpecificDisease
disease	I-SpecificDisease
,	O
we	O
have	O
studied	O
DNA	O
haplotypes	O
of	O
dinucleotide	O
repeat	O
polymorphisms	O
(	O
CA	O
repeats	O
)	O
in	O
the	O
13q14	O
.	O
3	O
region	O
,	O
to	O
examine	O
these	O
markers	O
for	O
association	O
with	O
the	O
Wilson	B-Modifier
disease	I-Modifier
gene	O
(	O
WND	O
)	O
.	O
In	O
addition	O
to	O
a	O
marker	O
(	O
D13S133	O
)	O
described	O
elsewhere	O
,	O
we	O
have	O
developed	O
three	O
new	O
highly	O
polymorphic	O
markers	O
(	O
D13S314	O
,	O
D13S315	O
,	O
and	O
D13S316	O
)	O
close	O
to	O
the	O
WND	O
locus	O
.	O
We	O
have	O
examined	O
the	O
distribution	O
of	O
marker	O
alleles	O
at	O
the	O
loci	O
studied	O
and	O
have	O
found	O
that	O
D13S314	O
,	O
D13S133	O
,	O
and	O
D13S316	O
each	O
show	O
nonrandom	O
distribution	O
on	O
chromosomes	O
carrying	O
the	O
WND	O
mutation	O
.	O
We	O
have	O
studied	O
haplotypes	O
of	O
these	O
three	O
markers	O
and	O
have	O
found	O
that	O
there	O
are	O
highly	O
significant	O
differences	O
between	O
WND	O
and	O
normal	O
haplotypes	O
in	O
northern	O
European	O
families	O
.	O
These	O
findings	O
have	O
important	O
implications	O
for	O
mutation	O
detection	O
and	O
molecular	O
diagnosis	O
in	O
families	O
with	O
Wilson	B-SpecificDisease
disease	I-SpecificDisease
.	O

1357962	O
Trisomy	B-SpecificDisease
15	I-SpecificDisease
with	O
loss	O
of	O
the	O
paternal	O
15	O
as	O
a	O
cause	O
of	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
due	O
to	O
maternal	B-SpecificDisease
disomy.	I-SpecificDisease
Uniparental	B-SpecificDisease
disomy	I-SpecificDisease
has	O
recently	O
been	O
recognized	O
to	O
cause	O
human	O
disorders	O
,	O
including	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
PWS	B-SpecificDisease
)	O
.	O
We	O
describe	O
a	O
particularly	O
instructive	O
case	O
which	O
raises	O
important	O
issues	O
concerning	O
the	O
mechanisms	O
producing	O
uniparental	B-SpecificDisease
disomy	I-SpecificDisease
and	O
whose	O
evaluation	O
provides	O
evidence	O
that	O
trisomy	O
may	O
precede	O
uniparental	B-SpecificDisease
disomy	I-SpecificDisease
in	O
a	O
fetus	O
.	O
Chorionic	O
villus	O
sampling	O
performed	O
for	O
advanced	O
maternal	O
age	O
revealed	O
trisomy	B-SpecificDisease
15	I-SpecificDisease
in	O
all	O
direct	O
and	O
cultured	O
cells	O
,	O
though	O
the	O
fetus	O
appeared	O
normal	O
.	O
Chromosome	O
analysis	O
of	O
amniocytes	O
obtained	O
at	O
15	O
wk	O
was	O
normal	O
in	O
over	O
100	O
cells	O
studied	O
.	O
The	O
child	O
was	O
hypotonic	B-SpecificDisease
at	O
birth	O
,	O
and	O
high-resolution	O
banding	O
failed	O
to	O
reveal	O
the	O
deletion	O
of	O
15q11-13	O
,	O
a	O
deletion	O
which	O
is	O
found	O
in	O
50	O
%	O
-70	O
%	O
of	O
patients	O
with	O
PWS	B-SpecificDisease
.	O
Over	O
time	O
,	O
typical	O
features	O
of	O
PWS	B-SpecificDisease
developed	O
.	O
Molecular	O
genetic	O
analysis	O
using	O
probes	O
for	O
chromosome	O
15	O
revealed	O
maternal	O
disomy	O
.	O
Maternal	O
nondisjunction	O
with	O
fertilization	O
of	O
a	O
disomic	O
egg	O
by	O
a	O
normal	O
sperm	O
,	O
followed	O
by	O
loss	O
of	O
the	O
paternal	O
15	O
,	O
is	O
a	O
likely	O
cause	O
of	O
confined	O
placental	O
mosaicism	O
and	O
uniparental	B-SpecificDisease
disomy	I-SpecificDisease
in	O
this	O
case	O
of	O
PWS	B-SpecificDisease
,	O
and	O
advanced	O
maternal	O
age	O
may	O
be	O
a	O
predisposing	O
factor	O
.	O
.	O

7450778	O
Further	O
evidence	O
for	O
heterogeneity	O
of	O
glucose-6-phosphate	B-SpecificDisease
dehydrogenase	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
Papua	O
New	O
Guinea.	O
Four	O
new	O
G6PD	O
variants	O
have	O
been	O
characterized	O
in	O
individuals	O
from	O
Papua	O
New	O
Guinea	O
.	O
This	O
study	O
demonstrates	O
that	O
the	O
previously	O
reported	O
Markham	O
variant	O
and	O
the	O
newly	O
characterized	O
Salata	O
variant	O
may	O
be	O
widely	O
distributed	O
in	O
Papua	O
New	O
Guinea	O
.	O
Th	O
data	O
presented	O
here	O
together	O
with	O
those	O
of	O
previously	O
published	O
studies	O
demonstrate	O
a	O
degree	O
of	O
heterogeneity	O
of	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
that	O
is	O
much	O
higher	O
than	O
that	O
in	O
other	O
regions	O
of	O
the	O
world	O
where	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
is	O
common	O
.	O
.	O

2355960	O
Screening	O
for	O
carriers	O
of	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
among	O
Ashkenazi	O
Jews.	O
A	O
comparison	O
of	O
DNA-based	O
and	O
enzyme-based	O
tests.	O
BACKGROUND	O
AND	O
METHODS	O
.	O
The	O
prevention	O
of	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
(	O
GM2	B-SpecificDisease
gangliosidosis	I-SpecificDisease
,	I-SpecificDisease
type	I-SpecificDisease
1	I-SpecificDisease
)	O
depends	O
on	O
the	O
identification	O
of	O
carriers	O
of	O
the	O
gene	O
for	O
this	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
.	O
We	O
compared	O
the	O
enzyme-based	O
test	O
widely	O
used	O
in	O
screening	O
for	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
with	O
a	O
test	O
based	O
on	O
analysis	O
of	O
DNA	O
.	O
We	O
developed	O
methods	O
to	O
detect	O
the	O
three	O
mutations	O
in	O
the	O
HEXA	O
gene	O
that	O
occur	O
with	O
high	O
frequency	O
among	O
Ashkenazi	O
Jews	O
two	O
mutations	O
cause	O
infantile	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
,	O
and	O
the	O
third	O
causes	O
the	O
adult-onset	O
form	O
of	O
the	O
disease	O
.	O
DNA	O
segments	O
containing	O
these	O
mutation	O
sites	O
were	O
amplified	O
with	O
the	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
for	O
the	O
presence	O
of	O
the	O
mutations	O
.	O
RESULTS	O
.	O
Among	O
62	O
Ashkenazi	O
obligate	O
carriers	O
of	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
,	O
the	O
three	O
specific	O
mutations	O
accounted	O
for	O
all	O
but	O
one	O
of	O
the	O
mutant	O
alleles	O
(	O
98	O
percent	O
)	O
.	O
In	O
216	O
Ashkenazi	O
carriers	O
identified	O
by	O
the	O
enzyme	O
test	O
,	O
DNA	O
analysis	O
showed	O
that	O
177	O
(	O
82	O
percent	O
)	O
had	O
one	O
of	O
the	O
identified	O
mutations	O
.	O
Of	O
the	O
177	O
,	O
79	O
percent	O
had	O
the	O
exon	O
11	O
insertion	O
mutation	O
,	O
18	O
percent	O
had	O
the	O
intron	O
12	O
splice-junction	O
mutation	O
,	O
and	O
3	O
percent	O
had	O
the	O
less	O
severe	O
exon	O
7	O
mutation	O
associated	O
with	O
adult-onset	B-DiseaseClass
disease	I-DiseaseClass
.	O
The	O
results	O
of	O
the	O
enzyme	O
tests	O
in	O
the	O
39	O
subjects	O
(	O
18	O
percent	O
)	O
who	O
were	O
defined	O
as	O
carriers	O
but	O
in	O
whom	O
DNA	O
analysis	O
did	O
not	O
identify	O
a	O
mutant	O
allele	O
were	O
probably	O
false	O
positive	O
(	O
although	O
there	O
remains	O
some	O
possibility	O
of	O
unidentified	O
mutations	O
)	O
.	O
In	O
addition	O
,	O
of	O
152	O
persons	O
defined	O
as	O
noncarriers	O
by	O
the	O
enzyme-based	O
test	O
,	O
1	O
was	O
identified	O
as	O
a	O
carrier	O
by	O
DNA	O
analysis	O
(	O
i	O
.	O
e	O
e	O
.	O
,	O
a	O
false	O
negative	O
enzyme-test	O
result	O
)	O
.	O
CONCLUSIONS	O
.	O
The	O
increased	O
specificity	O
and	O
predictive	O
value	O
of	O
the	O
DNA-based	O
test	O
make	O
it	O
a	O
useful	O
adjunct	O
to	O
the	O
diagnostic	O
tests	O
currently	O
used	O
to	O
screen	O
for	O
carriers	O
of	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
.	O

10441343	O
French	O
Machado-Joseph	B-Modifier
disease	I-Modifier
patients	O
do	O
not	O
exhibit	O
gametic	O
segregation	O
distortion:	O
a	O
sperm	O
typing	O
analysis.	O
Segregation	O
distortion	O
has	O
been	O
reported	O
to	O
occur	O
in	O
a	O
number	O
of	O
the	O
trinucleotide	B-DiseaseClass
repeat	I-DiseaseClass
disorders	I-DiseaseClass
.	O
On	O
the	O
basis	O
of	O
a	O
sperm	O
typing	O
study	O
performed	O
in	O
patients	O
of	O
Japanese	O
descent	O
with	O
Machado-Joseph	B-SpecificDisease
disease	I-SpecificDisease
(	O
MJD	B-SpecificDisease
)	O
,	O
it	O
was	O
reported	O
that	O
disease	O
alleles	O
are	O
preferentially	O
transmitted	O
during	O
meiosis	O
.	O
We	O
performed	O
a	O
sperm	O
typing	O
study	O
of	O
five	O
MJD	B-Modifier
patients	O
of	O
French	O
descent	O
and	O
analysis	O
of	O
the	O
pooled	O
data	O
shows	O
a	O
ratio	O
of	O
mutant	O
to	O
normal	O
alleles	O
of	O
379	O
436	O
(	O
46	O
.	O
5	O
53	O
.	O
5	O
%	O
)	O
,	O
which	O
does	O
not	O
support	O
meiotic	O
segregation	O
distortion	O
.	O
To	O
confirm	O
these	O
results	O
,	O
sperm	O
typing	O
analysis	O
was	O
also	O
performed	O
using	O
a	O
polymorphic	O
marker	O
,	O
D14S1050	O
,	O
closely	O
linked	O
to	O
the	O
MJD1	O
gene	O
.	O
Among	O
910	O
sperm	O
analyzed	O
,	O
the	O
allele	O
linked	O
to	O
the	O
disease	O
chromosome	O
was	O
detected	O
in	O
50	O
.	O
3	O
%	O
of	O
the	O
samples	O
and	O
the	O
allele	O
linked	O
to	O
the	O
normal	O
chromosome	O
was	O
found	O
in	O
49	O
.	O
6	O
%	O
of	O
the	O
sperm	O
.	O
The	O
difference	O
in	O
frequency	O
of	O
these	O
two	O
alleles	O
is	O
not	O
significant	O
(	O
P	O
=	O
0	O
.	O
8423	O
)	O
.	O
Likelihood-based	O
analysis	O
of	O
segregation	O
distortion	O
in	O
the	O
single	O
sperm	O
data	O
using	O
the	O
SPERMSEG	O
program	O
also	O
showed	O
no	O
support	O
for	O
segregation	O
distortion	O
at	O
the	O
gamete	O
level	O
in	O
this	O
patient	O
population	O
.	O
The	O
previous	O
report	O
on	O
the	O
Japanese	O
patients	O
also	O
suggested	O
that	O
disease	O
allele	O
stability	O
may	O
be	O
influenced	O
by	O
a	O
trans	O
effect	O
of	O
an	O
intragenic	O
polymorphism	O
(	O
987	O
G	O
/	O
C	O
)	O
in	O
the	O
wild-type	O
allele	O
.	O
All	O
of	O
the	O
French	O
patients	O
were	O
heterozygous	O
for	O
this	O
polymorphism	O
.	O
However	O
,	O
analysis	O
of	O
the	O
variance	O
in	O
repeat	O
number	O
in	O
sperm	O
from	O
the	O
French	O
MJD	B-Modifier
patients	O
overlapped	O
significantly	O
with	O
the	O
variance	O
in	O
repeat	O
number	O
observed	O
in	O
the	O
C	O
/	O
C	O
homozygous	O
Japanese	O
patients	O
.	O

8075631	O
Familial	B-SpecificDisease
male	I-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
is	O
not	O
linked	O
to	O
the	O
BRCA1	O
locus	O
on	O
chromosome	O
17q.	O
Breast	B-SpecificDisease
cancer	I-SpecificDisease
in	O
men	O
is	O
about	O
a	O
hundredfold	O
less	O
common	O
than	O
in	O
women	O
and	O
this	O
has	O
hindered	O
research	O
into	O
its	O
genetic	O
basis	O
.	O
We	O
have	O
examined	O
22	O
families	O
with	O
at	O
least	O
one	O
case	O
of	O
male	B-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
for	O
linkage	O
to	O
the	O
hereditary	B-Modifier
breast	I-Modifier
and	I-Modifier
ovarian	I-Modifier
cancer	I-Modifier
locus	O
,	O
BRCA1	O
,	O
on	O
chromosome	O
17q	O
.	O
We	O
found	O
strong	O
evidence	O
against	O
linkage	O
to	O
BRCA1	O
(	O
lod	O
score-16	O
.	O
63	O
)	O
and	O
the	O
best	O
estimate	O
of	O
the	O
proportion	O
of	O
linked	O
families	O
was	O
0	O
%	O
(	O
95	O
%	O
CI	O
0-18	O
%	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
there	O
is	O
a	O
gene	O
(	O
s	O
)	O
other	O
than	O
BRCA1	O
which	O
predisposes	O
to	O
early-onset	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
in	O
women	O
and	O
which	O
confers	O
a	O
higher	O
risk	O
of	O
male	B-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
.	O
Identification	O
of	O
additional	O
pedigrees	O
that	O
include	O
cases	O
of	O
male	B-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
may	O
therefore	O
facilitate	O
the	O
mapping	O
and	O
isolation	O
of	O
this	O
gene	O
.	O

3600794	O
Localization	O
of	O
the	O
region	O
homologous	O
to	O
the	O
Duchenne	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
locus	O
on	O
the	O
mouse	O
X	O
chromosome.	O
Recent	O
progress	O
has	O
resulted	O
in	O
part	O
of	O
the	O
gene	O
mutated	O
in	O
Duchenne	B-CompositeMention
and	I-CompositeMention
the	I-CompositeMention
milder	I-CompositeMention
Becker	I-CompositeMention
muscular	I-CompositeMention
dystrophies	I-CompositeMention
being	O
cloned	O
and	O
has	O
suggested	O
that	O
the	O
gene	O
itself	O
extends	O
over	O
1	O
,	O
000	O
to	O
2	O
,	O
000	O
kilobases	O
(	O
kb	O
)	O
.	O
To	O
study	O
how	O
mutations	O
in	O
this	O
gene	O
affect	O
muscle	O
development	O
and	O
integrity	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
have	O
available	O
a	O
mouse	O
model	O
of	O
the	O
human	O
disease	O
.	O
The	O
mouse	O
mdx	O
mutation	O
affects	O
muscle	O
and	O
confers	O
a	O
mild	O
dystrophic	B-SpecificDisease
syndrome	I-SpecificDisease
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
mutation	O
is	O
equivalent	O
to	O
Duchenne	B-CompositeMention
/	I-CompositeMention
Becker	I-CompositeMention
muscular	I-CompositeMention
dystrophy	I-CompositeMention
in	O
man	O
.	O
Here	O
we	O
describe	O
the	O
use	O
of	O
two	O
sequences	O
from	O
the	O
human	O
Duchenne	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
(	O
DMD	B-Modifier
)	O
gene	O
that	O
cross-hybridize	O
to	O
mouse	O
X-linked	O
sequences	O
to	O
localize	O
the	O
gene	O
homologous	O
to	O
DMD	B-SpecificDisease
in	O
the	O
mouse	O
.	O
Both	O
sequences	O
map	O
to	O
the	O
region	O
of	O
10	O
centimorgan	O
lying	O
between	O
the	O
Tabby	O
(	O
Ta	O
)	O
and	O
St14-1	O
(	O
DxPas8	O
)	O
loci	O
,	O
close	O
to	O
the	O
phosphorylase	O
b	O
kinase	O
locus	O
(	O
Phk	O
)	O
.	O
By	O
analogy	O
with	O
the	O
human	O
X-chromosome	O
,	O
we	O
conclude	O
that	O
the	O
region	O
in	O
the	O
mouse	O
around	O
the	O
G6pd	O
and	O
St14-1	O
loci	O
may	O
contain	O
two	O
genes	O
corresponding	O
to	O
distinct	O
human	O
myopathies	B-DiseaseClass
Emery	B-SpecificDisease
Dreifuss	I-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
which	O
is	O
known	O
to	O
be	O
closely	O
linked	O
to	O
St14-1	O
in	O
man	O
and	O
the	O
DMD	B-Modifier
homologue	O
described	O
here	O
.	O
.	O

10484765	O
Cis	O
and	O
trans	O
effects	O
of	O
the	O
myotonic	B-Modifier
dystrophy	I-Modifier
(	O
DM	B-Modifier
)	O
mutation	O
in	O
a	O
cell	O
culture	O
model.	O
The	O
mutation	O
causing	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
has	O
been	O
identified	O
as	O
a	O
CTG	O
expansion	O
in	O
the	O
3-untranslated	O
region	O
(	O
3-UTR	O
)	O
of	O
the	O
DM	B-Modifier
protein	O
kinase	O
gene	O
(	O
DMPK	O
)	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
pathogenesis	O
remain	O
unknown	O
.	O
Studies	O
using	O
DM	B-Modifier
patient	O
materials	O
have	O
often	O
produced	O
confusing	O
results	O
.	O
Therefore	O
,	O
to	O
study	O
the	O
effects	O
of	O
the	O
DM	B-Modifier
mutation	O
in	O
a	O
controlled	O
environment	O
,	O
we	O
have	O
established	O
a	O
cell	O
culture	O
model	O
system	O
using	O
C2C12	O
mouse	O
myoblasts	O
.	O
By	O
expressing	O
chimeric	O
reporter	O
constructs	O
containing	O
a	O
reporter	O
gene	O
fused	O
to	O
a	O
human	O
DMPK	O
3-UTR	O
,	O
we	O
identified	O
both	O
cis	O
and	O
trans	O
effects	O
that	O
are	O
mediated	O
by	O
the	O
DM	B-Modifier
mutation	O
.	O
Our	O
data	O
show	O
that	O
a	O
mutant	O
DMPK	O
3-UTR	O
,	O
with	O
as	O
few	O
as	O
57	O
CTGs	O
,	O
had	O
a	O
negative	O
cis	O
effect	O
on	O
protein	O
expression	O
and	O
resulted	O
in	O
the	O
aggregation	O
of	O
reporter	O
transcripts	O
into	O
discrete	O
nuclear	O
foci	O
.	O
We	O
determined	O
by	O
deletion	O
analysis	O
that	O
an	O
expanded	O
(	O
CTG	O
)	O
(	O
n	O
)	O
tract	O
alone	O
was	O
sufficient	O
to	O
mediate	O
these	O
cis	O
effects	O
.	O
Furthermore	O
,	O
in	O
contrast	O
to	O
the	O
normal	O
DMPK	O
3-UTR	O
mRNA	O
,	O
a	O
mutant	O
DMPK	O
3-UTR	O
mRNA	O
with	O
(	O
CUG	O
)	O
(	O
200	O
)	O
selectively	O
inhibited	O
myogenic	O
differentiation	O
of	O
C2C12	O
myoblasts	O
.	O
Genetic	O
analysis	O
and	O
the	O
Cre-	O
loxP	O
system	O
were	O
used	O
to	O
clearly	O
demonstrate	O
that	O
the	O
myoblast	O
fusion	O
defect	O
could	O
be	O
rescued	O
by	O
eliminating	O
the	O
expression	O
of	O
the	O
mutant	O
DMPK	O
3-UTR	O
transcript	O
.	O
Characterization	O
of	O
spontaneous	O
deletion	O
events	O
mapped	O
the	O
inhibitory	O
effect	O
to	O
the	O
(	O
CTG	O
)	O
(	O
n	O
)	O
expansion	O
and	O
/	O
or	O
the	O
3	O
end	O
of	O
the	O
DMPK	O
3-UTR	O
.	O
These	O
results	O
provide	O
evidence	O
that	O
the	O
DM	B-Modifier
mutation	O
acts	O
in	O
cis	O
to	O
reduce	O
protein	O
production	O
(	O
consistent	O
with	O
DMPK	B-SpecificDisease
haploinsufficiency	I-SpecificDisease
)	O
and	O
in	O
trans	O
as	O
a	O
riboregulator	O
to	O
inhibit	O
myogenesis	O
.	O
.	O

1678319	O
Identification	O
of	O
deletion	O
mutations	O
and	O
three	O
new	O
genes	O
at	O
the	O
familial	B-Modifier
polyposis	I-Modifier
locus.	O
Small	O
(	O
100-260	O
kb	O
)	O
,	O
nested	O
deletions	O
were	O
characterized	O
in	O
DNA	O
from	O
two	O
unrelated	O
patients	O
with	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
coli	I-SpecificDisease
(	O
APC	B-SpecificDisease
)	O
.	O
Three	O
candidate	O
genes	O
located	O
within	O
the	O
deleted	O
region	O
were	O
ascertained	O
and	O
a	O
previous	O
candidate	O
gene	O
,	O
MCC	O
,	O
was	O
shown	O
to	O
be	O
located	O
outside	O
the	O
deleted	O
region	O
.	O
One	O
of	O
the	O
new	O
genes	O
contained	O
sequence	O
identical	O
to	O
SRP19	O
,	O
the	O
gene	O
coding	O
for	O
the	O
19	O
kd	O
component	O
of	O
the	O
ribosomal	O
signal	O
recognition	O
particle	O
.	O
The	O
second	O
,	O
provisionally	O
designated	O
DP1	O
(	O
deleted	O
in	O
polyposis	O
1	O
)	O
,	O
was	O
found	O
to	O
be	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
MCC	O
.	O
Two	O
other	O
cDNAs	O
,	O
DP2	O
and	O
DP3	O
,	O
were	O
found	O
to	O
overlap	O
,	O
forming	O
a	O
single	O
gene	O
,	O
DP2	O
.	O
5	O
,	O
that	O
is	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
SRP19	O
.	O

8401501	O
Genetic	O
mapping	O
of	O
the	O
breast-ovarian	B-DiseaseClass
cancer	I-DiseaseClass
syndrome	I-DiseaseClass
to	O
a	O
small	O
interval	O
on	O
chromosome	O
17q12-21:	O
exclusion	O
of	O
candidate	O
genes	O
EDH17B2	O
and	O
RARA.	O
A	O
susceptibility	O
gene	O
for	O
hereditary	B-DiseaseClass
breast-ovarian	I-DiseaseClass
cancer	I-DiseaseClass
,	O
BRCA1	O
,	O
has	O
been	O
assigned	O
by	O
linkage	O
analysis	O
to	O
chromosome	O
17q21	O
.	O
Candidate	O
genes	O
in	O
this	O
region	O
include	O
EDH17B2	O
,	O
which	O
encodes	O
estradiol	O
17	O
beta-hydroxysteroid	O
dehydrogenase	O
II	O
(	O
17	O
beta-HSD	O
II	O
)	O
,	O
and	O
RARA	O
,	O
the	O
gene	O
for	O
retinoic	O
acid	O
receptor	O
alpha	O
.	O
We	O
have	O
typed	O
22	O
breast	B-Modifier
and	I-Modifier
breast-ovarian	I-Modifier
cancer	I-Modifier
families	O
with	O
eight	O
polymorphisms	O
from	O
the	O
chromosome	O
17q12-21	O
region	O
,	O
including	O
two	O
in	O
the	O
EDH17B2	O
gene	O
.	O
Genetic	O
recombination	O
with	O
the	O
breast	B-Modifier
cancer	I-Modifier
trait	O
excludes	O
RARA	O
from	O
further	O
consideration	O
as	O
a	O
candidate	O
gene	O
for	O
BRCA1	O
.	O
Both	O
BRCA1	O
and	O
EDH17B2	O
map	O
to	O
a	O
6	O
cM	O
interval	O
(	O
between	O
THRA1	O
and	O
D17S579	O
)	O
and	O
no	O
recombination	O
was	O
observed	O
between	O
the	O
two	O
genes	O
.	O
However	O
,	O
direct	O
sequencing	O
of	O
overlapping	O
PCR	O
products	O
containing	O
the	O
entire	O
EDH17B2	O
gene	O
in	O
four	O
unrelated	O
affected	O
women	O
did	O
not	O
uncover	O
any	O
sequence	O
variation	O
,	O
other	O
than	O
previously	O
described	O
polymorphisms	O
.	O
Mutations	O
in	O
the	O
EDH17B2	O
gene	O
,	O
therefore	O
do	O
not	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
hereditary	B-DiseaseClass
breast-ovarian	I-DiseaseClass
cancer	I-DiseaseClass
syndrome	I-DiseaseClass
.	O
Single	O
meiotic	O
crossovers	O
in	O
affected	O
women	O
suggest	O
that	O
BRCA1	O
is	O
flanked	O
by	O
the	O
loci	O
RARA	O
and	O
D17S78	O
.	O
.	O

10323740	O
Microdeletions	O
at	O
chromosome	O
bands	O
1q32-q41	O
as	O
a	O
cause	O
of	O
Van	B-SpecificDisease
der	I-SpecificDisease
Woude	I-SpecificDisease
syndrome.	I-SpecificDisease
Van	B-SpecificDisease
der	I-SpecificDisease
Woude	I-SpecificDisease
syndrome	I-SpecificDisease
(	O
VWS	B-SpecificDisease
)	O
is	O
an	O
autosomal	B-DiseaseClass
dominant	I-DiseaseClass
disorder	I-DiseaseClass
comprising	O
cleft	B-SpecificDisease
lip	I-SpecificDisease
and	O
/	O
or	O
cleft	B-SpecificDisease
palate	I-SpecificDisease
and	O
lip	B-SpecificDisease
pits	I-SpecificDisease
.	O
We	O
reported	O
previously	O
a	O
family	O
whose	O
underlying	O
mutation	O
is	O
a	O
500-800	O
kb	O
deletion	O
localized	O
to	O
chromosome	O
bands	O
1q32-q41	O
[	O
Sander	O
et	O
al	O
.	O
,	O
1994	O
Hum	O
Mol	O
Genet	O
3	O
576-578	O
]	O
.	O
Along	O
with	O
cleft	B-CompositeMention
lip	I-CompositeMention
/	I-CompositeMention
palate	I-CompositeMention
and	O
lip	B-SpecificDisease
pits	I-SpecificDisease
,	O
affected	O
relatives	O
exhibit	O
developmental	B-DiseaseClass
delays	I-DiseaseClass
,	O
suggesting	O
that	O
the	O
function	O
of	O
a	O
gene	O
nearby	O
may	O
also	O
be	O
disrupted	O
.	O
To	O
further	O
localize	O
the	O
VWS	B-Modifier
gene	O
we	O
searched	O
for	O
other	O
deletions	O
that	O
cause	O
VWS	B-SpecificDisease
.	O
An	O
allele	O
loss	O
assay	O
was	O
performed	O
using	O
a	O
novel	O
highly	O
polymorphic	O
marker	O
,	O
D1S3753	O
.	O
From	O
a	O
panel	O
of	O
37	O
unrelated	O
individuals	O
,	O
we	O
detected	O
an	O
allele	O
loss	O
in	O
one	O
family	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
deletion	O
.	O
In	O
this	O
family	O
,	O
the	O
phenotype	O
in	O
three	O
generations	O
of	O
affected	O
individuals	O
was	O
confined	O
to	O
the	O
cardinal	O
signs	O
of	O
VWS	B-SpecificDisease
.	O
Surprisingly	O
,	O
mapping	O
of	O
the	O
new	O
deletion	O
showed	O
that	O
it	O
extended	O
0	O
.	O
2-1	O
Mb	O
beyond	O
the	O
proximal	O
breakpoint	O
for	O
the	O
deletion	O
described	O
previously	O
.	O
No	O
deletions	O
were	O
detected	O
in	O
seven	O
cases	O
of	O
popliteal	B-SpecificDisease
pterygia	I-SpecificDisease
syndrome	I-SpecificDisease
,	O
76	O
cases	O
of	O
mixed	O
syndromic	B-CompositeMention
forms	I-CompositeMention
of	I-CompositeMention
cleft	I-CompositeMention
lip	I-CompositeMention
and	I-CompositeMention
palate	I-CompositeMention
,	O
and	O
178	O
cases	O
of	O
nonsyndromic	B-CompositeMention
cleft	I-CompositeMention
lip	I-CompositeMention
and	I-CompositeMention
palate	I-CompositeMention
.	O

8551426	O
A	O
prevalent	O
mutation	O
for	O
galactosemia	B-SpecificDisease
among	O
black	O
Americans.	O
OBJECTIVE	O
To	O
define	O
the	O
mutation	O
causing	O
galactosemia	B-SpecificDisease
in	O
patients	O
of	O
black	O
American	O
origin	O
who	O
have	O
no	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
activity	O
in	O
erythrocytes	O
but	O
good	O
clinical	O
outcome	O
.	O
METHODS	O
We	O
discovered	O
a	O
mutation	O
caused	O
by	O
a	O
C--	O
>	O
T	O
transition	O
at	O
base-pair	O
1158	O
of	O
the	O
GALT	O
gene	O
that	O
results	O
in	O
a	O
serine-to-leucine	O
substitution	O
at	O
codon	O
135	O
(	O
S135L	O
)	O
.	O
We	O
developed	O
a	O
method	O
with	O
which	O
to	O
screen	O
populations	O
for	O
its	O
prevalence	O
.	O
We	O
compared	O
galactose-1-phosphate	O
uridyltransferase	O
among	O
erythrocytes	O
,	O
leukocytes	O
,	O
and	O
transformed	O
lymphoblasts	O
,	O
as	O
well	O
as	O
total	O
body	O
oxidation	O
of	O
D-	O
(	O
13C	O
)	O
-galactose	O
to	O
13CO2	O
among	O
three	O
genotypes	O
for	O
GALT	O
(	O
S135L	O
/	O
S135L	O
,	O
Q188R	O
/	O
Q188R	O
,	O
and	O
Normal	O
/	O
Normal	O
)	O
.	O
RESULTS	O
We	O
found	O
a	O
48	O
%	O
prevalence	O
of	O
the	O
S135L	O
mutation	O
among	O
17	O
black	O
American	O
patients	O
with	O
classic	B-SpecificDisease
galactosemia	I-SpecificDisease
and	O
a	O
1	O
%	O
prevalence	O
in	O
a	O
population	O
of	O
50	O
black	O
Americans	O
without	O
galactosemia	B-SpecificDisease
.	O
The	O
S135L	O
mutation	O
was	O
not	O
found	O
in	O
84	O
white	O
patients	O
with	O
G	O
/	O
G	O
galactosemia	B-SpecificDisease
nor	O
in	O
87	O
white	O
control	O
subjects	O
without	O
galactosemia	B-SpecificDisease
.	O
We	O
found	O
normal	O
whole	O
body	O
oxidation	O
of	O
D-	O
(	O
13C	O
)	O
-galactose	O
by	O
the	O
patient	O
homozygous	O
for	O
S135L	O
and	O
various	O
degrees	O
of	O
enzyme	O
impairment	O
among	O
different	O
tissues	O
.	O
CONCLUSIONS	O
The	O
S135L	O
mutation	O
in	O
the	O
GALT	O
gene	O
is	O
a	O
prevalent	O
cause	O
of	O
galactosemia	B-SpecificDisease
among	O
black	O
patients	O
.	O
Because	O
GALT	O
activity	O
varies	O
in	O
different	O
tissues	O
of	O
patients	O
homozygous	O
for	O
S135L	O
,	O
they	O
may	O
have	O
a	O
better	O
clinical	O
outcome	O
than	O
patients	O
who	O
are	O
homozygous	O
for	O
Q188R	O
when	O
both	O
are	O
treated	O
from	O
infancy	O
.	O
.	O

10441329	O
Null	O
mutation	O
of	O
the	O
murine	O
ATP7B	O
(	O
Wilson	B-SpecificDisease
disease	I-SpecificDisease
)	O
gene	O
results	O
in	O
intracellular	B-DiseaseClass
copper	I-DiseaseClass
accumulation	I-DiseaseClass
and	O
late-onset	B-DiseaseClass
hepatic	I-DiseaseClass
nodular	I-DiseaseClass
transformation.	I-DiseaseClass
The	O
Atp7b	O
protein	O
is	O
a	O
copper-transporting	O
ATPase	O
expressed	O
predominantly	O
in	O
the	O
liver	O
and	O
to	O
a	O
lesser	O
extent	O
in	O
most	O
other	O
tissues	O
.	O
Mutations	O
in	O
the	O
ATP7B	O
gene	O
lead	O
to	O
Wilson	B-SpecificDisease
disease	I-SpecificDisease
,	I-SpecificDisease
a	O
copper	B-DiseaseClass
toxicity	I-DiseaseClass
disorder	I-DiseaseClass
characterized	O
by	O
dramatic	O
build-up	O
of	O
intracellular	O
hepatic	O
copper	O
with	O
subsequent	O
hepatic	B-CompositeMention
and	I-CompositeMention
neuro-logical	I-CompositeMention
abnormalities	I-CompositeMention
.	O
Using	O
homologous	O
recombination	O
to	O
disrupt	O
the	O
normal	O
translation	O
of	O
ATP7B	O
,	O
we	O
have	O
generated	O
a	O
strain	O
of	O
mice	O
that	O
are	O
homozygous	O
mutants	O
(	O
null	O
)	O
for	O
the	O
Wilson	B-Modifier
disease	I-Modifier
gene	O
.	O
The	O
ATP7B	O
null	O
mice	O
display	O
a	O
gradual	O
accumulation	O
of	O
hepatic	O
copper	O
that	O
increases	O
to	O
a	O
level	O
60-fold	O
greater	O
than	O
normal	O
by	O
5	O
months	O
of	O
age	O
.	O
An	O
increase	O
in	O
copper	O
concentration	O
was	O
also	O
observed	O
in	O
the	O
kidney	O
,	O
brain	O
,	O
placenta	O
and	O
lactating	O
mammary	O
glands	O
of	O
homo-zygous	O
mutants	O
,	O
although	O
milk	O
from	O
the	O
mutant	O
glands	O
was	O
copper	B-DiseaseClass
deficient	I-DiseaseClass
.	O
Morphological	B-DiseaseClass
abnormalities	I-DiseaseClass
resembling	O
cirrhosis	B-SpecificDisease
developed	O
in	O
the	O
majority	O
of	O
the	O
livers	O
from	O
homozygous	O
mutants	O
older	O
than	O
7	O
months	O
of	O
age	O
.	O
Progeny	O
of	O
the	O
homozygous	O
mutant	O
females	O
demonstrated	O
neurological	B-DiseaseClass
abnormalities	I-DiseaseClass
and	O
growth	B-DiseaseClass
retardation	I-DiseaseClass
characteristic	O
of	O
copper	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
Copper	O
concentration	O
in	O
the	O
livers	O
of	O
the	O
newborn	O
homozygous	O
null	O
mutants	O
was	O
decreased	O
dramatically	O
.	O
In	O
summary	O
,	O
inactivation	O
of	O
the	O
murine	O
ATP7B	O
gene	O
produces	O
a	O
form	O
of	O
cirrhotic	B-DiseaseClass
liver	I-DiseaseClass
disease	I-DiseaseClass
that	O
resembles	O
Wilson	B-SpecificDisease
disease	I-SpecificDisease
in	O
humans	O
and	O
the	O
toxic	O
milk	O
phenotype	O
in	O
the	O
mouse	O
.	O
.	O

10545613	O
Synergistic	O
effect	O
of	O
histone	O
hyperacetylation	O
and	O
DNA	O
demethylation	O
in	O
the	O
reactivation	O
of	O
the	O
FMR1	O
gene.	O
Most	O
fragile	B-Modifier
X	I-Modifier
syndrome	I-Modifier
patients	O
have	O
expansion	O
of	O
a	O
(	O
CGG	O
)	O
(	O
n	O
)	O
sequence	O
with	O
>	O
200	O
repeats	O
(	O
full	O
mutation	O
)	O
in	O
the	O
FMR1	O
gene	O
responsible	O
for	O
this	O
condition	O
.	O
Hypermethylation	O
of	O
the	O
expanded	O
repeat	O
and	O
of	O
the	O
FMR1	O
promoter	O
is	O
almost	O
always	O
present	O
and	O
apparently	O
suppresses	O
transcription	O
,	O
resulting	O
in	O
absence	O
of	O
the	O
FMR1	O
protein	O
.	O
We	O
recently	O
showed	O
that	O
transcriptional	O
reactivation	O
of	O
FMR1	O
full	O
mutations	O
can	O
be	O
achieved	O
by	O
inducing	O
DNA	O
demethylation	O
with	O
5-azadeoxycytidine	O
(	O
5-azadC	O
)	O
.	O
The	O
level	O
of	O
histone	O
acetylation	O
is	O
another	O
important	O
factor	O
in	O
regulating	O
gene	O
expression	O
;	O
therefore	O
,	O
we	O
treated	O
lymphoblastoid	O
cell	O
lines	O
of	O
non-mosaic	O
full	O
mutation	O
patients	O
with	O
three	O
drugs	O
capable	O
of	O
inducing	O
histone	O
hyperacetylation	O
.	O
We	O
observed	O
a	O
consistent	O
,	O
although	O
modest	O
,	O
reactivation	O
of	O
the	O
FMR1	O
gene	O
with	O
4-phenylbutyrate	O
,	O
sodium	O
butyrate	O
and	O
trichostatin	O
A	O
,	O
as	O
shown	O
by	O
RT-PCR	O
.	O
However	O
,	O
we	O
report	O
that	O
combining	O
these	O
drugs	O
with	O
5-azadC	O
results	O
in	O
a	O
2-	O
to	O
5-fold	O
increase	O
in	O
FMR1	O
mRNA	O
levels	O
obtained	O
with	O
5-azadC	O
alone	O
,	O
thus	O
showing	O
a	O
marked	O
synergistic	O
effect	O
of	O
histone	O
hyperacetylation	O
and	O
DNA	O
demethylation	O
in	O
the	O
reactivation	O
of	O
FMR1	O
full	O
mutations	O
.	O
.	O

8098245	O
Illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
lymphocytes	O
for	O
identification	O
of	O
mutations	O
in	O
phenylketonuria.	B-SpecificDisease
Taking	O
advantage	O
of	O
the	O
illegitimate	O
transcription	O
of	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
,	O
we	O
have	O
been	O
able	O
to	O
analyse	O
the	O
PAH	O
cDNA	O
sequence	O
of	O
hyperphenylalaninemic	B-Modifier
children	O
in	O
circulating	O
lymphocytes	O
.	O
Using	O
this	O
approach	O
,	O
we	O
have	O
also	O
identified	O
3	O
novel	O
mutations	O
in	O
cDNA	O
from	O
liver	O
and	O
lymphocytes	O
of	O
two	O
patients	O
.	O
One	O
mutation	O
,	O
detected	O
by	O
the	O
abnormal	O
pattern	O
of	O
migration	O
of	O
an	O
amplified	O
fragment	O
,	O
is	O
a	O
C	O
to	O
T	O
transition	O
in	O
the	O
splice	O
acceptor	O
site	O
of	O
intron	O
10	O
,	O
which	O
resulted	O
in	O
the	O
skipping	O
of	O
exon	O
11	O
with	O
the	O
premature	O
termination	O
of	O
RNA	O
translation	O
downstream	O
from	O
exon	O
12	O
(	O
-3	O
IVS10	O
)	O
.	O
The	O
other	O
two	O
mutations	O
are	O
missense	O
mutations	O
in	O
exons	O
10	O
and	O
11	O
(	O
respectively	O
,	O
L333F	O
and	O
E390G	O
)	O
.	O
The	O
present	O
study	O
supports	O
the	O
view	O
that	O
circulating	O
lymphocytes	O
give	O
easy	O
access	O
to	O
PAH	O
gene	O
transcripts	O
whose	O
nucleotide	O
sequence	O
is	O
identical	O
to	O
that	O
reported	O
in	O
liver	O
and	O
therefore	O
represent	O
a	O
useful	O
tool	O
for	O
molecular	O
genetic	O
studies	O
in	O
phenylketonuria	B-SpecificDisease
.	O
.	O

7874117	O
A	O
single	O
amino	O
acid	O
substitution	O
(G103D)	O
in	O
the	O
type	O
II	O
collagen	O
triple	O
helix	O
produces	O
Kniest	B-SpecificDisease
dysplasia.	I-SpecificDisease
Kniest	B-SpecificDisease
dysplasia	I-SpecificDisease
is	O
a	O
moderately	O
severe	O
chondrodysplasia	B-Modifier
phenotype	O
that	O
results	O
from	O
mutations	O
in	O
the	O
gene	O
for	O
type	O
II	O
collagen	O
,	O
COL2A1	O
.	O
Characteristics	O
of	O
the	O
disorder	O
include	O
a	O
short	O
trunk	O
and	O
extremities	O
,	O
mid-face	B-DiseaseClass
hypoplasia	I-DiseaseClass
,	O
cleft	B-DiseaseClass
palate	I-DiseaseClass
,	O
myopia	B-DiseaseClass
,	O
retinal	B-SpecificDisease
detachment	I-SpecificDisease
,	O
and	O
hearing	B-DiseaseClass
loss	I-DiseaseClass
.	O
Recently	O
,	O
deletions	O
of	O
all	O
or	O
part	O
of	O
exon	O
12	O
have	O
been	O
identified	O
in	O
individuals	O
with	O
Kniest	B-SpecificDisease
dysplasia	I-SpecificDisease
,	O
suggesting	O
that	O
mutations	O
within	O
this	O
region	O
of	O
the	O
protein	O
may	O
primarily	O
result	O
in	O
the	O
Kniest	B-Modifier
dysplasia	I-Modifier
phenotype	O
.	O
We	O
used	O
SSCP	O
to	O
analyze	O
an	O
amplified	O
genomic	O
DNA	O
fragment	O
containing	O
exon	O
12	O
from	O
seven	O
individuals	O
with	O
Kniest	B-SpecificDisease
dysplasia	I-SpecificDisease
.	O
An	O
abnormality	O
was	O
identified	O
in	O
one	O
patient	O
.	O
DNA	O
sequence	O
analysis	O
demonstrated	O
that	O
the	O
patient	O
was	O
heterozygous	O
for	O
a	O
G	O
to	O
A	O
transition	O
that	O
implied	O
substitution	O
of	O
glycine103	O
of	O
the	O
triple	O
helical	O
domain	O
by	O
aspartate	O
.	O
The	O
mutation	O
was	O
not	O
observed	O
in	O
DNA	O
from	O
either	O
of	O
the	O
clinically	O
unaffected	O
parents	O
of	O
the	O
proband	O
.	O
Protein	O
microsequencing	O
demonstrated	O
expression	O
of	O
the	O
abnormal	O
allele	O
in	O
cartilage	O
.	O
These	O
data	O
demonstrate	O
that	O
point	O
mutations	O
which	O
result	O
in	O
single	O
amino	O
acid	O
substitutions	O
can	O
produce	O
Kniest	B-SpecificDisease
dysplasia	I-SpecificDisease
and	O
further	O
support	O
the	O
hypothesis	O
that	O
alteration	O
of	O
a	O
domain	O
,	O
which	O
includes	O
the	O
region	O
encoded	O
by	O
exon	O
12	O
,	O
in	O
the	O
type	O
II	O
collagen	O
protein	O
leads	O
to	O
this	O
disorder	O
.	O
.	O

6650504	O
The	O
Tay-Sachs	B-Modifier
disease	I-Modifier
gene	O
in	O
North	O
American	O
Jewish	O
populations:	O
geographic	O
variations	O
and	O
origin.	O
From	O
data	O
collected	O
in	O
a	O
North	O
American	O
Tay-Sachs	B-Modifier
disease	I-Modifier
(	O
TSD	B-Modifier
)	O
heterozygote	O
screening	O
program	O
,	O
the	O
TSD	B-Modifier
carrier	O
frequency	O
among	O
46	O
,	O
304	O
Jewish	O
individuals	O
was	O
found	O
to	O
be	O
.	O
0324	O
(	O
1	O
in	O
31	O
individuals	O
)	O
.	O
This	O
frequency	O
is	O
consistent	O
with	O
earlier	O
estimates	O
based	O
on	O
TSD	B-Modifier
incidence	O
data	O
.	O
TSD	B-Modifier
carrier	O
frequencies	O
were	O
then	O
examined	O
by	O
single	O
country	O
and	O
single	O
region	O
of	O
origin	O
in	O
28	O
,	O
029	O
Jews	O
within	O
this	O
sample	O
for	O
whom	O
such	O
data	O
were	O
available	O
for	O
analysis	O
.	O
Jews	O
with	O
Polish	O
and	O
/	O
or	O
Russian	O
ancestry	O
constituted	O
88	O
%	O
of	O
this	O
sample	O
and	O
had	O
a	O
TSD	B-Modifier
carrier	O
frequency	O
of	O
.	O
0327	O
.	O
No	O
TSD	B-Modifier
carriers	O
were	O
observed	O
among	O
the	O
166	O
Jews	O
of	O
Near	O
Eastern	O
origins	O
.	O
Relative	O
to	O
Jews	O
of	O
Polish	O
and	O
Russian	O
origins	O
,	O
there	O
was	O
at	O
least	O
a	O
twofold	O
increase	O
in	O
the	O
TSD	B-Modifier
carrier	O
frequency	O
in	O
Jews	O
of	O
Austrian	O
,	O
Hungarian	O
,	O
and	O
Czechoslovakian	O
origins	O
(	O
P	O
less	O
than	O
.	O
005	O
)	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
TSD	B-Modifier
gene	O
proliferated	O
among	O
the	O
antecedents	O
of	O
modern	O
Ashkenazi	O
Jewry	O
after	O
the	O
Second	O
Diaspora	O
(	O
70	O
A	O
.	O
D	O
.	O
)	O
and	O
before	O
their	O
major	O
migrations	O
to	O
regions	O
of	O
Poland	O
and	O
Russia	O
(	O
before	O
1100	O
A	O
.	O
D	O
.	O
)	O
.	O

10607954	O
Knobloch	B-SpecificDisease
syndrome	I-SpecificDisease
involving	O
midline	B-DiseaseClass
scalp	I-DiseaseClass
defect	I-DiseaseClass
of	I-DiseaseClass
the	I-DiseaseClass
frontal	I-DiseaseClass
region.	I-DiseaseClass
We	O
report	O
on	O
a	O
4-year-old	O
boy	O
with	O
Knobloch	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
He	O
has	O
vitreoretinal	B-SpecificDisease
degeneration	I-SpecificDisease
,	O
high	B-SpecificDisease
myopia	I-SpecificDisease
,	O
cataract	B-SpecificDisease
,	O
telecanthus	B-SpecificDisease
,	O
hypertelorism	B-SpecificDisease
,	O
and	O
a	O
high-arched	B-SpecificDisease
palate	I-SpecificDisease
.	O
He	O
also	O
has	O
a	O
defect	B-DiseaseClass
of	I-DiseaseClass
the	I-DiseaseClass
anterior	I-DiseaseClass
midline	I-DiseaseClass
scalp	I-DiseaseClass
with	O
involvement	O
of	O
the	O
frontal	O
bone	O
as	O
documented	O
by	O
a	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
.	O
The	O
brain	O
was	O
normal	O
on	O
CT	O
scan	O
and	O
magnetic	O
resonance	O
imaging	O
.	O
We	O
present	O
a	O
review	O
of	O
the	O
23	O
published	O
cases	O
with	O
this	O
syndrome	O
.	O
Our	O
patient	O
illustrates	O
the	O
importance	O
of	O
investigating	O
for	O
underlying	O
ocular	O
and	O
central	O
nervous	O
system	O
pathology	O
whenever	O
midline	B-DiseaseClass
scalp	I-DiseaseClass
defects	I-DiseaseClass
are	O
present	O
.	O
.	O

10381492	O
The	O
C282Y	O
mutation	O
causing	O
hereditary	B-SpecificDisease
hemochromatosis	I-SpecificDisease
does	O
not	O
produce	O
a	O
null	O
allele.	O
Targeted	O
mutagenesis	O
was	O
used	O
to	O
produce	O
two	O
mutations	O
in	O
the	O
murine	O
hemochromatosis	B-Modifier
gene	O
(	O
Hfe	O
)	O
locus	O
.	O
The	O
first	O
mutation	O
deletes	O
a	O
large	O
portion	O
of	O
the	O
coding	O
sequence	O
,	O
generating	O
a	O
null	O
allele	O
.	O
The	O
second	O
mutation	O
introduces	O
a	O
missense	O
mutation	O
(	O
C282Y	O
)	O
into	O
the	O
Hfe	O
locus	O
,	O
but	O
otherwise	O
leaves	O
the	O
gene	O
intact	O
.	O
This	O
mutation	O
is	O
identical	O
to	O
the	O
disease-causing	O
mutation	O
in	O
patients	O
with	O
hereditary	B-SpecificDisease
hemochromatosis	I-SpecificDisease
.	O
Mice	O
carrying	O
each	O
of	O
the	O
two	O
mutations	O
were	O
bred	O
and	O
analyzed	O
.	O
Homozygosity	O
for	O
either	O
mutation	O
results	O
in	O
postnatal	O
iron	O
loading	O
.	O
The	O
effects	O
of	O
the	O
null	O
mutation	O
are	O
more	O
severe	O
than	O
the	O
effects	O
of	O
the	O
C282Y	O
mutation	O
.	O
Mice	O
heterozygous	O
for	O
either	O
mutation	O
accumulate	O
more	O
iron	O
than	O
normal	O
controls	O
.	O
Interestingly	O
,	O
although	O
liver	O
iron	O
stores	O
are	O
greatly	O
increased	O
,	O
splenic	O
iron	O
is	O
decreased	O
.	O
We	O
conclude	O
that	O
the	O
C282Y	O
mutation	O
does	O
not	O
result	O
in	O
a	O
null	O
allele	O
.	O
.	O

1577763	O
Type	B-SpecificDisease
I	I-SpecificDisease
human	I-SpecificDisease
complement	I-SpecificDisease
C2	I-SpecificDisease
deficiency.	I-SpecificDisease
A	O
28-base	O
pair	O
gene	O
deletion	O
causes	O
skipping	O
of	O
exon	O
6	O
during	O
RNA	O
splicing.	O
Two	O
variants	O
of	O
a	O
genetic	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
complement	I-SpecificDisease
protein	I-SpecificDisease
C2	I-SpecificDisease
(	O
C2D	O
)	O
have	O
been	O
previously	O
identified	O
.	O
No	O
C2	O
protein	O
translation	O
is	O
detected	O
in	O
type	O
I	O
deficiency	O
,	O
while	O
type	O
II	O
deficiency	O
is	O
characterized	O
by	O
a	O
selective	O
block	O
in	O
C2	O
secretion	O
.	O
Type	B-SpecificDisease
I	I-SpecificDisease
C2	I-SpecificDisease
deficiency	I-SpecificDisease
was	O
described	O
in	O
a	O
family	O
in	O
which	O
the	O
C2	O
null	O
allele	O
(	O
C2Q0	O
)	O
is	O
associated	O
with	O
the	O
major	O
histocompatibility	O
haplotype	O
/	O
complotype	O
HLA-A25	O
,	O
B18	O
,	O
C2Q0	O
,	O
BfS	O
,	O
C4A4	O
,	O
C4B2	O
,	O
Drw2	O
;	O
this	O
extended	O
haplotype	O
occurs	O
in	O
over	O
90	O
%	O
of	O
C2-deficient	B-Modifier
individuals	O
(	O
common	O
complotype	O
/	O
haplotype	O
)	O
.	O
To	O
determine	O
the	O
molecular	O
basis	O
of	O
type	B-SpecificDisease
I	I-SpecificDisease
C2	I-SpecificDisease
deficiency	I-SpecificDisease
,	O
the	O
C2	O
gene	O
and	O
cDNA	O
were	O
characterized	O
from	O
a	O
homozygous	O
type	B-Modifier
I	I-Modifier
C2-deficient	I-Modifier
individual	O
with	O
the	O
common	O
associated	O
haplotype	O
/	O
complotype	O
.	O
We	O
found	O
a	O
28-base	O
pair	O
deletion	O
in	O
the	O
type	O
I	O
C2Q0	O
gene	O
,	O
beginning	O
9	O
base	O
pairs	O
upstream	O
of	O
the	O
3-end	O
of	O
exon	O
6	O
,	O
that	O
generates	O
a	O
C2	O
transcript	O
with	O
a	O
complete	O
deletion	O
of	O
exon	O
6	O
(	O
134	O
base	O
pair	O
)	O
and	O
a	O
premature	O
termination	O
codon	O
.	O
In	O
studies	O
of	O
eight	O
kindred	O
,	O
the	O
28-base	O
pair	O
deletion	O
was	O
observed	O
in	O
all	O
C2Q0	O
alleles	O
associated	O
with	O
the	O
common	O
type	O
I	O
deficient	O
complotype	O
/	O
haplotype	O
;	O
this	O
deletion	O
was	O
not	O
present	O
in	O
normal	O
C2	O
nor	O
in	O
type	B-Modifier
II	I-Modifier
C2-deficient	I-Modifier
genes	O
.	O
These	O
data	O
demonstrate	O
that	O
1	O
)	O
type	B-SpecificDisease
I	I-SpecificDisease
human	I-SpecificDisease
complement	I-SpecificDisease
C2	I-SpecificDisease
deficiency	I-SpecificDisease
is	O
caused	O
by	O
a	O
28-base	O
pair	O
genomic	O
deletion	O
that	O
causes	O
skipping	O
of	O
exon	O
6	O
during	O
RNA	O
splicing	O
,	O
resulting	O
in	O
generation	O
of	O
a	O
premature	O
termination	O
codon	O
,	O
2	O
)	O
the	O
28-base	O
pair	O
deletion	O
in	O
the	O
type	O
I	O
C2Q0	O
gene	O
is	O
strongly	O
associated	O
with	O
the	O
HLA	O
haplotype	O
/	O
complotype	O
A25	O
,	O
B18	O
,	O
C2Q0	O
,	O
BfS	O
,	O
C4A4	O
,	O
C4B2	O
,	O
Drw2	O
,	O
suggesting	O
that	O
all	O
C2-deficient	B-Modifier
individuals	O
with	O
this	O
haplotype	O
/	O
complotype	O
will	O
harbor	O
the	O
28-base	O
pair	O
C2	O
gene	O
deletion	O
,	O
and	O
3	O
)	O
type	B-SpecificDisease
II	I-SpecificDisease
C2	I-SpecificDisease
deficiency	I-SpecificDisease
is	O
caused	O
by	O
a	O
different	O
,	O
as	O
yet	O
uncharacterized	O
,	O
molecular	O
genetic	B-DiseaseClass
defect	I-DiseaseClass
.	O
.	O

3169738	O
Patterns	O
of	O
exon	O
deletions	O
in	O
Duchenne	B-CompositeMention
and	I-CompositeMention
Becker	I-CompositeMention
muscular	I-CompositeMention
dystrophy.	I-CompositeMention
A	O
panel	O
of	O
patients	O
with	O
Duchenne	B-CompositeMention
and	I-CompositeMention
Becker	I-CompositeMention
muscular	I-CompositeMention
dystrophy	I-CompositeMention
(	O
DMD	B-SpecificDisease
and	O
BMD	B-SpecificDisease
)	O
has	O
been	O
screened	O
with	O
the	O
cDNA	O
probes	O
Cf56a	O
and	O
Cf23a	O
,	O
which	O
detect	O
exons	O
in	O
the	O
central	O
part	O
of	O
the	O
DMD	B-Modifier
gene	O
.	O
One	O
or	O
more	O
exons	O
were	O
deleted	O
in	O
60	O
%	O
of	O
patients	O
.	O
The	O
deletions	O
were	O
mapped	O
and	O
prove	O
to	O
be	O
heterogeneous	O
in	O
size	O
and	O
extent	O
,	O
particularly	O
in	O
DMD	B-SpecificDisease
.	O
Deletions	O
specific	O
to	O
DMD	B-SpecificDisease
and	O
to	O
BMD	B-SpecificDisease
are	O
described	O
.	O
Half	O
of	O
all	O
BMD	B-Modifier
patients	O
have	O
a	O
deletion	O
of	O
one	O
particular	O
small	O
group	O
of	O
exons	O
;	O
smaller	O
deletions	O
within	O
this	O
same	O
group	O
produce	O
the	O
more	O
severe	O
DMD	B-SpecificDisease
.	O
.	O

2989709	O
DNA	O
restriction	O
fragments	O
associated	O
with	O
alpha	O
1-antitrypsin	O
indicate	O
a	O
single	O
origin	O
for	O
deficiency	O
allele	O
PI	O
Z.	O
The	O
alpha	O
1-protease	O
inhibitor	O
,	O
or	O
alpha-antitrypsin	O
(	O
AAT	O
)	O
,	O
a	O
major	O
plasma	O
inhibitor	O
of	O
leukocyte	O
elastase	O
and	O
bacterial	O
proteases	O
,	O
is	O
encoded	O
at	O
the	O
PI	O
locus	O
on	O
chromosome	O
14	O
(	O
14q24	O
.	O
3-q32	O
.	O
1	O
)	O
.	O
A	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
AAT	I-SpecificDisease
in	O
individuals	O
homozygous	O
for	O
the	O
PI	O
Z	O
allele	O
occurs	O
in	O
about	O
1	O
in	O
2	O
,	O
000-8	O
,	O
000	O
caucasians	O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
early	O
adult	O
onset	O
emphysema	B-DiseaseClass
and	O
liver	B-DiseaseClass
disease	I-DiseaseClass
in	O
childhood	O
.	O
We	O
have	O
now	O
used	O
DNA	O
polymorphisms	O
associated	O
with	O
the	O
AAT	O
gene	O
to	O
investigate	O
the	O
origin	O
of	O
the	O
PI	O
Z	O
allele	O
.	O
Using	O
two	O
genomic	O
probes	O
extending	O
into	O
the	O
5	O
and	O
3	O
flanking	O
regions	O
,	O
respectively	O
,	O
we	O
have	O
identified	O
eight	O
polymorphic	O
restriction	O
sites	O
.	O
Extensive	O
linkage	O
disequilibrium	O
occurs	O
throughout	O
the	O
probed	O
region	O
with	O
the	O
PI	O
Z	O
allele	O
,	O
but	O
not	O
with	O
normal	O
PI	O
M	O
alleles	O
.	O
The	O
Z	O
allele	O
occurs	O
mainly	O
with	O
one	O
haplotype	O
,	O
indicating	O
a	O
single	O
,	O
relatively	O
recent	O
,	O
origin	O
in	O
caucasians	O

6902670	O
Familial	B-SpecificDisease
discoid	I-SpecificDisease
lupus	I-SpecificDisease
erythematosus	I-SpecificDisease
associated	O
with	O
heterozygote	O
C2	B-SpecificDisease
deficiency.	I-SpecificDisease
Two	O
siblings	O
with	O
chronic	B-SpecificDisease
discoid	I-SpecificDisease
lupus	I-SpecificDisease
erythematosus	I-SpecificDisease
and	O
several	O
family	O
members	O
were	O
found	O
with	O
heterozygous	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
An	O
association	O
with	O
histocompatibility	O
markers	O
HLA-B18	O
and	O
HLA-Dw2	O
was	O
demonstrated	O
,	O
and	O
the	O
slow	O
allotype	O
of	O
factor	O
B	O
was	O
present	O
.	O
Linkage	O
studies	O
in	O
this	O
family	O
suggested	O
a	O
close	O
linkage	O
between	O
the	O
C2	B-Modifier
deficiency	I-Modifier
gene	O
and	O
genes	O
coding	O
for	O
B18	O
,	O
Dw2	O
,	O
and	O
BfS	O
antigens	O
.	O
One	O
HLA-ACB	O
/	O
DBf	O
recombinant	O
was	O
observed	O
showing	O
closer	O
linkage	O
between	O
HLA-D	O
and	O
Bf	O
than	O
between	O
HLA-B	O
and	O
Bf	O
.	O
.	O

102474	O
Combined	B-CompositeMention
genetic	I-CompositeMention
deficiency	I-CompositeMention
of	I-CompositeMention
C6	I-CompositeMention
and	I-CompositeMention
C7	I-CompositeMention
in	O
man.	O
By	O
routine	O
screening	O
of	O
sera	O
,	O
a	O
subject	O
was	O
discovered	O
who	O
showed	O
a	O
sub-total	B-CompositeMention
deficiency	I-CompositeMention
of	I-CompositeMention
C6	I-CompositeMention
and	I-CompositeMention
C7	I-CompositeMention
.	O
No	O
clinical	O
disease	O
was	O
associated	O
with	O
this	O
deficiency	O
which	O
was	O
transmitted	O
through	O
the	O
subjects	O
family	O
as	O
a	O
single	O
genetic	O
characteristic	O
,	O
the	O
C6	B-SpecificDisease
deficiency	I-SpecificDisease
being	O
associated	O
with	O
a	O
silent	O
allele	O
at	O
the	O
structural	O
locus	O
.	O
The	O
propositus	O
was	O
found	O
to	O
have	O
low	O
quantities	O
of	O
an	O
abnormal	O
C6	O
which	O
was	O
both	O
antigenically	O
deficient	O
and	O
smaller	O
in	O
size	O
than	O
normal	O
C6	O
(	O
110	O
,	O
000	O
daltons	O
compared	O
with	O
140	O
,	O
000	O
daltons	O
)	O
and	O
small	O
quantities	O
of	O
apparently	O
normal	O
C7	O
.	O
It	O
is	O
concluded	O
that	O
the	O
most	O
likely	O
explanation	O
for	O
this	O
defect	O
is	O
that	O
the	O
subject	O
has	O
a	O
structural	O
mutation	O
in	O
his	O
C6	O
gene	O
which	O
produces	O
hyopsynthesis	O
not	O
only	O
of	O
C6	O
but	O
also	O
of	O
the	O
closely	O
linked	O
gene	O
for	O
C7	O
.	O
These	O
findings	O
suggest	O
the	O
possibility	O
that	O
C6	O
and	O
C7	O
may	O
function	O
as	O
a	O
single	O
genetic	O
unit	O
and	O
that	O
the	O
primary	O
transcript	O
copied	O
from	O
the	O
genome	O
includes	O
information	O
for	O
both	O
proteins	O
.	O
.	O

1999552	O
Hereditary	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
C5	I-SpecificDisease
in	O
association	O
with	O
discoid	B-SpecificDisease
lupus	I-SpecificDisease
erythematosus.	I-SpecificDisease
A	O
29-year-old	O
woman	O
with	O
discoid	B-SpecificDisease
lupus	I-SpecificDisease
erythematosus	I-SpecificDisease
had	O
undetectable	O
classic	O
pathway	O
complement	O
activity	O
.	O
Hypocomplementemia	B-DiseaseClass
was	O
due	O
to	O
selective	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
C5	I-SpecificDisease
.	O
One	O
of	O
her	O
children	O
was	O
also	O
deficient	O
.	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
documented	O
case	O
of	O
an	O
association	O
between	O
discoid	B-SpecificDisease
lupus	I-SpecificDisease
erythematosus	I-SpecificDisease
and	O
C5	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
.	O

1282899	O
A	O
germ	O
line	O
mutation	O
within	O
the	O
coding	O
sequence	O
for	O
the	O
putative	O
5-phosphoribosyl-1-pyrophosphate	O
binding	O
site	O
of	O
hypoxanthine-guanine	O
phosphoribosyltransferase	O
(HPRT)	O
in	O
a	O
Lesch-Nyhan	B-Modifier
patient:	O
missense	O
mutations	O
within	O
a	O
functionally	O
important	O
region	O
probably	O
cause	O
disease.	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
caused	O
by	O
a	O
complete	B-SpecificDisease
deficiency	I-SpecificDisease
of	I-SpecificDisease
hypoxanthine	I-SpecificDisease
guanine	I-SpecificDisease
phosphoribosyltransferase	I-SpecificDisease
(	O
HPRT	O
)	O
is	O
the	O
result	O
of	O
a	O
heterogeneous	O
group	O
of	O
germ	O
line	O
mutations	O
.	O
Identification	O
of	O
each	O
mutant	O
gene	O
provides	O
valuable	O
information	O
as	O
to	O
the	O
type	O
of	O
mutation	O
that	O
occurs	O
spontaneously	O
.	O
We	O
report	O
here	O
a	O
newly	O
identified	O
HPRT	O
mutation	O
in	O
a	O
Japanese	O
patient	O
with	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
This	O
gene	O
,	O
designated	O
HPRT	O
Tokyo	O
,	O
had	O
a	O
single	O
nucleotide	O
change	O
from	O
G	O
to	O
A	O
,	O
as	O
identified	O
by	O
sequencing	O
cDNA	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Allele	O
specific	O
oligonucleotide	O
hybridization	O
analysis	O
using	O
amplified	O
genomic	O
DNA	O
showed	O
that	O
the	O
mutant	O
gene	O
was	O
transmitted	O
from	O
the	O
maternal	O
germ	O
line	O
.	O
This	O
mutation	O
would	O
lead	O
to	O
an	O
amino	O
acid	O
substitution	O
of	O
Asp	O
for	O
Gly	O
at	O
the	O
amino	O
acid	O
position	O
140	O
located	O
within	O
the	O
putative	O
5-phosphoribosyl-1-pyrophosphate	O
(	O
PRPP	O
)	O
binding	O
region	O
.	O
Missense	O
mutations	O
in	O
human	O
HPRT	B-Modifier
deficient	I-Modifier
patients	O
thus	O
far	O
reported	O
tend	O
to	O
accumulate	O
in	O
this	O
functionally	O
active	O
region	O
.	O
However	O
,	O
a	O
comparison	O
of	O
the	O
data	O
suggested	O
that	O
both	O
missense	O
and	O
synonymous	O
mutations	O
can	O
occur	O
at	O
any	O
coding	O
sequence	O
of	O
the	O
human	O
germ	O
line	O
HPRT	O
gene	O
,	O
but	O
that	O
a	O
limited	O
percentage	O
of	O
all	O
the	O
missense	O
mutations	O
cause	O
disease	O
.	O
The	O
probability	O
that	O
a	O
mutation	O
will	O
cause	O
disease	O
tends	O
to	O
be	O
higher	O
when	O
the	O
missense	O
mutation	O
is	O
within	O
a	O
functionally	O
important	O
sequence	O
.	O
.	O

10827109	O
The	O
exon	O
13	O
duplication	O
in	O
the	O
BRCA1	O
gene	O
is	O
a	O
founder	O
mutation	O
present	O
in	O
geographically	O
diverse	O
populations.	O
The	O
BRCA1	O
Exon	O
13	O
Duplication	O
Screening	O
Group.	O
Recently	O
,	O
a	O
6-kb	O
duplication	O
of	O
exon	O
13	O
,	O
which	O
creates	O
a	O
frameshift	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
BRCA1	O
gene	O
,	O
has	O
been	O
described	O
in	O
three	O
unrelated	O
U	O
.	O
S	O
S	O
.	O
families	O
of	O
European	O
ancestry	O
and	O
in	O
one	O
Portuguese	O
family	O
.	O
Here	O
,	O
our	O
goal	O
was	O
to	O
estimate	O
the	O
frequency	O
and	O
geographic	O
diversity	O
of	O
carriers	O
of	O
this	O
duplication	O
.	O
To	O
do	O
this	O
,	O
a	O
collaborative	O
screening	O
study	O
was	O
set	O
up	O
that	O
involved	O
39	O
institutions	O
from	O
19	O
countries	O
and	O
included	O
3	O
,	O
580	O
unrelated	O
individuals	O
with	O
a	O
family	O
history	O
of	O
the	O
disease	O
and	O
934	O
early-onset	O
breast	B-Modifier
and	I-Modifier
/	I-Modifier
or	I-Modifier
ovarian	I-Modifier
cancer	I-Modifier
cases	O
.	O
A	O
total	O
of	O
11	O
additional	O
families	O
carrying	O
this	O
mutation	O
were	O
identified	O
in	O
Australia	O
(	O
1	O
)	O
,	O
Belgium	O
(	O
1	O
)	O
,	O
Canada	O
(	O
1	O
)	O
,	O
Great	O
Britain	O
(	O
6	O
)	O
,	O
and	O
the	O
United	O
States	O
(	O
2	O
)	O
.	O
Haplotyping	O
showed	O
that	O
they	O
are	O
likely	O
to	O
derive	O
from	O
a	O
common	O
ancestor	O
,	O
possibly	O
of	O
northern	O
British	O
origin	O
.	O
Our	O
results	O
demonstrate	O
that	O
it	O
is	O
strongly	O
advisable	O
,	O
for	O
laboratories	O
carrying	O
out	O
screening	O
either	O
in	O
English-speaking	O
countries	O
or	O
in	O
countries	O
with	O
historical	O
links	O
with	O
Britain	O
,	O
to	O
include	O
within	O
their	O
BRCA1	O
screening	O
protocols	O
the	O
polymerase	O
chain	O
reaction-based	O
assay	O
described	O
in	O
this	O
report	O
.	O

7795596	O
Aniridia-associated	B-Modifier
cytogenetic	O
rearrangements	O
suggest	O
that	O
a	O
position	O
effect	O
may	O
cause	O
the	O
mutant	O
phenotype.	O
Current	O
evidence	O
suggests	O
that	O
aniridia	B-SpecificDisease
(	O
absence	B-SpecificDisease
of	I-SpecificDisease
iris	I-SpecificDisease
)	O
is	O
caused	O
by	O
loss	O
of	O
function	O
of	O
one	O
copy	O
of	O
the	O
PAX6	O
gene	O
,	O
which	O
maps	O
to	O
11p13	O
.	O
We	O
present	O
the	O
further	O
characterisation	O
of	O
two	O
aniridia	B-Modifier
pedigrees	O
in	O
which	O
the	O
disease	O
segregates	O
with	O
chromosomal	O
rearrangements	O
which	O
involve	O
11p13	O
but	O
do	O
not	O
disrupt	O
the	O
PAX6	O
gene	O
.	O
We	O
have	O
isolated	O
three	O
human	O
YAC	O
clones	O
which	O
encompass	O
the	O
PAX6	O
locus	O
and	O
we	O
have	O
used	O
these	O
to	O
show	O
that	O
in	O
both	O
cases	O
the	O
chromosomal	O
breakpoint	O
is	O
at	O
least	O
85	O
kb	O
distal	O
of	O
the	O
3	O
end	O
of	O
PAX6	O
.	O
In	O
addition	O
,	O
the	O
open	O
reading	O
frame	O
of	O
PAX6	O
is	O
apparently	O
free	O
of	O
mutations	O
.	O
We	O
propose	O
that	O
the	O
PAX6	O
gene	O
on	O
the	O
rearranged	O
chromosome	O
11	O
is	O
in	O
an	O
inappropriate	O
chromatin	O
environment	O
for	O
normal	O
expression	O
and	O
therefore	O
that	O
a	O
position	O
effect	O
is	O
the	O
underlying	O
mechanism	O
of	O
disease	O
in	O
these	O
families	O
.	O
.	O

2569949	O
Haplotype	O
analysis	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
in	O
Turkish	O
phenylketonuria	B-Modifier
families.	O
We	O
have	O
estimated	O
the	O
haplotype	O
distribution	O
of	O
mutant	O
and	O
normal	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
alleles	O
for	O
17	O
Turkish	O
phenylketonuria	B-Modifier
(	O
PKU	B-Modifier
)	O
families	O
20	O
normal	O
and	O
27	O
mutated	O
PAH	O
alleles	O
could	O
be	O
identified	O
.	O
Of	O
the	O
latter	O
,	O
the	O
most	O
prevalent	O
were	O
associated	O
with	O
haplotype	O
6	O
(	O
29	O
.	O
6	O
%	O
)	O
,	O
1	O
(	O
18	O
.	O
5	O
%	O
)	O
and	O
36	O
(	O
11	O
.	O
1	O
%	O
)	O
,	O
while	O
the	O
normal	O
alleles	O
were	O
preferentially	O
associated	O
with	O
haplotype	O
1	O
(	O
20	O
%	O
)	O
.	O
Of	O
the	O
19	O
different	O
haplotypes	O
observed	O
,	O
5	O
have	O
not	O
been	O
described	O
previously	O
.	O
The	O
haplotype	O
distribution	O
differed	O
significantly	O
from	O
that	O
of	O
the	O
Northern	O
European	O
population	O
.	O
Two	O
of	O
the	O
eight	O
polymorphic	O
sites	O
were	O
in	O
association	O
with	O
PKU	B-SpecificDisease
.	O
No	O
deletions	O
of	O
exon	O
sequences	O
were	O
found	O
in	O
the	O
families	O
analysed	O
.	O

3417303	O
Tight	O
linkage	O
between	O
myotonic	B-Modifier
dystrophy	I-Modifier
and	O
apolipoprotein	O
E	O
genes	O
revealed	O
with	O
allele-specific	O
oligonucleotides.	O
In	O
16	O
families	O
with	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
a	O
novel	O
approach	O
based	O
on	O
use	O
of	O
allele-specific	O
oligonucleotides	O
has	O
been	O
employed	O
to	O
study	O
the	O
linkage	O
relationship	O
between	O
the	O
apolipoprotein	O
E	O
(	O
APOE	O
)	O
gene	O
and	O
DM	B-SpecificDisease
.	O
Synthetic	O
oligonucleotides	O
,	O
designed	O
to	O
discriminate	O
between	O
APOE	O
alleles	O
epsilon	O
3	O
and	O
epsilon	O
4	O
,	O
enabled	O
us	O
to	O
distinguish	O
heterozygous	O
carriers	O
in	O
a	O
hybridization	O
assay	O
.	O
In	O
a	O
subset	O
of	O
families	O
,	O
the	O
relevant	O
segment	O
of	O
the	O
APOE	O
gene	O
was	O
enzymatically	O
amplified	O
to	O
increase	O
the	O
sensitivity	O
of	O
the	O
method	O
.	O
For	O
DM	O
and	O
APOE	O
,	O
a	O
maximum	O
lod	O
score	O
(	O
zmax	O
of	O
7	O
.	O
47	O
was	O
obtained	O
at	O
a	O
recombination	O
frequency	O
(	O
theta	O
)	O
of	O
0	O
.	O
047	O
(	O
male	O
theta	O
=	O
female	O
theta	O
)	O
.	O
No	O
recombination	O
(	O
maximum	O
lod	O
score	O
of	O
5	O
.	O
61	O
at	O
theta	O
=	O
0	O
.	O
0	O
)	O
was	O
found	O
between	O
APOE	O
and	O
the	O
apolipoprotein	O
CII	O
(	O
APOC2	O
)	O
gene	O
.	O
These	O
results	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
APOC2	O
,	O
APOE	O
is	O
a	O
useful	O
marker	O
for	O
presymptomatic	O
DM	B-Modifier
diagnosis	O
.	O

2910902	O
Identification	O
of	O
a	O
single	O
nucleotide	O
change	O
in	O
the	O
hypoxanthine-guanine	O
phosphoribosyltransferase	O
gene	O
(HPRTYale)	O
responsible	O
for	O
Lesch-Nyhan	B-SpecificDisease
syndrome.	I-SpecificDisease
Complete	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
hypoxanthine-guanine	I-SpecificDisease
phosphoribosyltransferase	I-SpecificDisease
(	O
HPRT	O
)	O
causes	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
Previous	O
characterization	O
of	O
a	O
mutant	O
form	O
of	O
HPRT	O
,	O
HPRTYale	O
,	O
from	O
a	O
subject	O
with	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
revealed	O
normal	O
mRNA	O
and	O
protein	O
concentrations	O
,	O
no	O
residual	O
catalytic	O
activity	O
,	O
and	O
cathodal	O
migration	O
upon	O
PAGE	O
.	O
We	O
have	O
cloned	O
and	O
sequenced	O
HPRTYale	O
cDNA	O
.	O
The	O
nucleotide	O
sequence	O
of	O
full-length	O
HPRTYale	O
cDNA	O
revealed	O
a	O
single	O
nucleotide	O
substitution	O
compared	O
with	O
normal	O
HPRT	O
cDNA	O
G----C	O
at	O
nucleotide	O
position	O
211	O
.	O
This	O
transversion	O
predicts	O
substitution	O
of	O
arginine	O
for	O
glycine	O
at	O
amino	O
acid	O
position	O
71	O
,	O
explaining	O
the	O
cathodal	O
migration	O
of	O
HPRTYale	O
.	O
Chou-Fasman	O
secondary	O
structure	O
analysis	O
predicts	O
a	O
change	O
in	O
the	O
probability	O
of	O
beta-turn	O
formation	O
in	O
the	O
region	O
containing	O
the	O
mutation	O
.	O
Inclusion	O
of	O
the	O
bulky	O
arginine	O
side	O
chain	O
in	O
place	O
of	O
glycine	O
probably	O
disrupts	O
protein	O
folding	O
as	O
well	O
.	O
Cloning	O
mutant	O
forms	O
of	O
cDNA	O
allows	O
identification	O
of	O
specific	O
mutations	O
,	O
provides	O
insight	O
into	O
mutational	O
mechanisms	O
,	O
and	O
facilitates	O
structure-function	O
analysis	O
of	O
mutant	O
proteins	O
.	O
.	O

10198641	O
Centrosome	O
amplification	O
and	O
a	O
defective	O
G2-M	O
cell	O
cycle	O
checkpoint	O
induce	O
genetic	O
instability	O
in	O
BRCA1	O
exon	O
11	O
isoform-deficient	O
cells.	O
Germline	O
mutations	O
of	O
the	O
Brca1	O
tumor	B-Modifier
suppressor	O
gene	O
predispose	O
women	O
to	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancers	I-CompositeMention
.	O
To	O
study	O
mechanisms	O
underlying	O
BRCA1-related	O
tumorigenesis	O
,	O
we	O
derived	O
mouse	O
embryonic	O
fibroblast	O
cells	O
carrying	O
a	O
targeted	O
deletion	O
of	O
exon	O
11	O
of	O
the	O
Brca1	O
gene	O
.	O
We	O
show	O
that	O
the	O
mutant	O
cells	O
maintain	O
an	O
intact	O
G1-S	O
cell	O
cycle	O
checkpoint	O
and	O
proliferate	O
poorly	O
.	O
However	O
,	O
a	O
defective	O
G2-M	O
checkpoint	O
in	O
these	O
cells	O
is	O
accompanied	O
by	O
extensive	O
chromosomal	B-DiseaseClass
abnormalities	I-DiseaseClass
.	O
Mutant	O
fibroblasts	O
contain	O
multiple	O
,	O
functional	O
centrosomes	O
,	O
which	O
lead	O
to	O
unequal	O
chromosome	O
segregation	O
,	O
abnormal	O
nuclear	O
division	O
,	O
and	O
aneuploidy	B-SpecificDisease
.	O
These	O
data	O
uncover	O
an	O
essential	O
role	O
of	O
BRCA1	O
in	O
maintaining	O
genetic	O
stability	O
through	O
the	O
regulation	O
of	O
centrosome	O
duplication	O
and	O
the	O
G2-M	O
checkpoint	O
and	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
role	O
of	O
BRCA1	O
in	O
tumorigenesis	O
.	O
.	O

10861282	O
Polymorphisms	O
of	O
the	O
CYP2D6	O
gene	O
increase	O
susceptibility	O
to	O
ankylosing	B-SpecificDisease
spondylitis.	I-SpecificDisease
Ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
(	O
AS	B-SpecificDisease
)	O
is	O
a	O
common	O
and	O
highly	O
familial	O
rheumatic	B-DiseaseClass
disorder	I-DiseaseClass
.	O
The	O
sibling	O
recurrence	O
risk	O
ratio	O
for	O
the	O
disease	O
is	O
63	O
and	O
heritability	O
assessed	O
in	O
twins	O
>	O
90	O
%	O
.	O
Although	O
MHC	O
genes	O
,	O
including	O
HLA-B27	O
,	O
contribute	O
only	O
20-50	O
%	O
of	O
the	O
genetic	O
risk	O
for	O
the	O
disease	O
,	O
no	O
non-MHC	O
gene	O
has	O
yet	O
been	O
convincingly	O
demonstrated	O
to	O
influence	O
either	O
susceptibility	O
to	O
the	O
disease	O
or	O
its	O
phenotypic	O
expression	O
.	O
Previous	O
linkage	O
and	O
association	O
studies	O
have	O
suggested	O
the	O
presence	O
of	O
a	O
susceptibility	O
gene	O
for	O
AS	B-SpecificDisease
close	O
to	O
,	O
or	O
within	O
,	O
the	O
cytochrome	O
P450	O
2D6	O
gene	O
(	O
CYP2D6	O
,	O
debrisoquine	O
hydroxylase	O
)	O
located	O
at	O
chromosome	O
22q13	O
.	O
1	O
1	O
.	O
We	O
performed	O
a	O
linkage	O
study	O
of	O
chromosome	O
22	O
in	O
200	O
families	O
with	O
AS	B-Modifier
affected	O
sibling-pairs	O
.	O
Association	O
of	O
alleles	O
of	O
the	O
CYP2D6	O
gene	O
was	O
examined	O
by	O
both	O
case-control	O
and	O
within-family	O
means	O
.	O
For	O
case-control	O
studies	O
,	O
617	O
unrelated	O
individuals	O
with	O
AS	B-SpecificDisease
(	O
361	O
probands	O
from	O
sibling-pair	O
and	O
parent-case	O
trio	O
families	O
and	O
256	O
unrelated	O
non-familial	O
sporadic	O
cases	O
)	O
and	O
402	O
healthy	O
ethnically	O
matched	O
controls	O
were	O
employed	O
.	O
For	O
within-family	O
association	O
studies	O
,	O
361	O
families	O
including	O
161	O
parent-case	O
trios	O
and	O
200	O
affected	O
sibling-pair	O
families	O
were	O
employed	O
.	O
Homozygosity	O
for	O
poor	O
metabolizer	O
alleles	O
was	O
found	O
to	O
be	O
associated	O
with	O
AS	B-SpecificDisease
.	O
Heterozygosity	O
for	O
the	O
most	O
frequent	O
poor	O
metabolizer	O
allele	O
(	O
CYP2D6	O
*	O
4	O
)	O
was	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
AS	B-SpecificDisease
.	O
Significant	O
within-family	O
association	O
of	O
CYP2D6	O
*	O
4	O
alleles	O
and	O
AS	B-SpecificDisease
was	O
demonstrated	O
.	O
Weak	O
linkage	O
was	O
also	O
demonstrated	O
between	O
CYP2D6	O
and	O
AS	B-SpecificDisease
.	O
We	O
postulate	O
that	O
altered	O
metabolism	O
of	O
a	O
natural	O
toxin	O
or	O
antigen	O
by	O
the	O
CYP2D6	O
gene	O
may	O
increase	O
susceptibility	O
to	O
AS	B-SpecificDisease
.	O

7939630	O
BRCA1	O
mutations	O
in	O
primary	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
carcinomas.	I-CompositeMention
Loss	O
of	O
heterozygosity	O
data	O
from	O
familial	B-DiseaseClass
tumors	I-DiseaseClass
suggest	O
that	O
BRCA1	O
,	O
a	O
gene	O
that	O
confers	O
susceptibility	O
to	O
ovarian	B-CompositeMention
and	I-CompositeMention
early-onset	I-CompositeMention
breast	B-CompositeMention
cancer	I-CompositeMention
,	O
encodes	O
a	O
tumor	B-Modifier
suppressor	O
.	O
The	O
BRCA1	O
region	O
is	O
also	O
subject	O
to	O
allelic	O
loss	O
in	O
sporadic	B-SpecificDisease
breast	I-SpecificDisease
and	I-SpecificDisease
ovarian	I-SpecificDisease
cancers	I-SpecificDisease
,	O
an	O
indication	O
that	O
BRCA1	O
mutations	O
may	O
occur	O
somatically	O
in	O
these	O
tumors	B-DiseaseClass
.	O
The	O
BRCA1	O
coding	O
region	O
was	O
examined	O
for	O
mutations	O
in	O
primary	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
tumors	I-CompositeMention
that	O
show	O
allele	O
loss	O
at	O
the	O
BRCA1	O
locus	O
.	O
Mutations	O
were	O
detected	O
in	O
3	O
of	O
32	O
breast	O
and	O
1	O
of	O
12	O
ovarian	B-SpecificDisease
carcinomas	I-SpecificDisease
;	O
all	O
four	O
mutations	O
were	O
germline	O
alterations	O
and	O
occurred	O
in	O
early-onset	O
cancers	B-DiseaseClass
.	O
These	O
results	O
suggest	O
that	O
mutation	O
of	O
BRCA1	O
may	O
not	O
be	O
critical	O
in	O
the	O
development	O
of	O
the	O
majority	O
of	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancers	I-CompositeMention
that	O
arise	O
in	O
the	O
absence	O
of	O
a	O
mutant	O
germline	O
allele	O
.	O
.	O

1302008	O
Germline	O
intronic	O
and	O
exonic	O
mutations	O
in	O
the	O
Wilms"	B-Modifier
tumour	I-Modifier
gene	O
(WT1)	O
affecting	O
urogenital	O
development.	O
Denys-Drash	B-SpecificDisease
syndrome	I-SpecificDisease
is	O
a	O
rare	O
human	O
developmental	B-DiseaseClass
disorder	I-DiseaseClass
affecting	O
the	O
urogenital	O
system	O
and	O
leading	O
to	O
renal	B-DiseaseClass
failure	I-DiseaseClass
,	O
intersex	B-DiseaseClass
disorders	I-DiseaseClass
and	O
Wilms	B-SpecificDisease
tumour	I-SpecificDisease
.	O
In	O
this	O
report	O
,	O
four	O
individuals	O
with	O
this	O
syndrome	O
are	O
described	O
carrying	O
germline	O
point	O
mutations	O
in	O
the	O
Wilms	B-Modifier
tumour	I-Modifier
suppressor	O
gene	O
,	O
WT1	O
.	O
Three	O
of	O
these	O
mutations	O
were	O
in	O
the	O
zinc	O
finger	O
domains	O
of	O
WT1	O
.	O
The	O
fourth	O
occurred	O
within	O
intron	O
9	O
,	O
preventing	O
splicing	O
at	O
one	O
of	O
the	O
alternatively	O
chosen	O
splice	O
donor	O
sites	O
of	O
exon	O
9	O
when	O
assayed	O
in	O
vitro	O
.	O
These	O
results	O
provide	O
genetic	O
evidence	O
for	O
distinct	O
functional	O
roles	O
of	O
the	O
WT1	O
isoforms	O
in	O
urogenital	O
development	O
.	O
.	O

7759076	O
Linkage	O
analysis	O
of	O
26	O
Canadian	O
breast	B-Modifier
and	I-Modifier
breast-ovarian	I-Modifier
cancer	I-Modifier
families.	O
We	O
have	O
examined	O
26	O
Canadian	O
families	O
with	O
hereditary	B-CompositeMention
breast	I-CompositeMention
or	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
for	O
linkage	O
to	O
markers	O
flanking	O
the	O
BRCA1	O
gene	O
on	O
chromosome	O
17q12-q21	O
.	O
Of	O
the	O
15	O
families	O
that	O
contain	O
cases	O
of	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
,	O
94	O
%	O
were	O
estimated	O
to	O
be	O
linked	O
to	O
BRCA1	O
.	O
In	O
contrast	O
,	O
there	O
was	O
no	O
overall	O
evidence	O
of	O
linkage	O
in	O
the	O
group	O
of	O
10	O
families	O
with	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
without	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
.	O
A	O
genetic	O
recombinant	O
in	O
a	O
breast-ovarian	B-Modifier
cancer	I-Modifier
family	O
indicates	O
a	O
placement	O
of	O
BRCA1	O
telomeric	O
to	O
D17S776	O
,	O
and	O
helps	O
to	O
define	O
the	O
region	O
of	O
assignment	O
of	O
the	O
cancer	B-Modifier
susceptibility	O
gene	O
.	O
Other	O
cancers	B-DiseaseClass
of	O
interest	O
that	O
appeared	O
in	O
the	O
BRCA1-linked	O
families	O
included	O
primary	B-SpecificDisease
peritoneal	I-SpecificDisease
cancer	I-SpecificDisease
,	O
cancer	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
fallopian	I-SpecificDisease
tube	I-SpecificDisease
,	O
and	O
malignant	B-SpecificDisease
melanoma	I-SpecificDisease
.	O
.	O

10190819	O
Mutational	O
analysis	O
and	O
genotype-phenotype	O
correlation	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
X-linked	B-SpecificDisease
adrenoleukodystrophy.	I-SpecificDisease
BACKGROUND	O
X-linked	B-SpecificDisease
adrenoleukodystrophy	I-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
is	O
an	O
inherited	B-DiseaseClass
disease	I-DiseaseClass
characterized	O
by	O
progressive	O
neurologic	B-SpecificDisease
dysfunction	I-SpecificDisease
,	O
occasionally	O
associated	O
with	O
adrenal	B-DiseaseClass
insufficiency	I-DiseaseClass
.	O
The	O
classic	O
form	O
of	O
ALD	B-SpecificDisease
usually	O
has	O
onset	O
in	O
childhood	O
(	O
childhood	B-SpecificDisease
cerebral	I-SpecificDisease
ALD	I-SpecificDisease
)	O
,	O
with	O
rapid	O
neurologic	B-DiseaseClass
deterioration	I-DiseaseClass
leading	O
to	O
a	O
vegetative	O
state	O
.	O
Adult-onset	O
cerebral	B-SpecificDisease
ALD	I-SpecificDisease
also	O
presents	O
with	O
rapidly	O
progressive	O
neurologic	B-DiseaseClass
dysfunction	I-DiseaseClass
.	O
Milder	O
phenotypes	O
such	O
as	O
adrenomyeloneuropathy	B-SpecificDisease
and	O
Addison	B-SpecificDisease
disease	I-SpecificDisease
only	O
also	O
have	O
been	O
recognized	O
.	O
Despite	O
discovery	O
of	O
the	O
causative	O
gene	O
,	O
a	O
molecular	O
basis	O
for	O
the	O
diverse	O
clinical	O
presentations	O
remains	O
to	O
be	O
elucidated	O
.	O
OBJECTIVES	O
To	O
conduct	O
mutational	O
analyses	O
in	O
29	O
Japanese	O
patients	O
with	O
ALD	B-SpecificDisease
from	O
29	O
unrelated	O
families	O
,	O
to	O
obtain	O
knowledge	O
of	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
,	O
and	O
to	O
study	O
genotype-phenotype	O
correlations	O
in	O
Japanese	O
patients	O
.	O
METHODS	O
The	O
29	O
patients	O
comprised	O
13	O
patients	O
with	O
childhood	B-SpecificDisease
cerebral	I-SpecificDisease
ALD	I-SpecificDisease
,	O
11	O
patients	O
with	O
adult-onset	O
cerebral	B-SpecificDisease
ALD	I-SpecificDisease
,	O
and	O
5	O
patients	O
with	O
adrenomyeloneuropathy	B-SpecificDisease
.	O
We	O
conducted	O
detailed	O
mutational	O
analyses	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
ALD	B-SpecificDisease
by	O
genomic	O
Southern	O
blot	O
analysis	O
and	O
direct	O
nucleotide	O
sequence	O
analysis	O
of	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
products	O
derived	O
from	O
total	O
RNA	O
that	O
was	O
extracted	O
from	O
cultured	O
skin	O
fibroblasts	O
,	O
lymphoblastoid	O
cells	O
,	O
or	O
peripheral	O
blood	O
leukocytes	O
.	O
RESULTS	O
Three	O
patients	O
with	O
adult-onset	O
cerebral	B-SpecificDisease
ALD	I-SpecificDisease
were	O
identified	O
as	O
having	O
large	O
genomic	O
rearrangements	O
.	O
The	O
remaining	O
26	O
patients	O
were	O
identified	O
as	O
having	O
21	O
independent	O
mutations	O
,	O
including	O
12	O
novel	O
mutations	O
resulting	O
in	O
small	O
nucleotide	O
alterations	O
in	O
the	O
ALD	B-Modifier
gene	O
.	O
Eighteen	O
(	O
69	O
%	O
)	O
of	O
26	O
mutations	O
were	O
missense	O
mutations	O
.	O
Most	O
missense	O
mutations	O
involved	O
amino	O
acids	O
conserved	O
in	O
homologous	O
gene	O
products	O
,	O
including	O
PMP70	O
,	O
mALDRP	O
,	O
and	O
Pxa1p	O
.	O
The	O
AG	O
dinucleotide	O
deletion	O
at	O
position	O
1081-1082	O
,	O
which	O
has	O
been	O
reported	O
previously	O
to	O
be	O
the	O
most	O
common	O
mutation	O
in	O
white	O
patients	O
(	O
12	O
%	O
-17	O
%	O
)	O
,	O
was	O
also	O
identified	O
as	O
the	O
most	O
common	O
mutation	O
in	O
Japanese	O
patients	O
(	O
12	O
%	O
)	O
.	O
All	O
phenotypes	O
were	O
associated	O
with	O
mutations	O
resulting	O
in	O
protein	O
truncation	O
or	O
subtle	O
amino	O
acid	O
changes	O
.	O
There	O
were	O
no	O
differences	O
in	O
phenotypic	O
expressions	O
between	O
missense	O
mutations	O
involving	O
conserved	O
amino	O
acids	O
and	O
those	O
involving	O
nonconserved	O
amino	O
acids	O
.	O
CONCLUSIONS	O
There	O
are	O
no	O
obvious	O
correlations	O
between	O
the	O
phenotypes	O
of	O
patients	O
with	O
ALD	B-SpecificDisease
and	O
their	O
genotypes	O
,	O
suggesting	O
that	O
other	O
genetic	O
or	O
environmental	O
factors	O
modify	O
the	O
phenotypic	O
expressions	O
of	O
ALD	B-SpecificDisease
.	O
.	O

8471773	O
Molecular	O
characterization	O
of	O
glucose-6-phosphate	B-SpecificDisease
dehydrogenase	I-SpecificDisease
(G6PD)	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
patients	O
of	O
Chinese	O
descent	O
and	O
identification	O
of	O
new	O
base	O
substitutions	O
in	O
the	O
human	O
G6PD	O
gene.	O
The	O
underlying	O
DNA	O
changes	O
associated	O
with	O
glucose-6-phosphate	B-Modifier
dehydrogenase	I-Modifier
(	I-Modifier
G6PD	I-Modifier
)	I-Modifier
-deficient	I-Modifier
Asians	O
have	O
not	O
been	O
extensively	O
investigated	O
.	O
To	O
fill	O
this	O
gap	O
,	O
we	O
sequenced	O
the	O
G6PD	O
gene	O
of	O
43	O
G6PD-deficient	B-Modifier
Chinese	O
whose	O
G6PD	O
was	O
well	O
characterized	O
biochemically	O
.	O
DNA	O
samples	O
were	O
obtained	O
from	O
peripheral	O
blood	O
of	O
these	O
individuals	O
for	O
sequencing	O
using	O
a	O
direct	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
sequencing	O
procedure	O
.	O
From	O
these	O
43	O
samples	O
,	O
we	O
have	O
identified	O
five	O
different	O
types	O
of	O
nucleotide	O
substitutions	O
in	O
the	O
G6PD	O
gene	O
at	O
cDNA	O
1388	O
from	O
G	O
to	O
A	O
(	O
Arg	O
to	O
His	O
)	O
;	O
at	O
cDNA	O
1376	O
from	O
G	O
to	O
T	O
(	O
Arg	O
to	O
Leu	O
)	O
;	O
at	O
cDNA	O
1024	O
from	O
C	O
to	O
T	O
(	O
Leu	O
to	O
Phe	O
)	O
;	O
at	O
cDNA	O
392	O
from	O
G	O
to	O
T	O
(	O
Gly	O
to	O
Val	O
)	O
;	O
at	O
cDNA	O
95	O
from	O
A	O
to	O
G	O
(	O
His	O
to	O
Arg	O
)	O
.	O
These	O
five	O
nucleotide	O
substitutions	O
account	O
for	O
over	O
83	O
%	O
of	O
our	O
43	O
G6PD-deficient	B-Modifier
samples	O
and	O
these	O
substitutions	O
have	O
not	O
been	O
reported	O
in	O
non-Asians	O
.	O
The	O
substitutions	O
found	O
at	O
cDNA	O
392	O
and	O
cDNA	O
1024	O
are	O
new	O
findings	O
.	O
The	O
substitutions	O
at	O
cDNA	O
1376	O
and	O
1388	O
account	O
for	O
over	O
50	O
%	O
of	O
the	O
43	O
samples	O
examined	O
indicating	O
a	O
high	O
prevalence	O
of	O
these	O
two	O
alleles	O
among	O
G6PD-deficient	B-Modifier
Chinese	O
.	O
Our	O
findings	O
add	O
support	O
to	O
the	O
notion	O
that	O
diverse	O
point	O
mutations	O
may	O
account	O
largely	O
for	O
much	O
of	O
the	O
phenotypic	O
heterogeneity	O
of	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
.	O

3591825	O
Phenotype	O
heterogeneity	O
among	O
hemizygotes	O
in	O
a	O
family	O
biochemically	O
screened	O
for	O
adrenoleukodystrophy.	B-SpecificDisease
We	O
report	O
on	O
two	O
clinically	O
,	O
neurologically	O
normal	O
relatives	O
of	O
a	O
boy	O
affected	O
by	O
adrenoleukodystrophy	B-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
;	O
they	O
were	O
found	O
repeatedly	O
to	O
have	O
the	O
biochemical	O
defect	O
of	O
an	O
ALD	B-Modifier
hemizygote	O
.	O
The	O
assay	O
consisted	O
in	O
the	O
determination	O
of	O
very-long-chain	O
fatty	O
acids	O
in	O
lyophilized	O
and	O
reconstituted	O
plasma	O
.	O
While	O
no	O
evidence	O
of	O
neurologic	B-DiseaseClass
disease	I-DiseaseClass
(	O
leukodystrophy	B-SpecificDisease
or	O
myeloneuropathy	B-SpecificDisease
)	O
was	O
present	O
in	O
these	O
hemizygotes	O
,	O
adrenocortical	B-DiseaseClass
insufficiency	I-DiseaseClass
provoking	O
compensatory	O
high	O
ACTH	O
release	O
was	O
found	O
in	O
both	O
.	O
These	O
findings	O
should	O
be	O
taken	O
into	O
consideration	O
when	O
counseling	O
families	O
in	O
which	O
cases	O
with	O
clinically	O
expressed	O
ALD	B-SpecificDisease
are	O
represented	O
in	O
several	O
generations	O
.	O
.	O

7437512	O
Wiskott-Aldrich	B-SpecificDisease
syndrome:	I-SpecificDisease
cellular	B-DiseaseClass
impairments	I-DiseaseClass
and	O
their	O
implication	O
for	O
carrier	O
detection.	O
A	O
family	O
in	O
which	O
two	O
male	O
siblings	O
were	O
affected	O
with	O
Wiskott-Aldrich	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
WAS	B-SpecificDisease
)	O
was	O
studied	O
using	O
G-6-PD	O
isoenzymes	O
as	O
an	O
X-linked	O
marker	O
in	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
cellular	B-DiseaseClass
abnormalities	I-DiseaseClass
.	O
Isolated	O
peripheral	O
blood	O
cell	O
types	O
from	O
the	O
doubly	O
heterozygous	O
mother	O
of	O
the	O
affected	O
males	O
seemingly	O
failed	O
to	O
express	O
the	O
G-6-PD	O
allele	O
in	O
cis	O
position	O
with	O
the	O
WAS	B-Modifier
allele	O
while	O
her	O
cultured	O
skin	O
fibroblasts	O
expressed	O
both	O
G-6-PD	O
alleles	O
.	O
Additionally	O
,	O
a	O
histogram	O
analysis	O
of	O
platelet	O
size	O
revealed	O
a	O
single	O
population	O
of	O
abnormally	O
small	O
platelets	O
in	O
the	O
affected	O
propositus	O
,	O
whereas	O
the	O
heterozygous	O
mother	O
had	O
no	O
appreciable	O
small	O
platelet	O
subpopulation	O
.	O
In	O
vitro	O
culture	O
of	O
hemopoietic	O
progenitor	O
cells	O
of	O
the	O
heterozygous	O
mother	O
showed	O
that	O
the	O
majority	O
of	O
progenitor	O
cells	O
did	O
not	O
express	O
the	O
WAS	B-Modifier
allele	O
.	O
However	O
,	O
a	O
small	O
number	O
of	O
cells	O
expressing	O
the	O
G-6-PD	O
type	O
linked	O
with	O
the	O
WAS	B-Modifier
allele	O
were	O
detected	O
.	O
The	O
proportion	O
of	O
the	O
latter	O
progenitors	O
was	O
significantly	O
higher	O
among	O
more	O
primitive	O
progenitors	O
(	O
those	O
giving	O
rise	O
to	O
later	O
appearing	O
colonies	O
)	O
.	O
This	O
observation	O
suggests	O
that	O
selection	O
against	O
cells	O
expressing	O
the	O
Wiskott-Aldrich	B-SpecificDisease
defect	I-SpecificDisease
takes	O
place	O
in	O
the	O
hemopoietic	O
system	O
of	O
the	O
heterozygous	O
female	O
and	O
offers	O
a	O
possible	O
means	O
of	O
carrier	O
detection	O
in	O
some	O
women	O
.	O
Linkage	O
studies	O
in	O
this	O
family	O
revealed	O
one	O
example	O
of	O
probable	O
recombination	O
between	O
the	O
loci	O
for	O
WAS	B-SpecificDisease
and	O
G-6-PD	O
among	O
three	O
informative	O
subjects	O
,	O
suggesting	O
that	O
these	O
two	O
loci	O
may	O
not	O
be	O
closely	O
linked	O
on	O
the	O
X-chromosome	O
.	O
.	O

10802667	O
Mice	O
deficient	B-SpecificDisease
in	I-SpecificDisease
Six5	I-SpecificDisease
develop	O
cataracts:	B-SpecificDisease
implications	O
for	O
myotonic	B-SpecificDisease
dystrophy.	I-SpecificDisease
Expansion	O
of	O
a	O
CTG	O
trinucleotide	O
repeat	O
in	O
the	O
3	O
UTR	O
of	O
the	O
gene	O
DMPK	O
at	O
the	O
DM1	O
locus	O
on	O
chromosome	O
19	O
causes	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
,	O
a	O
dominantly	B-DiseaseClass
inherited	I-DiseaseClass
disease	I-DiseaseClass
characterized	O
by	O
skeletal	O
muscle	B-SpecificDisease
dystrophy	I-SpecificDisease
and	O
myotonia	B-DiseaseClass
,	O
cataracts	B-SpecificDisease
and	O
cardiac	B-DiseaseClass
conduction	I-DiseaseClass
defects	I-DiseaseClass
.	O
Targeted	O
deletion	O
of	O
Dm15	O
,	O
the	O
mouse	O
orthologue	O
of	O
human	O
DMPK	O
,	O
produced	O
mice	O
with	O
a	O
mild	O
myopathy	B-DiseaseClass
and	O
cardiac	B-DiseaseClass
conduction	I-DiseaseClass
abnormalities	I-DiseaseClass
,	O
but	O
without	O
other	O
features	O
of	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
,	O
such	O
as	O
myotonia	B-DiseaseClass
and	O
cataracts	B-SpecificDisease
.	O
We	O
,	O
and	O
others	O
,	O
have	O
demonstrated	O
that	O
repeat	O
expansion	O
decreases	O
expression	O
of	O
the	O
adjacent	O
gene	O
SIX5	O
(	O
refs	O
7	O
,	O
8	O
)	O
,	O
which	O
encodes	O
a	O
homeodomain	O
transcription	O
factor	O
.	O
To	O
determine	O
whether	O
SIX5	B-SpecificDisease
deficiency	I-SpecificDisease
contributes	O
to	O
the	O
myotonic	B-Modifier
dystrophy	I-Modifier
phenotype	O
,	O
we	O
disrupted	O
mouse	O
Six5	O
by	O
replacing	O
the	O
first	O
exon	O
with	O
a	O
beta-galactosidase	O
reporter	O
.	O
Six5-mutant	O
mice	O
showed	O
reporter	O
expression	O
in	O
multiple	O
tissues	O
,	O
including	O
the	O
developing	O
lens	O
.	O
Homozygous	O
mutant	O
mice	O
had	O
no	O
apparent	O
abnormalities	B-DiseaseClass
of	I-DiseaseClass
skeletal	I-DiseaseClass
muscle	I-DiseaseClass
function	I-DiseaseClass
,	O
but	O
developed	O
lenticular	B-SpecificDisease
opacities	I-SpecificDisease
at	O
a	O
higher	O
rate	O
than	O
controls	O
.	O
Our	O
results	O
suggest	O
that	O
SIX5	B-SpecificDisease
deficiency	I-SpecificDisease
contributes	O
to	O
the	O
cataract	B-Modifier
phenotype	O
in	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
,	O
and	O
that	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
represents	O
a	O
multigenic	B-DiseaseClass
disorder	I-DiseaseClass
.	O
.	O

10208645	O
Pharmacokinetics	O
of	O
chlorpheniramine,	O
phenytoin,	O
glipizide	O
and	O
nifedipine	O
in	O
an	O
individual	O
homozygous	O
for	O
the	O
CYP2C9*3	O
allele.	O
Genetic	O
polymorphisms	O
in	O
the	O
cytochrome	O
P450	O
(	O
CYP	O
)	O
family	O
are	O
widely	O
known	O
to	O
contribute	O
to	O
interindividual	O
differences	O
in	O
the	O
pharmacokinetics	O
of	O
many	O
drugs	O
.	O
Several	O
alleles	O
for	O
the	O
CYP2C9	O
gene	O
have	O
been	O
reported	O
.	O
Individuals	O
homozygous	O
for	O
the	O
Leu359	O
variant	O
(	O
CYP2C9	O
*	O
3	O
)	O
have	O
been	O
shown	O
to	O
have	O
significantly	O
lower	O
drug	O
clearances	O
compared	O
with	O
Ile359	O
(	O
CYP2C9	O
*	O
1	O
)	O
homozygous	O
individuals	O
.	O
A	O
male	O
Caucasian	O
who	O
participated	O
in	O
six	O
bioavailability	O
studies	O
in	O
our	O
laboratory	O
over	O
a	O
period	O
of	O
several	O
years	O
showed	O
extremely	O
low	O
clearance	O
of	O
two	O
drugs	O
phenytoin	O
and	O
glipizide	O
(	O
both	O
substrates	O
of	O
CYP2C9	O
)	O
,	O
but	O
not	O
for	O
nifedipine	O
(	O
a	O
CYP3A4	O
substrate	O
)	O
and	O
chlorpheniramine	O
(	O
a	O
CYP2D6	O
substrate	O
)	O
.	O
His	O
oral	O
clearance	O
of	O
phenytoin	O
was	O
21	O
%	O
of	O
the	O
mean	O
of	O
the	O
other	O
11	O
individuals	O
participating	O
in	O
the	O
study	O
,	O
and	O
his	O
oral	O
clearance	O
of	O
glipizide	O
,	O
a	O
second	O
generation	O
sulfonylurea	O
structurally	O
similar	O
to	O
tolbutamide	O
,	O
was	O
only	O
188	O
%	O
of	O
the	O
mean	O
of	O
the	O
other	O
10	O
individuals	O
.	O
However	O
,	O
his	O
oral	O
clearance	O
of	O
nifedipine	O
and	O
chlorpheniramine	O
did	O
not	O
differ	O
from	O
individuals	O
in	O
other	O
studies	O
performed	O
at	O
our	O
laboratories	O
.	O
An	O
additional	O
blood	O
sample	O
was	O
obtained	O
from	O
this	O
individual	O
to	O
determine	O
if	O
he	O
possessed	O
any	O
of	O
the	O
known	O
CYP2C9	O
or	O
CYP2C19	O
allelic	O
variants	O
that	O
would	O
account	O
for	O
his	O
poor	O
clearance	O
of	O
the	O
CYP2C9	O
substrates	O
(	O
phenytoin	O
and	O
glipizide	O
)	O
compared	O
with	O
the	O
CYP3A4	O
(	O
nifedipine	O
)	O
and	O
CYP2D6	O
(	O
chlorpheniramine	O
)	O
substrates	O
.	O
The	O
results	O
of	O
the	O
genotype	O
testing	O
showed	O
that	O
this	O
individual	O
was	O
homozygous	O
for	O
the	O
CYP2C9	O
*	O
3	O
allele	O
and	O
did	O
not	O
possess	O
any	O
of	O
the	O
known	O
defective	O
CYP2C19	O
alleles	O
.	O
This	O
study	O
establishes	O
that	O
the	O
Leu359	O
mutation	O
is	O
responsible	O
for	O
the	O
phenytoin	O
and	O
glipizide	O
/	O
tolbutamide	O
poor	O
metabolizer	O
phenotype	O
.	O
.	O

7422429	O
Nephropathy	B-SpecificDisease
in	O
the	O
Wiskott-Aldrich	B-SpecificDisease
syndrome.	I-SpecificDisease
Nephropathy	B-SpecificDisease
was	O
detected	O
in	O
five	O
of	O
32	O
patients	O
with	O
the	O
Wiskott-Aldrich	B-SpecificDisease
syndrome	I-SpecificDisease
who	O
were	O
participating	O
in	O
a	O
study	O
of	O
transfer	O
factor	O
(	O
TF	O
)	O
therapy	O
.	O
In	O
two	O
patients	O
,	O
nephropathy	B-SpecificDisease
was	O
present	O
before	O
TF	O
and	O
did	O
not	O
appear	O
changed	O
by	O
TF	O
therapy	O
.	O
One	O
of	O
these	O
patients	O
subsequently	O
developed	O
progressive	O
renal	B-SpecificDisease
failure	I-SpecificDisease
requiring	O
dialysis	O
beginning	O
5	O
1	O
/	O
2	O
years	O
after	O
TF	O
therapy	O
.	O
In	O
two	O
patients	O
,	O
decreased	O
renal	O
function	O
appeared	O
very	O
soon	O
after	O
the	O
administration	O
of	O
TF	O
.	O
One	O
patient	O
showed	O
gradually	O
decreasing	O
renal	O
function	O
beginning	O
after	O
two	O
years	O
of	O
TF	O
therapy	O
.	O
An	O
additional	O
patient	O
was	O
identified	O
who	O
died	O
with	O
renal	B-SpecificDisease
failure	I-SpecificDisease
without	O
having	O
received	O
TF	O
.	O
The	O
results	O
suggest	O
that	O
renal	B-SpecificDisease
failure	I-SpecificDisease
occurs	O
in	O
the	O
Wiskott-Aldrich	B-SpecificDisease
syndrome	I-SpecificDisease
more	O
frequently	O
than	O
generally	O
recognized	O
and	O
that	O
administration	O
of	O
TF	O
may	O
precipitate	O
or	O
accelerate	O
the	O
renal	B-SpecificDisease
disease	I-SpecificDisease
in	O
patients	O
with	O
this	O
syndrome	O
.	O
.	O

10766245	O
ATM	O
phosphorylates	O
p95/nbs1	O
in	O
an	O
S-phase	O
checkpoint	O
pathway.	O
The	O
rare	B-DiseaseClass
diseases	I-DiseaseClass
ataxia-telangiectasia	B-SpecificDisease
(	O
AT	B-SpecificDisease
)	O
,	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
,	O
and	O
Nijmegen	B-SpecificDisease
breakage	I-SpecificDisease
syndrome	I-SpecificDisease
(	O
NBS	B-SpecificDisease
)	O
,	O
with	O
mutations	O
in	O
the	O
p95	O
/	O
nbs1	O
gene	O
,	O
share	O
a	O
variety	O
of	O
phenotypic	B-DiseaseClass
abnormalities	I-DiseaseClass
such	O
as	O
chromosomal	B-DiseaseClass
instability	I-DiseaseClass
,	O
radiation	O
sensitivity	O
and	O
defects	O
in	O
cell-cycle	O
checkpoints	O
in	O
response	O
to	O
ionizing	O
radiation	O
.	O
The	O
ATM	O
gene	O
encodes	O
a	O
protein	O
kinase	O
that	O
is	O
activated	O
by	O
ionizing	O
radiation	O
or	O
radiomimetic	O
drugs	O
,	O
whereas	O
p95	O
/	O
nbs1	O
is	O
part	O
of	O
a	O
protein	O
complex	O
that	O
is	O
involved	O
in	O
responses	O
to	O
DNA	O
double-strand	O
breaks	O
.	O
Here	O
,	O
because	O
of	O
the	O
similarities	O
between	O
AT	B-SpecificDisease
and	O
NBS	B-SpecificDisease
,	O
we	O
evaluated	O
the	O
functional	O
interactions	O
between	O
ATM	O
and	O
p95	O
/	O
nbs1	O
.	O
Activation	O
of	O
the	O
ATM	O
kinase	O
by	O
ionizing	O
radiation	O
and	O
induction	O
of	O
ATM-dependent	O
responses	O
in	O
NBS	B-Modifier
cells	O
indicated	O
that	O
p95	O
/	O
nbs1	O
may	O
not	O
be	O
required	O
for	O
signalling	O
to	O
ATM	O
after	O
ionizing	O
radiation	O
.	O
However	O
,	O
p95	O
/	O
nbs1	O
was	O
phosphorylated	O
on	O
serine	O
343	O
in	O
an	O
ATM-dependent	O
manner	O
in	O
vitro	O
and	O
in	O
vivo	O
after	O
ionizing	O
radiation	O
.	O
A	O
p95	O
/	O
nbs1	O
construct	O
mutated	O
at	O
the	O
ATM	O
phosphorylation	O
site	O
abrogated	O
an	O
S-phase	O
checkpoint	O
induced	O
by	O
ionizing	O
radiation	O
in	O
normal	O
cells	O
and	O
failed	O
to	O
compensate	O
for	O
this	O
functional	O
deficiency	O
in	O
NBS	B-Modifier
cells	O
.	O
These	O
observations	O
link	O
ATM	O
and	O
p95	O
/	O
nbs1	O
in	O
a	O
common	O
signalling	O
pathway	O
and	O
provide	O
an	O
explanation	O
for	O
phenotypic	O
similarities	O
in	O
these	O
two	O
diseases	O
.	O
.	O

1301161	O
The	O
Norrie	B-Modifier
disease	I-Modifier
gene	O
maps	O
to	O
a	O
150	O
kb	O
region	O
on	O
chromosome	O
Xp11.3.	O
Norrie	B-SpecificDisease
disease	I-SpecificDisease
is	O
a	O
human	O
X-linked	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
of	O
unknown	O
etiology	O
characterized	O
by	O
congenital	B-SpecificDisease
blindness	I-SpecificDisease
,	O
sensory	B-SpecificDisease
neural	I-SpecificDisease
deafness	I-SpecificDisease
and	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
.	O
This	O
disease	O
gene	O
was	O
previously	O
linked	O
to	O
the	O
DXS7	O
(	O
L1	O
.	O
28	O
)	O
locus	O
and	O
the	O
MAO	O
genes	O
in	O
band	O
Xp11	O
.	O
3	O
3	O
.	O
We	O
report	O
here	O
fine	O
physical	O
mapping	O
of	O
the	O
obligate	O
region	O
containing	O
the	O
Norrie	B-Modifier
disease	I-Modifier
gene	O
(	O
NDP	O
)	O
defined	O
by	O
a	O
recombination	O
and	O
by	O
the	O
smallest	O
submicroscopic	O
chromosomal	O
deletion	O
associated	O
with	O
Norrie	B-SpecificDisease
disease	I-SpecificDisease
identified	O
to	O
date	O
.	O
Analysis	O
,	O
using	O
in	O
addition	O
two	O
overlapping	O
YAC	O
clones	O
from	O
this	O
region	O
,	O
allowed	O
orientation	O
of	O
the	O
MAOA	O
and	O
MAOB	O
genes	O
in	O
a	O
5-3-3-5	O
configuration	O
.	O
A	O
recombination	O
event	O
between	O
a	O
(	O
GT	O
)	O
n	O
polymorphism	O
in	O
intron	O
2	O
of	O
the	O
MAOB	O
gene	O
and	O
the	O
NDP	O
locus	O
,	O
in	O
a	O
family	O
previously	O
reported	O
to	O
have	O
a	O
recombination	O
between	O
DXS7	O
and	O
NDP	O
,	O
delineates	O
a	O
flanking	O
marker	O
telomeric	O
to	O
this	O
disease	O
gene	O
.	O
An	O
anonymous	O
DNA	O
probe	O
,	O
dc12	O
,	O
present	O
in	O
one	O
of	O
the	O
YACs	O
and	O
in	O
a	O
patient	O
with	O
a	O
submicroscopic	O
deletion	O
which	O
includes	O
MAOA	O
and	O
MAOB	O
but	O
not	O
L1	O
.	O
28	O
,	O
serves	O
as	O
a	O
flanking	O
marker	O
centromeric	O
to	O
the	O
disease	O
gene	O
.	O
An	O
Alu-PCR	O
fragment	O
from	O
the	O
right	O
arm	O
of	O
the	O
MAO	O
YAC	O
(	O
YMAO	O
.	O
AluR	O
)	O
is	O
not	O
deleted	O
in	O
this	O
patient	O
and	O
also	O
delineates	O
the	O
centromeric	O
extent	O
of	O
the	O
obligate	O
disease	O
region	O
.	O
The	O
apparent	O
order	O
of	O
these	O
loci	O
is	O
telomere	O
.	O
DXS7-MAOA-MAOB-NDP-dc12-YMAO	O
DXS7-MAOA-MAOB-NDP-dc12-YMAO	O
.	O
AluR	O
.	O
centromere	O
.	O
Together	O
these	O
data	O
define	O
the	O
obligate	O
region	O
containing	O
the	O
NDP	O
gene	O
to	O
a	O
chromosomal	O
segment	O
less	O
than	O
150	O
kb	O
.	O

10639175	O
Atm	O
and	O
Bax	O
cooperate	O
in	O
ionizing	O
radiation-induced	O
apoptosis	O
in	O
the	O
central	O
nervous	O
system.	O
Ataxia-telangiectasia	B-SpecificDisease
is	O
a	O
hereditary	B-DiseaseClass
multisystemic	I-DiseaseClass
disease	I-DiseaseClass
resulting	O
from	O
mutations	O
of	O
ataxia	B-SpecificDisease
telangiectasia	I-SpecificDisease
,	O
mutated	O
(	O
ATM	O
)	O
and	O
is	O
characterized	O
by	O
neurodegeneration	B-DiseaseClass
,	O
cancer	B-DiseaseClass
,	O
immune	B-DiseaseClass
defects	I-DiseaseClass
,	O
and	O
hypersensitivity	B-DiseaseClass
to	I-DiseaseClass
ionizing	I-DiseaseClass
radiation	I-DiseaseClass
.	O
The	O
molecular	O
details	O
of	O
ATM	O
function	O
in	O
the	O
nervous	O
system	O
are	O
unclear	O
,	O
although	O
the	O
neurological	B-DiseaseClass
lesion	I-DiseaseClass
in	O
ataxia-telangiectasia	B-SpecificDisease
becomes	O
apparent	O
early	O
in	O
life	O
,	O
suggesting	O
a	O
developmental	O
origin	O
.	O
The	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
Atm-null	O
mice	O
shows	O
a	O
pronounced	O
defect	O
in	O
apoptosis	O
induced	O
by	O
genotoxic	O
stress	O
,	O
suggesting	O
ATM	O
functions	O
to	O
eliminate	O
neurons	O
with	O
excessive	O
genomic	O
damage	O
.	O
Here	O
,	O
we	O
report	O
that	O
the	O
death	O
effector	O
Bax	O
is	O
required	O
for	O
a	O
large	O
proportion	O
of	O
Atm-dependent	O
apoptosis	O
in	O
the	O
developing	O
CNS	O
after	O
ionizing	O
radiation	O
(	O
IR	O
)	O
.	O
Although	O
many	O
of	O
the	O
same	O
regions	O
of	O
the	O
CNS	O
in	O
both	O
Bax-	O
/	O
-	O
and	O
Atm-	O
/	O
-	O
mice	O
were	O
radioresistant	O
,	O
mice	O
nullizygous	O
for	O
both	O
Bax	O
and	O
Atm	O
showed	O
additional	O
reduction	O
in	O
IR-induced	O
apoptosis	O
in	O
the	O
CNS	O
.	O
Therefore	O
,	O
although	O
the	O
major	O
IR-induced	O
apoptotic	O
pathway	O
in	O
the	O
CNS	O
requires	O
Atm	O
and	O
Bax	O
,	O
a	O
p53-dependent	O
collateral	O
pathway	O
exists	O
that	O
has	O
both	O
Atm-	O
and	O
Bax-independent	O
branches	O
.	O
Further	O
,	O
Atm-	O
and	O
Bax-dependent	O
apoptosis	O
in	O
the	O
CNS	O
also	O
required	O
caspase-3	O
activation	O
.	O
These	O
data	O
implicate	O
Bax	O
and	O
caspase-3	O
as	O
death	O
effectors	O
in	O
neurodegenerative	O
pathways	O
.	O
.	O

7937795	O
Genetic	O
instability	O
in	O
human	O
ovarian	B-Modifier
cancer	I-Modifier
cell	O
lines.	O
We	O
have	O
analyzed	O
the	O
stability	O
of	O
microsatellites	O
in	O
cell	O
lines	O
derived	O
from	O
human	O
ovarian	B-SpecificDisease
cancers	I-SpecificDisease
and	O
found	O
that	O
5	O
out	O
of	O
10	O
of	O
the	O
ovarian	B-Modifier
tumor	I-Modifier
cell	O
lines	O
are	O
genetically	B-DiseaseClass
unstable	I-DiseaseClass
at	O
the	O
majority	O
of	O
the	O
loci	O
analyzed	O
.	O
In	O
clones	O
and	O
subclones	O
derived	O
serially	O
from	O
one	O
of	O
these	O
cell	O
lines	O
(	O
2774	O
;	O
serous	B-SpecificDisease
cystadenocarcinoma	I-SpecificDisease
)	O
,	O
a	O
very	O
high	O
proportion	O
of	O
microsatellites	O
distributed	O
in	O
many	O
different	O
regions	O
of	O
the	O
genome	O
change	O
their	O
size	O
in	O
a	O
mercurial	O
fashion	O
.	O
We	O
conclude	O
that	O
genomic	O
instability	O
in	O
ovarian	B-SpecificDisease
tumors	I-SpecificDisease
is	O
a	O
dynamic	O
and	O
ongoing	O
process	O
whose	O
high	O
frequency	O
may	O
have	O
been	O
previously	O
underestimated	O
by	O
PCR-based	O
allelotyping	O
of	O
bulk	O
tumor	B-Modifier
tissue	O
.	O
We	O
have	O
identified	O
the	O
source	O
of	O
the	O
genetic	O
instability	O
in	O
one	O
ovarian	B-SpecificDisease
tumor	I-SpecificDisease
as	O
a	O
point	O
mutation	O
(	O
R524P	O
)	O
in	O
the	O
human	O
mismatch-repair	O
gene	O
MSH2	O
(	O
Salmonella	O
MutS	O
homologue	O
)	O
,	O
which	O
has	O
recently	O
been	O
shown	O
to	O
be	O
involved	O
in	O
hereditary	B-SpecificDisease
nonpolyposis	I-SpecificDisease
colorectal	I-SpecificDisease
cancer	I-SpecificDisease
.	O
Patient	O
2774	O
was	O
a	O
38-year-old	O
heterozygote	O
,	O
and	O
her	O
normal	O
tissue	O
carried	O
both	O
mutant	O
and	O
wild-type	O
alleles	O
of	O
the	O
human	O
MSH2	O
gene	O
.	O
However	O
the	O
wild-type	O
allele	O
was	O
lost	O
at	O
some	O
point	O
early	O
during	O
tumorigenesis	O
so	O
that	O
DNA	O
isolated	O
either	O
from	O
the	O
patients	O
ovarian	B-SpecificDisease
tumor	I-SpecificDisease
or	O
from	O
the	O
2774	O
cell	O
line	O
carries	O
only	O
the	O
mutant	O
allele	O
of	O
the	O
human	O
MSH2	O
gene	O
.	O
The	O
genetic	O
instability	O
observed	O
in	O
the	O
tumor	B-DiseaseClass
and	O
cell	O
line	O
DNA	O
,	O
together	O
with	O
the	O
germ-line	O
mutation	O
in	O
a	O
mismatch-repair	O
gene	O
,	O
suggest	O
that	O
the	O
MSH2	O
gene	O
is	O
involved	O
in	O
the	O
onset	O
and	O
/	O
or	O
progression	O
in	O
a	O
subset	O
of	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
.	O
.	O

10077651	O
Mechanism	O
of	O
increased	O
iron	O
absorption	O
in	O
murine	O
model	O
of	O
hereditary	B-SpecificDisease
hemochromatosis	I-SpecificDisease
:	O
increased	O
duodenal	O
expression	O
of	O
the	O
iron	O
transporter	O
DMT1	O
.	O
Hereditary	B-SpecificDisease
hemochromatosis	I-SpecificDisease
(	O
HH	B-SpecificDisease
)	O
is	O
a	O
common	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
characterized	O
by	O
tissue	O
iron	O
deposition	O
secondary	O
to	O
excessive	O
dietary	O
iron	O
absorption	O
.	O
We	O
recently	O
reported	O
that	O
HFE	O
,	O
the	O
protein	O
defective	O
in	O
HH	B-SpecificDisease
,	O
was	O
physically	O
associated	O
with	O
the	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
in	O
duodenal	O
crypt	O
cells	O
and	O
proposed	O
that	O
mutations	O
in	O
HFE	O
attenuate	O
the	O
uptake	O
of	O
transferrin-bound	O
iron	O
from	O
plasma	O
by	O
duodenal	O
crypt	O
cells	O
,	O
leading	O
to	O
up-regulation	O
of	O
transporters	O
for	O
dietary	O
iron	O
.	O
Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
HFE-	O
/	O
-	O
mice	O
have	O
increased	O
duodenal	O
expression	O
of	O
the	O
divalent	O
metal	O
transporter	O
(	O
DMT1	O
)	O
.	O
By	O
4	O
weeks	O
of	O
age	O
,	O
the	O
HFE-	O
/	O
-	O
mice	O
demonstrated	O
iron	O
loading	O
when	O
compared	O
with	O
HFE	O
+	O
/	O
+	O
littermates	O
,	O
with	O
elevated	O
transferrin	O
saturations	O
(	O
68	O
.	O
4	O
%	O
vs	O
.	O
49	O
.	O
8	O
%	O
)	O
and	O
elevated	O
liver	O
iron	O
concentrations	O
(	O
985	O
micrograms	O
vs	O
.	O
381	O
micrograms	O
)	O
.	O
By	O
using	O
Northern	O
blot	O
analyses	O
,	O
we	O
quantitated	O
duodenal	O
expression	O
of	O
both	O
classes	O
of	O
DMT1	O
transcripts	O
one	O
containing	O
an	O
iron	O
responsive	O
element	O
(	O
IRE	O
)	O
,	O
called	O
DMT1	O
(	O
IRE	O
)	O
,	O
and	O
one	O
containing	O
no	O
IRE	O
,	O
called	O
DMT1	O
(	O
non-IRE	O
)	O
.	O
The	O
positive	O
control	O
for	O
DMT1	O
up-regulation	O
was	O
a	O
murine	O
model	O
of	O
dietary	B-SpecificDisease
iron	I-SpecificDisease
deficiency	I-SpecificDisease
that	O
demonstrated	O
greatly	O
increased	O
levels	O
of	O
duodenal	O
DMT1	O
(	O
IRE	O
)	O
mRNA	O
.	O
HFE-	O
/	O
-	O
mice	O
also	O
demonstrated	O
an	O
increase	O
in	O
duodenal	O
DMT1	O
(	O
IRE	O
)	O
mRNA	O
(	O
average	O
7	O
.	O
7-fold	O
)	O
,	O
despite	O
their	O
elevated	O
transferrin	O
saturation	O
and	O
hepatic	O
iron	O
content	O
.	O
Duodenal	O
expression	O
of	O
DMT1	O
(	O
non-IRE	O
)	O
was	O
not	O
increased	O
,	O
nor	O
was	O
hepatic	O
expression	O
of	O
DMT1	O
increased	O
.	O
These	O
data	O
support	O
the	O
model	O
for	O
HH	O
in	O
which	O
HFE	O
mutations	O
lead	O
to	O
inappropriately	O
low	O
crypt	O
cell	O
iron	O
,	O
with	O
resultant	O
stabilization	O
of	O
DMT1	O
(	O
IRE	O
)	O
mRNA	O
,	O
up-regulation	O
of	O
DMT1	O
,	O
and	O
increased	O
absorption	O
of	O
dietary	O
iron	O
.	O

8195156	O
Structure	O
of	O
the	O
human	O
Na+/glucose	O
cotransporter	O
gene	O
SGLT1.	O
Intestinal	O
uptake	O
of	O
dietary	O
glucose	O
and	O
galactose	O
is	O
mediated	O
by	O
the	O
SGLT1	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
of	O
the	O
brush	O
border	O
.	O
An	O
SGLT1	O
missense	O
mutation	O
underlies	O
hereditary	B-SpecificDisease
glucose	I-SpecificDisease
/	I-SpecificDisease
galactose	I-SpecificDisease
malabsorption	I-SpecificDisease
,	O
characterized	O
by	O
potentially	O
fatal	O
diarrhea	B-SpecificDisease
;	O
conversely	O
,	O
oral	O
rehydration	O
therapy	O
exploits	O
normal	O
transport	O
to	O
alleviate	O
life-threatening	O
diarrhea	B-SpecificDisease
of	O
infectious	O
origin	O
.	O
We	O
have	O
mapped	O
the	O
entire	O
human	O
SGLT1	O
Na	O
+	O
/	O
glucose	O
cotransporter	O
gene	O
from	O
cosmid	O
and	O
lambda	O
phage	O
clones	O
representing	O
a	O
genomic	O
region	O
of	O
112	O
kilobases	O
.	O
Transcription	O
initiation	O
occurred	O
from	O
a	O
site	O
27	O
base	O
pairs	O
3	O
of	O
a	O
TATAA	O
sequence	O
.	O
All	O
exon-flanking	O
regions	O
were	O
sequenced	O
,	O
and	O
the	O
entire	O
112-kilobase	O
region	O
mapped	O
with	O
four	O
restriction	O
enzymes	O
.	O
SGLT1	O
is	O
comprised	O
of	O
15	O
exons	O
(	O
spanning	O
72	O
kilobases	O
)	O
;	O
a	O
possible	O
evolutionary	O
origin	O
from	O
a	O
six-membrane-span	O
ancestral	O
precursor	O
via	O
a	O
gene	O
duplication	O
event	O
is	O
suggested	O
from	O
comparison	O
of	O
exons	O
against	O
protein	O
secondary	O
structure	O
and	O
from	O
sequence	O
considerations	O
.	O
A	O
new	O
missense	O
mutation	O
in	O
exon	O
1	O
causing	O
glucose	B-SpecificDisease
/	I-SpecificDisease
galactose	I-SpecificDisease
malabsorption	I-SpecificDisease
is	O
also	O
described	O
.	O
This	O
is	O
the	O
first	O
Na	O
(	O
+	O
)	O
-dependent	O
cotransporter	O
gene	O
structure	O
reported	O
.	O
These	O
data	O
facilitate	O
the	O
search	O
for	O
new	O
glucose	B-Modifier
/	I-Modifier
galactose	I-Modifier
malabsorption-related	I-Modifier
mutations	O
in	O
this	O
important	O
gene	O
and	O
provide	O
a	O
basis	O
for	O
future	O
evolutionary	O
comparisons	O
with	O
other	O
Na	O
(	O
+	O
)	O
-dependent	O
cotransporters	O
.	O
.	O

8434621	O
Familial	B-SpecificDisease
Mediterranean	I-SpecificDisease
fever	I-SpecificDisease
in	O
the	O
colchicine	O
era:	O
the	O
fate	O
of	O
one	O
family.	O
In	O
order	O
to	O
demonstrate	O
the	O
effect	O
of	O
prophylactic	O
colchicine	O
treatment	O
on	O
the	O
natural	O
history	O
of	O
familial	B-SpecificDisease
Mediterranean	I-SpecificDisease
fever	I-SpecificDisease
(	O
FMF	B-SpecificDisease
)	O
,	O
a	O
family	O
is	O
presented	O
with	O
6	O
out	O
of	O
9	O
siblings	O
affected	O
by	O
FMF	B-SpecificDisease
.	O
Each	O
patient	O
represents	O
a	O
different	O
stage	O
of	O
the	O
amyloidotic	B-SpecificDisease
kidney	I-SpecificDisease
disease	I-SpecificDisease
of	O
FMF	B-SpecificDisease
and	O
the	O
effect	O
of	O
continuous	O
colchicine	O
treatment	O
on	O
its	O
course	O
.	O
Considered	O
together	O
,	O
the	O
members	O
of	O
this	O
family	O
present	O
an	O
almost	O
complete	O
clinical	O
,	O
genetic	O
,	O
and	O
behavioral	O
picture	O
of	O
the	O
disease	O
.	O
.	O

10581027	O
Loss-of-function	O
mutations	O
in	O
the	O
cathepsin	O
C	O
gene	O
result	O
in	O
periodontal	B-SpecificDisease
disease	I-SpecificDisease
and	O
palmoplantar	B-DiseaseClass
keratosis.	I-DiseaseClass
Papillon-Lefevre	B-SpecificDisease
syndrome	I-SpecificDisease
,	O
or	O
keratosis	B-DiseaseClass
palmoplantaris	I-DiseaseClass
with	O
periodontopathia	B-SpecificDisease
(	O
PLS	B-SpecificDisease
,	O
MIM	O
245000	O
)	O
,	O
is	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
that	O
is	O
mainly	O
ascertained	O
by	O
dentists	O
because	O
of	O
the	O
severe	O
periodontitis	B-SpecificDisease
that	O
afflicts	O
patients	O
.	O
Both	O
the	O
deciduous	O
and	O
permanent	O
dentitions	O
are	O
affected	O
,	O
resulting	O
in	O
premature	O
tooth	B-SpecificDisease
loss	I-SpecificDisease
.	O
Palmoplantar	B-DiseaseClass
keratosis	I-DiseaseClass
,	O
varying	O
from	O
mild	O
psoriasiform	O
scaly	O
skin	O
to	O
overt	O
hyperkeratosis	B-SpecificDisease
,	O
typically	O
develops	O
within	O
the	O
first	O
three	O
years	O
of	O
life	O
.	O
Keratosis	B-SpecificDisease
also	O
affects	O
other	O
sites	O
such	O
as	O
elbows	O
and	O
knees	O
.	O
Most	O
PLS	B-Modifier
patients	O
display	O
both	O
periodontitis	B-SpecificDisease
and	O
hyperkeratosis	B-SpecificDisease
.	O
Some	O
patients	O
have	O
only	O
palmoplantar	B-DiseaseClass
keratosis	I-DiseaseClass
or	O
periodontitis	B-SpecificDisease
,	O
and	O
in	O
rare	O
individuals	O
the	O
periodontitis	B-SpecificDisease
is	O
mild	O
and	O
of	O
late	O
onset	O
.	O
The	O
PLS	O
locus	O
has	O
been	O
mapped	O
to	O
chromosome	O
11q14-q21	O
(	O
refs	O
7	O
,	O
8	O
,	O
9	O
)	O
.	O
Using	O
homozygosity	O
mapping	O
in	O
eight	O
small	O
consanguineous	O
families	O
,	O
we	O
have	O
narrowed	O
the	O
candidate	O
region	O
to	O
a	O
1	O
.	O
2-cM	O
interval	O
between	O
D11S4082	O
and	O
D11S931	O
.	O
The	O
gene	O
(	O
CTSC	O
)	O
encoding	O
the	O
lysosomal	O
protease	O
cathepsin	O
C	O
(	O
or	O
dipeptidyl	O
aminopeptidase	O
I	O
)	O
lies	O
within	O
this	O
interval	O
.	O
We	O
defined	O
the	O
genomic	O
structure	O
of	O
CTSC	O
and	O
found	O
mutations	O
in	O
all	O
eight	O
families	O
.	O
In	O
two	O
of	O
these	O
families	O
we	O
used	O
a	O
functional	O
assay	O
to	O
demonstrate	O
an	O
almost	O
total	O
loss	O
of	O
cathepsin	O
C	O
activity	O
in	O
PLS	B-Modifier
patients	O
and	O
reduced	O
activity	O
in	O
obligate	O
carriers	O
.	O

1301938	O
A	O
mutation	O
common	O
in	O
non-Jewish	O
Tay-Sachs	B-SpecificDisease
disease:	I-SpecificDisease
frequency	O
and	O
RNA	O
studies.	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
(	O
TSD	B-SpecificDisease
)	O
is	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
genetic	I-DiseaseClass
disorder	I-DiseaseClass
resulting	O
from	O
mutation	O
of	O
the	O
HEXA	O
gene	O
encoding	O
the	O
alpha-subunit	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
beta-N-acetylhexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
.	O
We	O
have	O
discovered	O
that	O
a	O
Tay-Sachs	B-Modifier
mutation	O
,	O
IVS-9	O
+	O
1	O
G--	O
>	O
A	O
,	O
first	O
detected	O
by	O
Akli	O
et	O
al	O
.	O
(	O
Genomics	O
11	O
124-134	O
,	O
1991	O
)	O
,	O
is	O
a	O
common	O
disease	O
allele	O
in	O
non-Jewish	O
Caucasians	O
(	O
10	O
/	O
58	O
alleles	O
examined	O
)	O
.	O
A	O
PCR-based	O
diagnostic	O
test	O
,	O
which	O
detects	O
an	O
NlaIII	O
site	O
generated	O
by	O
the	O
mutation	O
,	O
revealed	O
a	O
frequency	O
among	O
enzyme-defined	O
carriers	O
of	O
9	O
/	O
64	O
(	O
14	O
%	O
)	O
.	O
Most	O
of	O
those	O
carrying	O
the	O
allele	O
trace	O
their	O
origins	O
to	O
the	O
United	O
Kingdom	O
,	O
Ireland	O
,	O
or	O
Western	O
Europe	O
.	O
It	O
was	O
not	O
identified	O
among	O
12	O
Black	O
American	O
TSD	B-Modifier
alleles	O
or	O
in	O
any	O
of	O
18	O
Ashkenazi	O
Jewish	O
,	O
enzyme-defined	O
carriers	O
who	O
did	O
not	O
carry	O
any	O
of	O
the	O
mutations	O
common	O
to	O
this	O
population	O
.	O
No	O
normally	O
spliced	O
RNA	O
was	O
detected	O
in	O
PCR	O
products	O
generated	O
from	O
reverse	O
transcription	O
of	O
RNA	O
carrying	O
the	O
IVS-9	O
mutation	O
.	O
Instead	O
,	O
the	O
low	O
levels	O
of	O
mRNA	O
from	O
this	O
allele	O
were	O
comprised	O
of	O
aberrant	O
species	O
resulting	O
from	O
the	O
use	O
of	O
either	O
of	O
two	O
cryptic	O
donor	O
sites	O
,	O
one	O
truncating	O
exon	O
9	O
and	O
the	O
other	O
within	O
IVS-9	O
,	O
spliced	O
to	O
exon	O
10	O
.	O
Numerous	O
additional	O
splice	O
products	O
were	O
detected	O
,	O
most	O
involving	O
skipping	O
of	O
one	O
or	O
more	O
surrounding	O
exons	O
.	O
Together	O
with	O
a	O
recently	O
identified	O
allele	O
responsible	O
for	O
Hex	O
A	O
pseudodeficiency	O
(	O
Triggs-Raine	O
et	O
al	O
.	O
Am	O
J	O
Hum	O
Genet	O
,	O
1992	O
)	O
,	O
these	O
two	O
alleles	O
accounted	O
for	O
almost	O
50	O
%	O
(	O
29	O
/	O
64	O
)	O
of	O
TSD	B-Modifier
or	O
carrier	O
alleles	O
ascertained	O
by	O
enzyme	O
screening	O
tests	O
in	O
non-Jewish	O
Caucasians	O
.	O
.	O

10090890	O
Multicentric	O
origin	O
of	O
hemochromatosis	B-Modifier
gene	O
(HFE)	O
mutations	O
.	O
Genetic	B-SpecificDisease
hemochromatosis	I-SpecificDisease
(GH	O
)	O
is	O
believed	O
to	O
be	O
a	O
disease	O
restricted	O
to	O
those	O
of	O
European	O
ancestry	O
.	O
In	O
northwestern	O
Europe	O
,	O
>	O
80	O
%	O
of	O
GH	B-Modifier
patients	O
are	O
homozygous	O
for	O
one	O
mutation	O
,	O
the	O
substitution	O
of	O
tyrosine	O
for	O
cysteine	O
at	O
position	O
282	O
(	O
C282Y	O
)	O
in	O
the	O
unprocessed	O
protein	O
.	O
In	O
a	O
proportion	O
of	O
GH	B-Modifier
patients	O
,	O
two	O
mutations	O
are	O
present	O
,	O
C282Y	O
and	O
H63D	O
.	O
The	O
clinical	O
significance	O
of	O
this	O
second	O
mutation	O
is	O
such	O
that	O
it	O
appears	O
to	O
predispose	O
1	O
%	O
-2	O
%	O
of	O
compound	O
heterozygotes	O
to	O
expression	O
of	O
the	O
disease	O
.	O
The	O
distribution	O
of	O
the	O
two	O
mutations	O
differ	O
,	O
C282Y	O
being	O
limited	O
to	O
those	O
of	O
northwestern	O
European	O
ancestry	O
and	O
H63D	O
being	O
found	O
at	O
allele	O
frequencies	O
>	O
5	O
%	O
,	O
in	O
Europe	O
,	O
in	O
countries	O
bordering	O
the	O
Mediterranean	O
,	O
in	O
the	O
Middle	O
East	O
,	O
and	O
in	O
the	O
Indian	O
subcontinent	O
.	O
The	O
C282Y	O
mutation	O
occurs	O
on	O
a	O
haplotype	O
that	O
extends	O
<	O
/	O
=	O
6	O
Mb	O
,	O
suggesting	O
that	O
this	O
mutation	O
has	O
arisen	O
during	O
the	O
past	O
2	O
,	O
000	O
years	O
.	O
The	O
H63D	O
mutation	O
is	O
older	O
and	O
does	O
not	O
occur	O
on	O
such	O
a	O
large	O
extended	O
haplotype	O
,	O
the	O
haplotype	O
in	O
this	O
case	O
extending	O
<	O
/	O
=	O
700	O
kb	O
.	O
Here	O
we	O
report	O
the	O
finding	O
of	O
the	O
H63D	O
and	O
C282Y	O
mutations	O
on	O
new	O
haplotypes	O
.	O
In	O
Sri	O
Lanka	O
we	O
have	O
found	O
H63D	O
on	O
three	O
new	O
haplotypes	O
and	O
have	O
found	O
C282Y	O
on	O
one	O
new	O
haplotype	O
,	O
demonstrating	O
that	O
these	O
mutations	O
have	O
arisen	O
independently	O
on	O
this	O
island	O
.	O
These	O
results	O
suggest	O
that	O
the	O
HFE	O
gene	O
has	O
been	O
the	O
subject	O
of	O
selection	O
pressure	O
.	O
These	O
selection	O
pressures	O
could	O
be	O
due	O
to	O
infectious	B-DiseaseClass
diseases	I-DiseaseClass
,	O
environmental	O
conditions	O
,	O
or	O
other	O
genetic	B-DiseaseClass
disorders	I-DiseaseClass
such	O
as	O
anemia	B-DiseaseClass
.	O

6540752	O
Genetic	O
polymorphism	O
of	O
G6PD	O
in	O
a	O
Bulgarian	O
population.	O
Considerable	O
genetic	O
heterogeneity	O
in	O
G6PD	O
was	O
found	O
in	O
the	O
Bulgarian	O
population-14	O
G6PD	O
variants	O
isolated	O
from	O
117	O
hemizygous	O
carriers	O
of	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
Of	O
these	O
,	O
G6PD	O
Mediterranean	O
type	O
was	O
a	O
polymorphic	O
variant	O
and	O
G6PD	O
Corinth	O
occurred	O
with	O
high	O
frequency	O
.	O
Two	O
new	O
variants	O
were	O
identified-G6PD	O
Rudosem	O
and	O
G6PD	O
Nedelino	O
.	O
In	O
a	O
selected	O
group	O
of	O
78	O
subjects	O
with	O
clinical	O
manifestations	O
,	O
four	O
variants	O
were	O
established	O
G6PD	O
Mediterranian	O
,	O
G6PD	O
Corinth	O
,	O
G6PD	O
Seattle	O
and	O
G6PD	O
Ohut	O
II	O
.	O
.	O

2895982	O
Tightly	O
linked	O
flanking	O
markers	O
for	O
the	O
Lowe	B-SpecificDisease
oculocerebrorenal	I-SpecificDisease
syndrome,	I-SpecificDisease
with	O
application	O
to	O
carrier	O
assessment.	O
The	O
Lowe	B-SpecificDisease
oculocerebrorenal	I-SpecificDisease
syndrome	I-SpecificDisease
(	O
OCRL	B-SpecificDisease
)	O
is	O
characterized	O
by	O
congenital	O
cataract	B-SpecificDisease
,	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
,	O
and	O
defective	B-DiseaseClass
renal	I-DiseaseClass
tubular	I-DiseaseClass
function	I-DiseaseClass
.	O
A	O
map	O
assignment	O
of	O
OCRL	B-SpecificDisease
to	O
Xq24-q26	O
has	O
been	O
made	O
previously	O
by	O
linkage	O
analysis	O
with	O
DXS42	O
at	O
Xq24-q26	O
(	O
theta	O
=	O
0	O
,	O
z	O
=	O
5	O
.	O
09	O
)	O
and	O
with	O
DXS10	O
at	O
Xq26	O
(	O
theta	O
=	O
0	O
,	O
z	O
=	O
6	O
.	O
45	O
)	O
.	O
Two	O
additional	O
families	O
were	O
studied	O
and	O
three	O
additional	O
polymorphisms	O
were	O
identified	O
at	O
DXS42	O
by	O
using	O
a	O
35-kb	O
sequence	O
isolated	O
with	O
the	O
probe	O
detecting	O
the	O
original	O
polymorphism	O
at	O
DXS42	O
.	O
With	O
additional	O
OCRL	B-Modifier
families	O
made	O
informative	O
for	O
DXS42	O
,	O
theta	O
remained	O
0	O
with	O
z	O
=	O
6	O
.	O
63	O
;	O
and	O
for	O
DXS10	O
theta	O
=	O
0	O
.	O
03	O
and	O
z	O
=	O
7	O
.	O
07	O
.	O
Evidence	O
for	O
placing	O
OCRL	O
at	O
Xq25	O
also	O
comes	O
from	O
a	O
female	O
with	O
Lowe	B-SpecificDisease
syndrome	I-SpecificDisease
and	O
an	O
X	O
;	O
3	O
translocation	O
.	O
We	O
have	O
used	O
the	O
Xq25	O
breakpoint	O
in	O
this	O
patient	O
to	O
determine	O
the	O
position	O
of	O
OCRL	O
relative	O
to	O
the	O
two	O
linked	O
markers	O
.	O
Each	O
derivative	O
chromosome	O
was	O
isolated	O
away	O
from	O
its	O
normal	O
counterpart	O
in	O
somatic	O
cell	O
hybrids	O
.	O
DXS42	O
was	O
mapped	O
to	O
the	O
derivative	O
chromosome	O
X	O
containing	O
Xpterq25	O
,	O
and	O
DXS10	O
was	O
mapped	O
to	O
the	O
derivative	O
chromosome	O
3	O
containing	O
Xq25-qter	O
.	O
The	O
markers	O
DXS10	O
and	O
DXS42	O
therefore	O
show	O
tight	O
linkage	O
with	O
OCRL	B-SpecificDisease
in	O
six	O
families	O
and	O
flank	O
the	O
Xq25	O
breakpoint	O
in	O
a	O
female	O
patient	O
with	O
an	O
X	O
;	O
3	O
translocation	O
.	O
Linkage	O
analysis	O
with	O
flanking	O
markers	O
was	O
used	O
to	O
assess	O
OCRL	B-Modifier
carrier	O
status	O
in	O
women	O
at	O
risk	O
.	O
Results	O
,	O
when	O
compared	O
with	O
carrier	O
determination	O
by	O
ophthalmologic	O
examination	O
,	O
indicated	O
that	O
the	O
slit-lamp	O
exam	O
can	O
be	O
a	O
sensitive	O
and	O
specific	O
method	O
of	O
carrier	O
determination	O
in	O
many	O
cases	O

8209890	O
Investigation	O
of	O
thermoregulatory	O
characteristics	O
in	O
patients	O
with	O
Prader-Willi	B-SpecificDisease
syndrome.	I-SpecificDisease
A	O
survey	O
instrument	O
is	O
used	O
to	O
assess	O
temperature	O
regulation	O
characteristics	O
in	O
children	O
with	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
PWS	B-SpecificDisease
)	O
compared	O
to	O
3	O
control	O
groups	O
sibs	O
of	O
PWS	B-Modifier
patients	O
(	O
SIB	O
)	O
,	O
neurodevelopmentally	B-Modifier
handicapped	I-Modifier
children	O
(	O
ND	O
)	O
,	O
and	O
age	O
and	O
gender	O
matched	O
well	O
children	O
(	O
WC	O
)	O
.	O
Significant	O
differences	O
were	O
found	O
between	O
PWS	B-Modifier
patients	O
,	O
SIB	O
controls	O
,	O
and	O
WC	O
controls	O
in	O
the	O
prevalence	O
of	O
febrile	O
convulsions	O
,	O
fever-associated	O
symptoms	O
,	O
and	O
temperature	O
less	O
than	O
94	O
degrees	O
F	O
.	O
No	O
differences	O
were	O
noted	O
in	O
any	O
variable	O
between	O
the	O
PWS	B-Modifier
patients	O
and	O
the	O
ND	O
controls	O
,	O
suggesting	O
that	O
these	O
abnormalities	O
are	O
not	O
unique	O
to	O
PWS	B-SpecificDisease
,	O
but	O
can	O
occur	O
in	O
any	O
neurodevelopmentally	B-Modifier
handicapped	I-Modifier
individual	O
,	O
further	O
suggesting	O
these	O
do	O
not	O
necessarily	O
reflect	O
syndrome-specific	O
hypothalamic	B-DiseaseClass
abnormalities	I-DiseaseClass
.	O
.	O

10724175	O
hCds1-mediated	O
phosphorylation	O
of	O
BRCA1	O
regulates	O
the	O
DNA	O
damage	O
response.	O
Mutations	O
in	O
the	O
BRCA1	O
(	O
ref	O
.	O
1	O
)	O
tumour	B-Modifier
suppressor	O
gene	O
are	O
found	O
in	O
almost	O
all	O
of	O
the	O
families	O
with	O
inherited	B-CompositeMention
breast	I-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancers	I-CompositeMention
and	O
about	O
half	O
of	O
the	O
families	O
with	O
only	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
.	O
Although	O
the	O
biochemical	O
function	O
of	O
BRCA1	O
is	O
not	O
well	O
understood	O
,	O
it	O
is	O
important	O
for	O
DNA	O
damage	O
repair	O
and	O
cell-cycle	O
checkpoint	O
.	O
BRCA1	O
exists	O
in	O
nuclear	O
foci	O
but	O
is	O
hyperphosphorylated	O
and	O
disperses	O
after	O
DNA	O
damage	O
.	O
It	O
is	O
not	O
known	O
whether	O
BRCA1	O
phosphorylation	O
and	O
dispersion	O
and	O
its	O
function	O
in	O
DNA	O
damage	O
response	O
are	O
related	O
.	O
In	O
yeast	O
the	O
DNA	O
damage	O
response	O
and	O
the	O
replication-block	O
checkpoint	O
are	O
mediated	O
partly	O
through	O
the	O
Cds1	O
kinase	O
family	O
.	O
Here	O
we	O
report	O
that	O
the	O
human	O
Cds1	O
kinase	O
(	O
hCds1	O
/	O
Chk2	O
)	O
regulates	O
BRCA1	O
function	O
after	O
DNA	O
damage	O
by	O
phosphorylating	O
serine	O
988	O
of	O
BRCA1	O
.	O
We	O
show	O
that	O
hCds1	O
and	O
BRCA1	O
interact	O
and	O
co-localize	O
within	O
discrete	O
nuclear	O
foci	O
but	O
separate	O
after	O
gamma	O
irradiation	O
.	O
Phosphorylation	O
of	O
BRCA1	O
at	O
serine	O
988	O
is	O
required	O
for	O
the	O
release	O
of	O
BRCA1	O
from	O
hCds1	O
.	O
This	O
phosphorylation	O
is	O
also	O
important	O
for	O
the	O
ability	O
of	O
BRCA1	O
to	O
restore	O
survival	O
after	O
DNA	O
damage	O
in	O
the	O
BRCA1-mutated	O
cell	O
line	O
HCC1937	O
.	O
.	O

523196	O
Utilization	O
of	O
purines	O
by	O
an	O
HPRT	O
variant	O
in	O
an	O
intelligent,	O
nonmutilative	O
patient	O
with	O
features	O
of	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome.	I-SpecificDisease
The	O
patient	O
,	O
H	O
.	O
Chr	O
.	O
B	O
.	O
,	O
was	O
among	O
the	O
first	O
reported	O
with	O
hyperuricemia	B-SpecificDisease
and	O
central	B-DiseaseClass
nervous	I-DiseaseClass
system	I-DiseaseClass
symptoms	I-DiseaseClass
.	O
He	O
has	O
been	O
found	O
to	O
have	O
a	O
variant	O
of	O
hypoxanthine	O
guanine	O
phosphoribosyl	O
transferase	O
(	O
HPRT	O
;	O
E	O
.	O
C	O
.	O
2	O
.	O
4	O
.	O
2	O
.	O
8	O
)	O
distinct	O
from	O
the	O
enzyme	O
present	O
in	O
patients	O
with	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
The	O
patient	O
had	O
chroeoathetosis	B-SpecificDisease
,	O
spasticity	B-SpecificDisease
,	O
dysarthric	B-SpecificDisease
speech	I-SpecificDisease
,	O
and	O
hyperuricemia	B-SpecificDisease
.	O
However	O
,	O
his	O
intelligence	O
was	O
normal	O
and	O
he	O
had	O
no	O
evidence	O
of	O
self-mutilation	O
.	O
There	O
was	O
no	O
activity	O
of	O
HPRT	O
in	O
the	O
lysates	O
of	O
erythrocytes	O
and	O
cultured	O
fibroblasts	O
when	O
analyzed	O
in	O
the	O
usual	O
manner	O
.	O
Using	O
a	O
newly	O
developed	O
method	O
for	O
the	O
study	O
of	O
purine	O
metabolism	O
in	O
intact	O
cultured	O
cells	O
,	O
this	O
patient	O
was	O
found	O
to	O
metabolize	O
some	O
9	O
%	O
of	O
8-14C-hypoxanthine	O
,	O
and	O
90	O
%	O
of	O
the	O
isotope	O
utilized	O
was	O
converted	O
to	O
adenine	O
and	O
guanine	O
nucleotides	O
.	O
In	O
contrast	O
,	O
cells	O
from	O
patients	O
with	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
were	O
virtually	O
completely	O
unable	O
to	O
convert	O
hypoxanthine	O
to	O
nucleotides	O
.	O
The	O
patients	O
fibroblasts	O
were	O
even	O
more	O
efficient	O
in	O
the	O
metabolism	O
of	O
8-14C-guanine	O
,	O
which	O
was	O
utilized	O
to	O
the	O
extent	O
of	O
27	O
%	O
,	O
over	O
80	O
%	O
of	O
which	O
was	O
converted	O
to	O
guanine	O
and	O
adenine	O
nucleotides	O
.	O
The	O
growth	O
of	O
the	O
cultured	O
fibroblasts	O
of	O
this	O
patient	O
was	O
intermediate	O
in	O
media	O
containing	O
hypoxanthine	O
aminopterin	O
thymidine	O
(	O
HAT	O
)	O
,	O
whereas	O
the	O
growth	O
of	O
Lesch-Nyhan	B-Modifier
cells	O
was	O
inhibited	O
and	O
normal	O
cells	O
grew	O
normally	O
.	O
Similarly	O
in	O
8-azaguanine	O
,	O
6-thioguanine	O
,	O
and	O
8-azahypoxanthine	O
,	O
the	O
growth	O
of	O
the	O
patients	O
cells	O
was	O
intermediate	O
between	O
normal	O
and	O
Lesch-Nyhan	B-Modifier
cells	O
.	O
These	O
observations	O
provide	O
further	O
evidence	O
for	O
genetic	O
heterogeneity	O
among	O
patients	O
with	O
disorders	O
in	O
purine	O
metabolism	O
involving	O
the	O
HPRT	O
gene	O
.	O
They	O
document	O
that	O
this	O
famous	O
patient	O
did	O
not	O
have	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease

1999339	O
Some	O
Mexican	O
glucose-6-phosphate	O
dehydrogenase	O
variants	O
revisited.	O
Glucose-6-phosphate	B-SpecificDisease
dehydrogenase	I-SpecificDisease
(	I-SpecificDisease
G6PD	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
appears	O
to	O
be	O
fairly	O
common	O
in	O
Mexico	O
.	O
We	O
have	O
now	O
examined	O
the	O
DNA	O
of	O
three	O
previously	O
reported	O
electrophoretically	O
fast	O
Mexican	O
G6PD	O
variants	O
,	O
-G6PD	O
Distrito	O
Federal	O
,	O
G6PD	O
Tepic	O
,	O
and	O
G6PD	O
Castilla	O
.	O
All	O
three	O
of	O
these	O
variants	O
,	O
believed	O
on	O
the	O
basis	O
of	O
biochemical	O
characterization	O
and	O
population	O
origin	O
to	O
be	O
unique	O
,	O
have	O
the	O
G----A	O
transition	O
at	O
nucleotide	O
202	O
and	O
the	O
A----G	O
transition	O
at	O
nucleotide	O
376	O
,	O
mutations	O
that	O
we	O
now	O
recognize	O
to	O
be	O
characteristic	O
of	O
G6PD	O
A-	O
.	O
Two	O
other	O
Mexican	O
males	O
with	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
were	O
found	O
to	O
have	O
the	O
same	O
mutation	O
.	O
All	O
five	O
have	O
the	O
(	O
NlaIII	O
/	O
FokI	O
/	O
PvuII	O
/	O
PstI	O
)	O
haplotype	O
characteristic	O
of	O
G6PD	O
A	O
-in	O
Africa	O
.	O
Since	O
the	O
PvuII	O
+	O
genotype	O
seems	O
to	O
be	O
rare	O
in	O
Europe	O
,	O
we	O
conclude	O
that	O
all	O
of	O
these	O
G6PD	O
A	O
-	O
genes	O
had	O
their	O
ancient	O
origin	O
in	O
Africa	O
,	O
although	O
in	O
many	O
of	O
the	O
Mexican	O
patients	O
with	O
G6PD	O
A	O
-202A	O
/	O
376G	O
the	O
gene	O
may	O
have	O
been	O
imported	O
more	O
recently	O
from	O
Spain	O
,	O
where	O
this	O
variant	O
,	O
formerly	O
known	O
as	O
G6PD	O
Betica	O
,	O
is	O
also	O
prevalent	O
.	O
.	O

8111379	O
Mutations	O
in	O
the	O
PAX6	O
gene	O
in	O
patients	O
with	O
hereditary	O
aniridia.	B-SpecificDisease
The	O
14	O
exons	O
of	O
the	O
PAX6	O
gene	O
have	O
been	O
analysed	O
exon-by-exon	O
using	O
SSCP	O
in	O
6	O
aniridia	B-Modifier
families	O
.	O
In	O
each	O
family	O
band	O
shifts	O
were	O
observed	O
on	O
the	O
SSCP	O
gels	O
for	O
only	O
one	O
exon	O
and	O
direct	O
PCR-sequencing	O
revealed	O
mutations	O
in	O
each	O
case	O
.	O
Two	O
mutations	O
involved	O
C--	O
>	O
T	O
transitions	O
in	O
CGAarg	O
codons	O
in	O
exons	O
9	O
and	O
11	O
.	O
Another	O
C--	O
>	O
T	O
transition	O
converted	O
a	O
CAG-glutamine	O
to	O
a	O
TAG-stop	O
in	O
exon	O
7	O
.	O
Small	O
insertions	O
created	O
frameshifts	O
which	O
produced	O
downstream	O
stop	O
codons	O
in	O
another	O
two	O
patients	O
and	O
an	O
A--	O
>	O
T	O
mutation	O
disrupted	O
the	O
splice	O
donor	O
site	O
of	O
exon	O
5	O
in	O
the	O
remaining	O
family	O
.	O
Thus	O
,	O
complete	O
inactivation	O
of	O
the	O
PAX6	O
gene	O
is	O
predicted	O
in	O
all	O
cases	O
.	O
Analysis	O
of	O
other	O
affected	O
members	O
of	O
the	O
families	O
showed	O
that	O
,	O
in	O
each	O
case	O
,	O
all	O
affected	O
individuals	O
carried	O
the	O
same	O
family-specific	O
mutation	O
.	O
One	O
polymorphism	O
was	O
found	O
in	O
exon	O
7	O
.	O
This	O
data	O
strongly	O
supports	O
the	O
candidature	O
of	O
PAX6	O
as	O
the	O
gene	O
responsible	O
for	O
hereditary	O
aniridia	B-SpecificDisease
.	O
.	O

7981671	O
Mutation	O
spectrum	O
in	O
the	O
CHM	B-Modifier
gene	O
of	O
Danish	O
and	O
Swedish	O
choroideremia	B-Modifier
patients.	O
The	O
recent	O
isolation	O
of	O
the	O
complete	O
open	O
reading	O
frame	O
of	O
the	O
choroideremia	B-Modifier
(	O
CHM	B-Modifier
)	O
gene	O
and	O
the	O
characterization	O
of	O
the	O
exon-intron	O
boundaries	O
has	O
paved	O
the	O
way	O
to	O
mutation	O
detection	O
in	O
patients	O
with	O
classical	O
choroideremia	B-SpecificDisease
.	O
We	O
have	O
performed	O
mutation	O
screening	O
in	O
patients	O
from	O
15	O
Danish	O
and	O
Swedish	O
families	O
by	O
using	O
Southern	O
blot	O
hybridization	O
and	O
the	O
polymerase	O
chain	O
reaction	O
single-strand	O
conformation	O
polymorphism	O
(	O
PCR-SSCP	O
)	O
technique	O
.	O
Causative	O
mutations	O
in	O
the	O
CHM	B-Modifier
gene	O
were	O
detected	O
in	O
at	O
least	O
12	O
families	O
,	O
indicating	O
that	O
a	O
substantial	O
part	O
of	O
the	O
mutations	O
can	O
be	O
identified	O
by	O
this	O
approach	O
.	O
In	O
four	O
of	O
these	O
families	O
deletions	O
of	O
different	O
sizes	O
were	O
found	O
.	O
Thus	O
,	O
in	O
one	O
patient	O
,	O
the	O
deletion	O
resulted	O
in	O
the	O
absence	O
of	O
only	O
one	O
exon	O
,	O
while	O
in	O
another	O
the	O
deletion	O
comprised	O
the	O
entire	O
CHM	B-Modifier
gene	O
.	O
Mapping	O
of	O
the	O
deletion	O
endpoints	O
in	O
these	O
four	O
patients	O
and	O
in	O
another	O
11	O
male	O
patients	O
with	O
sizeable	O
deletions	O
enabled	O
us	O
to	O
construct	O
a	O
very	O
detailed	O
map	O
of	O
intervals	O
2	O
and	O
3	O
of	O
Xq21	O
.	O
In	O
the	O
remaining	O
11	O
Danish	O
and	O
Swedish	O
families	O
at	O
least	O
8	O
causative	O
mutations	O
were	O
found	O
by	O
PCR-SSCP	O
analysis	O
and	O
direct	O
sequencing	O
.	O
Interestingly	O
,	O
all	O
CHM	B-Modifier
gene	O
mutations	O
detected	O
thus	O
far	O
in	O
choroideremia	B-Modifier
patients	O
give	O
rise	O
to	O
the	O
introduction	O
of	O
a	O
premature	O
stop	O
codon	O
.	O
.	O

10369870	O
Functional	O
consequences	O
of	O
mutations	O
in	O
the	O
early	O
growth	O
response	O
2	O
gene	O
(EGR2)	O
correlate	O
with	O
severity	O
of	O
human	O
myelinopathies.	B-DiseaseClass
The	O
early	O
growth	O
response	O
2	O
gene	O
(	O
EGR2	O
)	O
is	O
a	O
Cys2His2zinc	O
finger	O
transcription	O
factor	O
which	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
peripheral	O
nervous	O
system	O
myelination	O
.	O
This	O
idea	O
is	O
based	O
partly	O
on	O
the	O
phenotype	O
of	O
homozygous	O
Krox20	O
(	O
Egr2	O
)	O
knockout	O
mice	O
,	O
which	O
display	O
hypomyelination	B-DiseaseClass
of	I-DiseaseClass
the	I-DiseaseClass
PNS	I-DiseaseClass
and	O
a	O
block	O
of	O
Schwann	O
cells	O
at	O
an	O
early	O
stage	O
of	O
differentiation	O
.	O
Mutations	O
in	O
the	O
human	O
EGR2	O
gene	O
have	O
recently	O
been	O
associated	O
with	O
the	O
inherited	B-DiseaseClass
peripheral	I-DiseaseClass
neuropathies	I-DiseaseClass
Charcot-Marie-Tooth	B-SpecificDisease
type	I-SpecificDisease
1	I-SpecificDisease
,	O
Dejerine-Sottas	B-SpecificDisease
syndrome	I-SpecificDisease
and	O
congenital	B-SpecificDisease
hypomyelinating	I-SpecificDisease
neuropathy	I-SpecificDisease
.	O
Three	O
of	O
the	O
four	O
EGR2	O
mutations	O
are	O
dominant	O
and	O
occur	O
within	O
the	O
zinc	O
finger	O
DNA-binding	O
domain	O
.	O
The	O
fourth	O
mutation	O
is	O
recessive	O
and	O
affects	O
the	O
inhibitory	O
domain	O
(	O
R1	O
)	O
that	O
binds	O
the	O
NAB	O
transcriptional	O
co-repressors	O
.	O
A	O
combination	O
of	O
DNA-binding	O
assays	O
and	O
transcriptional	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
functional	O
consequences	O
of	O
these	O
mutations	O
.	O
The	O
zinc	O
finger	O
mutations	O
affect	O
DNA	O
binding	O
and	O
the	O
amount	O
of	O
residual	O
binding	O
directly	O
correlates	O
with	O
disease	O
severity	O
.	O
The	O
R1	O
domain	O
mutation	O
prevents	O
interaction	O
of	O
EGR2	O
with	O
the	O
NAB	O
co-repressors	O
and	O
thereby	O
increases	O
transcriptional	O
activity	O
.	O
These	O
data	O
provide	O
insight	O
into	O
the	O
possible	O
disease	O
mechanisms	O
underlying	O
EGR2	O
mutations	O
and	O
the	O
reason	O
for	O
varying	O
severity	O
and	O
differences	O
in	O
inheritance	O
patterns	O
.	O
.	O

7951316	O
A	O
physical	O
map	O
and	O
candidate	O
genes	O
in	O
the	O
BRCA1	O
region	O
on	O
chromosome	O
17q12-21.	O
We	O
have	O
constructed	O
a	O
physical	O
map	O
of	O
a	O
4	O
cM	O
region	O
on	O
chromosome	O
17q12-21	O
that	O
contains	O
the	O
hereditary	B-Modifier
breast	I-Modifier
and	I-Modifier
ovarian	I-Modifier
cancer	I-Modifier
gene	O
BRCA1	O
.	O
The	O
map	O
comprises	O
a	O
contig	O
of	O
137	O
overlapping	O
yeast	O
artificial	O
chromosomes	O
and	O
P1	O
clones	O
,	O
onto	O
which	O
we	O
have	O
placed	O
112	O
PCR	O
markers	O
.	O
We	O
have	O
localized	O
more	O
than	O
20	O
genes	O
on	O
this	O
map	O
,	O
ten	O
of	O
which	O
had	O
not	O
been	O
mapped	O
to	O
the	O
region	O
previously	O
,	O
and	O
have	O
isolated	O
30	O
cDNA	O
clones	O
representing	O
partial	O
sequences	O
of	O
as	O
yet	O
unidentified	O
genes	O
.	O
Two	O
genes	O
that	O
lie	O
within	O
a	O
narrow	O
region	O
defined	O
by	O
meiotic	O
breakpoints	O
in	O
BRCA1	O
patients	O
have	O
been	O
sequenced	O
in	O
breast	B-Modifier
cancer	I-Modifier
patients	O
without	O
revealing	O
any	O
deleterious	O
mutations	O
.	O
These	O
new	O
reagents	O
should	O
facilitate	O
the	O
identification	O
of	O
BRCA1	O
.	O
.	O

2760209	O
Molecular	O
analysis	O
of	O
a	O
female	O
Lesch-Nyhan	B-Modifier
patient.	O
We	O
report	O
the	O
identification	O
of	O
a	O
female	O
patient	O
with	O
the	O
X-linked	O
recessive	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
hypoxanthine	B-SpecificDisease
phosphoribosyltransferase	I-SpecificDisease
[	I-SpecificDisease
HPRT	I-SpecificDisease
]	I-SpecificDisease
deficiency	I-SpecificDisease
)	O
.	O
Cytogenetic	O
and	O
carrier	O
studies	O
revealed	O
structurally	O
normal	O
chromosomes	O
for	O
this	O
patient	O
and	O
her	O
parents	O
and	O
demonstrated	O
that	O
this	O
mutation	O
arose	O
through	O
a	O
de	O
novo	O
gametic	O
event	O
.	O
Comparison	O
of	O
this	O
patients	O
DNA	O
with	O
the	O
DNA	O
of	O
her	O
parents	O
revealed	O
that	O
a	O
microdeletion	O
,	O
which	O
occurred	O
within	O
a	O
maternal	O
gamete	O
and	O
involved	O
the	O
entire	O
HPRT	O
gene	O
,	O
was	O
partially	O
responsible	O
for	O
the	O
disease	O
in	O
this	O
patient	O
.	O
Somatic	O
cell	O
hybrids	O
,	O
generated	O
to	O
separate	O
maternal	O
and	O
paternal	O
X	O
chromosomes	O
,	O
showed	O
that	O
expression	O
of	O
two	O
additional	O
X-linked	O
enzymes	O
,	O
phosphoglycerate	O
kinase	O
and	O
glucose-6-phosphate	O
dehydrogenase	O
,	O
were	O
expressed	O
only	O
in	O
cells	O
that	O
contained	O
the	O
maternal	O
X	O
chromosome	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
functionally	O
inactive	O
paternal	O
X	O
chromosome	O
.	O
Furthermore	O
,	O
comparison	O
of	O
methylation	O
patterns	O
within	O
a	O
region	O
of	O
the	O
HPRT	O
gene	O
known	O
to	O
be	O
important	O
in	O
gene	O
regulation	O
revealed	O
differences	O
between	O
DNA	O
from	O
the	O
father	O
and	O
the	O
patient	O
,	O
in	O
keeping	O
with	O
an	O
active	O
HPRT	O
locus	O
in	O
the	O
father	O
and	O
an	O
inactive	O
HPRT	O
locus	O
in	O
the	O
patient	O
.	O
Together	O
these	O
data	O
indicate	O
that	O
nonrandom	O
inactivation	O
of	O
the	O
cytogenetically	O
normal	O
paternal	O
X	O
chromosome	O
and	O
a	O
microdeletion	O
of	O
the	O
HPRT	O
gene	O
on	O
an	O
active	O
maternal	O
X	O
chromosome	O
were	O
responsible	O
for	O
the	O
absence	O
of	O
HPRT	O
in	O
this	O
patient	O
.	O
.	O

10441573	O
Penetrances	O
of	O
BRCA1	O
1675delA	O
and	O
1135insA	O
with	O
respect	O
to	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
and	O
ovarian	B-SpecificDisease
cancer.	I-SpecificDisease
For	O
genetic	O
counseling	O
and	O
predictive	O
testing	O
in	O
families	O
with	O
inherited	B-CompositeMention
breast-ovarian	I-CompositeMention
cancer	I-CompositeMention
,	O
penetrances	O
and	O
expressions	O
of	O
the	O
underlying	O
mutations	O
should	O
be	O
known	O
.	O
We	O
have	O
previously	O
reported	O
two	O
BRCA1	O
founder	O
mutations	O
in	O
the	O
Norwegian	O
population	O
.	O
Index	O
cases	O
for	O
the	O
present	O
study	O
were	O
found	O
two	O
different	O
ways	O
through	O
a	O
series	O
of	O
consecutive	O
ovarian	B-SpecificDisease
cancers	I-SpecificDisease
(	O
n	O
=	O
16	O
)	O
and	O
through	O
our	O
family	O
cancer	B-Modifier
clinic	O
(	O
n	O
=	O
14	O
)	O
.	O
Altogether	O
,	O
20	O
of	O
the	O
patients	O
had	O
BRCA1	O
1675delA	O
,	O
and	O
10	O
had	O
1135insA	O
.	O
Their	O
relatives	O
were	O
described	O
with	O
respect	O
to	O
absence	O
/	O
presence	O
of	O
breast	B-CompositeMention
and	I-CompositeMention
/	I-CompositeMention
or	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
.	O
Of	O
133	O
living	O
female	O
relatives	O
,	O
83	O
(	O
62	O
%	O
)	O
were	O
tested	O
for	O
the	O
presence	O
of	O
a	O
mutation	O
.	O
No	O
difference	O
,	O
in	O
penetrance	O
and	O
expression	O
,	O
between	O
the	O
two	O
mutations	O
were	O
found	O
,	O
whereas	O
differences	O
according	O
to	O
method	O
of	O
ascertainment	O
were	O
seen	O
.	O
The	O
overall	O
findings	O
were	O
that	O
disease	O
started	O
to	O
occur	O
at	O
age	O
30	O
years	O
and	O
that	O
by	O
age	O
50	O
years	O
48	O
%	O
of	O
the	O
mutation-carrying	O
women	O
had	O
experienced	O
breast	B-CompositeMention
and	I-CompositeMention
/	I-CompositeMention
or	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
.	O
More	O
ovarian	B-SpecificDisease
cancers	I-SpecificDisease
than	O
breast	B-SpecificDisease
cancers	I-SpecificDisease
were	O
recorded	O
.	O
Both	O
penetrance	O
and	O
expression	O
(	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
vs	O
.	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
)	O
were	O
different	O
from	O
those	O
in	O
reports	O
of	O
the	O
Ashkenazi	O
founder	O
mutations	O
.	O
Whether	O
the	O
reported	O
differences	O
reflect	O
true	O
differences	O
and	O
/	O
or	O
methodological	O
problems	O
is	O
discussed	O
.	O
An	O
observed	O
excess	O
of	O
mutation	O
carriers	O
could	O
not	O
be	O
accounted	O
for	O
by	O
methodological	O
problems	O
;	O
possible	O
explanations	O
were	O
a	O
"	O
true	O
"	O
low	O
penetrance	O
or	O
preferential	O
segregation	O
.	O
.	O

8188241	O
The	O
human	O
gene	O
for	O
alkaptonuria	B-SpecificDisease
(AKU)	O
maps	O
to	O
chromosome	O
3q.	O
Alkaptonuria	B-SpecificDisease
(	O
AKU	B-SpecificDisease
;	O
McKusick	O
no	O
.	O
203500	O
)	O
is	O
a	O
rare	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
caused	O
by	O
the	O
lack	O
of	O
homogentisic	O
acid	O
oxidase	O
activity	O
.	O
Patients	O
excrete	O
large	O
amounts	O
of	O
homogentisic	O
acid	O
in	O
their	O
urine	O
and	O
a	O
black	O
ochronotic	O
pigment	O
is	O
deposited	O
in	O
their	O
cartilage	O
and	O
collagenous	O
tissues	O
.	O
Ochronosis	B-SpecificDisease
is	O
the	O
predominant	O
clinical	O
complication	O
of	O
the	O
disease	O
leading	O
to	O
ochronotic	B-SpecificDisease
arthropathy	I-SpecificDisease
,	O
dark	O
urine	O
,	O
pigment	O
changes	O
of	O
the	O
skin	O
,	O
and	O
other	O
clinical	O
features	O
.	O
A	O
mutation	O
causing	O
alkaptonuria	B-SpecificDisease
in	O
the	O
mouse	O
has	O
mapped	O
to	O
chromosome	O
16	O
.	O
Considering	O
conserved	O
synteny	O
,	O
we	O
were	O
able	O
to	O
map	O
the	O
human	O
gene	O
to	O
chromosome	O
3q	O
in	O
six	O
alkaptonuria	B-Modifier
pedigrees	O
of	O
Slovak	O
origin	O
.	O
.	O

7790377	O
Human	O
peroxisomal	O
targeting	O
signal-1	O
receptor	O
restores	O
peroxisomal	O
protein	O
import	O
in	O
cells	O
from	O
patients	O
with	O
fatal	O
peroxisomal	B-DiseaseClass
disorders.	I-DiseaseClass
Two	O
peroxisomal	O
targeting	O
signals	O
,	O
PTS1	O
and	O
PTS2	O
,	O
are	O
involved	O
in	O
the	O
import	O
of	O
proteins	O
into	O
the	O
peroxisome	O
matrix	O
.	O
Human	O
patients	O
with	O
fatal	O
generalized	O
peroxisomal	B-DiseaseClass
deficiency	I-DiseaseClass
disorders	I-DiseaseClass
fall	O
into	O
at	O
least	O
nine	O
genetic	O
complementation	O
groups	O
.	O
Cells	O
from	O
many	O
of	O
these	O
patients	O
are	O
deficient	O
in	O
the	O
import	O
of	O
PTS1-containing	O
proteins	O
,	O
but	O
the	O
causes	O
of	O
the	O
protein-import	O
defect	O
in	O
these	O
patients	O
are	O
unknown	O
.	O
We	O
have	O
cloned	O
and	O
sequenced	O
the	O
human	O
cDNA	O
homologue	O
(	O
PTS1R	O
)	O
of	O
the	O
Pichia	O
pastoris	O
PAS8	O
gene	O
,	O
the	O
PTS1	O
receptor	O
(	O
McCollum	O
,	O
D	O
.	O
,	O
E	O
.	O
Monosov	O
,	O
and	O
S	O
.	O
Subramani	O
.	O
1993	O
.	O
J	O
.	O
Cell	O
Biol	O
.	O
121	O
761-774	O
)	O
.	O
The	O
PTS1R	O
mRNA	O
is	O
expressed	O
in	O
all	O
human	O
tissues	O
examined	O
.	O
Antibodies	O
to	O
the	O
human	O
PTS1R	O
recognize	O
this	O
protein	O
in	O
human	O
,	O
monkey	O
,	O
rat	O
,	O
and	O
hamster	O
cells	O
.	O
The	O
protein	O
is	O
localized	O
mainly	O
in	O
the	O
cytosol	O
but	O
is	O
also	O
found	O
to	O
be	O
associated	O
with	O
peroxisomes	O
.	O
Part	O
of	O
the	O
peroxisomal	O
PTS1R	O
protein	O
is	O
tightly	O
bound	O
to	O
the	O
peroxisomal	O
membrane	O
.	O
Antibodies	O
to	O
PTS1R	O
inhibit	O
peroxisomal	O
protein-import	O
of	O
PTS1-containing	O
proteins	O
in	O
a	O
permeabilized	O
CHO	O
cell	O
system	O
.	O
In	O
vitro-translated	O
PTS1R	O
protein	O
specifically	O
binds	O
a	O
serine-lysine-leucine-peptide	O
.	O
A	O
PAS8-PTS1R	O
fusion	O
protein	O
complements	O
the	O
P	O
.	O
pastoris	O
pas8	O
mutant	O
.	O
The	O
PTS1R	O
cDNA	O
also	O
complements	O
the	O
PTS1	B-SpecificDisease
protein-import	I-SpecificDisease
defect	I-SpecificDisease
in	O
skin	O
fibroblasts	O
from	O
patients--belonging	O
to	O
complementation	O
group	O
two--diagnosed	O
as	O
having	O
neonatal	B-SpecificDisease
adrenoleukodystrophy	I-SpecificDisease
or	O
Zellweger	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
The	O
PTS1R	O
gene	O
has	O
been	O
localized	O
to	O
a	O
chromosomal	O
location	O
where	O
no	O
other	O
peroxisomal	B-Modifier
disorder	I-Modifier
genes	O
are	O
known	O
to	O
map	O
.	O
Our	O
findings	O
represent	O
the	O
only	O
case	O
in	O
which	O
the	O
molecular	O
basis	O
of	O
the	O
protein-import	B-DiseaseClass
deficiency	I-DiseaseClass
in	O
human	O
peroxisomal	B-DiseaseClass
disorders	I-DiseaseClass
is	O
understood	O
.	O

10777718	O
Gaucher	B-SpecificDisease
disease:	I-SpecificDisease
the	O
origins	O
of	O
the	O
Ashkenazi	O
Jewish	O
N370S	O
and	O
84GG	O
acid	O
beta-glucosidase	O
mutations.	O
Type	O
1	O
Gaucher	B-SpecificDisease
disease	I-SpecificDisease
(	O
GD	B-SpecificDisease
)	O
,	O
a	O
non-neuronopathic	O
lysosomal	B-DiseaseClass
storage	I-DiseaseClass
disorder	I-DiseaseClass
,	O
results	O
from	O
the	O
deficient	O
activity	O
of	O
acid	O
beta-glucosidase	O
(	O
GBA	O
)	O
.	O
Type	O
1	O
disease	O
is	O
panethnic	O
but	O
is	O
more	O
prevalent	O
in	O
individuals	O
of	O
Ashkenazi	O
Jewish	O
(	O
AJ	O
)	O
descent	O
.	O
Of	O
the	O
causative	O
GBA	O
mutations	O
,	O
N370S	O
is	O
particularly	O
frequent	O
in	O
the	O
AJ	O
population	O
,	O
(	O
q	O
approximately	O
.	O
03	O
)	O
,	O
whereas	O
the	O
84GG	O
insertion	O
(	O
q	O
approximately	O
.	O
003	O
)	O
occurs	O
exclusively	O
in	O
the	O
Ashkenazim	O
.	O
To	O
investigate	O
the	O
genetic	O
history	O
of	O
these	O
mutations	O
in	O
the	O
AJ	O
population	O
,	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
were	O
used	O
to	O
map	O
a	O
9	O
.	O
3-cM	O
region	O
containing	O
the	O
GBA	O
locus	O
and	O
to	O
genotype	O
261	O
AJ	O
N370S	O
chromosomes	O
,	O
60	O
European	O
non-Jewish	O
N370S	O
chromosomes	O
,	O
and	O
62	O
AJ	O
84GG	O
chromosomes	O
.	O
A	O
highly	O
conserved	O
haplotype	O
at	O
four	O
markers	O
flanking	O
GBA	O
(	O
PKLR	O
,	O
D1S1595	O
,	O
D1S2721	O
,	O
and	O
D1S2777	O
)	O
was	O
observed	O
on	O
both	O
the	O
AJ	O
chromosomes	O
and	O
the	O
non-Jewish	O
N370S	O
chromosomes	O
,	O
suggesting	O
the	O
occurrence	O
of	O
a	O
founder	O
common	O
to	O
both	O
populations	O
.	O
Of	O
note	O
,	O
the	O
presence	O
of	O
different	O
divergent	O
haplotypes	O
suggested	O
the	O
occurrence	O
of	O
de	O
novo	O
,	O
recurrent	O
N370S	O
mutations	O
.	O
In	O
contrast	O
,	O
a	O
different	O
conserved	O
haplotype	O
at	O
these	O
markers	O
was	O
identified	O
on	O
the	O
84GG	O
chromosomes	O
,	O
which	O
was	O
unique	O
to	O
the	O
AJ	O
population	O
.	O
On	O
the	O
basis	O
of	O
the	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
delta	O
values	O
,	O
the	O
non-Jewish	O
European	O
N370S	O
chromosomes	O
had	O
greater	O
haplotype	O
diversity	O
and	O
less	O
LD	O
at	O
the	O
markers	O
flanking	O
the	O
conserved	O
haplotype	O
than	O
did	O
the	O
AJ	O
N370S	O
chromosomes	O
.	O
This	O
finding	O
is	O
consistent	O
with	O
the	O
presence	O
of	O
the	O
N370S	O
mutation	O
in	O
the	O
non-Jewish	O
European	O
population	O
prior	O
to	O
the	O
founding	O
of	O
the	O
AJ	O
population	O
.	O
Coalescence	O
analyses	O
for	O
the	O
N370S	O
and	O
84GG	O
mutations	O
estimated	O
similar	O
coalescence	O
times	O
,	O
of	O
48	O
and	O
55.5	O
generations	O
ago	O
,	O
respectively	O
.	O
The	O
results	O
of	O
these	O
studies	O
are	O
consistent	O
with	O
a	O
significant	O
bottleneck	O
occurring	O
in	O
the	O
AJ	O
population	O
during	O
the	O
first	O
millennium	O
,	O
when	O
the	O
population	O
became	O
established	O
in	O
Europe	O
.	O

7617034	O
Natural	O
selection	O
of	O
hemi-	O
and	O
heterozygotes	O
for	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
in	O
Africa	O
by	O
resistance	O
to	O
severe	O
malaria.	B-SpecificDisease
Glucose-6-phosphate	B-SpecificDisease
dehydrogenase	I-SpecificDisease
(	I-SpecificDisease
G6PD	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
,	O
the	O
most	O
common	O
enzymopathy	B-DiseaseClass
of	O
humans	O
,	O
affects	O
over	O
400	O
million	O
people	O
.	O
The	O
geographical	O
correlation	O
of	O
its	O
distribution	O
with	O
the	O
historical	O
endemicity	O
of	O
malaria	B-SpecificDisease
suggests	O
that	O
this	O
disorder	O
has	O
risen	O
in	O
frequency	O
through	O
natural	O
selection	O
by	O
malaria	B-SpecificDisease
.	O
However	O
,	O
attempts	O
to	O
confirm	O
that	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
is	O
protective	O
in	O
case-control	O
studies	O
of	O
malaria	B-SpecificDisease
have	O
yielded	O
conflicting	O
results	O
.	O
Hence	O
,	O
for	O
this	O
X-linked	B-DiseaseClass
disorder	I-DiseaseClass
,	O
it	O
is	O
unclear	O
whether	O
both	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
are	O
protected	O
or	O
,	O
as	O
frequently	O
suggested	O
,	O
only	O
females	O
.	O
Furthermore	O
,	O
how	O
much	O
protection	O
may	O
be	O
afforded	O
is	O
unknown	O
.	O
Here	O
we	O
report	O
that	O
,	O
in	O
two	O
large	O
case-control	O
studies	O
of	O
over	O
2	O
,	O
000	O
African	O
children	O
,	O
the	O
common	O
African	O
form	O
of	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
(	O
G6PD	B-SpecificDisease
A-	I-SpecificDisease
)	O
is	O
associated	O
with	O
a	O
46-58	O
%	O
reduction	O
in	O
risk	O
of	O
severe	O
malaria	B-SpecificDisease
for	O
both	O
female	O
heterozygotes	O
and	O
male	O
hemizygotes	O
.	O
A	O
mathematical	O
model	O
incorporating	O
the	O
measured	O
selective	O
advantage	O
against	O
malaria	B-SpecificDisease
suggests	O
that	O
a	O
counterbalancing	O
selective	O
disadvantage	O
,	O
associated	O
with	O
this	O
enzyme	B-DiseaseClass
deficiency	I-DiseaseClass
,	O
has	O
retarded	O
its	O
rise	O
in	O
frequency	O
in	O
malaria-endemic	B-Modifier
regions	O
.	O
Although	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
is	O
now	O
regarded	O
as	O
a	O
generally	O
benign	O
disorder	O
,	O
in	O
earlier	O
environmental	O
conditions	O
it	O
could	O
have	O
been	O
significantly	O
disadvantageous	O
.	O
.	O

8566952	O
Identification	O
of	O
mutations	O
in	O
the	O
ALD-gene	O
of	O
20	O
families	O
with	O
adrenoleukodystrophy/adrenomyeloneuropathy.	B-SpecificDisease
Adrenoleukodystrophy	B-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
,	O
an	O
X-linked	B-DiseaseClass
inherited	I-DiseaseClass
metabolic	I-DiseaseClass
disorder	I-DiseaseClass
,	O
is	O
the	O
most	O
frequent	O
inborn	B-DiseaseClass
peroxisomal	I-DiseaseClass
disease	I-DiseaseClass
.	O
It	O
leads	O
to	O
demyelination	B-DiseaseClass
in	I-DiseaseClass
the	I-DiseaseClass
central	I-DiseaseClass
and	I-DiseaseClass
peripheral	I-DiseaseClass
nervous	I-DiseaseClass
system	I-DiseaseClass
.	O
Defective	O
beta-oxidation	O
of	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
VLCFAs	O
;	O
C22	O
0-C26	O
0	O
)	O
in	O
peroxisomes	O
has	O
been	O
shown	O
to	O
lead	O
to	O
an	O
accumulation	O
of	O
VLCFAs	O
in	O
leukoid	O
areas	O
of	O
the	O
central	O
nervous	O
system	O
,	O
peripheral	O
nerves	O
,	O
adrenal	O
gland	O
,	O
and	O
blood	O
.	O
The	O
ALD	B-Modifier
gene	O
has	O
been	O
recently	O
identified	O
and	O
encodes	O
a	O
745-amino-acid	O
protein	O
.	O
We	O
screened	O
patients	O
with	O
adrenoleukodystrophy	B-SpecificDisease
/	O
adrenomyeloneuropathy	B-SpecificDisease
(	O
ALD	B-SpecificDisease
/	O
AMN	B-SpecificDisease
)	O
from	O
20	O
kindreds	O
for	O
mutations	O
in	O
the	O
ALD	B-Modifier
gene	O
.	O
Eleven	O
missense	O
and	O
two	O
nonsense	O
mutations	O
,	O
five	O
deletions	O
,	O
and	O
one	O
insertion	O
were	O
detected	O
by	O
direct	O
sequencing	O
of	O
eight	O
reverse	O
transcribed	O
fragments	O
of	O
the	O
ALD-gene	B-Modifier
mRNA	O
.	O
Four	O
mutations	O
could	O
be	O
shown	O
to	O
be	O
de	O
novo	O
.	O
All	O
mutations	O
could	O
be	O
confirmed	O
in	O
carriers	O
by	O
sequencing	O
genomic	O
DNA	O
.	O
No	O
correlation	O
between	O
the	O
type	O
of	O
mutation	O
and	O
the	O
severity	O
of	O
the	O
phenotype	O
could	O
be	O
observed	O
.	O
The	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
ALD	B-Modifier
gene	O
of	O
30	O
healthy	O
persons	O
.	O
.	O

313733	O
Hereditary	B-SpecificDisease
C2	I-SpecificDisease
deficiency	I-SpecificDisease
associated	O
with	O
common	O
variable	O
immunodeficiency.	B-DiseaseClass
Homozygous	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
in	O
a	O
19-year-old	O
boy	O
was	O
associated	O
with	O
variable	O
immunodeficiency	B-DiseaseClass
manifested	O
by	O
marked	O
hypoimmunoglobulinemia	B-DiseaseClass
and	O
impaired	O
antibody	O
responses	O
,	O
normal	O
circulating	O
B	O
lymphocytes	O
,	O
and	O
subnormal	O
T-cell	O
functions	O
.	O
Neither	O
antilymphocytic	O
autoantibodies	O
nor	O
chromosomal	B-DiseaseClass
abnormalities	I-DiseaseClass
were	O
found	O
.	O
Serum	O
immunoglobulin	O
levels	O
were	O
within	O
normal	O
limits	O
in	O
his	O
parents	O
and	O
brother	O
who	O
were	O
heterozygous	O
for	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
The	O
patients	O
lymphocytes	O
were	O
homozygous	O
at	O
the	O
HLA-D	O
locus	O
but	O
expressed	O
an	O
antigen	O
different	O
from	O
DW2	O
.	O
.	O

10500204	O
Deficit	O
of	O
in	O
vivo	O
mitochondrial	O
ATP	O
production	O
in	O
patients	O
with	O
Friedreich	B-SpecificDisease
ataxia.	I-SpecificDisease
Friedreich	B-SpecificDisease
ataxia	I-SpecificDisease
(	O
FRDA	B-SpecificDisease
)	O
,	O
the	O
most	O
common	O
of	O
the	O
inherited	B-DiseaseClass
ataxias	I-DiseaseClass
,	O
is	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
degenerative	I-DiseaseClass
disorder	I-DiseaseClass
,	O
characterized	O
clinically	O
by	O
onset	O
before	O
the	O
age	O
of	O
25	O
of	O
progressive	B-CompositeMention
gait	I-CompositeMention
and	I-CompositeMention
limb	I-CompositeMention
ataxia	I-CompositeMention
,	O
absence	B-DiseaseClass
of	I-DiseaseClass
deep	I-DiseaseClass
tendon	I-DiseaseClass
reflexes	I-DiseaseClass
,	O
extensor	B-DiseaseClass
plantar	I-DiseaseClass
responses	I-DiseaseClass
,	O
and	O
loss	B-CompositeMention
of	I-CompositeMention
position	I-CompositeMention
and	I-CompositeMention
vibration	I-CompositeMention
sense	I-CompositeMention
in	O
the	O
lower	O
limbs	O
.	O
FRDA	B-SpecificDisease
is	O
caused	O
by	O
a	O
GAA	O
triplet	O
expansion	O
in	O
the	O
first	O
intron	O
of	O
the	O
FRDA	B-Modifier
gene	O
on	O
chromosome	O
9q13	O
in	O
97	O
%	O
of	O
patients	O
.	O
The	O
FRDA	B-Modifier
gene	O
encodes	O
a	O
widely	O
expressed	O
210-aa	O
protein	O
,	O
frataxin	O
,	O
which	O
is	O
located	O
in	O
mitochondria	O
and	O
is	O
severely	O
reduced	O
in	O
FRDA	B-Modifier
patients	O
.	O
Frataxin	O
function	O
is	O
still	O
unknown	O
but	O
the	O
knockout	O
of	O
the	O
yeast	O
frataxin	O
homologue	O
gene	O
(	O
YFH1	O
)	O
showed	O
a	O
severe	O
defect	O
of	O
mitochondrial	O
respiration	O
and	O
loss	O
of	O
mtDNA	O
associated	O
with	O
elevated	O
intramitochondrial	O
iron	O
.	O
Here	O
we	O
report	O
in	O
vivo	O
evidence	O
of	O
impaired	O
mitochondrial	O
respiration	O
in	O
skeletal	O
muscle	O
of	O
FRDA	B-Modifier
patients	O
.	O
Using	O
phosphorus	O
magnetic	O
resonance	O
spectroscopy	O
we	O
demonstrated	O
a	O
maximum	O
rate	O
of	O
muscle	O
mitochondrial	O
ATP	O
production	O
(	O
V	O
(	O
max	O
)	O
)	O
below	O
the	O
normal	O
range	O
in	O
all	O
12	O
FRDA	B-Modifier
patients	O
and	O
a	O
strong	O
negative	O
correlation	O
between	O
mitochondrial	O
V	O
(	O
max	O
)	O
and	O
the	O
number	O
of	O
GAA	O
repeats	O
in	O
the	O
smaller	O
allele	O
.	O
Our	O
results	O
show	O
that	O
FRDA	B-SpecificDisease
is	O
a	O
nuclear-encoded	O
mitochondrial	B-DiseaseClass
disorder	I-DiseaseClass
affecting	O
oxidative	O
phosphorylation	O
and	O
give	O
a	O
rationale	O
for	O
treatments	O
aimed	O
to	O
improve	O
mitochondrial	O
function	O
in	O
this	O
condition	O
.	O
.	O

7726234	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
and	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
in	O
the	O
same	O
patient.	O
We	O
report	O
on	O
the	O
first	O
patient	O
identified	O
with	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
and	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)	O
.	O
The	O
family	O
of	O
the	O
propositus	O
had	O
a	O
strong	O
history	O
of	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
,	O
and	O
there	O
was	O
an	O
intrafamilial	O
pathological	O
expansion	O
of	O
the	O
responsible	O
CTG	O
repeat	O
between	O
the	O
mildly	O
affected	O
mother	O
(	O
160	O
repeats	O
;	O
normal	O
27	O
repeats	O
)	O
and	O
her	O
more	O
severely	O
affected	O
son	O
(	O
650	O
repeats	O
)	O
,	O
and	O
his	O
sister	O
(	O
650	O
repeats	O
)	O
.	O
The	O
propositus	O
was	O
an	O
isolated	O
case	O
of	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
with	O
marked	O
dystrophin	B-SpecificDisease
deficiency	I-SpecificDisease
in	O
muscle	O
biopsy	O
.	O
The	O
patient	O
was	O
still	O
ambulatory	O
post	O
age	O
16	O
.	O
Myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
could	O
interfere	O
to	O
some	O
extent	O
with	O
the	O
progression	O
of	O
Duchenne	B-SpecificDisease
dystrophy	I-SpecificDisease
.	O
However	O
,	O
other	O
interpretations	O
are	O
possible	O
.	O
Twelve	O
percent	O
of	O
dystrophin	O
revertant	O
fibers	O
as	O
observed	O
by	O
immunohistochemistry	O
could	O
be	O
sufficient	O
to	O
ameliorate	O
typical	O
DMD	B-Modifier
clinical	O
severity	O
,	O
or	O
the	O
patient	O
may	O
present	O
a	O
somatic	O
mosaic	O
.	O
The	O
pathophysiological	O
interactions	O
of	O
these	O
two	O
unlinked	O
disorders	O
are	O
discussed	O
at	O
the	O
clinical	O
and	O
histopathological	O
levels	O
.	O
.	O

10466420	O
Homozygosity	O
for	O
a	O
novel	O
DTDST	O
mutation	O
in	O
a	O
child	O
with	O
a	O
"broad	O
bone-platyspondylic"	O
variant	O
of	O
diastrophic	B-SpecificDisease
dysplasia.	I-SpecificDisease
Atypical	O
or	O
variant	O
forms	O
of	O
well-known	O
chondrodysplasias	B-DiseaseClass
may	O
pose	O
diagnostic	O
problems	O
.	O
We	O
report	O
on	O
a	O
girl	O
with	O
clinical	O
features	O
suggesting	O
diastrophic	B-SpecificDisease
dysplasia	I-SpecificDisease
but	O
with	O
unusual	O
radiographic	O
features	O
including	O
severe	O
platyspondyly	B-DiseaseClass
,	O
wide	B-DiseaseClass
metaphyses	I-DiseaseClass
,	O
and	O
fibular	B-DiseaseClass
overgrowth	I-DiseaseClass
,	O
which	O
are	O
partially	O
reminiscent	O
of	O
metatropic	B-SpecificDisease
dysplasia	I-SpecificDisease
.	O
The	O
diagnosis	O
was	O
clarified	O
by	O
molecular	O
analysis	O
of	O
the	O
DTDST	O
gene	O
,	O
which	O
revealed	O
homozygosity	O
for	O
a	O
previously	O
undescribed	O
mutation	O
leading	O
to	O
a	O
Q454P	O
substitution	O
in	O
the	O
10th	O
transmembrane	O
domain	O
of	O
the	O
DTDST	O
sulfate	O
transporter	O
.	O
Molecular	O
analysis	O
may	O
be	O
of	O
particular	O
value	O
in	O
such	O
atypical	O
cases	O
.	O
.	O

10078749	O
GCH1	O
mutation	O
in	O
a	O
patient	O
with	O
adult-onset	O
oromandibular	B-SpecificDisease
dystonia	I-SpecificDisease
.	O
The	O
authors	O
report	O
a	O
mutation	O
in	O
exon	O
5	O
of	O
GCH1	O
in	O
a	O
patient	O
with	O
adult-onset	O
oromandibular	B-SpecificDisease
dystonia	I-SpecificDisease
and	O
no	O
obvious	O
family	O
history	O
of	O
dystonia	B-DiseaseClass
.	O
The	O
patient	O
responded	O
positively	O
to	O
treatment	O
with	O
L-dopa	O
.	O
These	O
findings	O
demonstrate	O
that	O
GCH1	O
mutations	O
must	O
be	O
considered	O
even	O
in	O
patients	O
with	O
dystonic	B-Modifier
symptoms	O
not	O
typical	O
of	O
dopa-responsive	B-SpecificDisease
dystonia	I-SpecificDisease
.	O

8301658	O
X	B-SpecificDisease
linked	I-SpecificDisease
recessive	I-SpecificDisease
thrombocytopenia.	I-SpecificDisease
A	O
Saudi	O
Arab	O
boy	O
presented	O
in	O
early	O
childhood	O
with	O
thrombocytopenia	B-SpecificDisease
,	O
morphologically	O
large	O
and	O
normal	O
sized	O
platelets	O
,	O
increased	O
mean	O
platelet	O
volume	O
,	O
and	O
a	O
hypermegakaryocytic	O
bone	O
marrow	O
.	O
There	O
was	O
no	O
clinical	O
and	O
laboratory	O
evidence	O
of	O
any	O
significant	O
immunological	B-DiseaseClass
abnormalities	I-DiseaseClass
.	O
Similar	O
findings	O
in	O
two	O
other	O
brothers	O
suggested	O
strongly	O
that	O
they	O
were	O
all	O
suffering	O
from	O
an	O
X	B-SpecificDisease
linked	I-SpecificDisease
recessive	I-SpecificDisease
thrombocytopenic	I-SpecificDisease
disorder	I-SpecificDisease
.	O
Results	O
of	O
DNA	O
analysis	O
with	O
the	O
probe	O
M27	O
beta	O
are	O
consistent	O
with	O
X	O
linkage	O
and	O
indicate	O
also	O
that	O
the	O
locus	O
of	O
the	O
relevant	O
gene	O
lies	O
close	O
to	O
or	O
is	O
identical	O
to	O
the	O
locus	O
of	O
the	O
gene	O
for	O
the	O
Wiskott-Aldrich	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
WAS	B-SpecificDisease
)	O
.	O
Because	O
of	O
various	O
features	O
which	O
include	O
the	O
presence	O
of	O
large	O
and	O
normal	O
sized	O
platelets	O
(	O
rather	O
than	O
small	O
platelets	O
)	O
and	O
freedom	O
from	O
significant	O
immune	B-DiseaseClass
deficiencies	I-DiseaseClass
,	O
it	O
is	O
likely	O
that	O
the	O
X	B-SpecificDisease
linked	I-SpecificDisease
recessive	I-SpecificDisease
thrombocytopenia	I-SpecificDisease
in	O
this	O
family	O
is	O
an	O
isolated	O
entity	O
quite	O
distinct	O
from	O
the	O
classical	O
WAS	B-Modifier
phenotype	O
.	O
However	O
,	O
a	O
modified	O
expression	O
of	O
the	O
WAS	B-Modifier
gene	O
producing	O
a	O
mild	O
phenotypic	O
variant	O
cannot	O
be	O
excluded	O
entirely	O
.	O
.	O

8440142	O
Detection	O
of	O
a	O
new	O
submicroscopic	O
Norrie	B-Modifier
disease	I-Modifier
deletion	O
interval	O
with	O
a	O
novel	O
DNA	O
probe	O
isolated	O
by	O
differential	O
Alu	O
PCR	O
fingerprint	O
cloning.	O
Differential	O
Alu	O
PCR	O
fingerprint	O
cloning	O
was	O
used	O
to	O
isolate	O
a	O
DNA	O
probe	O
from	O
the	O
Xp11	O
.	O
4--	O
>	O
p11	O
.	O
21	O
region	O
of	O
the	O
human	O
X	O
chromosome	O
.	O
This	O
novel	O
sequence	O
,	O
cpXr318	O
(	O
DXS742	O
)	O
,	O
detects	O
a	O
new	O
submicroscopic	O
deletion	O
interval	O
at	O
the	O
Norrie	B-Modifier
disease	I-Modifier
locus	O
(	O
NDP	O
)	O
.	O
Combining	O
our	O
data	O
with	O
the	O
consensus	O
genetic	O
map	O
of	O
the	O
proximal	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
we	O
propose	O
the	O
physical	O
order	O
Xcen-DXS14-DXS255-	O
(	O
DXS426	O
,	O
TIMP	O
)	O
-	O
(	O
DXS742-	O
(	O
[	O
MAOB-MAOA-DXS7	O
]	O
,	O
NDP	O
)	O
-DXS77-DXS228	O
)	O
-DXS209-DXS148-DXS196-	O
+	O
+	O
+	O
Xpter	O
.	O
The	O
cpXr318	O
probe	O
and	O
a	O
subclone	O
from	O
a	O
cosmid	O
corresponding	O
to	O
the	O
DXS7	O
locus	O
were	O
converted	O
into	O
sequence-tagged	O
sites	O
.	O
Finally	O
,	O
DXS742	O
,	O
DSX7	O
,	O
DXS77	O
,	O
and	O
MAOA	O
were	O
integrated	O
into	O
a	O
physical	O
map	O
spanning	O
the	O
Norrie	B-Modifier
disease	I-Modifier
locus	O

8116611	O
Characteristics	O
of	O
intergenerational	O
contractions	O
of	O
the	O
CTG	O
repeat	O
in	O
myotonic	B-SpecificDisease
dystrophy.	I-SpecificDisease
In	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
,	O
the	O
size	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
DM	B-Modifier
kinase	O
gene	O
generally	O
increases	O
in	O
successive	O
generations	O
with	O
clinical	O
evidence	O
of	O
anticipation	O
.	O
However	O
,	O
there	O
have	O
also	O
been	O
cases	O
with	O
an	O
intergenerational	O
contraction	O
of	O
the	O
repeat	O
.	O
We	O
examined	O
1	O
,	O
489	O
DM	B-Modifier
parent-offspring	O
pairs	O
,	O
of	O
which	O
95	O
(	O
6	O
.	O
4	O
%	O
)	O
showed	O
such	O
contractions	O
in	O
peripheral	O
blood	O
leukocytes	O
(	O
PBL	O
)	O
.	O
In	O
56	O
of	O
the	O
95	O
pairs	O
,	O
clinical	O
data	O
allowed	O
an	O
analysis	O
of	O
their	O
anticipation	O
status	O
.	O
It	O
is	O
surprising	O
that	O
anticipation	O
occurred	O
in	O
27	O
(	O
48	O
%	O
)	O
of	O
these	O
56	O
pairs	O
,	O
while	O
none	O
clearly	O
showed	O
a	O
later	O
onset	O
of	O
DM	B-SpecificDisease
in	O
the	O
symptomatic	O
offspring	O
.	O
The	O
contraction	O
occurred	O
in	O
76	O
(	O
10	O
%	O
)	O
of	O
753	O
paternal	O
transmissions	O
and	O
in	O
19	O
(	O
3	O
%	O
)	O
of	O
736	O
maternal	O
transmissions	O
.	O
Anticipation	O
was	O
observed	O
more	O
frequently	O
in	O
maternal	O
(	O
85	O
%	O
)	O
than	O
in	O
paternal	O
(	O
37	O
%	O
)	O
transmissions	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O
The	O
parental	O
repeat	O
size	O
correlated	O
with	O
the	O
size	O
of	O
intergenerational	O
contraction	O
(	O
r2	O
=	O
.	O
50	O
,	O
P	O
<	O
<	O
.	O
001	O
)	O
,	O
and	O
the	O
slope	O
of	O
linear	O
regression	O
was	O
steeper	O
in	O
paternal	O
(	O
-	O
.	O
62	O
)	O
than	O
in	O
maternal	O
(	O
-	O
.	O
30	O
)	O
transmissions	O
(	O
P	O
<	O
<	O
.	O
001	O
)	O
.	O
Sixteen	O
DM	B-Modifier
parents	O
had	O
multiple	O
DM	B-Modifier
offspring	O
with	O
the	O
CTG	O
repeat	O
contractions	O
.	O
This	O
frequency	O
was	O
higher	O
than	O
the	O
frequency	O
expected	O
from	O
the	O
probability	O
of	O
the	O
repeat	O
contractions	O
(	O
6	O
.	O
4	O
%	O
)	O
and	O
the	O
size	O
of	O
DM	B-Modifier
sib	O
population	O
(	O
1	O
.	O
54	O
DM	B-Modifier
offspring	O
per	O
DM	B-Modifier
parent	O
,	O
in	O
968	O
DM	B-Modifier
parents	O
)	O
.	O
We	O
conclude	O
that	O
(	O
1	O
)	O
intergenerational	O
contractions	O
of	O
the	O
CTG	O
repeat	O
in	O
leukocyte	O
DNA	O
frequently	O
accompanies	O
apparent	O
anticipation	O
,	O
especially	O
when	O
DM	B-SpecificDisease
is	O
maternally	O
transmitted	O
,	O
and	O
(	O
2	O
)	O
the	O
paternal	O
origin	O
of	O
the	O
repeat	O
and	O
the	O
presence	O
of	O
the	O
repeat	O
contraction	O
in	O
a	O
sibling	O
increase	O
the	O
probability	O
of	O
the	O
CTG	O
repeat	O
contraction	O

3678494	O
Nebulin	O
and	O
titin	O
expression	O
in	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
appears	O
normal.	O
Monoclonal	O
antibodies	O
which	O
recognize	O
different	O
epitopes	O
on	O
either	O
titin	O
or	O
nebulin	O
show	O
normal	O
staining	O
patterns	O
on	O
frozen	O
sections	O
of	O
three	O
muscle	O
biopsies	O
of	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)	O
.	O
Gel	O
electrophoresis	O
and	O
immunoblotting	O
performed	O
on	O
two	O
of	O
these	O
muscle	O
biopsies	O
show	O
the	O
normal	O
pattern	O
of	O
titin	O
and	O
nebulin	O
polypeptides	O
.	O
Since	O
the	O
donor	O
of	O
one	O
of	O
these	O
biopsies	O
has	O
a	O
large	O
deletion	O
of	O
the	O
5-region	O
of	O
the	O
DMD	B-Modifier
gene	O
,	O
our	O
results	O
argue	O
against	O
the	O
recent	O
proposal	O
that	O
nebulin	O
is	O
the	O
gene	O
mutated	O
in	O
DMD	B-SpecificDisease
.	O
.	O

10366443	O
Molecular	O
basis	O
of	O
feline	O
beta-glucuronidase	B-SpecificDisease
deficiency:	I-SpecificDisease
an	O
animal	O
model	O
of	O
mucopolysaccharidosis	B-SpecificDisease
VII.	I-SpecificDisease
A	O
family	O
of	O
domestic	O
cats	O
was	O
found	O
that	O
exhibited	O
clinical	O
and	O
biochemical	B-DiseaseClass
abnormalities	I-DiseaseClass
consistent	O
with	O
mucopolysaccharidosis	B-SpecificDisease
VII	I-SpecificDisease
,	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
lysosomal	I-DiseaseClass
storage	I-DiseaseClass
disorder	I-DiseaseClass
caused	O
by	O
beta-glucuronidase	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
beta-Glucuronidase	O
activity	O
was	O
undetectable	O
in	O
affected	O
cat	O
fibroblasts	O
and	O
restored	O
by	O
retroviral	O
gene	O
transfer	O
of	O
rat	O
beta-glucuronidase	O
cDNA	O
.	O
beta-Glucuronidase	O
mRNA	O
was	O
normal	O
in	O
affected	O
cat	O
testis	O
by	O
Northern	O
blot	O
analysis	O
.	O
Normal	O
feline	O
beta-glucuronidase	O
cDNA	O
was	O
cloned	O
and	O
characterized	O
,	O
and	O
amplified	O
from	O
affected	O
cat	O
fibroblasts	O
by	O
reverse	O
transcription	O
coupled	O
polymerase	O
chain	O
reaction	O
.	O
There	O
was	O
a	O
G-to-A	O
transition	O
in	O
the	O
affected	O
cat	O
cDNA	O
that	O
predicted	O
an	O
E351K	O
substitution	O
,	O
destroyed	O
a	O
BssSI	O
site	O
,	O
and	O
eliminated	O
GUSB	O
enzymatic	O
activity	O
in	O
expression	O
studies	O
.	O
Multiple	O
species	O
comparison	O
and	O
the	O
crystal	O
structure	O
of	O
human	O
beta-glucuronidase	O
indicated	O
that	O
E351	O
is	O
a	O
highly	O
conserved	O
residue	O
most	O
likely	O
essential	O
in	O
maintenance	O
of	O
the	O
enzymes	O
conformation	O
.	O
BssSI	O
digestion	O
of	O
polymerase	O
chain	O
reaction	O
products	O
amplified	O
from	O
genomic	O
DNA	O
indicated	O
that	O
affected	O
cats	O
were	O
homozygous	O
and	O
cats	O
with	O
half-normal	O
beta-glucuronidase	O
activity	O
were	O
heterozygous	O
for	O
the	O
missense	O
mutation	O
.	O
Carriers	O
identified	O
in	O
this	O
manner	O
produced	O
affected	O
kittens	O
in	O
prospective	O
breedings	O
,	O
and	O
a	O
feline	O
MPS	B-Modifier
VII	I-Modifier
breeding	O
colony	O
has	O
been	O
established	O
.	O
.	O

7811247	O
X-linked	B-SpecificDisease
adrenoleukodystrophy	I-SpecificDisease
(ALD):	O
a	O
novel	O
mutation	O
of	O
the	O
ALD	B-Modifier
gene	O
in	O
6	O
members	O
of	O
a	O
family	O
presenting	O
with	O
5	O
different	O
phenotypes.	O
Fragments	O
of	O
the	O
adrenoleukodystrophy	B-Modifier
(	O
ALD	B-Modifier
)	O
cDNA	O
from	O
a	O
patient	O
with	O
adolescent	B-SpecificDisease
ALD	I-SpecificDisease
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
subcloned	O
.	O
Bidirectional	O
sequencing	O
of	O
the	O
entire	O
coding	O
ALD	B-Modifier
gene	O
disclosed	O
a	O
cytosine	O
to	O
guanine	O
transversion	O
at	O
nucleotide	O
1451	O
in	O
exon	O
five	O
,	O
resulting	O
in	O
substitution	O
of	O
proline	O
484	O
by	O
arginine	O
.	O
Five	O
of	O
nine	O
siblings	O
of	O
the	O
patient	O
,	O
comprising	O
two	O
cerebral	B-SpecificDisease
ALD	I-SpecificDisease
,	O
one	O
adrenomyeloneuropathy	B-SpecificDisease
,	O
one	O
Addison	B-SpecificDisease
only	I-SpecificDisease
as	O
well	O
as	O
the	O
symptomatic	O
mother	O
(	O
all	O
accumulating	O
very	O
long	O
chain	O
fatty	O
acids	O
)	O
carried	O
this	O
mutation	O
,	O
which	O
was	O
not	O
found	O
in	O
the	O
unaffected	O
persons	O
,	O
in	O
five	O
unrelated	O
ALD	B-Modifier
patients	O
,	O
and	O
in	O
twenty	O
controls	O
.	O
We	O
propose	O
that	O
this	O
missense	O
mutation	O
generated	O
the	O
disease	O
per	O
se	O
as	O
well	O
as	O
the	O
metabolic	O
defect	O
;	O
the	O
different	O
phenotypes	O
,	O
however	O
,	O
must	O
have	O
originated	O
by	O
means	O
of	O
additional	O
pathogenetic	O
factors	O
.	O
.	O

10417279	O
Proteolipoprotein	O
gene	O
analysis	O
in	O
82	O
patients	O
with	O
sporadic	O
Pelizaeus-Merzbacher	B-SpecificDisease
Disease:	I-SpecificDisease
duplications,	O
the	O
major	O
cause	O
of	O
the	O
disease,	O
originate	O
more	O
frequently	O
in	O
male	O
germ	O
cells,	O
but	O
point	O
mutations	O
do	O
not.	O
The	O
Clinical	O
European	O
Network	O
on	O
Brain	B-DiseaseClass
Dysmyelinating	I-DiseaseClass
Disease.	I-DiseaseClass
Pelizaeus-Merzbacher	B-SpecificDisease
Disease	I-SpecificDisease
(	O
PMD	B-SpecificDisease
)	O
is	O
an	O
X-linked	B-DiseaseClass
developmental	I-DiseaseClass
defect	I-DiseaseClass
of	I-DiseaseClass
myelination	I-DiseaseClass
affecting	O
the	O
central	O
nervous	O
system	O
and	O
segregating	O
with	O
the	O
proteolipoprotein	O
(	O
PLP	O
)	O
locus	O
.	O
Investigating	O
82	O
strictly	O
selected	O
sporadic	O
cases	O
of	O
PMD	B-SpecificDisease
,	O
we	O
found	O
PLP	O
mutations	O
in	O
77	O
%	O
;	O
complete	O
PLP-gene	O
duplications	O
were	O
the	O
most	O
frequent	O
abnormality	O
(	O
62	O
%	O
)	O
,	O
whereas	O
point	O
mutations	O
in	O
coding	O
or	O
splice-site	O
regions	O
of	O
the	O
gene	O
were	O
involved	O
less	O
frequently	O
(	O
38	O
%	O
)	O
.	O
We	O
analyzed	O
the	O
maternal	O
status	O
of	O
56	O
cases	O
to	O
determine	O
the	O
origin	O
of	O
both	O
types	O
of	O
PLP	O
mutation	O
,	O
since	O
this	O
is	O
relevant	O
to	O
genetic	O
counseling	O
.	O
In	O
the	O
22	O
point	O
mutations	O
,	O
68	O
%	O
of	O
mothers	O
were	O
heterozygous	O
for	O
the	O
mutation	O
,	O
a	O
value	O
identical	O
to	O
the	O
two-thirds	O
of	O
carrier	O
mothers	O
that	O
would	O
be	O
expected	O
if	O
there	O
were	O
an	O
equal	O
mutation	O
rate	O
in	O
male	O
and	O
female	O
germ	O
cells	O
.	O
In	O
sharp	O
contrast	O
,	O
among	O
the	O
34	O
duplicated	O
cases	O
,	O
91	O
%	O
of	O
mothers	O
were	O
carriers	O
,	O
a	O
value	O
significantly	O
(	O
chi2	O
=	O
9	O
.	O
20	O
,	O
P	O
<	O
.	O
01	O
)	O
in	O
favor	O
of	O
a	O
male	O
bias	O
,	O
with	O
an	O
estimation	O
of	O
the	O
male	O
/	O
female	O
mutation	O
frequency	O
(	O
k	O
)	O
of	O
9	O
.	O
3	O
3	O
.	O
Moreover	O
,	O
we	O
observed	O
the	O
occurrence	O
of	O
de	O
novo	O
mutations	O
between	O
parental	O
and	O
grandparental	O
generations	O
in	O
17	O
three-generation	O
families	O
,	O
which	O
allowed	O
a	O
direct	O
estimation	O
of	O
the	O
k	O
value	O
(	O
k	O
=	O
11	O
)	O
.	O
Again	O
,	O
a	O
significant	O
male	O
mutation	O
imbalance	O
was	O
observed	O
only	O
for	O
the	O
duplications	O
.	O

10484772	O
Coats"	B-SpecificDisease
disease	I-SpecificDisease
of	O
the	O
retina	O
(unilateral	O
retinal	B-SpecificDisease
telangiectasis)	I-SpecificDisease
caused	O
by	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene:	O
a	O
role	O
for	O
norrin	O
in	O
retinal	O
angiogenesis.	O
Coats	B-SpecificDisease
disease	I-SpecificDisease
is	O
characterized	O
by	O
abnormal	B-DiseaseClass
retinal	I-DiseaseClass
vascular	I-DiseaseClass
development	I-DiseaseClass
(	O
so-called	O
retinal	B-SpecificDisease
telangiectasis	I-SpecificDisease
)	O
which	O
results	O
in	O
massive	O
intraretinal	B-CompositeMention
and	I-CompositeMention
subretinal	I-CompositeMention
lipid	I-CompositeMention
accumulation	I-CompositeMention
(	O
exudative	B-DiseaseClass
retinal	I-DiseaseClass
detachment	I-DiseaseClass
)	O
.	O
The	O
classical	O
form	O
of	O
Coats	B-SpecificDisease
disease	I-SpecificDisease
is	O
almost	O
invariably	O
isolated	O
,	O
unilateral	O
and	O
seen	O
in	O
males	O
.	O
A	O
female	O
with	O
a	O
unilateral	O
variant	O
of	O
Coats	B-SpecificDisease
disease	I-SpecificDisease
gave	O
birth	O
to	O
a	O
son	O
affected	O
by	O
Norrie	B-SpecificDisease
disease	I-SpecificDisease
.	O
Both	O
carried	O
a	O
missense	O
mutation	O
within	O
the	O
NDP	O
gene	O
on	O
chromosome	O
Xp11	O
.	O
2	O
2	O
.	O
Subsequently	O
analysis	O
of	O
the	O
retinas	O
of	O
nine	O
enucleated	O
eyes	O
from	O
males	O
with	O
Coats	B-SpecificDisease
disease	I-SpecificDisease
demonstrated	O
in	O
one	O
a	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
which	O
was	O
not	O
present	O
within	O
non-retinal	O
tissue	O
.	O
We	O
suggest	O
that	O
Coats	B-SpecificDisease
telangiectasis	I-SpecificDisease
is	O
secondary	O
to	O
somatic	O
mutation	O
in	O
the	O
NDP	O
gene	O
which	O
results	O
in	O
a	O
deficiency	B-DiseaseClass
of	I-DiseaseClass
norrin	I-DiseaseClass
(	O
the	O
protein	O
product	O
of	O
the	O
NDP	O
gene	O
)	O
within	O
the	O
developing	O
retina	O
.	O
This	O
supports	O
recent	O
observations	O
that	O
the	O
protein	O
is	O
critical	O
for	O
normal	O
retinal	O
vasculogenesis	O
.	O

3876122	O
Heterogeneity	O
of	O
type	B-SpecificDisease
I	I-SpecificDisease
von	I-SpecificDisease
Willebrand	I-SpecificDisease
disease:	I-SpecificDisease
evidence	O
for	O
a	O
subgroup	O
with	O
an	O
abnormal	O
von	B-Modifier
Willebrand	I-Modifier
factor.	O
Type	B-SpecificDisease
I	I-SpecificDisease
von	I-SpecificDisease
Willebrand	I-SpecificDisease
disease	I-SpecificDisease
(	O
vWD	B-SpecificDisease
)	O
is	O
characterized	O
by	O
equally	O
low	O
plasma	O
concentrations	O
of	O
von	B-Modifier
Willebrand	I-Modifier
factor	O
antigen	O
(	O
vWF	O
Ag	O
)	O
and	O
ristocetin	O
cofactor	O
(	O
RiCof	O
)	O
and	O
by	O
the	O
presence	O
of	O
all	O
vWF	O
multimers	O
in	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
-agarose	O
gel	O
electrophoresis	O
.	O
For	O
17	O
patients	O
(	O
13	O
kindreds	O
)	O
diagnosed	O
with	O
these	O
criteria	O
,	O
we	O
have	O
studied	O
the	O
platelet	O
contents	O
of	O
vWF	O
Ag	O
and	O
RiCof	O
and	O
the	O
changes	O
of	O
these	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
.	O
Platelet	O
vWF	O
Ag	O
and	O
RiCof	O
were	O
normal	O
in	O
four	O
kindreds	O
(	O
called	O
"	O
platelet	O
normal	O
"	O
subgroup	O
)	O
;	O
following	O
1-deamino-8-D-arginine	O
vasopressin	O
;	O
plasma	O
vWF	O
Ag	O
,	O
RiCof	O
and	O
the	O
bleeding	O
time	O
(	O
BT	O
)	O
became	O
normal	O
.	O
In	O
six	O
kindreds	O
,	O
platelet	O
vWF	O
Ag	O
and	O
RiCof	O
were	O
equally	O
low	O
(	O
platelet	O
low	O
)	O
;	O
after	O
DDAVP	O
,	O
plasma	O
vWF	O
Ag	O
and	O
RiCof	O
remained	O
low	O
,	O
and	O
the	O
BT	O
was	O
prolonged	O
.	O
In	O
three	O
additional	O
kindreds	O
,	O
platelets	O
contained	O
normal	O
concentrations	O
of	O
vWF	O
Ag	O
,	O
but	O
RiCof	O
was	O
very	O
low	O
(	O
platelet	O
discordant	O
)	O
;	O
even	O
though	O
a	O
complete	O
set	O
of	O
multimers	O
was	O
found	O
in	O
plasma	O
and	O
platelets	O
,	O
there	O
was	O
a	O
relatively	O
small	O
amount	O
of	O
large	O
multimers	O
.	O
After	O
DDAVP	O
,	O
plasma	O
vWF	O
Ag	O
became	O
normal	O
,	O
but	O
RiCof	O
remained	O
low	O
and	O
the	O
BT	O
was	O
very	O
prolonged	O
.	O
These	O
findings	O
demonstrated	O
that	O
there	O
can	O
be	O
an	O
abnormal	O
vWF	O
(	O
RiCof	O
less	O
than	O
vWF	O
Ag	O
)	O
even	O
in	O
type	B-SpecificDisease
I	I-SpecificDisease
vWD	I-SpecificDisease
,	O
coexisting	O
with	O
a	O
complete	O
set	O
of	O
vWF	O
multimers	O
(	O
platelet	O
discordant	O
)	O
;	O
that	O
the	O
abnormal	O
vWF	O
can	O
be	O
shown	O
more	O
clearly	O
in	O
platelets	O
than	O
in	O
plasma	O
or	O
else	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
;	O
and	O
that	O
DDAVP	O
normalizes	O
the	O
BT	O
only	O
in	O
those	O
patients	O
with	O
normal	O
platelet	O
levels	O
of	O
both	O
vWF	O
Ag	O
and	O
RiCof	O
(	O
platelet	O
normal	O
)	O
.	O
.	O

1316718	O
Coincident	O
Kaposi	B-SpecificDisease
sarcoma	I-SpecificDisease
and	O
T-cell	B-SpecificDisease
lymphoma	I-SpecificDisease
in	O
a	O
patient	O
with	O
the	O
Wiskott-Aldrich	B-SpecificDisease
syndrome.	I-SpecificDisease
A	O
24	O
year	O
old	O
male	O
with	O
a	O
history	O
of	O
eczema	B-DiseaseClass
,	O
recurrent	O
mild	O
infections	O
,	O
and	O
thrombocytopenia	B-SpecificDisease
consistent	O
with	O
the	O
Wiskott-Aldrich	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
WAS	B-SpecificDisease
)	O
presented	O
with	O
a	O
mediastinal	O
mass	O
,	O
generalized	O
lymphadenopathy	B-SpecificDisease
,	O
splenomegaly	B-SpecificDisease
,	O
and	O
severe	O
thrombocytopenia	B-SpecificDisease
.	O
Studies	O
of	O
immune	O
function	O
including	O
immunoglobulin	O
levels	O
and	O
T-cell	O
subsets	O
were	O
normal	O
.	O
Furthermore	O
,	O
his	O
T	O
lymphocytes	O
proliferated	O
normally	O
in	O
response	O
to	O
phytohemagglutinin	O
,	O
concanavalin	O
A	O
,	O
and	O
the	O
combination	O
of	O
neuraminidase	O
/	O
galactose	O
oxidase	O
.	O
However	O
,	O
their	O
proliferative	O
responses	O
to	O
anti-CD43	O
antibody	O
and	O
periodate	O
were	O
diminished	O
,	O
consistent	O
with	O
the	O
clinical	O
diagnosis	O
of	O
WAS	B-SpecificDisease
.	O
An	O
initial	O
inguinal	O
lymph	O
node	O
biopsy	O
surprisingly	O
revealed	O
Kaposi	B-SpecificDisease
sarcoma	I-SpecificDisease
.	O
However	O
,	O
following	O
splenectomy	O
to	O
increase	O
the	O
platelet	O
count	O
,	O
biopsy	O
of	O
the	O
mediastinal	O
mass	O
revealed	O
T-cell	B-SpecificDisease
large	I-SpecificDisease
cell	I-SpecificDisease
lymphoma	I-SpecificDisease
.	O
Studies	O
of	O
biopsied	O
tissue	O
for	O
the	O
presence	O
of	O
Epstein-Barr	B-SpecificDisease
virus	I-SpecificDisease
and	O
cytomegalovirus	B-SpecificDisease
were	O
negative	O
,	O
as	O
were	O
studies	O
of	O
blood	O
,	O
including	O
the	O
polymerase	O
chain	O
reaction	O
,	O
for	O
the	O
presence	O
of	O
the	O
human	B-SpecificDisease
immunodeficiency	I-SpecificDisease
virus	I-SpecificDisease
(	O
HIV	B-SpecificDisease
)	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
Kaposi	B-SpecificDisease
sarcoma	I-SpecificDisease
arising	O
in	O
a	O
patient	O
with	O
a	O
congenital	B-DiseaseClass
immunodeficiency	I-DiseaseClass
syndrome	I-DiseaseClass
.	O
Although	O
Kaposi	B-SpecificDisease
sarcoma	I-SpecificDisease
can	O
arise	O
in	O
the	O
face	O
of	O
the	O
severe	O
immunosuppression	O
that	O
follows	O
allograft	O
transplantation	O
and	O
in	O
patients	O
infected	O
with	O
HIV	B-SpecificDisease
,	O
we	O
postulate	O
that	O
longevity	O
in	O
the	O
face	O
of	O
mild	O
immunosuppression	O
was	O
the	O
major	O
factor	O
in	O
the	O
development	O
of	O
Kaposi	B-SpecificDisease
sarcoma	I-SpecificDisease
in	O
this	O
patient	O
.	O
.	O

7166314	O
A	O
new	O
glucose-6-phosphate	O
dehydrogenase	O
variant	O
(G6PD	O
Nagano)	O
associated	O
with	O
congenital	B-SpecificDisease
hemolytic	I-SpecificDisease
anemia.	I-SpecificDisease
A	O
new	O
glucose-6-phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
variant	O
associated	O
with	O
chronic	B-SpecificDisease
nonspherocytic	I-SpecificDisease
hemolytic	I-SpecificDisease
anemia	I-SpecificDisease
was	O
reported	O
.	O
The	O
patient	O
,	O
a	O
6-year-old	O
Japanese	O
male	O
,	O
was	O
noticed	O
to	O
have	O
hemolytic	B-SpecificDisease
anemia	I-SpecificDisease
soon	O
after	O
birth	O
,	O
and	O
a	O
diagnosis	O
of	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
was	O
made	O
at	O
the	O
age	O
of	O
2	O
.	O
He	O
had	O
episodes	O
of	O
hemolytic	B-DiseaseClass
crisis	I-DiseaseClass
several	O
times	O
after	O
upper	B-SpecificDisease
respiratory	I-SpecificDisease
infection	I-SpecificDisease
.	O
G6PD	O
activity	O
of	O
the	O
patient	O
was	O
5	O
.	O
5	O
%	O
of	O
normal	O
.	O
The	O
enzymatic	O
characteristics	O
were	O
examined	O
when	O
he	O
was	O
5	O
years	O
old	O
,	O
and	O
his	O
G6PD	O
showed	O
faster-than-normal	O
electrophoretic	O
mobility	O
,	O
low	O
Km	O
G6P	O
,	O
high	O
Km	O
NADP	O
,	O
low	O
Ki	O
NADPH	O
,	O
normal	O
utilization	O
of	O
substrate	O
analogues	O
,	O
heat	O
instability	O
,	O
and	O
a	O
normal	O
pH	O
optimum	O
curve	O
.	O
From	O
these	O
results	O
,	O
this	O
was	O
considered	O
to	O
be	O
a	O
new	O
variant	O
and	O
was	O
designated	O
G6PD	O
Nagano	O
.	O
Infection-induced	O
hemolysis	B-SpecificDisease
and	O
chronic	B-SpecificDisease
hemolytic	I-SpecificDisease
anemia	I-SpecificDisease
seem	O
to	O
be	O
due	O
to	O
markedly	O
impaired	O
enzyme	O
activity	O
and	O
thermal	O
instability	O
.	O

3455778	O
Retroviral-mediated	O
gene	O
transfer	O
of	O
human	O
phenylalanine	O
hydroxylase	O
into	O
NIH	O
3T3	O
and	O
hepatoma	B-Modifier
cells.	O
Phenylketonuria	B-SpecificDisease
(	O
PKU	B-SpecificDisease
)	O
is	O
caused	O
by	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
hepatic	I-SpecificDisease
enzyme	I-SpecificDisease
phenylalanine	I-SpecificDisease
hydroxylase	I-SpecificDisease
(	O
PAH	O
)	O
.	O
A	O
full-length	O
human	O
PAH	O
cDNA	O
sequence	O
has	O
been	O
inserted	O
into	O
pzip-neoSV	O
(	O
X	O
)	O
,	O
which	O
is	O
a	O
retroviral	O
vector	O
containing	O
the	O
bacterial	O
neo	O
gene	O
.	O
The	O
recombinant	O
has	O
been	O
transfected	O
into	O
psi	O
2	O
cells	O
,	O
which	O
provide	O
synthesis	O
of	O
the	O
retroviral	O
capsid	O
.	O
Recombinant	O
virus	O
was	O
detected	O
in	O
the	O
culture	O
medium	O
of	O
the	O
transfected	O
psi	O
2	O
cells	O
,	O
which	O
is	O
capable	O
of	O
transmitting	O
the	O
human	O
PAH	O
gene	O
into	O
mouse	O
NIH	O
3T3	O
cells	O
by	O
infection	O
leading	O
to	O
stable	O
incorporation	O
of	O
the	O
recombinant	O
provirus	O
.	O
Infected	O
cells	O
express	O
PAH	O
mRNA	O
,	O
immunoreactive	O
PAH	O
protein	O
,	O
and	O
exhibit	O
pterin-dependent	O
phenylalanine	O
hydroxylase	O
activity	O
.	O
The	O
recombinant	O
virus	O
is	O
also	O
capable	O
of	O
infecting	O
a	O
mouse	O
hepatoma	B-Modifier
cell	O
line	O
that	O
does	O
not	O
normally	O
synthesize	O
PAH	O
.	O
PAH	O
activity	O
is	O
present	O
in	O
the	O
cellular	O
extracts	O
and	O
the	O
entire	O
hydroxylation	O
system	O
is	O
reconstituted	O
in	O
the	O
hepatoma	B-Modifier
cells	O
infected	O
with	O
the	O
recombinant	O
viruses	O
.	O
Thus	O
,	O
recombinant	O
viruses	O
containing	O
human	O
PAH	O
cDNA	O
provide	O
a	O
means	O
for	O
introducing	O
functional	O
PAH	O
into	O
mammalian	O
cells	O
of	O
hepatic	O
origin	O
and	O
can	O
potentially	O
be	O
introduced	O
into	O
whole	O
animals	O
as	O
a	O
model	O
for	O
somatic	O
gene	O
therapy	O
for	O
PKU	B-SpecificDisease
.	O
.	O

1682919	O
PRAD1,	O
a	O
candidate	O
BCL1	O
oncogene:	O
mapping	O
and	O
expression	O
in	O
centrocytic	B-DiseaseClass
lymphoma.	I-DiseaseClass
Rearrangement	O
of	O
the	O
BCL1	O
(	O
B-cell	O
lymphoma	O
1	O
)	O
region	O
on	O
chromosome	O
11q13	O
appears	O
to	O
be	O
highly	O
characteristic	O
of	O
centrocytic	B-DiseaseClass
lymphoma	I-DiseaseClass
and	O
also	O
is	O
found	O
infrequently	O
in	O
other	O
B-cell	B-SpecificDisease
neoplasms	I-SpecificDisease
.	O
Rearrangement	O
is	O
thought	O
to	O
deregulate	O
a	O
nearby	O
protooncogene	O
,	O
but	O
transcribed	O
sequences	O
in	O
the	O
immediate	O
vicinity	O
of	O
BCL1	O
breakpoints	O
had	O
not	O
been	O
identified	O
.	O
PRAD1	O
,	O
previously	O
designated	O
D11S287E	O
,	O
was	O
identified	O
on	O
11q13	O
as	O
a	O
chromosomal	O
breakpoint	O
region	O
rearranged	O
with	O
the	O
parathyroid	O
hormone	O
gene	O
in	O
a	O
subset	O
of	O
parathyroid	B-DiseaseClass
adenomas	I-DiseaseClass
;	O
this	O
highly	O
conserved	O
putative	O
oncogene	O
,	O
which	O
encodes	O
a	O
novel	O
cyclin	O
,	O
has	O
been	O
linked	O
to	O
BCL1	O
and	O
implicated	O
also	O
in	O
subsets	O
of	O
breast	B-CompositeMention
and	I-CompositeMention
squamous	I-CompositeMention
cell	I-CompositeMention
neoplasms	I-CompositeMention
with	O
11q13	O
amplification	O
.	O
We	O
report	O
pulsed-field	O
gel	O
electrophoresis	O
data	O
showing	O
BCL1	O
and	O
PRAD1	O
to	O
be	O
no	O
more	O
than	O
130	O
kilobases	O
apart	O
.	O
PRAD1	O
mRNA	O
is	O
abundantly	O
expressed	O
in	O
seven	O
of	O
seven	O
centrocytic	B-DiseaseClass
lymphomas	I-DiseaseClass
(	O
Kiel	O
classification	O
)	O
,	O
in	O
contrast	O
to	O
13	O
closely	O
related	O
but	O
noncentrocytic	B-DiseaseClass
lymphomas	I-DiseaseClass
.	O
Three	O
of	O
the	O
seven	O
centrocytic	B-DiseaseClass
lymphomas	I-DiseaseClass
had	O
detectable	O
BCL1	O
DNA	O
rearrangement	O
.	O
Also	O
,	O
two	O
unusual	O
cases	O
of	O
CLL	O
with	O
BCL1	O
rearrangement	O
overexpressed	O
PRAD1	O
,	O
in	O
contrast	O
to	O
five	O
CLL	O
controls	O
.	O
Thus	O
,	O
PRAD1	O
is	O
an	O
excellent	O
candidate	O
"	O
BCL1	O
oncogene	O
.	O
"	O
Its	O
overexpression	O
may	O
be	O
a	O
key	O
consequence	O
of	O
rearrangement	O
of	O
the	O
BCL1	O
vicinity	O
in	O
B-cell	B-SpecificDisease
neoplasms	I-SpecificDisease
and	O
a	O
unifying	O
pathogenetic	O
feature	O
in	O
centrocytic	B-DiseaseClass
lymphoma	I-DiseaseClass
.	O

10802669	O
ATM-dependent	O
phosphorylation	O
of	O
nibrin	O
in	O
response	O
to	O
radiation	O
exposure.	O
Mutations	O
in	O
the	O
gene	O
ATM	O
are	O
responsible	O
for	O
the	O
genetic	B-DiseaseClass
disorder	I-DiseaseClass
ataxia-telangiectasia	B-SpecificDisease
(	O
A-T	B-SpecificDisease
)	O
,	O
which	O
is	O
characterized	O
by	O
cerebellar	B-DiseaseClass
dysfunction	I-DiseaseClass
,	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B-Modifier
predisposition	O
.	O
Both	O
the	O
A-T	B-Modifier
phenotype	O
and	O
the	O
similarity	O
of	O
the	O
ATM	O
protein	O
to	O
other	O
DNA-damage	O
sensors	O
suggests	O
a	O
role	O
for	O
ATM	O
in	O
biochemical	O
pathways	O
involved	O
in	O
the	O
recognition	O
,	O
signalling	O
and	O
repair	O
of	O
DNA	O
double-strand	O
breaks	O
(	O
DSBs	O
)	O
.	O
There	O
are	O
strong	O
parallels	O
between	O
the	O
pattern	O
of	O
radiosensitivity	O
,	O
chromosomal	O
instability	O
and	O
cancer	B-Modifier
predisposition	O
in	O
A-T	B-SpecificDisease
patients	O
and	O
that	O
in	O
patients	O
with	O
Nijmegen	B-SpecificDisease
breakage	I-SpecificDisease
syndrome	I-SpecificDisease
(	O
NBS	B-SpecificDisease
)	O
.	O
The	O
protein	O
defective	O
in	O
NBS	B-SpecificDisease
,	O
nibrin	O
(	O
encoded	O
by	O
NBS1	O
)	O
,	O
forms	O
a	O
complex	O
with	O
MRE11	O
and	O
RAD50	O
(	O
refs	O
1	O
,	O
2	O
)	O
.	O
This	O
complex	O
localizes	O
to	O
DSBs	O
within	O
30	O
minutes	O
after	O
cellular	O
exposure	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
and	O
is	O
observed	O
in	O
brightly	O
staining	O
nuclear	O
foci	O
after	O
a	O
longer	O
period	O
of	O
time	O
.	O
The	O
overlap	O
between	O
clinical	O
and	O
cellular	O
phenotypes	O
in	O
A-T	B-SpecificDisease
and	O
NBS	B-SpecificDisease
suggests	O
that	O
ATM	O
and	O
nibrin	O
may	O
function	O
in	O
the	O
same	O
biochemical	O
pathway	O
.	O
Here	O
we	O
demonstrate	O
that	O
nibrin	O
is	O
phosphorylated	O
within	O
one	O
hour	O
of	O
treatment	O
of	O
cells	O
with	O
IR	O
.	O
This	O
response	O
is	O
abrogated	O
in	O
A-T	B-Modifier
cells	O
that	O
either	O
do	O
not	O
express	O
ATM	O
protein	O
or	O
express	O
near	O
full-length	O
mutant	O
protein	O
.	O
We	O
also	O
show	O
that	O
ATM	O
physically	O
interacts	O
with	O
and	O
phosphorylates	O
nibrin	O
on	O
serine	O
343	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
Phosphorylation	O
of	O
this	O
site	O
appears	O
to	O
be	O
functionally	O
important	O
because	O
mutated	O
nibrin	O
(	O
S343A	O
)	O
does	O
not	O
completely	O
complement	O
radiosensitivity	O
in	O
NBS	B-Modifier
cells	O
.	O
ATM	O
phosphorylation	O
of	O
nibrin	O
does	O
not	O
affect	O
nibrin-MRE11-RAD50	O
association	O
as	O
revealed	O
by	O
radiation-induced	O
foci	O
formation	O
.	O
Our	O
data	O
provide	O
a	O
biochemical	O
explanation	O
for	O
the	O
similarity	O
in	O
phenotype	O
between	O
A-T	B-SpecificDisease
and	O
NBS	B-SpecificDisease
.	O
.	O

6087154	O
Molecular	O
evidence	O
for	O
new	O
mutation	O
at	O
the	O
hprt	O
locus	O
in	O
Lesch-Nyhan	B-Modifier
patients.	O
Hypoxanthine-guanine	O
phosphoribosyltransferase	O
(	O
HPRT	O
;	O
EC2	O
.	O
4	O
.	O
2	O
.	O
8	O
)	O
,	O
which	O
functions	O
in	O
the	O
metabolic	O
salvage	O
of	O
purines	O
,	O
is	O
encoded	O
by	O
an	O
X-linked	O
gene	O
in	O
man	O
.	O
Partial	O
HPRT	B-DiseaseClass
deficiencies	I-DiseaseClass
are	O
associated	O
with	O
gouty	B-SpecificDisease
arthritis	I-SpecificDisease
,	O
while	O
absence	O
of	O
activity	O
results	O
in	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
L-N	B-SpecificDisease
)	O
.	O
L-N	B-Modifier
patients	O
fail	O
to	O
reproduce	O
and	O
the	O
heterozygous	O
state	O
appears	O
to	O
confer	O
no	O
selective	O
advantage	O
.	O
Thus	O
,	O
Haldanes	O
principle	O
predicts	O
that	O
new	O
mutations	O
at	O
the	O
hprt	O
locus	O
must	O
occur	O
frequently	O
in	O
order	O
for	O
L-N	B-SpecificDisease
syndrome	I-SpecificDisease
to	O
be	O
maintained	O
in	O
the	O
population	O
.	O
This	O
constant	O
introduction	O
of	O
new	O
mutations	O
would	O
be	O
expected	O
to	O
result	O
in	O
a	O
heterogeneous	O
collection	O
of	O
genetic	B-DiseaseClass
lesions	I-DiseaseClass
,	O
some	O
of	O
which	O
may	O
be	O
novel	O
.	O
As	O
we	O
report	O
here	O
,	O
the	O
mutations	O
in	O
the	O
hprt	O
gene	O
of	O
seven	O
L-N	B-Modifier
patients	O
,	O
selected	O
from	O
an	O
initial	O
survey	O
of	O
28	O
patients	O
,	O
have	O
been	O
characterized	O
and	O
all	O
were	O
found	O
to	O
be	O
distinctly	O
different	O
,	O
as	O
predicted	O
.	O
The	O
origin	O
of	O
one	O
unusual	O
mutation	O
has	O
been	O
identified	O
by	O
analysis	O
of	O
DNA	O
from	O
four	O
generations	O
of	O
family	O
members	O
.	O
Further	O
molecular	O
analysis	O
of	O
the	O
origin	O
of	O
new	O
mutations	O
at	O
the	O
hprt	O
locus	O
should	O
aid	O
in	O
resolving	O
the	O
issue	O
of	O
an	O
apparent	O
difference	O
in	O
the	O
frequency	O
of	O
hprt	O
mutations	O
in	O
males	O
and	O
females	O

1671851	O
Linkage	O
analysis	O
in	O
X-linked	B-SpecificDisease
adrenoleukodystrophy	I-SpecificDisease
and	O
application	O
in	O
post-	O
and	O
prenatal	O
diagnosis.	O
We	O
have	O
performed	O
linkage	O
analysis	O
with	O
the	O
DNA	O
markers	O
DXS52	O
and	O
the	O
clotting	O
factor	O
VIII	O
gene	O
(	O
F8C	O
)	O
,	O
in	O
several	O
large	O
families	O
with	O
X-linked	B-SpecificDisease
adrenoleukodystrophy	I-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
.	O
The	O
tight	O
linkage	O
to	O
DXS52	O
could	O
be	O
extended	O
giving	O
a	O
maximal	O
LOD	O
score	O
of	O
22	O
.	O
5	O
at	O
1	O
cM	O
.	O
F8C	O
was	O
also	O
tightly	O
linked	O
to	O
ALD	B-SpecificDisease
with	O
a	O
maximal	O
LOD	O
score	O
of	O
7	O
.	O
8	O
without	O
recombination	O
.	O
Multipoint	O
linkage	O
analysis	O
with	O
the	O
markers	O
DXS304	O
,	O
DXS52	O
,	O
and	O
F8C	O
indicated	O
that	O
both	O
the	O
gene	O
for	O
ALD	B-SpecificDisease
and	O
for	O
F8C	O
are	O
distal	O
to	O
DXS52	O
.	O
In	O
four	O
patients	O
with	O
ALD	B-SpecificDisease
,	O
no	O
major	O
structural	O
rearrangement	O
in	O
the	O
Xqter	O
region	O
was	O
observed	O
;	O
in	O
particular	O
,	O
there	O
were	O
no	O
abnormalities	B-DiseaseClass
in	I-DiseaseClass
the	I-DiseaseClass
vision	I-DiseaseClass
blindness	I-DiseaseClass
genes	I-DiseaseClass
.	O
DNA	O
analysis	O
appeared	O
to	O
be	O
of	O
use	O
in	O
determination	O
of	O
the	O
carrier	O
status	O
of	O
females	O
at	O
risk	O
,	O
for	O
the	O
determination	O
of	O
the	O
origin	O
of	O
the	O
mutation	O
in	O
a	O
particular	O
family	O
,	O
and	O
for	O
prenatal	O
diagnosis	O
.	O

7599636	O
Characterisation	O
of	O
molecular	O
defects	O
in	O
X-linked	B-SpecificDisease
amelogenesis	I-SpecificDisease
imperfecta	I-SpecificDisease
(AIH1).	O
Amelogenins	O
are	O
an	O
heterogenous	O
family	O
of	O
proteins	O
produced	O
by	O
ameloblasts	O
of	O
the	O
enamel	O
organ	O
during	O
tooth	O
development	O
.	O
Disturbances	O
of	O
enamel	O
formation	O
occur	O
in	O
amelogenesis	B-DiseaseClass
imperfecta	I-DiseaseClass
,	O
a	O
clinically	O
heterogenous	O
group	O
of	O
inherited	B-DiseaseClass
disorders	I-DiseaseClass
characterised	O
by	O
defective	O
enamel	O
biomineralisation	O
.	O
An	O
amelogenin	O
gene	O
,	O
AMGX	O
,	O
has	O
been	O
mapped	O
to	O
the	O
short	O
of	O
the	O
X	O
chromosome	O
(	O
Xp22	O
.	O
1-p22	O
.	O
3	O
)	O
and	O
has	O
been	O
implicated	O
in	O
the	O
molecular	O
pathology	O
of	O
X-linked	B-SpecificDisease
amelogenesis	I-SpecificDisease
imperfecta	I-SpecificDisease
(	O
AIH1	B-SpecificDisease
)	O
.	O
We	O
have	O
identified	O
three	O
families	O
exhibiting	O
AIH1	B-SpecificDisease
and	O
screened	O
the	O
AMGX	O
gene	O
for	O
mutations	O
using	O
single-strand	O
conformational	O
polymorphism	O
analysis	O
and	O
DNA	O
sequencing	O
.	O
Three	O
novel	O
mutations	O
were	O
identified	O
a	O
C-T	O
substitution	O
in	O
exon	O
5	O
,	O
and	O
a	O
G-T	O
substitution	O
and	O
single	O
cytosine	O
deletion	O
in	O
exon	O
6	O
,	O
confirming	O
the	O
existence	O
of	O
extensive	O
allelic	O
heterogeneity	O
in	O
this	O
condition	O
.	O
The	O
identification	O
of	O
family-specific	O
mutations	O
will	O
enable	O
early	O
identification	O
of	O
affected	O
individuals	O
and	O
correlation	O
of	O
clinical	O
phenotype	O
with	O
genotype	O
will	O
facilitate	O
an	O
objective	O
system	O
of	O
disease	O
classification	O
.	O

7535801	O
Molecular	O
basis	O
of	O
subtotal	B-SpecificDisease
complement	I-SpecificDisease
C6	I-SpecificDisease
deficiency.	I-SpecificDisease
A	O
carboxy-terminally	O
truncated	O
but	O
functionally	O
active	O
C6.	O
Individuals	O
with	O
subtotal	B-SpecificDisease
complement	I-SpecificDisease
C6	I-SpecificDisease
deficiency	I-SpecificDisease
possess	O
a	O
C6	O
molecule	O
that	O
is	O
14	O
%	O
shorter	O
than	O
normal	O
C6	O
and	O
present	O
in	O
low	O
but	O
detectable	O
concentrations	O
(	O
1-2	O
%	O
of	O
the	O
normal	O
mean	O
)	O
.	O
We	O
now	O
show	O
that	O
this	O
dysmorphic	O
C6	O
is	O
bactericidally	O
active	O
and	O
lacks	O
an	O
epitope	O
that	O
was	O
mapped	O
to	O
the	O
most	O
carboxy-terminal	O
part	O
of	O
C6	O
using	O
C6	O
cDNA	O
fragments	O
expressed	O
as	O
fusion	O
proteins	O
in	O
the	O
pUEX	O
expression	O
system	O
.	O
We	O
thus	O
predicted	O
that	O
the	O
abnormal	O
C6	O
molecule	O
might	O
be	O
carboxy-terminally	O
truncated	O
and	O
sought	O
a	O
mutation	O
in	O
an	O
area	O
approximately	O
14	O
%	O
from	O
the	O
carboxy-terminal	O
end	O
of	O
the	O
coding	O
sequence	O
.	O
By	O
sequencing	O
PCR-amplified	O
products	O
from	O
this	O
region	O
,	O
we	O
found	O
,	O
in	O
three	O
individuals	O
from	O
two	O
families	O
,	O
a	O
mutation	O
that	O
might	O
plausibly	O
be	O
responsible	O
for	O
the	O
defect	O
.	O
All	O
three	O
have	O
an	O
abnormal	O
5	O
splice	O
donor	O
site	O
of	O
intron	O
15	O
,	O
which	O
would	O
probably	O
prevent	O
splicing	O
.	O
An	O
in-frame	O
stop	O
codon	O
is	O
found	O
17	O
codons	O
downstream	O
from	O
the	O
intron	O
boundary	O
,	O
which	O
would	O
lead	O
to	O
a	O
truncated	O
polypeptide	O
13	O
.	O
5	O
%	O
smaller	O
than	O
normal	O
C6	O
.	O
This	O
result	O
was	O
unexpected	O
,	O
as	O
earlier	O
studies	O
mapped	O
the	O
C5b	O
binding	O
site	O
,	O
or	O
a	O
putative	O
enzymatic	O
region	O
,	O
to	O
this	O
part	O
of	O
C6	O
.	O
Interestingly	O
,	O
all	O
three	O
subjects	O
were	O
probably	O
heterozygous	O
for	O
both	O
subtotal	B-CompositeMention
C6	I-CompositeMention
and	I-CompositeMention
complete	I-CompositeMention
C6	I-CompositeMention
deficiency	I-CompositeMention
.	O

7668252	O
Cloning	O
of	O
human	O
very-long-chain	O
acyl-coenzyme	O
A	O
dehydrogenase	O
and	O
molecular	O
characterization	O
of	O
its	O
deficiency	O
in	O
two	O
patients.	O
Two	O
overlapping	O
cDNA	O
clones	O
(	O
1	O
,	O
991	O
bp	O
and	O
736	O
bp	O
,	O
respectively	O
)	O
encoding	O
the	O
precursor	O
of	O
human	O
mitochondrial	O
very-long-chain	O
acyl-coenzyme	O
A	O
dehydrogenase	O
(	O
VLCAD	O
)	O
were	O
cloned	O
and	O
sequenced	O
.	O
The	O
cDNA	O
inserts	O
of	O
these	O
clones	O
together	O
encompass	O
a	O
region	O
of	O
2	O
,	O
177	O
bases	O
,	O
encoding	O
the	O
entire	O
protein	O
of	O
655	O
amino	O
acids	O
,	O
including	O
a	O
40-amino	O
acid	O
leader	O
peptide	O
and	O
a	O
615-amino	O
acid	O
mature	O
polypeptide	O
.	O
PCR-amplified	O
VLCAD	O
cDNAs	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	O
from	O
two	O
VLCAD-deficient	B-Modifier
patients	O
.	O
In	O
both	O
patients	O
,	O
a	O
105-bp	O
deletion	O
encompassing	O
bases	O
1078-1182	O
in	O
VLCAD	O
cDNA	O
was	O
identified	O
.	O
The	O
deletion	O
seems	O
to	O
occur	O
due	O
to	O
exon	O
skipping	O
during	O
processing	O
of	O
VLCAD	O
pre-mRNA	O
.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	O
causing	O
VLCAD	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
Quantitative	O
cDNA	O
expression	O
of	O
normal	O
human	O
VLCAD	O
was	O
performed	O
in	O
the	O
patients	O
fibroblasts	O
,	O
using	O
vaccinia	O
viral	O
system	O
,	O
which	O
demonstrated	O
that	O
the	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
normal	I-SpecificDisease
VLCAD	I-SpecificDisease
protein	I-SpecificDisease
causes	O
impaired	O
long-chain	O
fatty	O
acid	O
beta-oxidation	O
activity	O
in	O
the	O
patients	O
fibroblasts	O
.	O
In	O
patient	O
fibroblasts	O
,	O
raising	O
VLCAD	O
activity	O
to	O
approximately	O
20	O
%	O
of	O
normal	O
control	O
fibroblast	O
activity	O
raised	O
palmitic	O
acid	O
beta-oxidation	O
flux	O
to	O
the	O
level	O
found	O
in	O
control	O
fibroblasts	O
,	O
which	O
may	O
offer	O
important	O
information	O
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	O
gene	O
therapy	O
for	O
VLCAD	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
.	O

10430841	O
Spinal	B-SpecificDisease
xanthomatosis:	I-SpecificDisease
a	O
variant	O
of	O
cerebrotendinous	B-DiseaseClass
xanthomatosis.	I-DiseaseClass
We	O
describe	O
seven	O
Dutch	O
patients	O
from	O
six	O
families	O
with	O
a	O
slowly	O
progressive	O
,	O
mainly	O
spinal	B-SpecificDisease
cord	I-SpecificDisease
syndrome	I-SpecificDisease
that	O
remained	O
for	O
many	O
years	O
the	O
sole	O
expression	O
of	O
cerebrotendinous	B-SpecificDisease
xanthomatosis	I-SpecificDisease
(	O
CTX	B-SpecificDisease
)	O
.	O
MRI	O
demonstrated	O
white	B-DiseaseClass
matter	I-DiseaseClass
abnormalities	I-DiseaseClass
in	O
the	O
lateral	O
and	O
dorsal	O
columns	O
of	O
the	O
spinal	O
cord	O
.	O
Post-mortem	O
examination	O
of	O
one	O
of	O
the	O
patients	O
showed	O
extensive	O
myelin	O
loss	O
in	O
these	O
columns	O
.	O
An	O
array	O
of	O
genotypes	O
was	O
found	O
in	O
these	O
patients	O
.	O
We	O
conclude	O
that	O
spinal	B-SpecificDisease
xanthomatosis	I-SpecificDisease
is	O
a	O
clinical	O
and	O
radiological	O
separate	O
entity	O
of	O
CTX	B-SpecificDisease
that	O
should	O
be	O
included	O
in	O
the	O
differential	O
diagnosis	O
of	O
chronic	B-DiseaseClass
myelopathy	I-DiseaseClass
.	O
.	O

3362213	O
Identification	O
of	O
an	O
altered	O
splice	O
site	O
in	O
Ashkenazi	O
Tay-Sachs	B-SpecificDisease
disease.	I-SpecificDisease
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
is	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
genetic	I-DiseaseClass
disorder	I-DiseaseClass
resulting	O
from	O
mutation	O
of	O
the	O
HEXA	O
gene	O
encoding	O
the	O
alpha-subunit	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
beta-N-acetylhexosaminidase	O
A	O
(	O
ref	O
.	O
1	O
)	O
.	O
A	O
relatively	O
high	O
frequency	O
of	O
carriers	O
(	O
1	O
/	O
27	O
)	O
of	O
a	O
lethal	O
,	O
infantile	O
form	O
of	O
the	O
disease	O
is	O
found	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
,	O
but	O
it	O
is	O
not	O
yet	O
evident	O
whether	O
this	O
has	O
resulted	O
from	O
a	O
founder	O
effect	O
and	O
random	O
genetic	O
drift	O
or	O
from	O
a	O
selective	O
advantage	O
of	O
heterozygotes	O
.	O
We	O
have	O
identified	O
a	O
single-base	O
mutation	O
in	O
a	O
cloned	O
fragment	O
of	O
the	O
HEXA	O
gene	O
from	O
an	O
Ashkenazi	O
Jewish	O
patient	O
.	O
This	O
change	O
,	O
the	O
substitution	O
of	O
a	O
C	O
for	O
G	O
in	O
the	O
first	O
nucleotide	O
of	O
intron	O
12	O
is	O
expected	O
to	O
result	O
in	O
defective	O
splicing	O
of	O
the	O
messenger	O
RNA	O
.	O
A	O
test	O
for	O
the	O
mutant	O
allele	O
based	O
on	O
amplification	O
of	O
DNA	O
by	O
the	O
polymerase	O
chain	O
rection	O
and	O
cleavage	O
of	O
a	O
DdeI	O
restriction	O
site	O
generated	O
by	O
the	O
mutation	O
revealed	O
that	O
this	O
case	O
and	O
two	O
other	O
cases	O
of	O
the	O
Ashkenazi	O
,	O
infantile	O
form	O
of	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
are	O
heterozygous	O
for	O
two	O
different	O
mutations	O
.	O
The	O
occurrence	O
of	O
multiple	O
mutant	O
alleles	O
warrants	O
further	O
examination	O
of	O
the	O
selective	O
advantage	O
hypothesis	O
.	O
.	O

1269174	O
Analbuminemia	B-SpecificDisease
in	O
an	O
American	O
Indian	O
girl.	O
Analbuminemia	B-SpecificDisease
was	O
fortuitously	O
detected	O
in	O
a	O
nonedematous	O
12-year-old	O
American	O
Indian	O
girl	O
with	O
atopic	B-SpecificDisease
dermatitis	I-SpecificDisease
,	O
mild	O
bronchial	B-SpecificDisease
asthma	I-SpecificDisease
,	O
a	O
mild	O
seizure	B-SpecificDisease
disorder	I-SpecificDisease
,	O
and	O
hyperlipoproteinemia	B-SpecificDisease
with	O
a	O
corneal	B-SpecificDisease
arcus	I-SpecificDisease
.	O
Immunologic	O
methods	O
revealed	O
trace	O
amounts	O
(	O
17	O
mg	O
/	O
100	O
ml	O
)	O
of	O
apparently	O
normal	O
serum	O
albumin	O
.	O
The	O
patients	O
parents	O
were	O
remotely	O
related	O
.	O
The	O
pedigree	O
and	O
clinical	O
findings	O
were	O
compatible	O
with	O
autosomal	O
recessive	O
transmission	O
of	O
analbuminemia	B-SpecificDisease
.	O
Heterozygotes	O
had	O
subnormal	O
levels	O
of	O
serum	O
albumin	O
.	O
The	O
Gc-locus	O
is	O
closely	O
linked	O
to	O
the	O
structural	O
albumin	O
locus	O
.	O
Gc-protein	O
levels	O
were	O
normal	O
in	O
the	O
patient	O
and	O
together	O
with	O
normal	O
chromosomal	O
banding	O
studies	O
make	O
it	O
unlikely	O
that	O
a	O
chromosomal	O
deletion	O
caused	O
analbuminemia	B-SpecificDisease
.	O
Gc-types	O
in	O
the	O
family	O
were	O
compatible	O
with	O
,	O
but	O
did	O
not	O
prove	O
,	O
linkage	O
of	O
analbuminemia	B-SpecificDisease
to	O
the	O
Gc-locus	O
.	O
These	O
findings	O
suggest	O
a	O
"	O
thalassemia	B-Modifier
"	O
-like	O
mutation	O
for	O
this	O
disorder	O
.	O
.	O

8002973	O
Adrenoleukodystrophy	B-Modifier
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein.	O
An	O
antibody	O
against	O
the	O
synthetic	O
C-terminal	O
peptides	O
deduced	O
from	O
the	O
cDNA	O
of	O
the	O
gene	O
responsible	O
for	O
X-linked	B-SpecificDisease
adrenoleukodystrophy	I-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
was	O
produced	O
to	O
characterize	O
the	O
product	O
of	O
the	O
ALD	B-Modifier
gene	O
.	O
The	O
antibody	O
reacted	O
with	O
the	O
80	O
kDa	O
band	O
protein	O
in	O
control	O
fibroblasts	O
,	O
while	O
no	O
bands	O
were	O
detected	O
in	O
the	O
fibroblasts	O
from	O
a	O
patient	O
with	O
ALD	B-SpecificDisease
(	O
#	O
163	O
)	O
,	O
in	O
which	O
mRNA	O
of	O
the	O
ALD	B-Modifier
gene	O
was	O
undetectable	O
based	O
on	O
Northern	O
blot	O
analysis	O
.	O
The	O
293T	O
cells	O
transfected	O
with	O
the	O
full-coding	O
cDNA	O
inserted	O
in	O
the	O
expression	O
vector	O
produced	O
a	O
new	O
80	O
kDa	O
protein	O
,	O
as	O
detected	O
by	O
Western	O
blot	O
.	O
In	O
an	O
immunocytological	O
study	O
,	O
the	O
staining	O
was	O
in	O
a	O
punctate	O
pattern	O
,	O
in	O
the	O
normal	O
fibroblasts	O
.	O
However	O
,	O
there	O
was	O
no	O
punctate	O
staining	O
in	O
the	O
#	O
163	O
cells	O
.	O
These	O
data	O
thus	O
indicate	O
that	O
the	O
ALD	B-Modifier
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein	O
.	O
.	O

7795652	O
Somatic	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
sporadic	B-SpecificDisease
ovarian	I-SpecificDisease
tumours.	I-SpecificDisease
The	O
BRCA1	O
gene	O
on	O
chromosome	O
17q21	O
is	O
responsible	O
for	O
an	O
autosomal	B-DiseaseClass
dominant	I-DiseaseClass
syndrome	I-DiseaseClass
of	O
increased	O
susceptibility	O
to	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
but	O
no	O
somatic	O
mutations	O
in	O
tumours	B-DiseaseClass
have	O
yet	O
been	O
described	O
.	O
To	O
study	O
the	O
potential	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
carcinogenesis	O
,	O
we	O
analysed	O
the	O
genomic	O
DNA	O
of	O
tumour	B-DiseaseClass
and	O
normal	O
fractions	O
of	O
47	O
ovarian	B-SpecificDisease
cancers	I-SpecificDisease
for	O
mutations	O
in	O
BRCA1	O
using	O
the	O
single-strand	O
conformation	O
polymorphism	O
technique	O
.	O
We	O
now	O
describe	O
somatic	O
mutations	O
in	O
the	O
DNA	O
of	O
four	O
tumours	B-DiseaseClass
which	O
also	O
had	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
a	O
BRCA1	O
intragenic	O
marker	O
.	O
Our	O
data	O
support	O
a	O
tumour	B-Modifier
suppressor	O
mechanism	O
for	O
BRCA1	O
;	O
somatic	O
mutations	O
and	O
LOH	O
may	O
result	O
in	O
inactivation	O
of	O
BRCA1	O
in	O
at	O
least	O
a	O
small	O
number	O
of	O
ovarian	B-SpecificDisease
cancers	I-SpecificDisease
.	O
.	O

8098180	O
Myotonic	B-SpecificDisease
dystrophy:	I-SpecificDisease
size-	O
and	O
sex-dependent	O
dynamics	O
of	O
CTG	O
meiotic	O
instability,	O
and	O
somatic	O
mosaicism.	O
Myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
is	O
a	O
progressive	O
neuromuscular	B-DiseaseClass
disorder	I-DiseaseClass
which	O
results	O
from	O
elongations	O
of	O
an	O
unstable	O
(	O
CTG	O
)	O
n	O
repeat	O
,	O
located	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DM	B-Modifier
gene	O
.	O
A	O
correlation	O
has	O
been	O
demonstrated	O
between	O
the	O
increase	O
in	O
the	O
repeat	O
number	O
of	O
this	O
sequence	O
and	O
the	O
severity	O
of	O
the	O
disease	O
.	O
However	O
,	O
the	O
clinical	O
status	O
of	O
patients	O
cannot	O
be	O
unambiguously	O
ascertained	O
solely	O
on	O
the	O
basis	O
of	O
the	O
number	O
of	O
CTG	O
repeats	O
.	O
Moreover	O
,	O
the	O
exclusive	O
maternal	O
inheritance	O
of	O
the	O
congenital	O
form	O
remains	O
unexplained	O
.	O
Our	O
observation	O
of	O
differently	O
sized	O
repeats	O
in	O
various	O
DM	B-Modifier
tissues	O
from	O
the	O
same	O
individual	O
may	O
explain	O
why	O
the	O
size	O
of	O
the	O
mutation	O
observed	O
in	O
lymphocytes	O
does	O
not	O
necessarily	O
correlate	O
with	O
the	O
severity	O
and	O
nature	O
of	O
symptoms	O
.	O
Through	O
a	O
molecular	O
and	O
genetic	O
study	O
of	O
142	O
families	O
including	O
418	O
DM	B-Modifier
patients	O
,	O
we	O
have	O
investigated	O
the	O
dynamics	O
of	O
the	O
CTG	O
repeat	O
meiotic	O
instability	O
.	O
A	O
positive	O
correlation	O
between	O
the	O
size	O
of	O
the	O
repeat	O
and	O
the	O
intergenerational	O
enlargement	O
was	O
observed	O
similarly	O
through	O
male	O
and	O
female	O
meioses	O
for	O
or	O
=	O
1	O
.	O
5-kb	O
fragments	O
.	O
This	O
implies	O
a	O
size-	O
and	O
sex-dependent	O
meiotic	O
instability	O
.	O
Moreover	O
,	O
segregation	O
analysis	O
supports	O
the	O
hypothesis	O
of	O
a	O
maternal	O
as	O
well	O
as	O
a	O
familial	O
predisposition	O
for	O
the	O
occurrence	O
of	O
the	O
congenital	O
form	O
.	O
Finally	O
,	O
this	O
analysis	O
reveals	O
a	O
significant	O
excess	O
of	O
transmitting	O
grandfathers	O
partially	O
accounted	O
for	O
by	O
increased	O
fertility	O
in	O
affected	O
males	O

624546	O
Heterogeneity	O
of	O
glucose-6-phosphate	B-SpecificDisease
dehydrogenase	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
Algeria.	O
Study	O
in	O
Northern	O
Algeria	O
with	O
description	O
of	O
five	O
new	O
variants.	O
Glucose-6-phosphate	B-SpecificDisease
dehydrogenase	I-SpecificDisease
(	I-SpecificDisease
G6PD	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
was	O
found	O
in	O
3	O
.	O
2	O
%	O
of	O
the	O
male	O
population	O
living	O
in	O
the	O
urban	O
area	O
of	O
Algiers	O
.	O
The	O
deficient	O
subjects	O
originated	O
from	O
multiple	O
geographic	O
regions	O
of	O
Northern	O
Algeria	O
,	O
with	O
prevalence	O
of	O
individuals	O
of	O
Berber-Kabyle	O
origin	O
.	O
Red	O
blood	O
cell	O
G6PD	O
was	O
partially	O
purified	O
and	O
characterized	O
in	O
deficient	O
males	O
from	O
17	O
families	O
,	O
and	O
six	O
different	O
variants	O
were	O
found	O
.	O
Among	O
them	O
,	O
only	O
one	O
,	O
the	O
Gd	O
(	O
-	O
)	O
Kabyle	O
variant	O
,	O
had	O
been	O
previously	O
described	O
.	O
It	O
was	O
detected	O
in	O
nine	O
families	O
.	O
The	O
other	O
five	O
variants	O
were	O
new	O
Gd	O
(	O
-	O
)	O
Laghouat	O
(	O
four	O
cases	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Blida	O
(	O
one	O
case	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Thenia	O
(	O
one	O
case	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Titteri	O
(	O
one	O
case	O
)	O
,	O
and	O
Gd	O
(	O
-	O
)	O
Alger	O
(	O
two	O
brothers	O
)	O
.	O
Strikingly	O
,	O
the	O
common	O
Mediterranean	O
variant	O
was	O
not	O
found	O
.	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
is	O
heterogeneous	O
in	O
northern	O
Algeria	O
where	O
autochtonous	O
variants	O
seem	O
to	O
prevail	O
.	O
The	O
Kabyle	O
variant	O
may	O
be	O
common	O
in	O
this	O
country	O
.	O

1733838	O
Localisation	O
of	O
the	O
gene	O
for	O
Norrie	B-SpecificDisease
disease	I-SpecificDisease
to	O
between	O
DXS7	O
and	O
DXS426	O
on	O
Xp.	O
A	O
highly	O
informative	O
microsatellite	O
marker	O
,	O
DXS426	O
,	O
which	O
maps	O
proximal	O
to	O
DXS7	O
in	O
the	O
interval	O
Xp11	O
.	O
4-Xp11	O
4-Xp11	O
.	O
23	O
,	O
has	O
been	O
used	O
to	O
refine	O
further	O
the	O
localisation	O
of	O
the	O
gene	O
for	O
Norrie	B-SpecificDisease
disease	I-SpecificDisease
(	O
NDP	B-SpecificDisease
)	O
.	O
The	O
results	O
from	O
a	O
multiply	O
informative	O
crossover	O
localize	O
the	O
NDP	B-Modifier
gene	O
proximal	O
to	O
DXS7	O
.	O
In	O
conjunction	O
with	O
information	O
from	O
2	O
NDP	B-Modifier
patients	O
who	O
have	O
a	O
deletion	O
for	O
DXS7	O
but	O
not	O
for	O
DSX426	O
,	O
our	O
data	O
indicate	O
that	O
the	O
NDP	B-Modifier
gene	O
lies	O
between	O
DXS7	O
and	O
DXS426	O
on	O
proximal	O
Xp	O
.	O

10196381	O
Adrenoleukodystrophy-related	O
protein	O
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	B-SpecificDisease
protein	I-SpecificDisease
deficiency	I-SpecificDisease
(X-ALD):	O
implications	O
for	O
therapy.	O
Inherited	B-DiseaseClass
defects	I-DiseaseClass
in	O
the	O
peroxisomal	O
ATP-binding	O
cassette	O
(	O
ABC	O
)	O
transporter	O
adrenoleukodystrophy	B-Modifier
protein	O
(	O
ALDP	O
)	O
lead	O
to	O
the	O
lethal	O
peroxisomal	B-DiseaseClass
disorder	I-DiseaseClass
X-linked	B-SpecificDisease
adrenoleukodystrophy	I-SpecificDisease
(	O
X-ALD	B-SpecificDisease
)	O
,	O
for	O
which	O
no	O
efficient	O
treatment	O
has	O
been	O
established	O
so	O
far	O
.	O
Three	O
other	O
peroxisomal	O
ABC	O
transporters	O
currently	O
are	O
known	O
adrenoleukodystrophy-related	O
protein	O
(	O
ALDRP	O
)	O
,	O
70	O
kDa	O
peroxisomal	O
membrane	O
protein	O
(	O
PMP70	O
)	O
and	O
PMP70-	O
related	O
protein	O
.	O
By	O
using	O
transient	O
and	O
stable	O
overexpression	O
of	O
human	O
cDNAs	O
encoding	O
ALDP	O
and	O
its	O
closest	O
relative	O
ALDRP	O
,	O
we	O
could	O
restore	O
the	O
impaired	O
peroxisomal	O
beta-oxidation	O
in	O
fibroblasts	O
of	O
X-ALD	B-Modifier
patients	O
.	O
The	O
pathognomonic	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
could	O
also	O
be	O
prevented	O
by	O
overexpression	O
of	O
ALDRP	O
in	O
immortalized	O
X-ALD	O
cells	O
.	O
Immunofluorescence	O
analysis	O
demonstrated	O
that	O
the	O
functional	O
replacement	O
of	O
ALDP	O
by	O
ALDRP	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
mutated	O
ALDP	O
itself	O
.	O
Moreover	O
,	O
we	O
were	O
able	O
to	O
restore	O
the	O
peroxisomal	O
beta-oxidation	O
defect	O
in	O
the	O
liver	O
of	O
ALDP-deficient	O
mice	O
by	O
stimulation	O
of	O
ALDRP	O
and	O
PMP70	O
gene	O
expression	O
through	O
a	O
dietary	O
treatment	O
with	O
the	O
peroxisome	O
proliferator	O
fenofibrate	O
.	O
These	O
results	O
suggest	O
that	O
a	O
correction	O
of	O
the	O
biochemical	O
defect	O
in	O
X-ALD	B-SpecificDisease
could	O
be	O
possible	O
by	O
drug-induced	O
overexpression	O
or	O
ectopic	O
expression	O
of	O
ALDRP	O
.	O
.	O

2884570	O
An	O
amino-acid	O
substitution	O
involved	O
in	O
phenylketonuria	B-SpecificDisease
is	O
in	O
linkage	O
disequilibrium	O
with	O
DNA	O
haplotype	O
2.	O
Phenylketonuria	B-SpecificDisease
(	O
PKU	B-SpecificDisease
)	O
is	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
human	I-DiseaseClass
genetic	I-DiseaseClass
disorder	I-DiseaseClass
caused	O
by	O
a	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
hepatic	I-SpecificDisease
phenylalanine	I-SpecificDisease
hydroxylase	I-SpecificDisease
(	O
PAH	O
,	O
phenylalanine	O
4-monooxygenase	O
,	O
EC	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O
PKU	B-SpecificDisease
is	O
a	O
common	O
inborn	B-DiseaseClass
error	I-DiseaseClass
of	I-DiseaseClass
amino-acid	I-DiseaseClass
metabolism	I-DiseaseClass
in	O
caucasian	O
populations	O
and	O
approximately	O
1	O
in	O
50	O
individuals	O
are	O
carriers	O
of	O
a	O
PKU	B-Modifier
allele	O
.	O
To	O
define	O
the	O
molecular	O
basis	O
of	O
PKU	B-SpecificDisease
,	O
we	O
characterized	O
twelve	O
restriction	O
fragment-length	O
polymorphism	O
(	O
RFLP	O
)	O
haplotypes	O
of	O
the	O
PAH	O
locus	O
in	O
the	O
northern	O
European	O
population	O
and	O
observed	O
that	O
90	O
%	O
of	O
the	O
PKU	B-Modifier
alleles	O
in	O
this	O
population	O
are	O
confined	O
to	O
four	O
common	O
RFLP	O
haplotypes	O
.	O
We	O
have	O
recently	O
reported	O
a	O
splicing	O
mutation	O
in	O
the	O
PAH	O
gene	O
that	O
is	O
associated	O
with	O
RFLP	O
haplotype	O
3	O
which	O
is	O
present	O
at	O
about	O
40	O
%	O
of	O
mutant	O
alleles	O
.	O
We	O
now	O
report	O
the	O
molecular	B-DiseaseClass
lesion	I-DiseaseClass
associated	O
with	O
the	O
RFLP	O
haplotype	O
2	O
mutant	O
allele	O
.	O
This	O
defect	O
is	O
caused	O
by	O
a	O
C-to-T	O
transition	O
in	O
exon	O
12	O
resulting	O
in	O
an	O
amino-acid	O
substitution	O
(	O
Arg	O
to	O
Trp	O
)	O
at	O
residue	O
408	O
of	O
PAH	O
.	O
Direct	O
hybridization	O
analysis	O
of	O
the	O
point	O
mutation	O
using	O
a	O
specific	O
oligonucleotide	O
probe	O
demonstrated	O
that	O
this	O
mutation	O
is	O
also	O
in	O
linkage	O
disequilibrium	O
with	O
RFLP	O
haplotype	O
2	O
alleles	O
that	O
make	O
up	O
about	O
20	O
%	O
of	O
mutant	O
PAH	O
genes	O

1302022	O
Characterization	O
of	O
the	O
myotonic	B-Modifier
dystrophy	I-Modifier
region	O
predicts	O
multiple	O
protein	O
isoform-encoding	O
mRNAs.	O
The	O
mutation	O
underlying	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
has	O
been	O
identified	O
as	O
an	O
expansion	O
of	O
a	O
polymorphic	O
CTG-repeat	O
in	O
a	O
gene	O
encoding	O
protein	O
kinase	O
activity	O
.	O
Brain	O
and	O
heart	O
transcripts	O
of	O
the	O
DM-kinase	O
(	O
DMR-B15	O
)	O
gene	O
are	O
subject	O
to	O
alternative	O
RNA	O
splicing	O
in	O
both	O
human	O
and	O
mouse	O
.	O
The	O
unstable	O
[	O
CTG	O
]	O
5-30	O
motif	O
is	O
found	O
uniquely	O
in	O
humans	O
,	O
although	O
the	O
flanking	O
nucleotides	O
are	O
also	O
present	O
in	O
mouse	O
.	O
Characterization	O
of	O
the	O
DM	B-Modifier
region	O
of	O
both	O
species	O
reveals	O
another	O
active	O
gene	O
(	O
DMR-N9	O
)	O
in	O
close	O
proximity	O
to	O
the	O
kinase	O
gene	O
.	O
DMR-N9	O
transcripts	O
,	O
mainly	O
expressed	O
in	O
brain	O
and	O
testis	O
,	O
possess	O
a	O
single	O
,	O
large	O
open	O
reading	O
frame	O
,	O
but	O
the	O
function	O
of	O
its	O
protein	O
product	O
is	O
unknown	O
.	O
Clinical	O
manifestation	O
of	O
DM	B-SpecificDisease
may	O
be	O
caused	O
by	O
the	O
expanded	O
CTG-repeat	O
compromising	O
the	O
(	O
alternative	O
)	O
expression	O
of	O
DM-kinase	O
or	O
DMR-N9	O
proteins	O
.	O
.	O

3674116	O
Familial	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
with	O
apparently	O
normal	O
chromosomes.	O
We	O
report	O
on	O
4	O
sibs	O
(	O
2F	O
,	O
2M	O
)	O
with	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
PWS	B-SpecificDisease
)	O
.	O
Diagnosis	O
was	O
made	O
clinically	O
on	O
the	O
basis	O
of	O
history	O
,	O
behavior	O
,	O
and	O
physical	O
findings	O
in	O
3	O
of	O
the	O
sibs	O
.	O
The	O
other	O
child	O
had	O
died	O
at	O
age	O
10	O
months	O
with	O
a	O
history	O
and	O
clinical	O
findings	O
typical	O
of	O
first	O
phase	O
of	O
PWS	B-SpecificDisease
.	O
Results	O
of	O
chromosome	O
studies	O
on	O
the	O
parents	O
and	O
surviving	O
sibs	O
were	O
normal	O
.	O
The	O
implications	O
of	O
this	O
unusual	O
familial	O
occurrence	O
for	O
our	O
understanding	O
of	O
PWS	B-SpecificDisease
are	O
discussed	O
.	O
.	O

3856322	O
Gene	O
transfer	O
and	O
expression	O
of	O
human	O
phenylalanine	O
hydroxylase.	O
Phenylketonuria	B-SpecificDisease
(	O
PKU	B-SpecificDisease
)	O
is	O
caused	O
by	O
a	O
genetic	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
enzyme	I-SpecificDisease
phenylalanine	I-SpecificDisease
hydroxylase	I-SpecificDisease
(	O
PAH	O
)	O
.	O
A	O
full-length	O
complementary	O
DNA	O
clone	O
of	O
human	O
PAH	O
was	O
inserted	O
into	O
a	O
eukaryotic	O
expression	O
vector	O
and	O
transferred	O
into	O
mouse	O
NIH3T3	O
cells	O
which	O
do	O
not	O
normally	O
express	O
PAH	O
.	O
The	O
transformed	O
mouse	O
cells	O
expressed	O
PAH	O
messenger	O
RNA	O
,	O
immunoreactive	O
protein	O
,	O
and	O
enzymatic	O
activity	O
that	O
are	O
characteristic	O
of	O
the	O
normal	O
human	O
liver	O
products	O
,	O
demonstrating	O
that	O
a	O
single	O
gene	O
contains	O
all	O
of	O
the	O
necessary	O
genetic	O
information	O
to	O
code	O
for	O
functional	O
PAH	O
.	O
These	O
results	O
support	O
the	O
use	O
of	O
the	O
human	O
PAH	O
probe	O
in	O
prenatal	O
diagnosis	O
and	O
detection	O
of	O
carriers	O
,	O
to	O
provide	O
new	O
opportunities	O
for	O
the	O
biochemical	O
characterization	O
of	O
normal	O
and	O
mutant	O
enzymes	O
,	O
and	O
in	O
the	O
investigation	O
of	O
alternative	O
genetic	O
therapies	O
for	O
PKU	B-SpecificDisease
.	O
.	O

1577476	O
An	O
error	O
in	O
dystrophin	O
mRNA	O
processing	O
in	O
golden	B-SpecificDisease
retriever	I-SpecificDisease
muscular	I-SpecificDisease
dystrophy,	I-SpecificDisease
an	O
animal	O
homologue	O
of	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy.	I-SpecificDisease
Golden	B-SpecificDisease
retriever	I-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
GRMD	B-SpecificDisease
)	O
is	O
a	O
spontaneous	O
,	O
X-linked	O
,	O
progressively	O
fatal	O
disease	O
of	O
dogs	O
and	O
is	O
also	O
a	O
homologue	O
of	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)	O
.	O
Two-thirds	O
of	O
DMD	B-Modifier
patients	O
carry	O
detectable	O
deletions	O
in	O
their	O
dystrophin	O
gene	O
.	O
The	O
defect	O
underlying	O
the	O
remaining	O
one-third	O
of	O
DMD	B-Modifier
patients	O
is	O
undetermined	O
.	O
Analysis	O
of	O
the	O
canine	O
dystrophin	O
gene	O
in	O
normal	O
and	O
GRMD	B-Modifier
dogs	O
has	O
failed	O
to	O
demonstrate	O
any	O
detectable	O
loss	O
of	O
exons	O
.	O
Here	O
,	O
we	O
have	O
demonstrated	O
a	O
RNA	O
processing	O
error	O
in	O
GRMD	B-SpecificDisease
that	O
results	O
from	O
a	O
single	O
base	O
change	O
in	O
the	O
3	O
consensus	O
splice	O
site	O
of	O
intron	O
6	O
.	O
The	O
seventh	O
exon	O
is	O
then	O
skipped	O
,	O
which	O
predicts	O
a	O
termination	O
of	O
the	O
dystrophin	O
reading	O
frame	O
within	O
its	O
N-terminal	O
domain	O
in	O
exon	O
8	O
.	O
This	O
is	O
the	O
first	O
example	O
of	O
dystrophin	B-SpecificDisease
deficiency	I-SpecificDisease
caused	O
by	O
a	O
splice-site	O
mutation	O
.	O
.	O

10364518	O
Characterization	O
of	O
a	O
germline	O
mosaicism	O
in	O
families	O
with	O
Lowe	B-SpecificDisease
syndrome,	I-SpecificDisease
and	O
identification	O
of	O
seven	O
novel	O
mutations	O
in	O
the	O
OCRL1	O
gene.	O
The	O
oculocerebrorenal	B-SpecificDisease
syndrome	I-SpecificDisease
of	I-SpecificDisease
Lowe	I-SpecificDisease
(	O
OCRL	B-SpecificDisease
)	O
is	O
an	O
X-linked	B-DiseaseClass
disorder	I-DiseaseClass
characterized	O
by	O
major	O
abnormalities	B-CompositeMention
of	I-CompositeMention
eyes	I-CompositeMention
,	I-CompositeMention
nervous	I-CompositeMention
system	I-CompositeMention
,	I-CompositeMention
and	I-CompositeMention
kidneys	I-CompositeMention
.	O
Mutations	O
in	O
the	O
OCRL1	O
gene	O
have	O
been	O
associated	O
with	O
the	O
disease	O
.	O
OCRL1	O
encodes	O
a	O
phosphatidylinositol	O
4	O
,	O
5-biphosphate	O
(	O
PtdIns	O
[	O
4	O
,	O
5	O
]	O
P2	O
)	O
5-phosphatase	O
.	O
We	O
have	O
examined	O
the	O
OCRL1	O
gene	O
in	O
eight	O
unrelated	O
patients	O
with	O
OCRL	B-SpecificDisease
and	O
have	O
found	O
seven	O
new	O
mutations	O
and	O
one	O
recurrent	O
in-frame	O
deletion	O
.	O
Among	O
the	O
new	O
mutations	O
,	O
two	O
nonsense	O
mutations	O
(	O
R317X	O
and	O
E558X	O
)	O
and	O
three	O
other	O
frameshift	O
mutations	O
caused	O
premature	O
termination	O
of	O
the	O
protein	O
.	O
A	O
missense	O
mutation	O
,	O
R483G	O
,	O
was	O
located	O
in	O
the	O
highly	O
conserved	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
5-phosphatase	O
domain	O
.	O
Finally	O
,	O
one	O
frameshift	O
mutation	O
,	O
2799delC	O
,	O
modifies	O
the	O
C-terminal	O
part	O
of	O
OCRL1	O
,	O
with	O
an	O
extension	O
of	O
six	O
amino	O
acids	O
.	O
Altogether	O
,	O
70	O
%	O
of	O
missense	O
mutations	O
are	O
located	O
in	O
exon	O
15	O
,	O
and	O
52	O
%	O
of	O
all	O
mutations	O
cluster	O
in	O
exons	O
11-15	O
.	O
We	O
also	O
identified	O
two	O
new	O
microsatellite	O
markers	O
for	O
the	O
OCRL1	O
locus	O
,	O
and	O
we	O
detected	O
a	O
germline	O
mosaicism	O
in	O
one	O
family	O
.	O
This	O
observation	O
has	O
direct	O
implications	O
for	O
genetic	O
counseling	O
of	O
Lowe	B-Modifier
syndrome	I-Modifier
families	O
.	O
.	O

1505217	O
Assignment	O
of	O
the	O
aspartylglucosaminidase	O
gene	O
(AGA)	O
to	O
4q33----q35	O
based	O
on	O
decreased	O
activity	O
in	O
a	O
girl	O
with	O
a	O
46,XX,del(4)(q33)	O
karyotype.	O
Aspartylglucosaminuria	B-SpecificDisease
(	O
AGU	B-SpecificDisease
)	O
is	O
a	O
recessive	O
autosomally	O
inherited	O
lysosomal	B-DiseaseClass
storage	I-DiseaseClass
disorder	I-DiseaseClass
due	O
to	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
enzyme	I-SpecificDisease
aspartylglucosaminidase	I-SpecificDisease
(	O
AGA	O
)	O
.	O
The	O
structural	O
gene	O
for	O
this	O
human	O
enzyme	O
(	O
AGA	O
)	O
has	O
been	O
assigned	O
to	O
the	O
region	O
4q21----qter	O
.	O
We	O
determined	O
the	O
AGA	O
activity	O
in	O
cultured	O
fibroblasts	O
of	O
a	O
girl	O
with	O
a	O
46	O
,	O
XX	O
,	O
del	O
(	O
4	O
)	O
(	O
q33	O
)	O
karyotype	O
.	O
The	O
results	O
indicate	O
that	O
the	O
girl	O
is	O
a	O
hemizygote	O
for	O
AGA	O
,	O
permitting	O
the	O
assignment	O
of	O
human	O
AGA	O
to	O
the	O
region	O
4q33----qter	O
.	O
.	O

10923035	O
Study	O
of	O
the	O
voltage-gated	O
sodium	O
channel	O
beta	O
1	O
subunit	O
gene	O
(SCN1B)	O
in	O
the	O
benign	B-SpecificDisease
familial	I-SpecificDisease
infantile	I-SpecificDisease
convulsions	I-SpecificDisease
syndrome	I-SpecificDisease
(BFIC).	O
Benign	B-SpecificDisease
familial	I-SpecificDisease
infantile	I-SpecificDisease
convulsions	I-SpecificDisease
(	O
BFIC	B-SpecificDisease
)	O
is	O
a	O
rare	O
autosomal	B-DiseaseClass
dominant	I-DiseaseClass
epilepsy	I-DiseaseClass
syndrome	I-DiseaseClass
.	O
This	O
syndrome	O
has	O
been	O
recently	O
described	O
in	O
Italian	O
and	O
French	O
pedigrees	O
.	O
Patients	O
present	O
with	O
partial	O
,	O
then	O
generalized	O
seizures	O
,	O
with	O
onset	O
at	O
age	O
three	O
months	O
.	O
The	O
seizures	O
usually	O
spontaneously	O
cease	O
after	O
one	O
year	O
without	O
treatment	O
,	O
leaving	O
no	O
neurological	B-DiseaseClass
abnormalities	I-DiseaseClass
.	O
We	O
have	O
mapped	O
BFIC	B-SpecificDisease
to	O
chromosome	O
19q	O
in	O
five	O
Italian	O
pedigrees	O
.	O
The	O
sodium	O
channel	O
beta1	O
subunit	O
gene	O
(	O
SCN1B	O
)	O
maps	O
to	O
this	O
candidate	O
region	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
one	O
Australian	O
pedigree	O
with	O
generalized	B-SpecificDisease
epilepsy	I-SpecificDisease
and	I-SpecificDisease
febrile	I-SpecificDisease
seizures	I-SpecificDisease
"	I-SpecificDisease
plus	I-SpecificDisease
"	I-SpecificDisease
(	O
GEFS	B-SpecificDisease
+	I-SpecificDisease
)	O
.	O
In	O
this	O
family	O
,	O
a	O
missense	O
mutation	O
in	O
SCN1B	O
cosegregates	O
with	O
the	O
GEFS	B-Modifier
+	I-Modifier
phenotype	O
.	O
BFIC	B-SpecificDisease
and	O
GEFS	B-SpecificDisease
+	I-SpecificDisease
have	O
clinical	O
features	O
in	O
common	O
,	O
therefore	O
SCN1B	O
is	O
a	O
candidate	O
gene	O
for	O
BFIC	B-SpecificDisease
.	O
We	O
studied	O
SCN1B	O
exons	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
,	O
using	O
four	O
SSCP	O
methods	O
in	O
10	O
Caucasian	O
BFIC	B-Modifier
probands	O
of	O
Western	O
Europe	O
.	O
We	O
found	O
no	O
exon	O
variants	O
.	O
One	O
variant	O
was	O
identified	O
in	O
intron	O
5	O
(	O
IVS5-10C	O
>	O
G	O
)	O
,	O
which	O
did	O
not	O
segregate	O
with	O
BFIC	B-SpecificDisease
and	O
was	O
observed	O
in	O
9	O
.	O
2	O
%	O
controls	O
.	O
A	O
second	O
variant	O
in	O
intron	O
5	O
was	O
identified	O
(	O
IVS5	O
+	O
30G	O
>	O
A	O
)	O
.	O
It	O
was	O
rare	O
,	O
as	O
not	O
observed	O
in	O
controls	O
,	O
but	O
not	O
segregating	O
with	O
the	O
BFIC	B-Modifier
phenotype	O
.	O

10556283	O
Spectrum	O
of	O
hSNF5/INI1	O
somatic	O
mutations	O
in	O
human	O
cancer	B-DiseaseClass
and	O
genotype-phenotype	O
correlations.	O
The	O
hSNF5	O
/	O
INI1	O
gene	O
which	O
encodes	O
a	O
member	O
of	O
the	O
SWI	O
/	O
SNF	O
chromatin	O
ATP-dependent	O
remodeling	O
complex	O
,	O
is	O
a	O
new	O
tumor	B-Modifier
suppressor	O
gene	O
localized	O
on	O
chromosome	O
22q11	O
.	O
2	O
and	O
recently	O
shown	O
to	O
be	O
mutated	O
in	O
malignant	B-DiseaseClass
rhabdoid	I-DiseaseClass
tumors	I-DiseaseClass
.	O
We	O
have	O
searched	O
for	O
hSNF5	O
/	O
INI1	O
mutations	O
in	O
229	O
tumors	B-DiseaseClass
of	O
various	O
origins	O
using	O
a	O
screening	O
method	O
based	O
on	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
.	O
A	O
total	O
of	O
31	O
homozygous	O
deletions	O
and	O
36	O
point	O
alterations	O
were	O
identified	O
.	O
Point	O
mutations	O
were	O
scattered	O
along	O
the	O
coding	O
sequence	O
and	O
included	O
15	O
nonsense	O
,	O
15	O
frameshift	O
,	O
three	O
splice	O
site	O
,	O
two	O
missense	O
and	O
one	O
editing	O
mutations	O
.	O
Mutations	O
were	O
retrieved	O
in	O
most	O
rhabdoid	B-DiseaseClass
tumors	I-DiseaseClass
,	O
whatever	O
their	O
sites	O
of	O
occurrence	O
,	O
indicating	O
the	O
common	O
pathogenetic	O
origin	O
of	O
these	O
tumors	B-DiseaseClass
.	O
Recurrent	O
hSNF5	O
/	O
INI1	O
alterations	O
were	O
also	O
observed	O
in	O
choroid	B-SpecificDisease
plexus	I-SpecificDisease
carcinomas	I-SpecificDisease
and	O
in	O
a	O
subset	O
of	O
central	O
primitive	O
neuroectodermal	B-DiseaseClass
tumors	I-DiseaseClass
(	O
cPNETs	O
)	O
and	O
medulloblastomas	B-SpecificDisease
.	O
In	O
contrast	O
,	O
hSNF5	O
/	O
INI1	O
point	O
mutations	O
were	O
not	O
detected	O
in	O
breast	B-SpecificDisease
cancers	I-SpecificDisease
,	O
Wilms	B-SpecificDisease
tumors	I-SpecificDisease
,	O
gliomas	B-SpecificDisease
,	O
ependymomas	B-SpecificDisease
,	O
sarcomas	B-DiseaseClass
and	O
other	O
tumor	B-Modifier
types	O
,	O
even	O
though	O
most	O
analyzed	O
cases	O
harbored	O
loss	O
of	O
heterozygosity	O
at	O
22q11	O
.	O
2	O
loci	O
.	O
These	O
results	O
suggest	O
that	O
rhabdoid	B-DiseaseClass
tumors	I-DiseaseClass
,	O
choroid	B-SpecificDisease
plexus	I-SpecificDisease
carcinomas	I-SpecificDisease
and	O
a	O
subset	O
of	O
medulloblastomas	B-SpecificDisease
and	O
cPNETs	O
share	O
common	O
pathways	O
of	O
oncogenesis	O
related	O
to	O
hSNF5	O
/	O
INI1	O
alteration	O
and	O
that	O
hSNF5	O
/	O
INI1	O
mutations	O
define	O
a	O
genetically	O
homogeneous	O
family	O
of	O
highly	O
aggressive	O
cancers	B-DiseaseClass
mainly	O
occurring	O
in	O
young	O
children	O
and	O
frequently	O
,	O
but	O
not	O
always	O
,	O
exhibiting	O
a	O
rhabdoid	B-Modifier
phenotype	O

1301200	O
Two	O
missense	O
mutations	O
causing	O
mild	O
hyperphenylalaninemia	B-DiseaseClass
associated	O
with	O
DNA	O
haplotype	O
12.	O
The	O
genetic	B-DiseaseClass
defects	I-DiseaseClass
responsible	O
for	O
most	O
phenylketonuria	B-SpecificDisease
(	O
PKU	B-SpecificDisease
)	O
and	O
hyperphenylalaninemia	B-DiseaseClass
(	O
HPA	B-DiseaseClass
)	O
cases	O
are	O
located	O
in	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
.	O
Approximately	O
50-60	O
mutations	O
have	O
been	O
reported	O
in	O
Caucasians	O
and	O
are	O
reflected	O
in	O
a	O
wide	O
range	O
of	O
clinical	O
severities	O
.	O
Most	O
mutations	O
are	O
linked	O
to	O
specific	O
haplotypes	O
,	O
as	O
defined	O
by	O
eight	O
polymorphic	O
restriction	O
sites	O
in	O
the	O
PAH	O
gene	O
.	O
We	O
hypothesized	O
that	O
there	O
is	O
at	O
least	O
one	O
mild	O
mutation	O
linked	O
to	O
haplotype	O
12	O
in	O
the	O
Swedish	O
PKU	B-Modifier
/	O
HPA	B-Modifier
population	O
,	O
since	O
7	O
of	O
8	O
patients	O
carrying	O
haplotype	O
12	O
had	O
mild	O
HPA	B-DiseaseClass
.	O
Sequence	O
analysis	O
revealed	O
a	O
C-to-G	O
transversion	O
at	O
the	O
second	O
base	O
of	O
codon	O
322	O
,	O
resulting	O
in	O
a	O
substitution	O
of	O
glycine	O
for	O
alanine	O
,	O
in	O
four	O
mutant	O
haplotype	O
12	O
genes	O
,	O
and	O
a	O
G-to-A	O
transition	O
at	O
the	O
second	O
base	O
of	O
codon	O
408	O
,	O
resulting	O
in	O
a	O
substitution	O
of	O
glutamine	O
for	O
arginine	O
,	O
in	O
another	O
three	O
mutant	O
haplotype	O
12	O
genes	O
.	O
These	O
mutations	O
segregated	O
with	O
mutant	O
haplotype	O
12	O
alleles	O
in	O
nuclear	O
families	O
but	O
were	O
not	O
present	O
on	O
normal	O
or	O
other	O
mutant	O
alleles	O
.	O
Both	O
mutations	O
were	O
tested	O
in	O
a	O
eukaryotic	O
expression	O
system	O
in	O
which	O
enzyme	O
activities	O
of	O
different	O
mutant	O
PAH	O
enzymes	O
reflect	O
the	O
relative	O
severities	O
of	O
the	O
mutations	O
,	O
although	O
these	O
in	O
vitro	O
activities	O
cannot	O
be	O
translated	O
directly	O
into	O
in	O
vivo	O
hepatic	O
activities	O
.	O
The	O
A322G	O
mutant	O
PAH	O
had	O
about	O
75	O
%	O
and	O
the	O
R408Q	O
mutant	O
PAH	O
about	O
55	O
%	O
of	O
the	O
wild-type	O
PAH	O
enzyme	O
activity	O
.	O
These	O
in	O
vitro	O
activities	O
are	O
the	O
highest	O
reported	O
for	O
mutant	O
PAH	O
enzymes	O
produced	O
in	O
the	O
same	O
expression	O
system	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

3348216	O
Glucose	B-SpecificDisease
6-phosphate	I-SpecificDisease
dehydrogenase	I-SpecificDisease
deficiency	I-SpecificDisease
and	O
incidence	O
of	O
hematologic	B-DiseaseClass
malignancy.	I-DiseaseClass
We	O
have	O
evaluated	O
the	O
hypothesis	O
of	O
a	O
negative	O
association	O
between	O
glucose	B-SpecificDisease
6-phosphate	I-SpecificDisease
dehydrogenase	I-SpecificDisease
(	I-SpecificDisease
G6PD	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
and	O
cancer	B-DiseaseClass
in	O
a	O
cohort	O
of	O
481	O
Sardinian	O
males	O
with	O
hematological	B-DiseaseClass
malignancies	I-DiseaseClass
.	O
The	O
frequency	O
of	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
in	O
the	O
patients	O
was	O
not	O
different	O
from	O
the	O
incidence	O
in	O
a	O
group	O
of	O
16	O
,	O
219	O
controls	O
.	O
The	O
same	O
conclusion	O
resulted	O
from	O
the	O
comparison	O
of	O
the	O
frequency	O
of	O
expression	O
of	O
the	O
GdB	O
gene	O
in	O
23	O
heterozygous	O
women	O
having	O
a	O
clonal	O
hematologic	B-DiseaseClass
disease	I-DiseaseClass
and	O
a	O
control	O
group	O
of	O
37	O
healthy	O
heterozygotes	O
.	O
Therefore	O
at	O
present	O
there	O
is	O
no	O
evidence	O
that	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
has	O
a	O
protective	O
effect	O
against	O
development	O
of	O
hematologic	B-DiseaseClass
neoplasms	I-DiseaseClass
.	O
.	O

10662807	O
Haim-Munk	B-SpecificDisease
syndrome	I-SpecificDisease
and	O
Papillon-Lefevre	B-SpecificDisease
syndrome	I-SpecificDisease
are	O
allelic	O
mutations	O
in	O
cathepsin	O
C.	O
Of	O
the	O
many	O
palmoplantar	B-DiseaseClass
keratoderma	I-DiseaseClass
(	I-DiseaseClass
PPK	I-DiseaseClass
)	I-DiseaseClass
conditions	I-DiseaseClass
,	O
only	O
Papillon-Lefevre	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
PLS	B-SpecificDisease
)	O
and	O
Haim-Munk	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
HMS	B-SpecificDisease
)	O
are	O
associated	O
with	O
premature	O
periodontal	O
destruction	O
.	O
Although	O
both	O
PLS	B-SpecificDisease
and	O
HMS	B-SpecificDisease
share	O
the	O
cardinal	O
features	O
of	O
PPK	B-DiseaseClass
and	O
severe	O
periodontitis	B-SpecificDisease
,	O
a	O
number	O
of	O
additional	O
findings	O
are	O
reported	O
in	O
HMS	B-SpecificDisease
including	O
arachnodactyly	B-SpecificDisease
,	O
acro-osteolysis	B-SpecificDisease
,	O
atrophic	B-SpecificDisease
changes	I-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
nails	I-SpecificDisease
,	O
and	O
a	O
radiographic	B-SpecificDisease
deformity	I-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
fingers	I-SpecificDisease
.	O
While	O
PLS	B-Modifier
cases	O
have	O
been	O
identified	O
throughout	O
the	O
world	O
,	O
HMS	B-SpecificDisease
has	O
only	O
been	O
described	O
among	O
descendants	O
of	O
a	O
religious	O
isolate	O
originally	O
from	O
Cochin	O
,	O
India	O
.	O
Parental	O
consanguinity	O
is	O
a	O
characteristic	O
of	O
many	O
cases	O
of	O
both	O
conditions	O
.	O
Although	O
autosomal	O
recessive	O
transmission	O
of	O
PLS	B-SpecificDisease
is	O
evident	O
,	O
a	O
more	O
"	O
complex	O
"	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
with	O
phenotypic	O
influences	O
from	O
a	O
closely	O
linked	O
modifying	O
locus	O
has	O
been	O
hypothesised	O
for	O
HMS	B-SpecificDisease
.	O
Recently	O
,	O
mutations	O
of	O
the	O
cathepsin	O
C	O
gene	O
have	O
been	O
identified	O
as	O
the	O
underlying	O
genetic	B-DiseaseClass
defect	I-DiseaseClass
in	O
PLS	B-SpecificDisease
.	O
To	O
determine	O
if	O
a	O
cathepsin	O
C	O
mutation	O
is	O
also	O
responsible	O
for	O
HMS	B-SpecificDisease
,	O
we	O
sequenced	O
the	O
gene	O
in	O
affected	O
and	O
unaffected	O
subjects	O
from	O
the	O
Cochin	O
isolate	O
in	O
which	O
both	O
the	O
PLS	B-Modifier
and	O
HMS	B-Modifier
phenotypes	O
appear	O
.	O
Here	O
we	O
report	O
identification	O
of	O
a	O
mutation	O
of	O
cathepsin	O
C	O
(	O
exon	O
6	O
,	O
2127A--	O
>	O
G	O
)	O
that	O
changes	O
a	O
highly	O
conserved	O
amino	O
acid	O
in	O
the	O
cathepsin	O
C	O
peptide	O
.	O
This	O
mutation	O
segregates	O
with	O
HMS	B-SpecificDisease
in	O
four	O
nuclear	O
families	O
.	O
Additionally	O
,	O
the	O
existence	O
of	O
a	O
shared	O
common	O
haplotype	O
for	O
genetic	O
loci	O
flanking	O
the	O
cathepsin	O
C	O
gene	O
suggests	O
that	O
affected	O
subjects	O
descended	O
from	O
the	O
Cochin	O
isolate	O
are	O
homozygous	O
for	O
a	O
mutation	O
inherited	O
"	O
identical	O
by	O
descent	O
"	O
from	O
a	O
common	O
ancestor	O
.	O
This	O
finding	O
supports	O
simple	O
autosomal	O
recessive	O
inheritance	O
for	O
HMS	B-SpecificDisease
in	O
these	O
families	O
.	O
We	O
also	O
report	O
a	O
mutation	O
of	O
the	O
same	O
exon	O
6	O
CTSC	O
codon	O
(	O
2126C--	O
>	O
T	O
)	O
in	O
a	O
Turkish	O
family	O
with	O
classical	O
PLS	B-SpecificDisease
.	O
These	O
findings	O
provide	O
evidence	O
that	O
PLS	B-SpecificDisease
and	O
HMS	B-SpecificDisease
are	O
allelic	O
variants	O
of	O
cathepsin	O
C	O
gene	O
mutations	O
.	O
.	O

2835825	O
Spontaneous	O
reversion	O
of	O
novel	O
Lesch-Nyhan	B-Modifier
mutation	O
by	O
HPRT	O
gene	O
rearrangement.	O
Molecular	O
analysis	O
of	O
an	O
unusual	O
patient	O
with	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
has	O
suggested	O
that	O
the	O
mutation	O
is	O
due	O
to	O
a	O
partial	O
HPRT	O
gene	O
duplication	O
.	O
We	O
now	O
report	O
the	O
cloning	O
and	O
sequencing	O
of	O
the	O
mutant	O
HPRT	O
cDNA	O
which	O
shows	O
the	O
precise	O
duplication	O
of	O
exons	O
2	O
and	O
3	O
.	O
This	O
mutation	O
is	O
the	O
result	O
of	O
an	O
internal	O
duplication	O
of	O
16-20	O
kilobases	O
of	O
the	O
gene	O
.	O
The	O
structure	O
of	O
the	O
mutant	O
gene	O
suggests	O
that	O
the	O
duplication	O
was	O
not	O
generated	O
by	O
a	O
single	O
unequal	O
crossing-over	O
event	O
between	O
two	O
normal	O
HPRT	O
alleles	O
.	O
Growth	O
of	O
Epstein-Barr	B-Modifier
virus-transformed	O
lymphoblasts	O
from	O
this	O
patient	O
in	O
selective	O
medium	O
has	O
permitted	O
isolation	O
of	O
spontaneous	O
HPRT	O
+	O
revertants	O
of	O
this	O
mutation	O
.	O
The	O
reversion	O
event	O
involves	O
a	O
second	O
major	O
HPRT	O
gene	O
rearrangement	O
where	O
most	O
or	O
all	O
of	O
the	O
duplicated	O
portion	O
of	O
the	O
mutant	O
gene	O
is	O
deleted	O
.	O
The	O
original	O
mutation	O
therefore	O
has	O
the	O
potential	O
for	O
spontaneous	O
somatic	O
reversion	O
.	O
This	O
may	O
explain	O
the	O
relatively	O
mild	O
symptoms	O
of	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
exhibited	O
by	O
this	O
patient	O
.	O
.	O

2037285	O
Localisation	O
of	O
the	O
myotonic	B-Modifier
dystrophy	I-Modifier
locus	O
to	O
19q13.2-19q13.3	O
and	O
its	O
relationship	O
to	O
twelve	O
polymorphic	O
loci	O
on	O
19q.	O
The	O
order	O
of	O
fourteen	O
polymorphic	O
markers	O
localised	O
to	O
the	O
long	O
arm	O
of	O
human	O
chromosome	O
19	O
has	O
been	O
established	O
by	O
multipoint	O
mapping	O
in	O
a	O
set	O
of	O
40	O
CEPH	O
(	O
Centre	O
dEtude	O
de	O
Polymorphisme	O
Humain	O
,	O
Paris	O
)	O
reference	O
families	O
.	O
We	O
report	O
here	O
the	O
linkage	O
relationship	O
of	O
the	O
myotonic	B-Modifier
dystrophy	I-Modifier
(	O
DM	B-Modifier
)	O
locus	O
to	O
twelve	O
of	O
these	O
markers	O
as	O
studied	O
in	O
45	O
families	O
with	O
DM	B-SpecificDisease
.	O
The	O
resulting	O
genetic	O
map	O
is	O
supported	O
by	O
the	O
localisation	O
of	O
the	O
DNA	O
markers	O
in	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
.	O
Ten	O
of	O
the	O
twelve	O
markers	O
have	O
been	O
shown	O
to	O
be	O
proximal	O
to	O
the	O
DM	B-Modifier
gene	O
and	O
two	O
,	O
PRKCG	O
and	O
D19S22	O
,	O
distal	O
but	O
at	O
distances	O
of	O
approximately	O
25	O
cM	O
and	O
15	O
cM	O
,	O
respectively	O
.	O
The	O
closest	O
proximal	O
markers	O
are	O
APOC2	O
(	O
apolipoprotein	O
C-II	O
)	O
and	O
CKM	O
(	O
creatine	O
kinase	O
,	O
muscle	O
)	O
approximately	O
3	O
cM	O
and	O
2	O
cM	O
from	O
the	O
DM	B-Modifier
gene	O
respectively	O
,	O
in	O
the	O
order	O
APOC2-CKM-DM	O
.	O
The	O
distance	O
between	O
APOC2	O
,	O
CKM	O
and	O
DM	B-SpecificDisease
(	O
of	O
the	O
order	O
of	O
2	O
million	O
base	O
pairs	O
)	O
and	O
their	O
known	O
orientation	O
should	O
permit	O
directional	O
chromosome	O
walking	O
and	O
jumping	O
.	O
The	O
data	O
presented	O
here	O
should	O
enable	O
us	O
to	O
determine	O
whether	O
or	O
not	O
new	O
markers	O
are	O
distal	O
to	O
APOC2	O
/	O
CKM	O
and	O
thus	O
potentially	O
flank	O
the	O
DM	B-Modifier
gene	O
.	O
.	O

7586656	O
Southern	O
analysis	O
reveals	O
a	O
large	O
deletion	O
at	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
locus	O
in	O
a	O
patient	O
with	O
Lesch-Nyhan	B-SpecificDisease
syndrome.	I-SpecificDisease
Whole	O
genomic	O
hprt	O
clones	O
were	O
used	O
in	O
Southern	O
analysis	O
to	O
screen	O
the	O
integrity	O
of	O
the	O
hprt	O
gene	O
in	O
a	O
family	O
that	O
includes	O
a	O
patient	O
with	O
HPRT	B-SpecificDisease
enzyme	I-SpecificDisease
deficiency	I-SpecificDisease
causal	O
to	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
A	O
5	O
kb	O
DNA	O
sequence	O
deletion	O
was	O
found	O
to	O
have	O
its	O
endpoints	O
in	O
the	O
first	O
and	O
third	O
introns	O
.	O
The	O
probes	O
identified	O
the	O
carrier	O
status	O
of	O
female	O
family	O
members	O
,	O
aided	O
by	O
an	O
RFLP	O
carried	O
by	O
the	O
mothers	O
normal	O
X-chromosome	O
.	O
.	O

2894613	O
Von	B-SpecificDisease
Hippel-Lindau	I-SpecificDisease
disease	I-SpecificDisease
maps	O
to	O
the	O
region	O
of	O
chromosome	O
3	O
associated	O
with	O
renal	B-SpecificDisease
cell	I-SpecificDisease
carcinoma.	I-SpecificDisease
Von	B-SpecificDisease
Hippel-Lindau	I-SpecificDisease
disease	I-SpecificDisease
(	O
VHL	B-SpecificDisease
)	O
is	O
an	O
autosomal	B-DiseaseClass
dominant	I-DiseaseClass
disorder	I-DiseaseClass
with	O
inherited	O
susceptibility	O
to	O
various	O
forms	O
of	O
cancer	B-DiseaseClass
,	O
including	O
hemangioblastomas	B-SpecificDisease
of	O
the	O
central	O
nervous	O
system	O
,	O
phaeochromocytomas	B-SpecificDisease
,	O
pancreatic	B-SpecificDisease
malignancies	I-SpecificDisease
,	O
and	O
renal	B-SpecificDisease
cell	I-SpecificDisease
carcinomas	I-SpecificDisease
.	O
Renal	B-SpecificDisease
cell	I-SpecificDisease
carcinomas	I-SpecificDisease
constitute	O
a	O
particularly	O
frequent	O
cause	O
of	O
death	O
in	O
this	O
disorder	O
,	O
occurring	O
as	O
bilateral	B-CompositeMention
and	I-CompositeMention
multifocal	I-CompositeMention
tumours	I-CompositeMention
,	O
and	O
presenting	O
at	O
an	O
earlier	O
age	O
than	O
in	O
sporadic	O
,	O
non-familial	O
cases	O
of	O
this	O
tumour	B-Modifier
type	O
.	O
We	O
report	O
here	O
that	O
the	O
VHL	B-Modifier
gene	O
is	O
linked	O
to	O
the	O
locus	O
encoding	O
the	O
human	O
homologoue	O
of	O
the	O
RAF1	O
oncogene	O
,	O
which	O
maps	O
to	O
chromosome	O
3p25	O
(	O
ref	O
.	O
4	O
)	O
.	O
Crossovers	O
with	O
the	O
VHL	B-Modifier
locus	O
suggest	O
that	O
the	O
defect	O
responsible	O
for	O
the	O
VHL	B-Modifier
phenotype	O
is	O
not	O
a	O
mutation	O
in	O
the	O
RAF1	O
gene	O
itself	O
.	O
An	O
alternative	O
or	O
prior	O
event	O
to	O
oncogene	O
activation	O
in	O
tumour	B-Modifier
formation	O
may	O
be	O
the	O
inactivation	O
of	O
a	O
putative	O
tumour	B-Modifier
suppressor	O
which	O
can	O
be	O
associated	O
with	O
both	O
the	O
inherited	B-CompositeMention
and	I-CompositeMention
sporadic	I-CompositeMention
forms	I-CompositeMention
of	I-CompositeMention
the	I-CompositeMention
cancer	I-CompositeMention
.	O
Sporadic	B-SpecificDisease
renal	I-SpecificDisease
cell	I-SpecificDisease
carcinomas	I-SpecificDisease
have	O
previously	O
been	O
associated	O
with	O
the	O
loss	O
of	O
regions	O
on	O
chromosome	O
3p	O
(	O
refs	O
5	O
,	O
6	O
)	O
.	O
Consequently	O
,	O
sporadic	O
and	O
VHL-associated	O
forms	O
of	O
renal	B-SpecificDisease
cell	I-SpecificDisease
carcinoma	I-SpecificDisease
might	O
both	O
result	O
from	O
alterations	O
causing	O
loss	O
of	O
function	O
of	O
the	O
same	O
tumour	B-Modifier
suppressor	O
gene	O
on	O
this	O
chromosome	O
.	O
.	O

7611277	O
Detection	O
of	O
eight	O
BRCA1	O
mutations	O
in	O
10	O
breast/ovarian	B-Modifier
cancer	I-Modifier
families,	O
including	O
1	O
family	O
with	O
male	B-SpecificDisease
breast	I-SpecificDisease
cancer.	I-SpecificDisease
Genetic	O
epidemiological	O
evidence	O
suggests	O
that	O
mutations	O
in	O
BRCA1	O
may	O
be	O
responsible	O
for	O
approximately	O
one	O
half	O
of	O
early	O
onset	O
familial	B-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
and	O
the	O
majority	O
of	O
familial	B-CompositeMention
breast	I-CompositeMention
/	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
.	O
The	O
recent	O
cloning	O
of	O
BRCA1	O
allows	O
for	O
the	O
direct	O
detection	O
of	O
mutations	O
,	O
but	O
the	O
feasibility	O
of	O
presymptomatic	O
screening	O
for	O
cancer	B-Modifier
susceptibility	O
is	O
unknown	O
.	O
We	O
analyzed	O
genomic	O
DNA	O
from	O
one	O
affected	O
individual	O
from	O
each	O
of	O
24	O
families	O
with	O
at	O
least	O
three	O
cases	O
of	O
ovarian	B-CompositeMention
or	I-CompositeMention
breast	I-CompositeMention
cancer	I-CompositeMention
,	O
using	O
SSCP	O
assays	O
.	O
Variant	O
SSCP	O
bands	O
were	O
subcloned	O
and	O
sequenced	O
.	O
Allele-specific	O
oligonucleotide	O
hybridization	O
was	O
used	O
to	O
verify	O
sequence	O
changes	O
and	O
to	O
screen	O
DNA	O
from	O
control	O
individuals	O
.	O
Six	O
frameshift	O
and	O
two	O
missense	O
mutations	O
were	O
detected	O
in	O
10	O
different	O
families	O
.	O
A	O
frameshift	O
mutation	O
was	O
detected	O
in	O
a	O
male	O
proband	O
affected	O
with	O
both	O
breast	B-CompositeMention
and	I-CompositeMention
prostate	I-CompositeMention
cancer	I-CompositeMention
.	O
A	O
40-bp	O
deletion	O
was	O
detected	O
in	O
a	O
patient	O
who	O
developed	O
intra-abdominal	B-DiseaseClass
carcinomatosis	I-DiseaseClass
1	O
year	O
after	O
prophylactic	O
oophorectomy	O
.	O
Mutations	O
were	O
detected	O
throughout	O
the	O
gene	O
,	O
and	O
only	O
one	O
was	O
detected	O
in	O
more	O
than	O
a	O
single	O
family	O
.	O
These	O
results	O
provide	O
further	O
evidence	O
that	O
inherited	B-CompositeMention
breast	I-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
can	O
occur	O
as	O
a	O
consequence	O
of	O
a	O
wide	O
array	O
of	O
BRCA1	O
mutations	O
.	O
These	O
results	O
suggests	O
that	O
development	O
of	O
a	O
screening	O
test	O
for	O
BRCA1	O
mutations	O
will	O
be	O
technically	O
challenging	O
.	O
The	O
finding	O
of	O
a	O
mutation	O
in	O
a	O
family	O
with	O
male	B-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
,	O
not	O
previously	O
thought	O
to	O
be	O
related	O
to	O
BRCA1	O
,	O
also	O
illustrates	O
the	O
potential	O
difficulties	O
of	O
genetic	O
counseling	O
for	O
individuals	O
known	O
to	O
carry	O
mutations	O
.	O
.	O

7605382	O
Frequency	O
of	O
exon	O
15	O
missense	O
mutation	O
(442D:G)	O
in	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
in	O
hyperalphalipoproteinemic	B-Modifier
Japanese	O
subjects.	O
Cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
transfers	O
cholesteryl	O
ester	O
from	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
to	O
apo	O
B-containing	O
lipoproteins	O
.	O
The	O
hyperalphalipoproteinemia	B-SpecificDisease
caused	O
by	O
CETP	B-SpecificDisease
deficiency	I-SpecificDisease
is	O
fairly	O
common	O
in	O
Japan	O
and	O
one	O
of	O
the	O
most	O
common	O
mutations	O
in	O
the	O
CETP	O
gene	O
is	O
the	O
splicing	O
defect	O
of	O
the	O
intron	O
14	O
,	O
the	O
allelic	O
frequency	O
of	O
which	O
has	O
been	O
shown	O
to	O
be	O
0	O
.	O
0049	O
in	O
the	O
Japanese	O
general	O
population	O
.	O
Recently	O
,	O
we	O
have	O
reported	O
a	O
missense	O
mutation	O
in	O
exon	O
15	O
of	O
the	O
CETP	O
gene	O
(	O
442D	O
G	O
)	O
,	O
showing	O
a	O
dominant	O
effect	O
on	O
the	O
CETP	O
activity	O
and	O
HDL-cholesterol	O
level	O
.	O
In	O
the	O
current	O
study	O
,	O
we	O
determined	O
the	O
frequency	O
of	O
this	O
new	O
mutation	O
in	O
Japanese	O
hyperalphalipoproteinemic	B-Modifier
(	O
HDL-cholesterol	O
>	O
or	O
=	O
100	O
mg	O
/	O
dl	O
)	O
subjects	O
.	O
A	O
rapid	O
and	O
easy	O
screening	O
method	O
for	O
this	O
new	O
mutation	O
was	O
developed	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-mediated	O
site-directed	O
mutagenesis	O
.	O
Among	O
117	O
Japanese	O
hyperalphalipoproteinemic	B-Modifier
subjects	O
(	O
HDL-cholesterol	O
;	O
116	O
.	O
7	O
+	O
/	O
-	O
16	O
.	O
5	O
mg	O
/	O
dl	O
,	O
mean	O
+	O
/	O
-	O
S	O
.	O
D	O
.	O
)	O
without	O
the	O
intron	O
14	O
splice	O
defect	O
,	O
three	O
homozygotes	O
(	O
2	O
.	O
5	O
%	O
)	O
and	O
34	O
heterozygotes	O
(	O
29	O
.	O
1	O
%	O
)	O
were	O
found	O
to	O
have	O
the	O
442D	O
G	O
mutation	O
.	O
The	O
relative	O
allelic	O
frequency	O
of	O
this	O
mutation	O
was	O
calculated	O
to	O
be	O
0	O
.	O
17	O
.	O
One	O
of	O
the	O
homozygotes	O
for	O
the	O
442D	O
G	O
mutation	O
was	O
the	O
patient	O
previously	O
described	O
by	O
us	O
as	O
having	O
hyperalphalipoproteinemia	B-SpecificDisease
with	O
corneal	B-SpecificDisease
opacity	I-SpecificDisease
and	O
coronary	B-SpecificDisease
heart	I-SpecificDisease
disease	I-SpecificDisease
.	O
This	O
was	O
the	O
first	O
reported	O
subject	O
homozygous	O
for	O
the	O
CETP	B-SpecificDisease
deficiency	I-SpecificDisease
who	O
also	O
demonstrated	O
atherosclerotic	B-DiseaseClass
symptoms	I-DiseaseClass
.	O
In	O
homozygous	O
subjects	O
,	O
CETP	O
activity	O
ranged	O
from	O
37	O
%	O
to	O
62	O
%	O
of	O
the	O
normal	O
value	O
,	O
which	O
was	O
consistent	O
with	O
the	O
results	O
obtained	O
from	O
the	O
transient	O
expression	O
experiment	O
previously	O
reported	O
;	O
however	O
,	O
the	O
specific	O
activity	O
of	O
CETP	O
was	O
not	O
as	O
low	O
as	O
expected	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

1833974	O
Sequence	O
of	O
DNA	O
flanking	O
the	O
exons	O
of	O
the	O
HEXA	O
gene,	O
and	O
identification	O
of	O
mutations	O
in	O
Tay-Sachs	B-SpecificDisease
disease.	I-SpecificDisease
The	O
rapid	O
identification	O
of	O
mutations	O
causing	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
requires	O
the	O
capacity	O
to	O
readily	O
screen	O
the	O
regions	O
of	O
the	O
HEXA	O
gene	O
most	O
likely	O
to	O
be	O
affected	O
by	O
mutation	O
.	O
We	O
have	O
sequenced	O
the	O
portions	O
of	O
the	O
introns	O
flanking	O
each	O
of	O
the	O
14	O
HEXA	O
exons	O
in	O
order	O
to	O
specify	O
oligonucleotide	O
primers	O
for	O
the	O
PCR-dependent	O
amplification	O
of	O
each	O
exon	O
and	O
splice-junction	O
sequence	O
.	O
The	O
amplified	O
products	O
were	O
analyzed	O
,	O
by	O
electrophoresis	O
in	O
nondenaturing	O
polyacrylamide	O
gels	O
,	O
for	O
the	O
presence	O
of	O
either	O
heteroduplexes	O
,	O
derived	O
from	O
the	O
annealing	O
of	O
normal	O
and	O
mutant	O
DNA	O
strands	O
,	O
or	O
single-strand	O
conformational	O
polymorphisms	O
(	O
SSCP	O
)	O
,	O
derived	O
from	O
the	O
renaturation	O
of	O
single-stranded	O
DNA	O
.	O
Five	O
novel	O
mutations	O
from	O
Tay-Sachs	B-Modifier
disease	I-Modifier
patients	O
were	O
detected	O
a	O
5-bp	O
deletion	O
of	O
TCTCC	O
in	O
IVS-9	O
;	O
a	O
2-bp	O
deletion	O
of	O
TG	O
in	O
exon	O
5	O
;	O
G78	O
to	O
A	O
,	O
giving	O
a	O
stop	O
codon	O
in	O
exon	O
1	O
;	O
G533	O
to	O
T	O
in	O
exon	O
5	O
,	O
producing	O
the	O
third	O
amino	O
acid	O
substitution	O
detected	O
at	O
this	O
site	O
;	O
and	O
G	O
to	O
C	O
at	O
position	O
1	O
of	O
IVS-2	O
,	O
expected	O
to	O
produce	O
abnormal	O
splicing	O
.	O
In	O
addition	O
,	O
two	O
mutations	O
,	O
(	O
G1496	O
to	O
A	O
in	O
exon	O
13	O
and	O
a	O
4-bp	O
insertion	O
in	O
exon	O
11	O
)	O
that	O
have	O
previously	O
been	O
reported	O
were	O
identified	O
.	O
.	O

7652577	O
A	O
p16INK4a-insensitive	O
CDK4	O
mutant	O
targeted	O
by	O
cytolytic	O
T	O
lymphocytes	O
in	O
a	O
human	O
melanoma.	B-SpecificDisease
A	O
mutated	O
cyclin-dependent	O
kinase	O
4	O
(	O
CDK4	O
)	O
was	O
identified	O
as	O
a	O
tumor-specific	B-Modifier
antigen	O
recognized	O
by	O
HLA-A2	O
.	O
1-restricted	O
autologous	O
cytolytic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
in	O
a	O
human	O
melanoma	B-SpecificDisease
.	O
The	O
mutated	O
CDK4	O
allele	O
was	O
present	O
in	O
autologous	O
cultured	O
melanoma	B-Modifier
cells	O
and	O
metastasis	O
tissue	O
,	O
but	O
not	O
in	O
the	O
patients	O
lymphocytes	O
.	O
The	O
mutation	O
,	O
an	O
arginine-to-cysteine	O
exchange	O
at	O
residue	O
24	O
,	O
was	O
part	O
of	O
the	O
CDK4	O
peptide	O
recognized	O
by	O
CTLs	O
and	O
prevented	O
binding	O
of	O
the	O
CDK4	O
inhibitor	O
p16INK4a	O
,	O
but	O
not	O
of	O
p21	O
or	O
of	O
p27KIP1	O
.	O
The	O
same	O
mutation	O
was	O
found	O
in	O
one	O
additional	O
melanoma	B-SpecificDisease
among	O
28	O
melanomas	B-SpecificDisease
analyzed	O
.	O
These	O
results	O
suggest	O
that	O
mutation	O
of	O
CDK4	O
can	O
create	O
a	O
tumor-specific	B-Modifier
antigen	O
and	O
can	O
disrupt	O
the	O
cell-cycle	O
regulation	O
exerted	O
by	O
the	O
tumor	B-Modifier
suppressor	O
p16INK4a	O
.	O
.	O

1307253	O
Detection	O
of	O
a	O
nonsense	O
mutation	O
in	O
the	O
dystrophin	O
gene	O
by	O
multiple	O
SSCP.	O
A	O
combination	O
of	O
multiplex	O
PCR	O
with	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
was	O
employed	O
to	O
screen	O
for	O
point	O
mutations	O
in	O
the	O
human	O
dystrophin	O
gene	O
.	O
Co-amplification	O
of	O
11	O
exons	O
from	O
genomic	O
DNA	O
of	O
Duchenne	B-Modifier
and	I-Modifier
Becker	I-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
(	O
DMD	B-Modifier
/	O
BMD	B-Modifier
)	O
patients	O
with	O
no	O
deletion	O
or	O
duplication	O
was	O
performed	O
and	O
the	O
samples	O
subjected	O
to	O
multiple	O
SSCP	O
analysis	O
.	O
We	O
report	O
the	O
case	O
of	O
a	O
nonsense	O
mutation	O
in	O
a	O
Duchenne	B-Modifier
patient	O
identified	O
by	O
this	O
approach	O
.	O
The	O
mutation	O
introduces	O
a	O
termination	O
codon	O
within	O
exon	O
8	O
of	O
the	O
dystrophin	O
gene	O
.	O
It	O
is	O
predicted	O
to	O
cause	O
a	O
very	O
premature	O
translational	O
termination	O
accounting	O
for	O
the	O
severe	O
phenotype	O
observed	O
.	O
The	O
patient	O
inherited	O
this	O
mutation	O
from	O
his	O
mother	O
.	O
In	O
addition	O
the	O
analysis	O
revealed	O
5	O
polymorphisms	O
useful	O
for	O
internal	O
control	O
.	O
.	O

10408776	O
Mutations	O
of	O
the	O
VHL	B-Modifier
gene	O
in	O
sporadic	B-SpecificDisease
renal	I-SpecificDisease
cell	I-SpecificDisease
carcinoma:	I-SpecificDisease
definition	O
of	O
a	O
risk	O
factor	O
for	O
VHL	B-Modifier
patients	O
to	O
develop	O
an	O
RCC.	B-SpecificDisease
To	O
investigate	O
the	O
nature	O
of	O
somatic	O
von	B-Modifier
Hippel-Lindau	I-Modifier
(	O
VHL	B-Modifier
)	O
mutations	O
,	O
we	O
analyzed	O
173	O
primary	O
sporadic	O
human	O
renal	B-SpecificDisease
cell	I-SpecificDisease
carcinomas	I-SpecificDisease
for	O
mutations	O
of	O
the	O
VHL	B-Modifier
tumor	I-Modifier
suppressor	O
gene	O
,	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
single-strand	O
conformational	O
polymorphism	O
analysis	O
(	O
SSCP	O
)	O
of	O
DNA	O
.	O
We	O
detected	O
abnormal	O
SSCP	O
pattern	O
in	O
73	O
samples	O
.	O
After	O
sequencing	O
,	O
we	O
identified	O
microdeletions	O
in	O
58	O
%	O
of	O
cases	O
,	O
microinsertions	O
in	O
17	O
%	O
,	O
nonsense	O
mutations	O
in	O
8	O
%	O
,	O
and	O
missense	O
mutations	O
in	O
17	O
%	O
.	O
Among	O
these	O
mutations	O
,	O
50	O
%	O
correspond	O
to	O
new	O
mutations	O
.	O
VHL	B-Modifier
mutations	O
were	O
found	O
only	O
in	O
the	O
nonpapillary	B-Modifier
renal	I-Modifier
cell	I-Modifier
carcinoma	I-Modifier
(	O
RCC	B-Modifier
)	O
subtype	O
,	O
as	O
previously	O
reported	O
.	O
To	O
compare	O
somatic	O
and	O
germline	O
mutations	O
,	O
we	O
used	O
the	O
VHL	B-Modifier
database	O
,	O
which	O
includes	O
507	O
mutations	O
.	O
The	O
study	O
of	O
mutational	O
events	O
revealed	O
a	O
significant	O
difference	O
between	O
somatic	O
and	O
germline	O
mutations	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
observed	O
in	O
78	O
%	O
of	O
somatic	O
mutations	O
vs	O
only	O
37	O
%	O
in	O
germline	O
mutations	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
We	O
postulated	O
that	O
a	O
specific	O
pattern	O
of	O
VHL	B-Modifier
mutations	O
is	O
associated	O
with	O
sporadic	B-SpecificDisease
RCC	I-SpecificDisease
.	O
This	O
pattern	O
corresponds	O
to	O
mutations	O
leading	O
mainly	O
to	O
truncated	O
proteins	O
with	O
few	O
specific	O
missense	O
mutations	O
.	O
We	O
then	O
analyzed	O
the	O
occurrence	O
of	O
RCC	B-SpecificDisease
in	O
VHL	B-Modifier
families	O
,	O
based	O
on	O
the	O
nature	O
of	O
mutations	O
.	O
We	O
observed	O
RCC	B-SpecificDisease
in	O
at	O
least	O
one	O
member	O
of	O
the	O
VHL	B-Modifier
families	O
in	O
77	O
%	O
of	O
cases	O
with	O
mutations	O
leading	O
to	O
truncated	O
proteins	O
versus	O
55	O
%	O
in	O
cases	O
with	O
missense	O
mutations	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Thus	O
,	O
mutations	O
resulting	O
in	O
truncated	O
proteins	O
may	O
lead	O
to	O
a	O
higher	O
risk	O
of	O
RCC	B-SpecificDisease
in	O
VHL	B-Modifier
patients	O

3480530	O
Deletions	O
of	O
a	O
DNA	O
sequence	O
in	O
retinoblastomas	B-SpecificDisease
and	O
mesenchymal	B-DiseaseClass
tumors:	I-DiseaseClass
organization	O
of	O
the	O
sequence	O
and	O
its	O
encoded	O
protein.	O
Retinoblastoma	B-SpecificDisease
is	O
a	O
childhood	B-DiseaseClass
tumor	I-DiseaseClass
that	O
can	O
arise	O
because	O
of	O
mutant	O
alleles	O
acquired	O
as	O
somatic	O
or	O
germinal	O
mutations	O
.	O
The	O
mutant	O
allele	O
can	O
be	O
carried	O
in	O
the	O
germ	O
line	O
.	O
The	O
mutations	O
creating	O
these	O
alleles	O
act	O
by	O
inactivating	O
copies	O
of	O
a	O
recessive	O
oncogene	O
located	O
within	O
band	O
q14	O
of	O
chromosome	O
13	O
and	O
termed	O
the	O
RB1	O
locus	O
.	O
We	O
have	O
reported	O
isolation	O
of	O
a	O
cDNA	O
fragment	O
that	O
recognizes	O
chromosomal	O
sequences	O
possessing	O
many	O
of	O
the	O
attributes	O
of	O
the	O
retinoblastoma	B-Modifier
gene	O
associated	O
with	O
the	O
RB1	O
locus	O
.	O
We	O
now	O
report	O
that	O
this	O
segment	O
is	O
additionally	O
the	O
target	O
of	O
somatic	O
mutations	O
in	O
mesenchymal	B-DiseaseClass
tumors	I-DiseaseClass
among	O
patients	O
having	O
no	O
apparent	O
predisposition	O
to	O
retinoblastoma	B-SpecificDisease
and	O
no	O
previous	O
evidence	O
of	O
retinoblastoma	B-SpecificDisease
.	O
These	O
tumors	B-DiseaseClass
provide	O
additional	O
evidence	O
that	O
the	O
cloned	O
sequences	O
are	O
representative	O
of	O
a	O
gene	O
that	O
is	O
a	O
frequent	O
target	O
of	O
inactivation	O
during	O
tumorigenesis	O
.	O
Sequence	O
analysis	O
of	O
this	O
cDNA	O
provides	O
little	O
insight	O
into	O
its	O
normal	O
functional	O
role	O
.	O
.	O

10924409	O
Inactivation	O
of	O
germline	O
mutant	O
APC	B-Modifier
alleles	O
by	O
attenuated	O
somatic	O
mutations:	O
a	O
molecular	O
genetic	O
mechanism	O
for	O
attenuated	B-SpecificDisease
familial	I-SpecificDisease
adenomatous	I-SpecificDisease
polyposis.	I-SpecificDisease
Germline	O
mutations	O
of	O
the	O
adenomatous	B-Modifier
polyposis	I-Modifier
coli	I-Modifier
(	I-Modifier
APC	I-Modifier
)	I-Modifier
tumor-suppressor	I-Modifier
gene	O
result	O
in	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
(	O
FAP	B-SpecificDisease
)	O
.	O
Patients	O
with	O
FAP	B-SpecificDisease
typically	O
develop	O
hundreds	O
to	O
thousands	O
of	O
benign	B-SpecificDisease
colorectal	I-SpecificDisease
tumors	I-SpecificDisease
and	O
early-onset	O
colorectal	B-SpecificDisease
cancer	I-SpecificDisease
.	O
A	O
subset	O
of	O
germline	O
APC	B-Modifier
mutations	O
results	O
in	O
an	O
attenuated	B-Modifier
FAP	I-Modifier
(	O
AFAP	B-Modifier
)	O
phenotype	O
,	O
in	O
which	O
patients	O
develop	O
fewer	O
tumors	B-DiseaseClass
and	O
develop	O
them	O
at	O
an	O
older	O
age	O
.	O
Although	O
a	O
genotype-phenotype	O
correlation	O
between	O
the	O
locations	O
of	O
APC	B-Modifier
germline	O
mutations	O
and	O
the	O
development	O
of	O
AFAP	B-SpecificDisease
has	O
been	O
well	O
documented	O
,	O
the	O
mechanism	O
for	O
AFAP	B-SpecificDisease
has	O
not	O
been	O
well	O
defined	O
.	O
We	O
investigated	O
the	O
mechanism	O
for	O
AFAP	B-SpecificDisease
in	O
patients	O
carrying	O
a	O
mutant	O
APC	B-Modifier
allele	O
(	O
APC	O
(	O
AS9	O
)	O
)	O
that	O
has	O
a	O
mutation	O
in	O
the	O
alternatively	O
spliced	O
region	O
of	O
exon	O
9	O
.	O
APC	O
(	O
AS9	O
)	O
was	O
found	O
to	O
down-regulate	O
beta-catenin-regulated	O
transcription	O
,	O
the	O
major	O
tumor-suppressor	B-Modifier
function	O
of	O
APC	O
,	O
as	O
did	O
the	O
wild-type	O
APC	O
.	O
Mutation	O
analysis	O
showed	O
that	O
both	O
APC	O
(	O
AS9	O
)	O
and	O
the	O
wild-type	O
APC	B-Modifier
alleles	O
were	O
somatically	O
mutated	O
in	O
most	O
colorectal	B-SpecificDisease
tumors	I-SpecificDisease
from	O
these	O
patients	O
.	O
Functional	O
analysis	O
showed	O
that	O
4666insA	O
,	O
a	O
common	O
somatic	O
mutation	O
in	O
APC	O
(	O
AS9	O
)	O
in	O
these	O
tumors	B-DiseaseClass
,	O
did	O
not	O
inactivate	O
the	O
wild-type	O
APC	O
.	O
Our	O
results	O
indicate	O
that	O
carriers	O
of	O
APC	O
(	O
AS9	O
)	O
develop	O
fewer	O
colorectal	B-SpecificDisease
tumors	I-SpecificDisease
than	O
do	O
typical	O
patients	O
with	O
FAP	B-SpecificDisease
because	O
somatic	O
inactivation	O
of	O
both	O
APC	B-Modifier
alleles	O
is	O
necessary	O
for	O
colorectal	O
tumorigenesis	O
.	O
However	O
,	O
these	O
patients	O
develop	O
colorectal	B-SpecificDisease
tumors	I-SpecificDisease
more	O
frequently	O
than	O
does	O
the	O
general	O
population	O
because	O
APC	O
(	O
AS9	O
)	O
is	O
inactivated	O
by	O
mutations	O
that	O
do	O
not	O
inactivate	O
the	O
wild-type	O
APC	O
.	O
.	O

10814710	O
Biochemical	O
and	O
structural	O
analysis	O
of	O
missense	O
mutations	O
in	O
N-acetylgalactosamine-6-sulfate	O
sulfatase	O
causing	O
mucopolysaccharidosis	B-Modifier
IVA	I-Modifier
phenotypes.	O
Mucopolysaccharidosis	B-SpecificDisease
IVA	I-SpecificDisease
(	O
MPS	B-SpecificDisease
IVA	I-SpecificDisease
;	O
OMIM	O
#	O
253000	O
)	O
,	O
a	O
lysosomal	B-DiseaseClass
storage	I-DiseaseClass
disorder	I-DiseaseClass
caused	O
by	O
a	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
N	I-SpecificDisease
-acetylgalactosamine-6-sulfate	I-SpecificDisease
sulfatase	I-SpecificDisease
(	O
GALNS	O
)	O
,	O
has	O
variable	O
clinical	O
phenotypes	O
.	O
To	O
date	O
we	O
have	O
identified	O
65	O
missense	O
mutations	O
in	O
the	O
GALNS	O
gene	O
from	O
MPS	B-Modifier
IVA	I-Modifier
patients	O
,	O
but	O
the	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
has	O
remained	O
unclear	O
.	O
We	O
studied	O
17	O
missense	O
mutations	O
using	O
biochemical	O
approaches	O
and	O
32	O
missense	O
mutations	O
,	O
using	O
structural	O
analyses	O
.	O
Fifteen	O
missense	O
mutations	O
and	O
two	O
newly	O
engineered	O
active	O
site	O
mutations	O
(	O
C79S	O
,	O
C79T	O
)	O
were	O
characterized	O
by	O
transient	O
expression	O
analysis	O
.	O
Mutant	O
proteins	O
,	O
except	O
for	O
C79S	O
and	O
C79T	O
,	O
were	O
destabilized	O
and	O
detected	O
as	O
insoluble	O
precursor	O
forms	O
while	O
the	O
C79S	O
and	O
C79T	O
mutants	O
were	O
of	O
a	O
soluble	O
mature	O
size	O
.	O
Mutants	O
found	O
in	O
the	O
severe	O
phenotype	O
had	O
no	O
activity	O
.	O
Mutants	O
found	O
in	O
the	O
mild	O
phenotype	O
had	O
a	O
considerable	O
residual	O
activity	O
(	O
1	O
.	O
3-13	O
.	O
3	O
%	O
of	O
wild-type	O
GALNS	O
activity	O
)	O
.	O
Sulfatases	O
,	O
including	O
GALNS	O
,	O
are	O
members	O
of	O
a	O
highly	O
conserved	O
gene	O
family	O
sharing	O
an	O
extensive	O
sequence	O
homology	O
.	O
Thus	O
,	O
a	O
tertiary	O
structural	O
model	O
of	O
human	O
GALNS	O
was	O
constructed	O
from	O
the	O
X-ray	O
crystal	O
structure	O
of	O
N	O
-acetylgalacto-samine-4-sulfatase	O
and	O
arylsulfatase	O
A	O
,	O
using	O
homology	O
modeling	O
,	O
and	O
32	O
missense	O
mutations	O
were	O
investigated	O
.	O
Consequently	O
,	O
we	O
propose	O
that	O
there	O
are	O
at	O
least	O
three	O
different	O
reasons	O
for	O
the	O
severe	O
phenotype	O
(	O
i	O
)	O
destruction	O
of	O
the	O
hydrophobic	O
core	O
or	O
modification	O
of	O
the	O
packing	O
;	O
(	O
ii	O
)	O
removal	O
of	O
a	O
salt	O
bridge	O
to	O
destabilize	O
the	O
entire	O
conformation	O
;	O
(	O
iii	O
)	O
modification	O
of	O
the	O
active	O
site	O
.	O
In	O
contrast	O
,	O
mild	O
mutations	O
were	O
mostly	O
located	O
on	O
the	O
surface	O
of	O
the	O
GALNS	O
protein	O
.	O
These	O
studies	O
shed	O
further	O
light	O
on	O
the	O
genotype-phenotype	O
correlation	O
of	O
MPS	B-SpecificDisease
IVA	I-SpecificDisease
and	O
structure-function	O
relationship	O
in	O
the	O
sulfatase	O
family	O
.	O

1673289	O
A	O
detailed	O
multipoint	O
map	O
of	O
human	O
chromosome	O
4	O
provides	O
evidence	O
for	O
linkage	O
heterogeneity	O
and	O
position-specific	O
recombination	O
rates.	O
Utilizing	O
the	O
CEPH	O
reference	O
panel	O
and	O
genotypic	O
data	O
for	O
53	O
markers	O
,	O
we	O
have	O
constructed	O
a	O
20-locus	O
multipoint	O
genetic	O
map	O
of	O
human	O
chromosome	O
4	O
.	O
New	O
RFLPs	O
are	O
reported	O
for	O
four	O
loci	O
.	O
The	O
map	O
integrates	O
a	O
high-resolution	O
genetic	O
map	O
of	O
4p16	O
into	O
a	O
continuous	O
map	O
extending	O
to	O
4q31	O
and	O
an	O
unlinked	O
cluster	O
of	O
three	O
loci	O
at	O
4q35	O
.	O
The	O
20	O
linked	O
markers	O
form	O
a	O
continuous	O
linkage	O
group	O
of	O
152	O
cM	O
in	O
males	O
and	O
202	O
cM	O
in	O
females	O
.	O
Likely	O
genetic	O
locations	O
are	O
provided	O
for	O
25	O
polymorphic	O
anonymous	O
sequences	O
and	O
28	O
gene-specific	O
RFLPs	O
.	O
The	O
map	O
was	O
constructed	O
employing	O
the	O
LINKAGE	O
and	O
CRIMAP	O
computational	O
methodologies	O
to	O
build	O
the	O
multipoint	O
map	O
via	O
a	O
stepwise	O
algorithm	O
.	O
A	O
detailed	O
10-point	O
map	O
of	O
the	O
4p16	O
region	O
constructed	O
from	O
the	O
CEPH	O
panel	O
provides	O
evidence	O
for	O
heterogeneity	O
in	O
the	O
linkage	O
maps	O
constructed	O
from	O
families	O
segregating	O
for	O
Huntington	B-SpecificDisease
disease	I-SpecificDisease
(	O
HD	B-SpecificDisease
)	O
.	O
It	O
additionally	O
provides	O
evidence	O
for	O
position-specific	O
recombination	O
frequencies	O
in	O
the	O
telomeric	O
region	O
of	O
4p	O
.	O
.	O

6086495	O
Localisation	O
of	O
the	O
Becker	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
gene	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
by	O
linkage	O
to	O
cloned	O
DNA	O
sequences.	O
A	O
linkage	O
study	O
in	O
30	O
Becker	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
BMD	B-SpecificDisease
)	O
kindreds	O
using	O
three	O
cloned	O
DNA	O
sequences	O
from	O
the	O
X	O
chromosome	O
which	O
demonstrate	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
,	O
suggests	O
that	O
the	O
BMD	B-Modifier
gene	O
is	O
located	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
in	O
the	O
p21	O
region	O
.	O
The	O
genes	O
for	O
Becker	B-CompositeMention
and	I-CompositeMention
Duchenne	I-CompositeMention
dystrophies	I-CompositeMention
must	O
therefore	O
be	O
closely	O
linked	O
,	O
if	O
not	O
allelic	O
,	O
and	O
any	O
future	O
DNA	O
probes	O
found	O
to	O
be	O
of	O
practical	O
use	O
in	O
one	O
disorder	O
should	O
be	O
equally	O
applicable	O
to	O
the	O
other	O
.	O
The	O
linkage	O
analysis	O
also	O
provides	O
data	O
on	O
the	O
frequency	O
of	O
recombination	O
along	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
and	O
across	O
the	O
centromeric	O
region	O
.	O
.	O

8500791	O
Autosomal	O
recessive	O
transmission	O
of	O
hemophilia	B-SpecificDisease
A	I-SpecificDisease
due	O
to	O
a	O
von	B-Modifier
Willebrand	I-Modifier
factor	O
mutation.	O
The	O
differential	O
diagnosis	O
of	O
the	O
genetic	B-DiseaseClass
bleeding	I-DiseaseClass
disorders	I-DiseaseClass
,	O
hemophilia	B-SpecificDisease
A	I-SpecificDisease
and	O
von	B-SpecificDisease
Willebrand	I-SpecificDisease
disease	I-SpecificDisease
,	O
is	O
occasionally	O
confounded	O
by	O
the	O
close	O
molecular	O
relationship	O
of	O
coagulation	O
factor	O
VIII	O
and	O
von	B-Modifier
Willebrand	I-Modifier
factor	O
(	O
vWF	O
)	O
.	O
This	O
report	O
describes	O
the	O
autosomal	O
inheritance	O
of	O
a	O
hemophilia	B-Modifier
A	I-Modifier
phenotype	O
due	O
to	O
a	O
mutation	O
of	O
vWF	O
that	O
results	O
in	O
defective	O
factor	O
VIII	O
binding	O
.	O
The	O
proband	O
was	O
a	O
female	O
patient	O
with	O
low	O
levels	O
of	O
factor	O
VIII	O
activity	O
.	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
DNA	O
sequencing	O
were	O
employed	O
to	O
examine	O
exons	O
encoding	O
the	O
putative	O
factor	O
VIII	O
binding	O
domain	O
of	O
vWF	O
.	O
The	O
patient	O
was	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
single	O
point	O
mutation	O
causing	O
a	O
Thr--	O
>	O
Met	O
substitution	O
at	O
amino	O
acid	O
position	O
28	O
in	O
the	O
mature	O
vWF	O
subunit	O
.	O
The	O
phenotypic	O
expression	O
of	O
the	O
mutation	O
was	O
determined	O
to	O
be	O
recessive	O
because	O
heterozygous	O
family	O
members	O
were	O
clinically	O
unaffected	O
.	O
Recombinant	O
vWF	O
containing	O
the	O
observed	O
amino	O
acid	O
substitution	O
was	O
expressed	O
in	O
COS-1	O
cells	O
.	O
The	O
mutant	O
vWF	O
was	O
processed	O
and	O
secreted	O
normally	O
,	O
and	O
was	O
functionally	O
equivalent	O
to	O
wild-type	O
vWF	O
in	O
its	O
ability	O
to	O
bind	O
to	O
platelets	O
.	O
However	O
,	O
the	O
mutant	O
failed	O
to	O
bind	O
factor	O
VIII	O
,	O
demonstrating	O
that	O
the	O
mutation	O
was	O
functionally	O
related	O
to	O
the	O
observed	O
hemophilia	B-Modifier
phenotype	O
.	O
The	O
family	O
we	O
describe	O
demonstrates	O
the	O
recessive	O
inheritance	O
of	O
a	O
recently	O
recognized	O
class	O
of	O
genetic	O
bleeding	O
disorders	O
,	O
we	O
call	O
"	O
autosomal	O
hemophilia	B-SpecificDisease
.	O
"	O
We	O
conclude	O
that	O
vWF	O
mutation	O
may	O
be	O
an	O
under	O
recognized	O
cause	O
of	O
hemophilia	B-SpecificDisease
,	O
especially	O
in	O
cases	O
where	O
the	O
inheritance	O
pattern	O
is	O
not	O
consistent	O
with	O
X-linked	O
transmission	O
.	O

8113388	O
Three	O
novel	O
mutations	O
in	O
five	O
unrelated	O
subjects	O
with	O
hereditary	O
protein	B-SpecificDisease
S	I-SpecificDisease
deficiency	I-SpecificDisease
type	I-SpecificDisease
I.	I-SpecificDisease
A	O
panel	O
of	O
eight	O
unrelated	O
subjects	O
with	O
inherited	O
type	B-SpecificDisease
I	I-SpecificDisease
protein	I-SpecificDisease
S	I-SpecificDisease
deficiency	I-SpecificDisease
was	O
screened	O
for	O
mutations	O
in	O
the	O
PROS1	O
gene	O
.	O
In	O
five	O
subjects	O
an	O
abnormality	O
was	O
found	O
but	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
remaining	O
three	O
subjects	O
.	O
Two	O
subjects	O
shared	O
a	O
G--	O
>	O
A	O
transition	O
at	O
position	O
+	O
5	O
of	O
the	O
donor	O
splice	O
site	O
consensus	O
sequence	O
of	O
intron	O
10	O
.	O
Also	O
in	O
two	O
subjects	O
an	O
A--	O
>	O
T	O
transversion	O
was	O
detected	O
in	O
the	O
stopcodon	O
of	O
the	O
PROS1	O
gene	O
;	O
this	O
transversion	O
predicts	O
a	O
protein	O
S	O
molecule	O
that	O
is	O
extended	O
by	O
14	O
amino	O
acids	O
.	O
The	O
fifth	O
subject	O
was	O
found	O
to	O
possess	O
two	O
sequence	O
abnormalities	O
.	O
One	O
allele	O
carried	O
a	O
G--	O
>	O
A	O
transition	O
near	O
the	O
donor	O
splice	O
junction	O
of	O
intron	O
2	O
,	O
but	O
this	O
abnormality	O
is	O
probably	O
neutral	O
,	O
since	O
it	O
was	O
inherited	O
from	O
the	O
parent	O
with	O
normal	O
protein	O
S	O
antigen	O
levels	O
.	O
In	O
the	O
other	O
allele	O
a	O
single	O
T	O
insertion	O
in	O
codon	O
-25	O
was	O
found	O
.	O
Analysis	O
of	O
platelet	O
RNA	O
showed	O
that	O
only	O
the	O
mRNA	O
with	O
the	O
A--	O
>	O
T	O
mutation	O
in	O
the	O
stopcodon	O
is	O
present	O
in	O
amounts	O
comparable	O
to	O
wildtype	O
RNA	O
.	O
mRNA	O
from	O
the	O
alleles	O
with	O
the	O
other	O
two	O
mutations	O
was	O
either	O
undetectable	O
or	O
present	O
in	O
greatly	O
reduced	O
amounts	O
.	O
The	O
latter	O
indicates	O
that	O
a	O
mRNA	O
based	O
approach	O
is	O
not	O
feasible	O
for	O
the	O
genetic	O
analysis	O
of	O
protein	B-SpecificDisease
S	I-SpecificDisease
deficiency	I-SpecificDisease
type	I-SpecificDisease
I	I-SpecificDisease
.	O
.	O

1831007	O
Huntington	B-SpecificDisease
disease	I-SpecificDisease
and	O
childhood-onset	O
Tourette	B-SpecificDisease
syndrome.	I-SpecificDisease
A	O
40-year-old	O
man	O
with	O
childhood-onset	O
Tourette	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
TS	B-SpecificDisease
)	O
developed	O
Huntington	B-SpecificDisease
disease	I-SpecificDisease
(	O
HD	B-SpecificDisease
)	O
.	O
We	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
childhood-onset	O
TS	B-SpecificDisease
with	O
adult	O
onset	O
HD	B-SpecificDisease
.	O
Discovery	O
of	O
other	O
cases	O
with	O
both	O
disorders	O
may	O
provide	O
clues	O
to	O
the	O
pathophysiology	O
of	O
both	O
conditions	O
.	O
.	O

8533757	O
Novel	O
inherited	O
mutations	O
and	O
variable	O
expressivity	O
of	O
BRCA1	O
alleles,	O
including	O
the	O
founder	O
mutation	O
185delAG	O
in	O
Ashkenazi	O
Jewish	O
families.	O
Thirty-seven	O
families	O
with	O
four	O
or	O
more	O
cases	O
of	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
or	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
were	O
analyzed	O
for	O
mutations	O
in	O
BRCA1	O
.	O
Twelve	O
different	O
germ-line	O
mutations	O
,	O
four	O
novel	O
and	O
eight	O
previously	O
observed	O
,	O
were	O
detected	O
in	O
16	O
families	O
.	O
Five	O
families	O
of	O
Ashkenazi	O
Jewish	O
descent	O
carried	O
the	O
185delAG	O
mutation	O
and	O
shared	O
the	O
same	O
haplotype	O
at	O
eight	O
polymorphic	O
markers	O
spanning	O
approximately	O
850	O
kb	O
at	O
BRCA1	O
.	O
Expressivity	O
of	O
185delAG	O
in	O
these	O
families	O
varied	O
,	O
from	O
early-onset	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
without	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
.	O
Mutation	O
4184delTCAA	O
occurred	O
independently	O
in	O
two	O
families	O
.	O
In	O
one	O
family	O
,	O
penetrance	O
was	O
complete	O
,	O
with	O
females	O
developing	O
early-onset	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
or	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
and	O
the	O
male	O
carrier	O
developing	O
prostatic	B-SpecificDisease
cancer	I-SpecificDisease
,	O
whereas	O
,	O
in	O
the	O
other	O
family	O
,	O
penetrance	O
was	O
incomplete	O
and	O
only	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
occurred	O
,	O
diagnosed	O
at	O
ages	O
38-81	O
years	O
.	O
Two	O
novel	O
nonsense	O
mutations	O
led	O
to	O
the	O
loss	O
of	O
mutant	O
BRCA1	O
transcript	O
in	O
families	O
with	O
10	O
and	O
6	O
cases	O
of	O
early-onset	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
and	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
.	O
A	O
665-nt	O
segment	O
of	O
the	O
BRCA1	O
3-UTR	O
and	O
1	O
.	O
3	O
kb	O
of	O
genomic	O
sequence	O
including	O
the	O
putative	O
promoter	O
region	O
were	O
invariant	O
by	O
single-strand	O
conformation	O
analysis	O
in	O
13	O
families	O
without	O
coding-sequence	O
mutations	O
.	O
Overall	O
in	O
our	O
series	O
,	O
BRCA1	O
mutations	O
have	O
been	O
detected	O
in	O
26	O
families	O
16	O
with	O
positive	O
BRCA1	O
lod	O
scores	O
,	O
7	O
with	O
negative	O
lod	O
scores	O
(	O
reflecting	O
multiple	O
sporadic	O
breast	B-SpecificDisease
cancers	I-SpecificDisease
)	O
,	O
and	O
3	O
not	O
tested	O
for	O
linkage	O
.	O
Three	O
other	O
families	O
have	O
positive	O
lod	O
scores	O
for	O
linkage	O
to	O
BRCA2	O
,	O
but	O
13	O
families	O
without	O
detected	O
BRCA1	O
mutations	O
have	O
negative	O
lod	O
scores	O
for	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

8266996	O
Difference	O
in	O
methylation	O
patterns	O
within	O
the	O
D15S9	O
region	O
of	O
chromosome	O
15q11-13	O
in	O
first	O
cousins	O
with	O
Angelman	B-SpecificDisease
syndrome	I-SpecificDisease
and	O
Prader-Willi	B-SpecificDisease
syndrome.	I-SpecificDisease
Abnormalities	O
of	O
chromosome	O
region	O
15q11-13	O
are	O
associated	O
with	O
Angelman	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
AS	B-SpecificDisease
)	O
and	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
PWS	B-SpecificDisease
)	O
.	O
Differences	O
between	O
the	O
methylation	O
patterns	O
of	O
the	O
region	O
of	O
chromosome	O
15q11-13	O
which	O
hybridizes	O
to	O
the	O
highly	O
conserved	O
DNA	O
,	O
DN34	O
,	O
in	O
normal	O
individuals	O
and	O
in	O
patients	O
with	O
AS	B-SpecificDisease
and	O
PWS	B-SpecificDisease
have	O
been	O
described	O
.	O
We	O
report	O
on	O
a	O
family	O
in	O
which	O
first	O
cousins	O
are	O
affected	O
by	O
AS	B-SpecificDisease
and	O
PWS	B-SpecificDisease
as	O
a	O
result	O
of	O
a	O
familial	O
paracentric	O
inversion	O
of	O
15q11-q13	O
.	O
The	O
results	O
of	O
the	O
studies	O
on	O
this	O
family	O
demonstrate	O
the	O
differences	O
in	O
the	O
methylation	O
patterns	O
in	O
the	O
2	O
conditions	O
and	O
the	O
phenomenon	O
of	O
genomic	O
imprinting	O
,	O
whereby	O
genetic	O
information	O
is	O
expressed	O
differently	O
dependent	O
on	O
the	O
parent	O
of	O
origin	O
.	O
.	O

10736265	O
Glycerol	O
as	O
a	O
correlate	O
of	O
impaired	B-SpecificDisease
glucose	I-SpecificDisease
tolerance:	I-SpecificDisease
dissection	O
of	O
a	O
complex	O
system	O
by	O
use	O
of	O
a	O
simple	O
genetic	O
trait.	O
Glycerol	O
kinase	O
(	O
GK	O
)	O
represents	O
the	O
primary	O
entry	O
of	O
glycerol	O
into	O
glucose	O
and	O
triglyceride	O
metabolism	O
.	O
Impaired	B-SpecificDisease
glucose	I-SpecificDisease
tolerance	I-SpecificDisease
(	O
IGT	B-SpecificDisease
)	O
and	O
hypertriglyceridemia	B-SpecificDisease
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
diabetes	B-SpecificDisease
mellitus	I-SpecificDisease
and	O
cardiovascular	B-SpecificDisease
disease	I-SpecificDisease
.	O
The	O
relationship	O
between	O
glycerol	O
and	O
the	O
risk	O
of	O
IGT	B-SpecificDisease
,	O
however	O
,	O
is	O
poorly	O
understood	O
.	O
We	O
therefore	O
undertook	O
the	O
study	O
of	O
fasting	O
plasma	O
glycerol	O
levels	O
in	O
a	O
cohort	O
of	O
1	O
,	O
056	O
unrelated	O
men	O
and	O
women	O
of	O
French-Canadian	O
descent	O
.	O
Family	O
screening	O
in	O
the	O
initial	O
cohort	O
identified	O
18	O
men	O
from	O
five	O
families	O
with	O
severe	O
hyperglycerolemia	B-SpecificDisease
(	O
values	O
above	O
2	O
.	O
0	O
mmol	O
/	O
liter	O
)	O
and	O
demonstrated	O
an	O
X-linked	O
pattern	O
of	O
inheritance	O
.	O
Linkage	O
analysis	O
of	O
the	O
data	O
from	O
12	O
microsatellite	O
markers	O
surrounding	O
the	O
Xp21	O
.	O
3	O
GK	O
gene	O
resulted	O
in	O
a	O
peak	O
LOD	O
score	O
of	O
3	O
.	O
46	O
,	O
centered	O
around	O
marker	O
DXS8039	O
.	O
In	O
addition	O
,	O
since	O
all	O
of	O
the	O
families	O
originated	O
in	O
a	O
population	O
with	O
a	O
proven	O
founder	O
effect-the	O
Saguenay	O
Lac-St	O
.	O
-Jean	O
region	O
of	O
Quebec-a	O
common	O
disease	O
haplotype	O
was	O
sought	O
.	O
Indeed	O
,	O
a	O
six-marker	O
haplotype	O
extending	O
over	O
a	O
region	O
of	O
5	O
.	O
5	O
cM	O
was	O
observed	O
in	O
all	O
families	O
.	O
Resequencing	O
of	O
the	O
GK	O
gene	O
in	O
family	O
members	O
led	O
to	O
the	O
discovery	O
of	O
a	O
N288D	O
missense	O
mutation	O
in	O
exon	O
10	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
asparagine	O
residue	O
by	O
a	O
negatively	O
charged	O
aspartic	O
acid	O
.	O

1301201	O
In	O
vitro	O
and	O
in	O
vivo	O
correlations	O
for	O
I65T	O
and	O
M1V	O
mutations	O
at	O
the	O
phenylalanine	O
hydroxylase	O
locus.	O
Mutations	O
at	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
locus	O
are	O
the	O
major	O
cause	O
of	O
hyperphenylalaninemia	B-DiseaseClass
.	O
We	O
have	O
previously	O
described	O
four	O
mutations	O
(	O
M1V	O
,	O
IVS12nt1	O
,	O
R408W	O
,	O
and	O
S349P	O
)	O
at	O
the	O
PAH	O
locus	O
in	O
French	O
Canadians	O
with	O
ancestry	O
in	O
eastern	O
Quebec	O
.	O
Here	O
we	O
report	O
(	O
1	O
)	O
identification	O
of	O
another	O
mutation	O
,	O
on	O
a	O
haplotype	O
9	O
chromosome	O
,	O
which	O
converts	O
codon	O
65	O
from	O
isoleucine	O
(	O
ATT	O
)	O
to	O
threonine	O
(	O
ACT	O
)	O
,	O
(	O
2	O
)	O
expression	O
analysis	O
of	O
the	O
I65T	O
mutation	O
in	O
COS	O
cells	O
demonstrating	O
75	O
%	O
loss	O
of	O
both	O
immunoreactive	O
protein	O
and	O
enzyme	O
activity	O
,	O
and	O
(	O
3	O
)	O
expression	O
analysis	O
of	O
the	O
most	O
prevalent	O
PKU	B-Modifier
allele	O
(	O
M1V	O
)	O
in	O
eastern	O
Quebec	O
,	O
showing	O
nondetectable	O
levels	O
of	O
PAH	O
protein	O
and	O
activity	O
,	O
a	O
finding	O
compatible	O
with	O
a	O
mutation	O
in	O
the	O
translation	O
initiation	O
codon	O
.	O
Homozygosity	O
for	O
M1V	O
and	O
codominant	O
inheritance	O
of	O
I65T	O
/	O
R408W	O
were	O
both	O
associated	O
with	O
classical	B-SpecificDisease
phenylketonuria	I-SpecificDisease
.	O
.	O

10874302	O
The	O
human	O
factor	O
IX	O
gene	O
as	O
germline	O
mutagen	O
test:	O
samples	O
from	O
Mainland	O
China	O
have	O
the	O
putatively	O
endogenous	O
pattern	O
of	O
mutation.	O
Germline	O
mutations	O
are	O
the	O
major	O
source	O
of	O
genetic	O
variation	O
that	O
allows	O
a	O
species	O
to	O
evolve	O
over	O
time	O
but	O
at	O
the	O
cost	O
of	O
Mendelian	B-DiseaseClass
disease	I-DiseaseClass
and	O
genetic	O
predisposition	O
to	O
multifactorial	B-DiseaseClass
diseases	I-DiseaseClass
.	O
Previous	O
analyses	O
have	O
revealed	O
that	O
the	O
pattern	O
of	O
germline	O
mutations	O
in	O
the	O
factor	O
IX	O
gene	O
(	O
F9	O
)	O
is	O
similar	O
among	O
a	O
variety	O
of	O
ethnically	O
and	O
geographically	O
diverse	O
populations	O
and	O
compatible	O
with	O
the	O
ancient	O
pattern	O
that	O
has	O
shaped	O
the	O
mammalian	O
genome	O
.	O
Here	O
,	O
we	O
compare	O
the	O
pattern	O
of	O
germline	O
mutation	O
in	O
a	O
population	O
of	O
hemophilia	B-Modifier
B	I-Modifier
patients	O
from	O
Mainland	O
China	O
(	O
n	O
=	O
66	O
)	O
to	O
that	O
in	O
U	O
.	O
S	O
.	O
Caucasians	O
,	O
Blacks	O
,	O
and	O
Mexican	O
Hispanics	O
and	O
stratify	O
by	O
disease	O
severity	O
and	O
ethnicity	O
.	O
The	O
similar	O
pattern	O
of	O
germline	O
mutation	O
in	O
all	O
ethnic	O
groups	O
studied	O
to	O
date	O
provides	O
additional	O
data	O
compatible	O
with	O
the	O
inference	O
that	O
endogenous	O
processes	O
predominate	O
in	O
germline	O
mutations	O
.	O

1345170	O
Linkage	O
disequilibrium	O
mapping	O
in	O
isolated	O
founder	O
populations:	O
diastrophic	B-SpecificDisease
dysplasia	I-SpecificDisease
in	O
Finland.	O
Linkage	O
disequilibrium	O
mapping	O
in	O
isolated	O
populations	O
provides	O
a	O
powerful	O
tool	O
for	O
fine	O
structure	O
localization	O
of	O
disease	O
genes	O
.	O
Here	O
,	O
Luria	O
and	O
Delbrucks	O
classical	O
methods	O
for	O
analysing	O
bacterial	O
cultures	O
are	O
adapted	O
to	O
the	O
study	O
of	O
human	O
isolated	O
founder	O
populations	O
in	O
order	O
to	O
estimate	O
(	O
i	O
)	O
the	O
recombination	O
fraction	O
between	O
a	O
disease	O
locus	O
and	O
a	O
marker	O
;	O
(	O
ii	O
)	O
the	O
expected	O
degree	O
of	O
allelic	O
homogeneity	O
in	O
a	O
population	O
;	O
and	O
(	O
iii	O
)	O
the	O
mutation	O
rate	O
of	O
marker	O
loci	O
.	O
Using	O
these	O
methods	O
,	O
we	O
report	O
striking	O
linkage	O
disequilibrium	O
for	O
diastrophic	B-SpecificDisease
dysplasia	I-SpecificDisease
(	O
DTD	B-SpecificDisease
)	O
in	O
Finland	O
indicating	O
that	O
the	O
DTD	B-Modifier
gene	O
should	O
lie	O
within	O
0	O
.	O
06	O
centimorgans	O
(	O
or	O
about	O
60	O
kilobases	O
)	O
of	O
the	O
CSF1R	O
gene	O
.	O
Predictions	O
about	O
allelic	O
homogeneity	O
in	O
Finland	O
and	O
mutation	O
rates	O
in	O
simple	O
sequence	O
repeats	O
are	O
confirmed	O
by	O
independent	O
observations	O
.	O

10712209	O
Combined	O
analysis	O
of	O
hereditary	B-Modifier
prostate	I-Modifier
cancer	I-Modifier
linkage	O
to	O
1q24-25:	O
results	O
from	O
772	O
hereditary	B-Modifier
prostate	I-Modifier
cancer	I-Modifier
families	O
from	O
the	O
International	O
Consortium	O
for	O
Prostate	B-Modifier
Cancer	I-Modifier
Genetics.	O
A	O
previous	O
linkage	O
study	O
provided	O
evidence	O
for	O
a	O
prostate	B-Modifier
cancer-susceptibility	I-Modifier
locus	O
at	O
1q24-25	O
.	O
Subsequent	O
reports	O
in	O
additional	O
collections	O
of	O
families	O
have	O
yielded	O
conflicting	O
results	O
.	O
In	O
addition	O
,	O
evidence	O
for	O
locus	O
heterogeneity	O
has	O
been	O
provided	O
by	O
the	O
identification	O
of	O
other	O
putative	O
hereditary	B-Modifier
prostate	I-Modifier
cancer	I-Modifier
loci	O
on	O
Xq27-28	O
,	O
1q42-43	O
,	O
and	O
1p36	O
.	O
The	O
present	O
study	O
describes	O
a	O
combined	O
analysis	O
for	O
six	O
markers	O
in	O
the	O
1q24-25	O
region	O
in	O
772	O
families	O
affected	O
by	O
hereditary	B-SpecificDisease
prostate	I-SpecificDisease
cancer	I-SpecificDisease
and	O
ascertained	O
by	O
the	O
members	O
of	O
the	O
International	O
Consortium	O
for	O
Prostate	B-Modifier
Cancer	I-Modifier
Genetics	O
(	O
ICPCG	O
)	O
from	O
North	O
America	O
,	O
Australia	O
,	O
Finland	O
,	O
Norway	O
,	O
Sweden	O
,	O
and	O
the	O
United	O
Kingdom	O
.	O
Overall	O
,	O
there	O
was	O
some	O
evidence	O
for	O
linkage	O
,	O
with	O
a	O
peak	O
parametric	O
multipoint	O
LOD	O
score	O
assuming	O
heterogeneity	O
(	O
HLOD	O
)	O
of	O
1	O
.	O
40	O
(	O
P	O
=	O
.	O
01	O
)	O
at	O
D1S212	O
.	O
The	O
estimated	O
proportion	O
of	O
families	O
(	O
alpha	O
)	O
linked	O
to	O
the	O
locus	O
was	O
.	O
06	O
(	O
1-LOD	O
support	O
interval	O
.	O
01-	O
.	O
12	O
)	O
.	O
This	O
evidence	O
was	O
not	O
observed	O
by	O
a	O
nonparametric	O
approach	O
,	O
presumably	O
because	O
of	O
the	O
extensive	O
heterogeneity	O
.	O
Further	O
parametric	O
analysis	O
revealed	O
a	O
significant	O
effect	O
of	O
the	O
presence	O
of	O
male-to-male	O
disease	O
transmission	O
within	O
the	O
families	O
.	O
In	O
the	O
subset	O
of	O
491	O
such	O
families	O
,	O
the	O
peak	O
HLOD	O
was	O
2	O
.	O
In	O
the	O
subset	O
of	O
491	O
such	O
families	O
,	O
the	O
peak	O
HLOD	O
was	O
2	O
.	O
56	O
(	O
P	O
=	O
.	O
0006	O
)	O
and	O
alpha	O
=	O
.	O
11	O
(	O
1-LOD	O
support	O
interval	O
.	O
04-	O
.	O
19	O
)	O
,	O
compared	O
with	O
HLODs	O
of	O
0	O
in	O
the	O
remaining	O
281	O
families	O
.	O
Within	O
the	O
families	O
with	O
male-to-male	O
disease	O
transmission	O
,	O
alpha	O
increased	O
with	O
the	O
early	O
mean	O
age	O
at	O
diagnosis	O
(	O
<	O
65	O
years	O
,	O
alpha	O
=	O
.	O
19	O
,	O
with	O
1-LOD	O
support	O
interval	O
.	O
06-	O
.	O
34	O
)	O
and	O
the	O
number	O
of	O
affected	O
family	O
members	O
(	O
five	O
or	O
more	O
family	O
members	O
,	O
alpha	O
=	O
.	O
15	O
,	O
with	O
1-LOD	O
support	O
interval	O
.	O
04-	O
.	O
28	O
)	O
.	O
The	O
highest	O
value	O
of	O
alpha	O
was	O
observed	O
for	O
the	O
48	O
families	O
that	O
met	O
all	O
three	O
criteria	O
(	O
peak	O
HLOD	O
=	O
2	O
.	O
25	O
,	O
P	O
=	O
.	O
001	O
,	O
alpha	O
=	O
.	O
29	O
,	O
with	O
1-LOD	O
support	O
interval	O
.	O
08-	O
.	O
53	O
).	O
These	O
results	O
support	O
the	O
finding	O
of	O
a	O
prostate	B-Modifier
cancer-susceptibility	I-Modifier
gene	O
linked	O
to	O
1q24-25	O
,	O
albeit	O
in	O
a	O
defined	O
subset	O
of	O
prostate	B-Modifier
cancer	I-Modifier
families	O
.	O
Although	O
HPC1	O
accounts	O
for	O
only	O
a	O
small	O
proportion	O
of	O
all	O
families	O
affected	O
by	O
hereditary	B-SpecificDisease
prostate	I-SpecificDisease
cancer	I-SpecificDisease
,	O
it	O
appears	O
to	O
play	O
a	O
more	O
prominent	O
role	O
in	O
the	O
subset	O
of	O
families	O
with	O
several	O
members	O
affected	O
at	O
an	O
early	O
age	O
and	O
with	O
male-to-male	O
disease	O
transmission	O
.	O

10891444	O
Mutations	O
in	O
the	O
fibrinogen	O
aalpha	O
gene	O
account	O
for	O
the	O
majority	O
of	O
cases	O
of	O
congenital	B-SpecificDisease
afibrinogenemia.	I-SpecificDisease
Congenital	B-SpecificDisease
afibrinogenemia	I-SpecificDisease
is	O
a	O
rare	O
,	O
autosomal	B-DiseaseClass
,	I-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
characterized	O
by	O
the	O
complete	O
absence	O
of	O
detectable	O
fibrinogen	O
.	O
We	O
previously	O
identified	O
the	O
first	O
causative	O
mutations	O
in	O
a	O
nonconsanguineous	O
Swiss	O
family	O
;	O
the	O
4	O
affected	O
persons	O
have	O
homozygous	O
deletions	O
of	O
approximately	O
11	O
kb	O
of	O
the	O
fibrinogen	O
alpha	O
(	O
FGA	O
)	O
gene	O
.	O
Haplotype	O
data	O
implied	O
that	O
these	O
deletions	O
occurred	O
on	O
distinct	O
ancestral	O
chromosomes	O
,	O
suggesting	O
that	O
this	O
region	O
may	O
be	O
susceptible	O
to	O
deletion	O
by	O
a	O
common	O
mechanism	O
.	O
We	O
subsequently	O
showed	O
that	O
all	O
the	O
deletions	O
were	O
identical	O
to	O
the	O
base	O
pair	O
and	O
probably	O
resulted	O
from	O
a	O
nonhomologous	O
recombination	O
mediated	O
by	O
7-bp	O
direct	O
repeats	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
collected	O
data	O
on	O
13	O
additional	O
unrelated	O
patients	O
to	O
identify	O
the	O
causative	O
mutations	O
and	O
to	O
determine	O
the	O
prevalence	O
of	O
the	O
11-kb	O
deletion	O
.	O
A	O
common	O
recurrent	O
mutation	O
,	O
at	O
the	O
donor	O
splice	O
site	O
of	O
FGA	O
intron	O
4	O
(	O
IVS4	O
+	O
1	O
G	O
>	O
T	O
)	O
,	O
accounted	O
for	O
14	O
of	O
the	O
26	O
(	O
54	O
%	O
)	O
alleles	O
.	O
One	O
patient	O
was	O
heterozygous	O
for	O
the	O
previously	O
identified	O
deletion	O
.	O
Three	O
more	O
frameshift	O
mutations	O
,	O
2	O
nonsense	O
mutations	O
,	O
and	O
a	O
second	O
splice	O
site	O
mutation	O
were	O
also	O
identified	O
.	O
Consequently	O
,	O
86	O
%	O
of	O
afibrinogenemia	B-Modifier
alleles	O
analyzed	O
to	O
date	O
have	O
truncating	O
mutations	O
of	O
FGA	O
,	O
though	O
mutations	O
in	O
all	O
3	O
fibrinogen	O
genes	O
,	O
FGG	O
,	O
FGA	O
,	O
and	O
FGB	O
,	O
might	O
be	O
predicted	O
to	O
cause	O
congenital	B-SpecificDisease
afibrinogenemia	I-SpecificDisease
.	O
.	O

7909252	O
High	O
resolution	O
genetic	O
analysis	O
suggests	O
one	O
ancestral	O
predisposing	O
haplotype	O
for	O
the	O
origin	O
of	O
the	O
myotonic	B-Modifier
dystrophy	I-Modifier
mutation.	O
The	O
mutation	O
causing	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
has	O
been	O
identified	O
as	O
an	O
amplification	O
of	O
an	O
unstable	O
trinucleotide	O
(	O
CTG	O
)	O
n	O
repeat	O
in	O
over	O
99	O
%	O
of	O
the	O
global	O
DM	B-Modifier
population	O
.	O
It	O
is	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
an	O
Alu	O
element	O
polymorphism	O
within	O
the	O
DM	B-Modifier
kinase	O
gene	O
,	O
suggesting	O
that	O
DM	B-SpecificDisease
is	O
a	O
consequence	O
of	O
one	O
or	O
few	O
ancestral	O
mutations	O
.	O
A	O
recent	O
analysis	O
utilizing	O
this	O
polymorphism	O
as	O
well	O
as	O
a	O
flanking	O
dinucleotide	O
marker	O
,	O
suggested	O
that	O
similar	O
to	O
Fragile	B-SpecificDisease
X	I-SpecificDisease
syndrome	I-SpecificDisease
,	O
DM	B-SpecificDisease
exhibited	O
a	O
founder	O
effect	O
(	O
Imbert	O
et	O
al	O
.	O
,	O
1993	O
Nature	O
Genet	O
.	O
4	O
,	O
72-76	O
)	O
.	O
In	O
contrast	O
,	O
the	O
low	O
reproductive	O
fitness	O
of	O
individuals	O
with	O
congenital	O
DM	B-SpecificDisease
(	O
the	O
endpoint	O
of	O
genetic	O
anticipation	O
in	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
)	O
suggests	O
a	O
higher	O
rate	O
of	O
new	O
mutations	O
.	O
We	O
present	O
a	O
high	O
resolution	O
genetic	O
analysis	O
of	O
the	O
DM	B-Modifier
locus	O
using	O
PCR	O
based	O
assays	O
of	O
nine	O
polymorphisms	O
,	O
spanning	O
a	O
physical	O
distance	O
of	O
30	O
kb	O
,	O
within	O
and	O
immediately	O
flanking	O
the	O
DM	B-Modifier
kinase	O
gene	O
.	O
The	O
persistent	O
complete	O
allelic	O
association	O
of	O
the	O
DM	B-Modifier
mutation	O
with	O
all	O
these	O
polymorphisms	O
provides	O
further	O
support	O
to	O
previous	O
observations	O
and	O
suggests	O
more	O
strongly	O
that	O
the	O
DM	B-Modifier
mutation	O
occurred	O
on	O
the	O
background	O
of	O
a	O
particular	O
haplotype	O
in	O
which	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
became	O
inherently	O
unstable	O
and	O
therefore	O
predisposed	O
to	O
amplification	O
.	O

3346018	O
Nebulin	O
seen	O
in	O
DMD	B-Modifier
males	O
including	O
one	O
patient	O
with	O
a	O
large	O
DNA	O
deletion	O
encompassing	O
the	O
DMD	B-Modifier
gene.	O
The	O
presence	O
of	O
nebulin	O
in	O
a	O
muscle	O
specimen	O
from	O
a	O
patient	O
with	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)	O
due	O
to	O
a	O
large	O
deletion	O
precludes	O
the	O
possibility	O
that	O
this	O
protein	O
is	O
the	O
DMD	B-Modifier
gene	O
product	O
.	O
.	O

10732816	O
Emerin,	B-SpecificDisease
deficiency	I-SpecificDisease
of	O
which	O
causes	O
Emery-Dreifuss	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy,	I-SpecificDisease
is	O
localized	O
at	O
the	O
inner	O
nuclear	O
membrane.	O
X-linked	B-SpecificDisease
recessive	I-SpecificDisease
Emery-Dreifuss	I-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
EDMD	B-SpecificDisease
)	O
is	O
an	O
inherited	B-DiseaseClass
muscle	I-DiseaseClass
disorder	I-DiseaseClass
characterized	O
by	O
the	O
clinical	O
triad	O
of	O
progressive	O
wasting	B-SpecificDisease
of	I-SpecificDisease
humero-peroneal	I-SpecificDisease
muscles	I-SpecificDisease
,	O
early	O
contractures	B-CompositeMention
of	I-CompositeMention
the	I-CompositeMention
elbows	I-CompositeMention
,	I-CompositeMention
Achilles	I-CompositeMention
tendons	I-CompositeMention
and	I-CompositeMention
postcervical	I-CompositeMention
muscles	I-CompositeMention
,	O
and	O
cardiac	B-SpecificDisease
conduction	I-SpecificDisease
block	I-SpecificDisease
with	O
a	O
high	O
risk	O
of	O
sudden	B-SpecificDisease
death	I-SpecificDisease
.	O
The	O
gene	O
for	O
EDMD	B-SpecificDisease
on	O
Xq28	O
encodes	O
a	O
novel	O
protein	O
named	O
emerin	O
that	O
localizes	O
at	O
the	O
nuclear	O
membrane	O
of	O
skeletal	O
,	O
cardiac	O
and	O
smooth	O
muscles	O
and	O
some	O
other	O
non-muscle	O
tissues	O
.	O
To	O
investigate	O
a	O
possible	O
physiological	O
role	O
for	O
emerin	O
,	O
we	O
examined	O
the	O
ultrastructural	O
localization	O
of	O
the	O
protein	O
in	O
human	O
skeletal	O
muscle	O
and	O
HeLa	O
cells	O
,	O
using	O
ultrathin	O
cryosections	O
.	O
We	O
found	O
that	O
the	O
immune-labeled	O
colloidal	O
gold	O
particles	O
were	O
localized	O
on	O
the	O
nucleoplasmic	O
surface	O
of	O
the	O
inner	O
nuclear	O
membrane	O
,	O
but	O
not	O
on	O
the	O
nuclear	O
pore	O
.	O
Emerin	O
stayed	O
on	O
the	O
cytoplasmic	O
surface	O
of	O
the	O
nuclear	O
lamina	O
,	O
even	O
after	O
detergent	O
treatment	O
that	O
solubilizes	O
membrane	O
lipids	O
and	O
washes	O
out	O
membrane	O
proteins	O
.	O
These	O
results	O
suggest	O
that	O
emerin	O
anchors	O
at	O
the	O
inner	O
nuclear	O
membrane	O
through	O
the	O
hydrophobic	O
stretch	O
,	O
and	O
protrudes	O
from	O
the	O
hydrophilic	O
region	O
to	O
the	O
nucleoplasm	O
where	O
it	O
interacts	O
with	O
the	O
nuclear	O
lamina	O
.	O
We	O
speculate	O
that	O
emerin	O
contributes	O
to	O
maintain	O
the	O
nuclear	O
structure	O
and	O
stability	O
,	O
as	O
well	O
as	O
nuclear	O
functions	O
,	O
particularly	O
in	O
muscle	O
tissues	O
that	O
have	O
severe	O
stress	O
with	O
rigorous	O
contraction-relaxation	O
movements	O
and	O
calcium	O
flux	O
.	O
.	O

6387532	O
Bone	O
marrow	O
transplant	O
in	O
adrenoleukodystrophy.	B-SpecificDisease
An	O
allogeneic	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
from	O
a	O
normal	O
HLA	O
identical	O
sibling	O
donor	O
was	O
performed	O
in	O
a	O
13-year-old	O
boy	O
with	O
rapidly	O
progressive	O
adrenoleukodystrophy	B-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
.	O
Engraftment	O
and	O
complete	O
hematologic	O
recovery	O
occurred	O
within	O
4	O
weeks	O
,	O
but	O
neurologic	B-DiseaseClass
deterioration	I-DiseaseClass
continued	O
.	O
The	O
patient	O
died	O
of	O
an	O
adenovirus	B-SpecificDisease
infection	I-SpecificDisease
141	O
days	O
after	O
BMT	O
.	O
ALD	B-SpecificDisease
is	O
characterized	O
by	O
abnormally	O
high	O
plasma	O
levels	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
VLCFA	O
)	O
as	O
a	O
result	O
of	O
impaired	O
capacity	O
to	O
degrade	O
them	O
.	O
Ten	O
days	O
after	O
BMT	O
,	O
the	O
white	O
blood	O
cell	O
VLCFA	O
levels	O
and	O
enzyme	O
activity	O
became	O
normal	O
;	O
after	O
3	O
months	O
,	O
there	O
was	O
progressive	O
reduction	O
of	O
plasma	O
VLCFA	O
to	O
levels	O
only	O
slightly	O
above	O
normal	O
.	O
.	O

7545954	O
A	O
strong	O
candidate	O
for	O
the	O
breast	B-Modifier
and	I-Modifier
ovarian	I-Modifier
cancer	I-Modifier
susceptibility	O
gene	O
BRCA1.	O
A	O
strong	O
candidate	O
for	O
the	O
17q-linked	O
BRCA1	O
gene	O
,	O
which	O
influences	O
susceptibility	O
to	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
,	O
has	O
been	O
identified	O
by	O
positional	O
cloning	O
methods	O
.	O
Probable	O
predisposing	O
mutations	O
have	O
been	O
detected	O
in	O
five	O
of	O
eight	O
kindreds	O
presumed	O
to	O
segregate	O
BRCA1	O
susceptibility	O
alleles	O
.	O
The	O
mutations	O
include	O
an	O
11-base	O
pair	O
deletion	O
,	O
a	O
1-base	O
pair	O
insertion	O
,	O
a	O
stop	O
codon	O
,	O
a	O
missense	O
substitution	O
,	O
and	O
an	O
inferred	O
regulatory	O
mutation	O
.	O
The	O
BRCA1	O
gene	O
is	O
expressed	O
in	O
numerous	O
tissues	O
,	O
including	O
breast	O
and	O
ovary	O
,	O
and	O
encodes	O
a	O
predicted	O
protein	O
of	O
1863	O
amino	O
acids	O
.	O
This	O
protein	O
contains	O
a	O
zinc	O
finger	O
domain	O
in	O
its	O
amino-terminal	O
region	O
,	O
but	O
is	O
otherwise	O
unrelated	O
to	O
previously	O
described	O
proteins	O
.	O
Identification	O
of	O
BRCA1	O
should	O
facilitate	O
early	O
diagnosis	O
of	O
breast	B-Modifier
and	I-Modifier
ovarian	I-Modifier
cancer	I-Modifier
susceptibility	O
in	O
some	O
individuals	O
as	O
well	O
as	O
a	O
better	O
understanding	O
of	O
breast	B-Modifier
cancer	I-Modifier
biology	O
.	O
.	O

1769645	O
Aberrant	O
splicing	O
of	O
phenylalanine	O
hydroxylase	O
mRNA:	O
the	O
major	O
cause	O
for	O
phenylketonuria	B-SpecificDisease
in	O
parts	O
of	O
southern	O
Europe.	O
We	O
report	O
a	O
mutation	O
within	O
the	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
gene	O
that	O
causes	O
aberrant	O
splicing	O
of	O
the	O
mRNA	O
and	O
that	O
is	O
in	O
tight	O
association	O
with	O
chromosomal	O
haplotypes	O
6	O
,	O
10	O
,	O
and	O
36	O
.	O
Because	O
of	O
the	O
high	O
frequency	O
of	O
these	O
particular	O
haplotypes	O
in	O
Bulgaria	O
,	O
Italy	O
,	O
and	O
Turkey	O
,	O
it	O
appears	O
to	O
be	O
one	O
of	O
the	O
more	O
frequent	O
defects	O
in	O
the	O
PAH	O
gene	O
causing	O
classical	O
phenylketonuria	B-SpecificDisease
in	O
this	O
part	O
of	O
Europe	O
.	O
The	O
mutation	O
is	O
a	O
G	O
to	O
A	O
transition	O
at	O
position	O
546	O
in	O
intron	O
10	O
of	O
the	O
PAH	O
gene	O
,	O
11	O
bp	O
upstream	O
from	O
the	O
intron	O
10	O
/	O
exon	O
11	O
boundary	O
.	O
It	O
activates	O
a	O
cryptic	O
splice	O
site	O
and	O
results	O
in	O
an	O
in-frame	O
insertion	O
of	O
9	O
nucleotides	O
between	O
exon	O
10	O
and	O
exon	O
11	O
of	O
the	O
processed	O
mRNA	O
.	O
Normal	O
amounts	O
of	O
liver	O
PAH	O
protein	O
are	O
present	O
in	O
homozygous	O
patients	O
,	O
but	O
no	O
catalytic	O
activity	O
can	O
be	O
detected	O
.	O
This	O
loss	O
of	O
enzyme	O
activity	O
is	O
probably	O
caused	O
by	O
conformational	O
changes	O
resulting	O
from	O
the	O
insertion	O
of	O
three	O
additional	O
amino	O
acids	O
(	O
Gly-Leu-Gln	O
)	O
between	O
the	O
normal	O
sequences	O
encoded	O
by	O
exon	O
10	O
and	O
exon	O
11	O
.	O
.	O

7191069	O
Heterozygous	O
C2-deficiency	B-SpecificDisease
and	O
myasthenia	B-SpecificDisease
gravis.	I-SpecificDisease
Complement	B-Modifier
deficiency	I-Modifier
states	O
in	O
myasthenia	B-SpecificDisease
gravis	I-SpecificDisease
(	O
MG	B-SpecificDisease
)	O
have	O
not	O
been	O
reported	O
previously	O
.	O
We	O
describe	O
a	O
19-year-old	O
woman	O
with	O
typical	O
MG	B-SpecificDisease
and	O
heterozygous	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
,	O
along	O
with	O
HLA	O
typing	O
of	O
the	O
patient	O
and	O
her	O
immediate	O
family	O
.	O
.	O

10364520	O
MEFV-Gene	O
analysis	O
in	O
armenian	O
patients	O
with	O
Familial	B-SpecificDisease
Mediterranean	I-SpecificDisease
fever:	I-SpecificDisease
diagnostic	O
value	O
and	O
unfavorable	O
renal	O
prognosis	O
of	O
the	O
M694V	O
homozygous	O
genotype-genetic	O
and	O
therapeutic	O
implications.	O
Familial	B-SpecificDisease
Mediterranean	I-SpecificDisease
fever	I-SpecificDisease
(	O
FMF	B-SpecificDisease
)	O
is	O
a	O
recessively	B-DiseaseClass
inherited	I-DiseaseClass
disorder	I-DiseaseClass
that	O
is	O
common	O
in	O
patients	O
of	O
Armenian	O
ancestry	O
.	O
To	O
date	O
,	O
its	O
diagnosis	O
,	O
which	O
can	O
be	O
made	O
only	O
retrospectively	O
,	O
is	O
one	O
of	O
exclusion	O
,	O
based	O
entirely	O
on	O
nonspecific	O
clinical	O
signs	O
that	O
result	O
from	O
serosal	B-SpecificDisease
inflammation	I-SpecificDisease
and	O
that	O
may	O
lead	O
to	O
unnecessary	O
surgery	O
.	O
Renal	B-SpecificDisease
amyloidosis	I-SpecificDisease
,	O
prevented	O
by	O
colchicine	O
,	O
is	O
the	O
most	O
severe	O
complication	O
of	O
FMF	B-SpecificDisease
,	O
a	O
disorder	O
associated	O
with	O
mutations	O
in	O
the	O
MEFV	O
gene	O
.	O
To	O
evaluate	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
MEFV-gene	O
analysis	O
,	O
we	O
investigated	O
90	O
Armenian	O
FMF	B-Modifier
patients	O
from	O
77	O
unrelated	O
families	O
that	O
were	O
not	O
selected	O
through	O
genetic-linkage	O
analysis	O
.	O
Eight	O
mutations	O
,	O
one	O
of	O
which	O
(	O
R408Q	O
)	O
is	O
new	O
,	O
were	O
found	O
to	O
account	O
for	O
93	O
%	O
of	O
the	O
163	O
independent	O
FMF	B-Modifier
alleles	O
,	O
with	O
both	O
FMF	B-Modifier
alleles	O
identified	O
in	O
89	O
%	O
of	O
the	O
patients	O
.	O
In	O
several	O
instances	O
,	O
family	O
studies	O
provided	O
molecular	O
evidence	O
for	O
pseudodominant	O
transmission	O
and	O
incomplete	O
penetrance	O
of	O
the	O
disease	O
phenotype	O
.	O
The	O
M694V	O
homozygous	O
genotype	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
higher	O
prevalence	O
of	O
renal	B-SpecificDisease
amyloidosis	I-SpecificDisease
and	O
arthritis	B-SpecificDisease
,	O
compared	O
with	O
other	O
genotypes	O
(	O
P	O
=	O
.	O
0002	O
and	O
P	O
=	O
.	O
006	O
,	O
respectively	O
)	O
.	O
The	O
demonstration	O
of	O
both	O
the	O
diagnostic	O
and	O
prognostic	O
value	O
of	O
MEFV	O
analysis	O
and	O
particular	O
modes	O
of	O
inheritance	O
should	O
lead	O
to	O
new	O
ways	O
for	O
management	O
of	O
FMF-including	O
genetic	O
counseling	O
and	O
therapeutic	O
decisions	O
in	O
affected	O
families	O
.	O

2161209	O
Linkage	O
of	O
DNA	O
markers	O
at	O
Xq28	O
to	O
adrenoleukodystrophy	B-SpecificDisease
and	O
adrenomyeloneuropathy	B-SpecificDisease
present	O
within	O
the	O
same	O
family.	O
We	O
present	O
a	O
large	O
kindred	O
that	O
contained	O
patients	O
with	O
either	O
adrenoleukodystrophy	B-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
or	O
adrenomyeloneuropathy	B-SpecificDisease
(	O
AMN	B-SpecificDisease
)	O
.	O
The	O
pedigree	O
clearly	O
supported	O
the	O
X-linked	O
mode	O
of	O
inheritance	O
of	O
the	O
nonneonatal	O
form	O
of	O
ALD	B-SpecificDisease
/	O
AMN	B-SpecificDisease
.	O
Analysis	O
with	O
DNA	O
markers	O
at	O
Xq28	O
suggested	O
segregation	O
of	O
both	O
ALD	B-SpecificDisease
and	O
AMN	B-SpecificDisease
with	O
an	O
identical	O
haplotype	O
.	O
This	O
indicated	O
that	O
nonneonatal	O
ALD	B-SpecificDisease
and	O
AMN	B-SpecificDisease
are	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
same	O
gene	O
at	O
Xq28	O
.	O
It	O
showed	O
,	O
furthermore	O
,	O
that	O
phenotypic	O
differences	O
between	O
ALD	B-SpecificDisease
and	O
AMN	B-SpecificDisease
are	O
not	O
necessarily	O
the	O
consequence	O
of	O
allelic	O
heterogeneity	O
due	O
to	O
different	O
mutations	O
within	O
the	O
same	O
gene	O
.	O
The	O
maximal	O
lod	O
score	O
for	O
linkage	O
of	O
the	O
ALD	B-Modifier
/	O
AMN	B-Modifier
gene	O
and	O
the	O
multiallelic	O
anonymous	O
DNA	O
marker	O
at	O
DXS52	O
was	O
3	O
.	O
0	O
at	O
a	O
recombination	O
fraction	O
of	O
0	O
.	O
00	O
.	O
This	O
made	O
a	O
prenatal	O
or	O
presymptomatic	O
diagnosis	O
and	O
heterozygote	O
detection	O
by	O
DNA	O
analysis	O
with	O
this	O
marker	O
reliable	O
.	O

8317477	O
The	O
normal	O
Huntington	B-Modifier
disease	I-Modifier
(HD)	O
allele,	O
or	O
a	O
closely	O
linked	O
gene,	O
influences	O
age	O
at	O
onset	O
of	O
HD.	B-SpecificDisease
We	O
evaluated	O
the	O
hypothesis	O
that	O
Huntington	B-SpecificDisease
disease	I-SpecificDisease
(	O
HD	B-SpecificDisease
)	O
is	O
influenced	O
by	O
the	O
normal	O
HD	B-Modifier
allele	O
by	O
comparing	O
transmission	O
patterns	O
of	O
genetically	O
linked	O
markers	O
at	O
the	O
D4S10	O
locus	O
in	O
the	O
normal	O
parent	O
against	O
age	O
at	O
onset	O
in	O
the	O
affected	O
offspring	O
.	O
Analysis	O
of	O
information	O
from	O
21	O
sibships	O
in	O
14	O
kindreds	O
showed	O
a	O
significant	O
tendency	O
for	O
sibs	O
who	O
have	O
similar	O
onset	O
ages	O
to	O
share	O
the	O
same	O
D4S10	O
allele	O
from	O
the	O
normal	O
parent	O
.	O
Affected	O
sibs	O
who	O
inherited	O
different	O
D4S10	O
alleles	O
from	O
the	O
normal	O
parent	O
tended	O
to	O
have	O
more	O
variable	O
ages	O
at	O
onset	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
expression	O
of	O
HD	B-SpecificDisease
is	O
modulated	O
by	O
the	O
normal	O
HD	B-Modifier
allele	O
or	O
by	O
a	O
closely	O
linked	O
locus	O
.	O
.	O

8084618	O
The	O
EWS	O
gene,	O
involved	O
in	O
Ewing	B-DiseaseClass
family	I-DiseaseClass
of	I-DiseaseClass
tumors,	I-DiseaseClass
malignant	B-DiseaseClass
melanoma	I-DiseaseClass
of	I-DiseaseClass
soft	I-DiseaseClass
parts	I-DiseaseClass
and	O
desmoplastic	B-SpecificDisease
small	I-SpecificDisease
round	I-SpecificDisease
cell	I-SpecificDisease
tumors,	I-SpecificDisease
codes	O
for	O
an	O
RNA	O
binding	O
protein	O
with	O
novel	O
regulatory	O
domains.	O
The	O
EWS	O
gene	O
,	O
which	O
maps	O
to	O
band	O
q12	O
of	O
human	O
chromosome	O
22	O
,	O
is	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
human	O
solid	B-DiseaseClass
tumors	I-DiseaseClass
including	O
Ewing	B-SpecificDisease
sarcoma	I-SpecificDisease
,	O
related	O
primitive	O
neuroectodermal	B-DiseaseClass
tumors	I-DiseaseClass
,	O
malignant	B-DiseaseClass
melanoma	I-DiseaseClass
of	I-DiseaseClass
soft	I-DiseaseClass
parts	I-DiseaseClass
and	O
desmoplastic	B-DiseaseClass
small	I-DiseaseClass
round	I-DiseaseClass
cell	I-DiseaseClass
tumors	I-DiseaseClass
.	O
In	O
these	O
tumors	B-DiseaseClass
,	O
the	O
EWS	O
is	O
fused	O
to	O
genes	O
encoding	O
transcriptional	O
activators	O
/	O
repressors	O
,	O
like	O
Fli-1	O
or	O
erg	O
or	O
ATF	O
1	O
or	O
wt1	O
.	O
To	O
better	O
understand	O
the	O
function	O
of	O
the	O
EWS	O
protein	O
,	O
we	O
cloned	O
the	O
EWS	O
cDNA	O
.	O
Sequence	O
analysis	O
of	O
this	O
cDNA	O
revealed	O
differential	O
splicing	O
involving	O
two	O
exons	O
encoding	O
72	O
amino	O
acids	O
.	O
Both	O
alternatively	O
spliced	O
transcripts	O
,	O
EWS	O
and	O
EWS-b	O
,	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cells	O
.	O
Because	O
EWS	O
proteins	O
contain	O
putative	O
conserved	O
RNA	O
binding	O
motifs	O
,	O
we	O
studied	O
the	O
RNA	O
binding	O
properties	O
of	O
the	O
EWS	O
protein	O
.	O
The	O
EWS-b	O
protein	O
binds	O
to	O
RNA	O
in	O
vitro	O
and	O
,	O
specifically	O
,	O
to	O
poly	O
G	O
and	O
poly	O
U	O
.	O
The	O
RNA	O
binding	O
activity	O
was	O
localized	O
to	O
the	O
carboxy	O
terminal	O
86	O
amino	O
acids	O
,	O
which	O
constitute	O
RGG	O
box	O
.	O
Thus	O
the	O
amino	O
terminal	O
domain	O
of	O
EWS	O
(	O
NTD-EWS	O
)	O
,	O
which	O
is	O
involved	O
in	O
chromosome	O
translocation	O
may	O
regulate	O
the	O
specificity	O
of	O
RNA	O
binding	O
activity	O
of	O
EWS	O
.	O
An	O
EWS-erg	O
chimeric	O
protein	O
,	O
which	O
is	O
found	O
in	O
Ewings	B-Modifier
sarcoma	I-Modifier
cells	O
,	O
functions	O
as	O
a	O
transcriptional	O
activator	O
.	O
Mutational	O
analysis	O
of	O
EWS-erg	O
chimeric	O
protein	O
revealed	O
that	O
NTD-EWS	O
functions	O
as	O
a	O
regulatory	O
domain	O
for	O
the	O
transcriptional	O
activation	O
properties	O
of	O
EWS-erg	O
chimeric	O
protein	O
.	O
.	O

10382910	O
Severe	O
clinical	O
expression	O
in	O
X-linked	B-SpecificDisease
Emery-Dreifuss	I-SpecificDisease
muscular	I-SpecificDisease
dystrophy.	I-SpecificDisease
X-linked	B-SpecificDisease
Emery-Dreifuss	I-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
EDMD	B-SpecificDisease
)	O
is	O
a	O
relatively	O
rare	O
benign	B-DiseaseClass
neuromuscular	I-DiseaseClass
disorder	I-DiseaseClass
which	O
can	O
vary	O
remarkably	O
in	O
onset	O
,	O
course	O
and	O
severity	O
.	O
In	O
the	O
present	O
study	O
,	O
a	O
TCTAC	O
deletion	O
spanning	O
the	O
nucleotides	O
631-635	O
of	O
the	O
emerin	O
gene	O
caused	O
an	O
unusually	O
severe	O
disease	O
phenotype	O
including	O
loss	B-DiseaseClass
of	I-DiseaseClass
ambulation	I-DiseaseClass
and	O
severe	O
muscle	B-DiseaseClass
wasting	I-DiseaseClass
in	O
two	O
affected	O
brothers	O
.	O
The	O
same	O
mutation	O
has	O
been	O
reported	O
previously	O
in	O
an	O
unrelated	O
family	O
showing	O
a	O
significantly	O
milder	O
phenotype	O
.	O
The	O
interfamilial	O
heterogeneity	O
in	O
distribution	O
and	O
in	O
severity	O
of	O
the	O
features	O
in	O
the	O
two	O
families	O
point	O
to	O
environmental	O
or	O
genetic	O
modification	O
as	O
the	O
cause	O
of	O
clinical	O
variability	O
in	O
Emery-Dreifuss	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
.	O
.	O

3718019	O
Heterozygous	B-SpecificDisease
C2	I-SpecificDisease
deficiency	I-SpecificDisease
associated	O
with	O
angioedema,	B-SpecificDisease
myasthenia	B-SpecificDisease
gravis,	I-SpecificDisease
and	O
systemic	B-SpecificDisease
lupus	I-SpecificDisease
erythematosus.	I-SpecificDisease
We	O
describe	O
a	O
patient	O
with	O
myasthenia	B-SpecificDisease
gravis	I-SpecificDisease
,	O
systemic	B-SpecificDisease
lupus	I-SpecificDisease
erythematosus	I-SpecificDisease
,	O
and	O
angioedema	B-SpecificDisease
associated	O
with	O
heterozygous	O
complement	B-SpecificDisease
factor	I-SpecificDisease
2	I-SpecificDisease
(	I-SpecificDisease
C2	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
.	O
The	O
significance	O
of	O
this	O
association	O
is	O
controversial	O
,	O
though	O
the	O
association	O
of	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
with	O
certain	O
histocompatibility	O
antigens	O
suggests	O
possible	O
linkage	O
to	O
immune	O
response	O
genes	O
.	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
of	O
heterozygous	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
in	O
association	O
with	O
this	O
combination	O
of	O
autoimmune	B-DiseaseClass
disorders	I-DiseaseClass
,	O
and	O
we	O
discuss	O
the	O
aetiological	O
implications	O
.	O
.	O

6859721	O
Absence	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
seventh	I-SpecificDisease
component	I-SpecificDisease
of	I-SpecificDisease
complement	I-SpecificDisease
in	O
a	O
patient	O
with	O
chronic	B-SpecificDisease
meningococcemia	I-SpecificDisease
presenting	O
as	O
vasculitis.	B-SpecificDisease
A	O
previously	O
healthy	O
40-year-old	O
man	O
presenting	O
with	O
fever	B-SpecificDisease
,	O
arthritis	B-SpecificDisease
,	O
and	O
cutaneous	B-SpecificDisease
vasculitis	I-SpecificDisease
was	O
found	O
to	O
have	O
chronic	B-SpecificDisease
meningococcemia	I-SpecificDisease
.	O
Evaluation	O
of	O
his	O
complement	O
system	O
showed	O
an	O
absence	O
of	O
functional	O
and	O
antigenic	O
C7	O
,	O
compatible	O
with	O
a	O
complete	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
seventh	I-SpecificDisease
component	I-SpecificDisease
of	I-SpecificDisease
complement	I-SpecificDisease
.	O
Study	O
of	O
the	O
patients	O
family	O
spanning	O
four	O
generations	O
showed	O
heterozygous	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
C7	I-SpecificDisease
in	O
five	O
members	O
.	O
Chronic	B-SpecificDisease
neisserial	I-SpecificDisease
infection	I-SpecificDisease
can	O
be	O
associated	O
with	O
C7	B-SpecificDisease
deficiency	I-SpecificDisease
and	O
must	O
be	O
distinguished	O
from	O
other	O
causes	O
of	O
cutaneous	B-SpecificDisease
vasculitis	I-SpecificDisease
.	O
.	O

10051007	O
Age	O
of	O
onset	O
in	O
Huntington	B-SpecificDisease
disease	I-SpecificDisease
:	O
sex	O
specific	O
influence	O
of	O
apolipoprotein	O
E	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length	O
.	O
Age	O
of	O
onset	O
(	O
AO	O
)	O
of	O
Huntington	B-SpecificDisease
disease	I-SpecificDisease
(	O
HD)	B-SpecificDisease
is	O
known	O
to	O
be	O
correlated	O
with	O
the	O
length	O
of	O
an	O
expanded	O
CAG	O
repeat	O
in	O
the	O
HD	B-Modifier
gene	O
.	O
Apolipoprotein	O
E	O
(	O
APOE	O
)	O
genotype	O
,	O
in	O
turn	O
,	O
is	O
known	O
to	O
influence	O
AO	O
in	O
Alzheimer	B-SpecificDisease
disease	I-SpecificDisease
,	O
rendering	O
the	O
APOE	O
gene	O
a	O
likely	O
candidate	O
to	O
affect	O
AO	O
in	O
other	O
neurological	B-DiseaseClass
diseases	I-DiseaseClass
too	O
.	O
We	O
therefore	O
determined	O
APOE	O
genotype	O
and	O
normal	O
CAG	O
repeat	O
length	O
in	O
the	O
HD	B-Modifier
gene	O
for	O
138	O
HD	B-Modifier
patients	O
who	O
were	O
previously	O
analysed	O
with	O
respect	O
to	O
CAG	O
repeat	O
length	O
.	O
Genotyping	O
for	O
APOE	O
was	O
performed	O
blind	O
to	O
clinical	O
information	O
.	O
In	O
addition	O
to	O
highlighting	O
the	O
effect	O
of	O
the	O
normal	O
repeat	O
length	O
upon	O
AO	O
in	O
maternally	O
inherited	O
HD	B-SpecificDisease
and	O
in	O
male	O
patients	O
,	O
we	O
show	O
that	O
the	O
APOE	O
epsilon2epsilon3	O
genotype	O
is	O
associated	O
with	O
significantly	O
earlier	O
AO	O
in	O
males	O
than	O
in	O
females	O
.	O
Such	O
a	O
sex	O
difference	O
in	O
AO	O
was	O
not	O
apparent	O
for	O
any	O
of	O
the	O
other	O
APOE	O
genotypes	O
.	O
Our	O
findings	O
suggest	O
that	O
subtle	O
differences	O
in	O
the	O
course	O
of	O
the	O
neurodegeneration	B-DiseaseClass
in	O
HD	B-SpecificDisease
may	O
allow	O
interacting	O
genes	O
to	O
exert	O
gender	O
specific	O
effects	O
upon	O
AO.	O

8370681	O
Detection	O
of	O
a	O
novel	O
arginine	O
vasopressin	O
defect	O
by	O
dideoxy	O
fingerprinting.	O
Autosomal	B-SpecificDisease
dominant	I-SpecificDisease
neurohypophyseal	I-SpecificDisease
diabetes	I-SpecificDisease
insipidus	I-SpecificDisease
is	O
a	O
familial	O
form	O
of	O
diabetes	B-DiseaseClass
insipidus	I-DiseaseClass
.	O
This	O
disorder	O
is	O
associated	O
with	O
variable	O
levels	O
of	O
arginine	O
vasopressin	O
(	O
AVP	O
)	O
and	O
diabetes	B-DiseaseClass
insipidus	I-DiseaseClass
of	O
varying	O
severity	O
,	O
which	O
responds	O
to	O
exogenous	O
AVP	O
.	O
To	O
determine	O
the	O
molecular	O
basis	O
of	O
autosomal	B-SpecificDisease
dominant	I-SpecificDisease
neurohypophyseal	I-SpecificDisease
diabetes	I-SpecificDisease
insipidus	I-SpecificDisease
,	O
the	O
AVP	O
genes	O
of	O
members	O
of	O
a	O
large	O
kindred	O
were	O
analyzed	O
.	O
A	O
new	O
method	O
,	O
called	O
dideoxy	O
fingerprinting	O
,	O
was	O
used	O
to	O
detect	O
an	O
AVP	O
mutation	O
that	O
was	O
characterized	O
by	O
DNA	O
sequencing	O
.	O
The	O
novel	O
defect	O
found	O
changes	O
the	O
last	O
codon	O
of	O
the	O
AVP	O
signal	O
peptide	O
from	O
alanine	O
to	O
threonine	O
,	O
which	O
should	O
perturb	O
cleavage	O
of	O
mature	O
AVP	O
from	O
its	O
precursor	O
protein	O
and	O
inhibit	O
its	O
secretion	O
or	O
action	O
.	O
.	O

7573040	O
Marked	O
phenotypic	O
heterogeneity	O
associated	O
with	O
expansion	O
of	O
a	O
CAG	O
repeat	O
sequence	O
at	O
the	O
spinocerebellar	B-Modifier
ataxia	I-Modifier
3/Machado-Joseph	I-Modifier
disease	I-Modifier
locus.	O
The	O
spinocerebellar	B-Modifier
ataxia	I-Modifier
3	I-Modifier
locus	O
(	O
SCA3	B-SpecificDisease
)	O
for	O
type	B-SpecificDisease
I	I-SpecificDisease
autosomal	I-SpecificDisease
dominant	I-SpecificDisease
cerebellar	I-SpecificDisease
ataxia	I-SpecificDisease
(	O
ADCA	B-SpecificDisease
type	I-SpecificDisease
I	I-SpecificDisease
)	O
,	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	B-DiseaseClass
disorders	I-DiseaseClass
,	O
has	O
been	O
mapped	O
to	O
chromosome	O
14q32	O
.	O
1	O
1	O
.	O
ADCA	B-Modifier
type	I-Modifier
I	I-Modifier
patients	O
from	O
families	O
segregating	O
SCA3	B-SpecificDisease
share	O
clinical	O
features	O
in	O
common	O
with	O
those	O
with	O
Machado-Joseph	B-SpecificDisease
disease	I-SpecificDisease
(	O
MJD	B-SpecificDisease
)	O
,	O
the	O
gene	O
of	O
which	O
maps	O
to	O
the	O
same	O
region	O
.	O
We	O
show	O
here	O
that	O
the	O
disease	O
gene	O
segregating	O
in	O
each	O
of	O
three	O
French	O
ADCA	B-Modifier
type	I-Modifier
I	I-Modifier
kindreds	O
and	O
in	O
a	O
French	O
family	O
with	O
neuropathological	O
findings	O
suggesting	O
the	O
ataxochoreic	O
form	O
of	O
dentatorubropallidoluysian	B-SpecificDisease
atrophy	I-SpecificDisease
carries	O
an	O
expanded	O
CAG	O
repeat	O
sequence	O
located	O
at	O
the	O
same	O
locus	O
as	O
that	O
for	O
MJD	B-SpecificDisease
.	O
Analysis	O
of	O
the	O
mutation	O
in	O
these	O
families	O
shows	O
a	O
strong	O
negative	O
correlation	O
between	O
size	O
of	O
the	O
expanded	O
CAG	O
repeat	O
and	O
age	O
at	O
onset	O
of	O
clinical	O
disease	O
.	O
Instability	O
of	O
the	O
expanded	O
triplet	O
repeat	O
was	O
not	O
found	O
to	O
be	O
affected	O
by	O
sex	O
of	O
the	O
parent	O
transmitting	O
the	O
mutation	O
.	O
Evidence	O
was	O
found	O
for	O
somatic	O
and	O
gonadal	O
mosaicism	O
for	O
alleles	O
carrying	O
expanded	O
trinucleotide	O
repeats	O
.	O

10716718	O
Abnormal	O
development	O
of	O
Purkinje	O
cells	O
and	O
lymphocytes	O
in	O
Atm	O
mutant	O
mice.	O
Motor	B-DiseaseClass
incoordination	I-DiseaseClass
,	O
immune	B-DiseaseClass
deficiencies	I-DiseaseClass
,	O
and	O
an	O
increased	O
risk	O
of	O
cancer	B-DiseaseClass
are	O
the	O
characteristic	O
features	O
of	O
the	O
hereditary	B-DiseaseClass
disease	I-DiseaseClass
ataxia-telangiectasia	B-SpecificDisease
(	O
A-T	B-SpecificDisease
)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
ATM	O
gene	O
.	O
Through	O
gene	O
targeting	O
,	O
we	O
have	O
generated	O
a	O
line	O
of	O
Atm	O
mutant	O
mice	O
,	O
Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
.	O
In	O
contrast	O
to	O
other	O
Atm	O
mutant	O
mice	O
,	O
Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
show	O
a	O
lower	O
incidence	O
of	O
thymic	B-SpecificDisease
lymphoma	I-SpecificDisease
and	O
survive	O
beyond	O
a	O
few	O
months	O
of	O
age	O
.	O
Atm	O
(	O
y	O
/	O
y	O
)	O
mice	O
exhibit	O
deficits	O
in	O
motor	O
learning	O
indicative	O
of	O
cerebellar	B-DiseaseClass
dysfunction	I-DiseaseClass
.	O
Even	O
though	O
we	O
found	O
no	O
gross	O
cerebellar	B-DiseaseClass
degeneration	I-DiseaseClass
in	O
older	O
Atm	O
(	O
y	O
/	O
y	O
)	O
animals	O
,	O
ectopic	O
and	O
abnormally	O
differentiated	O
Purkinje	O
cells	O
were	O
apparent	O
in	O
mutant	O
mice	O
of	O
all	O
ages	O
.	O
These	O
findings	O
establish	O
that	O
some	O
neuropathological	B-DiseaseClass
abnormalities	I-DiseaseClass
seen	O
in	O
A-T	B-Modifier
patients	O
also	O
are	O
present	O
in	O
Atm	O
mutant	O
mice	O
.	O
In	O
addition	O
,	O
we	O
report	O
a	O
previously	O
unrecognized	O
effect	O
of	O
Atm	B-SpecificDisease
deficiency	I-SpecificDisease
on	O
development	O
or	O
maintenance	O
of	O
CD4	O
(	O
+	O
)	O
8	O
(	O
+	O
)	O
thymocytes	O
.	O
We	O
discuss	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
hypothesis	O
that	O
abnormal	O
development	O
of	O
Purkinje	O
cells	O
and	O
lymphocytes	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
A-T	B-SpecificDisease
.	O
.	O

10590055	O
A	O
point	O
mutation	O
Thr(799)Met	O
on	O
the	O
alpha(2)	O
integrin	O
leads	O
to	O
the	O
formation	O
of	O
new	O
human	O
platelet	O
alloantigen	O
Sit(a)	O
and	O
affects	O
collagen-induced	O
aggregation.	O
A	O
new	O
platelet-specific	O
alloantigen	O
,	O
termed	O
Sit	O
(	O
a	O
)	O
,	O
was	O
identified	O
in	O
a	O
severe	O
case	O
of	O
neonatal	B-SpecificDisease
alloimmune	I-SpecificDisease
thrombocytopenia	I-SpecificDisease
.	O
The	O
Sit	O
(	O
a	O
)	O
alloantigen	O
is	O
of	O
low	O
frequency	O
(	O
1	O
/	O
400	O
)	O
in	O
the	O
German	O
population	O
.	O
Immunochemical	O
studies	O
demonstrated	O
that	O
the	O
Sit	O
(	O
a	O
)	O
epitopes	O
reside	O
on	O
platelet	O
glycoprotein	O
(	O
GP	O
)	O
Ia	O
.	O
Nucleotide	O
sequence	O
analysis	O
of	O
GPIa	O
cDNA	O
derived	O
from	O
Sit	O
(	O
a	O
)	O
-positive	O
platelets	O
showed	O
C	O
(	O
2531	O
)	O
--	O
>	O
T	O
(	O
2531	O
)	O
point	O
mutation	O
,	O
resulting	O
in	O
Thr	O
(	O
799	O
)	O
Met	O
dimorphism	O
.	O
Analysis	O
of	O
genomic	O
DNA	O
from	O
22	O
Sit	O
(	O
a	O
)	O
-negative	O
normal	O
individuals	O
showed	O
that	O
the	O
Thr	O
(	O
799	O
)	O
is	O
encoded	O
by	O
ACG	O
(	O
2532	O
)	O
(	O
90	O
.	O
9	O
%	O
)	O
or	O
ACA	O
(	O
2532	O
)	O
(	O
9	O
.	O
1	O
%	O
)	O
.	O
To	O
establish	O
a	O
DNA	O
typing	O
technique	O
,	O
we	O
elucidated	O
the	O
organization	O
of	O
the	O
GPIa	O
gene	O
adjacent	O
to	O
the	O
polymorphic	O
bases	O
.	O
The	O
introns	O
(	O
421	O
bp	O
and	O
1	O
.	O
2	O
kb	O
)	O
encompass	O
a	O
142-bp	O
exon	O
with	O
the	O
2	O
polymorphic	O
bases	O
2531	O
and	O
2532	O
.	O
Polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
on	O
DNA	O
derived	O
from	O
100	O
donors	O
using	O
the	O
restriction	O
enzyme	O
Mae	O
III	O
showed	O
that	O
the	O
Met	O
(	O
799	O
)	O
form	O
of	O
GPIa	O
is	O
restricted	O
to	O
Sit	O
(	O
a	O
)	O
(	O
+	O
)	O
phenotype	O
.	O
Analysis	O
of	O
stable	O
Chinese	O
hamster	O
ovary	O
transfectants	O
expressing	O
allele-specific	O
recombinant	O
forms	O
of	O
GPIa	O
showed	O
that	O
anti-Sit	O
(	O
a	O
)	O
exclusively	O
reacted	O
with	O
the	O
Glu	O
(	O
505	O
)	O
Met	O
(	O
799	O
)	O
,	O
but	O
not	O
with	O
the	O
Glu	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
and	O
the	O
Lys	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
isoforms	O
.	O
In	O
contrast	O
,	O
anti-Br	O
(	O
a	O
)	O
(	O
HPA-5b	O
)	O
only	O
recognized	O
the	O
Lys	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
form	O
,	O
whereas	O
anti-Br	O
(	O
b	O
)	O
(	O
HPA-5a	O
)	O
reacted	O
with	O
both	O
Glu	O
(	O
505	O
)	O
Thr	O
(	O
799	O
)	O
and	O
Glu	O
(	O
505	O
)	O
Met	O
(	O
799	O
)	O
isoforms	O
.	O
These	O
results	O
demonstrated	O
that	O
the	O
Met	O
(	O
799	O
)	O
is	O
responsible	O
for	O
formation	O
of	O
the	O
Sit	O
(	O
a	O
)	O
alloantigenic	O
determinants	O
,	O
whereas	O
amino	O
acid	O
505	O
(	O
Lys	O
or	O
Glu	O
)	O
specifically	O
controls	O
the	O
expression	O
of	O
Br	O
(	O
a	O
)	O
and	O
Br	O
(	O
b	O
)	O
epitopes	O
,	O
respectively	O
.	O
Platelet	O
aggregation	O
responses	O
of	O
Sit	O
(	O
a	O
)	O
(	O
+	O
)	O
individuals	O
were	O
diminished	O
in	O
response	O
to	O
collagen	O
,	O
indicating	O
that	O
the	O
Thr	O
(	O
799	O
)	O
Met	O
mutation	O
affects	O
the	O
function	O
of	O
the	O
GPIa	O
/	O
IIa	O
complex	O

10557309	O
cDNA	O
microarrays	O
detect	O
activation	O
of	O
a	O
myogenic	O
transcription	O
program	O
by	O
the	O
PAX3-FKHR	O
fusion	O
oncogene.	O
Alveolar	B-SpecificDisease
rhabdomyosarcoma	I-SpecificDisease
is	O
an	O
aggressive	O
pediatric	B-SpecificDisease
cancer	I-SpecificDisease
of	I-SpecificDisease
striated	I-SpecificDisease
muscle	I-SpecificDisease
characterized	O
in	O
60	O
%	O
of	O
cases	O
by	O
a	O
t	O
(	O
2	O
;	O
13	O
)	O
(	O
q35	O
;	O
q14	O
)	O
.	O
This	O
results	O
in	O
the	O
fusion	O
of	O
PAX3	O
,	O
a	O
developmental	O
transcription	O
factor	O
required	O
for	O
limb	O
myogenesis	O
,	O
with	O
FKHR	O
,	O
a	O
member	O
of	O
the	O
forkhead	O
family	O
of	O
transcription	O
factors	O
.	O
The	O
resultant	O
PAX3-FKHR	O
gene	O
possesses	O
transforming	O
properties	O
;	O
however	O
,	O
the	O
effects	O
of	O
this	O
chimeric	O
oncogene	O
on	O
gene	O
expression	O
are	O
largely	O
unknown	O
.	O
To	O
investigate	O
the	O
actions	O
of	O
these	O
transcription	O
factors	O
,	O
both	O
Pax3	O
and	O
PAX3-FKHR	O
were	O
introduced	O
into	O
NIH	O
3T3	O
cells	O
,	O
and	O
the	O
resultant	O
gene	O
expression	O
changes	O
were	O
analyzed	O
with	O
a	O
murine	O
cDNA	O
microarray	O
containing	O
2	O
,	O
225	O
elements	O
.	O
We	O
found	O
that	O
PAX3-FKHR	O
but	O
not	O
PAX3	O
activated	O
a	O
myogenic	O
transcription	O
program	O
including	O
the	O
induction	O
of	O
transcription	O
factors	O
MyoD	O
,	O
Myogenin	O
,	O
Six1	O
,	O
and	O
Slug	O
as	O
well	O
as	O
a	O
battery	O
of	O
genes	O
involved	O
in	O
several	O
aspects	O
of	O
muscle	O
function	O
.	O
Notable	O
among	O
this	O
group	O
were	O
the	O
growth	O
factor	O
gene	O
Igf2	O
and	O
its	O
binding	O
protein	O
Igfbp5	O
.	O
Relevance	O
of	O
this	O
model	O
was	O
suggested	O
by	O
verification	O
that	O
three	O
of	O
these	O
genes	O
(	O
IGFBP5	O
,	O
HSIX1	O
,	O
and	O
Slug	O
)	O
were	O
also	O
expressed	O
in	O
alveolar	B-Modifier
rhabdomyosarcoma	I-Modifier
cell	O
lines	O
.	O
This	O
study	O
utilizes	O
cDNA	O
microarrays	O
to	O
elucidate	O
the	O
pattern	O
of	O
gene	O
expression	O
induced	O
by	O
an	O
oncogenic	O
transcription	O
factor	O
and	O
demonstrates	O
the	O
profound	O
myogenic	O
properties	O
of	O
PAX3-FKHR	O
in	O
NIH	O
3T3	O
cells	O
.	O
.	O

10797418	O
Submicroscopic	O
deletion	O
in	O
cousins	O
with	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
causes	O
a	O
grandmatrilineal	O
inheritance	O
pattern:	O
effects	O
of	O
imprinting.	O
The	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
PWS	B-SpecificDisease
)	O
critical	O
region	O
on	O
15q11-q13	O
is	O
subject	O
to	O
imprinting	O
.	O
PWS	B-SpecificDisease
becomes	O
apparent	O
when	O
genes	O
on	O
the	O
paternally	O
inherited	O
chromosome	O
are	O
not	O
expressed	O
.	O
Familial	B-SpecificDisease
PWS	I-SpecificDisease
is	O
rare	O
.	O
We	O
report	O
on	O
a	O
family	O
in	O
which	O
a	O
male	O
and	O
a	O
female	O
paternal	O
first	O
cousin	O
both	O
have	O
PWS	B-SpecificDisease
with	O
cytogenetically	O
normal	O
karyotypes	O
.	O
Fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
analysis	O
shows	O
a	O
submicroscopic	O
deletion	O
of	O
SNRPN	O
,	O
but	O
not	O
the	O
closely	O
associated	O
loci	O
D15S10	O
,	O
D15S11	O
,	O
D15S63	O
,	O
and	O
GABRB3	O
.	O
The	O
cousins	O
fathers	O
and	O
two	O
paternal	O
aunts	O
have	O
the	O
same	O
deletion	O
and	O
are	O
clinically	O
normal	O
.	O
The	O
grandmother	O
of	O
the	O
cousins	O
is	O
deceased	O
and	O
not	O
available	O
for	O
study	O
,	O
and	O
their	O
grandfather	O
is	O
not	O
deleted	O
for	O
SNRPN	O
.	O
DNA	O
methylation	O
analysis	O
of	O
D15S63	O
is	O
consistent	O
with	O
an	O
abnormality	O
of	O
the	O
imprinting	O
center	O
associated	O
with	O
PWS	B-SpecificDisease
.	O
"	O
Grandmatrilineal	O
"	O
inheritance	O
occurs	O
when	O
a	O
woman	O
with	O
deletion	O
of	O
an	O
imprinted	O
,	O
paternally	O
expressed	O
gene	O
is	O
at	O
risk	O
of	O
having	O
affected	O
grandchildren	O
through	O
her	O
sons	O
.	O
In	O
this	O
case	O
,	O
PWS	B-SpecificDisease
does	O
not	O
become	O
evident	O
as	O
long	O
as	O
the	O
deletion	O
is	O
passed	O
through	O
the	O
matrilineal	O
line	O
.	O
This	O
represents	O
a	O
unique	O
inheritance	O
pattern	O
due	O
to	O
imprinting	O
.	O
.	O

7550230	O
Three	O
novel	O
aniridia	B-Modifier
mutations	O
in	O
the	O
human	O
PAX6	O
gene.	O
Aniridia	B-SpecificDisease
(	O
iris	B-SpecificDisease
hypoplasia	I-SpecificDisease
)	O
is	O
an	O
autosomal	B-DiseaseClass
dominant	I-DiseaseClass
congenital	I-DiseaseClass
disorder	I-DiseaseClass
of	I-DiseaseClass
the	I-DiseaseClass
eye	I-DiseaseClass
.	O
Mutations	O
in	O
the	O
human	O
aniridia	B-Modifier
(	O
PAX6	O
)	O
gene	O
have	O
now	O
been	O
identified	O
in	O
many	O
patients	O
from	O
various	O
ethnic	O
groups	O
.	O
In	O
the	O
study	O
reported	O
here	O
we	O
describe	O
PAX6	O
mutations	O
in	O
one	O
sporadic	O
and	O
five	O
familial	O
cases	O
with	O
aniridia	B-SpecificDisease
.	O
Of	O
the	O
four	O
different	O
mutations	O
identified	O
,	O
one	O
was	O
identical	O
to	O
a	O
previously	O
reported	O
mutation	O
(	O
C--	O
>	O
T	O
transition	O
at	O
codon	O
240	O
)	O
,	O
and	O
three	O
were	O
novel	O
two	O
in	O
the	O
glycine-rich	O
region	O
and	O
one	O
in	O
the	O
proline	O
/	O
serine	O
/	O
threonine-rich	O
(	O
PST	O
)	O
region	O
.	O
One	O
PAX6	O
mutation	O
found	O
in	O
the	O
PST	O
region	O
was	O
associated	O
with	O
cataracts	B-SpecificDisease
in	O
an	O
aniridia	B-Modifier
family	O
.	O
Another	O
splice	O
mutation	O
in	O
the	O
PST	O
domain	O
occurred	O
in	O
an	O
aniridia	B-Modifier
patient	O
with	O
anosmia	B-SpecificDisease
(	O
inability	O
to	O
smell	O
)	O
.	O
The	O
six	O
new	O
aniridia	B-Modifier
cases	O
reported	O
here	O
have	O
mutations	O
predicted	O
to	O
generate	O
incomplete	O
PAX6	O
proteins	O
.	O
These	O
results	O
support	O
the	O
theory	O
that	O
human	O
aniridia	B-SpecificDisease
is	O
caused	O
by	O
haploinsufficiency	B-SpecificDisease
of	I-SpecificDisease
PAX6	I-SpecificDisease
.	O
.	O

3347839	O
Expression	O
of	O
the	O
murine	O
Duchenne	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
gene	O
in	O
muscle	O
and	O
brain.	O
Complementary	O
DNA	O
clones	O
were	O
isolated	O
that	O
represent	O
the	O
5	O
terminal	O
2	O
.	O
5	O
kilobases	O
of	O
the	O
murine	O
Duchenne	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
(	O
Dmd	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
.	O
Mouse	O
Dmd	O
mRNA	O
was	O
detectable	O
in	O
skeletal	O
and	O
cardiac	O
muscle	O
and	O
at	O
a	O
level	O
approximately	O
90	O
percent	O
lower	O
in	O
brain	O
.	O
Dmd	O
mRNA	O
is	O
also	O
present	O
,	O
but	O
at	O
much	O
lower	O
than	O
normal	O
levels	O
,	O
in	O
both	O
the	O
muscle	O
and	O
brain	O
of	O
three	O
different	O
strains	O
of	O
dystrophic	B-Modifier
mdx	O
mice	O
.	O
The	O
identification	O
of	O
Dmd	O
mRNA	O
in	O
brain	O
raises	O
the	O
possibility	O
of	O
a	O
relation	O
between	O
human	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)	O
gene	O
expression	O
and	O
the	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
found	O
in	O
some	O
DMD	B-Modifier
males	O
.	O
These	O
results	O
also	O
provide	O
evidence	O
that	O
the	O
mdx	O
mutations	O
are	O
allelic	O
variants	O
of	O
mouse	O
Dmd	O
gene	O
mutations	O
.	O

8408659	O
A	O
missense	O
mutation	O
in	O
the	O
cholesteryl	O
ester	O
transfer	O
protein	O
gene	O
with	O
possible	O
dominant	O
effects	O
on	O
plasma	O
high	O
density	O
lipoproteins.	O
Plasma	O
HDL	O
are	O
a	O
negative	O
risk	O
factor	O
for	O
atherosclerosis	B-SpecificDisease
.	O
Cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
;	O
476	O
amino	O
acids	O
)	O
transfers	O
cholesteryl	O
ester	O
from	O
HDL	O
to	O
other	O
lipoproteins	O
.	O
Subjects	O
with	O
homozygous	O
CETP	B-SpecificDisease
deficiency	I-SpecificDisease
caused	O
by	O
a	O
gene	O
splicing	O
defect	O
have	O
markedly	O
elevated	O
HDL	O
;	O
however	O
,	O
heterozygotes	O
have	O
only	O
mild	O
increases	O
in	O
HDL	O
.	O
We	O
describe	O
two	O
probands	O
with	O
a	O
CETP	O
missense	O
mutation	O
(	O
442	O
D	O
G	O
)	O
.	O
Although	O
heterozygous	O
,	O
they	O
have	O
threefold	O
increases	O
in	O
HDL	O
concentration	O
and	O
markedly	O
decreased	O
plasma	O
CETP	O
mass	O
and	O
activity	O
,	O
suggesting	O
that	O
the	O
mutation	O
has	O
dominant	O
effects	O
on	O
CETP	O
and	O
HDL	O
in	O
vivo	O
.	O
Cellular	O
expression	O
of	O
mutant	O
cDNA	O
results	O
in	O
secretion	O
of	O
only	O
30	O
%	O
of	O
wild	O
type	O
CETP	O
activity	O
.	O
Moreover	O
,	O
coexpression	O
of	O
wild	O
type	O
and	O
mutant	O
cDNAs	O
leads	O
to	O
inhibition	O
of	O
wild	O
type	O
secretion	O
and	O
activity	O
.	O
The	O
dominant	O
effects	O
of	O
the	O
CETP	O
missense	O
mutation	O
during	O
cellular	O
expression	O
probably	O
explains	O
why	O
the	O
probands	O
have	O
markedly	O
increased	O
HDL	O
in	O
the	O
heterozygous	O
state	O
,	O
and	O
suggests	O
that	O
the	O
active	O
molecular	O
species	O
of	O
CETP	O
may	O
be	O
multimeric	O
.	O
.	O

1346924	O
Detection	O
of	O
an	O
unstable	O
fragment	O
of	O
DNA	O
specific	O
to	O
individuals	O
with	O
myotonic	B-SpecificDisease
dystrophy.	I-SpecificDisease
Myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
is	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-SpecificDisease
dystrophy	I-SpecificDisease
,	O
with	O
a	O
prevalence	O
of	O
2-14	O
per	O
100	O
,	O
000	O
individuals	O
.	O
The	O
disease	O
is	O
characterized	O
by	O
progressive	O
muscle	B-DiseaseClass
weakness	I-DiseaseClass
and	O
sustained	B-DiseaseClass
muscle	I-DiseaseClass
contraction	I-DiseaseClass
,	O
often	O
with	O
a	O
wide	O
range	O
of	O
accompanying	O
symptoms	O
.	O
The	O
age	O
at	O
onset	O
and	O
severity	O
of	O
the	O
disease	O
show	O
extreme	O
variation	O
,	O
both	O
within	O
and	O
between	O
families	O
.	O
Despite	O
its	O
clinical	O
variability	O
,	O
this	O
dominant	O
condition	O
segregates	O
as	O
a	O
single	O
locus	O
at	O
chromosome	O
19q13	O
.	O
3	O
in	O
every	O
population	O
studied	O
.	O
It	O
is	O
flanked	O
by	O
the	O
tightly	O
linked	O
genetic	O
markers	O
ERCC1	O
proximally	O
and	O
D19S51	O
distally	O
;	O
these	O
define	O
the	O
DM	B-Modifier
critical	O
region	O
.	O
We	O
report	O
the	O
isolation	O
of	O
an	O
expressed	O
sequence	O
from	O
this	O
region	O
which	O
detects	O
a	O
DNA	O
fragment	O
that	O
is	O
larger	O
in	O
affected	O
individuals	O
than	O
in	O
normal	O
siblings	O
or	O
unaffected	O
controls	O
.	O
The	O
size	O
of	O
this	O
fragment	O
varies	O
between	O
affected	O
siblings	O
,	O
and	O
increases	O
in	O
size	O
through	O
generations	O
in	O
parallel	O
with	O
increasing	O
severity	O
of	O
the	O
disease	O
.	O
We	O
postulate	O
that	O
this	O
unstable	O
DNA	O
sequence	O
is	O
the	O
molecular	O
feature	O
that	O
underlies	O
DM	B-SpecificDisease
.	O

2491010	O
Molecular	O
and	O
phenotypic	O
analysis	O
of	O
patients	O
with	O
deletions	O
within	O
the	O
deletion-rich	O
region	O
of	O
the	O
Duchenne	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
(DMD)	O
gene.	O
Eighty	O
unrelated	O
individuals	O
with	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)or	O
Becker	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
BMD	B-SpecificDisease
)	O
were	O
found	O
to	O
have	O
deletions	O
in	O
the	O
major	O
deletion-rich	O
region	O
of	O
the	O
DMD	B-Modifier
locus	O
.	O
This	O
region	O
includes	O
the	O
last	O
five	O
exons	O
detected	O
by	O
cDNA5b-7	O
,	O
all	O
exons	O
detected	O
by	O
cDNA8	O
,	O
and	O
the	O
first	O
two	O
exons	O
detected	O
by	O
cDNA9	O
.	O
These	O
80	O
individuals	O
account	O
for	O
approximately	O
75	O
%	O
of	O
109	O
deletions	O
of	O
the	O
gene	O
,	O
detected	O
among	O
181	O
patients	O
analyzed	O
with	O
the	O
entire	O
dystrophin	O
cDNA	O
.	O
Endpoints	O
for	O
many	O
of	O
these	O
deletions	O
were	O
further	O
characterized	O
using	O
two	O
genomic	O
probes	O
,	O
p20	O
(	O
DXS269	O
;	O
Wapenaar	O
et	O
al	O
.	O
)	O
and	O
GMGX11	O
(	O
DXS239	O
;	O
present	O
paper	O
)	O
.	O
Clinical	O
findings	O
are	O
presented	O
for	O
all	O
80	O
patients	O
allowing	O
a	O
correlation	O
of	O
phenotypic	O
severity	O
with	O
the	O
genotype	O
.	O
Thirty-eight	O
independent	O
patients	O
were	O
old	O
enough	O
to	O
be	O
classified	O
as	O
DMD	B-SpecificDisease
,	O
BMD	B-SpecificDisease
,	O
or	O
intermediate	O
phenotype	O
and	O
had	O
deletions	O
of	O
exons	O
with	O
sequenced	O
intron	O
/	O
exon	O
boundaries	O
.	O
Of	O
these	O
,	O
eight	O
BMD	B-Modifier
patients	O
and	O
one	O
intermediate	O
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
leave	O
the	O
reading	O
frame	O
intact	O
,	O
while	O
21	O
DMD	B-Modifier
patients	O
,	O
7	O
intermediate	O
patients	O
,	O
and	O
1	O
BMD	B-Modifier
patient	O
had	O
gene	O
deletions	O
predicted	O
to	O
disrupt	O
the	O
reading	O
frame	O
.	O
Thus	O
,	O
with	O
two	O
exceptions	O
,	O
frameshift	O
deletions	O
of	O
the	O
gene	O
resulted	O
in	O
more	O
severe	O
phenotype	O
than	O
did	O
in-frame	O
deletions	O
.	O
This	O
is	O
in	O
agreement	O
with	O
recent	O
findings	O
by	O
Baumbach	O
et	O
al	O
.	O
and	O
Koenig	O
et	O
al	O
.	O
but	O
is	O
in	O
contrast	O
to	O
findings	O
,	O
by	O
Malhotra	O
et	O
al	O
.	O
at	O
the	O
5	O
"	O
end	O
of	O
the	O
gene	O
.	O

10192399	O
The	O
Pendred	B-Modifier
syndrome	I-Modifier
gene	O
encodes	O
a	O
chloride-iodide	O
transport	O
protein.	O
Pendred	B-SpecificDisease
syndrome	I-SpecificDisease
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	B-DiseaseClass
deafness	I-DiseaseClass
and	O
characterized	O
by	O
congenital	O
sensorineural	B-SpecificDisease
hearing	I-SpecificDisease
loss	I-SpecificDisease
and	O
goitre	B-SpecificDisease
.	O
This	O
disorder	O
was	O
mapped	O
to	O
chromosome	O
7	O
and	O
the	O
gene	O
causing	O
Pendred	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
PDS	B-SpecificDisease
)	O
was	O
subsequently	O
identified	O
by	O
positional	O
cloning	O
.	O
PDS	O
encodes	O
a	O
putative	O
transmembrane	O
protein	O
designated	O
pendrin	O
.	O
Pendrin	O
is	O
closely	O
related	O
to	O
a	O
family	O
of	O
sulfate	O
transport	O
proteins	O
that	O
includes	O
the	O
rat	O
sulfate-anion	O
transporter	O
(	O
encoded	O
by	O
Sat-1	O
;	O
29	O
%	O
amino	O
acid	O
sequence	O
identity	O
)	O
,	O
the	O
human	O
diastrophic	B-Modifier
dysplasia	I-Modifier
sulfate	O
transporter	O
(	O
encoded	O
by	O
DTD	O
;	O
32	O
%	O
)	O
and	O
the	O
human	O
sulfate	O
transporter	O
downregulated	O
in	O
adenoma	B-DiseaseClass
(	O
encoded	O
by	O
DRA	O
;	O
45	O
%	O
)	O
.	O
On	O
the	O
basis	O
of	O
this	O
homology	O
and	O
the	O
presence	O
of	O
a	O
slightly	O
modified	O
sulfate-transporter	O
signature	O
sequence	O
comprising	O
its	O
putative	O
second	O
transmembrane	O
domain	O
,	O
pendrin	O
has	O
been	O
proposed	O
to	O
function	O
as	O
a	O
sulfate	O
transporter	O
.	O
We	O
were	O
unable	O
to	O
detect	O
evidence	O
of	O
sulfate	O
transport	O
following	O
the	O
expression	O
of	O
pendrin	O
in	O
Xenopus	O
laevis	O
oocytes	O
by	O
microinjection	O
of	O
PDS	O
cRNA	O
or	O
in	O
Sf9	O
cells	O
following	O
infection	O
with	O
PDS-recombinant	O
baculovirus	O
.	O
The	O
rates	O
of	O
transport	O
for	O
iodide	O
and	O
chloride	O
were	O
significantly	O
increased	O
following	O
the	O
expression	O
of	O
pendrin	O
in	O
both	O
cell	O
systems	O
.	O
Our	O
results	O
demonstrate	O
that	O
pendrin	O
functions	O
as	O
a	O
transporter	O
of	O
chloride	O
and	O
iodide	O
,	O
but	O
not	O
sulfate	O
,	O
and	O
may	O
provide	O
insight	O
into	O
thyroid	O
physiology	O
and	O
the	O
pathophysiology	O
of	O
Pendred	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
.	O

10915776	O
Retinoschisin,	O
the	O
X-linked	B-Modifier
retinoschisis	I-Modifier
protein,	O
is	O
a	O
secreted	O
photoreceptor	O
protein,	O
and	O
is	O
expressed	O
and	O
released	O
by	O
Weri-Rb1	O
cells.	O
X-linked	B-SpecificDisease
retinoschisis	I-SpecificDisease
is	O
characterized	O
by	O
microcystic-like	O
changes	O
of	O
the	O
macular	O
region	O
and	O
schisis	O
within	O
the	O
inner	O
retinal	O
layers	O
,	O
leading	O
to	O
visual	B-DiseaseClass
deterioration	I-DiseaseClass
in	O
males	O
.	O
Many	O
missense	O
and	O
protein-truncating	O
mutations	O
of	O
the	O
causative	O
gene	O
RS1	O
have	O
now	O
been	O
identified	O
and	O
are	O
thought	O
to	O
be	O
inactivating	O
.	O
RS1	O
encodes	O
a	O
224	O
amino	O
acid	O
protein	O
,	O
retinoschisin	O
,	O
which	O
contains	O
a	O
discoidin	O
domain	O
but	O
is	O
of	O
unknown	O
function	O
.	O
We	O
have	O
generated	O
a	O
polyclonal	O
antibody	O
against	O
a	O
peptide	O
from	O
a	O
unique	O
region	O
within	O
retinoschisin	O
,	O
which	O
detects	O
a	O
protein	O
of	O
approximately	O
28	O
kDa	O
in	O
retinal	O
samples	O
reduced	O
with	O
dithiothreitol	O
,	O
but	O
multimers	O
sized	O
>	O
40	O
kDa	O
under	O
non-reducing	O
conditions	O
.	O
A	O
screen	O
of	O
human	O
tissues	O
with	O
this	O
antibody	O
reveals	O
retinoschisin	O
to	O
be	O
retina	O
specific	O
and	O
the	O
antibody	O
detects	O
a	O
protein	O
of	O
similar	O
size	O
in	O
bovine	O
and	O
murine	O
retinae	O
.	O
We	O
investigated	O
the	O
expression	O
pattern	O
in	O
the	O
retina	O
of	O
both	O
RS1	O
mRNA	O
(	O
using	O
in	O
situ	O
hybridization	O
with	O
riboprobes	O
)	O
and	O
retinoschisin	O
(	O
using	O
immunohistochemistry	O
)	O
.	O
The	O
antisense	O
riboprobe	O
detected	O
RS1	O
mRNA	O
only	O
in	O
the	O
photoreceptor	O
layer	O
but	O
the	O
protein	O
product	O
of	O
the	O
gene	O
was	O
present	O
both	O
in	O
the	O
photoreceptors	O
and	O
within	O
the	O
inner	O
portions	O
of	O
the	O
retina	O
.	O
Furthermore	O
,	O
differentiated	O
retinoblastoma	B-Modifier
cells	O
(	O
Weri-Rb1	O
cells	O
)	O
were	O
found	O
to	O
express	O
RS1	O
mRNA	O
and	O
to	O
release	O
retinoschisin	O
.	O
These	O
results	O
suggest	O
that	O
retinoschisin	O
is	O
released	O
by	O
photo-receptors	O
and	O
has	O
functions	O
within	O
the	O
inner	O
retinal	O
layers	O
.	O
Thus	O
,	O
X-linked	B-SpecificDisease
retinoschisis	I-SpecificDisease
is	O
caused	O
by	O
abnormalities	O
in	O
a	O
putative	O
secreted	O
photoreceptor	O
protein	O
and	O
is	O
the	O
first	O
example	O
of	O
a	O
secreted	O
photo-receptor	O
protein	O
associated	O
with	O
a	O
retinal	B-DiseaseClass
dystrophy	I-DiseaseClass
.	O
.	O

10085150	O
The	O
hereditary	B-Modifier
hemochromatosis	I-Modifier
protein,	O
HFE,	O
specifically	O
regulates	O
transferrin-mediated	O
iron	O
uptake	O
in	O
HeLa	O
cells	O
.	O
HFE	O
is	O
the	O
protein	O
product	O
of	O
the	O
gene	O
mutated	O
in	O
the	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disease	I-DiseaseClass
hereditary	B-SpecificDisease
hemochromatosis	I-SpecificDisease
(	O
Feder	O
,	O
J	O
.	O
N	O
.	O
,	O
Gnirke	O
,	O
A	O
.	O
,	O
Thomas	O
,	O
W	O
.	O
,	O
Tsuchihashi	O
,	O
Z	O
.	O
,	O
Ruddy	O
,	O
D	O
.	O
A	O
.	O
,	O
Basava	O
,	O
A	O
.	O
,	O
Dormishian	O
,	O
F	O
.	O
,	O
Domingo	O
,	O
R	O
.	O
J	O
.	O
,	O
Ellis	O
,	O
M	O
.	O
C	O
.	O
,	O
Fullan	O
,	O
A	O
.	O
,	O
Hinton	O
,	O
L	O
.	O
M	O
.	O
,	O
Jones	O
,	O
N	O
.	O
L	O
.	O
,	O
Kimmel	O
,	O
B	O
.	O
E	O
.	O
,	O
Kronmal	O
,	O
G	O
.	O
S	O
.	O
,	O
Lauer	O
,	O
P	O
.	O
,	O
Lee	O
,	O
V	O
.	O
K	O
.	O
,	O
Loeb	O
,	O
D	O
.	O
B	O
.	O
,	O
Mapa	O
,	O
F	O
.	O
A	O
.	O
,	O
McClelland	O
,	O
E	O
.	O
,	O
Meyer	O
,	O
N	O
.	O
C	O
.	O
,	O
Mintier	O
,	O
G	O
.	O
A	O
.	O
,	O
Moeller	O
,	O
N	O
.	O
,	O
Moore	O
,	O
T	O
.	O
37	O
,	O
Morikang	O
,	O
E	O
.	O
,	O
Prasss	O
,	O
C	O
.	O
E	O
.	O
,	O
Quintana	O
,	O
L	O
.	O
,	O
Starnes	O
,	O
S	O
.	O
M	O
.	O
,	O
Schatzman	O
,	O
R	O
.	O
C	O
.	O
,	O
Brunke	O
,	O
K	O
.	O
J	O
.	O
,	O
Drayna	O
,	O
D	O
.	O
T	O
.	O
,	O
Risch	O
,	O
N	O
.	O
J	O
.	O
,	O
Bacon	O
,	O
B	O
.	O
R	O
.	O
,	O
and	O
Wolff	O
,	O
R	O
.	O
R	O
.	O
(	O
1996	O
)	O
Nat	O
.	O
Genet	O
.	O
13	O
,	O
399-408	O
)	O
.	O
At	O
the	O
cell	O
surface	O
,	O
HFE	O
complexes	O
with	O
transferrin	O
receptor	O
(	O
TfR	O
)	O
,	O
increasing	O
the	O
dissociation	O
constant	O
of	O
transferrin	O
(	O
Tf	O
)	O
for	O
its	O
receptor	O
10-fold	O
(	O
Gross	O
,	O
C	O
.	O
N	O
.	O
,	O
Irrinki	O
,	O
A	O
.	O
,	O
Feder	O
,	O
J	O
.	O
N	O
.	O
,	O
and	O
Enns	O
,	O
C	O
.	O
A	O
.	O
(	O
1998	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
273	O
,	O
22068-22074	O
;	O
Feder	O
,	O
J	O
.	O
N	O
.	O
,	O
Penny	O
,	O
D	O
.	O
M	O
.	O
,	O
Irrinki	O
,	O
A	O
.	O
,	O
Lee	O
,	O
V	O
.	O
K	O
.	O
,	O
Lebron	O
,	O
J	O
.	O
A	O
.	O
,	O
Watson	O
,	O
N	O
.	O
,	O
Tsuchihashi	O
,	O
Z	O
.	O
,	O
Sigal	O
,	O
E	O
.	O
,	O
Bjorkman	O
,	O
P	O
.	O
J	O
.	O
,	O
and	O
Schatzman	O
,	O
R	O
.	O
C	O
.	O
(	O
1998	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
S	O
A	O
95	O
,	O
1472-1477	O
)	O
.	O
HFE	O
does	O
not	O
remain	O
at	O
the	O
cell	O
surface	O
,	O
but	O
traffics	O
with	O
TfR	O
to	O
Tf-positive	O
internal	O
compartments	O
(	O
Gross	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O
Using	O
a	O
HeLa	O
cell	O
line	O
in	O
which	O
the	O
expression	O
of	O
HFE	O
is	O
controlled	O
by	O
tetracycline	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
HFE	O
reduces	O
55Fe	O
uptake	O
from	O
Tf	O
by	O
33	O
%	O
but	O
does	O
not	O
affect	O
the	O
endocytic	O
or	O
exocytic	O
rates	O
of	O
TfR	O
cycling	O
.	O
Therefore	O
,	O
HFE	O
appears	O
to	O
reduce	O
cellular	O
acquisition	O
of	O
iron	O
from	O
Tf	O
within	O
endocytic	O
compartments	O
.	O
HFE	O
specifically	O
reduces	O
iron	O
uptake	O
from	O
Tf	O
,	O
as	O
non-Tf-mediated	O
iron	O
uptake	O
from	O
Fe-nitrilotriacetic	O
acid	O
is	O
not	O
altered	O
.	O
These	O
results	O
explain	O
the	O
decreased	O
ferritin	O
levels	O
seen	O
in	O
our	O
HeLa	O
cell	O
system	O
and	O
demonstrate	O
the	O
specific	O
control	O
of	O
HFE	O
over	O
the	O
Tf-mediated	O
pathway	O
of	O
iron	O
uptake	O
.	O
These	O
results	O
also	O
have	O
implications	O
for	O
the	O
understanding	O
of	O
cellular	O
iron	O
homeostasis	O
in	O
organs	O
such	O
as	O
the	O
liver	O
,	O
pancreas	O
,	O
heart	O
,	O
and	O
spleen	O
that	O
are	O
iron	O
loaded	O
in	O
hereditary	B-Modifier
hemochromatotic	I-Modifier
individuals	O
lacking	O
functional	O
HFE	O
.	O

10484981	O
Hereditary	O
TP53	O
codon	O
292	O
and	O
somatic	O
P16INK4A	O
codon	O
94	O
mutations	O
in	O
a	O
Li-Fraumeni	B-Modifier
syndrome	I-Modifier
family.	O
Li-Fraumeni	B-SpecificDisease
syndrome	I-SpecificDisease
is	O
an	O
autosomal	B-DiseaseClass
dominant	I-DiseaseClass
disorder	I-DiseaseClass
that	O
is	O
characterized	O
by	O
various	O
types	O
of	O
cancer	B-DiseaseClass
in	O
childhood	O
and	O
adult	O
cases	O
.	O
Although	O
hereditary	O
TP53	O
mutation	O
is	O
very	O
rare	O
in	O
different	O
human	O
cancers	B-DiseaseClass
,	O
it	O
has	O
been	O
frequently	O
reported	O
in	O
Li-Fraumeni	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
On	O
the	O
other	O
hand	O
,	O
hereditary	O
mutations	O
of	O
TP57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
,	O
which	O
affect	O
the	O
cell	O
cycle	O
similar	O
to	O
TP53	O
,	O
were	O
observed	O
in	O
some	O
types	O
of	O
cancer	B-DiseaseClass
.	O
In	O
a	O
Turkish	O
family	O
with	O
the	O
diagnosis	O
of	O
Li-Fraumeni	B-SpecificDisease
syndrome	I-SpecificDisease
,	O
we	O
analyzed	O
the	O
mutation	O
pattern	O
of	O
TP53	O
,	O
P57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
in	O
the	O
peripheral	O
blood	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(	O
homo	O
/	O
hemizygous	O
deletion	O
)	O
pattern	O
of	O
TP53	O
and	O
P15INK4B	O
/	O
P16INK4A	O
in	O
two	O
tumor	B-Modifier
tissues	O
.	O
The	O
propositus	O
had	O
a	O
seminoma	B-SpecificDisease
,	O
his	O
daughter	O
a	O
medulloblastoma	B-SpecificDisease
,	O
and	O
one	O
of	O
his	O
healthy	O
cousins	O
,	O
a	O
TP53	O
codon	O
292	O
missense	O
point	O
mutation	O
(	O
AAA--	O
>	O
ATA	O
;	O
Lys--	O
>	O
Ile	O
)	O
in	O
the	O
peripheral	O
blood	O
cells	O
.	O
Tumor	O
tissue	O
obtained	O
from	O
the	O
propositus	O
with	O
the	O
seminoma	B-SpecificDisease
revealed	O
loss	O
of	O
heterozygosity	O
in	O
the	O
TP53	O
gene	O
.	O
In	O
the	O
analyses	O
of	O
tumor	B-Modifier
tissues	O
from	O
the	O
propositus	O
and	O
his	O
daughter	O
,	O
a	O
P16INK4A	O
codon	O
94	O
missense	O
point	O
mutation	O
(	O
GCG--	O
>	O
GAG	O
;	O
Ala--	O
>	O
Glu	O
)	O
was	O
observed	O
with	O
the	O
hereditary	O
TP53	O
mutation	O
.	O
P16INK4A	O
codon	O
94	O
mutation	O
observed	O
in	O
our	O
family	O
is	O
a	O
novel	O
mutation	O
in	O
Li-Fraumeni	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
No	O
other	O
gene	O
alteration	O
in	O
TP53	O
,	O
P57KIP2	O
,	O
P15INK4B	O
,	O
and	O
P16INK4A	O
was	O
observed	O
.	O
Existence	O
of	O
the	O
P16INK4A	O
mutation	O
and	O
the	O
hereditary	O
TP53	O
mutation	O
with	O
or	O
without	O
loss	O
of	O
heterozygosity	O
in	O
the	O
TP53	O
gene	O
(	O
seminoma	B-SpecificDisease
/	O
medulloblastoma	B-SpecificDisease
)	O
may	O
be	O
evidence	O
for	O
a	O
common	O
mechanism	O
involved	O
in	O
tumorogenesis	B-DiseaseClass
.	O
The	O
gene	O
alterations	O
in	O
TP53	O
and	O
P16INK4A	O
genes	O
may	O
be	O
used	O
as	O
tumor	B-Modifier
markers	O
in	O
our	O
family	O
.	O
.	O

2055114	O
Localization	O
of	O
histidase	O
to	O
human	O
chromosome	O
region	O
12q22----q24.1	O
and	O
mouse	O
chromosome	O
region	O
10C2----D1.	O
The	O
human	O
gene	O
for	O
histidase	O
(	O
histidine	O
ammonia-lyase	O
;	O
HAL	O
)	O
,	O
the	O
enzyme	O
deficient	O
in	O
histidinemia	B-SpecificDisease
,	O
was	O
assigned	O
to	O
human	O
chromosome	O
12	O
by	O
Southern	O
blot	O
analysis	O
of	O
human	O
X	O
mouse	O
somatic	O
cell	O
hybrid	O
DNA	O
.	O
The	O
gene	O
was	O
sublocalized	O
to	O
region	O
12q22----q24	O
.	O
1	O
by	O
in	O
situ	O
hybridization	O
,	O
using	O
a	O
human	O
histidase	O
cDNA	O
.	O
The	O
homologous	O
locus	O
in	O
the	O
mouse	O
(	O
Hal	O
)	O
was	O
mapped	O
to	O
region	O
10C2----D1	O
by	O
in	O
situ	O
hybridization	O
,	O
using	O
a	O
cell	O
line	O
from	O
a	O
mouse	O
homozygous	O
for	O
a	O
1	O
.	O
10	O
Robertsonian	O
translocation	O
.	O
These	O
assignments	O
extend	O
the	O
conserved	O
syntenic	O
region	O
between	O
human	O
chromosome	O
12	O
and	O
mouse	O
chromosome	O
10	O
that	O
includes	O
the	O
genes	O
for	O
phenylalanine	O
hydroxylase	O
,	O
gamma	O
interferon	O
,	O
peptidase	O
,	O
and	O
citrate	O
synthase	O
.	O
The	O
localization	O
of	O
histidase	O
to	O
mouse	O
chromosome	O
10	O
suggests	O
that	O
the	O
histidase	O
regulatory	O
locus	O
(	O
Hsd	O
)	O
and	O
the	O
histidinemia	O
mutation	O
(	O
his	O
)	O
,	O
which	O
are	O
both	O
known	O
to	O
be	O
on	O
chromosome	O
10	O
,	O
may	O
be	O
alleles	O
of	O
the	O
histidase	O
structural	O
gene	O
locus	O
.	O

116187	O
Carrier	O
detection	O
of	O
pyruvate	B-SpecificDisease
carboxylase	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
fibroblasts	O
and	O
lymphocytes.	O
Pyruvate	O
carboxylase	O
(	O
E	O
.	O
C	O
.	O
6	O
.	O
4	O
.	O
1	O
.	O
1	O
)	O
activity	O
was	O
determined	O
in	O
the	O
circulating	O
peripheral	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
family	O
of	O
a	O
patient	O
with	O
hepatic	O
,	O
cerebral	O
,	O
renal	O
cortical	O
,	O
leukocyte	O
,	O
and	O
fibroblast	O
pyruvate	B-SpecificDisease
carboxylase	I-SpecificDisease
deficiency	I-SpecificDisease
(	O
PC	B-SpecificDisease
Portland	I-SpecificDisease
deficiency	I-SpecificDisease
)	O
.	O
Lymphocyte	O
activities	O
were	O
mother	O
,	O
33--39	O
%	O
;	O
father	O
,	O
11--29	O
%	O
;	O
brother	O
,	O
82--103	O
%	O
;	O
and	O
sister	O
,	O
38--48	O
%	O
of	O
the	O
lowest	O
normal	O
.	O
Fibroblasts	O
from	O
the	O
patients	O
mother	O
and	O
father	O
had	O
42	O
and	O
34	O
%	O
,	O
respectively	O
,	O
of	O
the	O
activity	O
of	O
the	O
lowest	O
normal	O
.	O
These	O
data	O
demonstrate	O
that	O
the	O
disease	O
is	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
manner	O
and	O
that	O
lymphocytes	O
and	O
fibroblasts	O
can	O
be	O
used	O
to	O
detect	O
carriers	O
.	O
Neither	O
pyruvate	O
carboxylase	O
nor	O
mitochondrial	O
PEPCK	O
activity	O
in	O
lymphocytes	O
was	O
increased	O
by	O
a	O
21-hr	O
fast	O
.	O

7568002	O
Identification	O
and	O
localization	O
of	O
huntingtin	O
in	O
brain	O
and	O
human	O
lymphoblastoid	O
cell	O
lines	O
with	O
anti-fusion	O
protein	O
antibodies.	O
The	O
Huntington	B-Modifier
disease	I-Modifier
(	O
HD	B-Modifier
)	O
phenotype	O
is	O
associated	O
with	O
expansion	O
of	O
a	O
trinucleotide	O
repeat	O
in	O
the	O
IT15	O
gene	O
,	O
which	O
is	O
predicted	O
to	O
encode	O
a	O
348-kDa	O
protein	O
named	O
huntington	O
.	O
We	O
used	O
polyclonal	O
and	O
monoclonal	O
anti-fusion	O
protein	O
antibodies	O
to	O
identify	O
native	O
huntingtin	O
in	O
rat	O
,	O
monkey	O
,	O
and	O
human	O
.	O
Western	O
blots	O
revealed	O
a	O
protein	O
with	O
the	O
expected	O
molecular	O
weight	O
which	O
is	O
present	O
in	O
the	O
soluble	O
fraction	O
of	O
rat	O
and	O
monkey	O
brain	O
tissues	O
and	O
lymphoblastoid	O
cells	O
from	O
control	O
cases	O
.	O
In	O
lymphoblastoid	O
cell	O
lines	O
from	O
juvenile-onset	O
heterozygote	O
HD	B-Modifier
cases	O
,	O
both	O
normal	O
and	O
mutant	O
huntingtin	O
are	O
expressed	O
,	O
and	O
increasing	O
repeat	O
expansion	O
leads	O
to	O
lower	O
levels	O
of	O
the	O
mutant	O
protein	O
.	O
Immunocytochemistry	O
indicates	O
that	O
huntingtin	O
is	O
located	O
in	O
neurons	O
throughout	O
the	O
brain	O
,	O
with	O
the	O
highest	O
levels	O
evident	O
in	O
larger	O
neurons	O
.	O
In	O
the	O
human	O
striatum	O
,	O
huntingtin	O
is	O
enriched	O
in	O
a	O
patch-like	O
distribution	O
,	O
potentially	O
corresponding	O
to	O
the	O
first	O
areas	O
affected	O
in	O
HD	B-SpecificDisease
.	O
Subcellular	O
localization	O
of	O
huntingtin	O
is	O
consistent	O
with	O
a	O
cytosolic	O
protein	O
primarily	O
found	O
in	O
somatodendritic	O
regions	O
.	O
Huntingtin	O
appears	O
to	O
particularly	O
associate	O
with	O
microtubules	O
,	O
although	O
some	O
is	O
also	O
associated	O
with	O
synaptic	O
vesicles	O
.	O
On	O
the	O
basis	O
of	O
the	O
localization	O
of	O
huntingtin	O
in	O
association	O
with	O
microtubules	O
,	O
we	O
speculate	O
that	O
the	O
mutation	O
impairs	O
the	O
cytoskeletal	O
anchoring	O
or	O
transport	O
of	O
mitochondria	O
,	O
vesicles	O
,	O
or	O
other	O
organelles	O
or	O
molecules	O
.	O
.	O

10408771	O
Classical	B-SpecificDisease
galactosemia	I-SpecificDisease
and	O
mutations	O
at	O
the	O
galactose-1-phosphate	O
uridyl	O
transferase	O
(GALT)	O
gene.	O
Classical	B-SpecificDisease
galactosemia	I-SpecificDisease
is	O
caused	O
by	O
a	O
deficiency	O
in	O
activity	O
of	O
the	O
enzyme	O
galactose-1-phosphate	O
uridyl	O
transferase	O
(	O
GALT	O
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
caused	O
by	O
mutations	O
at	O
the	O
GALT	O
gene	O
.	O
The	O
disorder	O
exhibits	O
considerable	O
allelic	O
heterogeneity	O
and	O
,	O
at	O
the	O
end	O
of	O
1998	O
,	O
more	O
than	O
150	O
different	O
base	O
changes	O
were	O
recorded	O
in	O
24	O
different	O
populations	O
and	O
ethnic	O
groups	O
in	O
15	O
countries	O
worldwide	O
.	O
The	O
mutations	O
most	O
frequently	O
cited	O
are	O
Q188R	O
,	O
K285N	O
,	O
S135L	O
,	O
and	O
N314D	O
.	O
Q188R	O
is	O
the	O
most	O
common	O
mutation	O
in	O
European	O
populations	O
or	O
in	O
those	O
predominantly	O
of	O
European	O
descent	O
.	O
Overall	O
,	O
it	O
accounts	O
for	O
60-70	O
%	O
of	O
mutant	O
chromosomes	O
,	O
but	O
there	O
are	O
significant	O
differences	O
in	O
its	O
relative	O
frequency	O
in	O
individual	O
populations	O
.	O
Individuals	O
homoallelic	O
for	O
Q188R	O
tend	O
to	O
have	O
a	O
severe	O
phenotype	O
and	O
this	O
is	O
in	O
keeping	O
with	O
the	O
virtually	O
complete	O
loss	O
of	O
enzyme	O
activity	O
observed	O
in	O
in	O
vitro	O
expression	O
systems	O
.	O
Globally	O
,	O
K285N	O
is	O
rarer	O
,	O
but	O
in	O
many	O
European	O
populations	O
it	O
can	O
be	O
found	O
on	O
25-40	O
%	O
of	O
mutant	O
chromosomes	O
.	O
It	O
is	O
invariably	O
associated	O
with	O
a	O
severe	O
phenotype	O
.	O
S135L	O
is	O
found	O
almost	O
exclusively	O
in	O
African	O
Americans	O
.	O
In	O
vitro	O
expression	O
results	O
are	O
discrepant	O
,	O
but	O
some	O
individuals	O
carrying	O
S135L	O
appear	O
to	O
exhibit	O
GALT	O
activity	O
in	O
some	O
tissues	O
.	O
Duarte	O
1	O
(	O
or	O
Los	O
Angeles	O
)	O
and	O
Duarte	O
2	O
(	O
or	O
Duarte	O
)	O
variants	O
carry	O
the	O
same	O
amino	O
acid	O
substitution	O
,	O
N314D	O
,	O
even	O
though	O
D1	O
is	O
associated	O
with	O
increased	O
erythrocyte	O
GALT	O
activity	O
and	O
D2	O
with	O
reduced	O
activity	O
.	O
N314D	O
is	O
in	O
linkage	O
disequilibrium	O
with	O
other	O
base	O
changes	O
that	O
differ	O
on	O
the	O
D1	O
and	O
D2	O
alleles	O
.	O
N314D	O
does	O
not	O
impair	O
GALT	O
activity	O
in	O
in	O
vitro	O
expression	O
systems	O
.	O
However	O
,	O
there	O
are	O
differences	O
in	O
the	O
abundance	O
of	O
GALT	O
protein	O
in	O
lymphoblastoid	O
cells	O
lines	O
from	O
D2	O
and	O
D1	O
individuals	O
.	O
It	O
is	O
unclear	O
whether	O
the	O
specific	O
molecular	O
changes	O
that	O
distinguish	O
the	O
D1	O
and	O
D2	O
alleles	O
account	O
for	O
the	O
different	O
activities	O
.	O
The	O
considerable	O
genetic	O
heterogeneity	O
documented	O
to	O
date	O
undoubtedly	O
contributes	O
to	O
the	O
phenotypic	O
heterogeneity	O
that	O
is	O
observed	O
in	O
galactosemia	B-SpecificDisease
.	O
The	O
additional	O
effects	O
of	O
nonallelic	O
variation	O
and	O
other	O
constitutional	O
factors	O
on	O
phenotypic	O
variability	O
remain	O
to	O
be	O
elucidated	O
.	O
.	O

1424237	O
Typical	O
and	O
partial	O
cat	B-SpecificDisease
eye	I-SpecificDisease
syndrome:	I-SpecificDisease
identification	O
of	O
the	O
marker	O
chromosome	O
by	O
FISH.	O
Three	O
children	O
are	O
reported	O
with	O
typical	O
cat	B-SpecificDisease
eye	I-SpecificDisease
syndrome	I-SpecificDisease
(	O
CES	B-SpecificDisease
)	O
and	O
three	O
more	O
children	O
with	O
partial	O
CES	B-SpecificDisease
because	O
of	O
absence	O
of	O
coloboma	O
,	O
in	O
which	O
the	O
supernumerary	O
marker	O
chromosome	O
was	O
studied	O
by	O
FISH	O
.	O
Using	O
a	O
genomic	O
library	O
,	O
and	O
also	O
a	O
centromeric	O
and	O
particularly	O
a	O
cosmid	O
probe	O
of	O
22q11	O
,	O
partial	O
tetrasomy	B-DiseaseClass
was	O
shown	O
in	O
all	O
cases	O
.	O
.	O

6604602	O
Family	O
studies	O
in	O
Bechterew"s	B-SpecificDisease
syndrome	I-SpecificDisease
(ankylosing	O
spondylitis)	B-SpecificDisease
III.	O
Genetics.	O
The	O
results	O
of	O
segregation	O
analyses	O
in	O
75	O
families	O
where	O
the	O
proband	O
had	O
ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
,	O
are	O
presented	O
.	O
Of	O
the	O
278	O
adult	O
,	O
living	O
first	O
degree	O
relatives	O
,	O
approximately	O
85	O
%	O
cooperated	O
in	O
the	O
study	O
.	O
Clinical	O
and	O
radiographical	O
examinations	O
were	O
performed	O
and	O
HLA	O
typing	O
was	O
conducted	O
.	O
The	O
results	O
were	O
in	O
agreement	O
with	O
our	O
hypothesis	O
that	O
ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
is	O
part	O
of	O
a	O
syndrome	O
where	O
different	O
genetic	O
factors	O
interact	O
.	O
Such	O
known	O
factors	O
are	O
HLA	O
B27	O
associated	O
disease	O
susceptibility	O
,	O
susceptibility	O
to	O
psoriatic	B-SpecificDisease
arthropathy	I-SpecificDisease
and	O
susceptibility	O
to	O
entero-arthropathy	B-SpecificDisease
.	O
Radiographical	O
sacro-iliitis	B-SpecificDisease
was	O
restricted	O
to	O
HLA	O
B27	O
positive	O
relatives	O
,	O
and	O
was	O
more	O
frequently	O
found	O
in	O
relatives	O
to	O
probands	O
with	O
psoriasis	B-SpecificDisease
than	O
in	O
relatives	O
to	O
probands	O
without	O
psoriasis	B-SpecificDisease
.	O
Environmental	O
factors	O
(	O
intestinal	O
bacteria	O
)	O
are	O
known	O
to	O
trigger	O
the	O
disease	O
at	O
least	O
in	O
some	O
persons	O
,	O
and	O
we	O
have	O
postulated	O
that	O
all	O
or	O
most	O
of	O
them	O
have	O
the	O
predisposition	O
to	O
develop	O
disease	O
.	O
Thus	O
,	O
the	O
syndrome	O
has	O
a	O
multifactorial	O
etiology	O
.	O
The	O
phenotypic	O
expressions	O
of	O
the	O
different	O
genetic	O
predispositions	O
involved	O
,	O
include	O
sacro-iliitis	B-SpecificDisease
,	O
psoriasis	B-SpecificDisease
,	O
acute	B-SpecificDisease
anterior	I-SpecificDisease
uveitis	I-SpecificDisease
,	O
peripheral	O
arthropathy	B-SpecificDisease
and	O
inflammatory	B-SpecificDisease
bowel	I-SpecificDisease
disease	I-SpecificDisease
.	O
We	O
suggest	O
the	O
descriptive	O
name	O
HEREDITARY	B-SpecificDisease
MULTIFOCAL	I-SpecificDisease
RELAPSING	I-SpecificDisease
INFLAMMATION	I-SpecificDisease
(	O
HEMRI	B-SpecificDisease
)	O
for	O
this	O
syndrome	O
.	O
Ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
,	O
psoriatic	B-SpecificDisease
arthropathy	I-SpecificDisease
and	O
entero-arthropathy	B-SpecificDisease
may	O
be	O
regarded	O
as	O
clinical	O
sub-types	O
of	O
the	O
syndrome	O
.	O
.	O

3014348	O
Analysis	O
of	O
deletions	O
in	O
DNA	O
from	O
patients	O
with	O
Becker	B-CompositeMention
and	I-CompositeMention
Duchenne	I-CompositeMention
muscular	I-CompositeMention
dystrophy.	I-CompositeMention
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)	O
is	O
an	O
X-linked	B-DiseaseClass
recessive	I-DiseaseClass
genetic	I-DiseaseClass
disorder	I-DiseaseClass
for	O
which	O
the	O
biochemical	B-DiseaseClass
defect	I-DiseaseClass
is	O
as	O
yet	O
unknown	O
.	O
Recently	O
,	O
two	O
cloned	O
segments	O
of	O
human	O
X-chromosome	O
DNA	O
have	O
been	O
described	O
which	O
detect	O
structural	O
alterations	O
within	O
or	O
near	O
the	O
genetic	O
locus	O
responsible	O
for	O
the	O
disorder	O
.	O
Both	O
of	O
these	O
cloned	O
segments	O
were	O
described	O
as	O
tightly	O
linked	O
to	O
the	O
locus	O
and	O
were	O
capable	O
of	O
detecting	O
deletions	O
in	O
the	O
DNA	O
of	O
boys	O
affected	O
with	O
DMD	B-SpecificDisease
.	O
In	O
an	O
attempt	O
to	O
determine	O
more	O
precisely	O
the	O
occurrence	O
of	O
these	O
deletions	O
within	O
a	O
large	O
population	O
of	O
DMD	B-Modifier
patients	O
and	O
the	O
accuracy	O
of	O
one	O
of	O
the	O
segments	O
,	O
DXS164	O
(	O
pERT87	O
)	O
,	O
in	O
determining	O
the	O
inheritance	O
of	O
the	O
DMD	B-Modifier
X	O
chromosome	O
,	O
the	O
subclones	O
1	O
,	O
8	O
and	O
15	O
were	O
made	O
available	O
to	O
many	O
investigators	O
throughout	O
the	O
world	O
.	O
Here	O
we	O
describe	O
the	O
combined	O
results	O
of	O
more	O
than	O
20	O
research	O
laboratories	O
with	O
respect	O
to	O
the	O
occurrence	O
of	O
deletions	O
at	O
the	O
DXS164	O
locus	O
in	O
DNA	O
samples	O
isolated	O
from	O
patients	O
with	O
DMD	B-SpecificDisease
and	O
Becker	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
BMD	B-SpecificDisease
)	O
.	O
The	O
results	O
indicate	O
that	O
the	O
DXS164	O
locus	O
apparently	O
recombines	O
with	O
DMD	B-SpecificDisease
5	O
%	O
of	O
the	O
time	O
,	O
but	O
is	O
probably	O
located	O
between	O
independent	O
sites	O
of	O
mutation	O
which	O
yield	O
DMD	B-SpecificDisease
.	O
The	O
breakpoints	O
of	O
some	O
deletions	O
are	O
delineated	O
within	O
the	O
DXS164	O
locus	O
,	O
and	O
it	O
is	O
evident	O
that	O
the	O
deletions	O
at	O
the	O
DMD	B-Modifier
locus	O
are	O
frequent	O
and	O
extremely	O
large	O
.	O
.	O

6524872	O
Adrenoleukodystrophy:	B-SpecificDisease
survey	O
of	O
303	O
cases:	O
biochemistry,	O
diagnosis,	O
and	O
therapy.	O
Adrenoleukodystrophy	B-SpecificDisease
(	O
ALD	B-SpecificDisease
)	O
is	O
a	O
genetically	O
determined	O
disorder	O
associated	O
with	O
progressive	B-DiseaseClass
central	I-DiseaseClass
demyelination	I-DiseaseClass
and	O
adrenal	B-DiseaseClass
cortical	I-DiseaseClass
insufficiency	I-DiseaseClass
.	O
All	O
affected	O
persons	O
show	O
increased	O
levels	O
of	O
saturated	O
unbranched	O
very-long-chain	O
fatty	O
acids	O
,	O
particularly	O
hexacosanoate	O
(	O
C26	O
0	O
)	O
,	O
because	O
of	O
impaired	O
capacity	O
to	O
degrade	O
these	O
acids	O
.	O
This	O
degradation	O
normally	O
takes	O
place	O
in	O
a	O
subcellular	O
organelle	O
called	O
the	O
peroxisome	O
,	O
and	O
ALD	B-SpecificDisease
,	O
together	O
with	O
Zellwegers	B-SpecificDisease
cerebrohepatorenal	I-SpecificDisease
syndrome	I-SpecificDisease
,	O
is	O
now	O
considered	O
to	O
belong	O
to	O
the	O
newly	O
formed	O
category	O
of	O
peroxisomal	B-DiseaseClass
disorders	I-DiseaseClass
.	O
Biochemical	O
assays	O
permit	O
prenatal	O
diagnosis	O
,	O
as	O
well	O
as	O
identification	O
of	O
most	O
heterozygotes	O
.	O
We	O
have	O
identified	O
303	O
patients	O
with	O
ALD	B-SpecificDisease
in	O
217	O
kindreds	O
.	O
These	O
patients	O
show	O
a	O
wide	O
phenotypic	O
variation	O
.	O
Sixty	O
percent	O
of	O
patients	O
had	O
childhood	O
ALD	B-SpecificDisease
and	O
17	O
%	O
adrenomyeloneuropathy	B-SpecificDisease
,	O
both	O
of	O
which	O
are	O
X-linked	O
,	O
with	O
the	O
gene	O
mapped	O
to	O
Xq28	O
.	O
Neonatal	B-SpecificDisease
ALD	I-SpecificDisease
,	O
a	O
distinct	O
entity	O
with	O
autosomal	O
recessive	O
inheritance	O
and	O
points	O
of	O
resemblance	O
to	O
Zellwegers	B-SpecificDisease
syndrome	I-SpecificDisease
,	O
accounted	O
for	O
7	O
%	O
of	O
the	O
cases	O
.	O
Although	O
excess	O
C26	O
0	O
in	O
the	O
brain	O
of	O
patients	O
with	O
ALD	B-SpecificDisease
is	O
partially	O
of	O
dietary	O
origin	O
,	O
dietary	O
C26	O
0	O
restriction	O
did	O
not	O
produce	O
clear	O
benefit	O
.	O
Bone	O
marrow	O
transplant	O
lowered	O
the	O
plasma	O
C26	O
0	O
level	O
but	O
failed	O
to	O
arrest	O
neurological	O
progression	O
.	O
.	O

7802009	O
Additional	O
case	O
of	O
female	O
monozygotic	O
twins	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
due	O
to	O
opposite	O
X-chromosome	O
inactivation.	O
A	O
pair	O
of	O
female	O
monozygotic	O
(	O
MZ	O
)	O
twins	O
,	O
heterozygous	O
carriers	O
for	O
a	O
deletion	O
in	O
the	O
DMD	B-Modifier
gene	O
and	O
discordant	O
for	O
the	O
clinical	O
manifestations	O
of	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
,	O
were	O
analyzed	O
by	O
molecular	O
studies	O
,	O
in	O
situ	O
hybridization	O
,	O
and	O
methylation	O
pattern	O
of	O
X	O
chromosomes	O
to	O
search	O
for	O
opposite	O
X	O
inactivation	O
as	O
an	O
explanation	O
of	O
their	O
clinical	O
discordance	O
.	O
Results	O
in	O
lymphocytes	O
and	O
skin	O
fibroblast	O
cell	O
lines	O
suggest	O
a	O
partial	O
mirror	O
inactivation	O
with	O
the	O
normal	O
X	O
chromosome	O
preferentially	O
active	O
in	O
the	O
unaffected	O
twin	O
,	O
and	O
the	O
maternal	O
deleted	O
X	O
chromosome	O
preferentially	O
active	O
in	O
the	O
affected	O
twin	O
.	O
A	O
review	O
shows	O
that	O
MZ	O
female	O
twins	O
discordant	O
for	O
X-linked	B-DiseaseClass
diseases	I-DiseaseClass
are	O
not	O
uncommon	O
.	O
Twinning	O
and	O
X	O
inactivation	O
may	O
be	O
interrelated	O
and	O
could	O
explain	O
the	O
female	O
twins	O
discordant	O
for	O
X-linked	O
traits	O
.	O
.	O

2209091	O
Regional	O
localisation	O
of	O
the	O
Friedreich	B-Modifier
ataxia	I-Modifier
locus	O
to	O
human	O
chromosome	O
9q13----q21.1.	O
We	O
have	O
previously	O
assigned	O
the	O
Friedreich	B-Modifier
ataxia	I-Modifier
locus	O
(	O
FRDA	O
)	O
to	O
chromosome	O
9	O
;	O
the	O
current	O
maximal	O
lod	O
score	O
between	O
FRDA	O
and	O
MCT112	O
(	O
D9S15	O
)	O
is	O
greater	O
than	O
50	O
at	O
a	O
recombination	O
fraction	O
of	O
theta	O
=	O
0	O
.	O
The	O
physical	O
assignment	O
of	O
the	O
locus	O
defined	O
by	O
MCT112	O
,	O
and	O
hence	O
FRDA	O
,	O
has	O
not	O
been	O
determined	O
,	O
although	O
linkage	O
analysis	O
of	O
MCT112	O
with	O
other	O
chromosome	O
9	O
markers	O
inferred	O
a	O
location	O
close	O
to	O
the	O
centromere	O
.	O
We	O
have	O
used	O
in	O
situ	O
hybridisation	O
with	O
MCT112	O
,	O
a	O
corresponding	O
cosmid	O
MJ1	O
,	O
and	O
DR47	O
(	O
D9S5	O
)	O
,	O
coupled	O
with	O
mapping	O
studies	O
on	O
hybrid	O
cell	O
panels	O
,	O
to	O
define	O
more	O
precisely	O
the	O
location	O
of	O
the	O
disease	O
locus	O
.	O
The	O
in	O
situ	O
location	O
of	O
all	O
three	O
probes	O
is	O
9q13----q21	O
.	O
1	O
,	O
distal	O
to	O
the	O
variable	O
heterochromatin	O
region	O
.	O
Physical	O
assignment	O
of	O
FRDA	O
will	O
allow	O
us	O
to	O
identify	O
hybrid	O
cell	O
lines	O
containing	O
the	O
mutated	O
gene	O
.	O

2071157	O
Determination	O
of	O
the	O
mutations	O
responsible	O
for	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
in	O
17	O
subjects.	O
Hypoxanthine--guanine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
is	O
a	O
purine	O
salvage	O
enzyme	O
that	O
catalyzes	O
the	O
conversion	O
of	O
hypoxanthine	O
to	O
inosine	O
monophosphate	O
and	O
guanine	O
to	O
guanosine	O
monophosphate	O
.	O
Previous	O
studies	O
of	O
mutant	O
HPRT	O
proteins	O
analyzed	O
at	O
the	O
molecular	O
level	O
have	O
shown	O
a	O
significant	O
heterogeneity	O
.	O
This	O
investigation	O
further	O
verifies	O
this	O
heterogeneity	O
and	O
identifies	O
insertions	O
,	O
deletions	O
,	O
and	O
point	O
mutations	O
.	O
The	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction-amplified	O
product	O
of	O
reverse-transcribed	O
HPRT	O
mRNA	O
enabled	O
the	O
rapid	O
identification	O
of	O
the	O
mutations	O
found	O
in	O
17	O
previously	O
uncharacterized	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
the	O
Lesch-Nyhan	B-SpecificDisease
syndrome	I-SpecificDisease
.	O
.	O

10767347	O
Inactivation	O
of	O
the	O
Friedreich	B-Modifier
ataxia	I-Modifier
mouse	O
gene	O
leads	O
to	O
early	O
embryonic	B-SpecificDisease
lethality	I-SpecificDisease
without	O
iron	O
accumulation.	O
Friedreich	B-SpecificDisease
ataxia	I-SpecificDisease
(	O
FRDA	B-SpecificDisease
)	O
,	O
the	O
most	O
common	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
ataxia	I-DiseaseClass
,	O
is	O
caused	O
in	O
almost	O
all	O
cases	O
by	O
homozygous	O
intronic	O
expansions	O
resulting	O
in	O
the	O
loss	O
of	O
frataxin	O
,	O
a	O
mitochondrial	O
protein	O
conserved	O
through	O
evolution	O
,	O
and	O
involved	O
in	O
mitochondrial	O
iron	O
homeostasis	O
.	O
Yeast	O
knockout	O
models	O
,	O
and	O
histological	O
and	O
biochemical	O
data	O
from	O
patient	O
heart	O
biopsies	O
or	O
autopsies	O
indicate	O
that	O
the	O
frataxin	O
defect	O
causes	O
a	O
specific	O
iron-sulfur	B-SpecificDisease
protein	I-SpecificDisease
deficiency	I-SpecificDisease
and	O
mitochondrial	O
iron	O
accumulation	O
leading	O
to	O
the	O
pathological	O
changes	O
.	O
Affected	O
human	O
tissues	O
are	O
rarely	O
available	O
to	O
further	O
examine	O
this	O
hypothesis	O
.	O
To	O
study	O
the	O
mechanism	O
of	O
the	O
disease	O
,	O
we	O
generated	O
a	O
mouse	O
model	O
by	O
deletion	O
of	O
exon	O
4	O
leading	O
to	O
inactivation	O
of	O
the	O
Frda	B-Modifier
gene	O
product	O
.	O
We	O
show	O
that	O
homozygous	O
deletions	O
cause	O
embryonic	B-SpecificDisease
lethality	I-SpecificDisease
a	O
few	O
days	O
after	O
implantation	O
,	O
demonstrating	O
an	O
important	O
role	O
for	O
frataxin	O
during	O
early	O
development	O
.	O
These	O
results	O
suggest	O
that	O
the	O
milder	O
phenotype	O
in	O
humans	O
is	O
due	O
to	O
residual	O
frataxin	O
expression	O
associated	O
with	O
the	O
expansion	O
mutations	O
.	O
Surprisingly	O
,	O
in	O
the	O
frataxin	O
knockout	O
mouse	O
,	O
no	O
iron	O
accumulation	O
was	O
observed	O
during	O
embryonic	O
resorption	O
,	O
suggesting	O
that	O
cell	O
death	O
could	O
be	O
due	O
to	O
a	O
mechanism	O
independent	O
of	O
iron	O
accumulation	O
.	O
.	O

2817003	O
Translocation	O
t(5;11)(q13.1;p13)	O
associated	O
with	O
familial	O
isolated	B-SpecificDisease
aniridia.	I-SpecificDisease
A	O
father	O
and	O
daughter	O
with	O
isolated	B-SpecificDisease
aniridia	I-SpecificDisease
were	O
observed	O
to	O
have	O
an	O
apparently	O
balanced	O
,	O
reciprocal	O
translocation	O
involving	O
chromosomes	O
5	O
and	O
11	O
[	O
t	O
(	O
5	O
;	O
11	O
)	O
(	O
q13	O
.	O
1	O
;	O
p13	O
)	O
]	O
.	O
No	O
other	O
clinical	O
characteristics	O
often	O
associated	O
with	O
the	O
deletion	O
of	O
11p13	O
were	O
observed	O
in	O
this	O
family	O
.	O
This	O
finding	O
,	O
in	O
association	O
with	O
3	O
other	O
instances	O
of	O
single	O
breaks	O
at	O
11p13	O
and	O
aniridia	B-SpecificDisease
,	O
supports	O
the	O
assignment	O
of	O
AN2	O
to	O
11p13	O
.	O

2862466	O
Genetically	O
determined	O
low	O
C4:	O
a	O
predisposing	O
factor	O
to	O
autoimmune	B-SpecificDisease
chronic	I-SpecificDisease
active	I-SpecificDisease
hepatitis.	I-SpecificDisease
Of	O
26	O
patients	O
with	O
autoimmune	B-SpecificDisease
chronic	I-SpecificDisease
active	I-SpecificDisease
hepatitis	I-SpecificDisease
(	O
CAH	B-SpecificDisease
)	O
starting	O
in	O
childhood	O
18	O
(	O
69	O
%	O
)	O
had	O
low	O
C4	O
and	O
5	O
(	O
19	O
%	O
)	O
had	O
low	O
C3	O
serum	O
levels	O
.	O
Impaired	O
hepatic	O
synthesis	O
and	O
immune-consumption	O
were	O
unlikely	O
since	O
transferrin	O
levels	O
were	O
normal	O
in	O
all	O
patients	O
,	O
albumin	O
levels	O
were	O
persistently	O
low	O
in	O
only	O
3	O
,	O
and	O
only	O
3	O
had	O
raised	O
levels	O
of	O
activation	O
fragment	O
C3d	O
.	O
C4d	O
was	O
normal	O
in	O
all	O
patients	O
studied	O
.	O
In	O
the	O
families	O
of	O
12	O
probands	O
with	O
low	O
C4	O
,	O
7	O
parents	O
had	O
low	O
C4	O
and	O
2	O
had	O
levels	O
which	O
were	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
.	O
5	O
of	O
10	O
siblings	O
from	O
5	O
families	O
had	O
low	O
C4	O
.	O
These	O
results	O
suggest	O
that	O
low	O
C4	O
levels	O
in	O
CAH	B-SpecificDisease
are	O
genetically	O
determined	O
.	O
C4	O
phenotyping	O
in	O
20	O
patients	O
and	O
in	O
26	O
parents	O
showed	O
that	O
90	O
%	O
and	O
81	O
%	O
,	O
respectively	O
,	O
had	O
null	O
allotypes	O
at	O
either	O
the	O
C4A	O
or	O
C4B	O
locus	O
compared	O
with	O
59	O
%	O
in	O
controls	O
,	O
indicating	O
that	O
defective	O
expression	O
of	O
structural	O
genes	O
may	O
contribute	O
to	O
the	O
observed	O
C4	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
.	O

1301146	O
Characterisation	O
of	O
a	O
new	O
rare	O
fragile	O
site	O
easily	O
confused	O
with	O
the	O
fragile	B-SpecificDisease
X.	I-SpecificDisease
A	O
new	O
fragile	O
site	O
(	O
FRAXE	O
)	O
in	O
Xq28	O
is	O
described	O
.	O
It	O
appears	O
to	O
be	O
a	O
typical	O
folate	O
sensitive	O
fragile	O
site	O
.	O
The	O
fragile	O
site	O
is	O
not	O
associated	O
with	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
,	O
it	O
does	O
not	O
give	O
abnormal	O
results	O
when	O
subjected	O
to	O
Southern	O
analysis	O
with	O
probe	O
pfxa3	O
which	O
detects	O
the	O
unstable	O
DNA	O
sequence	O
characteristic	O
of	O
fragile	B-SpecificDisease
X	I-SpecificDisease
syndrome	I-SpecificDisease
.	O
In	O
situ	O
hybridization	O
mapping	O
locates	O
the	O
fragile	O
site	O
between	O
150	O
kb	O
and	O
600	O
kb	O
distal	O
to	O
FRAXA	O
.	O
The	O
distinction	O
between	O
the	O
two	O
fragile	O
sites	O
is	O
important	O
clinically	O
since	O
cytogenetic	O
detection	O
of	O
FRAXE	O
,	O
without	O
molecular	O
analysis	O
,	O
could	O
result	O
in	O
misdiagnosis	O
of	O
fragile	B-SpecificDisease
X	I-SpecificDisease
syndrome	I-SpecificDisease
.	O
.	O

8012387	O
X-linked	B-SpecificDisease
spastic	I-SpecificDisease
paraplegia	I-SpecificDisease
and	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease	I-SpecificDisease
are	O
allelic	B-DiseaseClass
disorders	I-DiseaseClass
at	O
the	O
proteolipid	O
protein	O
locus.	O
Three	O
forms	O
of	O
X-linked	B-SpecificDisease
spastic	I-SpecificDisease
paraplegia	I-SpecificDisease
(	O
SPG	B-SpecificDisease
)	O
have	O
been	O
defined	O
.	O
One	O
locus	O
(	O
SPG	O
1	O
)	O
maps	O
to	O
Xq28	O
while	O
two	O
clinically	O
distinct	O
forms	O
map	O
to	O
Xq22	O
(	O
SPG2	O
)	O
.	O
A	O
rare	O
X-linked	B-DiseaseClass
dysmyelinating	I-DiseaseClass
disorder	I-DiseaseClass
of	O
the	O
central	O
nervous	O
system	O
,	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease	I-SpecificDisease
(	O
PMD	B-SpecificDisease
)	O
,	O
has	O
also	O
been	O
mapped	O
to	O
Xq21-q22	O
,	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
proteolipid	O
protein	O
gene	O
(	O
PLP	O
)	O
which	O
encodes	O
two	O
myelin	O
proteins	O
,	O
PLP	O
and	O
DM20	O
.	O
While	O
narrowing	O
the	O
genetic	O
interval	O
containing	O
SPG2	O
in	O
a	O
large	O
pedigree	O
,	O
we	O
found	O
that	O
PLP	O
was	O
the	O
closest	O
marker	O
to	O
the	O
disease	O
locus	O
,	O
implicating	O
PLP	O
as	O
a	O
possible	O
candidate	O
gene	O
.	O
We	O
have	O
found	O
that	O
a	O
point	O
mutation	O
(	O
His139Tyr	O
)	O
in	O
exon	O
3B	O
of	O
an	O
affected	O
male	O
produces	O
a	O
mutant	O
PLP	O
but	O
a	O
normal	O
DM20	O
,	O
and	O
segregates	O
with	O
the	O
disease	O
(	O
Zmax	O
=	O
6	O
.	O
63	O
,	O
theta	O
=	O
0	O
.	O
00	O
)	O
.	O
It	O
appears	O
,	O
therefore	O
,	O
that	O
SPG2	O
and	O
PMD	B-SpecificDisease
are	O
allelic	B-DiseaseClass
disorders	I-DiseaseClass

3862128	O
Regional	O
mapping	O
of	O
the	O
phenylalanine	O
hydroxylase	O
gene	O
and	O
the	O
phenylketonuria	B-Modifier
locus	O
in	O
the	O
human	O
genome.	O
Phenylketonuria	B-SpecificDisease
(	O
PKU	B-SpecificDisease
)	O
is	O
an	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
disorder	I-DiseaseClass
of	O
amino	O
acid	O
metabolism	O
caused	O
by	O
a	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
hepatic	I-SpecificDisease
enzyme	I-SpecificDisease
phenylalanine	I-SpecificDisease
hydroxylase	I-SpecificDisease
(	O
PAH	O
;	O
phenylalanine	O
4-monooxygenase	O
,	O
EC	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
)	O
.	O
A	O
cDNA	O
clone	O
for	O
human	O
PAH	O
has	O
previously	O
been	O
used	O
to	O
assign	O
the	O
corresponding	O
gene	O
to	O
human	O
chromosome	O
12	O
.	O
To	O
define	O
the	O
regional	O
map	O
position	O
of	O
the	O
disease	O
locus	O
and	O
the	O
PAH	O
gene	O
on	O
human	O
chromosome	O
12	O
,	O
DNA	O
was	O
isolated	O
from	O
human-hamster	O
somatic	O
cell	O
hybrids	O
with	O
various	O
deletions	O
of	O
human	O
chromosome	O
12	O
and	O
was	O
analyzed	O
by	O
Southern	O
blot	O
analysis	O
using	O
the	O
human	O
cDNA	O
PAH	O
clone	O
as	O
a	O
hybridization	O
probe	O
.	O
From	O
these	O
results	O
,	O
together	O
with	O
detailed	O
biochemical	O
and	O
cytogenetic	O
characterization	O
of	O
the	O
hybrid	O
cells	O
,	O
the	O
region	O
on	O
chromosome	O
12	O
containing	O
the	O
human	O
PAH	O
gene	O
has	O
been	O
defined	O
as	O
12q14	O
.	O
3----qter	O
3----qter	O
.	O
The	O
PAH	O
map	O
position	O
on	O
chromosome	O
12	O
was	O
further	O
localized	O
by	O
in	O
situ	O
hybridization	O
of	O
125I-labeled	O
human	O
PAH	O
cDNA	O
to	O
chromosomes	O
prepared	O
from	O
a	O
human	O
lymphoblastoid	O
cell	O
line	O
.	O
Results	O
of	O
these	O
experiments	O
demonstrated	O
that	O
the	O
region	O
on	O
chromosome	O
12	O
containing	O
the	O
PAH	O
gene	O
and	O
the	O
PKU	B-Modifier
locus	O
in	O
man	O
is	O
12q22----12q24	O
.	O
1	O
.	O
These	O
results	O
not	O
only	O
provide	O
a	O
regionalized	O
map	O
position	O
for	O
a	O
major	O
human	O
disease	O
locus	O
but	O
also	O
can	O
serve	O
as	O
a	O
reference	O
point	O
for	O
linkage	O
analysis	O
with	O
other	O
DNA	O
markers	O
on	O
human	O
chromosome	O
12	O

133535	O
Linkage	O
of	O
gene	O
for	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
and	O
the	O
major	O
histocompatibility	O
complex	O
MHC	O
in	O
man.	O
Family	O
study	O
of	O
a	O
further	O
case.	O
Close	O
linkage	O
between	O
HL-A	O
and	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
was	O
first	O
reported	O
by	O
FU	O
and	O
co-workers	O
in	O
1974	O
.	O
We	O
present	O
here	O
a	O
pedigree	O
of	O
a	O
31-year-old	O
C2-deficient	B-Modifier
individual	O
with	O
clinical	O
manifestations	O
of	O
Hodgkins	B-SpecificDisease
disease	I-SpecificDisease
.	O
The	O
following	O
markers	O
were	O
tested	O
C2	O
levels	O
,	O
factor	O
B	O
polymorphism	O
,	O
blood	O
groups	O
,	O
and	O
enzyme	O
typing	O
.	O
In	O
addition	O
to	O
close	O
linkage	O
between	O
HL-A	O
and	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
,	O
both	O
parents	O
were	O
heterozygous	O
for	O
Bf	O
(	O
HL-A	O
linked	O
,	O
electrophoretic	O
variation	O
of	O
B	O
)	O
.	O
The	O
two	O
HL-A	O
haplotypes	O
closely	O
linked	O
to	O
C2	B-SpecificDisease
deficiency	I-SpecificDisease
are	O
different	O
2	O
,	O
W18	O
and	O
W24	O
,	O
W18	O
.	O
They	O
share	O
,	O
however	O
,	O
the	O
SD2	O
antigen	O
W18	O
and	O
the	O
LD	O
type	O
7a	O
.	O
.	O

2220826	O
Further	O
mapping	O
of	O
an	O
ataxia-telangiectasia	B-Modifier
locus	O
to	O
the	O
chromosome	O
11q23	O
region.	O
We	O
recently	O
mapped	O
the	O
gene	O
for	O
ataxia-telangiectasia	B-Modifier
group	O
A	O
(	O
ATA	O
)	O
to	O
chromosome	O
11q22-23	O
by	O
linkage	O
analysis	O
,	O
using	O
the	O
genetic	O
markers	O
THY1	O
and	O
pYNB3	O
.	O
12	O
(	O
D11S144	O
)	O
.	O
The	O
most	O
likely	O
order	O
was	O
cent-AT-S144-THY1	O
.	O
The	O
present	O
paper	O
describes	O
further	O
mapping	O
of	O
the	O
AT	B-Modifier
locus	O
by	O
means	O
of	O
a	O
panel	O
of	O
10	O
markers	O
that	O
span	O
approximately	O
60	O
cM	O
in	O
the	O
11q22-23	O
region	O
centered	O
around	O
S144	O
and	O
THY1	O
.	O
Location	O
scores	O
indicate	O
that	O
three	O
contiguous	O
subsegments	O
within	O
the	O
[	O
S144-THY1	O
]	O
segment	O
,	O
as	O
well	O
as	O
three	O
contiguous	O
segments	O
telomeric	O
to	O
THY1	O
,	O
are	O
each	O
unlikely	O
to	O
contain	O
the	O
AT	B-Modifier
locus	O
,	O
while	O
the	O
more	O
centromeric	O
[	O
STMY-S144	O
]	O
segment	O
is	O
most	O
likely	O
to	O
contain	O
the	O
AT	B-Modifier
locus	O
.	O
These	O
data	O
,	O
together	O
with	O
recent	O
refinements	O
in	O
the	O
linkage	O
and	O
physical	O
maps	O
of	O
11q22-23	O
,	O
place	O
the	O
AT	B-Modifier
locus	O
at	O
11q23	O
.	O

10735274	O
Locus	O
heterogeneity	O
in	O
Friedreich	B-SpecificDisease
ataxia.	I-SpecificDisease
Friedreich	B-SpecificDisease
ataxia	I-SpecificDisease
(	O
FRDA	B-SpecificDisease
)	O
is	O
the	O
most	O
common	O
form	O
of	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
ataxia	I-DiseaseClass
.	O
The	O
disease	O
locus	O
was	O
assigned	O
to	O
chromosome	O
9	O
and	O
the	O
disease	O
gene	O
,	O
STM7	O
/	O
X25	O
,	O
has	O
been	O
isolated	O
.	O
To	O
date	O
most	O
data	O
suggest	O
locus	O
homogeneity	O
in	O
FRDA	B-SpecificDisease
.	O
We	O
now	O
provide	O
strong	O
evidence	O
of	O
a	O
second	O
FRDA	B-Modifier
locus	O
.	O
Studying	O
two	O
siblings	O
with	O
FRDA	B-SpecificDisease
from	O
two	O
families	O
we	O
did	O
not	O
detect	O
a	O
mutation	O
in	O
STM7	O
/	O
X25	O
.	O
Haplotype	O
analysis	O
of	O
the	O
STM7	O
/	O
X25	O
region	O
of	O
chromosome	O
9	O
demonstrated	O
that	O
the	O
relevant	O
portion	O
of	O
chromosome	O
9	O
differs	O
in	O
the	O
patients	O
.	O
Although	O
the	O
patients	O
studied	O
had	O
typical	O
FRDA	B-SpecificDisease
,	O
one	O
sibpair	O
had	O
the	O
uncommon	O
symptom	O
of	O
retained	B-SpecificDisease
tendon	I-SpecificDisease
reflexes	I-SpecificDisease
.	O
In	O
order	O
to	O
investigate	O
whether	O
retained	B-SpecificDisease
tendon	I-SpecificDisease
reflexes	I-SpecificDisease
are	O
characteristic	O
of	O
FRDA	B-SpecificDisease
caused	O
by	O
the	O
second	O
locus	O
,	O
FRDA2	O
,	O
we	O
studied	O
an	O
unrelated	O
FRDA	B-Modifier
patient	O
with	O
retained	B-SpecificDisease
tendon	I-SpecificDisease
reflexes	I-SpecificDisease
.	O
The	O
observation	O
of	O
typical	O
mutations	O
in	O
STM7	O
/	O
X25	O
(	O
GAA	O
expansions	O
)	O
in	O
this	O
patient	O
demonstrates	O
that	O
the	O
two	O
genetically	O
different	O
forms	O
of	O
FRDA	B-SpecificDisease
cannot	O
be	O
distinguished	O
clinically	O
.	O
.	O

1303173	O
Both	O
mutations	O
in	O
G6PD	O
A-	O
are	O
necessary	O
to	O
produce	O
the	O
G6PD	B-Modifier
deficient	I-Modifier
phenotype.	O
The	O
high	O
prevalence	O
of	O
glucose	B-SpecificDisease
6-phosphate	I-SpecificDisease
dehydrogenase	I-SpecificDisease
(	I-SpecificDisease
G6PD	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
African	O
populations	O
is	O
due	O
almost	O
entirely	O
to	O
the	O
enzyme	O
variant	O
A-	O
,	O
which	O
differs	O
from	O
the	O
wild-type	O
G6PD	O
B	O
by	O
two	O
amino	O
acid	O
replacements	O
,	O
68	O
Val--	O
>	O
Met	O
and	O
126	O
Asn--	O
>	O
Asp	O
.	O
The	O
non-deficient	O
polymorphic	O
variant	O
G6PD	O
A	O
contains	O
only	O
the	O
mutation	O
126	O
Asn--	O
>	O
Asp	O
.	O
The	O
frequencies	O
of	O
the	O
G6PD	O
A	O
and	O
of	O
the	O
G6PD	O
A-	O
genes	O
in	O
parts	O
of	O
Africa	O
are	O
both	O
about	O
0	O
.	O
2	O
.	O
The	O
68	O
Val--	O
>	O
Met	O
mutation	O
has	O
not	O
been	O
found	O
in	O
a	O
B	O
background	O
.	O
This	O
could	O
be	O
because	O
the	O
68	O
Val--	O
>	O
Met	O
mutation	O
happened	O
to	O
arise	O
in	O
an	O
A	O
gene	O
in	O
the	O
first	O
instance	O
,	O
or	O
because	O
the	O
68	O
Val--	O
>	O
Met	O
mutation	O
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
We	O
have	O
approached	O
this	O
question	O
by	O
producing	O
G6PD	O
B	O
,	O
A	O
,	O
A-	O
,	O
and	O
G6PD	O
68	O
Val--	O
>	O
Met	O
in	O
a	O
bacterial	O
expression	O
system	O
and	O
analysing	O
their	O
biochemical	O
properties	O
.	O
With	O
each	O
single	O
mutation	O
we	O
found	O
a	O
slight	O
decrease	O
in	O
both	O
the	O
specific	O
activity	O
and	O
the	O
yield	O
of	O
enzyme	O
when	O
compared	O
to	O
G6PD	O
B	O
.	O
When	O
both	O
mutations	O
were	O
introduced	O
together	O
,	O
there	O
was	O
a	O
roughly	O
additive	O
effect	O
on	O
specific	O
activity	O
,	O
but	O
a	O
much	O
more	O
drastic	O
effect	O
on	O
enzyme	O
yield	O
(	O
4	O
%	O
of	O
normal	O
)	O
.	O
This	O
synergistic	O
effect	O
was	O
also	O
demonstrated	O
on	O
thermal	O
stability	O
,	O
especially	O
at	O
low	O
NADP	O
concentrations	O
.	O
Comparable	O
results	O
were	O
produced	O
when	O
the	O
replacement	O
119	O
Gln--	O
>	O
Glu	O
was	O
studied	O
instead	O
of	O
126	O
Asn--	O
>	O
Asp	O
.	O
We	O
infer	O
that	O
the	O
coexistence	O
of	O
the	O
two	O
mutations	O
is	O
responsible	O
for	O
enzyme	O
deficiency	B-SpecificDisease
in	I-SpecificDisease
G6PD	I-SpecificDisease
A-	O
because	O
they	O
act	O
synergistically	O
in	O
causing	O
instability	O
of	O
the	O
enzyme	O
.	O

10976074	O
Myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
in	O
transgenic	O
mice	O
expressing	O
an	O
expanded	O
CUG	O
repeat.	O
Myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
,	O
the	O
most	O
common	O
form	O
of	O
muscular	B-SpecificDisease
dystrophy	I-SpecificDisease
in	O
adult	O
humans	O
,	O
results	O
from	O
expansion	O
of	O
a	O
CTG	O
repeat	O
in	O
the	O
3	O
untranslated	O
region	O
of	O
the	O
DMPK	O
gene	O
.	O
The	O
mutant	O
DMPK	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
contains	O
an	O
expanded	O
CUG	O
repeat	O
and	O
is	O
retained	O
in	O
the	O
nucleus	O
.	O
We	O
have	O
expressed	O
an	O
untranslated	O
CUG	O
repeat	O
in	O
an	O
unrelated	O
mRNA	O
in	O
transgenic	O
mice	O
.	O
Mice	O
that	O
expressed	O
expanded	O
CUG	O
repeats	O
developed	O
myotonia	B-DiseaseClass
and	O
myopathy	B-DiseaseClass
,	O
whereas	O
mice	O
expressing	O
a	O
nonexpanded	O
repeat	O
did	O
not	O
.	O
Thus	O
,	O
transcripts	O
with	O
expanded	O
CUG	O
repeats	O
are	O
sufficient	O
to	O
generate	O
a	O
DM	B-Modifier
phenotype	O
.	O
This	O
result	O
supports	O
a	O
role	O
for	O
RNA	O
gain	O
of	O
function	O
in	O
disease	O
pathogenesis	O
.	O
.	O

10533068	O
Novel	O
mutations	O
in	O
XLRS1	O
causing	O
retinoschisis,	B-SpecificDisease
including	O
first	O
evidence	O
of	O
putative	O
leader	O
sequence	O
change.	O
Juvenile	B-SpecificDisease
retinoschisis	I-SpecificDisease
is	O
an	O
X-linked	B-DiseaseClass
recessive	I-DiseaseClass
disease	I-DiseaseClass
caused	O
by	O
mutations	O
in	O
the	O
XLRS1	O
gene	O
.	O
We	O
screened	O
31	O
new	O
unrelated	O
patients	O
and	O
families	O
for	O
XLRS1	O
mutations	O
in	O
addition	O
to	O
previously	O
reported	O
mutations	O
for	O
60	O
of	O
our	O
families	O
(	O
Retinoschisis	B-Modifier
Consortium	O
,	O
Hum	O
Mol	O
Genet	O
1998	O
;	O
7	O
1185-1192	O
)	O
.	O
Twenty-three	O
different	O
mutations	O
including	O
12	O
novel	O
ones	O
were	O
identified	O
in	O
28	O
patients	O
.	O
Mutations	O
identified	O
in	O
this	O
study	O
include	O
19	O
missense	O
mutations	O
,	O
two	O
nonsense	O
mutations	O
,	O
one	O
intragenic	O
deletion	O
,	O
four	O
microdeletions	O
,	O
one	O
insertion	O
,	O
and	O
one	O
intronic	O
sequence	O
substitution	O
that	O
is	O
likely	O
to	O
result	O
in	O
a	O
splice	O
site	O
defect	O
.	O
Two	O
novel	O
mutations	O
,	O
c	O
.	O
38T--	O
>	O
C	O
(	O
L13P	O
)	O
and	O
c	O
.	O
667T--	O
>	O
C	O
(	O
C223R	O
)	O
,	O
respectively	O
,	O
present	O
the	O
first	O
genetic	O
evidence	O
for	O
the	O
functional	O
significance	O
of	O
the	O
putative	O
leader	O
peptide	O
sequence	O
and	O
for	O
the	O
functional	O
significance	O
at	O
the	O
carboxyl	O
terminal	O
of	O
the	O
XLRS1	O
protein	O
beyond	O
the	O
discoidin	O
domain	O
.	O
Mutations	O
in	O
25	O
of	O
the	O
families	O
were	O
localized	O
to	O
exons	O
4-6	O
,	O
emphasizing	O
the	O
critical	O
functional	O
significance	O
of	O
the	O
discoidin	O
domain	O
of	O
the	O
XLRS1	O
protein	O

10208848	O
Fabry	B-SpecificDisease
disease:	I-SpecificDisease
identification	O
of	O
novel	O
alpha-galactosidase	O
A	O
mutations	O
and	O
molecular	O
carrier	O
detection	O
by	O
use	O
of	O
fluorescent	O
chemical	O
cleavage	O
of	O
mismatches.	O
Fabry	B-SpecificDisease
disease	I-SpecificDisease
(	O
FD	B-SpecificDisease
)	O
(	O
angiokeratoma	B-SpecificDisease
corporis	I-SpecificDisease
diffusum	I-SpecificDisease
)	O
is	O
an	O
X-linked	B-DiseaseClass
inborn	I-DiseaseClass
error	I-DiseaseClass
of	I-DiseaseClass
glycosphingolipid	I-DiseaseClass
metabolism	I-DiseaseClass
caused	O
by	O
defects	O
in	O
the	O
lysosomal	O
alpha-galactosidase	O
A	O
gene	O
(	O
GLA	O
)	O
.	O
The	O
enzymatic	O
defect	O
leads	O
to	O
the	O
systemic	O
accumulation	O
of	O
neutral	O
glycosphingolipids	O
with	O
terminal	O
alpha-galactosyl	O
moieties	O
.	O
Clinically	O
,	O
affected	O
hemizygous	O
males	O
have	O
angiokeratoma	B-SpecificDisease
,	O
severe	B-SpecificDisease
acroparesthesia	I-SpecificDisease
,	O
renal	B-SpecificDisease
failure	I-SpecificDisease
,	O
and	O
vasculopathy	B-CompositeMention
of	I-CompositeMention
the	I-CompositeMention
heart	I-CompositeMention
and	I-CompositeMention
brain	I-CompositeMention
.	O
While	O
demonstration	O
of	O
alpha-galactosidase	B-SpecificDisease
deficiency	I-SpecificDisease
in	O
leukocytes	O
is	O
diagnostic	O
in	O
affected	O
males	O
,	O
enzymatic	O
detection	O
of	O
female	O
carriers	O
is	O
often	O
inconclusive	O
,	O
due	O
to	O
random	O
X-chromosomal	O
inactivation	O
,	O
underlining	O
the	O
need	O
of	O
molecular	O
investigations	O
for	O
accurate	O
genetic	O
counseling	O
.	O
By	O
use	O
of	O
chemical	O
cleavage	O
of	O
mismatches	O
adapted	O
to	O
fluorescence-based	O
detection	O
systems	O
,	O
we	O
have	O
characterized	O
the	O
mutations	O
underlying	O
alpha-Gal	B-SpecificDisease
A	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
16	O
individuals	O
from	O
six	O
unrelated	O
families	O
with	O
FD	B-SpecificDisease
.	O
The	O
mutational	O
spectrum	O
included	O
five	O
missense	O
mutations	O
(	O
C202W	O
,	O
C223G	O
,	O
N224D	O
,	O
R301Q	O
,	O
and	O
Q327K	O
)	O
and	O
one	O
splice-site	O
mutation	O
[	O
IVS3	O
G	O
(	O
-1	O
)	O
--	O
>	O
C	O
]	O
.	O
Studies	O
at	O
the	O
mRNA	O
level	O
showed	O
that	O
the	O
latter	O
led	O
to	O
altered	O
pre-mRNA	O
splicing	O
with	O
consequent	O
alteration	O
of	O
the	O
mRNA	O
translational	O
reading	O
frame	O
and	O
generation	O
of	O
a	O
premature	O
termination	O
codon	O
of	O
translation	O
.	O
By	O
use	O
of	O
this	O
strategy	O
,	O
carrier	O
status	O
was	O
accurately	O
assessed	O
in	O
all	O
seven	O
at-risk	O
females	O
tested	O
,	O
whereas	O
enzymatic	O
dosages	O
failed	O
to	O
diagnose	O
or	O
exclude	O
heterozygosity	O
.	O
.	O

10434119	O
Linkage	O
analysis	O
of	O
5	O
novel	O
van	B-Modifier
der	I-Modifier
Woude	I-Modifier
syndrome	I-Modifier
kindreds	O
to	O
1q32-q41	O
markers	O
further	O
supports	O
locus	O
homogeneity	O
of	O
the	O
disease	O
trait.	O
van	B-SpecificDisease
der	I-SpecificDisease
Woude	I-SpecificDisease
syndrome	I-SpecificDisease
(	O
vWS	B-SpecificDisease
,	O
MIM	O
119300	O
)	O
is	O
a	O
rare	O
autosomal	B-DiseaseClass
dominant	I-DiseaseClass
clefting	I-DiseaseClass
condition	I-DiseaseClass
with	O
cardinal	O
features	O
of	O
mucous	B-SpecificDisease
cysts	I-SpecificDisease
(	O
lower-lip	B-SpecificDisease
pits	I-SpecificDisease
)	O
and	O
clefts	B-CompositeMention
to	I-CompositeMention
the	I-CompositeMention
lip	I-CompositeMention
and	I-CompositeMention
/	I-CompositeMention
or	I-CompositeMention
palate	I-CompositeMention
.	O
The	O
vWS	B-Modifier
gene	O
has	O
been	O
assigned	O
to	O
a	O
locus	O
in	O
1q32-q41	O
by	O
linkage	O
analysis	O
and	O
physical	O
mapping	O
.	O
We	O
have	O
investigated	O
5	O
novel	O
vWS	B-Modifier
families	O
through	O
probands	O
attended	O
for	O
cleft	B-Modifier
lip	I-Modifier
and	I-Modifier
/	I-Modifier
or	I-Modifier
palate	I-Modifier
repair	O
at	O
the	O
Department	O
of	O
Maxillofacial	O
Surgery	O
of	O
Hopital	O
Trousseau	O
,	O
Paris	O
,	O
in	O
order	O
to	O
tentatively	O
refine	O
the	O
genetic	O
map	O
of	O
the	O
vWS	B-Modifier
region	O
in	O
1q32-q41	O
and	O
possibly	O
identify	O
unlinked	O
pedigrees	O
.	O
Linkage	O
analysis	O
was	O
carried	O
out	O
to	O
6	O
microsatellite	O
markers	O
(	O
D1S249	O
,	O
D1S425	O
,	O
D1S491	O
,	O
D1S205	O
,	O
D1S414	O
,	O
D1S425	O
)	O
,	O
yielding	O
a	O
maximum	O
cumulative	O
LOD	O
score	O
of	O
Z	O
=	O
3	O
.	O
27	O
at	O
theta	O
=	O
0	O
.	O
00	O
for	O
D1S245	O
.	O
The	O
innermost	O
four	O
markers	O
were	O
found	O
to	O
be	O
tightly	O
linked	O
to	O
one	O
another	O
,	O
with	O
no	O
evidence	O
for	O
recombination	O
.	O
Our	O
results	O
support	O
linkage	O
of	O
vWS	B-SpecificDisease
within	O
a	O
region	O
of	O
tightly	O
linked	O
markers	O
and	O
do	O
not	O
favour	O
locus	O
heterogeneity	O
of	O
the	O
disease	O
trait	O
.	O

8198128	O
Recombinations	O
in	O
individuals	O
homozygous	O
by	O
descent	O
localize	O
the	O
Friedreich	B-SpecificDisease
ataxia	I-SpecificDisease
locus	O
in	O
a	O
cloned	O
450-kb	O
interval.	O
The	O
locus	O
for	O
Friedreich	B-SpecificDisease
ataxia	I-SpecificDisease
(	O
FRDA	B-SpecificDisease
)	O
,	O
a	O
severe	O
neurodegenerative	B-DiseaseClass
disease	I-DiseaseClass
,	O
is	O
tightly	O
linked	O
to	O
markers	O
D9S5	O
and	O
D9S15	O
,	O
and	O
analysis	O
of	O
rare	O
recombination	O
events	O
has	O
suggested	O
the	O
order	O
cen-FRDA-D9S5-D9S15-qter	O
.	O
We	O
report	O
here	O
the	O
construction	O
of	O
a	O
YAC	O
contig	O
extending	O
800	O
kb	O
centromeric	O
to	O
D9S5	O
and	O
the	O
isolation	O
of	O
five	O
new	O
microsatellite	O
markers	O
from	O
this	O
region	O
.	O
In	O
order	O
to	O
map	O
these	O
markers	O
with	O
respect	O
to	O
the	O
FRDA	B-Modifier
locus	O
,	O
all	O
within	O
a	O
1-cM	O
confidence	O
interval	O
,	O
we	O
sought	O
to	O
increase	O
the	O
genetic	O
information	O
of	O
available	O
FRDA	B-Modifier
families	O
by	O
considering	O
homozygosity	O
by	O
descent	O
and	O
association	O
with	O
founder	O
haplotypes	O
in	O
isolated	O
populations	O
.	O
This	O
approach	O
allowed	O
us	O
to	O
identify	O
one	O
phase-known	O
recombination	O
and	O
one	O
probable	O
historic	O
recombination	O
on	O
haplotypes	O
from	O
Reunion	O
Island	O
patients	O
,	O
both	O
of	O
which	O
place	O
three	O
of	O
the	O
five	O
markers	O
proximal	O
to	O
FRDA	B-SpecificDisease
.	O
This	O
represents	O
the	O
first	O
identification	O
of	O
close	O
FRDA	B-Modifier
flanking	O
markers	O
on	O
the	O
centromeric	O
side	O
.	O
The	O
two	O
other	O
markers	O
allowed	O
us	O
to	O
narrow	O
the	O
breakpoint	O
of	O
a	O
previously	O
identified	O
distal	O
recombination	O
that	O
is	O
>	O
180	O
kb	O
from	O
D9S5	O
(	O
26P	O
)	O
.	O
Taken	O
together	O
,	O
the	O
results	O
place	O
the	O
FRDA	B-Modifier
locus	O
in	O
a	O
450-kb	O
interval	O
,	O
which	O
is	O
small	O
enough	O
for	O
direct	O
search	O
of	O
candidate	O
genes	O
.	O
A	O
detailed	O
rare	O
cutter	O
restriction	O
map	O
and	O
a	O
cosmid	O
contig	O
covering	O
this	O
interval	O
were	O
constructed	O
and	O
should	O
facilitate	O
the	O
search	O
of	O
genes	O
in	O
this	O
region	O
.	O
.	O

10447259	O
Novel	O
mutations	O
in	O
the	O
Wiskott-Aldrich	B-Modifier
syndrome	I-Modifier
protein	O
gene	O
and	O
their	O
effects	O
on	O
transcriptional,	O
translational,	O
and	O
clinical	O
phenotypes.	O
Wiskott-Aldrich	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
WAS	B-SpecificDisease
)	O
is	O
an	O
X-linked	B-DiseaseClass
recessive	I-DiseaseClass
immunodeficiency	I-DiseaseClass
characterized	O
by	O
thrombocytopenia	B-DiseaseClass
,	O
eczema	B-DiseaseClass
,	O
and	O
recurrent	O
infections	O
,	O
and	O
caused	O
by	O
mutations	O
in	O
the	O
WAS	B-Modifier
protein	O
(	O
WASP	O
)	O
gene	O
.	O
WASP	O
contains	O
several	O
functional	O
domains	O
through	O
which	O
it	O
interacts	O
with	O
proteins	O
involved	O
in	O
intracellular	O
signaling	O
and	O
regulation	O
of	O
the	O
actin	O
cytoskeleton	O
.	O
In	O
this	O
report	O
,	O
17	O
WASP	O
gene	O
mutations	O
were	O
identified	O
,	O
12	O
of	O
which	O
are	O
novel	O
.	O
DNA	O
of	O
affected	O
males	O
and	O
obligate	O
carriers	O
was	O
PCR	O
amplified	O
and	O
analyzed	O
by	O
SSCA	O
,	O
heteroduplex	O
analysis	O
,	O
and	O
direct	O
sequencing	O
.	O
The	O
effects	O
of	O
the	O
mutations	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
were	O
ascertained	O
by	O
RT-PCR	O
and	O
Western	O
blot	O
analyses	O
.	O
All	O
missense	O
mutations	O
were	O
located	O
in	O
exons	O
1-4	O
.	O
Most	O
of	O
the	O
nonsense	O
,	O
frameshift	O
and	O
splice	O
site	O
mutations	O
were	O
found	O
in	O
exons	O
6-11	O
.	O
Mutations	O
that	O
alter	O
splice	O
sites	O
led	O
to	O
the	O
synthesis	O
of	O
several	O
types	O
of	O
mRNAs	O
,	O
a	O
fraction	O
of	O
which	O
represented	O
the	O
normally	O
spliced	O
product	O
.	O
The	O
presence	O
of	O
normally	O
spliced	O
transcripts	O
was	O
correlated	O
with	O
a	O
milder	O
phenotype	O
.	O
When	O
one	O
such	O
case	O
was	O
studied	O
by	O
Western	O
blotting	O
,	O
reduced	O
amounts	O
of	O
normal-size	O
WASP	O
were	O
present	O
.	O
In	O
other	O
cases	O
as	O
well	O
,	O
a	O
correlation	O
was	O
found	O
between	O
the	O
amount	O
of	O
normal	O
or	O
mutant	O
WASP	O
present	O
and	O
the	O
phenotypes	O
of	O
the	O
affected	O
individuals	O
.	O
No	O
protein	O
was	O
detected	O
in	O
two	O
individuals	O
with	O
severe	O
WAS	B-SpecificDisease
.	O
Reduced	O
levels	O
of	O
a	O
normal-size	O
WASP	O
with	O
a	O
missense	O
mutation	O
were	O
seen	O
in	O
two	O
individuals	O
with	O
XLT	B-SpecificDisease
.	O
It	O
is	O
concluded	O
that	O
mutation	O
analysis	O
at	O
the	O
DNA	O
level	O
is	O
not	O
sufficient	O
for	O
predicting	O
clinical	O
course	O
.	O
Studies	O
at	O
the	O
transcript	O
and	O
protein	O
level	O
are	O
needed	O
for	O
a	O
better	O
assessment	O
.	O
.	O

1676565	O
Carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
of	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease	I-SpecificDisease
using	O
a	O
combination	O
of	O
anonymous	O
DNA	O
polymorphisms	O
and	O
the	O
proteolipid	O
protein	O
(PLP)	O
gene	O
cDNA.	O
We	O
report	O
carrier	O
identification	O
and	O
a	O
prenatal	O
diagnosis	O
using	O
DNA	O
polymorphisms	O
in	O
2	O
families	O
with	O
X-linked	B-SpecificDisease
Pelizaeus-Merzbacher	I-SpecificDisease
disease	I-SpecificDisease
(	O
PMD	B-SpecificDisease
)	O
.	O
In	O
both	O
families	O
,	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
in	O
the	O
single	O
affected	O
male	O
could	O
be	O
traced	O
back	O
to	O
his	O
unaffected	O
maternal	O
grandfather	O
.	O
Therefore	O
,	O
each	O
family	O
contains	O
a	O
new	O
mutation	O
.	O
In	O
the	O
case	O
of	O
the	O
prenatal	O
diagnosis	O
,	O
the	O
fetus	O
was	O
shown	O
by	O
cytogenetic	O
analysis	O
to	O
be	O
a	O
female	O
,	O
who	O
we	O
predict	O
will	O
be	O
a	O
noncarrier	O
of	O
PMD	B-SpecificDisease
based	O
on	O
her	O
genotype	O
with	O
the	O
PLP	O
intragenic	O
polymorphism	O
.	O
.	O

7759106	O
Structural	O
analysis	O
of	O
the	O
5"	O
region	O
of	O
mouse	O
and	O
human	O
Huntington	B-Modifier
disease	I-Modifier
genes	O
reveals	O
conservation	O
of	O
putative	O
promoter	O
region	O
and	O
di-	O
and	O
trinucleotide	O
polymorphisms.	O
We	O
have	O
previously	O
cloned	O
and	O
characterized	O
the	O
murine	O
homologue	O
of	O
the	O
Huntington	B-Modifier
disease	I-Modifier
(	O
HD	B-Modifier
)	O
gene	O
and	O
shown	O
that	O
it	O
maps	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16	O
.	O
3	O
3	O
.	O
Here	O
we	O
present	O
a	O
detailed	O
comparison	O
of	O
the	O
sequence	O
of	O
the	O
putative	O
promoter	O
and	O
the	O
organization	O
of	O
the	O
5	O
genomic	O
region	O
of	O
the	O
murine	O
(	O
Hdh	O
)	O
and	O
human	O
HD	B-Modifier
genes	O
encompassing	O
the	O
first	O
five	O
exons	O
.	O
We	O
show	O
that	O
in	O
this	O
region	O
these	O
two	O
genes	O
share	O
identical	O
exon	O
boundaries	O
,	O
but	O
have	O
different-size	O
introns	O
.	O
Two	O
dinucleotide	O
(	O
CT	O
)	O
and	O
one	O
trinucleotide	O
intronic	O
polymorphism	O
in	O
Hdh	O
and	O
an	O
intronic	O
CA	O
polymorphism	O
in	O
the	O
HD	B-Modifier
gene	O
were	O
identified	O
.	O
Comparison	O
of	O
940-bp	O
sequence	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
reveals	O
a	O
highly	O
conserved	O
region	O
(	O
78	O
.	O
8	O
%	O
nucleotide	O
identity	O
)	O
between	O
Hdh	O
and	O
the	O
HD	B-Modifier
gene	O
from	O
nucleotide	O
-56	O
to	O
-206	O
(	O
of	O
Hdh	O
)	O
.	O
Neither	O
Hdh	O
nor	O
the	O
HD	B-Modifier
gene	O
have	O
typical	O
TATA	O
or	O
CCAAT	O
elements	O
,	O
but	O
both	O
show	O
one	O
putative	O
AP2	O
binding	O
site	O
and	O
numerous	O
potential	O
Sp1	O
binding	O
sites	O
.	O
The	O
high	O
sequence	O
identity	O
between	O
Hdh	O
and	O
the	O
HD	B-Modifier
gene	O
for	O
approximately	O
200	O
bp	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
indicates	O
that	O
these	O
sequences	O
may	O
play	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
the	O
Huntington	B-Modifier
disease	I-Modifier
gene	O

495634	O
Deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
fifth	I-SpecificDisease
component	I-SpecificDisease
of	I-SpecificDisease
complement	I-SpecificDisease
in	O
human	O
subjects.	O
Clinical,	O
genetic	O
and	O
immunologic	O
studies	O
in	O
a	O
large	O
kindred.	O
The	O
discovery	O
of	O
a	O
large	O
kindred	O
with	O
a	O
heritable	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
fifth	I-SpecificDisease
component	I-SpecificDisease
of	I-SpecificDisease
complement	I-SpecificDisease
(	O
C5	O
)	O
has	O
permitted	O
the	O
accumulation	O
of	O
new	O
clinical	O
,	O
genetic	O
and	O
immunologic	O
data	O
concerning	O
the	O
role	O
of	O
C5	O
in	O
human	O
subjects	O
.	O
The	O
proband	O
,	O
who	O
has	O
had	O
nine	O
episodes	O
of	O
disseminated	O
gonococcal	B-SpecificDisease
infection	I-SpecificDisease
,	O
has	O
a	O
hemolytic	O
C5	O
level	O
of	O
approximately	O
0	O
.	O
5	O
per	O
cent	O
of	O
normal	O
.	O
No	O
C5	O
protein	O
was	O
detectable	O
,	O
but	O
low	O
levels	O
of	O
functional	O
C5	O
activity	O
could	O
be	O
found	O
using	O
a	O
sensitive	O
bactericidal	O
assay	O
.	O
The	O
probands	O
twin	O
as	O
well	O
as	O
another	O
sister	O
also	O
had	O
extremely	O
low	O
levels	O
of	O
hemolytic	O
C5	O
(	O
approximately	O
0	O
.	O
5	O
per	O
cent	O
normal	O
)	O
,	O
but	O
both	O
these	O
subjects	O
have	O
been	O
healthy	O
.	O
Hemolytic	O
complement	O
and	O
bacteriolytic	O
activity	O
could	O
be	O
restored	O
by	O
the	O
addition	O
of	O
purified	O
C5	O
.	O
No	O
chemotactic	O
activity	O
for	O
polymorphonuclear	O
leukocytes	O
could	O
be	O
generated	O
in	O
the	O
C5-deficient	B-Modifier
serums	O
upon	O
activation	O
of	O
either	O
the	O
classic	O
or	O
alternative	O
pathways	O
,	O
again	O
demonstrating	O
the	O
importance	O
of	O
C5	O
in	O
human	O
subjects	O
for	O
the	O
production	O
of	O
chemotactic	O
factors	O
.	O
The	O
chemotactic	O
responsiveness	O
of	O
the	O
patients	O
polymorphonuclear	O
leukocytes	O
and	O
monocytes	O
to	O
preformed	O
chemotactic	O
factors	O
was	O
not	O
depressed	O
.	O
Twenty-two	O
of	O
32	O
other	O
family	O
members	O
from	O
three	O
generations	O
had	O
depressed	O
whole	O
hemolytic	O
complement	O
levels	O
.	O
In	O
19	O
of	O
30	O
family	O
members	O
,	O
levels	O
of	O
hemolytic	O
C5	O
ranged	O
from	O
13	O
to	O
64	O
per	O
cent	O
of	O
normal	O
.	O
No	O
linkage	O
for	O
C5	B-SpecificDisease
deficiency	I-SpecificDisease
and	O
the	O
A	O
or	O
B	O
loci	O
of	O
the	O
major	O
histocompatibility	O
complex	O
could	O
be	O
found	O
.	O
These	O
data	O
suggest	O
an	O
autosomal	O
codominant	O
mode	O
of	O
inheritance	O
of	O
C5	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
Deficiency	B-SpecificDisease
of	I-SpecificDisease
C5	I-SpecificDisease
is	O
compatible	O
with	O
good	O
health	O
,	O
but	O
it	O
can	O
be	O
associated	O
with	O
repeated	O
disseminated	O
gonococcal	B-SpecificDisease
infection	I-SpecificDisease

3198117	O
Glucose-6-phosphate	O
dehydrogenase	O
variants	O
and	O
their	O
frequency	O
in	O
Guangdong,	O
China.	O
Erythrocyte	O
glucose-6-phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
was	O
characterized	O
in	O
blood	O
samples	O
obtained	O
from	O
97	O
randomly	O
selected	O
males	O
with	O
enzyme	B-DiseaseClass
deficiency	I-DiseaseClass
from	O
various	O
regions	O
of	O
Guangdong	O
Province	O
,	O
China	O
.	O
Nine	O
new	O
variants	O
(	O
Gd	O
Kaiping	O
,	O
Gd	O
Boluo	O
,	O
Gd	O
Huiyang	O
,	O
Gd	O
Gaomin	O
,	O
Gd	O
Qing-Baijiang	O
,	O
Gd	O
Gaozhou	O
,	O
Gd	O
Huazhou	O
,	O
Gd	O
Nanhai	O
,	O
and	O
Gd	O
Guangzhou	O
)	O
were	O
identified	O
.	O
Of	O
the	O
31	O
variants	O
found	O
in	O
this	O
province	O
,	O
Gd	O
Kaiping	O
,	O
Gd	O
Taiwan-Hakka	O
,	O
Gd	O
Haad	O
Yai	O
,	O
Gd	O
Haad	O
Yai-like	O
and	O
Gd	O
Huiyang	O
occurred	O
most	O
frequently	O
.	O
The	O
frequency	O
of	O
each	O
variant	O
was	O
calculated	O
.	O
The	O
results	O
demonstrated	O
that	O
the	O
genetic	O
heterogeneity	O
of	O
G6PD	B-SpecificDisease
deficiency	I-SpecificDisease
was	O
high	O
in	O
this	O
area	O
.	O
.	O

10192393	O
A	O
common	O
human	O
skin	B-DiseaseClass
tumour	I-DiseaseClass
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta-catenin.	O
WNT	O
signalling	O
orchestrates	O
a	O
number	O
of	O
developmental	O
programs	O
.	O
In	O
response	O
to	O
this	O
stimulus	O
,	O
cytoplasmic	O
beta-catenin	O
(	O
encoded	O
by	O
CTNNB1	O
)	O
is	O
stabilized	O
,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	O
of	O
the	O
LEF	O
/	O
TCF	O
family	O
.	O
One	O
of	O
the	O
target	O
genes	O
for	O
beta-catenin	O
/	O
TCF	O
encodes	O
c-MYC	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer	B-DiseaseClass
,	O
particularly	O
in	O
the	O
colon	O
.	O
Most	O
colon	B-DiseaseClass
cancers	I-DiseaseClass
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	B-SpecificDisease
polyposis	I-SpecificDisease
coli	I-SpecificDisease
(	O
APC	B-SpecificDisease
)	O
,	O
a	O
protein	O
required	O
for	O
ubiquitin-mediated	O
degradation	O
of	O
beta-catenin	O
,	O
but	O
a	O
small	O
percentage	O
of	O
colon	B-CompositeMention
and	I-CompositeMention
some	I-CompositeMention
other	I-CompositeMention
cancers	I-CompositeMention
harbour	O
beta-catenin-stabilizing	O
mutations	O
.	O
Recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta-catenin	O
are	O
predisposed	O
to	O
developing	O
skin	B-DiseaseClass
tumours	I-DiseaseClass
resembling	O
pilomatricomas	B-SpecificDisease
.	O
Given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair-follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	B-SpecificDisease
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta-catenin-stabilizing	O
mutations	O
.	O
Here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	B-DiseaseClass
tumour	I-DiseaseClass
.	O
We	O
found	O
nuclear	O
LEF-1	O
in	O
the	O
dividing	O
tumour	B-Modifier
cells	O
,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	B-SpecificDisease
are	O
derived	O
from	O
hair	O
matrix	O
cells	O
.	O
At	O
least	O
75	O
%	O
of	O
these	O
tumours	B-DiseaseClass
possess	O
mutations	O
affecting	O
the	O
amino-terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation-dependent	O
,	O
ubiquitin-mediated	O
degradation	O
of	O
the	O
protein	O
.	O
This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	B-DiseaseClass
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta-catenin	O
/	O
LEF	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans	O
.	O
.	O

10210128	O
Prenatal	O
diagnosis	O
by	O
FISH	O
in	O
a	O
family	O
with	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease	I-SpecificDisease
caused	O
by	O
duplication	O
of	O
PLP	O
gene.	O
A	O
diagnosis	O
of	O
Pelizaeus-Merzbacher	B-SpecificDisease
disease	I-SpecificDisease
(	O
MIM	O
312080	O
)	O
was	O
made	O
in	O
a	O
young	O
boy	O
.	O
No	O
mutation	O
in	O
the	O
coding	O
region	O
of	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
had	O
been	O
found	O
.	O
The	O
boys	O
maternal	O
aunt	O
came	O
for	O
prenatal	O
diagnosis	O
when	O
16	O
+	O
weeks	O
pregnant	O
and	O
carrying	O
a	O
male	O
fetus	O
.	O
Samples	O
were	O
tested	O
for	O
duplication	O
of	O
the	O
PLP	O
gene	O
,	O
by	O
interphase	O
FISH	O
,	O
in	O
lymphocyte	O
preparations	O
from	O
the	O
proband	O
,	O
his	O
aunt	O
and	O
an	O
amniotic	O
fluid	O
cell	O
preparation	O
from	O
the	O
fetus	O
.	O
The	O
proband	O
was	O
found	O
to	O
carry	O
the	O
duplication	O
,	O
thus	O
confirming	O
the	O
diagnosis	O
of	O
Pelizaeus	B-SpecificDisease
Merzbacher	I-SpecificDisease
disease	I-SpecificDisease
,	O
but	O
neither	O
the	O
aunt	O
nor	O
the	O
fetus	O
carried	O
a	O
duplication	O
.	O
.	O

10746568	O
Molecular	O
analysis	O
of	O
the	O
genotype-phenotype	O
relationship	O
in	O
factor	B-SpecificDisease
X	I-SpecificDisease
deficiency.	I-SpecificDisease
Factor	B-SpecificDisease
X	I-SpecificDisease
deficiency	I-SpecificDisease
is	O
a	O
rare	O
haemorrhagic	B-DiseaseClass
condition	I-DiseaseClass
,	O
normally	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
,	O
in	O
which	O
a	O
variable	O
clinical	O
presentation	O
correlates	O
poorly	O
with	O
laboratory	O
phenotype	O
.	O
The	O
factor	O
X	O
(	O
F10	O
)	O
genes	O
of	O
14	O
unrelated	O
individuals	O
with	O
factor	B-SpecificDisease
X	I-SpecificDisease
deficiency	I-SpecificDisease
(	O
12	O
familial	O
and	O
two	O
sporadic	O
cases	O
)	O
were	O
sequenced	O
yielding	O
a	O
total	O
of	O
13	O
novel	O
mutations	O
.	O
Family	O
studies	O
were	O
performed	O
in	O
order	O
to	O
distinguish	O
the	O
contributions	O
of	O
individual	O
mutant	O
F10	O
alleles	O
to	O
the	O
clinical	O
and	O
laboratory	O
phenotypes	O
.	O
Missense	O
mutations	O
were	O
studied	O
by	O
means	O
of	O
molecular	O
modelling	O
,	O
whereas	O
single	O
basepair	O
substitutions	O
in	O
splice	O
sites	O
and	O
the	O
5	O
flanking	O
region	O
were	O
examined	O
by	O
in	O
vitro	O
splicing	O
assay	O
and	O
luciferase	O
reporter	O
gene	O
assay	O
respectively	O
.	O
The	O
deletion	O
allele	O
of	O
a	O
novel	O
hexanucleotide	O
insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
F10	O
gene	O
promoter	O
region	O
was	O
shown	O
by	O
reporter	O
gene	O
assay	O
,	O
to	O
reduce	O
promoter	O
activity	O
by	O
approximately	O
20	O
%	O
.	O
One	O
family	O
manifesting	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
possessed	O
three	O
clinically	O
affected	O
members	O
who	O
were	O
heterozygous	O
for	O
a	O
splice-site	O
mutation	O
that	O
was	O
predicted	O
to	O
lead	O
to	O
the	O
production	O
of	O
a	O
truncated	O
protein	O
product	O
.	O
A	O
model	O
which	O
accounts	O
for	O
the	O
dominant	O
negative	O
effect	O
of	O
this	O
lesion	O
is	O
presented	O
.	O
Variation	O
in	O
the	O
antigen	O
level	O
of	O
heterozygous	O
relatives	O
of	O
probands	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
between	O
families	O
than	O
within	O
families	O
,	O
consistent	O
with	O
the	O
view	O
that	O
the	O
nature	O
of	O
the	O
F10	O
lesion	O
(	O
s	O
)	O
segregating	O
in	O
a	O
given	O
family	O
is	O
a	O
prime	O
determinant	O
of	O
the	O
laboratory	O
phenotype	O
.	O
By	O
contrast	O
,	O
no	O
such	O
relationship	O
could	O
be	O
discerned	O
between	O
laboratory	O
phenotype	O
and	O
polymorphism	O
genotype	O
.	O
.	O

10767313	O
Understanding	O
the	O
molecular	O
basis	O
of	O
fragile	B-SpecificDisease
X	I-SpecificDisease
syndrome.	I-SpecificDisease
Fragile	B-SpecificDisease
X	I-SpecificDisease
syndrome	I-SpecificDisease
,	O
a	O
common	O
form	O
of	O
inherited	B-DiseaseClass
mental	I-DiseaseClass
retardation	I-DiseaseClass
,	O
is	O
mainly	O
caused	O
by	O
massive	O
expansion	O
of	O
CGG	O
triplet	O
repeats	O
located	O
in	O
the	O
5-untranslated	O
region	O
of	O
the	O
fragile	B-Modifier
X	I-Modifier
mental	I-Modifier
retardation-1	I-Modifier
(	O
FMR1	O
)	O
gene	O
.	O
In	O
patients	O
with	O
fragile	B-SpecificDisease
X	I-SpecificDisease
syndrome	I-SpecificDisease
,	O
the	O
expanded	O
CGG	O
triplet	O
repeats	O
are	O
hypermethylated	O
and	O
the	O
expression	O
of	O
the	O
FMR1	O
gene	O
is	O
repressed	O
,	O
which	O
leads	O
to	O
the	O
absence	O
of	O
FMR1	O
protein	O
(	O
FMRP	O
)	O
and	O
subsequent	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
.	O
FMRP	O
is	O
an	O
RNA-binding	O
protein	O
that	O
shuttles	O
between	O
the	O
nucleus	O
and	O
cytoplasm	O
.	O
This	O
protein	O
has	O
been	O
implicated	O
in	O
protein	O
translation	O
as	O
it	O
is	O
found	O
associated	O
with	O
polyribosomes	O
and	O
the	O
rough	O
endoplasmic	O
reticulum	O
.	O
We	O
discuss	O
here	O
the	O
recent	O
progress	O
made	O
towards	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
CGG	O
repeat	O
expansion	O
and	O
physiological	O
function	O
(	O
s	O
)	O
of	O
FMRP	O
.	O
These	O
studies	O
will	O
not	O
only	O
help	O
to	O
illuminate	O
the	O
molecular	O
basis	O
of	O
the	O
general	O
class	O
of	O
human	O
diseases	O
with	O
trinucleotide	O
repeat	O
expansion	O
but	O
also	O
provide	O
an	O
avenue	O
to	O
understand	O
aspects	O
of	O
human	O
cognition	O
and	O
intelligence	O
.	O
.	O

10194428	O
HFE	O
mutations	O
analysis	O
in	O
711	O
hemochromatosis	B-Modifier
probands:	O
evidence	O
for	O
S65C	O
implication	O
in	O
mild	O
form	O
of	O
hemochromatosis.	B-SpecificDisease
Hereditary	B-SpecificDisease
hemochromatosis	I-SpecificDisease
(	O
HH	B-SpecificDisease
)	O
is	O
a	O
common	O
autosomal	B-DiseaseClass
recessive	I-DiseaseClass
genetic	I-DiseaseClass
disorder	I-DiseaseClass
of	O
iron	O
metabolism	O
.	O
The	O
HFE	O
candidate	O
gene	O
encoding	O
an	O
HLA	O
class	O
I-like	O
protein	O
involved	O
in	O
HH	B-SpecificDisease
was	O
identified	O
in	O
1996	O
.	O
Two	O
missense	O
mutations	O
have	O
been	O
described	O
C282Y	O
,	O
accounting	O
for	O
80	O
%	O
to	O
90	O
%	O
of	O
HH	B-Modifier
chromosomes	O
,	O
and	O
H63D	O
,	O
which	O
is	O
associated	O
with	O
a	O
milder	O
form	O
of	O
the	O
disease	O
representing	O
40	O
%	O
to	O
70	O
%	O
of	O
non-C282Y	O
HH	B-Modifier
chromosomes	O
.	O
We	O
report	O
here	O
on	O
the	O
analysis	O
of	O
C282Y	O
,	O
H63D	O
,	O
and	O
the	O
193A--	O
>	O
T	O
substitution	O
leading	O
to	O
the	O
S65C	O
missense	O
substitution	O
in	O
a	O
large	O
series	O
of	O
probands	O
and	O
controls	O
.	O
The	O
results	O
confirm	O
that	O
the	O
C282Y	O
substitution	O
was	O
the	O
main	O
mutation	O
involved	O
in	O
hemochromatosis	B-SpecificDisease
,	O
accounting	O
for	O
85	O
%	O
of	O
carrier	O
chromosomes	O
,	O
whereas	O
the	O
H63D	O
substitution	O
represented	O
39	O
%	O
of	O
the	O
HH	B-Modifier
chromosomes	O
that	O
did	O
not	O
carry	O
the	O
C282Y	O
mutation	O
.	O
In	O
addition	O
,	O
our	O
screening	O
showed	O
that	O
the	O
S65C	O
substitution	O
was	O
significantly	O
enriched	O
in	O
probands	O
with	O
at	O
least	O
one	O
chromosome	O
without	O
an	O
assigned	O
mutation	O
.	O
This	O
substitution	O
accounted	O
for	O
7	O
.	O
8	O
%	O
of	O
HH	B-Modifier
chromosomes	O
that	O
were	O
neither	O
C282Y	O
nor	O
H63D	O
.	O
This	O
enrichment	O
of	O
S65C	O
among	O
HH	B-Modifier
chromosomes	O
suggests	O
that	O
the	O
S65C	O
substitution	O
is	O
associated	O
with	O
the	O
mild	O
form	O
of	O
hemochromatosis	B-SpecificDisease
.	O

1301189	O
A	O
glycine250-->	O
aspartate	O
substitution	O
in	O
the	O
alpha-subunit	O
of	O
hexosaminidase	O
A	O
causes	O
juvenile-onset	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
in	O
a	O
Lebanese-Canadian	O
family.	O
The	O
mutation	O
causing	O
juvenile	O
Tay-Sachs	B-SpecificDisease
disease	I-SpecificDisease
(	O
TSD	B-SpecificDisease
)	O
in	O
two	O
sibs	O
of	O
Lebanese-Maronite	O
origin	O
is	O
described	O
.	O
An	O
mRNA-containing	O
extract	O
of	O
cultured	O
fibroblasts	O
obtained	O
from	O
one	O
of	O
the	O
probands	O
was	O
used	O
as	O
a	O
template	O
to	O
amplify	O
the	O
coding	O
sequence	O
of	O
the	O
hexosaminidase	O
A	O
(	O
Hex	O
A	O
)	O
alpha-subunit	O
.	O
Sequencing	O
of	O
amplified	O
cDNA	O
fragments	O
revealed	O
a	O
single	O
alteration	O
,	O
guanine	O
to	O
adenine	O
at	O
nt	O
749	O
creating	O
a	O
G250D	O
mutation	O
.	O
The	O
mutation	O
introduces	O
a	O
new	O
recognition	O
site	O
for	O
the	O
restriction	O
enzyme	O
Eco	O
RV	O
,	O
permitting	O
identification	O
of	O
heterozygotes	O
for	O
this	O
allele	O
following	O
PCR	O
amplification	O
and	O
Eco	O
RV	O
digestion	O
of	O
exon	O
7	O
sequences	O
from	O
genomic	O
DNA	O
templates	O
.	O
In	O
order	O
to	O
test	O
the	O
effect	O
of	O
this	O
substitution	O
,	O
an	O
in	O
vitro	O
mutagenized	O
cDNA	O
construct	O
was	O
introduced	O
into	O
a	O
mammalian	O
expression	O
vector	O
and	O
transfected	O
into	O
monkey	O
Cos-1	O
cells	O
separately	O
or	O
along	O
with	O
a	O
beta-cDNA	O
expression	O
vector	O
.	O
When	O
the	O
mutant	O
alpha-cDNA	O
was	O
the	O
only	O
gene	O
introduced	O
into	O
COS	O
cells	O
no	O
enzymatic	O
activity	O
above	O
endogenous	O
COS	O
cell	O
activity	O
was	O
detected	O
.	O
Cotransfection	O
of	O
normal	O
alpha-cDNA	O
and	O
beta-cDNA	O
followed	O
by	O
immunoprecipitation	O
of	O
human	O
Hex	O
A	O
resulted	O
in	O
20-fold	O
increase	O
in	O
the	O
ratio	O
between	O
positive	O
and	O
negative	O
(	O
mock	O
transfection	O
)	O
control	O
values	O
.	O
This	O
allowed	O
the	O
detection	O
of	O
some	O
residual	O
activity	O
(	O
12	O
%	O
of	O
the	O
positive	O
control	O
)	O
when	O
the	O
mutant	O
alpha-cDNA	O
replaced	O
its	O
wild-type	O
counterpart	O
.	O
The	O
predicted	O
protein	O
environment	O
in	O
which	O
the	O
mutation	O
occurs	O
is	O
compared	O
to	O
that	O
of	O
the	O
adult-onset	O
Tay-Sachs	B-Modifier
disease	I-Modifier
mutation	O
caused	O
by	O
a	O
Gly269--	O
>	O
Ser	O
substitution	O
in	O
exon	O
7	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
.	O

10541953	O
Growth	O
hormone	O
treatment	O
increases	O
CO(2)	O
response,	O
ventilation	O
and	O
central	O
inspiratory	O
drive	O
in	O
children	O
with	O
Prader-Willi	B-SpecificDisease
syndrome.	I-SpecificDisease
We	O
studied	O
whether	O
the	O
beneficial	O
effects	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
treatment	O
on	O
growth	O
and	O
body	O
composition	O
in	O
PWS	B-SpecificDisease
are	O
accompanied	O
by	O
an	O
improvement	O
in	O
respiratory	O
function	O
.	O
We	O
measured	O
resting	O
ventilation	O
,	O
airway	O
occlusion	O
pressure	O
(	O
P	O
(	O
0	O
.	O
1	O
)	O
)	O
and	O
ventilatory	O
response	O
to	O
CO	O
(	O
2	O
)	O
in	O
nine	O
children	O
,	O
aged	O
7-14	O
years	O
,	O
before	O
and	O
6-9	O
months	O
after	O
the	O
start	O
of	O
GH	O
treatment	O
.	O
During	O
GH	O
treatment	O
,	O
resting	O
ventilation	O
increased	O
by	O
26	O
%	O
,	O
P	O
(	O
0	O
.	O
1	O
)	O
by	O
72	O
%	O
and	O
the	O
response	O
to	O
CO	O
(	O
2	O
)	O
by	O
65	O
%	O
(	O
P	O
<	O
0	O
.	O
002	O
,	O
<	O
0	O
.	O
04	O
and	O
<	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O
This	O
observed	O
increase	O
in	O
ventilatory	O
output	O
was	O
not	O
correlated	O
to	O
changes	O
in	O
body	O
mass	O
index	O
.	O
CONCLUSION	O
Treatment	O
of	O
children	O
with	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
PWS	B-SpecificDisease
)	O
seems	O
to	O
have	O
a	O
stimulatory	O
effect	O
on	O
central	O
respiratory	O
structures	O
.	O
The	O
observed	O
increase	O
in	O
ventilation	O
and	O
inspiratory	O
drive	O
may	O
contribute	O
to	O
the	O
improved	O
activity	O
level	O
reported	O
by	O
parents	O
of	O
PWS	B-Modifier
children	O
during	O
growth	O
hormone	O
therapy	O

7202134	O
Adrenoleukodystrophy:	B-SpecificDisease
increased	O
plasma	O
content	O
of	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids.	O
With	O
a	O
new	O
method	O
we	O
measured	O
the	O
saturated	O
very	O
long	O
chain	O
fatty	O
acids	O
in	O
the	O
plasma	O
of	O
adrenoleukodystrophy	B-Modifier
(	O
ALD	B-Modifier
)	O
hemizygotes	O
,	O
ALD	B-Modifier
heterozygotes	O
,	O
and	O
controls	O
.	O
ALD	B-Modifier
hemizygotes	O
showed	O
increased	O
levels	O
of	O
hexacosanoate	O
(	O
C26	O
fatty	O
acid	O
)	O
which	O
represented	O
0	O
.	O
081	O
+	O
/	O
-	O
0	O
.	O
0066	O
%	O
(	O
SEM	O
)	O
of	O
total	O
fatty	O
acids	O
,	O
compared	O
to	O
0	O
.	O
015	O
+	O
/	O
-	O
0	O
.	O
0032	O
%	O
in	O
the	O
controls	O
.	O
C25	O
,	O
C24	O
,	O
and	O
C23	O
fatty	O
acids	O
were	O
also	O
increased	O
,	O
but	O
the	O
C22	O
and	O
C20	O
fatty	O
acids	O
were	O
normal	O
.	O
C26	O
levels	O
were	O
also	O
increased	O
in	O
most	O
ALD	B-Modifier
heterozygotes	O
,	O
with	O
a	O
mean	O
level	O
0	O
.	O
057	O
+	O
/	O
-	O
0	O
.	O
0063	O
%	O
of	O
total	O
fatty	O
acids	O
.	O
The	O
technique	O
can	O
be	O
used	O
for	O
diagnosis	O
and	O
carrier	O
identification	O
,	O
and	O
in	O
the	O
evaluation	O
of	O
therapy	O
.	O

2006152	O
Founder	O
effect	O
of	O
a	O
prevalent	O
phenylketonuria	B-Modifier
mutation	O
in	O
the	O
Oriental	O
population.	O
A	O
missense	O
mutation	O
has	O
been	O
identified	O
in	O
the	O
human	O
phenylalanine	O
hydroxylase	O
[	O
PAH	O
;	O
phenylalanine	O
4-monooxygenase	O
;	O
L-phenylalanine	O
,	O
tetrahydrobiopterin	O
oxygen	O
oxidoreductase	O
(	O
4-hydroxylating	O
)	O
,	O
EC	O
1	O
.	O
14	O
.	O
16	O
.	O
1	O
]	O
gene	O
in	O
a	O
Chinese	O
patient	O
with	O
classic	O
phenylketonuria	B-SpecificDisease
(	O
PKU	B-SpecificDisease
)	O
.	O
A	O
G-to-C	O
transition	O
at	O
the	O
second	O
base	O
of	O
codon	O
413	O
in	O
exon	O
12	O
of	O
the	O
gene	O
results	O
in	O
the	O
substitution	O
of	O
Pro413	O
for	O
Arg413	O
in	O
the	O
mutant	O
protein	O
.	O
This	O
mutation	O
(	O
R413P	O
)	O
results	O
in	O
negligible	O
enzymatic	O
activity	O
when	O
expressed	O
in	O
heterologous	O
mammalian	O
cells	O
and	O
is	O
compatible	O
with	O
a	O
classic	O
PKU	B-Modifier
phenotype	O
in	O
the	O
patient	O
.	O
Population	O
genetic	O
studies	O
reveal	O
that	O
this	O
mutation	O
is	O
tightly	O
linked	O
to	O
restriction	O
fragment	O
length	O
polymorphism	O
haplotype	O
4	O
,	O
which	O
is	O
the	O
predominant	O
haplotype	O
of	O
the	O
PAH	O
locus	O
in	O
the	O
Oriental	O
population	O
.	O
It	O
accounts	O
for	O
13	O
.	O
8	O
%	O
of	O
northern	O
Chinese	O
and	O
27	O
%	O
of	O
Japanese	O
PKU	B-Modifier
alleles	O
,	O
but	O
it	O
is	O
rare	O
in	O
southern	O
Chinese	O
(	O
2	O
.	O
2	O
%	O
)	O
and	O
is	O
absent	O
in	O
the	O
Caucasian	O
population	O
.	O
The	O
data	O
demonstrate	O
unambiguously	O
that	O
the	O
mutation	O
occurred	O
after	O
racial	O
divergence	O
of	O
Orientals	O
and	O
Caucasians	O
and	O
suggest	O
that	O
the	O
allele	O
has	O
spread	O
throughout	O
the	O
Orient	O
by	O
a	O
founder	O
effect	O
.	O
Previous	O
protein	O
polymorphism	O
studies	O
in	O
eastern	O
Asia	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
"	O
northern	O
Mongoloids	O
"	O
represented	O
a	O
founding	O
population	O
in	O
Asia	O
.	O
Our	O
results	O
are	O
compatible	O
with	O
this	O
hypothesis	O
in	O
that	O
the	O
PKU	B-Modifier
mutation	O
might	O
have	O
occurred	O
in	O
northern	O
Mongoloids	O
and	O
subsequently	O
spread	O
to	O
the	O
Chinese	O
and	O
Japanese	O
populations	O
.	O

2575071	O
Haplotype	O
and	O
multipoint	O
linkage	O
analysis	O
in	O
Finnish	O
choroideremia	B-Modifier
families.	O
Multipoint	O
linkage	O
analysis	O
of	O
choroideremia	B-SpecificDisease
(	O
TCD	B-SpecificDisease
)	O
and	O
seven	O
X	O
chromosomal	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
was	O
carried	O
out	O
in	O
18	O
Finnish	O
TCD	B-Modifier
families	O
.	O
The	O
data	O
place	O
TCD	B-SpecificDisease
distal	O
to	O
PGK	O
and	O
DXS72	O
,	O
very	O
close	O
to	O
DXYS1	O
and	O
DXYS5	O
(	O
Zmax	O
=	O
24	O
at	O
theta	O
=	O
0	O
)	O
and	O
proximal	O
to	O
DXYS4	O
and	O
DXYS12	O
.	O
This	O
agrees	O
with	O
the	O
data	O
obtained	O
from	O
other	O
linkage	O
studies	O
and	O
from	O
physical	O
mapping	O
.	O
All	O
the	O
TCD	B-Modifier
males	O
and	O
carrier	O
females	O
studied	O
have	O
the	O
same	O
DXYS1	O
allele	O
in	O
coupling	O
with	O
TCD	B-SpecificDisease
.	O
In	O
Northeastern	O
Finland	O
,	O
66	O
/	O
69	O
chromosomes	O
carrying	O
TCD	B-SpecificDisease
had	O
the	O
same	O
haplotype	O
at	O
loci	O
DXS72	O
,	O
DXYS1	O
,	O
DXYS4	O
,	O
and	O
DXYS12	O
.	O
The	O
same	O
haplotype	O
is	O
seen	O
in	O
only	O
15	O
/	O
99	O
chromosomes	O
not	O
carrying	O
TCD	B-SpecificDisease
.	O
Moreover	O
,	O
in	O
71	O
/	O
104	O
non-TCD	O
chromosomes	O
,	O
the	O
haplotype	O
at	O
six	O
marker	O
loci	O
is	O
different	O
from	O
those	O
seen	O
in	O
any	O
of	O
the	O
76	O
TCD	B-Modifier
chromosomes	O
.	O
This	O
supports	O
the	O
previously	O
described	O
hypothesis	O
that	O
the	O
large	O
Northern	O
Finnish	O
choroideremia	B-Modifier
pedigrees	O
,	O
comprising	O
a	O
total	O
of	O
over	O
80	O
living	O
patients	O
representing	O
more	O
than	O
a	O
fifth	O
of	O
all	O
TCD	B-Modifier
patients	O
described	O
worldwide	O
,	O
carry	O
the	O
same	O
mutation	O
.	O
These	O
linkage	O
and	O
haplotype	O
data	O
provide	O
improved	O
opportunities	O
for	O
prenatal	O
diagnosis	O
based	O
on	O
RFLP	O
studies	O
.	O
.	O

8258524	O
The	O
effects	O
of	O
dystrophin	O
gene	O
mutations	O
on	O
the	O
ERG	O
in	O
mice	O
and	O
humans.	O
PURPOSE	O
.	O
The	O
authors	O
earlier	O
findings	O
of	O
a	O
negative	O
electroretinogram	O
(	O
ERG	O
)	O
in	O
a	O
boy	O
with	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DMD	B-SpecificDisease
)	O
led	O
them	O
to	O
investigate	O
dystrophin	O
gene	O
deletions	O
and	O
ERGs	O
in	O
five	O
boys	O
with	O
DMD	B-SpecificDisease
.	O
The	O
authors	O
wanted	O
to	O
determined	O
whether	O
there	O
were	O
similar	O
ERG	O
findings	O
in	O
an	O
animal	O
model	O
for	O
DMD	B-SpecificDisease
,	O
the	O
mdx	O
mouse	O
.	O
METHODS	O
.	O
Ganzfeld	O
ERGs	O
were	O
recorded	O
in	O
five	O
boys	O
with	O
DMD	B-SpecificDisease
after	O
a	O
complete	O
ophthalmic	O
examination	O
.	O
The	O
dystrophin	O
gene	O
was	O
analyzed	O
by	O
Southern	O
blot	O
hybridization	O
.	O
ERGs	O
were	O
recorded	O
in	O
anesthetized	O
mdx	O
and	O
control	O
mice	O
with	O
a	O
modified	O
Grass	O
photostimulator	O
(	O
Grass	O
Instrument	O
Company	O
,	O
Quincy	O
,	O
MA	O
)	O
.	O
RESULTS	O
.	O
Ophthalmic	O
examinations	O
in	O
all	O
five	O
boys	O
had	O
normal	O
findings	O
,	O
yet	O
an	O
abnormal	O
negative	O
ERG	O
was	O
recorded	O
for	O
each	O
subject	O
.	O
The	O
subjects	O
gene	O
deletions	O
were	O
variable	O
,	O
ranging	O
from	O
large	O
deletions	O
to	O
no	O
detectable	O
deletions	O
.	O
The	O
ERGs	O
of	O
the	O
mdx	O
mice	O
were	O
normal	O
and	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
of	O
the	O
control	O
mice	O
.	O
CONCLUSIONS	O
.	O
The	O
authors	O
believe	O
the	O
unique	O
ERG	O
recorded	O
for	O
the	O
human	O
subjects	O
is	O
a	O
manifestation	O
of	O
DMD	B-SpecificDisease
associated	O
with	O
defects	O
at	O
the	O
dystrophin	O
gene	O
locus	O
and	O
represents	O
a	O
new	O
clinical	O
entity	O
.	O
The	O
ERG	O
of	O
the	O
mdx	O
mouse	O
may	O
be	O
spared	O
for	O
several	O
reasons	O
,	O
including	O
milder	O
effects	O
of	O
the	O
mouse	O
gene	O
defect	O
,	O
differences	O
in	O
muscle	O
and	O
retinal	O
gene	O
product	O
,	O
or	O
species	O
differences	O
in	O
the	O
biochemical	O
role	O
of	O
dystrophin	O
.	O
The	O
ERG	O
shows	O
promise	O
of	O
becoming	O
a	O
noninvasive	O
diagnostic	O
tool	O
for	O
DMD	B-SpecificDisease
and	O
its	O
milder	O
allelic	O
forms	O
.	O
.	O

1505982	O
Resolution	O
of	O
the	O
two	O
loci	O
for	O
autosomal	O
dominant	O
aniridia,	B-SpecificDisease
AN1	O
and	O
AN2,	O
to	O
a	O
single	O
locus	O
on	O
chromosome	O
11p13.	O
Two	O
distinct	O
loci	O
have	O
been	O
proposed	O
for	O
aniridia	B-SpecificDisease
;	O
AN1	O
for	O
autosomal	O
dominant	O
aniridia	B-SpecificDisease
on	O
chromosome	O
2p	O
and	O
AN2	O
for	O
the	O
aniridia	B-SpecificDisease
in	O
the	O
WAGR	B-SpecificDisease
contiguous	I-SpecificDisease
gene	I-SpecificDisease
syndrome	I-SpecificDisease
on	O
chromosome	O
11p13	O
.	O
In	O
this	O
report	O
,	O
the	O
kindred	O
segregating	O
for	O
autosomal	O
dominant	O
aniridia	B-SpecificDisease
,	O
which	O
suggested	O
linkage	O
to	O
acid	O
phosphatase-1	O
(	O
ACP1	O
)	O
and	O
led	O
to	O
the	O
assignment	O
of	O
the	O
AN1	O
locus	O
on	O
chromosome	O
2p	O
,	O
has	O
been	O
updated	O
and	O
expanded	O
.	O
Linkage	O
analysis	O
between	O
the	O
aniridia	B-SpecificDisease
phenotype	O
and	O
ACP1	O
does	O
not	O
support	O
the	O
original	O
linkage	O
results	O
,	O
excluding	O
linkage	O
up	O
to	O
theta	O
=	O
0	O
.	O
17	O
with	O
Z	O
=	O
-2	O
.	O
Tests	O
for	O
linkage	O
to	O
other	O
chromosome	O
2p	O
markers	O
.	O
APOB	O
,	O
D2S71	O
,	O
D2S5	O
,	O
and	O
D2S1	O
,	O
also	O
excluded	O
linkage	O
to	O
aniridia	B-SpecificDisease
.	O
Markers	O
that	O
have	O
been	O
isolated	O
from	O
the	O
chromosome	O
11p13	O
region	O
were	O
then	O
analyzed	O
in	O
this	O
aniridia	B-Modifier
family	O
.	O
Two	O
RFLPs	O
at	O
the	O
D11S323	O
locus	O
give	O
significant	O
evidence	O
for	O
linkage	O
.	O
The	O
PvuII	O
polymorphism	O
detected	O
by	O
probe	O
p5S1	O
.	O
6	O
detects	O
no	O
recombinants	O
,	O
with	O
a	O
maximum	O
lod	O
score	O
of	O
Z	O
=	O
6	O
.	O
97	O
at	O
theta	O
=	O
0	O
.	O
00	O
00	O
.	O
The	O
HaeIII	O
polymorphism	O
detected	O
by	O
the	O
probe	O
p5BE1	O
.	O
2	O
gives	O
a	O
maximum	O
lod	O
score	O
of	O
Z	O
=	O
2	O
.	O
57	O
at	O
theta	O
=	O
0	O
.	O
00	O
00	O
.	O
Locus	O
D11S325	O
gives	O
a	O
lod	O
score	O
of	O
Z	O
=	O
1	O
.	O
53	O
at	O
theta	O
=	O
0	O
.	O
00	O
00	O
.	O
These	O
data	O
suggest	O
that	O
a	O
locus	O
for	O
aniridia	B-SpecificDisease
(	O
AN1	O
)	O
on	O
chromosome	O
2p	O
has	O
been	O
misassigned	O
and	O
that	O
this	O
autosomal	O
dominant	O
aniridia	B-Modifier
family	O
is	O
segregating	O
for	O
an	O
aniridia	B-Modifier
mutation	O
linked	O
to	O
markers	O
in	O
the	O
11p13	O
region	O
.	O

2703233	O
Myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
muscle-type	O
creatine	O
kinase	O
(CKMM).	O
We	O
have	O
studied	O
genetic	O
linkage	O
between	O
the	O
gene	O
for	O
creatine	O
kinase	O
muscle	O
type	O
(	O
CKMM	O
)	O
and	O
the	O
gene	O
for	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease
(	O
DM	B-SpecificDisease
)	O
.	O
In	O
a	O
panel	O
of	O
65	O
myotonic	B-Modifier
dystrophy	I-Modifier
families	O
from	O
Canada	O
and	O
the	O
Netherlands	O
,	O
a	O
maximum	O
lod	O
score	O
(	O
Zmax	O
)	O
of	O
22	O
.	O
8	O
at	O
a	O
recombination	O
frequency	O
(	O
theta	O
)	O
of	O
0	O
.	O
03	O
was	O
obtained	O
.	O
Tight	O
linkage	O
was	O
also	O
demonstrated	O
for	O
CKMM	O
and	O
the	O
gene	O
for	O
apolipoprotein	O
C2	O
(	O
ApoC2	O
)	O
.	O
This	O
establishes	O
CKMM	O
as	O
a	O
useful	O
marker	O
for	O
myotonic	B-SpecificDisease
dystrophy	I-SpecificDisease

10429004	O
Relationship	O
among	O
genotype,	O
biochemical	O
phenotype,	O
and	O
cognitive	O
performance	O
in	O
females	O
with	O
phenylalanine	B-SpecificDisease
hydroxylase	I-SpecificDisease
deficiency:	I-SpecificDisease
report	O
from	O
the	O
Maternal	B-Modifier
Phenylketonuria	I-Modifier
Collaborative	O
Study.	O
OBJECTIVE	O
To	O
examine	O
the	O
relationship	O
of	O
phenylalanine	O
hydroxylase	O
(	O
PAH	O
)	O
genotypes	O
to	O
biochemical	O
phenotype	O
and	O
cognitive	O
development	O
in	O
maternal	B-SpecificDisease
phenylketonuria	I-SpecificDisease
(	O
PKU	B-SpecificDisease
)	O
.	O
METHODOLOGY	O
PAH	O
gene	O
mutations	O
were	O
examined	O
in	O
222	O
hyperphenylalaninemic	B-Modifier
females	O
enrolled	O
in	O
the	O
Maternal	B-Modifier
PKU	I-Modifier
Collaborative	O
Study	O
(	O
MPKUCS	O
)	O
.	O
A	O
total	O
of	O
84	O
different	O
mutations	O
were	O
detected	O
,	O
and	O
complete	O
genotype	O
was	O
obtained	O
in	O
199	O
individuals	O
.	O
Based	O
on	O
previous	O
knowledge	O
about	O
mutation-phenotype	O
associations	O
,	O
78	O
of	O
the	O
mutations	O
could	O
be	O
assigned	O
to	O
one	O
of	O
four	O
classes	O
of	O
severity	O
(	O
severe	O
PKU	B-SpecificDisease
,	O
moderate	O
PKU	B-SpecificDisease
,	O
mild	O
PKU	B-SpecificDisease
,	O
and	O
mild	B-SpecificDisease
hyperphenylalaninemia	I-SpecificDisease
[	O
MHP	B-SpecificDisease
]	O
)	O
.	O
Then	O
,	O
189	O
MPKUCS	O
subjects	O
were	O
grouped	O
according	O
to	O
the	O
various	O
combinations	O
of	O
mutation	O
classifications	O
.	O
The	O
sample	O
sizes	O
were	O
large	O
enough	O
for	O
statistical	O
testing	O
in	O
four	O
groups	O
with	O
at	O
least	O
one	O
mutation	O
that	O
completely	O
abolishes	O
enzyme	O
activity	O
.	O
These	O
patients	O
are	O
considered	O
functionally	O
hemizygous	O
.	O
RESULTS	O
The	O
biochemical	O
phenotype	O
predicted	O
from	O
the	O
genotype	O
in	O
functionally	O
hemizygous	O
patients	O
was	O
related	O
significantly	O
to	O
the	O
assigned	O
phenylalanine	O
level	O
.	O
Cognitive	O
performance	O
(	O
IQ	O
)	O
was	O
also	O
significantly	O
related	O
to	O
genotype	O
.	O
The	O
IQ	O
of	O
PAH-deficient	B-Modifier
mothers	O
with	O
a	O
severe	O
PKU	B-Modifier
mutation	O
in	O
combination	O
with	O
a	O
MHP	B-Modifier
mutation	O
or	O
a	O
mild	O
PKU	B-Modifier
mutation	O
was	O
99	O
and	O
96	O
,	O
respectively	O
,	O
whereas	O
the	O
IQ	O
of	O
PKU	B-Modifier
mothers	O
with	O
two	O
severe	O
PKU	B-Modifier
mutations	O
or	O
with	O
one	O
severe	O
and	O
one	O
moderate	O
PKU	B-Modifier
mutation	O
was	O
83	O
and	O
84	O
,	O
respectively	O
.	O
Of	O
the	O
patients	O
with	O
PKU	B-SpecificDisease
,	O
92	O
%	O
had	O
been	O
treated	O
during	O
childhood	O
.	O
Those	O
who	O
were	O
untreated	O
or	O
treated	O
late	O
had	O
lower	O
than	O
average	O
IQ	O
scores	O
for	O
their	O
group	O
of	O
mutation	O
combinations	O
.	O
Females	O
with	O
moderate	O
or	O
mild	O
PKU	B-SpecificDisease
who	O
were	O
treated	O
early	O
and	O
treated	O
for	O
>	O
6	O
years	O
showed	O
IQ	O
scores	O
10	O
points	O
above	O
average	O
for	O
their	O
group	O
.	O
CONCLUSIONS	O
The	O
reproductive	O
outcome	O
in	O
maternal	B-SpecificDisease
phenylketonuria	I-SpecificDisease
is	O
dependent	O
on	O
prenatal	O
metabolic	O
control	O
and	O
postnatal	O
environmental	O
circumstances	O
.	O
Both	O
factors	O
depend	O
on	O
the	O
intellectual	O
resources	O
of	O
the	O
mother	O
with	O
PKU	B-SpecificDisease
.	O
The	O
significant	O
relationship	O
among	O
genotype	O
,	O
biochemical	O
phenotype	O
,	O
and	O
cognitive	O
performance	O
observed	O
in	O
the	O
present	O
study	O
is	O
of	O
importance	O
for	O
the	O
development	O
of	O
an	O
optimal	O
strategy	O
for	O
future	O
treatment	O
of	O
females	O
with	O
PKU	B-SpecificDisease
who	O
plan	O
pregnancy	O
.	O
.	O

1939657	O
Molecular	O
and	O
metabolic	O
basis	O
for	O
the	O
metabolic	B-DiseaseClass
disorder	I-DiseaseClass
normotriglyceridemic	B-SpecificDisease
abetalipoproteinemia.	I-SpecificDisease
We	O
have	O
previously	O
described	O
a	O
disorder	O
,	O
normotriglyceridemic	B-SpecificDisease
abetalipoproteinemia	I-SpecificDisease
,	O
that	O
is	O
characterized	O
by	O
the	O
virtual	O
absence	O
of	O
plasma	O
low	O
density	O
lipoproteins	O
and	O
complete	O
absence	O
of	O
apoB-100	O
,	O
but	O
with	O
apparently	O
normal	O
secretion	O
of	O
triglyceride-rich	O
lipoproteins	O
containing	O
apoB-48	O
.	O
The	O
patients	O
plasma	O
lipoproteins	O
were	O
shown	O
on	O
polyacrylamide	O
gels	O
and	O
by	O
antibody	O
mapping	O
to	O
have	O
a	O
new	O
truncated	O
apoB	O
variant	O
,	O
apoB-50	O
,	O
circulating	O
along	O
with	O
her	O
apoB-48	O
.	O
We	O
have	O
found	O
this	O
individual	O
to	O
be	O
homozygous	O
for	O
a	O
single	O
C-to-T	O
nucleotide	O
substitution	O
at	O
apoB	O
codon	O
2252	O
,	O
which	O
produces	O
a	O
premature	O
in-frame	O
stop	O
codon	O
.	O
Thus	O
,	O
this	O
is	O
a	O
rare	O
example	O
of	O
homozygous	B-SpecificDisease
hypobetalipoproteinemia	I-SpecificDisease
.	O
Electron	O
photomicrographs	O
revealed	O
that	O
the	O
diameters	O
of	O
particles	O
in	O
the	O
d	O
less	O
than	O
1	O
.	O
006	O
g	O
/	O
ml	O
lipoprotein	O
fraction	O
,	O
in	O
both	O
the	O
postprandial	O
and	O
postabsorptive	O
state	O
,	O
are	O
bimodally	O
distributed	O
.	O
The	O
molar	O
ratio	O
of	O
apoE	O
to	O
apoB	O
in	O
these	O
particles	O
is	O
3	O
.	O
5	O
1	O
,	O
similar	O
to	O
normal	O
VLDL	O
.	O
The	O
plasma	O
LDL	O
interval	O
contains	O
both	O
spherical	O
and	O
cuboidal	O
particles	O
.	O
Autologous	O
reinfusion	O
of	O
labeled	O
d	O
less	O
than	O
1	O
.	O
006	O
g	O
/	O
ml	O
lipoproteins	O
showed	O
exponential	O
disappearance	O
from	O
plasma	O
,	O
with	O
an	O
apparent	O
half-removal	O
time	O
of	O
50	O
min	O
,	O
somewhat	O
slower	O
than	O
for	O
normal	O
chylomicrons	O
but	O
within	O
the	O
normal	O
range	O
for	O
VLDL	O
.	O
The	O
calculated	O
production	O
rate	O
for	O
apoB	O
was	O
within	O
the	O
normal	O
range	O
in	O
this	O
subject	O
.	O

6783144	O
Human	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
sixth	I-SpecificDisease
component	I-SpecificDisease
of	I-SpecificDisease
complement	I-SpecificDisease
in	O
a	O
patient	O
with	O
meningococcal	B-SpecificDisease
meningitis	I-SpecificDisease
and	O
no	O
haemostasis	B-DiseaseClass
abnormality.	I-DiseaseClass
A	O
case	O
of	O
human	O
complete	O
C6	B-SpecificDisease
deficiency	I-SpecificDisease
is	O
reported	O
.	O
The	O
patient	O
,	O
a	O
31	O
year	O
old	O
white	O
male	O
,	O
was	O
seen	O
on	O
the	O
occasion	O
of	O
an	O
isolated	O
episode	O
of	O
meningococcal	B-SpecificDisease
meningitis	I-SpecificDisease
.	O
Serum	O
complement	O
hemolytic	O
and	O
bactericidal	O
activities	O
were	O
lacking	O
and	O
could	O
be	O
restored	O
to	O
normal	O
by	O
addition	O
of	O
appropriate	O
amounts	O
of	O
purified	O
C6	O
.	O
No	O
hemostatic	B-DiseaseClass
abnormalities	I-DiseaseClass
were	O
observed	O
.	O
.	O

1338764	O
Screening	O
for	O
germ-line	O
mutations	O
in	O
familial	B-Modifier
adenomatous	I-Modifier
polyposis	I-Modifier
patients:	O
61	O
new	O
patients	O
and	O
a	O
summary	O
of	O
150	O
unrelated	O
patients.	O
We	O
report	O
here	O
the	O
result	O
of	O
a	O
screening	O
for	O
germ-line	O
mutations	O
in	O
the	O
adenomatous	B-Modifier
polyposis	I-Modifier
coli	I-Modifier
(	O
APC	B-Modifier
)	O
gene	O
in	O
61	O
new	O
familial	B-Modifier
adenomatous	I-Modifier
polyposis	I-Modifier
(	O
FAP	B-Modifier
)	O
patients	O
as	O
well	O
as	O
a	O
summary	O
of	O
the	O
results	O
of	O
150	O
patients	O
.	O
Examination	O
of	O
the	O
entire	O
coding	O
region	O
of	O
the	O
APC	B-Modifier
gene	O
,	O
based	O
on	O
a	O
ribonuclease	O
protection	O
assay	O
coupled	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
disclosed	O
mutations	O
that	O
were	O
considered	O
to	O
cause	O
significant	O
defects	O
in	O
the	O
APC	B-Modifier
product	O
in	O
97	O
of	O
150	O
unrelated	O
FAP	B-Modifier
patients	O
.	O
Our	O
findings	O
revealed	O
the	O
following	O
characteristics	O
of	O
the	O
germ-line	O
mutations	O
of	O
APC	O
1	O
)	O
the	O
great	O
majority	O
of	O
the	O
mutations	O
were	O
found	O
to	O
truncate	O
the	O
APC	B-Modifier
product	O
;	O
2	O
)	O
almost	O
all	O
of	O
the	O
mutations	O
were	O
located	O
within	O
the	O
first	O
half	O
of	O
the	O
coding	O
region	O
;	O
3	O
)	O
no	O
correlation	O
was	O
observed	O
between	O
the	O
locations	O
of	O
germ-line	O
mutations	O
and	O
extracolonic	O
manifestations	O
in	O
FAP	B-Modifier
patients	O
;	O
4	O
)	O
more	O
than	O
80	O
%	O
of	O
base	O
substitutions	O
in	O
the	O
APC	B-Modifier
gene	O
were	O
from	O
cytosine	O
to	O
other	O
nucleotides	O
,	O
nearly	O
one-third	O
of	O
which	O
occurred	O
at	O
the	O
GpG	O
site	O
.	O
Our	O
results	O
provide	O
information	O
helpful	O
to	O
an	O
understanding	O
of	O
the	O
APC	B-Modifier
gene	O
and	O
will	O
also	O
contribute	O
to	O
presymptomatic	O
diagnosis	O
of	O
members	O
in	O
FAP	B-Modifier
families	O
.	O
.	O

1302003	O
Aberrant	O
splicing	O
of	O
the	O
CHM	B-Modifier
gene	O
is	O
a	O
significant	O
cause	O
of	O
choroideremia.	B-SpecificDisease
Choroideremia	B-SpecificDisease
(	O
CHM	B-SpecificDisease
)	O
is	O
an	O
X-linked	B-DiseaseClass
progressive	I-DiseaseClass
degeneration	I-DiseaseClass
of	I-DiseaseClass
the	I-DiseaseClass
choroid	I-DiseaseClass
and	I-DiseaseClass
retina	I-DiseaseClass
.	O
12	O
%	O
of	O
unrelated	O
male	O
patients	O
carry	O
deletions	O
of	O
the	O
partially	O
cloned	O
CHM	B-Modifier
gene	O
.	O
In	O
Finland	O
,	O
there	O
are	O
more	O
than	O
120	O
living	O
CHM	B-Modifier
patients	O
belonging	O
to	O
eight	O
apparently	O
unrelated	O
pedigrees	O
.	O
Molecular	O
deletions	O
involving	O
the	O
CHM	B-Modifier
gene	O
have	O
been	O
detected	O
in	O
three	O
families	O
.	O
We	O
have	O
screened	O
the	O
remaining	O
five	O
families	O
for	O
point	O
mutations	O
.	O
In	O
one	O
large	O
family	O
a	O
single	O
nucleotide	O
(	O
T	O
)	O
insertion	O
into	O
the	O
donor	O
splice	O
site	O
of	O
exon	O
C	O
leads	O
to	O
two	O
aberrantly	O
spliced	O
mRNAs	O
both	O
producing	O
a	O
premature	O
stop	O
codon	O
.	O
The	O
mutation	O
can	O
be	O
assayed	O
easily	O
by	O
amplification	O
and	O
digestion	O
with	O
Msel	O
.	O
Our	O
findings	O
provide	O
additional	O
evidence	O
for	O
the	O
pathogenetic	O
role	O
of	O
CHM	B-Modifier
mutations	O
and	O
provide	O
a	O
diagnostic	O
tool	O
for	O
one	O
fifth	O
of	O
the	O
worlds	O
known	O
CHM	B-Modifier
patients	O
.	O
.	O

1325652	O
Yeast	O
artificial	O
chromosomes	O
for	O
the	O
molecular	O
analysis	O
of	O
the	O
familial	B-Modifier
polyposis	I-Modifier
APC	I-Modifier
gene	O
region.	O
Two	O
yeast	O
artificial	O
chromosomes	O
(	O
YACs	O
)	O
spanning	O
a	O
total	O
distance	O
of	O
1	O
.	O
1	O
megabase	O
pairs	O
of	O
DNA	O
around	O
the	O
MCC	O
(	O
for	O
mutated	O
in	O
colorectal	B-SpecificDisease
carcinoma	I-SpecificDisease
)	O
and	O
APC	B-Modifier
(	O
for	O
adenomatous	B-Modifier
polyposis	I-Modifier
coli	I-Modifier
)	O
genes	O
at	O
5q21	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O
Starting	O
from	O
the	O
MCC	O
gene	O
,	O
a	O
strategy	O
was	O
undertaken	O
to	O
identify	O
constitutional	O
submicroscopic	O
deletions	O
in	O
familial	B-Modifier
adenomatous	I-Modifier
polyposis	I-Modifier
patients	O
that	O
might	O
considerably	O
narrow	O
down	O
the	O
position	O
of	O
the	O
APC	B-Modifier
gene	O
.	O
To	O
this	O
end	O
,	O
YACs	O
identified	O
by	O
the	O
MCC	O
gene	O
were	O
screened	O
across	O
a	O
chromosome	O
5-specific	O
cosmid	O
library	O
to	O
provide	O
a	O
source	O
of	O
DNA	O
probes	O
for	O
genomic	O
scanning	O
.	O
The	O
cosmids	O
isolated	O
from	O
these	O
experiments	O
were	O
used	O
to	O
screen	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
containing	O
chromosome	O
5	O
segregated	O
from	O
patients	O
suspected	O
to	O
carry	O
putative	O
interstitial	O
deletions	O
.	O
This	O
screening	O
approach	O
led	O
to	O
the	O
confirmation	O
of	O
a	O
small	O
heterozygous	O
deletion	O
in	O
a	O
polyposis	B-Modifier
patient	O
that	O
overlaps	O
one	O
of	O
the	O
two	O
isolated	O
YACs	O
.	O
This	O
YAC	O
has	O
been	O
shown	O
to	O
contain	O
the	O
entire	O
APC	B-Modifier
gene	O
,	O
in	O
addition	O
to	O
a	O
significant	O
portion	O
of	O
DNA	O
flanking	O
the	O
5	O
end	O
of	O
the	O
gene	O
,	O
and	O
should	O
therefore	O
prove	O
a	O
valuable	O
resource	O
for	O
functional	O
studies	O
by	O
transfer	O
to	O
colorectal	B-Modifier
tumor-derived	I-Modifier
cell	O
lines	O
.	O

1978564	O
Genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
DNA	O
markers	O
around	O
the	O
gene	O
for	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
on	O
chromosome	O
5.	O
A	O
genetic	O
linkage	O
map	O
of	O
six	O
polymorphic	O
DNA	O
markers	O
close	O
to	O
the	O
gene	O
(	O
APC	O
)	O
for	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
(	O
FAP	B-SpecificDisease
)	O
on	O
chromosome	O
5q	O
is	O
reported	O
.	O
One	O
hundred	O
fifty-five	O
typed	O
members	O
of	O
nine	O
FAP	B-Modifier
kindred	O
provided	O
more	O
than	O
90	O
meioses	O
for	O
linkage	O
analysis	O
.	O
A	O
number	O
of	O
crucial	O
recombination	O
events	O
have	O
been	O
identified	O
which	O
are	O
informative	O
at	O
three	O
or	O
more	O
loci	O
,	O
allowing	O
confident	O
ordering	O
of	O
parts	O
of	O
the	O
map	O
.	O
There	O
was	O
no	O
evidence	O
of	O
genetic	O
heterogeneity	O
,	O
with	O
all	O
families	O
showing	O
linkage	O
of	O
at	O
least	O
one	O
chromosome	O
5	O
marker	O
to	O
the	O
gene	O
.	O
Recombination	O
data	O
and	O
two-point	O
linkage	O
analysis	O
support	O
a	O
locus	O
order	O
of	O
centromere-pi	O
227-C11P11-ECB27-L5	O
.	O
62-APC-EF5	O
62-APC-EF5	O
.	O
44-YN5	O
44-YN5	O
.	O
48-telomer	O
e	O
,	O
although	O
EF5	O
.	O
44	O
could	O
lie	O
in	O
the	O
interval	O
L5	O
.	O
62-APC	O
or	O
ECB27-L5	O
.	O
62	O
.	O
No	O
recombinants	O
were	O
identified	O
between	O
APC	O
and	O
either	O
EF5	O
.	O
44	O
or	O
YN5	O
.	O
48	O
,	O
but	O
published	O
deletion	O
mapping	O
in	O
colorectal	B-SpecificDisease
carcinomas	I-SpecificDisease
and	O
linkage	O
analysis	O
in	O
FAP	B-SpecificDisease
suggest	O
that	O
YN5	O
.	O
48	O
is	O
1-3	O
cM	O
from	O
APC	O
.	O
The	O
present	O
study	O
suggests	O
that	O
YN5	O
.	O
48	O
and	O
L5	O
.	O
62	O
delineate	O
a	O
small	O
region	O
of	O
chromosome	O
5	O
within	O
which	O
the	O
EF5	O
.	O
44	O
locus	O
lies	O
very	O
close	O
to	O
the	O
APC	B-Modifier
gene	O
.	O
These	O
data	O
not	O
only	O
allow	O
use	O
of	O
flanking	O
markers	O
for	O
presymptomatic	O
diagnosis	O
of	O
FAP	B-SpecificDisease
but	O
also	O
provide	O
a	O
high-density	O
map	O
of	O
the	O
region	O
for	O
isolation	O
of	O
the	O
APC	B-Modifier
gene	O
itself	O
and	O
for	O
further	O
assessment	O
of	O
the	O
role	O
of	O
chromosome	O
5	O
deletions	O
in	O
the	O
biology	O
of	O
sporadic	O
colorectal	B-SpecificDisease
cancer	I-SpecificDisease
.	O

3346017	O
Germinal	B-DiseaseClass
mosaicism	I-DiseaseClass
in	O
Duchenne	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy.	I-SpecificDisease
We	O
have	O
identified	O
a	O
Duchenne	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
(	O
DMD	B-Modifier
)	O
pedigree	O
where	O
the	O
disease	O
is	O
associated	O
with	O
a	O
molecular	O
deletion	O
within	O
the	O
DMD	B-Modifier
locus	O
.	O
We	O
have	O
examined	O
the	O
meiotic	O
segregation	O
products	O
of	O
the	O
common	O
female	O
ancestor	O
using	O
marker	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
detected	O
by	O
probes	O
that	O
lie	O
within	O
this	O
deletion	O
.	O
These	O
studies	O
show	O
that	O
this	O
female	O
has	O
transmitted	O
three	O
distinct	O
types	O
of	O
X	O
chromosome	O
to	O
her	O
offspring	O
.	O
This	O
observation	O
may	O
be	O
explained	O
by	O
postulating	O
that	O
the	O
mutation	O
arose	O
as	O
a	O
postzygotic	O
deletion	O
within	O
this	O
common	O
ancestor	O
,	O
who	O
was	O
consequently	O
germinally	O
mosaic	O
.	O
.	O

10839544	O
Functional	O
link	O
between	O
ataxia-telangiectasia	B-Modifier
and	O
Nijmegen	B-Modifier
breakage	I-Modifier
syndrome	I-Modifier
gene	O
products.	O
Ataxia-telangiectasia	B-SpecificDisease
(	O
A-T	B-SpecificDisease
)	O
and	O
Nijmegen	B-SpecificDisease
breakage	I-SpecificDisease
syndrome	I-SpecificDisease
(	O
NBS	B-SpecificDisease
)	O
are	O
recessive	B-DiseaseClass
genetic	I-DiseaseClass
disorders	I-DiseaseClass
with	O
susceptibility	O
to	O
cancer	B-DiseaseClass
and	O
similar	O
cellular	O
phenotypes	O
.	O
The	O
protein	O
product	O
of	O
the	O
gene	O
responsible	O
for	O
A-T	B-SpecificDisease
,	O
designated	O
ATM	O
,	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
kinases	O
characterized	O
by	O
a	O
carboxy-terminal	O
phosphatidylinositol	O
3-kinase-like	O
domain	O
.	O
The	O
NBS1	O
protein	O
is	O
specifically	O
mutated	O
in	O
patients	O
with	O
Nijmegen	B-SpecificDisease
breakage	I-SpecificDisease
syndrome	I-SpecificDisease
and	O
forms	O
a	O
complex	O
with	O
the	O
DNA	O
repair	O
proteins	O
Rad50	O
and	O
Mrel1	O
.	O
Here	O
we	O
show	O
that	O
phosphorylation	O
of	O
NBS1	O
,	O
induced	O
by	O
ionizing	O
radiation	O
,	O
requires	O
catalytically	O
active	O
ATM	O
.	O
Complexes	O
containing	O
ATM	O
and	O
NBS1	O
exist	O
in	O
vivo	O
in	O
both	O
untreated	O
cells	O
and	O
cells	O
treated	O
with	O
ionizing	O
radiation	O
.	O
We	O
have	O
identified	O
two	O
residues	O
of	O
NBS1	O
,	O
Ser	O
278	O
and	O
Ser	O
343	O
that	O
are	O
phosphorylated	O
in	O
vitro	O
by	O
ATM	O
and	O
whose	O
modification	O
in	O
vivo	O
is	O
essential	O
for	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
.	O
This	O
response	O
includes	O
S-phase	O
checkpoint	O
activation	O
,	O
formation	O
of	O
the	O
NBS1	O
/	O
Mrel1	O
/	O
Rad50	O
nuclear	O
foci	O
and	O
rescue	O
of	O
hypersensitivity	B-DiseaseClass
to	I-DiseaseClass
ionizing	I-DiseaseClass
radiation	I-DiseaseClass
.	O
Together	O
,	O
these	O
results	O
demonstrate	O
a	O
biochemical	O
link	O
between	O
cell-cycle	O
checkpoints	O
activated	O
by	O
DNA	O
damage	O
and	O
DNA	O
repair	O
in	O
two	O
genetic	B-DiseaseClass
diseases	I-DiseaseClass
with	O
overlapping	O
phenotypes	O
.	O
.	O

1279971	O
Deletion	O
of	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
in	O
a	O
patient	O
with	O
piebaldism.	B-SpecificDisease
We	O
have	O
previously	O
shown	O
that	O
human	O
piebaldism	B-SpecificDisease
results	O
from	O
mutations	O
of	O
the	O
KIT	O
gene	O
,	O
which	O
encodes	O
the	O
receptor	O
for	O
the	O
mast	O
/	O
stem	O
cell	O
growth	O
factor	O
and	O
is	O
located	O
in	O
chromosome	O
segment	O
4q12	O
.	O
Using	O
DNA	O
of	O
a	O
patient	O
with	O
piebaldism	B-SpecificDisease
,	O
mental	B-DiseaseClass
retardation	I-DiseaseClass
,	O
and	O
multiple	B-DiseaseClass
congenital	I-DiseaseClass
anomalies	I-DiseaseClass
associated	O
with	O
a	O
46	O
,	O
XY	O
,	O
del	O
(	O
4	O
)	O
(	O
q12q21	O
.	O
1	O
)	O
karyotype	O
,	O
we	O
carried	O
out	O
quantitative	O
Southern	O
blot	O
hybridization	O
analyses	O
of	O
the	O
KIT	O
gene	O
and	O
the	O
adjacent	O
PDGFRA	O
(	O
platelet-derived	O
growth	O
factor	O
receptor	O
alpha	O
subunit	O
)	O
genes	O
.	O
The	O
patient	O
was	O
hemizygous	O
for	O
both	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
,	O
indicating	O
that	O
both	O
of	O
these	O
genes	O
are	O
included	O
within	O
the	O
deleted	O
region	O
.	O
Therefore	O
,	O
deletion	O
of	O
the	O
KIT	O
and	O
PDGFRA	O
genes	O
may	O
account	O
for	O
the	O
piebald	B-Modifier
phenotype	O
in	O
this	O
patient	O
.	O

1324223	O
Eight	O
novel	O
inactivating	O
germ	O
line	O
mutations	O
at	O
the	O
APC	B-Modifier
gene	O
identified	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis.	O
Familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
(	O
FAP	B-SpecificDisease
)	O
is	O
a	O
dominantly	O
inherited	O
condition	O
predisposing	O
to	O
colorectal	B-SpecificDisease
cancer	I-SpecificDisease
.	O
The	O
recent	O
isolation	O
of	O
the	O
responsible	O
gene	O
(	O
adenomatous	B-SpecificDisease
polyposis	I-SpecificDisease
coli	I-SpecificDisease
or	O
APC	B-SpecificDisease
)	O
has	O
facilitated	O
the	O
search	O
for	O
germ	O
line	O
mutations	O
in	O
affected	O
individuals	O
.	O
Previous	O
authors	O
have	O
used	O
the	O
RNase	O
protection	O
assay	O
and	O
the	O
single-strand	O
conformation	O
polymorphisms	O
procedure	O
to	O
screen	O
for	O
mutations	O
.	O
In	O
this	O
study	O
we	O
used	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
.	O
DGGE	O
analysis	O
of	O
10	O
APC	B-Modifier
exons	O
(	O
4	O
,	O
5	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
12	O
,	O
13	O
,	O
14	O
,	O
and	O
part	O
of	O
15	O
)	O
in	O
33	O
unrelated	O
Dutch	O
FAP	B-Modifier
patients	O
has	O
led	O
to	O
the	O
identification	O
of	O
eight	O
novel	O
germ	O
line	O
mutations	O
resulting	O
in	O
stop	O
codons	O
or	O
frameshifts	O
.	O
The	O
results	O
reported	O
here	O
indicate	O
that	O
(	O
1	O
)	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
is	O
caused	O
by	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
point	O
mutations	O
;	O
(	O
2	O
)	O
all	O
the	O
mutations	O
found	O
in	O
this	O
study	O
are	O
chain	O
terminating	O
;	O
and	O
(	O
3	O
)	O
DGGE	O
represents	O
a	O
rapid	O
and	O
sensitive	O
technique	O
for	O
the	O
detection	O
of	O
mutations	O
in	O
the	O
unusually	O
large	O
APC	B-Modifier
gene	O
.	O
An	O
extension	O
of	O
the	O
DGGE	O
analysis	O
to	O
the	O
entire	O
coding	O
region	O
in	O
a	O
sufficient	O
number	O
of	O
clinically	O
well-characterized	O
,	O
unrelated	O
patients	O
will	O
facilitate	O
the	O
establishment	O
of	O
genotype-phenotype	O
correlations	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
occurrence	O
of	O
an	O
extremely	O
heterogeneous	O
spectrum	O
of	O
mutations	O
spread	O
throughout	O
the	O
entire	O
length	O
of	O
the	O
large	O
APC	B-Modifier
gene	O
among	O
the	O
FAP	B-Modifier
patients	O
indicates	O
that	O
this	O
approach	O
may	O
not	O
be	O
useful	O
as	O
a	O
rapid	O
presymptomatic	O
diagnostic	O
procedure	O
in	O
a	O
routine	O
laboratory	O
.	O
Nevertheless	O
,	O
the	O
above	O
DGGE	O
approach	O
has	O
incidentally	O
led	O
to	O
the	O
identification	O
of	O
a	O
common	O
polymorphism	O
in	O
exon	O
13	O
.	O
Such	O
intragenic	O
polymorphisms	O
offer	O
a	O
practical	O
approach	O
to	O
a	O
more	O
rapid	O
procedure	O
for	O
presymptomatic	O
diagnosis	O
of	O
FAP	B-SpecificDisease
by	O
linkage	O
analysis	O
in	O
informative	O
families	O
.	O
.	O

10330430	O
Alpha-cardiac	O
actin	O
is	O
a	O
novel	O
disease	O
gene	O
in	O
familial	B-SpecificDisease
hypertrophic	I-SpecificDisease
cardiomyopathy.	I-SpecificDisease
We	O
identified	O
the	O
alpha-cardiac	O
actin	O
gene	O
(	O
ACTC	O
)	O
as	O
a	O
novel	O
disease	O
gene	O
in	O
a	O
pedigree	O
suffering	O
from	O
familial	B-SpecificDisease
hypertrophic	I-SpecificDisease
cardiomyopathy	I-SpecificDisease
(	O
FHC	B-SpecificDisease
)	O
.	O
Linkage	O
analyses	O
excluded	O
all	O
the	O
previously	O
reported	O
FHC	B-Modifier
loci	O
as	O
possible	O
disease	O
loci	O
in	O
the	O
family	O
studied	O
,	O
with	O
lod	O
scores	O
varying	O
between	O
-2	O
.	O
5	O
and	O
-6	O
.	O
0	O
0	O
.	O
Further	O
linkage	O
analyses	O
of	O
plausible	O
candidate	O
genes	O
highly	O
expressed	O
in	O
the	O
adult	O
human	O
heart	O
identified	O
ACTC	O
as	O
the	O
most	O
likely	O
disease	O
gene	O
,	O
showing	O
a	O
maximal	O
lod	O
score	O
of	O
3	O
.	O
6	O
6	O
.	O
Mutation	O
analysis	O
of	O
ACTC	O
revealed	O
an	O
Ala295Ser	O
mutation	O
in	O
exon	O
5	O
close	O
to	O
2	O
missense	O
mutations	O
recently	O
described	O
to	O
cause	O
the	O
inherited	O
form	O
of	O
idiopathic	B-SpecificDisease
dilated	I-SpecificDisease
cardiomyopathy	I-SpecificDisease
(	O
IDC	B-SpecificDisease
)	O
.	O

8531967	O
BRCA1	O
mutations	O
in	O
a	O
population-based	O
sample	O
of	O
young	O
women	O
with	O
breast	B-SpecificDisease
cancer.	I-SpecificDisease
BACKGROUND	O
.	O
Inherited	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
are	O
associated	O
with	O
a	O
high	O
risk	O
of	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
in	O
some	O
families	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
contribution	O
of	O
BRCA1	O
mutations	O
to	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
in	O
the	O
general	O
population	O
.	O
We	O
analyzed	O
DNA	O
samples	O
from	O
women	O
enrolled	O
in	O
a	O
population-based	O
study	O
of	O
early-onset	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
to	O
assess	O
the	O
spectrum	O
and	O
frequency	O
of	O
germ-line	O
BRCA1	O
mutations	O
in	O
young	O
women	O
with	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
.	O
METHODS	O
.	O
We	O
studied	O
80	O
women	O
in	O
whom	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
was	O
diagnosed	O
before	O
the	O
age	O
of	O
35	O
,	O
and	O
who	O
were	O
not	O
selected	O
on	O
the	O
basis	O
of	O
family	O
history	O
.	O
Genomic	O
DNA	O
was	O
studied	O
for	O
BRCA1	O
mutations	O
by	O
analysis	O
involving	O
single-strand	O
conformation	O
polymorphisms	O
and	O
with	O
allele-specific	O
assays	O
.	O
Alterations	O
were	O
defined	O
by	O
DNA	O
sequencing	O
.	O
RESULTS	O
.	O
Germ-line	O
BRCA1	O
mutations	O
were	O
identified	O
in	O
6	O
of	O
the	O
80	O
women	O
.	O
Four	O
additional	O
rare	O
sequence	O
variants	O
of	O
unknown	O
functional	O
importance	O
were	O
also	O
identified	O
.	O
Two	O
of	O
the	O
mutations	O
and	O
three	O
of	O
the	O
rare	O
sequence	O
variants	O
were	O
found	O
among	O
the	O
39	O
women	O
who	O
reported	O
no	O
family	O
history	O
of	O
breast	B-CompositeMention
or	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
.	O
None	O
of	O
the	O
mutations	O
and	O
only	O
one	O
of	O
the	O
rare	O
variants	O
was	O
identified	O
in	O
a	O
reference	O
population	O
of	O
73	O
unrelated	O
subjects	O
.	O
CONCLUSIONS	O
.	O
Alterations	O
in	O
BRCA1	O
were	O
identified	O
in	O
approximately	O
10	O
percent	O
of	O
this	O
cohort	O
of	O
young	O
women	O
with	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
.	O
The	O
risk	O
of	O
harboring	O
a	O
mutation	O
was	O
not	O
limited	O
to	O
women	O
with	O
family	O
histories	O
of	O
breast	B-CompositeMention
or	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
.	O
These	O
results	O
represent	O
a	O
minimal	O
estimate	O
of	O
the	O
frequency	O
of	O
BRCA1	O
mutations	O
in	O
this	O
population	O
.	O
Comprehensive	O
methods	O
of	O
identifying	O
BRCA1	O
mutations	O
and	O
understanding	O
their	O
importance	O
will	O
be	O
needed	O
before	O
testing	O
of	O
women	O
in	O
the	O
general	O
population	O
can	O
be	O
undertaken	O
.	O
.	O

10790204	O
Molecular	O
basis	O
of	O
very	B-SpecificDisease
long	I-SpecificDisease
chain	I-SpecificDisease
acyl-CoA	I-SpecificDisease
dehydrogenase	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
three	O
Israeli	O
patients:	O
identification	O
of	O
a	O
complex	O
mutant	O
allele	O
with	O
P65L	O
and	O
K247Q	O
mutations,	O
the	O
former	O
being	O
an	O
exonic	O
mutation	O
causing	O
exon	O
3	O
skipping.	O
Very	B-SpecificDisease
long	I-SpecificDisease
chain	I-SpecificDisease
acyl-CoA	I-SpecificDisease
dehydrogenase	I-SpecificDisease
(	I-SpecificDisease
VLCAD	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
is	O
a	O
life-threatening	O
disorder	O
of	O
mitochondrial	O
fatty	O
acid	O
beta-oxidation	O
.	O
We	O
identified	O
four	O
novel	O
mutations	O
in	O
three	O
unrelated	O
patients	O
.	O
All	O
patients	O
had	O
the	O
severe	O
childhood	O
form	O
of	O
VLCAD	B-SpecificDisease
deficiency	I-SpecificDisease
with	O
early	O
onset	O
and	O
high	O
mortality	O
.	O
Immunoblot	O
analysis	O
revealed	O
that	O
VLCAD	O
protein	O
was	O
undetectable	O
in	O
patients	O
2	O
and	O
3	O
,	O
whereas	O
normal-size	O
VLCAD	O
protein	O
and	O
an	O
aberrant	O
form	O
of	O
VLCAD	O
(	O
4kDa	O
smaller	O
)	O
were	O
detected	O
in	O
patient	O
1	O
.	O
As	O
expected	O
,	O
null	O
mutations	O
were	O
found	O
in	O
patients	O
2	O
and	O
3	O
patient	O
2	O
is	O
homozygous	O
for	O
a	O
frameshift	O
mutation	O
,	O
del	O
4	O
bp	O
at	O
798-801	O
,	O
and	O
patient	O
3	O
is	O
homozygous	O
for	O
a	O
nonsense	O
mutation	O
65C	O
>	O
A	O
(	O
S22X	O
)	O
.	O
Patient	O
1	O
was	O
homozygous	O
for	O
a	O
complex	O
mutant	O
allele	O
containing	O
two	O
alterations	O
,	O
including	O
a	O
194C	O
>	O
T	O
transition	O
(	O
P65L	O
)	O
and	O
739A	O
>	O
C	O
transversion	O
(	O
K247Q	O
)	O
;	O
in	O
the	O
case	O
of	O
P65L	O
,	O
the	O
amino	O
acid	O
change	O
does	O
not	O
reduce	O
enzyme	O
activity	O
.	O
However	O
,	O
the	O
nucleotide	O
change	O
resulted	O
in	O
exon	O
3	O
skipping	O
,	O
whereas	O
the	O
latter	O
K247Q	O
mutation	O
had	O
a	O
drastic	O
effect	O
on	O
enzyme	O
activity	O
.	O
We	O
verified	O
these	O
events	O
by	O
in	O
vivo	O
splicing	O
experiments	O
and	O
transient	O
expression	O
analysis	O
of	O
mutant	O
cDNAs	O
.	O
The	O
P65L	O
mutation	O
locates	O
11	O
bases	O
upstream	O
of	O
a	O
splice	O
donor	O
site	O
of	O
intron	O
3	O
.	O
This	O
is	O
an	O
example	O
of	O
an	O
exonic	O
mutation	O
which	O
affects	O
exon-splicing	O
.	O
.	O

8259519	O
Association	O
of	O
the	O
APC	B-Modifier
tumor	I-Modifier
suppressor	O
protein	O
with	O
catenins.	O
Mutations	O
of	O
APC	O
appear	O
to	O
initiate	O
sporadic	O
and	O
inherited	O
forms	O
of	O
human	O
colorectal	B-SpecificDisease
cancer	I-SpecificDisease
.	O
Although	O
these	O
mutations	O
have	O
been	O
well	O
characterized	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
the	O
APC	B-Modifier
gene	O
product	O
.	O
Two	O
cellular	O
proteins	O
that	O
associate	O
with	O
APC	B-SpecificDisease
were	O
identified	O
by	O
nucleotide	O
sequence	O
analysis	O
and	O
peptide	O
mapping	O
as	O
the	O
E-cadherin-associated	O
proteins	O
alpha-	O
and	O
beta-catenin	O
.	O
A	O
27-residue	O
fragment	O
of	O
APC	O
containing	O
a	O
15-amino	O
acid	O
repeat	O
was	O
sufficient	O
for	O
the	O
interaction	O
with	O
the	O
catenins	O
.	O
These	O
results	O
suggest	O
an	O
important	O
link	O
between	O
tumor	B-Modifier
initiation	O
and	O
cell	O
adhesion	O
.	O
.	O

10618304	O
Cardiac	O
Na(+)	O
channel	O
dysfunction	O
in	O
Brugada	B-SpecificDisease
syndrome	I-SpecificDisease
is	O
aggravated	O
by	O
beta(1)-subunit.	O
BACKGROUND	O
Mutations	O
in	O
the	O
gene	O
encoding	O
the	O
human	O
cardiac	O
Na	O
(	O
+	O
)	O
channel	O
alpha-subunit	O
(	O
hH1	O
)	O
are	O
responsible	O
for	O
chromosome	O
3-linked	O
congenital	B-SpecificDisease
long-QT	I-SpecificDisease
syndrome	I-SpecificDisease
(	O
LQT3	B-SpecificDisease
)	O
and	O
idiopathic	B-SpecificDisease
ventricular	I-SpecificDisease
fibrillation	I-SpecificDisease
(	O
IVF	B-SpecificDisease
)	O
.	O
An	O
auxiliary	O
beta	O
(	O
1	O
)	O
-subunit	O
,	O
widely	O
expressed	O
in	O
excitable	O
tissues	O
,	O
shifts	O
the	O
voltage	O
dependence	O
of	O
steady-state	O
inactivation	O
toward	O
more	O
negative	O
potentials	O
and	O
restores	O
normal	O
gating	O
kinetics	O
of	O
brain	O
and	O
skeletal	O
muscle	O
Na	O
(	O
+	O
)	O
channels	O
expressed	O
in	O
Xenopus	O
oocytes	O
but	O
has	O
little	O
if	O
any	O
functional	O
effect	O
on	O
the	O
cardiac	O
isoform	O
.	O
Here	O
,	O
we	O
characterize	O
the	O
altered	O
effects	O
of	O
a	O
human	O
beta	O
(	O
1	O
)	O
-subunit	O
(	O
hbeta	O
(	O
1	O
)	O
)	O
on	O
the	O
heterologously	O
expressed	O
hH1	O
mutation	O
(	O
T1620M	O
)	O
previously	O
associated	O
with	O
IVF	B-SpecificDisease
.	O
METHODS	O
AND	O
RESULTS	O
When	O
expressed	O
alone	O
in	O
Xenopus	O
oocytes	O
,	O
T1620M	O
exhibited	O
no	O
persistent	O
currents	O
,	O
in	O
contrast	O
to	O
the	O
LQT3	B-Modifier
mutant	O
channels	O
,	O
but	O
the	O
midpoint	O
of	O
steady-state	O
inactivation	O
(	O
V	O
(	O
1	O
/	O
2	O
)	O
)	O
was	O
significantly	O
shifted	O
toward	O
more	O
positive	O
potentials	O
than	O
for	O
wild-type	O
hH1	O
.	O
Coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
did	O
not	O
significantly	O
alter	O
current	O
decay	O
or	O
recovery	O
from	O
inactivation	O
of	O
wild-type	O
hH1	O
;	O
however	O
,	O
it	O
further	O
shifted	O
the	O
V	O
(	O
1	O
/	O
2	O
)	O
and	O
accelerated	O
the	O
recovery	O
from	O
inactivation	O
of	O
T1620M	O
.	O
Oocyte	O
macropatch	O
analysis	O
revealed	O
that	O
the	O
activation	O
kinetics	O
of	O
T1620M	O
were	O
normal	O
.	O
CONCLUSIONS	O
It	O
is	O
suggested	O
that	O
coexpression	O
of	O
hbeta	O
(	O
1	O
)	O
exposes	O
a	O
more	O
severe	O
functional	O
defect	O
that	O
results	O
in	O
a	O
greater	O
overlap	O
in	O
the	O
relationship	O
between	O
channel	O
inactivation	O
and	O
activation	O
(	O
window	O
current	O
)	O
in	O
T1620M	O
,	O
which	O
is	O
proposed	O
to	O
be	O
a	O
potential	O
pathophysiological	O
mechanism	O
of	O
IVF	B-SpecificDisease
in	O
vivo	O
.	O
One	O
possible	O
explanation	O
for	O
our	O
finding	O
is	O
an	O
altered	O
alpha-	O
/	O
beta	O
(	O
1	O
)	O
-subunit	O
association	O
in	O
the	O
mutant	O
.	O
.	O

3377761	O
X-linked	B-SpecificDisease
glucose-6-phosphate	I-SpecificDisease
dehydrogenase	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
Mus	O
musculus.	O
A	O
mouse	O
with	O
X-linked	B-SpecificDisease
glucose-6-phosphate	I-SpecificDisease
dehydrogenase	I-SpecificDisease
(	I-SpecificDisease
G6PD	I-SpecificDisease
)	I-SpecificDisease
deficiency	I-SpecificDisease
has	O
been	O
recovered	O
in	O
offspring	O
of	O
1-ethyl-1-nitrosourea-treated	O
male	O
mice	O
.	O
The	O
activity	O
alteration	O
was	O
detected	O
in	O
blood	O
but	O
can	O
also	O
be	O
observed	O
in	O
other	O
tissue	O
extracts	O
.	O
Hemizygous	O
,	O
heterozygous	O
,	O
and	O
homozygous	O
mutants	O
have	O
,	O
respectively	O
,	O
about	O
15	O
,	O
60	O
,	O
and	O
15	O
%	O
G6PD	O
remaining	O
activity	O
in	O
the	O
blood	O
as	O
compared	O
to	O
the	O
wild	O
type	O
.	O
Erythrocyte	O
indices	O
did	O
not	O
show	O
differences	O
between	O
mutants	O
and	O
wild	O
types	O
.	O
The	O
mutation	O
does	O
not	O
affect	O
the	O
electrophoretic	O
migration	O
,	O
the	O
isoelectric	O
point	O
,	O
or	O
the	O
thermal	O
stability	O
.	O
Kinetic	O
properties	O
,	O
such	O
as	O
the	O
Km	O
for	O
glucose-6-phosphate	O
or	O
for	O
NADP	O
and	O
the	O
relative	O
utilization	O
of	O
substrate	O
analogues	O
,	O
showed	O
no	O
differences	O
between	O
wild	O
types	O
and	O
mutants	O
with	O
the	O
exception	O
of	O
the	O
relative	O
utilization	O
of	O
deamino-NADP	O
which	O
was	O
significantly	O
lower	O
in	O
mutants	O
.	O
This	O
is	O
presently	O
the	O
only	O
animal	O
model	O
for	O
X-linked	B-SpecificDisease
G6PD	I-SpecificDisease
deficiency	I-SpecificDisease
in	O
humans	O
.	O
.	O

7550349	O
The	O
carrier	O
frequency	O
of	O
the	O
BRCA1	O
185delAG	O
mutation	O
is	O
approximately	O
1	O
percent	O
in	O
Ashkenazi	O
Jewish	O
individuals.	O
Since	O
BRCA1	O
,	O
the	O
first	O
major	O
gene	O
responsible	O
for	O
inherited	B-SpecificDisease
breast	I-SpecificDisease
cancer	I-SpecificDisease
,	O
was	O
cloned	O
,	O
more	O
than	O
50	O
unique	O
mutations	O
have	O
been	O
detected	O
in	O
the	O
germline	O
of	O
individuals	O
with	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
.	O
In	O
high-risk	O
pedigrees	O
,	O
female	O
carriers	O
of	O
BRCA1	O
mutations	O
have	O
an	O
80-90	O
%	O
lifetime	O
risk	O
of	O
breast	B-SpecificDisease
cancer	I-SpecificDisease
,	O
and	O
a	O
40-50	O
%	O
risk	O
of	O
ovarian	B-SpecificDisease
cancer	I-SpecificDisease
.	O
However	O
,	O
the	O
mutation	O
stats	O
of	O
individuals	O
unselected	O
for	O
breast	B-CompositeMention
or	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
has	O
not	O
been	O
determined	O
,	O
and	O
it	O
is	O
not	O
known	O
whether	O
mutations	O
in	O
such	O
individuals	O
confer	O
the	O
same	O
risk	O
of	O
cancer	B-DiseaseClass
as	O
in	O
individuals	O
from	O
the	O
high-risk	O
families	O
studied	O
so	O
far	O
.	O
Following	O
the	O
finding	O
of	O
a	O
185delAG	O
frameshift	O
mutation	O
in	O
several	O
Ashkenazi	O
Jewish	O
breast	O
/	O
ovarian	O
families	O
,	O
we	O
have	O
determined	O
the	O
frequency	O
of	O
this	O
mutation	O
in	O
858	O
Ashkenazim	O
seeking	O
genetic	O
testing	O
for	O
conditions	O
unrelated	O
to	O
cancer	B-DiseaseClass
,	O
and	O
in	O
815	O
reference	O
individuals	O
not	O
selected	O
for	O
ethnic	O
origin	O
.	O
We	O
observed	O
the	O
185delAG	O
mutation	O
in	O
0	O
.	O
9	O
%	O
of	O
Ashkenazim	O
(	O
95	O
%	O
confidence	O
limit	O
,	O
0	O
.	O
4-1	O
.	O
8	O
%	O
)	O
and	O
in	O
none	O
of	O
the	O
reference	O
samples	O
.	O
Our	O
results	O
suggest	O
that	O
one	O
in	O
a	O
hundred	O
women	O
of	O
Ashkenazi	O
descent	O
may	O
be	O
at	O
especially	O
high	O
risk	O
of	O
developing	O
breast	B-CompositeMention
and	I-CompositeMention
/	I-CompositeMention
or	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
.	O

8589715	O
Emerin	B-SpecificDisease
deficiency	I-SpecificDisease
at	O
the	O
nuclear	O
membrane	O
in	O
patients	O
with	O
Emery-Dreifuss	B-SpecificDisease
muscular	I-SpecificDisease
dystrophy.	I-SpecificDisease
Mutations	O
in	O
the	O
STA	O
gene	O
at	O
the	O
Xq28	O
locus	O
have	O
been	O
found	O
in	O
patients	O
with	O
X-linked	B-SpecificDisease
Emery-Dreifuss	I-SpecificDisease
muscular	I-SpecificDisease
dystrophy	I-SpecificDisease
(	O
EDMD	B-SpecificDisease
)	O
.	O
This	O
gene	O
encodes	O
a	O
hitherto	O
unknown	O
protein	O
named	O
emerin	O
.	O
To	O
elucidate	O
the	O
subcellular	O
localization	O
of	O
emerin	O
,	O
we	O
raised	O
two	O
antisera	O
against	O
synthetic	O
peptide	O
fragments	O
predicted	O
from	O
emerin	O
cDNA	O
.	O
Using	O
both	O
antisera	O
,	O
we	O
found	O
positive	O
nuclear	O
membrane	O
staining	O
in	O
skeletal	O
,	O
cardiac	O
and	O
smooth	O
muscles	O
in	O
the	O
normal	O
controls	O
and	O
in	O
patients	O
with	O
neuromuscular	B-DiseaseClass
diseases	I-DiseaseClass
other	O
than	O
EDMD	B-SpecificDisease
.	O
In	O
contrast	O
,	O
a	O
deficiency	O
in	O
immunofluorescent	O
staining	O
of	O
skeletal	O
and	O
cardiac	O
muscle	O
from	O
EDMD	B-Modifier
patients	O
was	O
observed	O
.	O
A	O
34	O
kD	O
protein	O
is	O
immunoreactive	O
with	O
the	O
antisera--the	O
protein	O
is	O
equivalent	O
to	O
that	O
predicted	O
for	O
emerin	O
.	O
Together	O
,	O
our	O
findings	O
suggest	O
the	O
specific	O
deficiency	B-SpecificDisease
of	I-SpecificDisease
emerin	I-SpecificDisease
in	O
the	O
nuclear	O
membrane	O
of	O
muscle	O
cells	O
in	O
patients	O
with	O
EDMD	B-SpecificDisease
.	O
.	O

10470088	O
The	O
type	O
of	O
somatic	O
mutation	O
at	O
APC	O
in	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
is	O
determined	O
by	O
the	O
site	O
of	O
the	O
germline	O
mutation:	O
a	O
new	O
facet	O
to	O
Knudson"s	O
"two-hit"	O
hypothesis.	O
APC	O
is	O
often	O
cited	O
as	O
a	O
prime	O
example	O
of	O
a	O
tumor	B-Modifier
suppressor	O
gene	O
.	O
Truncating	O
germline	O
and	O
somatic	O
mutations	O
(	O
or	O
,	O
infrequently	O
,	O
allelic	O
loss	O
)	O
occur	O
in	O
tumors	B-DiseaseClass
in	O
FAP	B-SpecificDisease
(	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
)	O
.	O
Most	O
sporadic	B-SpecificDisease
colorectal	I-SpecificDisease
cancers	I-SpecificDisease
also	O
have	O
two	O
APC	B-Modifier
mutations	O
.	O
Clues	O
from	O
attenuated	B-Modifier
polyposis	I-Modifier
,	O
missense	O
germline	O
variants	O
with	O
mild	O
disease	O
and	O
the	O
somatic	O
mutation	O
cluster	O
region	O
(	O
codons	O
1	O
,	O
250-1	O
,	O
450	O
)	O
indicate	O
,	O
however	O
,	O
that	O
APC	B-Modifier
mutations	O
might	O
not	O
result	O
in	O
simple	O
loss	O
of	O
protein	O
function	O
.	O
We	O
have	O
found	O
that	O
FAP	B-Modifier
patients	O
with	O
germline	O
APC	B-Modifier
mutations	O
within	O
a	O
small	O
region	O
(	O
codons	O
1	O
,	O
194-1	O
,	O
392	O
at	O
most	O
)	O
mainly	O
show	O
allelic	O
loss	O
in	O
their	O
colorectal	B-SpecificDisease
adenomas	I-SpecificDisease
,	O
in	O
contrast	O
to	O
other	O
FAP	B-Modifier
patients	O
,	O
whose	O
second	O
hits	O
tend	O
to	O
occur	O
by	O
truncating	O
mutations	O
in	O
the	O
mutation	O
cluster	O
region	O
.	O
Our	O
results	O
indicate	O
that	O
different	O
APC	B-Modifier
mutations	O
provide	O
cells	O
with	O
different	O
selective	O
advantages	O
,	O
with	O
mutations	O
close	O
to	O
codon	O
1	O
,	O
300	O
providing	O
the	O
greatest	O
advantage	O
.	O
Allelic	O
loss	O
is	O
selected	O
strongly	O
in	O
cells	O
with	O
one	O
mutation	O
near	O
codon	O
1	O
,	O
300	O
.	O
A	O
different	O
germline-somatic	O
APC	B-Modifier
mutation	O
association	O
exists	O
in	O
FAP	B-SpecificDisease
desmoids	I-SpecificDisease
.	O
APC	O
is	O
not	O
,	O
therefore	O
,	O
a	O
classical	O
tumor	B-Modifier
suppressor	O
.	O
Our	O
findings	O
also	O
indicate	O
a	O
new	O
mechanism	O
for	O
disease	O
severity	O
if	O
a	O
broader	O
spectrum	O
of	O
mutations	O
is	O
selected	O
in	O
tumors	B-DiseaseClass
,	O
the	O
somatic	O
mutation	O
rate	O
is	O
effectively	O
higher	O
and	O
more	O
tumors	B-DiseaseClass
grow	O
.	O
.	O

10083734	O
Molecular	O
epidemiology	O
of	O
C9	B-Modifier
deficiency	I-Modifier
heterozygotes	O
with	O
an	O
Arg95Stop	O
mutation	O
of	O
the	O
C9	O
gene	O
in	O
Japan	O
.	O
Deficiency	B-SpecificDisease
of	I-SpecificDisease
the	I-SpecificDisease
ninth	I-SpecificDisease
component	I-SpecificDisease
of	I-SpecificDisease
human	I-SpecificDisease
complement	I-SpecificDisease
(	O
C9	O
)	O
is	O
the	O
most	O
common	O
complement	B-DiseaseClass
deficiency	I-DiseaseClass
in	O
Japan	O
,	O
with	O
an	O
incidence	O
of	O
approximately	O
one	O
homozygote	O
in	O
1000	O
,	O
but	O
is	O
very	O
rare	O
in	O
other	O
countries	O
.	O
Genetic	O
analyses	O
of	O
Japanese	O
C9	B-SpecificDisease
deficiency	I-SpecificDisease
have	O
shown	O
that	O
a	O
C-to-T	O
transition	O
leading	O
to	O
TGA	O
stop	O
codon	O
for	O
Arg95	O
in	O
exon	O
4	O
of	O
the	O
C9	O
gene	O
(	O
Arg95Stop	O
)	O
is	O
common	O
in	O
Japanese	O
C9	B-SpecificDisease
deficiency	I-SpecificDisease
.	O
To	O
determine	O
the	O
prevalence	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Arg95Stop	O
mutation	O
in	O
a	O
Japanese	O
population	O
,	O
we	O
collected	O
DNA	O
samples	O
from	O
300	O
individuals	O
in	O
two	O
of	O
the	O
four	O
main	O
islands	O
of	O
Japan	O
.	O
Heterozygote	O
detection	O
was	O
performed	O
with	O
an	O
allele-specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
system	O
designed	O
to	O
detect	O
exclusively	O
only	O
one	O
of	O
the	O
normal	O
and	O
mutant	O
alleles	O
,	O
followed	O
by	O
confirmation	O
with	O
PCR	O
/	O
single-strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
Twenty	O
individuals	O
were	O
heterozygous	O
for	O
the	O
Arg95Stop	O
mutation	O
.	O
None	O
was	O
homozygous	O
.	O
The	O
prevalence	O
of	O
carriers	O
of	O
the	O
Arg95Stop	O
mutation	O
was	O
6	O
.	O
7	O
%	O
(	O
20	O
/	O
300	O
)	O
.	O
An	O
estimated	O
frequency	O
(	O
0	O
.	O
12	O
%	O
)	O
of	O
complete	O
C9	B-SpecificDisease
deficiency	I-SpecificDisease
due	O
to	O
homozygous	O
Arg95Stop	O
mutation	O
was	O
consistent	O
with	O
frequencies	O
determined	O
by	O
serological	O
studies	O

7894493	O
Confirmation	O
of	O
BRCA1	O
by	O
analysis	O
of	O
germline	O
mutations	O
linked	O
to	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
in	O
ten	O
families.	O
We	O
provide	O
genetic	O
evidence	O
supporting	O
the	O
identity	O
of	O
the	O
candidate	O
gene	O
for	O
BRCA1	O
through	O
the	O
characterization	O
of	O
germline	O
mutations	O
in	O
63	O
breast	B-Modifier
cancer	I-Modifier
patients	O
and	O
10	O
ovarian	B-Modifier
cancer	I-Modifier
patients	O
in	O
ten	O
families	O
with	O
cancer	B-DiseaseClass
linked	O
to	O
chromosome	O
17q21	O
.	O
Nine	O
different	O
mutations	O
were	O
detected	O
by	O
screening	O
BRCA1	O
DNA	O
and	O
RNA	O
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
.	O
Seven	O
mutations	O
lead	O
to	O
protein	O
truncations	O
at	O
sites	O
throughout	O
the	O
gene	O
.	O
One	O
missense	O
mutation	O
(	O
which	O
occurred	O
independently	O
in	O
two	O
families	O
)	O
leads	O
to	O
loss	O
of	O
a	O
cysteine	O
in	O
the	O
zinc	O
binding	O
domain	O
.	O
An	O
intronic	O
single	O
basepair	O
substitution	O
destroys	O
an	O
acceptor	O
site	O
and	O
activates	O
a	O
cryptic	O
splice	O
site	O
,	O
leading	O
to	O
a	O
59	O
basepair	O
insertion	O
and	O
chain	O
termination	O
.	O
The	O
four	O
families	O
with	O
both	O
breast	B-CompositeMention
and	I-CompositeMention
ovarian	I-CompositeMention
cancer	I-CompositeMention
had	O
chain	O
termination	O
mutations	O
in	O
the	O
N-terminal	O
half	O
of	O
the	O
protein	O
.	O
.	O

1319059	O
A	O
71-kilodalton	O
protein	O
is	O
a	O
major	O
product	O
of	O
the	O
Duchenne	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
gene	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues.	O
The	O
known	O
Duchenne	B-Modifier
muscular	I-Modifier
dystrophy	I-Modifier
(	O
DMD	B-Modifier
)	O
gene	O
products	O
,	O
the	O
muscle-	O
and	O
brain-type	O
dystrophin	O
isoforms	O
,	O
are	O
427-kDa	O
proteins	O
translated	O
from	O
14-kilobase	O
(	O
kb	O
)	O
mRNAs	O
.	O
Recently	O
we	O
described	O
a	O
6	O
.	O
5-kb	O
mRNA	O
that	O
also	O
is	O
transcribed	O
from	O
the	O
DMD	B-Modifier
gene	O
.	O
Cloning	O
and	O
in	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
entire	O
coding	O
region	O
show	O
that	O
the	O
6	O
.	O
5-kb	O
mRNA	O
encodes	O
a	O
70	O
.	O
8-kDa	O
protein	O
that	O
is	O
a	O
major	O
product	O
of	O
the	O
DMD	B-Modifier
gene	O
.	O
It	O
contains	O
the	O
C-terminal	O
and	O
the	O
cysteine-rich	O
domains	O
of	O
dystrophin	O
,	O
seven	O
additional	O
amino	O
acids	O
at	O
the	O
N	O
terminus	O
,	O
and	O
some	O
modifications	O
formed	O
by	O
alternative	O
splicing	O
in	O
the	O
C-terminal	O
domain	O
.	O
It	O
lacks	O
the	O
entire	O
large	O
domain	O
of	O
spectrin-like	O
repeats	O
and	O
the	O
actin-binding	O
N-terminal	O
domain	O
of	O
dystrophin	O
.	O
This	O
protein	O
is	O
the	O
major	O
DMD	B-Modifier
gene	O
product	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues	O
but	O
is	O
undetectable	O
in	O
skeletal	O
muscle	O
extracts	O
.	O

107868	O
HLA	O
B27	O
and	O
the	O
genetics	O
of	O
ankylosing	B-SpecificDisease
spondylitis.	I-SpecificDisease
One	O
hundred	O
and	O
twenty-eight	O
of	O
145	O
patients	O
with	O
ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
(	O
AS	B-SpecificDisease
)	O
were	O
found	O
to	O
be	O
HLA	O
B27	O
positive	O
.	O
Five	O
patients	O
had	O
evidence	O
of	O
a	O
sero-negative	O
peripheral	B-SpecificDisease
arthritis	I-SpecificDisease
resembling	O
peripheral	B-SpecificDisease
psoriatic	I-SpecificDisease
arthritis	I-SpecificDisease
and	O
3	O
of	O
these	O
were	O
B27	O
negative	O
.	O
One	O
further	O
B27	O
negative	O
patients	O
had	O
a	O
sister	O
with	O
ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
and	O
ulcerative	B-SpecificDisease
colitis	I-SpecificDisease
and	O
a	O
mother	O
with	O
ulcerative	B-SpecificDisease
colitis	I-SpecificDisease
.	O
There	O
was	O
evidence	O
of	O
a	O
somewhat	O
later	O
age	O
of	O
onset	O
of	O
symptoms	O
in	O
B27	O
negative	O
patients	O
.	O
These	O
findings	O
are	O
interpreted	O
as	O
suggesting	O
some	O
degree	O
of	O
clinical	O
and	O
genetic	O
heterogeneity	O
in	O
ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
with	O
genes	O
for	O
psoriasis	B-SpecificDisease
and	O
inflammatory	B-SpecificDisease
bowel	I-SpecificDisease
disease	I-SpecificDisease
being	O
important	O
in	O
some	O
individuals	O
,	O
particularly	O
those	O
who	O
are	O
B27	O
negative	O
.	O
Twenty-five	O
first-degree	O
relatives	O
with	O
ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
were	O
all	O
B27	O
positive	O
.	O
The	O
only	O
instance	O
of	O
disassociation	O
of	O
B27	O
and	O
spondylitis	B-SpecificDisease
in	O
a	O
family	O
was	O
where	O
the	O
proband	O
had	O
ulcerative	B-SpecificDisease
colitis	I-SpecificDisease
as	O
well	O
as	O
spondylitis	B-SpecificDisease
.	O
Of	O
13	O
B27	O
positive	O
fathers	O
3	O
could	O
be	O
diagnosed	O
as	O
having	O
definite	O
ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
(	O
23	O
%	O
)	O
.	O
These	O
findings	O
are	O
thought	O
to	O
provide	O
evidence	O
against	O
the	O
concept	O
that	O
the	O
gene	O
for	O
ankylosing	B-SpecificDisease
spondylitis	I-SpecificDisease
is	O
not	O
B27	O
but	O
a	O
closely	O
linked	O
gene	O
and	O
favour	O
the	O
occurrence	O
of	O
an	O
environmental	O
event	O
affecting	O
approximately	O
one-fifth	O
of	O
B27	O
positive	O
males	O
to	O
result	O
in	O
disease	O
.	O
.	O

1351034	O
Loss	O
of	O
normal	O
allele	O
of	O
the	O
APC	B-Modifier
gene	O
in	O
an	O
adrenocortical	B-SpecificDisease
carcinoma	I-SpecificDisease
from	O
a	O
patient	O
with	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis.	I-SpecificDisease
Endocrine	B-DiseaseClass
neoplasms	I-DiseaseClass
have	O
been	O
reported	O
occasionally	O
in	O
patients	O
with	O
familial	B-SpecificDisease
adenomatous	I-SpecificDisease
polyposis	I-SpecificDisease
(	O
FAP	B-SpecificDisease
)	O
.	O
An	O
adrenocorotical	B-SpecificDisease
carcinoma	I-SpecificDisease
was	O
studied	O
in	O
a	O
patient	O
with	O
a	O
family	O
history	O
of	O
FAP	B-SpecificDisease
.	O
Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
the	O
region	O
close	O
to	O
the	O
adenomatous	B-Modifier
polyposis	I-Modifier
coli	I-Modifier
(	O
APC	B-Modifier
)	O
gene	O
was	O
detected	O
in	O
this	O
carcinoma	B-DiseaseClass
,	O
and	O
evidence	O
was	O
obtained	O
that	O
there	O
was	O
a	O
loss	O
of	O
the	O
normal	O
allele	O
of	O
the	O
APC	B-Modifier
gene	O
.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
LOH	O
at	O
the	O
APC	B-Modifier
locus	O
in	O
adrenocortical	B-SpecificDisease
tumors	I-SpecificDisease
.	O
The	O
present	O
results	O
and	O
our	O
previous	O
data	O
on	O
LOH	O
in	O
a	O
recurring	O
desmoid	B-SpecificDisease
tumor	I-SpecificDisease
suggest	O
that	O
the	O
heterozygous	O
mutant	O
/	O
wild-type	O
condition	O
of	O
the	O
APC	B-Modifier
gene	O
may	O
give	O
rise	O
to	O
benign	B-DiseaseClass
tumors	I-DiseaseClass
,	O
and	O
that	O
functional	O
loss	O
of	O
this	O
gene	O
leads	O
to	O
development	O
of	O
tumors	B-DiseaseClass
not	O
only	O
in	O
the	O
colon	O
but	O
also	O
in	O
other	O
various	O
parts	O
of	O
the	O
body	O
in	O
FAP	B-Modifier
patients	O
.	O
.	O

6618488	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
and	O
chromosome	O
15.	O
A	O
clinical	O
discussion	O
of	O
20	O
cases.	O
A	O
chromosome	B-SpecificDisease
15	I-SpecificDisease
anomaly	I-SpecificDisease
was	O
observed	O
in	O
12	O
of	O
20	O
patients	O
,	O
17	O
of	O
whom	O
were	O
clinically	O
suspected	O
of	O
having	O
Prader-Willi	B-SpecificDisease
syndrome	I-SpecificDisease
(	O
PWS	B-SpecificDisease
)	O
.	O
The	O
clinical	O
features	O
of	O
eight	O
cases	O
with	O
15q11-12	O
deletion	O
were	O
very	O
similar	O
to	O
those	O
originally	O
described	O
in	O
PWS	B-SpecificDisease
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
group	O
of	O
normal	O
karyotype	O
patients	O
is	O
heterogeneous	O
,	O
and	O
their	O
features	O
do	O
not	O
strictly	O
correspond	O
to	O
the	O
clinical	O
definition	O
of	O
PWS	B-SpecificDisease
.	O
However	O
,	O
the	O
hypothesis	O
that	O
PWS	B-SpecificDisease
is	O
associated	O
with	O
deletion	O
of	O
15q11-12	O
can	O
neither	O
explain	O
the	O
apparently	O
balanced	O
translocations	O
of	O
chromosome	O
15	O
nor	O
account	O
for	O
the	O
small	O
supernumerary	O
metacentric	O
chromosomes	O
corresponding	O
to	O
an	O
isochromosome	O
15	O
for	O
band	O
15q11	O
observed	O
in	O
some	O
cases	O
.	O
.	O

